<SEC-DOCUMENT>0000906709-19-000010.txt : 20191107
<SEC-HEADER>0000906709-19-000010.hdr.sgml : 20191107
<ACCEPTANCE-DATETIME>20191106194321
ACCESSION NUMBER:		0000906709-19-000010
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		55
CONFORMED PERIOD OF REPORT:	20190930
FILED AS OF DATE:		20191107
DATE AS OF CHANGE:		20191106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		191197775

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nktr2019-09x30x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:22F83EC5B37E51AD8703EECF28B61852,x:cd7d4fe1512c43139be042a85ed8a745-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2019 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:nktr="http://www.nektar.com/20190930" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:AmendmentFlag" id="Fact-B0D20C8E345A5631AB6C49D63D57F5DB-wk-Fact-B0D20C8E345A5631AB6C49D63D57F5DB" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-533BD43F066A5135A05BCD3AA48F08AE-wk-Fact-533BD43F066A5135A05BCD3AA48F08AE">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-7A269BD6D8585750BBB03CFD638B424B-wk-Fact-7A269BD6D8585750BBB03CFD638B424B">Q3</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:DocumentFiscalYearFocus" id="Fact-082CE4F299C057DE9D171D7C15E08BCE-wk-Fact-082CE4F299C057DE9D171D7C15E08BCE">2019</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:EntityCentralIndexKey" id="Fact-6304204534DD5D168146B978135EBFE0-wk-Fact-6304204534DD5D168146B978135EBFE0">0000906709</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="nktr:DebtInvestmentMaturityTerm" id="Fact-3300F5555CD55F0E8AEE0FCEC178AD92-wk-Fact-3300F5555CD55F0E8AEE0FCEC178AD92">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="nktr:DebtInvestmentMaximumMaturityPeriod" id="Fact-15CC8E82CF845D3E92066C0186569019-wk-Fact-15CC8E82CF845D3E92066C0186569019">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember" name="nktr:LongTermInvestmentMaturityPeriod" id="Fact-3CDAD09CC02D55D69A953713156AE21A-wk-Fact-3CDAD09CC02D55D69A953713156AE21A">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember" name="nktr:LongTermInvestmentMaturityPeriod" id="Fact-C4A5CA3EAE785A66A3C30BC698FADDA5-wk-Fact-C4A5CA3EAE785A66A3C30BC698FADDA5">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember" name="nktr:LongTermInvestmentMaturityPeriod" id="Fact-4264FF26E213558789474D50350C021F-wk-Fact-4264FF26E213558789474D50350C021F">P1Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="nktr:PreferredStockShareDesignated" id="Fact-6192F77A09E456869C31CA9F6F151007-wk-Fact-6192F77A09E456869C31CA9F6F151007">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q3" name="nktr:PreferredStockShareDesignated" id="Fact-488ADC777EBE5AE4A4E3EB162D58F320-wk-Fact-488ADC777EBE5AE4A4E3EB162D58F320">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-83B31E4667575151887915C26CAD1166-wk-Fact-83B31E4667575151887915C26CAD1166">0.0001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q3" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-A63FDA3BC192573288B147B00C0C2394-wk-Fact-A63FDA3BC192573288B147B00C0C2394">0.0001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-10E775F26115557584EA084D31CAA47C-wk-Fact-10E775F26115557584EA084D31CAA47C">300000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q3" name="us-gaap:CommonStockSharesAuthorized" id="Fact-89A2A28AE7E7586CAEB6A6265404780C-wk-Fact-89A2A28AE7E7586CAEB6A6265404780C">300000000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-C3C4F2BFC64958AEA38ABE45A16EF814-wk-Fact-C3C4F2BFC64958AEA38ABE45A16EF814">173530000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="shares" contextRef="FI2019Q3" name="us-gaap:CommonStockSharesOutstanding" id="Fact-45DA1ACA13A05B69A0014F2C99604777-wk-Fact-45DA1ACA13A05B69A0014F2C99604777">175786000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FI2019Q3_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_AstraZenecaAgreementWithKirinMember" name="us-gaap:ContractWithCustomerLiability" id="Fact-219113E2F6A553F7B8DA56018CF632A1-wk-Fact-219113E2F6A553F7B8DA56018CF632A1">0</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2019Q3QTD_srt_StatementGeographicalAxis_country_IN" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact-59EBC93BD4E853D8978C47703D3C9FDF-wk-Fact-59EBC93BD4E853D8978C47703D3C9FDF">0.33</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FI2018Q3" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" id="Fact-EB8FFACF6B4D577C85C844522A7596E7-wk-Fact-EB8FFACF6B4D577C85C844522A7596E7">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FI2018Q3" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" id="Fact-ED5EC0CC5A39509C8A9052C801074BE6-wk-Fact-ED5EC0CC5A39509C8A9052C801074BE6">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FI2019Q3" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" id="Fact-0D6116EAF65E5891B65532B12B27C1F7-wk-Fact-0D6116EAF65E5891B65532B12B27C1F7">0</ix:nonFraction><ix:nonNumeric contextRef="I2017Q3Aug31_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Fact-EDD77977837FE55891FE23E0EDD2F2B9-wk-Fact-EDD77977837FE55891FE23E0EDD2F2B9">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="I2018Q2May31_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Fact-A05785C5043B8E5BAFEC23E2D9F3D18B-wk-Fact-A05785C5043B8E5BAFEC23E2D9F3D18B">P5Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FI2018Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_IndemnificationGuaranteeMember" name="us-gaap:LossContingencyAccrualAtCarryingValue" id="Fact-F8882BCB7E345390AF7C9BFD35050391-wk-Fact-F8882BCB7E345390AF7C9BFD35050391">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-3F48871C692F5BD08A37AA4CBC3F0B00-wk-Fact-3F48871C692F5BD08A37AA4CBC3F0B00">0.0001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q3" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-1D7CCB56C3FE5C53A08E4B3233210C1E-wk-Fact-1D7CCB56C3FE5C53A08E4B3233210C1E">0.0001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-54DECBE6527B595EB1427D9B464D3D33-wk-Fact-54DECBE6527B595EB1427D9B464D3D33">10000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q3" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-D9EEEF08CBD65F3ABF20BCD1348DEC84-wk-Fact-D9EEEF08CBD65F3ABF20BCD1348DEC84">10000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-898509888A53595698C32F4A1084D381-wk-Fact-898509888A53595698C32F4A1084D381">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q3" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-8CDB806E33E05237BFDF292D38D19C04-wk-Fact-8CDB806E33E05237BFDF292D38D19C04">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2018Q3QTD" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" id="Fact-677F8523088553D1A6836AF6C286DC18-wk-Fact-677F8523088553D1A6836AF6C286DC18">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="nktr-20190930.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2019Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Nov01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-11-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_nktr_LicenseCollaborationAndOtherRevenueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_nktr_LicenseCollaborationAndOtherRevenueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_nktr_LicenseCollaborationAndOtherRevenueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_nktr_LicenseCollaborationAndOtherRevenueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CounterpartyNameAxis_nktr_CollaborationPartnerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:CollaborationPartnerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_StatementGeographicalAxis_country_IN">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_CounterpartyNameAxis_nktr_CollaborationPartnerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:CollaborationPartnerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Jan1-Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_StatementGeographicalAxis_country_IN">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_DebtInstrumentAxis_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2015Q4Oct5_us-gaap_DebtInstrumentAxis_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-10-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:ARESanFranciscoNumberOneNineLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:KilroyRealtyFinancePartnershipLPMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:KilroyRealtyFinancePartnershipLPMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q3Aug31_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:ARESanFranciscoNumberOneNineLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Aug01-Aug31_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:ARESanFranciscoNumberOneNineLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-08-01</xbrli:startDate>
			<xbrli:endDate>2017-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:ARESanFranciscoNumberOneNineLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:KilroyRealtyFinancePartnershipLPMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2May31_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:KilroyRealtyFinancePartnershipLPMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Dec1-Dec31_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:KilroyRealtyFinancePartnershipLPMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Aug31_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:KilroyRealtyFinancePartnershipLPMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2012Q4Feb23-Dec31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-02-23</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2012Q1Feb24_us-gaap_TypeOfArrangementAxis_nktr_PurchaseAndSaleAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-02-24</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2012Q1Feb23-Feb24_us-gaap_TypeOfArrangementAxis_nktr_PurchaseAndSaleAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-02-23</xbrli:startDate>
			<xbrli:endDate>2012-02-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_IndemnificationGuaranteeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_IndemnificationGuaranteeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Sep1-Sep30_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightLicenseMember_us-gaap_TypeOfArrangementAxis_nktr_PhaseOneClinicalDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarThreeFiveEightLicenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PhaseOneClinicalDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Aug22-Aug23_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-08-22</xbrli:startDate>
			<xbrli:endDate>2017-08-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Aug22-Aug23_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-08-22</xbrli:startDate>
			<xbrli:endDate>2017-08-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Apr1-Apr30_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2010Q4Oct1-Dec31_dei_LegalEntityAxis_nktr_AmgenIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-10-01</xbrli:startDate>
			<xbrli:endDate>2010-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Dec1-Dec31_dei_LegalEntityAxis_nktr_BaxaltaIncorporatedOrTakedaPLCMember_us-gaap_ContractWithCustomerSalesChannelAxis_nktr_AnnualSalesLevelMilestoneMember_us-gaap_TypeOfArrangementAxis_nktr_HemophiliaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">nktr:AnnualSalesLevelMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q3Sep1-Sep30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_ClinicalTrialAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:ClinicalTrialAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q4Sep01-Dec31_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_MOVANTIKAndMOVENTIGMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MOVANTIKAndMOVENTIGMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2009-09-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Feb13-Feb13_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-13</xbrli:startDate>
			<xbrli:endDate>2018-02-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Sep1-Sep30_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightLicenseMember_us-gaap_TypeOfArrangementAxis_nktr_DrugProductDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarThreeFiveEightLicenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:DrugProductDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Aug01-Aug31_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-08-01</xbrli:startDate>
			<xbrli:endDate>2017-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BaxaltaIncorporatedOrTakedaPLCMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_TypeOfArrangementAxis_nktr_HemophiliaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Apr1-Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q3Aug23_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-08-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Feb13-Feb13_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nktr_OpdivoAndYervoyMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoAndYervoyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-13</xbrli:startDate>
			<xbrli:endDate>2018-02-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Apr1-Apr30_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Aug22-Aug23_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-08-22</xbrli:startDate>
			<xbrli:endDate>2017-08-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Apr1-Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_MOVANTIKAndMOVENTIGMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MOVANTIKAndMOVENTIGMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Sep1-Sep30_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Sep1-Sep30_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightLicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarThreeFiveEightLicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-09-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Feb13-Feb13_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nktr_OpdivoMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-13</xbrli:startDate>
			<xbrli:endDate>2018-02-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_dei_LegalEntityAxis_nktr_OtherPartnerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Nov1-Nov30_dei_LegalEntityAxis_nktr_BaxaltaIncorporatedOrTakedaPLCMember_us-gaap_TypeOfArrangementAxis_nktr_HemophiliaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-01</xbrli:startDate>
			<xbrli:endDate>2017-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Feb13-Feb13_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-13</xbrli:startDate>
			<xbrli:endDate>2018-02-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Feb13-Feb13_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nktr_OpdivoMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-13</xbrli:startDate>
			<xbrli:endDate>2018-02-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Feb13-Feb13_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nktr_OpdivoAndYervoyMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoAndYervoyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-13</xbrli:startDate>
			<xbrli:endDate>2018-02-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Aug22-Aug23_dei_LegalEntityAxis_nktr_EliLillyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-08-22</xbrli:startDate>
			<xbrli:endDate>2017-08-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q1Mar1-Mar31_us-gaap_TypeOfArrangementAxis_nktr_NektarMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-03-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Aug22-Aug23_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-08-22</xbrli:startDate>
			<xbrli:endDate>2017-08-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q1Mar1-Mar31_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_AstraZenecaAgreementWithKirinMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:AstraZenecaAgreementWithKirinMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-03-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Jan1-Jan31_dei_LegalEntityAxis_nktr_BaxaltaIncorporatedOrTakedaPLCMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_TypeOfArrangementAxis_nktr_HemophiliaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarTwoOneFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_TypeOfArrangementAxis_nktr_NeulastaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_TypeOfArrangementAxis_nktr_NeulastaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_dei_LegalEntityAxis_nktr_OtherPartnerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarTwoOneFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarTwoOneFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_TypeOfArrangementAxis_nktr_NeulastaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarTwoOneFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_dei_LegalEntityAxis_nktr_OtherPartnerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_dei_LegalEntityAxis_nktr_OtherPartnerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_TypeOfArrangementAxis_nktr_NeulastaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_dei_LegalEntityAxis_nktr_OtherPartnerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_AstraZenecaAgreementWithKirinMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:AstraZenecaAgreementWithKirinMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_nktr_StockOptionsAndRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_nktr_StockOptionsAndRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="space">
		<xbrli:measure>nktr:space</xbrli:measure>
	</xbrli:unit><xbrli:unit id="extension_period">
		<xbrli:measure>nktr:extension_period</xbrli:measure>
	</xbrli:unit><xbrli:unit id="U_nktrSegment">
		<xbrli:measure>nktr:Segment</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="s7A90AAFB53455ED7B1794A5E0DF42536"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">_______________________________________________________________________</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:14pt;"><span style="font-family:inherit;font-size:14pt;font-weight:bold;">FORM </span><span><ix:nonNumeric id="d103432234e380-wk-Fact-016CC5E3EB1C5CC582D4F8A3E2217E16" name="dei:DocumentType" contextRef="FD2019Q3YTD"><span style="font-size:14pt;font-weight:bold;">10-Q</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:14pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">_______________________________________________________________________</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:Arial Unicode MS;font-size:11pt;"><span><ix:nonNumeric id="d103432234e400-wk-Fact-B41605800C3159D6BEF39BE1DBE3B9AA" name="dei:DocumentQuarterlyReport" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the quarterly period ended </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d103432234e410-wk-Fact-498D261A5EA55D02AB052CDA9AC9EE54" name="dei:DocumentPeriodEndDate" contextRef="FD2019Q3YTD" format="ixt:datemonthdayyearen">September 30, 2019</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">or</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:Arial Unicode MS;font-size:11pt;"><span><ix:nonNumeric id="d103432234e429-wk-Fact-D4D6DFAADD315054A60300034310AD82" name="dei:DocumentTransitionReport" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number: </span><span><ix:nonNumeric id="d103432234e443-wk-Fact-A7019E720CF25E6DA3D0354EF9864C31" name="dei:EntityFileNumber" contextRef="FD2019Q3YTD"><span style="font-weight:bold;">0-24006</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">_______________________________________________________________________</span></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:23pt;"><span><ix:nonNumeric id="d103432234e452-wk-Fact-59B3A1601D53521481DF35608E57F619" name="dei:EntityRegistrantName" contextRef="FD2019Q3YTD"><span style="font-size:23pt;font-weight:bold;">NEKTAR THERAPEUTICS</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:23pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">_______________________________________________________________________</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d103432234e476-wk-Fact-A6A2E7E4A2A750D1AAD6FFE9DE6A6326" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2019Q3YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d103432234e486-wk-Fact-0A8D70C5BA7B592282C19A5415777632" name="dei:EntityTaxIdentificationNumber" contextRef="FD2019Q3YTD">94-3134940</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(IRS Employer</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d103432234e511-wk-Fact-249A866EF31259CBBABEFBCB69460ECD" name="dei:EntityAddressAddressLine1" contextRef="FD2019Q3YTD"><span style="font-weight:bold;">455 Mission Bay Boulevard South</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d103432234e517-wk-Fact-D60F683170935CF1B61A1AE6AA9E6044" name="dei:EntityAddressCityOrTown" contextRef="FD2019Q3YTD"><span style="font-weight:bold;">San Francisco</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d103432234e522-wk-Fact-E68B2485FF34537A8CDD70495AEC492E" name="dei:EntityAddressStateOrProvince" contextRef="FD2019Q3YTD" format="ixt-sec:stateprovnameen"><span style="font-weight:bold;">California</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d103432234e527-wk-Fact-ED034A4351435E5D8096B0A9A0034508" name="dei:EntityAddressPostalZipCode" contextRef="FD2019Q3YTD"><span style="font-weight:bold;">94158</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive offices)</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d103432234e536-wk-Fact-EA9CF9118B6D5665890101B58486934D" name="dei:CityAreaCode" contextRef="FD2019Q3YTD"><span style="font-weight:bold;">415</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">-</span><span><ix:nonNumeric id="d103432234e541-wk-Fact-6469CB420D19566A8BA8E233DF7F1C55" name="dei:LocalPhoneNumber" contextRef="FD2019Q3YTD"><span style="font-weight:bold;">482-5300</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:8%;"></td><td style="width:28%;"></td><td style="width:20%;"></td><td style="width:37%;"></td><td style="width:7%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Trading symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Name of each exchange on which registered</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d103432234e622-wk-Fact-D005A59520075B9A8A8267AA294C540C" name="dei:Security12bTitle" contextRef="FD2019Q3YTD">Common Stock, $0.0001 par value</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d103432234e627-wk-Fact-32B2B23AA24C59ABBBF1440E18C36150" name="dei:TradingSymbol" contextRef="FD2019Q3YTD">NKTR</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d103432234e632-wk-Fact-C791CC8F4C54571FABD94C073B255682" name="dei:SecurityExchangeName" contextRef="FD2019Q3YTD" format="ixt-sec:exchnameen">NASDAQ Global Select Market</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d103432234e644-wk-Fact-E633A65D7A105825A01FF5FB331CAF00" name="dei:EntityCurrentReportingStatus" contextRef="FD2019Q3YTD">Yes</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Wingdings;font-size:8pt;">x</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;No &#9744;</span></div><div style="line-height:120%;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d103432234e655-wk-Fact-F8C894E9F22B515CB9C2176D8FD156BF" name="dei:EntityInteractiveDataCurrent" contextRef="FD2019Q3YTD">Yes</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Wingdings;font-size:8pt;">x</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;No &#9744;</span></div><div style="line-height:120%;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:23%;"></td><td style="width:2%;"></td><td style="width:44%;"></td><td style="width:3%;"></td><td style="width:22%;"></td><td style="width:3%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d103432234e683-wk-Fact-072652D474BA51CEB89E6D3797A2B0AE" name="dei:EntityFilerCategory" contextRef="FD2019Q3YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial Unicode MS;font-size:11pt;">&#9746;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accelerated&#160;filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial Unicode MS;font-size:11pt;">&#9744;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-accelerated filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Arial Unicode MS;font-size:11pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Smaller&#160;reporting&#160;company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:Arial Unicode MS;font-size:11pt;"><span><ix:nonNumeric id="d103432234e785-wk-Fact-6156413FB4EE5380AE5C048EF7B955A7" name="dei:EntitySmallBusiness" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging growth company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:Arial Unicode MS;font-size:11pt;"><span><ix:nonNumeric id="d103432234e837-wk-Fact-FE702BF31349579685582690504AA137" name="dei:EntityEmergingGrowthCompany" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div><div style="line-height:120%;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).&#160;&#160;Yes </span><span><ix:nonNumeric id="d103432234e867-wk-Fact-A9030AE9DAF45637A7540B603F46D7AB" name="dei:EntityShellCompany" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;No </span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9746;</span></div><div style="line-height:120%;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The number of outstanding shares of the registrant&#8217;s Common Stock, $0.0001 par value, was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103432234e877-wk-Fact-FB8EF0887A5DBA74105A378D24AC4F7B" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2019Q3Nov01" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">175,922,206</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> on </span><span style="font-family:inherit;font-size:10pt;">November&#160;1, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s0D6175B8F89758B9AB40E630E36615D1"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NEKTAR THERAPEUTICS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:89%;"></td><td style="width:3%;"></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s73F6938D124459ED90328987D8FF2618"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I: FINANCIAL INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFBA804ACB0A15F45A7B01569EE6721C8"><span style="font-family:inherit;font-size:10pt;">Item 1.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFBA804ACB0A15F45A7B01569EE6721C8"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Financial Statements &#8212; Unaudited:</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sFBA804ACB0A15F45A7B01569EE6721C8">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA6BDC70BA3895864B1A1526246BE50EA"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets &#8212; September 30, 2019 and December 31, 2018</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sA6BDC70BA3895864B1A1526246BE50EA">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s153447834FCB550ABFA5A94A2B8820C0"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2019 and 2018</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s153447834FCB550ABFA5A94A2B8820C0">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D107E80094E5FE89B8768C962112BD1"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2019 and 2018</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s0D107E80094E5FE89B8768C962112BD1">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF815B8342467580B95DBCA7C85C49AFD"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Stockholders&#8217; Equity for the three and nine months ended September 30, 2019 and 2018</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s75F3C73D5EFA5D77818EC321969FC7B9"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2019 and 2018</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s75F3C73D5EFA5D77818EC321969FC7B9">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s894AA03583E45D339BD474D8F245FC00"><span style="font-family:inherit;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s894AA03583E45D339BD474D8F245FC00">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC9792DF6D2295DD4997463C16DDAD956"><span style="font-family:inherit;font-size:10pt;">Item 2.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC9792DF6D2295DD4997463C16DDAD956"><span style="font-family:inherit;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sC9792DF6D2295DD4997463C16DDAD956">23</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2F6DBFB25F985479BE41E1F3C0D37D35"><span style="font-family:inherit;font-size:10pt;">Item 3.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2F6DBFB25F985479BE41E1F3C0D37D35"><span style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s2F6DBFB25F985479BE41E1F3C0D37D35">33</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21A137D2F7D250AB8792CA4384490827"><span style="font-family:inherit;font-size:10pt;">Item 4.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21A137D2F7D250AB8792CA4384490827"><span style="font-family:inherit;font-size:10pt;">Controls and Procedures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s21A137D2F7D250AB8792CA4384490827">33</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s79543C0FC4BA5385BA0DAB27FC69DD0B"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II: OTHER INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s380832B7A2D75983B7FBC53DFB64D5AD"><span style="font-family:inherit;font-size:10pt;">Item 1.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s380832B7A2D75983B7FBC53DFB64D5AD"><span style="font-family:inherit;font-size:10pt;">Legal Proceedings</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s380832B7A2D75983B7FBC53DFB64D5AD">35</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s73E292CA6AA15C8DA3BF0EBAD79F9E01"><span style="font-family:inherit;font-size:10pt;">Item 1A.</span></a><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s73E292CA6AA15C8DA3BF0EBAD79F9E01"><span style="font-family:inherit;font-size:10pt;">Risk Factors</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s73E292CA6AA15C8DA3BF0EBAD79F9E01">35</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBED438EF8A3B5DD2848898CD66C1093D"><span style="font-family:inherit;font-size:10pt;">Item 2.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBED438EF8A3B5DD2848898CD66C1093D"><span style="font-family:inherit;font-size:10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sBED438EF8A3B5DD2848898CD66C1093D">52</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7E8A7191ECAB502E820B32C6AB5F4A4C"><span style="font-family:inherit;font-size:10pt;">Item 3.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7E8A7191ECAB502E820B32C6AB5F4A4C"><span style="font-family:inherit;font-size:10pt;">Defaults Upon Senior Securities</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s7E8A7191ECAB502E820B32C6AB5F4A4C">52</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6324675F70625C38B502D7D5512B9790"><span style="font-family:inherit;font-size:10pt;">Item 4.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6324675F70625C38B502D7D5512B9790"><span style="font-family:inherit;font-size:10pt;">Mine Safety Disclosures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s6324675F70625C38B502D7D5512B9790">52</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAAEA73AB93DB5C459F0093157FC75EE9"><span style="font-family:inherit;font-size:10pt;">Item 5.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAAEA73AB93DB5C459F0093157FC75EE9"><span style="font-family:inherit;font-size:10pt;">Other Information</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sAAEA73AB93DB5C459F0093157FC75EE9">52</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB5BD69B42BB354B795D0E90DDF4CB75B"><span style="font-family:inherit;font-size:10pt;">Item 6.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB5BD69B42BB354B795D0E90DDF4CB75B"><span style="font-family:inherit;font-size:10pt;">Exhibits</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sB5BD69B42BB354B795D0E90DDF4CB75B">53</a></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA7F65855E94059629F3D9913E034738C"><span style="font-family:inherit;font-size:10pt;">Signatures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sA7F65855E94059629F3D9913E034738C">54</a></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="sD7864DF03DA15FE7919D75E942C581BC"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward-Looking Statements</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This report includes &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (Securities Act), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (Exchange Act). All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this quarterly report on Form 10-Q, including any projections of market size, earnings, revenue, milestone payments, royalties, sales or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, preclinical development, clinical trials and manufacturing), any statements related to our financial condition and future working capital needs, any statements regarding potential future financing alternatives, any statements concerning proposed drug candidates, any statements regarding the timing for the start or end of clinical trials or submission of regulatory approval filings, any statements regarding future economic conditions or performance, any statements regarding the initiation, formation, or success of our collaboration arrangements, timing of commercial launches and product sales levels by our collaboration partners and future payments that may come due to us under these arrangements, any statements regarding our plans and objectives to initiate or continue clinical trials, any statements related to potential, anticipated, or ongoing litigation and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, such expectations or any of the forward-looking statements may prove to be incorrect and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not limited to, the risk factors set forth in Part II, Item&#160;1A &#8220;Risk Factors&#8221; below and for the reasons described elsewhere in this quarterly report on Form 10-Q. All forward-looking statements and reasons why results may differ included in this report are made as of the date hereof and we do not intend to update any forward-looking statements except as required by law or applicable regulations. Except where the context otherwise requires, in this quarterly report on Form 10-Q, the &#8220;Company,&#8221; &#8220;Nektar,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Nektar Therapeutics, a Delaware corporation, and, where appropriate, its subsidiaries.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Trademarks</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Nektar brand and product names, including but not limited to Nektar</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, contained in this document are trademarks and registered trademarks of Nektar Therapeutics in the United States (U.S.) and certain other countries. This document also contains references to trademarks and service marks of other companies that are the property of their respective owners.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></div><hr style="page-break-after:always"></hr><div><a id="s73F6938D124459ED90328987D8FF2618"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I: FINANCIAL INFORMATION</span></div><div><a id="sFBA804ACB0A15F45A7B01569EE6721C8"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Financial Statements&#8212;Unaudited:</span></div></td></tr></table><div><a id="sA6BDC70BA3895864B1A1526246BE50EA"></a></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NEKTAR THERAPEUTICS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except par value)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e515-wk-Fact-C7A2AE7C68775A439814DA049308CCE0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">81,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e534-wk-Fact-0A046CD4CFDD5C44AB78FE4E6C5314BD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">194,905</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e549-wk-Fact-0AEF18E786665F2FAEBCBCB3D5386580" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,414,448</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e568-wk-Fact-D62AACC5E6A9595AA4AC531814DAB31B" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,140,445</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e588-wk-Fact-3EF320A72A825C11B68E939CF863BF03" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,205</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e607-wk-Fact-FBC3973AE8EF5B379365CA7B557C76BC" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">43,213</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e627-wk-Fact-D3F1F8DC7AB6516098B11FCDFB3E6D69" name="us-gaap:InventoryNet" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,720</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e646-wk-Fact-59492ABDF60153D4BA438B78B7470CB8" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,381</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Advance payments to contract manufacturers</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e666-wk-Fact-B3A5D118EDD456F09241ABE722D70281" name="nktr:AdvancePaymentsToContractManufacturers" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,015</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e685-wk-Fact-7361B8702F295AD581A123CF3E50012A" name="nktr:AdvancePaymentsToContractManufacturers" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e705-wk-Fact-831834B3A2AD5B20B2EDBADF6012D9B5" name="us-gaap:OtherAssetsCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,212</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e724-wk-Fact-882D4B407D09569ABE9B90D81D5CDFD3" name="us-gaap:OtherAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,293</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e744-wk-Fact-FE269227A18D55A1AE7EF202A520CC5D" name="us-gaap:AssetsCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,578,824</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e763-wk-Fact-B25258D7E527528795B6250B8F0C3917" name="us-gaap:AssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,437,687</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e783-wk-Fact-0D4AE566CE7B54188DDCDEB656199CE3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">231,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e802-wk-Fact-326539B35D8A5187AE1F3CF50F026C2B" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">582,889</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e823-wk-Fact-B2B086AC613F5C7EA4E28ED4C14E7425" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">64,614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e842-wk-Fact-0390508D6FA25DDD8A666AC3DD17EF1C" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e862-wk-Fact-D5C3E1AD1AB45A32A92F8FB0BA74FF51" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">134,888</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e881-wk-Fact-1EE83566912E56768BAD761839C55ED1" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e901-wk-Fact-3B7C23058C095F58B31DFEFD50B1A19C" name="us-gaap:Goodwill" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">76,501</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e920-wk-Fact-9608F99D57AF53EDBC13AB52C12067F1" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">76,501</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e940-wk-Fact-526582D8C8845948A070DDF6B804354B" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,385</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e959-wk-Fact-925C6C3D0AA95E3A82C307A613F25683" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,244</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e984-wk-Fact-90D4416F9A4C5B7CAC99584E45363966" name="us-gaap:Assets" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,088,294</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1003-wk-Fact-EB1B162E76DD560A8906F93D8C4E4680" name="us-gaap:Assets" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,150,172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1105-wk-Fact-6AEFC54F4D635E7AAEB30A6C47E1E630" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,963</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1124-wk-Fact-742A036C446E56C38FB621E2B50A080F" name="us-gaap:AccountsPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,854</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1139-wk-Fact-22CE95B5217A53DDB2CFF07D9B7C378F" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1158-wk-Fact-0C66579A3CF1516C991B560A286E09B1" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,937</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued clinical trial expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1178-wk-Fact-6FE3131A439D59AF9BE063B789CB12E9" name="nktr:AccruedClinicalTrialExpensesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,338</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1197-wk-Fact-4A0F4EF911F95240A07BCDFA53E03E9E" name="nktr:AccruedClinicalTrialExpensesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued contract manufacturing expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1217-wk-Fact-37C54E554B9350DF8E069EF198DF1858" name="nktr:AccruedContractManufacturingExpenseCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,646</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1236-wk-Fact-C2625AC6F20B5BF7A8946AD454F9CAF6" name="nktr:AccruedContractManufacturingExpenseCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,841</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1257-wk-Fact-CB466845BB9C5C30B79B74460F5CB7D3" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,394</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1276-wk-Fact-101BDB992E685B1BB3199823DE366260" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,580</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1296-wk-Fact-91DD95E2EBAA5A179EAD892D2BC0C7D3" name="us-gaap:InterestPayableCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1315-wk-Fact-D65856DCFC6654C0B2B2AF803C0DAB7A" name="us-gaap:InterestPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities, current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1335-wk-Fact-9DF62218E4F95D648FC7684BADFBFC0A" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,318</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1354-wk-Fact-78A37B4E6EA453CB9A472759D024D73F" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue, current portion</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1374-wk-Fact-C52BCEB748C958139CBD9D2B1B5CB2F8" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,392</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1393-wk-Fact-98380AAF04255AE7AAD65125EF70D144" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,892</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1413-wk-Fact-06B8DAC6B8EE51B6AAD9E5D59B359F68" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">125,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1432-wk-Fact-17309742D02956C5A46653F28CDC6802" name="us-gaap:LiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Senior secured notes, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1452-wk-Fact-D0354DF713665B9ABC2848BA5FD89FC1" name="us-gaap:SeniorLongTermNotes" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">248,257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1471-wk-Fact-2C4BDAFD72F45EDAAE886835361FB0C5" name="us-gaap:SeniorLongTermNotes" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">246,950</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities, less current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1491-wk-Fact-4DC14A4ACA6254F9876DFB66F2EAAF81" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">145,099</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1510-wk-Fact-829D1B5642A053288961708823B39E71" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liability related to the sale of future royalties, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1530-wk-Fact-9C9124555FEF58B6B80CE556C226F8B7" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1549-wk-Fact-BC2D7EFF1FE657C3AF72B3165ACC0889" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82,911</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue, less current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1569-wk-Fact-C013E6C1FDEC59BFBADAA04E4A3CCA89" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,779</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1588-wk-Fact-E54AD2E930585241986DDF62B126DD3E" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1608-wk-Fact-9D5C3BE5298C531C9C10C7924FD6B95B" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">643</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1627-wk-Fact-99F7DF085455533E9A19A50C146BB947" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,990</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1647-wk-Fact-BAAF447486D45880AE72DC4144D16F00" name="us-gaap:Liabilities" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">599,583</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1666-wk-Fact-3DBDDCF4DE0159C1822E2FD7EFA0FF47" name="us-gaap:Liabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">432,597</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commitments and contingencies</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1687-wk-Fact-C84CBC818ECD51EC842A832640B003D8" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q3" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1705-wk-Fact-0D46FAC9EB0F5EF6B7257CCAC8552FB7" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2018Q4" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred stock, </span><span style="font-family:inherit;font-size:8pt;">$0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at September 30, 2019 or December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1767-wk-Fact-6451D4857CB5535BA4C915ABCDE880F1" name="us-gaap:PreferredStockValue" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1786-wk-Fact-567D5A1E73EF5D4F8E3B2D6D7C233372" name="us-gaap:PreferredStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock, </span><span style="font-family:inherit;font-size:8pt;">$0.0001 par value; 300,000 shares authorized; 175,786 shares and 173,530 shares outstanding at September 30, 2019 and December 31, 2018, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1808-wk-Fact-94D779EF54B55C908162ABA3EC6BEB5E" name="us-gaap:CommonStockValue" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1827-wk-Fact-7449D344F6F8509FA48BC008BDFB4DAE" name="us-gaap:CommonStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital in excess of par value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1847-wk-Fact-B5909FB2D63B58EA8BD42F42248D1133" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,241,160</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1866-wk-Fact-6F3FECBFBF2159D282771E8E63B1010A" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,147,925</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103445858e1886-wk-Fact-B1EC96FE5F0352FC848067011F2590E7" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,186</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103445858e1906-wk-Fact-A597B561E8DA55AEB814BD94DE2F8D20" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,316</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103445858e1927-wk-Fact-75A4343331915634B80610E6C9B7CC25" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,751,280</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103445858e1947-wk-Fact-B6F07C017B505698958601DA8D5CC926" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,424,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1968-wk-Fact-B678F4F136865CEF9F87800AB7F87743" name="us-gaap:StockholdersEquity" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,488,711</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e1987-wk-Fact-DCD6BC68154A5F7B8D85D40C60BE3EDB" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,717,575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities and stockholders&#8217; equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e2012-wk-Fact-8DAF82086DBA58A78695DBA1EB7F218B" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,088,294</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103445858e2031-wk-Fact-5A2DE51A86CE51908AD3DD961C50FEAC" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,150,172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="s153447834FCB550ABFA5A94A2B8820C0"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NEKTAR THERAPEUTICS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except per share information)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e646-wk-Fact-11E91C2A18B854BE933737684F281F63" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,558</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e665-wk-Fact-59B1434592FC5E09BD2B4DF750E7E592" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e684-wk-Fact-D31E7ED4FAB55FDDAF2458EE4CE7B87C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,302</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e704-wk-Fact-70728217C6975D828F443FD27D795C06" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,414</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalty revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e719-wk-Fact-367B8E3203D05EEB863C648CE2E3B101" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e738-wk-Fact-91360F29085D56658D30B42034965981" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,259</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e757-wk-Fact-E02BF72F4EDA521AA45CAFA120EF92FE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,008</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e777-wk-Fact-E7978B7DF0FA57269A5B548870879704" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,898</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash royalty revenue related to sale of future royalties</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e797-wk-Fact-07F4CB988500513C895EF1F01F28DA5E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,264</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e816-wk-Fact-50138912970750EA811F5EB072C04637" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,372</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e835-wk-Fact-B46B7CB57EC45220921450DBCFE51856" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,585</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e855-wk-Fact-484E5970CB445C31993585F60293F0DC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,337</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License, collaboration and other revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e875-wk-Fact-7D00AFF99FD15D91BE435EBB42AF05F4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_nktr_LicenseCollaborationAndOtherRevenueMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e894-wk-Fact-80C1A77E0E00588389D316EDCA79341C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_nktr_LicenseCollaborationAndOtherRevenueMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e913-wk-Fact-71D9E73C64385A6EB67BF8592F08DC02" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_nktr_LicenseCollaborationAndOtherRevenueMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,860</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e933-wk-Fact-D4242468F9FE53E689B288B453A4089B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_nktr_LicenseCollaborationAndOtherRevenueMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,082,848</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e953-wk-Fact-DF934E5E1B885A1597FEB851AEDD6454" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e972-wk-Fact-473AF8C568065B9BB6FFDA94FA51D747" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,762</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e991-wk-Fact-A26A18206DF45033A866D3CB5BF4BC6E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">80,755</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1011-wk-Fact-AAC4AF9FC7FB547FAC062D6967DB301F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,153,497</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating costs and expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of goods sold</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1113-wk-Fact-680B91C761835D2193037A549A6D10E5" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,927</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1132-wk-Fact-64EA6A4C662D5F2A8920737E71327EF6" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1151-wk-Fact-197F4A9007C65828859A42360506B032" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,385</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1171-wk-Fact-C8092FC0721D51E2AE3EDF6497CFF4FA" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,951</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1191-wk-Fact-C69216BDDBB355AE8A2A3EBB7D109B8B" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">99,048</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1210-wk-Fact-BBBBA6CE21EF51A2A173A21FFA7E2F08" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">102,895</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1229-wk-Fact-2239742565255586AE31C703938A53B0" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">324,197</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1249-wk-Fact-DFE47604C70D546CBEE0C362E368DD68" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">290,653</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1270-wk-Fact-692AF676F6595E97B2C5092AABABAEB7" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,983</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1289-wk-Fact-E4F4407B25485D70A533213A9491A2D7" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,718</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1308-wk-Fact-FAED8DD3A6DD566D80863F977AC9EF02" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,570</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1328-wk-Fact-86CD37D81CF759D0A27823E5934F7C4A" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57,666</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating costs and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1348-wk-Fact-9ED1991307A05268AD61123A0D3A8507" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">127,958</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1367-wk-Fact-E86C60AAF8FF5E848B915CCA051C3C90" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">126,396</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1386-wk-Fact-89C470974F4B54AC86489111651001D4" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">411,152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1406-wk-Fact-96A2EA34A9FC5646ADEB07AE12D13A02" name="us-gaap:CostsAndExpenses" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">365,270</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) from operations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e1426-wk-Fact-F28A571EA9A556B189C76DAA5816B0E3" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">98,740</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e1446-wk-Fact-0295221CD3E85EE4917DAC4973709D0E" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">98,634</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e1466-wk-Fact-654252F668A95C1BB31855477C2F26A6" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">330,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1487-wk-Fact-1BC57A2830785FC48822967A10137C18" name="us-gaap:OperatingIncomeLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">788,227</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-operating income (expense):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e1589-wk-Fact-D2984EB146CF53A0A3D945CD9F6C484C" name="us-gaap:InterestExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,425</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e1609-wk-Fact-89E81FFBA1F359A3804311A524ED9638" name="us-gaap:InterestExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,442</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e1629-wk-Fact-E8729B69FC6B5DB98EB9E0772B1B6E42" name="us-gaap:InterestExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,882</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e1650-wk-Fact-90A3020EC53153A39B2EEBC5ADE7E243" name="us-gaap:InterestExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,167</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash interest expense on liability related to sale of future royalties</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e1671-wk-Fact-F7BC5B5CFD2C510582E628BD7AE75A83" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,813</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e1691-wk-Fact-0BA0B4AE955153EA84EB12424A57BC40" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,814</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e1711-wk-Fact-1259198267AB52A0ADD3A2BBBAEFD915" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,853</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e1732-wk-Fact-790B3066DF1D58ABA7DFD64D6C7CF71C" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,808</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income and other income (expense), net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1753-wk-Fact-1B686D885EE85A91A4B49036ECB3A97C" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,492</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1772-wk-Fact-19523F84434E55D597D1B771668E721A" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,847</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1791-wk-Fact-0D57A1B063D756A38C4F1D9BB05FF4BD" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,964</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1811-wk-Fact-16253954A07D54349C114A4480075116" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,523</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total non-operating income (expense), net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1831-wk-Fact-0A2BC7BC8ACC5AC29E8BDF8856CC05AC" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">254</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1850-wk-Fact-CA6B8053EFFF5FDC96521AB72B349F91" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,591</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1869-wk-Fact-00680C506E63565ABD274A4D74ECF6ED" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e1889-wk-Fact-FC38F4D8FB1C553CB81FC65EC5549874" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,452</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) before provision for income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e1910-wk-Fact-0D821D81FFF05400AAD5EFE802AAD6A0" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">98,486</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e1930-wk-Fact-60BB42A8992B5DF998DE60794D5DA4E8" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">97,043</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e1950-wk-Fact-7A8E714FDFB953AE87870CB99E6FAF39" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">328,168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1971-wk-Fact-3B7A5A9EB8735E8AAA57F26946D95565" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">782,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision (benefit) for income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e1991-wk-Fact-2C701C642FCC5010B2A0051ADBA279D0" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">322</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e2010-wk-Fact-75F7502996AF58A3BC9872E7D44EEE75" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">900</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e2030-wk-Fact-A1E1407F13B35D9CAFA734E23F33A5FE" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">939</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e2051-wk-Fact-77F3102C78CD5D48A9534FE23DC2890F" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e2076-wk-Fact-96FE79C957FC5199AFAE69FD1F6EB6B0" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">98,808</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e2096-wk-Fact-3CF3ED7F676A50F88B47DC66A978B759" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">96,143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e2116-wk-Fact-3ACDCA10646F5B9E86C244BF888CF7C6" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">327,229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e2137-wk-Fact-621CD3A72F9C55B69FC8DC281DF4A682" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">779,525</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per share</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e2322-wk-Fact-2B4FA178B0E85A918823DA71E31CC318" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e2342-wk-Fact-12F03FA832E25759BB4166B07348C42A" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e2362-wk-Fact-FA86278E7DF956348A12695AAB4E0039" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">1.87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e2383-wk-Fact-72BF57175E5A5595A068738551CB2202" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e2403-wk-Fact-A7BCEE5C4EB9548FAFABBBFC6F3D644A" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e2423-wk-Fact-382D09C09AB75B2293D6EE9DC8BE3124" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103454968e2443-wk-Fact-EB2D6943BD9F5B8B89BEE30D92071DEE" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">1.87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e2464-wk-Fact-6A969138F90F591A9A269DC3B74FE915" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding used in computing net income (loss) per share</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Basic</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e2561-wk-Fact-4E3BA6614B3254898B020C181B05D89C" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">175,402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e2580-wk-Fact-D1BECD626E1655A59E869A3926B49834" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">172,698</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e2599-wk-Fact-32954A9782F65EF6AF8C9B1C14D7E6C5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">174,609</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e2619-wk-Fact-5B7F965C19555DE79A4611B68C056ABA" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">168,363</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e2639-wk-Fact-7266EDB4F0E95917B90B5A3E12C8D4EC" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">175,402</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e2658-wk-Fact-B9469E1891B45E3BA1E0B780D3F0A438" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">172,698</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e2677-wk-Fact-722EAC3DDB1858D3B9A28AABB4E1835D" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">174,609</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103454968e2697-wk-Fact-EE8CC40D7AB351179347901C87AD0FA6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">179,619</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s0D107E80094E5FE89B8768C962112BD1"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NEKTAR THERAPEUTICS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103444155e568-wk-Fact-4AEE8CAB47425CC99B15CF03C14A0DD4" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">99,206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103444155e588-wk-Fact-2BE5910257E5586A8F486115BD622862" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">97,519</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103444155e608-wk-Fact-6CDF04BD3D545CB8B6029DC0D4377362" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">322,099</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103444155e629-wk-Fact-2A1F956172FD548BA22C5CB9797F07D5" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">776,258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF815B8342467580B95DBCA7C85C49AFD"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NEKTAR THERAPEUTICS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90817263544535%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:39%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three and nine months ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Par</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Excess of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Par Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Stockholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e670-wk-Fact-DADC43442816590BB46C918ED2DC3B7B" name="us-gaap:SharesOutstanding" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">173,530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e689-wk-Fact-337BEE240C83595A8C7817A72C6F98E4" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e708-wk-Fact-C1B0777DB6235649BFAECD51334A5102" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,147,925</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e728-wk-Fact-A21E86AF7C97576E88EC51BF25061539" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,316</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e748-wk-Fact-84A89777B3F752889D42D0B3A2FB51C6" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,424,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e768-wk-Fact-DCD6BC68154A5F7B8D85D40C60BE3EDB" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,717,575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Shares issued under equity compensation plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e784-wk-Fact-8EDD12D513235E2498D7F96DD32728F9" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">698</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e817-wk-Fact-96F941EB0B885127AA692E82E3990F04" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,463</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e875-wk-Fact-6FBF023C1AE3599E9857463058158D02" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,463</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e929-wk-Fact-6624CA703D16558C82FB6A74DA355969" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,385</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e987-wk-Fact-69B17CFF90F15944950C7E0EFA78AAA7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,385</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Other comprehensive income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1061-wk-Fact-F1DDFC6004E05E3AAC9864C52D1FEAEB" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1099-wk-Fact-EDD8FA9E41B154D6B77CD7804209B062" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e1192-wk-Fact-77A9FC586F9956BC95ED8C2C55460830" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">118,512</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e1212-wk-Fact-0A2BA8FD84315DA482DA33A1FB51AF9F" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">118,512</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1234-wk-Fact-7AB6A532E06F50ABA7614185B1B9F6A8" name="us-gaap:SharesOutstanding" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">174,228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1253-wk-Fact-4AA0A2B0A60F51269E34350DB74AE487" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1272-wk-Fact-371ABB72350B5EF3AE7B400195F85F11" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,178,773</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e1292-wk-Fact-34E8BC6B96D35C28A20F7E90F24743C9" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,716</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e1312-wk-Fact-C35431C4D2CC5DFBAA4D303E4993F260" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,542,563</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1332-wk-Fact-5EBD765E2D20500F850624417C076789" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,633,511</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Shares issued under equity compensation plans</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1348-wk-Fact-C2F1DC0135BF51D48E3CC80A8A828DC5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">738</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1381-wk-Fact-FF453767F7375077908C4406313DDD0E" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1439-wk-Fact-7DE98755F11C5671B5B348458F201402" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1493-wk-Fact-CD83B3C884A35221A9BFBCE7A55EDBD6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,522</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1551-wk-Fact-1D781EC4D88D56B48C71A71B63DEE5C5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,522</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Other comprehensive income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1625-wk-Fact-DFCAE5AA3634546DB37AE079BB349788" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1663-wk-Fact-2C072DDAE4AA5282AF39C2839E0F2FB0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e1757-wk-Fact-D5C4484D791F531185E23067C8CA469C" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">109,909</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e1777-wk-Fact-92AA5D47DBB158FBBAC38851B72A95BF" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">109,909</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1799-wk-Fact-1AB2858A72BE5813BA5809A73CFED188" name="us-gaap:SharesOutstanding" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">174,966</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1813-wk-Fact-37514D286F0A5A6DA6A5146890153073" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1832-wk-Fact-151DEA7D49A45EC1B431CF9D2EDB764F" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,210,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e1852-wk-Fact-265EC092832D5AFC94534A5835CDF8D2" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">788</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e1872-wk-Fact-B4DCFB0C2F17500DA379721C006AC509" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,652,472</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1892-wk-Fact-602A1B167F9A580B9FA1755F9189FBF6" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,557,155</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Shares issued under equity compensation plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1913-wk-Fact-B2435ABDCB14F364722722D7AF411B02" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">820</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e1946-wk-Fact-4ACD4394C2E388A7DAA822D7B1A14F5A" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,882</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e2004-wk-Fact-70FEB0FE24696AD6CD8D22D7B51A18E2" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,882</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e2058-wk-Fact-A03CDACA440B26602B7422D7DF4020FB" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,880</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e2116-wk-Fact-E47D157598F7D40575A622D7E2988E40" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,880</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Other comprehensive loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e2190-wk-Fact-3BAC4B80BD61036AA96122D80450A2C3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e2229-wk-Fact-3FDFE5CC340F457B326922D806B87310" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e2323-wk-Fact-FDC4F322AF8AFBE09D2F22D83CF432E0" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">98,808</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e2343-wk-Fact-96FE79C957FC5199AFAE69FD1F6EB6B0" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">98,808</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e2365-wk-Fact-C6AB9F278020E0FE744822D862D93A02" name="us-gaap:SharesOutstanding" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">175,786</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e2384-wk-Fact-6F2FBE86BCD15BF7CBC422D864592216" name="us-gaap:StockholdersEquity" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e2403-wk-Fact-63582AB361457D84F5AC22D865CEBADB" name="us-gaap:StockholdersEquity" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,241,160</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e2423-wk-Fact-396D0A7C0558B66098EC22D8674A9BB0" name="us-gaap:StockholdersEquity" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,186</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e2443-wk-Fact-1E6B98DA44402D0F461322D868BA8977" name="us-gaap:StockholdersEquity" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,751,280</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e2463-wk-Fact-B678F4F136865CEF9F87800AB7F87743" name="us-gaap:StockholdersEquity" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,488,711</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NEKTAR THERAPEUTICS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.72451790633609%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:38%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three and nine months ended September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Par</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Excess of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Par Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Stockholders&#8217;</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e2795-wk-Fact-4FF61FDBB1D559569EE84AC171B0C95C" name="us-gaap:SharesOutstanding" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">159,524</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e2814-wk-Fact-D08E4A0AB8E2516E87D720DA7D681531" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e2833-wk-Fact-BF6A637C186958C1BA99A1FAE176EC29" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,207,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e2853-wk-Fact-FB51F14B67AB5AA68B98B039194B7CC1" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e2873-wk-Fact-52A90500FDAD5AE9A1617C2424C67AE6" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,117,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e2893-wk-Fact-638D017E13EC5A578CA023A0F84DCF0B" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Adoption of new accounting standards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e2981-wk-Fact-2D128BFABB3E5ED3A5F6CFAB5260160B" name="us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1" contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,577</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3000-wk-Fact-8F366604C6DD59CE80A4FDFC7FF533FC" name="us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,577</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Shares issued under equity compensation plans</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3021-wk-Fact-847BBF041F6B5F889ABC3D215F6AA79B" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">2,855</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3035-wk-Fact-6BEB9F0E29815354A8C35EE742AD6599" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3054-wk-Fact-2CA2D4B452405BC09EF06EADB9ABDA40" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,405</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3112-wk-Fact-3A8EF5B7A8E35DC8A43C303BBCB241CD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,406</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3166-wk-Fact-96DE997E90BE513DB28D178F048B6310" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,949</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3224-wk-Fact-CC3EC7108A7653198197561C3344C215" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,949</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Other comprehensive loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e3298-wk-Fact-2CB0284F62C4560AB4BC42E09F0C2838" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e3337-wk-Fact-95ACA4FA92F25875B3D9B7BDED2C04A0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Net loss</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e3431-wk-Fact-0487349609C25432A3190C8796223524" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">95,792</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e3451-wk-Fact-E166094F0C5150DDA10E89E1F2ED9B7C" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">95,792</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at March 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3473-wk-Fact-7BA3BA0A6A565D7B91A339CAFF7A5487" name="us-gaap:SharesOutstanding" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">162,379</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3492-wk-Fact-4827443C64635C4EB4AE8355A8AA74D6" name="us-gaap:StockholdersEquity" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3511-wk-Fact-8C576092484B5A889E541F7456E0C0A8" name="us-gaap:StockholdersEquity" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,262,219</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e3531-wk-Fact-8949F78DBAE85C509F256D8D507A01F5" name="us-gaap:StockholdersEquity" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,796</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e3551-wk-Fact-82F5143336EB55238B9E61650879F609" name="us-gaap:StockholdersEquity" contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,201,156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3571-wk-Fact-4DF65A5733645C7E83B086D65E716558" name="us-gaap:StockholdersEquity" contextRef="FI2018Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Sale of stock to Bristol-Myers Squibb</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3587-wk-Fact-BE80ABAFC2D55DE0BAA00C1C1C2FC6CF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">8,285</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3601-wk-Fact-F72A3A6626765FDEB62E13E66B9CA525" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3620-wk-Fact-152176BF66855D08B5A79F7C91820D5F" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">790,230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3640-wk-Fact-FCF20C03087A56ABAB297DF149EFBE17" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3659-wk-Fact-997EEEC21A8251428EADDBAF6D72BCD4" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3678-wk-Fact-353804B17BEF5E5ABC798AF14DC7D019" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">790,231</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Shares issued under equity compensation plans</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3699-wk-Fact-6307FC334BEA576C997F7D4A5ADE72AF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,751</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3732-wk-Fact-3AB85DB5D5375CE2ABF3A50CC20A47DF" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,987</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3790-wk-Fact-4CAF59FD16DA5FC5B6E968F90BC26D9F" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,987</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3845-wk-Fact-ACA07E8F0D72593087760D3E024ACEFD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,659</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e3903-wk-Fact-A61FC157974353EE8BDAD4937D9D6E4F" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,659</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Other comprehensive loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e3977-wk-Fact-713109E16D7D52BBBC2805048634FF19" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e4016-wk-Fact-C1BBCFBDD58A58BD9E86D138E86D82FD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e4110-wk-Fact-0326D9D848945591A761D1AF6B3668E2" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">971,460</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e4129-wk-Fact-25BD7E955FD050B5BC61F5DAE33D628B" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">971,460</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at June 30, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e4150-wk-Fact-E16E6243F056524BB1733030A58810D7" name="us-gaap:SharesOutstanding" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">172,415</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e4169-wk-Fact-1D9B32EC5BB95A5CB475900CC1BC964F" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e4188-wk-Fact-36FC07465D29511F8F94B3C0895CDD3D" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,094,095</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e4208-wk-Fact-E5CAE93A4C3B59CEA8516F77684C7E2E" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e4228-wk-Fact-13AAE89FBFE25FBBB974938B4807F0D2" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,229,696</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e4248-wk-Fact-9371B22AAEAD589292A93A208F0E0907" name="us-gaap:StockholdersEquity" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,860,414</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Shares issued under equity compensation plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e4264-wk-Fact-05F6934A99355EF801B822DA91D6CC1A" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">642</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e4297-wk-Fact-9B2656E9F1723D64216822DA943D72A0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,940</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e4355-wk-Fact-42D663229332FE9E626322DA97B0AF19" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,940</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e4409-wk-Fact-5AA1B3568F0D8BEEFA2C22DAB79761A0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,287</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e4467-wk-Fact-92F309E5E28AFFDC189822DABB004EEB" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,287</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Other comprehensive loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e4541-wk-Fact-1BFE179C58E21EB8DD6B22DADDCFE06D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,376</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e4580-wk-Fact-C42CD8A49EB313E66DCC22DAE0BE0ECE" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,376</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e4674-wk-Fact-A2B92CA573ACA30FDDD422DAFD564CF1" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">96,143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e4694-wk-Fact-3CF3ED7F676A50F88B47DC66A978B759" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">96,143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e4716-wk-Fact-3A557D433F51FD238C0E22DB23256288" name="us-gaap:SharesOutstanding" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">173,057</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e4735-wk-Fact-94B3734880AD761CB87722DB24A2FE8D" name="us-gaap:StockholdersEquity" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e4754-wk-Fact-A8AD28537FBC654E296722DB2612CFF6" name="us-gaap:StockholdersEquity" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,121,322</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e4774-wk-Fact-36E76DAFD8DC22AFED4D22DB27928FBE" name="us-gaap:StockholdersEquity" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,378</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103439808e4794-wk-Fact-6F335128C8807470598622DB29008B6A" name="us-gaap:StockholdersEquity" contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,325,839</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439808e4814-wk-Fact-B51E314B44FE14BCB07B22DB2A80B4CE" name="us-gaap:StockholdersEquity" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,790,122</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><a id="s75F3C73D5EFA5D77818EC321969FC7B9"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NEKTAR THERAPEUTICS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e517-wk-Fact-2DAAF8D96463574CA92936C4E8414737" name="us-gaap:ProfitLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">327,229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e537-wk-Fact-20963A7CECAF5EFFB84B4E886DE55486" name="us-gaap:ProfitLoss" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">779,525</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash royalty revenue related to sale of future royalties</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e593-wk-Fact-68485AE8AC8756DBBFE076B40A0D5B21" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,585</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e613-wk-Fact-ECCC1D73CC045BFB8D6A26176917A7FA" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,337</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash interest expense on liability related to sale of future royalties</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e634-wk-Fact-1259198267AB52A0ADD3A2BBBAEFD915" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,853</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e653-wk-Fact-790B3066DF1D58ABA7DFD64D6C7CF71C" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,808</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e673-wk-Fact-B1BCA189DB1959319F6A8B4FBCF38A2E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">74,787</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e692-wk-Fact-3BC234129E875B5891EA667CAB9217B1" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,895</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e712-wk-Fact-CE06CB6A565853BCB452202AD1B852A2" name="us-gaap:DepreciationAndAmortization" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,582</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e731-wk-Fact-F85CEDD8C8B151E5AC969C63012B8189" name="us-gaap:DepreciationAndAmortization" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,799</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accretion of discounts, net and other non-cash transactions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e751-wk-Fact-F917255C50D85B37AE0D89B210210C49" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,421</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e771-wk-Fact-838C560380CB55718FC670E30176ABE3" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e834-wk-Fact-FB611C18F1565CC2A08BAC1220C6A9AE" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,008</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e853-wk-Fact-F6A882D16FD05CA99B232F321682BAAA" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e874-wk-Fact-334AC6E8E72758C4ADE8B35486D58BCD" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,339</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e894-wk-Fact-A96D5BD742F158838B0C0216AF69ECF0" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,570</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e915-wk-Fact-FFDEFCDF517D5E018BBAB60018898DBB" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e934-wk-Fact-F9BB4AFA211E529BB0FF29369A492BD2" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,087</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e955-wk-Fact-34C6600EFFA65763A04300E92A947713" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,109</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e974-wk-Fact-000C0CF9D6F55FECBAD8262AFE2A03C2" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,611</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e994-wk-Fact-ED3B34C4B6F55373AA84A137BEF2FA37" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,164</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1013-wk-Fact-14BD1F10905250A49857CBD8EF4EFD16" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,659</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1033-wk-Fact-C34F14BC11175744AB543A4E6497A0D6" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,019</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1052-wk-Fact-FE2E63C5737D5A219CA4BB69A9B64DE0" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,603</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e1072-wk-Fact-1D7EC5A95AA95CF39084C20853523AEF" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e1092-wk-Fact-D6CB98B2133C5B16A38BC851F5796880" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,931</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1113-wk-Fact-FE068176AE2D5A3E908BAFB841486D8F" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,932</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1132-wk-Fact-CDCD1E92E8C15DA79DE34E46A644C287" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,104</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e1157-wk-Fact-8155047C6E535DF4B3C6833AAFEA4E82" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">203,458</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1177-wk-Fact-C8A9638096FB5476B3F33448BAD63B8E" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">835,764</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from investing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e1233-wk-Fact-3BF9113144855AEE86D9E97A1314E623" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,028,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e1253-wk-Fact-74A6CBDF5F1255A9AFDFE74117DCD58B" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,944,178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities of investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1275-wk-Fact-7AABCE1BEB5E5367856075C8FD344826" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,122,902</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1294-wk-Fact-8C079234461B5C64B91863539C87EFF4" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">467,658</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales of investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1314-wk-Fact-26ED553E8D36563EAC8CA5D45436AB3B" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1333-wk-Fact-8D05DD808FE4505890C549F59C59D6AF" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,963</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e1353-wk-Fact-5E1D9B86CB4D58F590206C38DDD6C90C" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e1373-wk-Fact-A23D09F3C0E35F36B0C5F947624F70FA" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,552</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales of property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1394-wk-Fact-BADC636209AD568F83548A4E7CD9FECC" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1413-wk-Fact-39C3DAF22F17559CB5077609175DF1E5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,633</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1438-wk-Fact-FE92A87BD60B5147AE57ED4CDB208E3A" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,405</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e1457-wk-Fact-74BD4D36F8F158ACBB06E6EE5A65B575" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,467,476</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1514-wk-Fact-E1F6B23408E55A5C8013B4A37CF65ABB" name="nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1533-wk-Fact-88EBE07AFAC254F19551C24BA75E0533" name="nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">790,231</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from shares issued under equity compensation plans</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1553-wk-Fact-30F702F0C9A9541EA577CA8978A68705" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1572-wk-Fact-F5C28F62628A55BC9D216B08718D4016" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">59,067</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1597-wk-Fact-AB48D4722C17547CA9CF801184D5DDC7" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1616-wk-Fact-3FBA5CC68E2256B9864F4E87AFD47958" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">849,298</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of exchange rates on cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e1631-wk-Fact-3CCDCA85E1FB57F79AA08D2597659E60" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">77</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e1651-wk-Fact-5D422788DEC25542B4DAC6AB7CE2F356" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net increase (decrease) in cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103434252e1677-wk-Fact-E85E3C5F14EC59539D4C72A52FA68AF7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">113,681</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1697-wk-Fact-905A02AD6B8A5903A10F6E6F05AD84A6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">217,499</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1713-wk-Fact-5DBAF7AD834C50418F1605E1820A2C56" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">194,905</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1732-wk-Fact-EB6571B361DE5BA79BC94F06D047001B" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2017Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,762</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at end of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1757-wk-Fact-8FDF80523DC7573BA5267FF6D33529BD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">81,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1776-wk-Fact-F682FB2FC7C151E0A4657211F14CF402" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">222,261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental disclosures of cash flow information:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for interest</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1837-wk-Fact-1CB5FBC8391E5EC3B7D0EB6655C10693" name="us-gaap:InterestPaidNet" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1856-wk-Fact-0CD9A21F3C315F6F8B29FEADD49BAC41" name="us-gaap:InterestPaidNet" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,701</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets recognized in exchange for lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1876-wk-Fact-1AD12742B8FAF4B4E9BE42504430ECB4" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">56,025</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434252e1895-wk-Fact-4045D05D733B3F00D1864250447892C1" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><a id="s894AA03583E45D339BD474D8F245FC00"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NEKTAR THERAPEUTICS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, 2019</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div><a id="s74E6E43889D150FF94BB64EEDD75AE0C"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 1 &#8212; <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="TextSelection-9F10E181172155F081E82E7D18805DD2-0-wk-Fact-BE3B4B882A8357D4815343ACD8A7ADF8" continuedAt="TextSelection-9F10E181172155F081E82E7D18805DD2-1" escape="true">Organization and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-9F10E181172155F081E82E7D18805DD2-1" continuedAt="TextSelection-9F10E181172155F081E82E7D18805DD2-2"><ix:nonNumeric contextRef="FD2019Q3YTD" name="nktr:OrganizationPolicyTextBlock" id="TextSelection-41B1447C37BD50E790B98EF5435826C4-0-wk-Fact-580B7C6DAE105FB49B643D9D9131733A" continuedAt="TextSelection-41B1447C37BD50E790B98EF5435826C4-1" escape="true"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Organization</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes treatments for cancer, autoimmune disease and chronic pain.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-41B1447C37BD50E790B98EF5435826C4-1">Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</ix:continuation> At </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103434634e376-wk-Fact-874CA20948255B3FA3DDADAF3CC44BA5" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" contextRef="FI2019Q3" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.7</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> in cash and investments in marketable securities and debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103434634e380-wk-Fact-DA055AF3B6A658AE91A44C5F4073DE16" name="us-gaap:SeniorNotes" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">250.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in principal of senior secured notes due in </span><span style="font-family:inherit;font-size:10pt;">October 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ConsolidationPolicyTextBlock" id="TextSelection-9B467C3B9E1D5C6E8C58E9CA9194E3C3-0-wk-Fact-546AB5A36E355CB9BD5545BABF32A9AE" escape="true"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our consolidated financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries:  Inheris Biopharma, Inc., Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our comprehensive income (loss) consists of our net income (loss) plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities, neither of which were significant during the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. In addition, there were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> filed with the SEC on March 1, 2019. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:UseOfEstimates" id="TextSelection-04AF13CBF1925D75A2910A32CC997337-0-wk-Fact-F136220799515852ADB8515F8A39E7DA" continuedAt="TextSelection-04AF13CBF1925D75A2910A32CC997337-1" escape="true"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-9F10E181172155F081E82E7D18805DD2-2" continuedAt="TextSelection-9F10E181172155F081E82E7D18805DD2-3"><ix:continuation id="TextSelection-04AF13CBF1925D75A2910A32CC997337-1"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.</span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="TextSelection-6B92C60D8D185E90AF6BDCC4D193576F-0-wk-Fact-88CD074AF4BD5418BE65C2527C4EA426" escape="true"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We operate in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434634e476-wk-Fact-E2E68A2CBE8F5220B3B1ADDE3571CA61" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2019Q3YTD" unitRef="U_nktrSegment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434634e480-wk-Fact-E2E68A2CBE8F5220B3B1ADDE3571CA61" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2019Q3YTD" unitRef="U_nktrSegment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> business segment by our Chief Executive Officer.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ConcentrationRiskCreditRisk" id="TextSelection-682F12D598E15647AB35EF0280D925FF-0-wk-Fact-169774DFD9E85C0BB39B816FDB4420D2" escape="true"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant Concentrations</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones, other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, our accounts receivable includes </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103434634e502-wk-Fact-3DC0219196A65CF29AEA8E8D49BEF29C" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q3_srt_CounterpartyNameAxis_nktr_CollaborationPartnerMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103434634e506-wk-Fact-E9B861B8067B58BABC4CAF4AFAFB3127" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2018Q4_srt_CounterpartyNameAxis_nktr_CollaborationPartnerMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, for net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS). </span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:LesseeLeasesPolicyTextBlock" id="TextSelection-965090F40245504B8199C57DBFF72EFE-0-wk-Fact-890AF05245A95C34A174C36F023BD747" continuedAt="TextSelection-965090F40245504B8199C57DBFF72EFE-1" escape="true"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2019, we adopted Accounting Standards Codification (ASC) 842, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (ASC 842). ASC 842 supersedes the guidance in ASC 840, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (ASC 840). Under ASC 842, an entity recognizes a right-of-use asset and a corresponding lease liability, measured as the present value of the lease payments. In our adoption, we used the package of practical expedients, which, among other things, allowed us to carry forward our historical lease classification of those leases in effect as of January 1, 2019. We present results for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> under ASC 842. We have not restated the results for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and our financial position as of December 31, 2018, and continue to report them under ASC 840.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. However, in determining the present value of our lease payments for leases in effect when we adopted ASC 842, we used our incremental borrowing rate as of January 1, 2019. </span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our real estate leases, and elected the short-term lease recognition exemption for our short-term leases, which allows us not to recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-965090F40245504B8199C57DBFF72EFE-1">We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts. For leases in effect as of January 1, 2019, we recognized our lease incentives as part of our transition adjustment.</ix:continuation> </span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of our adoption of ASC 842, we recorded right-of-use assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103434634e567-wk-Fact-5C187D19796574065CA222E16FA392ED" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">83.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103434634e571-wk-Fact-843518803F3FAA95112D22E1AA321B74" name="us-gaap:OperatingLeaseLiability" contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">96.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for our facilities operating leases, with </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434634e575-wk-Fact-7519867B8CBEFAF2BD5423ED7409E613" name="us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1" contextRef="D2019Q1Jan1-Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> effect on our opening balance of accumulated deficit. Please see Note 4 for additional information regarding our leases.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-9F10E181172155F081E82E7D18805DD2-3" continuedAt="TextSelection-9F10E181172155F081E82E7D18805DD2-4"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="TextSelection-FD8CF47F19F054068F966E87407AFE39-0-wk-Fact-F74B435CA8875637B94E2C9DFD7860A5" escape="true"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:inherit;font-size:10pt;"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="TextSelection-9FA6AF816D2E505C912EEB43978588E8-0-wk-Fact-A91CEEFEC6BB54E6B8063093D0C53FDD" continuedAt="TextSelection-9FA6AF816D2E505C912EEB43978588E8-1" escape="true"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Sales</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Royalty Revenue</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Generally, we are entitled to royalties from our collaboration partners based on the net sales of their approved drugs that are marketed and sold in one or more countries where we hold royalty rights. For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-9F10E181172155F081E82E7D18805DD2-4" continuedAt="TextSelection-9F10E181172155F081E82E7D18805DD2-5"><ix:continuation id="TextSelection-9FA6AF816D2E505C912EEB43978588E8-1"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">License, Collaboration and other Revenue</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">License Grants</span><span style="font-family:inherit;font-size:10pt;">:&#160;For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Milestone Payments</span><span style="font-family:inherit;font-size:10pt;">:&#160;At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">a clinical study or filing for or receipt of regulatory approval, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. Our partners generally pay development milestones</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">subsequent to</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">achievement of the triggering event.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Services</span><span style="font-family:inherit;font-size:10pt;">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="TextSelection-D562C6FC70A15B1CA23FE285D4CB883C-0-wk-Fact-4A2FCF1A6D7655E59044C25B3B270966" continuedAt="TextSelection-D562C6FC70A15B1CA23FE285D4CB883C-1" escape="true"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expense</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a clinical joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined to be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-9F10E181172155F081E82E7D18805DD2-5"><ix:continuation id="TextSelection-D562C6FC70A15B1CA23FE285D4CB883C-1"><div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div></ix:continuation><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:IncomeTaxPolicyTextBlock" id="TextSelection-E3D24D29990850B3B283F2CF9605548F-0-wk-Fact-247824AB65E05E8A86D5A5875484D9EB" escape="true"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we recorded an income tax provision for our Nektar India operations at an effective tax rate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434634e705-wk-Fact-812330CC110755E5BE87422BDFC1128D" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q3YTD_srt_StatementGeographicalAxis_country_IN" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">33</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">. Due to our net loss and unrealized gain on available-for-sale securities in the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we recorded a tax provision against such unrealized gain with an offsetting tax benefit in continuing operations of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103434634e713-wk-Fact-415803F94B8856AA8A621A12A6FC5561" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. For the three months ended September 30, 2019, however, since we had a loss on our available-for-sale securities, we recorded a benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103434634e718-wk-Fact-8264B6782CC0450A7EB51986A15F286D" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> against our unrealized loss in available-for-sale securities with an offsetting expense in continuing operations. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, as a result of taxable income in India and the U.S., resulting primarily from income recognized from the upfront payment from BMS, we recorded a global income tax provision at an effective tax rate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103434634e731-wk-Fact-383B1D05F26C50ACB1215E7FE25CA54E" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2018Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">. The income tax benefit for the three months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> reflects our pre-tax loss for that period. Our income resulted in tax liabilities in certain states where we did not have sufficient net operating losses to offset our estimated apportioned taxable income. Our effective tax rate was based on certain assumptions and other estimates regarding the apportionment of taxable income and the states in which we had nexus in 2018. Our apportionment of taxable income included estimates of the apportionment of the BMS upfront payment based on estimates of activities to be carried out under the collaboration agreement with BMS, as well as estimates of the apportionment of other sources of income. Our effective tax rate reflected the release of the valuation allowance of net operating loss carryforwards and other tax credits to offset U.S. federal and state taxable income. </span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-390FCB32C82A5A6C86DC6394905DC0B6-0-wk-Fact-9EE86353D1825AA8B538FE60AC7843AB" escape="true"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is effective in the first quarter of 2020 and should be applied retrospectively to January 1, 2018, when we adopted ASC 606. Early adoption is permitted. We are evaluating the effect of adoption, but we do not expect a material effect on our revenue.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#8220;incurred loss&#8221; model with an &#8220;expected loss&#8221; model. Accordingly, we will present these financial assets at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. ASU 2016-13 is effective in the first quarter of 2020. Early adoption is permitted. We are currently evaluating the impact of adoption of this ASU, but we do not anticipate that adoption will have a material effect on our Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC508BFB88D4450C6B8226338B1E89129"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 2 &#8212; <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-3592237DF8FF555A9324FCCD34254E8D-0-wk-Fact-C44B908FDD9650BCA339BB55F9BDAA78" continuedAt="TextSelection-3592237DF8FF555A9324FCCD34254E8D-1" escape="true">Cash and Investments in Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="TextSelection-3592237DF8FF555A9324FCCD34254E8D-1" continuedAt="TextSelection-3592237DF8FF555A9324FCCD34254E8D-2"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="TextSelection-77E59C22B45855EA8C324B7EDB0AB223-0-wk-Fact-EDB879DAE35C5F5B989F1222FFA37BCC" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value at</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e473-wk-Fact-C7A2AE7C68775A439814DA049308CCE0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">81,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e492-wk-Fact-0A046CD4CFDD5C44AB78FE4E6C5314BD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">194,905</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e507-wk-Fact-0AEF18E786665F2FAEBCBCB3D5386580" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,414,448</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e526-wk-Fact-D62AACC5E6A9595AA4AC531814DAB31B" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,140,445</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e546-wk-Fact-0D4AE566CE7B54188DDCDEB656199CE3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">231,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e565-wk-Fact-326539B35D8A5187AE1F3CF50F026C2B" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">582,889</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash and investments in marketable securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e590-wk-Fact-452068453D9854C3A344E31FEA012C2C" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,726,754</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e609-wk-Fact-BC24C8C3E6CB5CDD97DFE80E883AC03B" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,918,239</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, all of our long-term investments had maturities between </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d103443569e633-wk-Fact-54B56E3EC0E552E391CD042272F07229" name="nktr:LongTermInvestmentMaturityPeriod" contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:durwordsen">two years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross unrealized gains and losses were not significant at either </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">. During the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the three months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, we sold </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e661-wk-Fact-EDD865A6822A5D0DA3A0A430EE25EBBE" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> available-for-sale securities. During the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, we sold available-for-sale securities totaling&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103443569e673-wk-Fact-35E565DFCA33574A83F4A171CC060DA0" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and  gross realized gains and losses on those </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> sales were not significant.&#160;The cost of securities sold is based on the specific identification method.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of our </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e684-wk-Fact-C747187FE4075737A0C77A757CC065AB" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2015Q4Oct5_us-gaap_DebtInstrumentAxis_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">7.75</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> senior secured notes due </span><span style="font-family:inherit;font-size:10pt;">October 2020</span><span style="font-family:inherit;font-size:10pt;">, we are required to maintain a minimum cash and investments in marketable securities balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103443569e692-wk-Fact-2502601DF59758C88DED2B4948938804" name="nktr:MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained" contextRef="I2015Q4Oct5_us-gaap_DebtInstrumentAxis_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="TextSelection-693315B671E55D158B9A10FC0C1BFE1A-0-wk-Fact-510731A5AE4B5C3C8EEBE3E0A6B027ED" escape="true"><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our portfolio of cash and investments in marketable securities includes (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:59%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value at</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hierarchy</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate notes and bonds</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e849-wk-Fact-C4DEA3487976526CBF8B57CACFA41208" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,163,575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e868-wk-Fact-578814FE32865973943583F6DE0CFA5F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,288,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e893-wk-Fact-B6B8E77E09C25EC6AB028617608B8531" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">482,468</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e912-wk-Fact-2890B0589C675C4292AD933AEDD49963" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">498,048</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Obligations of U.S. government agencies</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e942-wk-Fact-C90B144A80615D0BBDD8413BA7505171" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e961-wk-Fact-CC653838F4065AF891B90490D6AD82EB" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,977</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e991-wk-Fact-4D582123064C5C1BB4908253D108A499" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,646,043</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e1010-wk-Fact-060C748118A05634A54DDA9E0AB061D4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,800,011</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e1040-wk-Fact-D180B1300ABD5654A115E1907ACF69C5" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">45,674</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e1059-wk-Fact-1C0803938E5D5BA9AF966C2C078A97A5" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">105,656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificate of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">N/A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e1089-wk-Fact-57009B04F7E65B4DB21FF8CC0DA6691A" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,871</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e1108-wk-Fact-88090A1967EB518292A8F4CA17199479" name="us-gaap:InvestmentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,760</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">N/A</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e1138-wk-Fact-3258BF2B60BC5FBB9DF50CFF657DD474" name="us-gaap:Cash" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e1157-wk-Fact-3A4507E3EC105EA690067B38AB5E175F" name="us-gaap:Cash" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,812</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash and investments in marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e1192-wk-Fact-452068453D9854C3A344E31FEA012C2C" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,726,754</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e1211-wk-Fact-BC24C8C3E6CB5CDD97DFE80E883AC03B" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,918,239</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">____________________________</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;1&#160;&#8212;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities.</span></div></td></tr></table><div style="line-height:120%;padding-left:84px;text-indent:-84px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;2&#160;&#8212;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div></td></tr></table><div style="line-height:120%;padding-left:84px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-left:84px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We use a market approach to value our Level 2 investments. The disclosed fair value related to our investments is based on market prices from a variety of industry standard data providers and generally represents quoted prices for similar assets in active markets or has been derived from observable market data. </span></div><div style="line-height:120%;padding-left:84px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-left:84px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e1266-wk-Fact-AD8E00F6814C57708C4F385FB1153096" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" contextRef="FI2019Q3" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> transfers between Level 1 and Level 2 of the fair value hierarchy.</span></div><div style="line-height:120%;padding-left:84px;text-indent:-84px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;3&#160;&#8212;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></td></tr></table></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-3592237DF8FF555A9324FCCD34254E8D-2"><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, based on a discounted cash flow analysis using Level 3 inputs including financial discount rates, we believe the fair value of the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103443569e1286-wk-Fact-2E52C9AF45265AA7A4FA0FD8998C6248" name="us-gaap:SeniorNotes" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">250.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in principal amount of our </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103443569e1290-wk-Fact-0EFEA024259A5F32B12116BFED63536D" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">7.75</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> senior secured notes due </span><span style="font-family:inherit;font-size:10pt;">October 2020</span><span style="font-family:inherit;font-size:10pt;"> is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103443569e1298-wk-Fact-30030661BAA05A9C8AA2F945CA59F815" name="us-gaap:NotesPayableFairValueDisclosure" contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">252.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. We may redeem some or all of these notes at a redemption price equal to the principal amount of the notes plus accrued and unpaid interest to the redemption date.</span></div></ix:continuation><div><a id="sD5D10B29172B57B2B7AFBD8B5E7D072B"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 3 &#8212; <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-C3C7CCBEA9F554589F0EF07A8310C415-0-wk-Fact-AB930819968754D882F414F40751A274" continuedAt="TextSelection-C3C7CCBEA9F554589F0EF07A8310C415-1" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="TextSelection-C3C7CCBEA9F554589F0EF07A8310C415-1"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-E620C21816F2526FBDBDDB0A51935D81-0-wk-Fact-31042DCB06C950789E1F2A4F571ECBDA" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory consists of the following (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103456137e433-wk-Fact-8C17B3DE2C4B5039B91373D1C61F8A83" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,586</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103456137e452-wk-Fact-4371DF8B88085AFEBB352CDEE956E9B3" name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,846</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103456137e467-wk-Fact-B53AD903DF40589C983E4EC254D7ACEC" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,961</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103456137e486-wk-Fact-D3E285C1776E582B88C9267973DB9B32" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103456137e506-wk-Fact-5EE919FAF3ED51AC9B34F615CD20ACEE" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,173</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103456137e525-wk-Fact-9CBC70D89D3F59C08DE240ECF986A900" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,132</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103456137e550-wk-Fact-D3F1F8DC7AB6516098B11FCDFB3E6D69" name="us-gaap:InventoryNet" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,720</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103456137e569-wk-Fact-59492ABDF60153D4BA438B78B7470CB8" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,381</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value i<ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:InventoryPolicyTextBlock" id="TextSelection-FC18D540BE0955ABAB41C5B954E9B767-0-wk-Fact-A9F3A57B280858258B2499F2D70E99A0" escape="true">nventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.</ix:nonNumeric> Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.</span></div></ix:continuation><div><a id="s322C960D7D9C5B90A8332C829AEEA5D8"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 4 &#8212; <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:LesseeOperatingLeasesTextBlock" id="TextSelection-EE714ED2BE2F50249C54A8D80A3A67E4-0-wk-Fact-8C9C421130195E47B87AE7E349E64947" continuedAt="TextSelection-EE714ED2BE2F50249C54A8D80A3A67E4-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="TextSelection-EE714ED2BE2F50249C54A8D80A3A67E4-1" continuedAt="TextSelection-EE714ED2BE2F50249C54A8D80A3A67E4-2"><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2017, we entered into a Lease Agreement (the Mission Bay Lease) with ARE-San Francisco No. </span><span style="font-family:inherit;font-size:10pt;">19</span><span style="font-family:inherit;font-size:10pt;">, LLC (ARE) and terminated our sublease with Pfizer, Inc., effectively extending our lease term from </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">2030</span><span style="font-family:inherit;font-size:10pt;"> for our </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e373-wk-Fact-008C65BF8D075B55AEF8B097DC044382" name="nktr:AreaOfLeasedSpace" contextRef="I2017Q3Aug31_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">145,085</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square foot corporate office and R&amp;D facility located at 455 Mission Bay Boulevard, San Francisco, California (the Mission Bay Facility). The term of the Mission Bay Lease commenced on </span><span style="font-family:inherit;font-size:10pt;">September&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, and will expire on </span><span style="font-family:inherit;font-size:10pt;">January&#160;31, 2030</span><span style="font-family:inherit;font-size:10pt;">, subject to our right to extend the term of the lease for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e386-wk-Fact-881048915EAF570B8699A110BF53E6D0" name="nktr:NumberOfConsecutiveFiveYearTermsToExtendLease" contextRef="D2017Q3Aug01-Aug31_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember" unitRef="extension_period" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> consecutive </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year periods, which we have excluded from our determination of the lease term. The monthly base rent for the Mission Bay Facility will escalate over the term of the lease at various intervals. During the term of the Mission Bay Lease, we are responsible for paying our share of operating expenses specified in the lease, including utilities, common area maintenance, insurance and taxes. The Mission Bay Lease also obligates us to rent from ARE a total of an additional approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e394-wk-Fact-C70CF1BDD37C5AEE8371A706ADFE963C" name="nktr:AdditionalSpaceRequiredToBeLeasedInFuture" contextRef="I2017Q3Aug31_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember" unitRef="sqft" decimals="-3" scale="0" format="ixt:numdotdecimal">8,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet of space at the Mission Bay Facility. During the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, ARE delivered </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e407-wk-Fact-B7908C13394B53A4A0A8932C9420F583" name="nktr:AreaOfLeasedSpace" contextRef="FI2019Q3_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">10,729</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet of space, and therefore we recognized right-of-use assets and lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103440843e411-wk-Fact-F47A040E17685F49B1E9C6EFF5E9EFFF" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q3YTD_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the space. The Mission Bay Lease includes various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2018, we entered into a Lease Agreement (the Third Street Lease) with Kilroy Realty Finance Partnership, L.P. (Kilroy) to lease </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e418-wk-Fact-6B83716C9F86548DB279E6A56CAC0F2F" name="nktr:AreaOfLeasedSpace" contextRef="I2018Q2May31_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">135,936</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet of space located at 360 Third Street, San Francisco, California (the Third Street Facility) from June 2018 to </span><span style="font-family:inherit;font-size:10pt;">January&#160;31, 2030</span><span style="font-family:inherit;font-size:10pt;">, subject to our right to extend the term for a consecutive </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year period, which we have excluded from our determination of the lease term. Kilroy delivered an initial </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e430-wk-Fact-3AEC16750D2051F68DD8DFC231721B3D" name="nktr:AreaOfLeasedSpace" contextRef="FI2018Q2_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">1,726</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet in June 2018, a total of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e434-wk-Fact-CD744E2EEF6D5E9BB316143029EFFB03" name="nktr:AreaOfLeasedSpace" contextRef="FI2018Q4_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">67,105</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e439-wk-Fact-3F12AE63FDCD53C4A18B37112104ABCF" name="nktr:NumberOfLeasedSpacesDelivered" contextRef="D2018Q4Dec1-Dec31_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember" unitRef="space" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> additional spaces in December 2018, and the final </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e443-wk-Fact-63230AED80CB37233214239723E714C3" name="nktr:AreaOfLeasedSpace" contextRef="I2019Q3Aug31_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">67,105</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> square feet for four spaces in August 2019. As a result of the delivery of the final spaces during the nine months ended September 30, 2019, we recognized an additional right-of-use asset and lease liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103440843e447-wk-Fact-285D09B136852E2BC27F2398A8B5E8FA" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q3YTD_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">51.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The Third Street Lease provides us additional facilities to support our San Francisco-based R&amp;D activities. Our fixed monthly base rent on an industrial gross lease basis includes certain expenses and property taxes paid directly by the landlord and will escalate each year over the term at specified intervals. We have a one-time right of first offer with respect to certain additional rental space at the Third Street Facility. The Third Street Lease includes various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-EE714ED2BE2F50249C54A8D80A3A67E4-2" continuedAt="TextSelection-EE714ED2BE2F50249C54A8D80A3A67E4-3"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:LeaseCostTableTextBlock" id="TextSelection-DD6EA6A203F35E99B03B7BFCC4757768-0-wk-Fact-5777A52251A559A29F22ACDCABB9B0C3" escape="true"><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of lease costs, which we include in operating expenses in our Condensed Consolidated Statements of Operations, were as follows (in thousands):</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80842911877394%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e656-wk-Fact-5962E9FB825F5FD68503ECB1E1E081B7" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e675-wk-Fact-7F7764E1040652829496577575856B71" name="us-gaap:OperatingLeaseCost" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,927</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e694-wk-Fact-EDB4BCA820EE5A3291A60DCA1C469788" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,030</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e714-wk-Fact-1AACE147EAA853D0AE76241409FB807F" name="us-gaap:OperatingLeaseCost" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,651</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e729-wk-Fact-3FDAFB0917ED5CF581D7038EF66C01A6" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,485</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e748-wk-Fact-F6B3B80738BC5D28B2E411FEACF4B1CF" name="us-gaap:VariableLeaseCost" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,096</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e767-wk-Fact-3C9517648E5B544AA09FE2C3F8B621E0" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,539</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e787-wk-Fact-42531FA67F1B5C4CA67CC5C822B019B6" name="us-gaap:VariableLeaseCost" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e812-wk-Fact-C0A5E2A13CF6530E9F003066ED480188" name="us-gaap:LeaseCost" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,601</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e831-wk-Fact-734F048FD1FE54F2964D29C2D8E7D9D3" name="us-gaap:LeaseCost" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,023</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e850-wk-Fact-7C0D117FE2855F25BB0CDFF860D53776" name="us-gaap:LeaseCost" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,569</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e870-wk-Fact-58B94252FA8558419A0A7BF9C3995F6D" name="us-gaap:LeaseCost" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,022</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we paid </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103440843e890-wk-Fact-E748631121585B86AD96285AEBF58721" name="us-gaap:OperatingLeasePayments" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for amounts included in the measurement of lease liabilities, which we include in net cash provided by (used in) operating activities in our Condensed Consolidated Statement of Cash Flows.</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="TextSelection-8C893C1C71B759FAA5D0CF6C70DD38BA-0-wk-Fact-D63C5CA1104B5BDA93EA980EEB5F928D" escape="true"><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the maturities of our operating lease liabilities were as follows (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:88%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year ended December&#160;31,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">2019 (Three months ended)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e949-wk-Fact-4857ACA474A55146ABFC2935C0129749" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,400</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e964-wk-Fact-56DD175A00355961B599A217199CC69B" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e984-wk-Fact-A235C401ECD95479A78B6B8482C3FCEF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,026</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e1004-wk-Fact-776A34B72EF65269AF2E7587B43D2666" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,633</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e1024-wk-Fact-75FD17CF06F75FB58EDCECA15517D206" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e1044-wk-Fact-967E2CD90AED5930B42B7106D70F83B7" name="nktr:LesseeOperatingLeaseLiabilityPaymentsDueYearSix" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,899</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e1064-wk-Fact-977C4B7863CE5907B1FDA70E1357FDE6" name="nktr:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">116,881</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e1084-wk-Fact-9D2B53C824805F7EABD7F58189C71A52" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">214,379</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: portion representing interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103440843e1104-wk-Fact-333505C2379457AAA97191E24EDE0E64" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">56,621</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: lease incentives</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103440843e1125-wk-Fact-E52953FAB1B15E58A3AC9AC61A0D4429" name="nktr:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,341</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e1147-wk-Fact-B0A07921E12252CE9DD043CB2188E81B" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,417</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: current portion</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103440843e1167-wk-Fact-9DF62218E4F95D648FC7684BADFBFC0A" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,318</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities, less current portion</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e1193-wk-Fact-4DC14A4ACA6254F9876DFB66F2EAAF81" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">145,099</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><ix:continuation id="TextSelection-EE714ED2BE2F50249C54A8D80A3A67E4-3" continuedAt="TextSelection-EE714ED2BE2F50249C54A8D80A3A67E4-4"><span style="font-family:inherit;font-size:10pt;"> As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the weighted-average remaining lease term is </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d103440843e1209-wk-Fact-0AF0B2D52CA45A0090A6279E63B6AFFC" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2019Q3" format="ixt-sec:duryear">10.3</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;"> and the weighted-average discount rate used to determine the operating lease liability was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103440843e1213-wk-Fact-26B9302C971A5BDF90946A3100B42D5F" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2019Q3" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">5.9</ix:nonFraction>%</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-EE714ED2BE2F50249C54A8D80A3A67E4-4">.</ix:continuation> </span></div><div><a id="s6AD49F2EBEA557B4B9B6FDE3BD2DF504"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 5 &#8212; <ix:nonNumeric contextRef="FD2019Q3YTD" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" id="TextSelection-DD0137CEB54F50E5A3DA2AA225D426B8-0-wk-Fact-FC85B41CAD6F5B37800B2B4AD10C92B5" continuedAt="TextSelection-DD0137CEB54F50E5A3DA2AA225D426B8-1" escape="true">Liability Related to Sale of Future Royalties</ix:nonNumeric></span></div><ix:continuation id="TextSelection-DD0137CEB54F50E5A3DA2AA225D426B8-1" continuedAt="TextSelection-DD0137CEB54F50E5A3DA2AA225D426B8-2"><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February&#160;24, 2012, we entered into a Purchase and Sale Agreement (the Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the Royalty Entitlement) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103442172e369-wk-Fact-B9FE5E408E0B53E993840FA707CC6443" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" contextRef="D2012Q1Feb23-Feb24_us-gaap_TypeOfArrangementAxis_nktr_PurchaseAndSaleAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">124.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the Royalty Entitlement.&#160;As part of this sale, we incurred approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103442172e373-wk-Fact-4612CBCEDC845D16979AB281456671F2" name="us-gaap:DeferredFinanceCostsGross" contextRef="I2012Q1Feb24_us-gaap_TypeOfArrangementAxis_nktr_PurchaseAndSaleAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in transaction costs, which are amortized to interest expense over the estimated life of the Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from the CIMZIA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and MIRCERA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103442172e386-wk-Fact-B9FE5E408E0B53E993840FA707CC6443" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" contextRef="D2012Q1Feb23-Feb24_us-gaap_TypeOfArrangementAxis_nktr_PurchaseAndSaleAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">124.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in proceeds from this transaction as a liability (Royalty Obligation) that is amortized using the interest method over the estimated life of the Purchase and Sale Agreement as royalties from the CIMZIA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and MIRCERA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> products are remitted directly to RPI. During the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, we recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103442172e411-wk-Fact-CECA3421CBAA5EFA9ED156A9DB12AEE0" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103442172e415-wk-Fact-88D8E1E2AE975C8288293F1DF1579747" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">24.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in non-cash royalty revenue from net sales of CIMZIA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and MIRCERA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, and we recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103442172e428-wk-Fact-FD5B6128CF1152C681F230977954AE2C" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103442172e432-wk-Fact-7DE8976D395D56E69482BA4F1E5675E0" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of related non-cash interest expense.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2019Q3YTD" name="nktr:LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" id="TextSelection-D25874D9328E5A1E9C0FC77EF5C500F0-0-wk-Fact-6A2D74E99AE3581995CC976FE13AAED6" escape="true">We periodically assess the estimated royalty payments to RPI from UCB and Roche, and, to the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different from our original estimates, we will prospectively adjust the amortization of the Royalty Obligation.</ix:nonNumeric> From inception through </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, our estimate of the total interest expense on the Royalty Obligation resulted in an effective annual interest rate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442172e448-wk-Fact-99B07B7962C951148396D6C6975F6AEB" name="nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" contextRef="D2012Q4Feb23-Dec31" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">17</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">. During the three months ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">, our estimate of the effective annual interest rate over the life of the agreement increased to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442172e456-wk-Fact-B26C46A1500C5013AE605E400A6D3A34" name="nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" contextRef="FD2017Q4QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">17.6</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, which resulted in a prospective interest rate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442172e460-wk-Fact-F35A3981408C5EAEAA2C2E8334021E6D" name="nktr:ProspectiveInterestRatePercentage" contextRef="FD2017Q4QTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">.&#160;&#160;During the three months ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, primarily </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-DD0137CEB54F50E5A3DA2AA225D426B8-2"><div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">as a result of increases in the forecasted sales of MIRCERA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, our estimate of the effective annual interest rate over the life of the agreement increased to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442172e476-wk-Fact-F99891C017465AABAC5F3FC02D39B577" name="nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" contextRef="FD2018Q4QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">18.7</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, which results in a prospective interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442172e480-wk-Fact-428520AC777651BABEE74026D6AB45DC" name="nktr:ProspectiveInterestRatePercentage" contextRef="FD2018Q4QTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">29</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Purchase and Sale Agreement grants RPI the right to receive certain reports and other information relating to the Royalty Entitlement and contains other representations and warranties, covenants and indemnification obligations that are customary for a transaction of this nature. To our knowledge, we are currently in compliance with these provisions of the Purchase and Sale Agreement; however, if we were to breach our obligations, we could be required to pay damages to RPI that are not limited to the purchase price we received in the sale transaction.</span></div></ix:continuation><div><a id="s2C89B67805365F1AAFCBAC0E07F594D8"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 6 &#8212; <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-CA7F0F1D64A55A8AA72451E9B3F11423-0-wk-Fact-B90B9FE7EE0A5D7A8E980875B117EFF0" continuedAt="TextSelection-CA7F0F1D64A55A8AA72451E9B3F11423-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-CA7F0F1D64A55A8AA72451E9B3F11423-1"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Matters</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 30, 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California, which complaint was subsequently amended on May 15, 2019.&#160;&#160;Also, on February 13, 2019, and February 18, 2019, shareholder derivative complaints were filed in the U.S. District Court for the District of Delaware naming the CEO, CFO and certain members of Nektar&#8217;s board. Both the class action and shareholder derivative actions assert, among other things, that for a period beginning at least from November 11, 2017 through October 2, 2018, our stock was inflated due to alleged misrepresentations about the efficacy and safety of NKTR-214. In addition, on August 19, 2019, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California, which complaint asserted, among other things, that for a period between February 15, 2019 and August 8, 2019, inclusive, our stock was inflated due to an alleged failure to disclose a NKTR-214 manufacturing issue. All of these cases are in the early stages. Accordingly, we cannot reasonably estimate any range of potential future charges, and we have not recorded any accrual for a contingent liability associated with these legal proceedings. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Indemnifications in Connection with Commercial Agreements</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual any time after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants, including our obligation to RPI described in Note 5. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification obligations, representations or warranties. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103439949e379-wk-Fact-0A145EC93D3356ED8E5579DE68227FB5" name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="FI2019Q3_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_IndemnificationGuaranteeMember" unitRef="usd" decimals="INF" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> liabilities for these obligations in our Condensed Consolidated Balance Sheets at either </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><a id="s6AFDD60A554555A5B898C2D16440529A"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 7 &#8212; <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="TextSelection-171960C5AAAB5E17A5ED068B0C510F1E-0-wk-Fact-53B00E16930B506D80A45DCDF5D085D7" continuedAt="TextSelection-171960C5AAAB5E17A5ED068B0C510F1E-1" escape="true">License and Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="TextSelection-171960C5AAAB5E17A5ED068B0C510F1E-1" continuedAt="TextSelection-171960C5AAAB5E17A5ED068B0C510F1E-2"><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. Our partners may generally cancel our collaboration agreements without significant financial penalty. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606. </span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="TextSelection-4A9F0B0B4BD652CBA812877DBF1DEB24-0-wk-Fact-4B23EDAB839E535B927568D4A477EC4C" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.42528735632183%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Partner</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Drug or Drug Candidate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Bristol-Myers Squibb Company</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NKTR-214</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e614-wk-Fact-4B9DEE19AB395E54ABC136D1BABF99B6" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2019Q3QTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarTwoOneFourMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e633-wk-Fact-6DE55BDD66AC549E805BF1B9943F2DBF" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2018Q3QTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarTwoOneFourMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e653-wk-Fact-A72D0DB259C15B85821690F4A6A6C40B" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2019Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarTwoOneFourMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e672-wk-Fact-0C2D44BEE5995DD78939968A91BC3463" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarTwoOneFourMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,059,768</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Eli Lilly and Company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NKTR-358</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e702-wk-Fact-B1C32D09154554549D1D284A5200BC32" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2019Q3QTD_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e721-wk-Fact-BF3B39BD05BF5B53A969975519F5AE3A" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2018Q3QTD_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e741-wk-Fact-5F19ECD6FE015F1FBA4982E6BC43D3F4" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2019Q3YTD_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e760-wk-Fact-C9C3B54F1F2B52B5B808D15DE3D391CF" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2018Q3YTD_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,627</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amgen, Inc.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Neulasta</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e797-wk-Fact-D24262B5DC4D5542A81CA88D0F88E47D" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2019Q3QTD_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_TypeOfArrangementAxis_nktr_NeulastaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e816-wk-Fact-091C7F5C1F0F507D9CB8432312B17255" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2018Q3QTD_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_TypeOfArrangementAxis_nktr_NeulastaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e836-wk-Fact-CA7722ACB7F154BB94A731996B7A8180" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2019Q3YTD_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_TypeOfArrangementAxis_nktr_NeulastaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e855-wk-Fact-935174F3D2725488843277FDE25610E0" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2018Q3YTD_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_TypeOfArrangementAxis_nktr_NeulastaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Baxalta Inc. / Takeda Pharmaceutical Company Ltd. and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ADYNOVATE</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e892-wk-Fact-EF260FD26FD650798060F9DB8C17204F" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2019Q3QTD_dei_LegalEntityAxis_nktr_OtherPartnerMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e911-wk-Fact-12F1BA5AAAE4590C88EA3E792D458AFA" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2018Q3QTD_dei_LegalEntityAxis_nktr_OtherPartnerMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">404</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e931-wk-Fact-38CEDA60E0AB5409A0337607328B64B0" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2019Q3YTD_dei_LegalEntityAxis_nktr_OtherPartnerMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">910</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e950-wk-Fact-F2AF06ACDC63572CA026FEAC56350732" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2018Q3YTD_dei_LegalEntityAxis_nktr_OtherPartnerMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,703</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License, collaboration and other revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e990-wk-Fact-14FFA03AF63B58FAB142EA88BF292AD2" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1009-wk-Fact-EEB5B84A8627546985E87D07ECC8932C" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1024-wk-Fact-EB306C31C12452CBB920A1A11D90DC96" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,860</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1048-wk-Fact-DBA0B93BD9FA57C3B30358F85ECD2D87" name="nktr:LicenseCollaborationOtherRevenue" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,082,848</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1068-wk-Fact-4D2E5DF486685CA7BD8F34AFF53556E7" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1072-wk-Fact-437C416A0B9A588FAA0295356DB384C8" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">56.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of revenue for performance obligations that we had satisfied in prior periods, respectively. This amount includes all of our royalty revenue and non-cash royalty revenue because these royalties substantially relate to the licenses that we had previously granted. </span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the three and nine months ended September 30, 2018, we recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1079-wk-Fact-F4AD62256B36537B9F2999AB600AD89E" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1083-wk-Fact-C01489E1188C571380B984056410073B" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">64.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of revenue for performance obligations that we had satisfied in prior periods. This amount includes all of our royalty revenue and non-cash royalty revenue because these royalties substantially relate to the licenses that we had previously granted. This amount also includes the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1087-wk-Fact-EE334EE2C39D58639D715F02FC935E0A" name="nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" contextRef="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BaxaltaIncorporatedOrTakedaPLCMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_TypeOfArrangementAxis_nktr_HemophiliaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> development milestone payment earned and received from Baxalta Inc. in the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> described below.</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="TextSelection-66C4EBF39B9F58809DA9460193489262-0-wk-Fact-A43FBEF4CAC352439265361B3940CD5B" escape="true"><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the changes in our deferred revenue balance from our collaboration agreements during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended <br/>September 30,<br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue&#8212;December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1158-wk-Fact-349EF174C7E453418A83DBCF61CFB34A" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of previously unearned revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d103457909e1173-wk-Fact-2A538D8B8D755B18A19AD734319AC813" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue&#8212;September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1199-wk-Fact-DFAA08BB19FE5363A6DB28C2F18F304E" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our balance of deferred revenue contains the transaction price from our collaboration agreements allocated to performance obligations which are partially unsatisfied. We expect to recognize approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1211-wk-Fact-BEBE47B0FF415EC093A9E6F4A8003B75" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of our deferred revenue over the next twelve months and recognize the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1215-wk-Fact-317A3EC837A256F08310CABC2DE0CCF1" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> over several years.&#160;</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, our collaboration agreements with partners included potential future payments for development and regulatory milestones totaling approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1226-wk-Fact-5FF6F313B8125AE0A6132FA3A68A2BD5" name="nktr:PotentialDevelopmentAndRegulatoryMilestones" contextRef="FI2019Q3" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.7</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">, including amounts from our agreements with BMS and Eli Lilly and Company described below. In addition, under our collaboration agreements we are entitled to receive contingent sales milestone payments, other contingent payments and royalty payments, as described below.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have been no material changes to our collaboration agreements in the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, except as described below.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Bristol-Myers Squibb Company (BMS)</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Bempegaldesleukin, also referred to as NKTR-214 </span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 13, 2018, we entered into a Strategic Collaboration Agreement (BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to these agreements, we and BMS are </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-171960C5AAAB5E17A5ED068B0C510F1E-2" continuedAt="TextSelection-171960C5AAAB5E17A5ED068B0C510F1E-3"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">jointly developing NKTR-214, including, without limitation, in combination with BMS&#8217;s Opdivo</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (nivolumab) and Opdivo</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> plus Yervoy</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (ipilimumab), and other compounds of BMS, us or any third party. The parties have agreed to jointly commercialize NKTR-214 on a worldwide basis. We retained the right to record all worldwide sales for NKTR-214. We will share global commercialization profits and losses with BMS for NKTR-214, with Nektar sharing </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1265-wk-Fact-EABD52E452405249BB69C78CB4204974" name="nktr:ProfitsAndLossesSharingPercentage" contextRef="D2018Q1Feb13-Feb13_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">65</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and BMS sharing </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1269-wk-Fact-B038D58B0DCA579D80F86028E557FDAE" name="nktr:ProfitsAndLossesSharingPercentage" contextRef="D2018Q1Feb13-Feb13_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the net profits and losses. The parties will share the internal and external development costs for NKTR-214 in combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties will share development costs for&#160;NKTR-214&#160;in combination with&#160;Opdivo</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1278-wk-Fact-65AF7E5CA0DE5CEA95BC663D7C36004B" name="nktr:PercentageOfSharingInDevelopmentCosts" contextRef="D2018Q1Feb13-Feb13_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nktr_OpdivoMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">67.5</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of costs to BMS and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1282-wk-Fact-5603B85F9CF554D88769A15E2E954FC7" name="nktr:PercentageOfSharingInDevelopmentCosts" contextRef="D2018Q1Feb13-Feb13_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nktr_OpdivoMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">32.5</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> to Nektar, and for&#160;NKTR-214&#160;in a triplet combination with&#160;Opdivo</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;and&#160;Yervoy</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1294-wk-Fact-66B61D88013D5B038D967A08D198B6E6" name="nktr:PercentageOfSharingInDevelopmentCosts" contextRef="D2018Q1Feb13-Feb13_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nktr_OpdivoAndYervoyMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">78</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of costs to BMS and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1299-wk-Fact-158AE323BB1A5C74A121BCAC4073AB7D" name="nktr:PercentageOfSharingInDevelopmentCosts" contextRef="D2018Q1Feb13-Feb13_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nktr_OpdivoAndYervoyMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">22</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> to Nektar.&#160;The parties will share costs for the manufacturing of NKTR-214, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1303-wk-Fact-324B90B4AC2E55D9932843AD0AA1FD8D" name="nktr:PercentageOfSharingInProductionCosts" contextRef="D2018Q1Feb13-Feb13_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of costs to BMS and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1307-wk-Fact-AF86936142C05DE79AF4E2FAC38769C3" name="nktr:PercentageOfSharingInProductionCosts" contextRef="D2018Q1Feb13-Feb13_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">65</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> to Nektar.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The BMS Collaboration Agreement superseded and replaced the Clinical Trial Agreement we entered into with BMS in September 2016 to develop NKTR-214 in combination with Opdivo</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. Under the Clinical Trial Agreement, we acted as the sponsor of each Combination Therapy Trial and BMS was responsible for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1318-wk-Fact-0D5BACCA7AC1545281A6046CD8BBC6FD" name="nktr:PercentageOfOutOfPocketCostsToBeReimbursedByPartner" contextRef="D2016Q3Sep1-Sep30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_ClinicalTrialAgreementMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of all out-of-pocket costs reasonably incurred in connection with third party contract research organizations, laboratories, clinical sites and institutional review boards. We recorded cost reimbursement payments to us from BMS as a reduction to research and development expense. Each party was otherwise responsible for its own internal costs, including internal personnel costs, incurred in connection with each Combination Therapy Trial.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1325-wk-Fact-9788EB79B6ED52BAA2FE4ABC085F296C" name="nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" contextRef="D2018Q2Apr1-Apr30_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">. We are eligible to receive additional cash payments up to a total of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1329-wk-Fact-E5D3CBF836FE576DAB8D6AF6A5F4F296" name="nktr:CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" contextRef="D2018Q2Apr1-Apr30_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.4</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> upon the achievement of certain development and regulatory milestones and up to a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1333-wk-Fact-718E5ED9A4D656F2AD7EB1E3067C3EBA" name="nktr:EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" contextRef="D2018Q2Apr1-Apr30_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">350.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the achievement of certain sales milestones. In April 2018, BMS also purchased </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1337-wk-Fact-856A33E90A2B569A9DAA327943C183C5" name="us-gaap:SharesIssued" contextRef="I2018Q2Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,284,600</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1341-wk-Fact-45298F108256595285DE7BD50ED78D67" name="nktr:SaleOfStockConsiderationReceived" contextRef="D2018Q2Apr1-Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">850.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808, and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#8217; reimbursement of our costs as a reduction of research and development expense and our reimbursement of BMS&#8217; costs as research and development expense. During the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1356-wk-Fact-8E14A56549395958BD85D7377579F7FA" name="nktr:ReimbursementOfExpenses" contextRef="FD2019Q3QTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1360-wk-Fact-AFF5BA6DE63B5E53A89EC704AC81ED96" name="nktr:ReimbursementOfExpenses" contextRef="FD2019Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">81.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, as a reduction of research and development expense for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses.&#160;During the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, we recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1373-wk-Fact-BC10003EC53050DEAA040573C3DB3324" name="nktr:ReimbursementOfExpenses" contextRef="FD2018Q3QTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;text-align:right;"><span>$<ix:nonFraction id="d103457909e1377-wk-Fact-E4C6440853FE547B819108D068BC612D" name="nktr:ReimbursementOfExpenses" contextRef="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, as a reduction of research and development expense for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have recorded a receivable of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1385-wk-Fact-D4693778639D589892D30FB2BA6CCDC6" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q3_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> from BMS in accounts receivable in our Condensed Consolidated Balance Sheet.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We analogized to ASC 606 for the accounting for our two performance obligations, consisting of the delivery of the licenses to develop and commercialize NKTR-214 and our participation on joint steering and other collaboration committees. We determined that our committee participation is not material.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We aggregated the total consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1395-wk-Fact-E860D909A57057E0B0AA1ACE82C811A9" name="nktr:AggregateConsiderationReceivedFromAgreements" contextRef="D2018Q2Apr1-Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="usd" decimals="-7" scale="9" format="ixt:numdotdecimal">1.85</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> received under the agreements and allocated it between the stock purchase and the revenue-generating elements, because we and BMS negotiated the agreements together and the effective date of the BMS Collaboration Agreement was dependent upon the effective date of the Share Purchase Agreement. We recorded the estimated fair value of the shares of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1399-wk-Fact-41337E5107E35F4FA4D15EEBE3124C13" name="nktr:EstimatedFairValueOfShares" contextRef="I2018Q2Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">790.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in stockholders&#8217; equity based on the closing date price of our common stock of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1403-wk-Fact-F586BFD3C87A511CB926EFB78F92EF7C" name="us-gaap:SaleOfStockPricePerShare" contextRef="I2018Q2Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">99.36</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, adjusted for a discount for lack of marketability reflecting the unregistered nature of the shares. We allocated the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1407-wk-Fact-692C8C3945D155F5AB298CD373E56702" name="nktr:RemainingAmountAllocatedToTransactionPrice" contextRef="D2018Q2Apr1-Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,059.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to the transaction price of the collaboration agreement. We consider the future potential development, regulatory and sales milestones of up to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1411-wk-Fact-F6CF1EC712045267941693293EA12620" name="nktr:PotentialDevelopmentRegulatoryAndSalesMilestones" contextRef="I2018Q2Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.8</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;"> to be variable consideration. We excluded these milestones from the transaction price during 2018 and as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> due to the significant uncertainties involved with clinical development and regulatory approval. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accordingly, we allocated the entire transaction price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1423-wk-Fact-0117A02329525157ABD19B56744C1B82" name="nktr:AmountRecognizedForGrantingLicenses" contextRef="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,059.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to the granting of the licenses and therefore recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1427-wk-Fact-0117A02329525157ABD19B56744C1B82" name="nktr:AmountRecognizedForGrantingLicenses" contextRef="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1,059.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> during the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> as license, collaboration and other revenue.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Eli Lilly and Company (Lilly</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">): NKTR-358 </span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), which became effective on August 23, 2017, to co-develop NKTR-358, a novel immunological drug candidate that we invented. Under the terms of the agreement, we (i) received an initial payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1443-wk-Fact-F0E2BB8C119B5DD8AFC69410D9AF6C57" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" contextRef="D2017Q3Sep1-Sep30_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in September 2017 and are eligible for up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1447-wk-Fact-0A336A4AC66156BCA5DB3FA68EDDB2F4" name="nktr:PotentialDevelopmentAndRegulatoryMilestones" contextRef="I2017Q3Aug23_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">250.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in additional development milestones, (ii) will co-develop NKTR-358 with Lilly, for which we are responsible for completing </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-171960C5AAAB5E17A5ED068B0C510F1E-3" continuedAt="TextSelection-171960C5AAAB5E17A5ED068B0C510F1E-4"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Phase 1 clinical development and certain drug product development and supply activities, (iii) will share with Lilly Phase 2 development costs with </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1455-wk-Fact-895356AD72DE56D681A05337639EF88B" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" contextRef="D2017Q3Aug22-Aug23_dei_LegalEntityAxis_nktr_EliLillyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">75</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of those costs borne by Lilly and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1459-wk-Fact-D798E6A88E22578AB9A2A772FA520674" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" contextRef="D2017Q3Aug22-Aug23_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the costs borne by us, (iv) will have the option to contribute funding to Phase 3 development on an indication-by-indication basis ranging from </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1463-wk-Fact-507E4E894AD15608B674C93B25895048" name="nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" contextRef="D2017Q3Aug22-Aug23_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember" unitRef="number" decimals="INF" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1467-wk-Fact-AF1D2001000556BBAEE2346706454EF2" name="nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" contextRef="D2017Q3Aug22-Aug23_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of development costs, and (v) will have the opportunity to receive up to double-digit sales royalty rates that escalate based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1471-wk-Fact-1D38E4A1399D55CF8A39C3A6D9576EBE" name="nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" contextRef="D2017Q3Aug22-Aug23_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1476-wk-Fact-FE204216587958B7AF427072326CC4B9" name="nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" contextRef="D2017Q3Aug22-Aug23_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">75</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> if both conditions occur.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We identified our license grant to Lilly, our ongoing Phase 1 clinical development obligation and our drug product development obligation as the significant performance obligations in the arrangement. The valuation of each performance obligation involves significant estimates and assumptions, including but not limited to, expected market opportunity and pricing, assumed royalty rates, clinical trial costs, timelines and likelihood of success; in each case these estimates and assumptions covering long time periods. We determined the selling price for the license based on a discounted cash flow analysis of projected revenues from NKTR-358 and development and commercial costs using a discount rate based on a market participant&#8217;s weighted-average cost of capital adjusted for forecasting risk. We determined the selling prices for our Phase 1 clinical development and drug product development deliverables based on the nature of the services to be performed and estimates of the associated efforts and third-party rates for similar services.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although we are entitled to significant development milestones under this arrangement, through </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We have therefore determined the transaction price to consist of the upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1493-wk-Fact-F0E2BB8C119B5DD8AFC69410D9AF6C57" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" contextRef="D2017Q3Sep1-Sep30_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in September 2017. Based on our estimates of the standalone selling prices of the performance obligations, we allocated the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1497-wk-Fact-F0E2BB8C119B5DD8AFC69410D9AF6C57" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" contextRef="D2017Q3Sep1-Sep30_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment as </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1501-wk-Fact-9776C0033BF55D82AFED661711FA9528" name="nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation" contextRef="D2017Q3Sep1-Sep30_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightLicenseMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">125.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to the license, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1505-wk-Fact-547A929E351C5EF38CC2315676A816E8" name="nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation" contextRef="D2017Q3Sep1-Sep30_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightLicenseMember_us-gaap_TypeOfArrangementAxis_nktr_PhaseOneClinicalDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to the Phase 1 clinical development and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1510-wk-Fact-BD3A872ADC33598EADE83F80FBA54DFB" name="nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation" contextRef="D2017Q3Sep1-Sep30_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightLicenseMember_us-gaap_TypeOfArrangementAxis_nktr_DrugProductDevelopmentMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to the drug product development.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognized the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1517-wk-Fact-35D6949C54BB5F519E27275EE5B855DE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q3Aug01-Aug31_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">125.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of revenue allocated to the license upon the effective date of the license agreement in August 2017, since we determined that the license was a right to use our intellectual property, for which, as of the effective date, we had provided all necessary information to Lilly to benefit from the license and the license term had begun. We recognize revenue for the Phase 1 clinical development and drug product development using an input method, using costs incurred, as this method depicts our progress towards providing Lilly with the results of clinical trials and drug production processes. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have deferred revenue of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1525-wk-Fact-9FF580609A9855F994713896BDF5A948" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q3_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> related to this agreement, which we expect to recognize through early 2020, the estimated end of our performance obligations under this agreement.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Baxalta Inc. / Takeda Pharmaceutical Company Ltd</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Hemophilia</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a party to an exclusive research, development, license and manufacturing and supply agreement with Baxalta Inc. (Baxalta), a subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), entered into in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology. Under the terms of the agreement, we are entitled to research and development funding for our active programs, which are now complete for Factor VIII, and are responsible for supplying Takeda with its requirements for our proprietary materials. Takeda is responsible for all clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This Hemophilia A program includes ADYNOVATE</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, which was approved by the United States Food and Drug Administration (FDA) in November 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A, and is now marketed in the U.S., the European Union, and many other countries. As a result of the marketing authorization in the EU in January 2018, we earned a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1544-wk-Fact-EB019ACFFC3556429F3C64A943334C6A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q1Jan1-Jan31_dei_LegalEntityAxis_nktr_BaxaltaIncorporatedOrTakedaPLCMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_TypeOfArrangementAxis_nktr_HemophiliaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> development milestone, which we received in March 2018. We updated the transaction price for this milestone in January 2018 since we had previously excluded it due to the significant uncertainty from regulatory approval. Based on the terms of this milestone, we allocated the entire milestone to the license grant and research and development services, and therefore recognized the entire </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1548-wk-Fact-DCD019827B9B5494AC0BCBA7CFE0DB7B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BaxaltaIncorporatedOrTakedaPLCMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_TypeOfArrangementAxis_nktr_HemophiliaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> as we had previously satisfied those performance obligations. In </span><span style="font-family:inherit;font-size:10pt;">December 2018</span><span style="font-family:inherit;font-size:10pt;">, we earned an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1565-wk-Fact-D04E3C7211C659FDBC55DB7A90AA28FF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Dec1-Dec31_dei_LegalEntityAxis_nktr_BaxaltaIncorporatedOrTakedaPLCMember_us-gaap_ContractWithCustomerSalesChannelAxis_nktr_AnnualSalesLevelMilestoneMember_us-gaap_TypeOfArrangementAxis_nktr_HemophiliaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone for annual sales of ADYNOVATE</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">/ADYNOVI</span><span style="font-family:inherit;font-size:9pt;">&#8482;</span><span style="font-family:inherit;font-size:10pt;"> reaching a certain specified amount.&#160;In addition, we are entitled to an additional </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-171960C5AAAB5E17A5ED068B0C510F1E-4" continuedAt="TextSelection-171960C5AAAB5E17A5ED068B0C510F1E-5"><div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">sales milestone upon achievement of an annual worldwide net sales target and royalties based on worldwide net sales of products resulting from this agreement.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents that were previously exclusively licensed to Baxalta under our 2005 agreement. Under the right to sublicense agreement, Baxalta paid us </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1583-wk-Fact-0BF076993ECA58FE8B403D2E73492B76" name="nktr:PaymentsReceivedUnderRightsToSublicenseAgreement" contextRef="D2017Q4Nov1-Nov30_dei_LegalEntityAxis_nktr_BaxaltaIncorporatedOrTakedaPLCMember_us-gaap_TypeOfArrangementAxis_nktr_HemophiliaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in November 2017 and agreed to pay us single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our remaining unsatisfied performance obligation consists of our ongoing supply of PEGylation materials at a price less than the standalone selling price of these materials. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, our deferred revenue from this arrangement is not significant.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Amgen, Inc</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.: Neulasta</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup>&#160;</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2010, we amended and restated an existing supply and license agreement by entering into a supply, dedicated suite and manufacturing guarantee agreement (the Amended and Restated Agreement) and a license agreement with Amgen, Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of the Amended and Restated Agreement, we received a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1605-wk-Fact-45F63DF7CA6654CB8AFACDF88372B601" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" contextRef="D2010Q4Oct1-Dec31_dei_LegalEntityAxis_nktr_AmgenIncMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> payment in the fourth quarter of 2010 in return for our guaranteeing the supply of certain quantities of our proprietary PEGylation materials to Amgen.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determined that our obligation to manufacture and supply our PEGylation materials and to maintain the dedicated manufacturing suite solely for the production of such materials for Amgen represented an obligation to stand ready to manufacture such materials. We concluded that we should recognize revenue based on the passage of time as this method depicts the satisfaction of Amgen&#8217;s right to require production of PEGylation materials at any time. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have deferred revenue of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1616-wk-Fact-967FB54A1116503EA38AA16E466D97E6" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q3_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> related to this agreement, which we expect to recognize through October 2020, the estimated end of our obligations under this agreement.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">AstraZeneca AB</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(naloxegol oxalate), previously referred to as naloxegol and NKTR-118 </span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2009, we entered into an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our patents and other intellectual property to develop, market, and sell MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. AstraZeneca is responsible for all research, development and commercialization costs and related decisions for MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. In September 2014 and December 2014, MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> /MOVENTIG</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> was approved in the US and EU, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have received a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1655-wk-Fact-97C9791A40FB55F2881EAFCD04A9FAF5" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" contextRef="D2015Q4Sep01-Dec31_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_MOVANTIKAndMOVENTIGMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">385.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of upfront and contingent milestone payments from this agreement, all of which was received in or before 2015. In addition, we are entitled to significant and escalating double-digit royalty payments and sales milestone payments based on annual worldwide net sales of MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2016, AstraZeneca announced that it had entered into an agreement with ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd. (Kirin), granting Kirin exclusive marketing rights to MOVENTIG</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in the EU, Iceland, Liechtenstein, Norway and Switzerland. Under our license agreement with AstraZeneca, we and AstraZeneca will share the upfront payment, market access milestone payments, royalties and sales milestone payments made by Kirin to AstraZeneca with AstraZeneca receiving </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1670-wk-Fact-83A9C0ED59D8577E927417F65D8D13D2" name="nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" contextRef="D2016Q1Mar1-Mar31_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_AstraZenecaAgreementWithKirinMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and Nektar receiving </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1674-wk-Fact-B46008E439C0595A800BE244674517B8" name="nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" contextRef="D2016Q1Mar1-Mar31_us-gaap_TypeOfArrangementAxis_nktr_NektarMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we do not have deferred revenue related to our agreement with AstraZeneca.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of its approval of MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, the FDA required AstraZeneca to perform a post-marketing, observational epidemiological study comparing MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> to other treatments of opioid-induced constipation in patients with chronic, non-cancer pain. As a result, the royalty rate payable to us from net sales of MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in the U.S. by AstraZeneca can be reduced by up to two percentage points to fund </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103457909e1700-wk-Fact-3A10AC0208252A074C9E23BE86282CBF" name="nktr:CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement" contextRef="FD2019Q3YTD_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_MOVANTIKAndMOVENTIGMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">33</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the external costs incurred by AstraZeneca to fund such post approval study, subject to a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1704-wk-Fact-CAE9F1F4957C7B8D283F23BF8BBA5DC4" name="nktr:CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum" contextRef="FD2019Q3YTD_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_MOVANTIKAndMOVENTIGMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">35.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate cap. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, our cumulative share of the post-approval study expenses since 2015 totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1713-wk-Fact-25D35499B69FDA4CE04423CF6EF7DF22" name="nktr:CostsIncurredShareOfExpenses" contextRef="FD2019Q3YTD_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_MOVANTIKAndMOVENTIGMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. AstraZeneca may only recover costs incurred by the reduction of the royalty payable to us. In no case can amounts be recovered by the reduction of a contingent payment due from AstraZeneca to us or through a payment from us to AstraZeneca.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have a number of other collaboration agreements, including with our collaboration partners UCB Pharma and Halozyme Therapeutics, Inc., under which we are entitled to up to a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1727-wk-Fact-EDD5D3A5B67C528B9BA1E8AB33E0049D" name="nktr:PotentialDevelopmentMilestones" contextRef="FI2019Q3_dei_LegalEntityAxis_nktr_OtherPartnerMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">45.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of development milestone payments upon achievement of certain development objectives, as well as sales milestones upon </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-171960C5AAAB5E17A5ED068B0C510F1E-5"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration agreements, we cannot estimate the probability or timing of achieving these milestones and, therefore, have excluded all development milestones from the respective transaction prices for these agreements. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have deferred revenue of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d103457909e1738-wk-Fact-037FF69C902E5AD4BF15D29DBFA91CE6" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q3_dei_LegalEntityAxis_nktr_OtherPartnerMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> related to these other collaboration agreements.</span></div></ix:continuation><div><a id="s51FCEF8702BA50C38271E4C4DF76343F"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 8 &#8212; <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-7E0BB8FC5C785883BB8653FA1A510087-0-wk-Fact-804C185B5D8150B4A7E3B12D3455D368" continuedAt="TextSelection-7E0BB8FC5C785883BB8653FA1A510087-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-7E0BB8FC5C785883BB8653FA1A510087-1"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-72AD93B849295A4D826DF2693D4422FA-0-wk-Fact-461F104C6E265519B3BC08B4137D07F8" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80842911877394%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e564-wk-Fact-E62084A31D40584B8DB62D9670EABD65" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,119</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e583-wk-Fact-63A2D38AD9B45EADA5CD9705BA39C6D2" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e602-wk-Fact-B78865A3BFD051FF856699AE0DDAAEA8" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,208</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e622-wk-Fact-A110D595BE865E47BEC44C34F030B080" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,470</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e637-wk-Fact-966F5422ED2C5D51B560D44C057B87C7" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,680</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e656-wk-Fact-6DBAC5483C4A5587BB392992F0320393" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,365</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e675-wk-Fact-8ED4DBB15D9157AA8C7EF578A8D5C601" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,549</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e695-wk-Fact-A912775E52865E4CAA08A23C03521D66" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e715-wk-Fact-7966DDB757065392B675DBDC8BFF1962" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,081</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e734-wk-Fact-76FD1E1C7F375FD78EE67F7DC8EE5E35" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,746</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e753-wk-Fact-07A2C1BB53DB5184978259A459900345" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,030</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e773-wk-Fact-D73C151CA3325861AF58533A9EE22BEC" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,976</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e798-wk-Fact-85E41C500D845BBF9F5D0C5FC655F460" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,880</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e817-wk-Fact-08EC09F54E0C58FDA0B9CE1C01A691A5" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,287</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e836-wk-Fact-B1BCA189DB1959319F6A8B4FBCF38A2E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">74,787</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e856-wk-Fact-3BC234129E875B5891EA667CAB9217B1" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,895</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="TextSelection-48470127683A2E4BD54423D7F22B7E96-0-wk-Fact-28CC4B059694E2A11A7523D824BBDD87" escape="true"><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options granted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1064-wk-Fact-9398F82F56C4541FBAAAD5BDBA3D0A7C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">131</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1083-wk-Fact-1C9A302C27B25A0DAE17F66E714465B7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">190</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1102-wk-Fact-C38BD20089735AE5A16C77E51BC014DC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">246</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1122-wk-Fact-9E85B6AAB5455CD5A946F3BB8A872B75" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">929</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average grant-date fair value of options granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1147-wk-Fact-4CF89C287D1957059C53099B0F4D6240" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.43</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1166-wk-Fact-292A4DBA09E6578B8C263919703A45DF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">30.52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1185-wk-Fact-12DA8440C322517AA70B1CEE125B14B7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.81</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1205-wk-Fact-26CA33E46226558C8B0821AAED832330" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">39.28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSUs granted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1220-wk-Fact-24F973298C465AAB9D46E844F0755461" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">316</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1239-wk-Fact-E4CB38EDDEE054B68FA7739F05E25763" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1258-wk-Fact-3F12EC5B15CC549D9C5F5467E893B61D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">712</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1278-wk-Fact-6B6DBB0E019A543794289B5525F4071C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">558</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average grant-date fair value of RSUs granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1303-wk-Fact-F50D16668A8013CF281E198A57106E59" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">28.00</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1322-wk-Fact-72BE3552DB7CB7E2B691198A58EAAC2A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">57.27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1341-wk-Fact-CA34F71A23145A63A4B62330692E18BB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">31.80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1361-wk-Fact-69650CD8511B0CEB2FEF1989F388524F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">54.49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares issued under equity compensation plans</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1376-wk-Fact-0D6D128183115981A26D8211E23FFC99" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q3QTD" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">820</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1395-wk-Fact-071CD2B8744058AFA988EE9F64C71AE8" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2018Q3QTD" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">642</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1414-wk-Fact-292F0256C56356D2B2E4C7F04A9E74BC" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q3YTD" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">2,256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442105e1434-wk-Fact-5230F5A4D3915D97B830F8427FBAB1DF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2018Q3YTD" unitRef="shares" decimals="INF" scale="3" format="ixt:numdotdecimal">5,248</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><a id="sEABB3FC1D0A15AA3BE4E95A0D4FE25CB"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Note 9 &#8212; <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-7DD3D0403DA75014BD5862285AE59026-0-wk-Fact-E851136122F85D98A8C89A7BA3459E8A" continuedAt="TextSelection-7DD3D0403DA75014BD5862285AE59026-1" escape="true">Net Income (Loss) Per Share</ix:nonNumeric></span></div><ix:continuation id="TextSelection-7DD3D0403DA75014BD5862285AE59026-1" continuedAt="TextSelection-7DD3D0403DA75014BD5862285AE59026-2"><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We calculate basic net income (loss) per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net income (loss) per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, our net income (loss) available to common stockholders equals the reported net income (loss). </span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the three months ended September 30, 2018, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. During the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the three months ended September 30, 2018, potentially dilutive securities consisted of the weighted-average common shares underlying outstanding stock options and RSUs, which totaled </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442218e380-wk-Fact-C2BDDFA6C08E5566BB0760145B5740DD" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_nktr_StockOptionsAndRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">17.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442218e385-wk-Fact-F287B2D5916852169F7D7AF0B9F4CD9F" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_nktr_StockOptionsAndRestrictedStockUnitsMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">18.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442218e389-wk-Fact-735C079881674B10D689197FCA39CABA" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">17.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares, respectively.</span></div></ix:continuation><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><ix:continuation id="TextSelection-7DD3D0403DA75014BD5862285AE59026-2" continuedAt="TextSelection-7DD3D0403DA75014BD5862285AE59026-3"><span style="font-family:inherit;font-size:10pt;">For the computation of diluted earnings per share for nine months ended September 30, 2018, we included approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442218e396-wk-Fact-72D9A5D15BE42CEB3CEF19812EC4A19A" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">11.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> weighted-average common shares underlying stock options and RSUs under the treasury stock method and excluded approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d103442218e400-wk-Fact-09D9B58E7D54EA0296C41980D5D652DE" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q3YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-7DD3D0403DA75014BD5862285AE59026-3"> of shares of common stock underlying stock options because their effect was antidilutive.</ix:continuation> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC9792DF6D2295DD4997463C16DDAD956"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;2.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed here. Factors that could cause or contribute to such differences include, but are not limited to those discussed in this section as well as factors described in Part II, Item&#160;1A &#8220;Risk Factors.&#8221;</span></div><div><a id="sB65351701B3B5A1B940655288DF20D24"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Strategic Direction of Our Business</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nektar Therapeutics is a research-based biopharmaceutical company that discovers and develops innovative new medicines in areas of high unmet medical need. Our research and development pipeline of new investigational drugs includes treatments for cancer, autoimmune disease and chronic pain. We leverage our proprietary and proven chemistry platform to discover and design new drug candidates. These drug candidates utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. We continue to make significant investments in building and advancing our pipeline of proprietary drug candidates as we believe that this is the best strategy to build long-term stockholder value.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In immuno-oncology, we are executing a clinical development for bempegaldesleukin, also referred to as NKTR-214, in collaboration with Bristol-Myers Squibb Company (BMS) as well as other independent development work evaluating NKTR-214 in combination with other agents with potential complementary mechanisms of action. We announced in August that the FDA informed us that it had granted a Breakthrough Therapy designation for NKTR-214 in combination with Opdivo</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> for the treatment of patients with untreated unresectable or metastatic melanoma. We expect our research and development expense to continue to grow over the next few years as we expand and execute a broad clinical development program for NKTR-214. Under our collaboration development plan, we and BMS have started registration-enabling studies in first line metastatic melanoma, first line metastatic renal cell carcinoma, first line cisplatin ineligible, PD-L1 negative, locally advanced or metastatic urothelial cancer, second line metastatic non-small cell lung cancer (post-checkpoint inhibitor and chemotherapy), and we are in the process of finalizing the next set of registrational and non-registrational studies in additional tumor types that we will execute under the collaboration. For development work within our collaboration development plan, we share development costs based on each party&#8217;s relative ownership interest in the compounds included in the regimen. For example, we share development costs for NKTR-214 in combination with Opdivo</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, BMS 67.5% and Nektar 32.5%, and for NKTR-214 in a triplet combination with Opdivo</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and Yervoy</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, BMS 78% and Nektar 22%. For costs of manufacturing NKTR-214, however, BMS is responsible for 35% and Nektar is responsible for 65% of costs. Our share of development costs under the collaboration development plan is limited to an annual cap of $125 million. To the extent this annual cap is exceeded, we will recognize our full share of the research and development expense and BMS will reimburse us for the amount over the annual cap which will be recorded as a contingent liability. This contingent liability will be paid to BMS only if NKTR-214 is approved and solely by reducing a portion of our share of net profits following the first commercial sale of NKTR-214. In addition, under the BMS collaboration agreement, we are entitled to $1.43 billion of regulatory and commercial launch milestones, $650 million of which are associated with approval and launch of NKTR-214 in its first indication in the U.S., EU and Japan. As a result, whether and when NKTR-214 is approved in any indication will have a significant impact on our future results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outside of the collaboration development plan with BMS, we are conducting additional research and development activities evaluating NKTR-214 in combination with other agents that have potential complementary mechanisms of action. Our strategic objective is to establish NKTR-214 as a key component of many immuno-oncology combination regimens with the potential to enhance the standard of care in multiple oncology settings. On November 6, 2018, we entered into a clinical collaboration with Pfizer Inc. (Pfizer) to evaluate several combination regimens in multiple cancer settings, including metastatic castration-resistant prostate cancer and squamous cell carcinoma of the head and neck.&#160;&#160;The combination regimens in this collaboration will evaluate NKTR-214 with avelumab, a human anti-PD-L1 antibody in development by Merck KGaA (Merck), and Pfizer; talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor developed by Pfizer; or enzalutamide, an androgen receptor inhibitor in development by Pfizer and Astellas Pharma Inc. We are planning a Phase 1 study this year in pancreatic cancer patients in collaboration with BioXcel Therapeutics Inc. (BioXcel) to evaluate a triplet combination of NKTR-214, BXCL-701 (a small molecule immune-modulator, DPP 8/9), and avelumab being supplied to BioXcel by Pfizer and Merck. We are also working in collaboration with Vaccibody AS (Vaccibody) to evaluate in a Phase 1 proof-of-concept study combining NKTR-214 with Vaccibody&#8217;s personalized cancer neoantigen vaccine. With our non-BMS clinical collaborations for NKTR-214, we generally share clinical development costs on a substantially pro-rata basis commensurate with our ownership interest in the underlying compounds. We expect to continue to make significant and increasing investments exploring the potential of NKTR-214 with mechanisms of action that we believe are synergistic with NKTR-214 based on emerging scientific findings in cancer biology and preclinical development work.&#160;&#160;</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also advancing other molecules, including NKTR-262 and NKTR-255, in our immuno-oncology portfolio. NKTR-262 is a small molecule agonist that targets toll-like receptors found on innate immune cells in the body. NKTR-262 is designed to stimulate the innate immune system and promote maturation and activation of antigen-presenting cells (APC), such as dendritic cells, which are critical to induce the body&#8217;s adaptive immunity and create antigen-specific cytotoxic T cells. NKTR-262 is being developed as an intra-tumoral injection in combination with systemic NKTR-214 in order to induce an abscopal response and achieve the goal of complete tumor regression in cancer patients treated with both therapies. The Phase 1 dose-escalation trial is currently ongoing. NKTR-255 is a biologic that targets the interleukin-15 (IL-15) pathway in order to activate the body&#8217;s innate and adaptive immunity. Signaling of the IL-15 pathway enhances the survival and function of natural killer (NK) cells and induces survival of both effector and CD8 memory T cells. Preclinical findings suggest NKTR-255 has the potential to synergistically combine with antibody dependent cellular toxicity molecules as well as enhance CAR-T therapies. We have initiated a first-in-human Phase 1 clinical study of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma. We are also designing other clinical trials in both liquid and solid tumor settings.&#160;&#160;</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In immunology, we are developing NKTR-358, which is designed to correct the underlying immune system imbalance in the body that occurs in patients with autoimmune disease. NKTR-358 is designed to optimally target the IL-2 receptor complex in order to stimulate proliferation and growth of regulatory T cells. NKTR-358 is being developed as a once or twice monthly self-administered injection for a number of autoimmune diseases. In 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly) to co-develop NKTR-358. We received an initial payment of $150.0 million in September 2017 and are eligible for up to an additional $250.0 million for development and regulatory milestones. We are responsible for completing Phase 1 clinical development and certain drug product development and supply activities. We also share Phase 2 development costs with Lilly, with 75% of those costs borne by Lilly and 25% of the costs borne by us. We will have the option to contribute funding to Phase 3 development on an indication-by-indication basis, ranging from zero to 25% of the Phase 3 development costs. Lilly will be responsible for all costs of global commercialization and we will have an option to co-promote in the U.S. under certain conditions. We have completed the first Phase 1 dose-finding trial of NKTR-358 to evaluate single-ascending doses of NKTR-358 in approximately 100 healthy patients. The Phase 1 multiple-ascending dose trial to evaluate NKTR-358 in patients with systemic lupus erythematosus (SLE) was initiated in May 2018 and has completed treatment.  On October 7, 2019, we announced initiation of two Phase 1b clinical studies of NKTR-358 in patients with psoriasis and atopic dermatitis.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In pain, we are developing NKTR-181 for the treatment of chronic low back pain in adult patients. NKTR-181 met its primary and key secondary endpoints in the SUMMIT-07 Phase 3 efficacy study in opioid-na&#239;ve patients with chronic low back pain and also demonstrated positive results in a pivotal human abuse potential study, long-term safety study, and several other clinical and non-clinical studies.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 31, 2018, we announced that we submitted an NDA for NKTR-181. The FDA missed the target action date of August 29, 2019 that it had assigned to our application under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), and postponed product-specific advisory committee meetings for opioid analgesics, including one that was previously scheduled for NKTR-181 on August 21, 2019.  We continue to work closely with the FDA as they review our NDA for NKTR-181, and we currently anticipate an advisory committee meeting for NKTR-181 will be formally scheduled to occur within the next several months.  </span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> If approved, we plan to commercialize NKTR-181 through our wholly owned subsidiary, Inheris Biopharma, Inc., with one or more potential capital partners to support commercial launch. Although substantial risks and uncertainties related to a successful and timely completion of establishing a commercialization infrastructure for NKTR-181 remain, we continue our work to establish a commercial launch capability for NKTR-181.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The level of our future research and development investment will depend on a number of trends and uncertainties including clinical outcomes, future studies required to advance programs to regulatory approval, and the economics related to potential future collaborations that may include up-front payments, development funding, milestones, and royalties. Over the next several years, we plan to continue to make significant investments to advance our early drug candidate pipeline.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have historically derived all of our revenue and substantial amounts of operating capital from our collaboration agreements including the BMS collaboration for NKTR-214 that was effective on April 3, 2018, pursuant to which we recognized $1.06 billion in revenue and recorded $790.2 million in additional paid in capital for shares of our common stock issued in the transaction. While in the near-term we continue to expect to generate substantially all of our revenue from collaboration arrangements, including the potential $1.43 billion in development and regulatory milestones under the BMS collaboration, in the medium- to long-term, our plan is to generate significant revenue from proprietary products including NKTR-181 and NKTR-214. Since we do not have experience commercializing products or an established commercialization organization, there will be substantial risks and uncertainties in future years as we build commercial, organizational, and operational capabilities.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also receive royalties and milestones from two approved drugs. We have a collaboration with AstraZeneca for MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, an oral peripherally-acting mu-opioid antagonist for the treatment of opioid-induced constipation in adult patients with non-cancer pain which was approved by the FDA and subsequently launched in March 2015 and MOVENTIG</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives, which was approved by health authorities in the European Union and many other countries beginning in 2014. We also have a collaboration with Baxalta Inc. (a wholly-owned subsidiary of Takeda Pharmaceutical Company Ltd.) for ADYNOVATE</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, that was approved by the FDA in late 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. ADYNOVI</span><span style="font-family:inherit;font-size:9pt;">&#8482;</span><span style="font-family:inherit;font-size:10pt;"> was approved by health authorities in Europe in January 2018, and has also been approved in many other countries.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our business is subject to significant risks, including the risks inherent in our development efforts, the results of our clinical trials, our dependence on the marketing efforts by our collaboration partners, uncertainties associated with obtaining and enforcing patents, the lengthy and expensive regulatory approval process and competition from other products. For a discussion of these and some of the other key risks and uncertainties affecting our business, see Part II, Item 1A &#8220;Risk Factors.&#8221;</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While the approved drugs and clinical development programs described above are key elements of our future success, we believe it is critically important that we continue to make substantial investments in our earlier-stage drug candidate pipeline. We have several drug candidates in earlier stage clinical development or being explored in research that we are preparing to advance into the clinic in future years. We are also advancing several other drug candidates in preclinical development in the areas of immuno-oncology, immunology, and other therapeutic indications. We believe that our substantial investment in research and development has the potential to create significant value if one or more of our drug candidates demonstrates positive clinical results, receives regulatory approval in one or more major markets and achieves commercial success. Drug research and development is an inherently uncertain process with a high risk of failure at every stage prior to approval. The timing and outcome of clinical trial results are extremely difficult to predict. Clinical development successes and failures can have a disproportionately positive or negative impact on our scientific and medical prospects, financial condition and prospects, results of operations and market value.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Key Developments and Trends in Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate that we have working capital to fund our current business plans through at least the next twelve months. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had approximately </span><span style="font-family:inherit;font-size:10pt;">$1.7 billion</span><span style="font-family:inherit;font-size:10pt;"> in cash and investments in marketable securities and had debt of $250.0 million in principal of senior secured notes due in October 2020.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Results of Operations</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Three and Nine Months Ended September 30, 2019 and 2018</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue (in thousands, except percentages)</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three months ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Decrease)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 vs. 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Decrease)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 vs. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,558</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,256</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,302</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalty revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,275</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,259</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash royalty revenue related to sale of future royalties</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,264</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,372</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,892</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License, collaboration and other revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,121</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,875</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,754</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(36</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29,218</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27,762</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,456</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage<br/>Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,302</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16,414</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2,112</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(13</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalty revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29,008</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29,898</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(890</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash royalty revenue related to sale of future royalties</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27,585</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24,337</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,248</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License, collaboration and other revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,860</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,082,848</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,072,988</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(99</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">80,755</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,153,497</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,072,742</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(93</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our revenue is derived from our collaboration agreements, under which we may receive product sales revenue, royalties, license fees, milestone and other contingent payments and/or contract research payments. Revenue is recognized when we transfer promised goods or services to our collaboration partners. The amount of upfront fees received under our license and collaboration agreements allocated to continuing obligations, such as manufacturing and supply commitments, is generally recognized as we deliver products or provide development services. As a result, there may be significant variations in the timing of receipt of cash payments and our recognition of revenue. We make our best estimate of the timing and amount of products and services expected to be required to fulfill our performance obligations. Given the uncertainties in research and development collaborations, significant judgment is required by us to make these estimates.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Sales</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales include predominantly fixed price manufacturing and supply agreements with our collaboration partners and are the result of firm purchase orders from those partners. The timing of shipments is based solely on the demand and requirements of our collaboration partners and is not ratable throughout the year.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales increased for the three months ended September 30, 2019 and decreased for the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to the comparable periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> primarily due to fluctuations in product demand from our collaboration partners. We expect product sales for the full year of 2019 to be consistent with 2018. </span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Royalty Revenue</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We receive royalty revenue from certain of our collaboration partners based on their net sales of commercial products. Royalty revenue for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> was consistent with the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, and we expect royalty revenue for the full year of 2019 to be consistent with 2018.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Non-cash Royalty Revenue Related to Sale of Future Royalties</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For a discussion of our Non-cash royalty revenue, please see our discussion below &#8220;Non-Cash Royalty Revenue and Non-Cash Interest Expense.&#8221;</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License, Collaboration and Other Revenue</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License, collaboration and other revenue includes the recognition of upfront payments, milestone and other contingent payments received in connection with our license and collaboration agreements and certain research and development activities. The level of license, collaboration and other revenue depends in part upon the achievement of milestones and other contingent events, the continuation of existing collaborations, the amount of our research and development services, and entering into new collaboration agreements, if any.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License, collaboration and other revenue decreased for the three months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to the three months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> due to a decrease in revenue recognized under our collaboration agreement with Lilly. License, collaboration and other revenue decreased for the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> primarily due to the recognition of $1,059.8 million from the BMS Collaboration Agreement as described in Note 7 to our Condensed Consolidated Financial Statements. In addition, during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, we recognized a $10.0 million milestone payment received in March 2018 as a result of the marketing authorization of ADYNOVI</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></span><span style="font-family:inherit;font-size:10pt;"> in the EU in January 2018. </span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect that our license, collaboration and other revenue will decrease significantly in the full year of 2019 compared to 2018 as a result of the revenue recognized in 2018 from the BMS Collaboration Agreement.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Goods Sold and Product Gross Margin (in thousands, except percentages)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80842911877394%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three months ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Decrease)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 vs. 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Decrease)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 vs. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,927</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,783</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">144</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product gross profit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">631</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(527</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,158</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&lt;(100)%</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product gross margin</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(12</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage<br/>Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15,385</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16,951</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,566</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(9</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product gross profit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(1,083</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(537</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(546</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&gt;100%</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product gross margin</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our strategy is to manufacture and supply polymer reagents to support our proprietary drug candidates or our third-party collaborators where we have a strategic development and commercialization relationship or where we derive substantial economic benefit. We have elected to only enter into and maintain those manufacturing relationships associated with long-term collaboration agreements which include multiple sources of revenue, which we view holistically and in aggregate. We have a predominantly fixed cost base associated with our manufacturing activities. As a result, our product gross profit and margin are significantly impacted by the mix and volume of products sold in each period.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The changes in cost of goods sold for the three and nine months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, as compared to the comparable periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, are consistent with the changes in product sales for such periods. The changes in product gross profit and product gross margin for the three and nine months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, as compared to the comparable periods ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, reflect the changes in product sales and mix of products sold. We have a manufacturing arrangement with a partner that includes a fixed price which is less than the fully burdened manufacturing cost for the reagent, and we expect this situation to continue with this partner in future years. This arrangement resulted in negative product gross profit for product sales to this partner for all periods presented. In addition to product sales from reagent materials </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">supplied to this partner, we also receive royalty revenue from this collaboration. In the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the royalty revenue from this collaboration exceeded the related negative gross profit.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect product gross margin to continue to fluctuate in future periods depending on the level and mix of manufacturing orders from our customers due to the predominantly fixed cost base associated with our manufacturing activities. We currently expect product gross margin to be negative in 2019 primarily as a result of the shipments to our partner where our sales are less than our fully burdened manufacturing cost.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expense (in thousands, except percentages)</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.31800766283524%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three months ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Decrease)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 vs. 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Decrease)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 vs. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">99,048</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">102,895</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(3,847</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(4</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage<br/>Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">324,197</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">290,653</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33,544</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expense consists primarily of clinical study costs, contract manufacturing costs, direct costs of outside research, materials, supplies, licenses and fees as well as personnel costs (including salaries, benefits, and stock-based compensation). Research and development expense also includes certain overhead allocations consisting of support and facilities-related costs. Where we perform research and development activities under a clinical joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense, and we record our share of our partners&#8217; expenses as an increase to research and development expense.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expense increased during the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> primarily due to our clinical development of NKTR-214, NKTR-358 and NKTR-262, and preclinical activities for NKTR-255. These increases were partially offset by a decrease in pre-commercial manufacturing and costs related to our NDA filing for NKTR-181. In particular, we incurred significant contract manufacturing costs for NKTR-214 and our other drug candidates for our broad clinical development for NKTR-214 under the BMS Collaboration Agreement, collaboration agreements with third parties and our own studies. However, these contract manufacturing costs are not ratable and may vary from period to period. We commenced significant manufacturing campaigns in nine months ended September 30, 2018 which were substantially completed in the six months ended June 30, 2019. The conclusion of these manufacturing campaigns resulted in the decrease in research and development expense for the three months ended September 30, 2019 as compared to the three months ended September 30, 2018. This decrease was partially offset by the increase in clinical development costs noted above. </span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These increases were partially offset by cost reimbursements by BMS under our collaboration agreement. During the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we recorded net reductions to research and development expense for BMS&#8217; reimbursements of our costs of </span><span style="font-family:inherit;font-size:10pt;">$28.3 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$81.4 million</span><span style="font-family:inherit;font-size:10pt;">, respectively.&#160;During the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, we recorded net reductions to research and development expense for BMS&#8217; reimbursements of our costs of </span><span style="font-family:inherit;font-size:10pt;">$18.9 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;text-align:right;">$42.8 million</span><span style="font-family:inherit;font-size:10pt;">, respectively. Under the BMS Collaboration Agreement, BMS bears 67.5% of internal and external expenses for development costs for NKTR-214 in combination with Opdivo</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and 35% of costs for manufacturing NKTR-214.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the research and development expense during the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, as compared to the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, reflects increases in personnel costs, including non-cash stock-based compensation. </span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect research and development expense to increase for the full year of 2019 compared to 2018 primarily as a result of the development of NKTR-214 under the BMS Collaboration Agreement, as well as the ongoing development of NKTR-358 and NKTR-255.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other than as described in the Overview section above, there have been no material changes to the status of clinical programs in the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> from the activities discussed in our Annual Report on Form 10-K for the year ended December&#160;31, 2018 on file with the SEC.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expense (in thousands, except percentages)</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three months ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Decrease)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 vs. 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Decrease)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 vs. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23,983</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18,718</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,265</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage<br/>Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">71,570</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">57,666</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,904</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expense includes the cost of administrative staffing, business development, marketing, finance and legal activities. General and administrative expense increased during the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared with the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> primarily due to increased costs related to NKTR-181 and NKTR-214 commercialization readiness activities and non-cash stock-based compensation. We expect general and administrative expenses in the full year of 2019 to increase compared to 2018, primarily due to increased costs for commercialization readiness activities and non-cash stock-based compensation. If NKTR-181 receives regulatory approval, we initially plan to commercialize NKTR-181 through our subsidiary, Inheris Biopharma, Inc. (Inheris), and we expect significant increases in commercialization costs, including sales personnel and related costs to support Inheris.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense (in thousands, except percentages)</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.23371647509579%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three months ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage<br/>Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,425</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,442</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(17</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage<br/>Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15,882</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16,167</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(285</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense during the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> primarily consists of interest from our senior secured notes. In October 2015, we issued $250.0 million in aggregate principal amount of 7.75% senior secured notes due October 2020. Interest on the 7.75% senior secured notes is calculated based on actual days outstanding over a 360 day year. Interest expense for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is consistent with the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, and we expect interest expense during the full year of 2019 to be consistent with 2018.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Non-Cash Royalty Revenue and Non-Cash Interest Expense</span></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three months ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage<br/>Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash royalty revenue related to sale of future royalties</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,264</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,372</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,892</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash interest expense on liability related to sale of future royalties</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,813</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,814</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">999</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage<br/>Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash royalty revenue related to sale of future royalties</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27,585</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24,337</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,248</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash interest expense on liability related to sale of future royalties</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17,853</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,808</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,045</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For a discussion of the sale of future royalties for CIMZIA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and MIRCERA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, see Note 5 to our Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As discussed in Note 5, we continue to recognize non-cash royalty revenue, which increased for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared with the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> due to increases in sales of  CIMZIA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and MIRCERA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash interest expense increased for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared with the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> due our increase of the estimated effective interest rate. During the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, we recognized interest expense at a rate of 21%. During the three month period ended December 31, 2018, primarily as a result of increases in the forecasted sales of MIRCERA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, our estimate of the effective annual interest rate over the life of the agreement increased from 17.6% to approximately 18.7%, which results in a prospective interest rate of 29%.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> Over the term of this arrangement, the net proceeds of the transaction of $114.0 million, consisting of the original proceeds of $124.0 million, net of $10.0 million in payments from us to RPI, is amortized as the difference between the non-cash royalty revenue and the non-cash interest expense. To date, we have amortized $38.9 million of the net proceeds. We periodically assess future non-cash royalty revenues, and we may adjust the prospective effective interest rate based on our best estimates of future non-cash royalty revenue such that future non-cash interest expense will amortize the remaining $75.1 million of the net proceeds. There are a number of factors that could materially affect our estimated interest rate, in particular, the amount and timing of royalty payments from future net sales of CIMZIA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and MIRCERA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. As a result, future interest rates could differ significantly, and we will adjust any such change in our estimated interest rate prospectively. We expect non-cash interest expense on the liability related to sale of future royalties for the full year of 2019 to increase compared to 2018 as a result of the increase of the estimated prospective interest rate noted above.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Income and Other Income (Expense), net (in thousands, except percentages)</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.31800766283524%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three months ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Decrease)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 vs. 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Decrease)</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019 vs. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income and other income (expense), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11,492</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11,847</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(355</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage<br/>Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income and other income (expense), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35,964</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25,523</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,441</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income and other income (expense) decreased marginally for the three months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to the three months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">. Interest income and other income (expense) for the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> increased significantly compared to the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> primarily due to increased interest income resulting from our investments in debt securities purchased with the $1.85 billion received in April 2018 from BMS under the BMS Collaboration Agreement and the Share Purchase Agreement. We expect that our interest income and other income (expense), net will increase in the full year of 2019 compared to 2018 as a result of the increased interest income resulting from our increased investments balances.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Tax Expense</span></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.31800766283524%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage<br/>Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision (benefit) for income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">322</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(900</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,222</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&gt;(100%)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage<br/>Increase/<br/>(Decrease)<br/>2019 vs. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision (benefit) for income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(939</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,250</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(4,189</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&lt;(100%)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we recorded an income tax provision for our Nektar India operations at an effective tax rate of approximately </span><span style="font-family:inherit;font-size:10pt;">33%</span><span style="font-family:inherit;font-size:10pt;">. Due to our net loss and unrealized gain on available-for-sale securities in the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we recorded a tax provision against such unrealized gain with an offsetting tax benefit in continuing operations of </span><span style="font-family:inherit;font-size:10pt;">$1.3 million</span><span style="font-family:inherit;font-size:10pt;">. For the three months ended September 30, 2019, since we had a loss on our available-for-sale securities, we recorded a benefit of $0.3 million against our unrealized loss on available-for-sale securities with an offsetting expense in continuing operations. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, as a result of taxable income in India and the U.S., primarily resulting from income recognized from the upfront payment from BMS, we recorded a global income tax provision at an effective tax rate of approximately 0.4%. The income tax benefit for the three months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> reflects our pre-tax loss for that period. Our income resulted in tax liabilities in certain states where we did not have sufficient net operating losses to offset our estimated apportioned taxable income. We based our effective tax rate on certain assumptions and other estimates regarding the apportionment of taxable income and the states in which we had nexus in 2018. Our apportionment of taxable income included estimates of the apportionment of the BMS upfront payment based on estimates of activities to be carried out </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">under the collaboration agreement with BMS, as well as estimates of the apportionment of other sources of income. Our effective tax rate reflected the release of the valuation allowance of net operating loss carryforwards and other tax credits to offset U.S. federal and state taxable income. </span></div><div><a id="sE2A423CB5CCE587D923AE7DB5110A3D6"></a></div><div style="line-height:120%;padding-top:24px;text-indent:2px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have financed our operations primarily through revenue from product sales, royalties and strategic collaboration agreements, as well as public offering and private placements of debt and equity securities. At </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had approximately </span><span style="font-family:inherit;font-size:10pt;">$1.7 billion</span><span style="font-family:inherit;font-size:10pt;"> in cash and investments in marketable securities and had debt of $250.0 million in principal of senior secured notes due on October 2020.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate that we have working capital to fund our current business plans through at least the next twelve months. We expect the clinical development of our proprietary drug candidates, including NKTR-214, NKTR-358, NKTR-262, NKTR-255, NKTR-181, and ONZEALD</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, will continue to require significant investment in order to continue to advance in clinical development and to obtain regulatory approval, as well as for NKTR-181 commercialization activities. In the past, we have received a number of significant payments from collaboration agreements and other significant transactions. In April 2018, we received a total of $1.85 billion from BMS under the BMS Collaboration Agreement and the Share Purchase Agreement. Under the BMS Collaboration Agreement, BMS is responsible for 67.5% of the development costs for NKTR-214 in combination with Opdivo</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and 35% of the costs of manufacturing NKTR-214. In the future, we expect to receive substantial payments from our collaboration agreements with BMS and Lilly and other existing and future collaboration transactions if drug candidates in our pipeline achieve positive clinical or regulatory outcomes. In particular, under the BMS Collaboration Agreement, we are entitled to $1.43 billion of regulatory and commercial launch milestones, $650 million of which are associated with approval and launch of NKTR-214 in its first indication in the U.S., EU and Japan. As a result, whether and when NKTR-214 is approved in any indication will have a significant impact on our future liquidity and capital resources. We have no credit facility or any other sources of committed capital.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due to the potential for adverse developments in the credit markets, we may experience reduced liquidity with respect to some of our investments in marketable securities. These investments are generally held to maturity, which, in accordance with our investment policy, is less than two years. However, if the need arises to liquidate such securities before maturity, we may experience losses on liquidation. At </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the average time to maturity of the investments held in our portfolio was approximately six months. To date we have not experienced any liquidity issues with respect to these securities. We believe that, even allowing for potential liquidity issues with respect to these securities, our remaining cash and investments in marketable securities will be sufficient to meet our anticipated cash needs for at least the next twelve months.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our current business plan is subject to significant uncertainties and risks as a result of, among other factors, clinical and regulatory outcomes for NKTR-214, the sales levels of our products, if and when they are approved, the sales levels for those products for which we are entitled to royalties, clinical program outcomes, whether, when and on what terms we are able to enter into new collaboration transactions, expenses being higher than anticipated, unplanned expenses, cash receipts being lower than anticipated, and the need to satisfy contingent liabilities, including litigation matters and indemnification obligations.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The availability and terms of various financing alternatives, if required in the future, substantially depend on many factors including the success or failure of drug development programs in our pipeline. The availability and terms of financing alternatives and any future significant payments from existing or new collaborations depend on the positive outcome of ongoing or planned clinical studies, whether we or our partners are successful in obtaining regulatory authority approvals in major markets, and if approved, the commercial success of these drugs, as well as general capital market conditions.&#160;We may pursue various financing alternatives to fund the expansion of our business as appropriate.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash flows from operating activities</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flows used in operating activities for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> totaled $203.5 million, which includes $199.2 million of net operating cash uses as well as $14.3 million for interest payments on our senior secured notes, partially offset by the receipt of a $10.0 million sales milestone payment from our collaboration agreement with Baxalta. </span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flows provided by operating activities for the nine months ended September 30, 2018 totaled $835.8 million, which includes $1,059.8 million of the payments received under the BMS Collaboration Agreement in April 2018 and a $10.0 million milestone payment from our collaboration agreement with Baxalta, partially offset by $219.3 million of net operating cash uses as well as $14.7 million for interest payments on our senior secured notes. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect that cash flows used in operating activities, excluding upfront, milestone and other contingent payments received, will increase in the full year of 2019 compared to 2018 primarily as a result of increased research and development expenses.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash flows from investing activities</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We paid $22.6&#160;million and $5.6&#160;million for the purchase or construction of property, plant and equipment in the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. The increase for the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared with </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> resulted from the construction of leasehold improvements at our new facilities lease on Third St. as described in Note 4 to our Condensed Consolidated Financial Statements. We expect our capital expenditures in the full year of 2019 to increase significantly compared with 2018, primarily due to the construction of these leasehold improvements. </span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash flows from financing activities</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We received proceeds from issuance of common stock related to our employee option and stock purchase plans of </span><span style="font-family:inherit;font-size:10pt;">$18.4 million</span><span style="font-family:inherit;font-size:10pt;"> and $59.1&#160;million in the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. We received $790.2 million for the issuance of our common stock to BMS under our Share Purchase Agreement in the nine months ended September 30, 2018. </span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contractual Obligations</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other than the increase in our facilities lease obligations as disclosed in Note 4 to our Condensed Consolidated Financial Statements, there were no material changes outside the ordinary course of business during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> to the summary of contractual obligations included in our Annual Report on Form 10-K for the year ended December&#160;31, 2018 on file with the SEC.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not utilize off-balance sheet financing arrangements as a source of liquidity or financing.</span></div><div><a id="s193490C1FCA15A1C8704C5CF76233C77"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Estimates</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates on an ongoing basis. Actual results may differ from those estimates under different assumptions or conditions. Other than as the result of the adoption of the new lease accounting guidance (ASC 842) as described in Note 1 to our Condensed Consolidated Financial Statements, there have been no material changes to our critical accounting policies and estimates discussed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2018.</span></div><div><a id="s2F6DBFB25F985479BE41E1F3C0D37D35"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quantitative and Qualitative Disclosures about Market Risk</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our market risks at </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> have not changed materially from those discussed in Item&#160;7A of our Annual Report on Form 10-K for the year ended December&#160;31, 2018 on file with the SEC.</span></div><div><a id="s21A137D2F7D250AB8792CA4384490827"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;4.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Controls and Procedures</span></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Disclosure Controls and Procedures</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 (Exchange Act) reports is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon, and as of the date of, this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in Internal Control Over Financial Reporting</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We continuously seek to improve the efficiency and effectiveness of our internal controls. This results in refinements to processes throughout the Company. However, there was no change in our internal control over financial reporting that occurred in the three months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Limitations on the Effectiveness of Controls</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34</span></div></div><hr style="page-break-after:always"></hr><div><a id="s79543C0FC4BA5385BA0DAB27FC69DD0B"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II: OTHER INFORMATION</span></div><div><a id="s380832B7A2D75983B7FBC53DFB64D5AD"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reference is hereby made to our disclosures in &#8220;Legal Matters&#8221; under Note 6 to our Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q and the information under the heading &#8220;Legal Matters&#8221; is incorporated by reference herein.</span></div><div><a id="s73E292CA6AA15C8DA3BF0EBAD79F9E01"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1A.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk Factors</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. The risks described below may not be the only ones relating to our company. This description includes any material changes to and supersedes the description of the risk factors associated with our business previously disclosed in Item&#160;1A of our Annual Report on Form 10-K for the year ended December&#160;31, 2018. Additional risks that we currently believe are immaterial may also impair our business operations. Our business, results of operations, financial condition, cash flows and future prospects and the trading price of our common stock and our ability to repay our senior secured notes could be harmed as a result of any of these risks, and investors may lose all or part of their investment. In assessing these risks, investors should also refer to the other information contained or incorporated by reference in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December&#160;31, 2018, including our consolidated financial statements and related notes, and our other filings made from time to time with the SEC.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Business</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are highly dependent on the success of NKTR-214, our lead immuno-oncology (I-O) candidate.&#160;We are executing a clinical development program for NKTR-214 and clinical and regulatory outcomes for NKTR-214, if not successful, will significantly harm our business.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our future success is highly dependent on our ability to successfully develop, obtain regulatory approval for, and commercialize NKTR-214. In general, most early stage investigation drugs, including immuno-oncology drug candidates such as NKTR-214, do not become approved drugs. Accordingly, there is a very meaningful risk that NKTR-214 will not succeed in one or more clinical trials sufficient to support one or more regulatory approvals.&#160;To date, reported clinical outcomes from NKTR-214 have had a significant impact on our market valuation, financial position, and business prospects and we expect this to continue in future periods.&#160;If one or more clinical studies of NKTR-214 are delayed or not successful, it would materially harm our market valuation, prospects, financial condition and results of operations.&#160;For example, under the BMS Collaboration Agreement, we are entitled to up to $1.43 billion in development milestones that are based upon clinical and regulatory successes from the NKTR-214 development program. One or more failures in NKTR-214 studies could jeopardize such milestone payments, and any product sales or royalty revenue or commercial milestones that we would otherwise be entitled to receive could be reduced, delayed or eliminated.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Delays in clinical studies are common and have many causes, and any significant delay in clinical studies being conducted by us or our partners could result in delay in regulatory approvals and jeopardize the ability to proceed to commercialization.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We or our partners may experience delays in clinical trials of drug candidates. We have ongoing trials evaluating NKTR-214 including trials evaluating NKTR-214 as a potential combination treatment with BMS&#8217;s Opdivo</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (nivolumab) as well as other ongoing and planned combination trials. Our partner Lilly has initiated clinical Phase 1b studies of NKTR-358 in patients with psoriasis and atopic dermatitis. We also continue to enroll patients in a Phase 1/2 study evaluating NKTR-214 in combination with NKTR-262.&#160;&#160;In addition, we have initiated a first-in-human Phase 1 clinical study of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma. These and other clinical studies may not begin on time, enroll a sufficient number of patients or be completed on schedule, if at all. Clinical trials for any of our product candidates could be delayed for a variety of reasons, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays in obtaining regulatory authorization to commence a clinical study;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays in reaching agreement with applicable regulatory authorities on a clinical study design;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">for product candidates (such as NKTR-214) partnered with other companies, delays caused by our partner;  </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">imposition of a clinical hold by the FDA or other health authorities, which may occur at any time including after any inspection of clinical trial operations or trial sites;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">suspension or termination of a clinical study by us, our partners, the FDA or foreign regulatory authorities due to adverse side effects of a drug on subjects in the trial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays in recruiting suitable patients to participate in a trial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">clinical sites dropping out of a trial to the detriment of enrollment rates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays in manufacturing and delivery of sufficient supply of clinical trial materials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in regulatory authorities policies or guidance applicable to our drug candidates; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays caused by changing standards of care or new treatment options.</span></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the initiation or completion of any of the planned clinical studies for our drug candidates is delayed for any of the above or other reasons, the regulatory approval process would be delayed and the ability to commercialize and commence sales of these drug candidates could be materially harmed, which could have a material adverse effect on our business, financial condition and results of operations. Clinical study delays could also shorten any commercial periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The outcomes from competitive I-O and combination therapy clinical trials, and the discovery and development of new potential oncology therapies, could have a material and adverse impact on the value of our I-O research and development pipeline.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The research and development of I-O therapies is a very competitive global segment in the biopharmaceutical industry attracting billions of dollars of investment each year.&#160; Our clinical trial plans for NKTR-214, NKTR-262, and NKTR-255 face substantial competition from other I-O combination regimens already approved, and many more combination therapies that are either ahead of or in parallel development in patient populations where we are studying our drug candidates. As I-O combination therapies are relatively new approaches in cancer treatment and few have successfully completed late stage development, I-O drug development entails substantial risks and uncertainties that include rapidly changing standards of care, patient enrollment competition, evolving regulatory frameworks to evaluate combination regimens, and varying risk-benefit profiles of competing therapies, any or all of which could have a material and adverse impact on the probability of success of I-O drug candidates.&#160;</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Drug development is a long and inherently uncertain process with a high risk of failure at every stage of development.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have a number of proprietary drug candidates and partnered drug candidates in research and development ranging from the early discovery research phase through preclinical testing and clinical trials. Preclinical testing and clinical studies are long, expensive, difficult to design and implement and highly uncertain as to outcome. It will take us, or our collaborative partners, many years to conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidates. The start or end of a clinical study is often delayed or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparator drug or required prior therapy, clinical outcomes, or our and our partners&#8217; financial constraints.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Drug development is a highly uncertain scientific and medical endeavor, and failure can unexpectedly occur at any stage of preclinical and clinical development. Typically, there is a high rate of attrition for drug candidates in preclinical and clinical trials due to scientific feasibility, safety, efficacy, changing standards of medical care (including commercialization of a competing therapy in the same or similar indication for which our drug candidate is being studied) and other variables (such as commercial supply challenges). The risk of failure increases for our drug candidates that are based on new technologies, such as the application of our advanced polymer conjugate technology to NKTR-214, NKTR-358, NKTR-262, NKTR-255, NKTR-181, ONZEALD</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, and other drug candidates currently in discovery research or preclinical development. The failure of one or more of our drug candidates could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The risk of clinical failure for any drug candidate remains high prior to regulatory approval.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of companies have suffered significant unforeseen failures in clinical studies due to factors such as inconclusive efficacy or safety, even after achieving preclinical proof-of-concept or positive results from earlier clinical studies that were satisfactory both to them and to reviewing regulatory authorities. Clinical study outcomes remain very unpredictable and it is possible that one or more of our clinical studies could fail at any time due to efficacy, safety or other important clinical findings or regulatory requirements. The results from preclinical testing or early clinical trials of a product candidate may not predict the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">results that will be obtained in later phase clinical trials of the product candidate. We, the FDA, an independent Institutional Review Board (IRB), an independent ethics committee (IEC), or other applicable regulatory authorities may suspend clinical trials of a product candidate at any time for various reasons, including a belief that patients participating in such trials are being exposed to unacceptable health risks or adverse side effects. Similarly, an IRB or IEC may suspend a clinical trial at a particular trial site. If one or more of our drug candidates fail in clinical studies, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we or our contract manufacturers are not able to manufacture drugs or drug substances in sufficient quantities that meet applicable quality standards, it could delay clinical studies, result in reduced sales or constitute a breach of our contractual obligations, any of which could significantly harm our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we or our contract manufacturers are not able to manufacture and supply sufficient drug quantities meeting applicable quality standards required to support large clinical studies or commercial manufacturing in a timely manner, it could delay our or our collaboration partners&#8217; clinical studies or result in a breach of our contractual obligations, which could in turn reduce the potential commercial sales of our or our collaboration partners&#8217; products. As a result, we could incur substantial costs and damages and any product sales or royalty revenue that we would otherwise be entitled to receive could be reduced, delayed or eliminated. In most cases, we rely on contract manufacturing organizations to manufacture and supply drug product for our clinical studies and those of our collaboration partners. The manufacturing of drugs involves significant risks and uncertainties related to the demonstration of adequate stability, sufficient purification of the drug substance and drug product, the identification and elimination of impurities, optimal formulations, process and analytical methods validations, and challenges in controlling for all of these variables. We have faced and may in the future face significant difficulties, delays and unexpected expenses as we validate third party contract manufacturers required for drug supply to support our clinical studies and the clinical studies and products of our collaboration partners. Failure by us or our contract manufacturers to supply API or drug products in sufficient quantities that meet all applicable quality requirements could result in supply shortages for our clinical studies or the clinical studies and commercial activities of our collaboration partners. Such failures could significantly and materially delay clinical trials and regulatory submissions or result in reduced sales, any of which could significantly harm our business prospects, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Building and validating large scale clinical or commercial-scale manufacturing facilities and processes, recruiting and training qualified personnel and obtaining necessary regulatory approvals is complex, expensive and time consuming. In the past, we have encountered challenges in scaling up manufacturing to meet the requirements of large scale clinical trials without making modifications to the drug formulation, which may cause significant delays in clinical development. There continues to be substantial and unpredictable risk and uncertainty related to manufacturing and supply until such time as the commercial supply chain is validated and proven.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We purchase some of the starting material for drugs and drug candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause production delays, clinical trial delays, substantial loss of revenue and contract liability to third parties.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We often face very limited supply of a critical raw material that can only be obtained from a single, or a limited number of, suppliers, which could cause production delays, clinical trial delays, substantial lost revenue opportunities or contract liabilities to third parties. For example, there are only a limited number of qualified suppliers, and in some cases single source suppliers, for the raw materials included in our PEGylation and advanced polymer conjugate drug formulations. Any interruption in supply or failure to procure such raw materials on commercially feasible terms could harm our business by delaying our clinical trials, impeding commercialization of approved drugs or increasing our costs.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our manufacturing operations and those of our contract manufacturers are subject to laws and other governmental regulatory requirements, which, if not met, would have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and our contract manufacturers are required in certain cases to maintain compliance with current good manufacturing practices (cGMP), including cGMP guidelines applicable to active pharmaceutical ingredients, and drug products, and with laws and regulations governing manufacture and distribution of controlled substances, and are subject to inspections by the FDA, the Drug Enforcement Administration or comparable agencies in other jurisdictions administering such requirements. We anticipate periodic regulatory inspections of our drug manufacturing facilities and the manufacturing facilities of our contract manufacturers for compliance with applicable regulatory requirements. Any failure to follow and document our or our contract manufacturers&#8217; adherence to such cGMP and other laws and governmental regulations or satisfy other manufacturing and product release regulatory requirements may disrupt our ability to meet our manufacturing obligations to our customers, lead to significant delays </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">in the availability of products for commercial use or clinical study, result in the termination or hold on a clinical study or delay or prevent filing or approval of marketing applications for our products. Failure to comply with applicable laws and regulations may also result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, license revocation, seizures, administrative detention, or recalls of products, operating restrictions and criminal prosecutions, any of which could harm our business. Regulatory inspections could result in costly manufacturing changes or facility or capital equipment upgrades to satisfy the FDA that our manufacturing and quality control procedures are in substantial compliance with cGMP. Manufacturing delays, for us or our contract manufacturers, pending resolution of regulatory deficiencies or suspensions could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we or our partners do not obtain regulatory approval for our drug candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, our business, results of operations and financial condition will be negatively affected.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We or our partners may not obtain regulatory approval for drug candidates on a timely basis, or at all, or the terms of any approval (which in some countries includes pricing approval) may impose significant restrictions or limitations on use. Drug candidates must undergo rigorous animal and human testing and an extensive review process for safety and efficacy by the FDA and equivalent foreign regulatory authorities. The time required for obtaining regulatory decisions is uncertain and difficult to predict. For example, although the FDA granted a Breakthrough Therapy designation to NKTR-214 in combination with nivolumab for the treatment of patients with previously untreated unresectable or metastatic melanoma, there is no guarantee regulatory approval will follow, if at all, for this or any indication of NKTR-214 on a timely basis. The FDA and other U.S. and foreign regulatory authorities have substantial discretion, at any phase of development, to terminate clinical studies, require additional clinical development or other testing, delay or withhold registration and marketing approval and mandate product withdrawals, including recalls. For example, while data from certain pre-specified subgroups in our BEACON study for ONZEALD</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in 2015 was positive, the study did not achieve statistical significance for its primary endpoint and the FDA and European Medicines Agency rarely approve drugs on the basis of studies that do not achieve statistical significance on the primary endpoint. Further, regulatory authorities have the discretion to analyze data using their own methodologies that may differ from those used by us or our partners, which could lead such authorities to arrive at different conclusions regarding the safety or efficacy of a drug candidate. In addition, undesirable side effects caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restricted label or the delay or denial of regulatory approval by regulatory authorities. For example, AstraZeneca is&#160;conducting a post-marketing, observational epidemiological study comparing MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> to other treatments of opioid-induced constipation (OIC) in patients with chronic, non-cancer pain and the results of this study could at some point in the future negatively impact the labeling, regulatory status, and commercial potential of MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we or our partners receive regulatory approval of a product, the approval may limit the indicated uses for which the drug may be marketed. Our and our partnered drugs that have obtained regulatory approval, and the manufacturing processes for these products, are subject to continued review and periodic inspections by the FDA and other regulatory authorities. Discovery from such review and inspection of previously unknown problems may result in restrictions on marketed products or on us, including withdrawal or recall of such products from the market, suspension of related manufacturing operations or a more restricted label. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:24px;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The NKTR-181 program is subject to important risks and uncertainties related to likelihood of FDA approval, commercial potential, and nonconvertibility of NKTR-181, any of which could significantly and negatively impact the economic value of NKTR-181.&#160;</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 31, 2018, we announced that we submitted an NDA for NKTR-181 and on July 30, 2018, we announced that the NDA for NKTR-181 for the treatment of chronic low back pain in opioid-na&#239;ve adult patients was accepted by the FDA for review.  The FDA missed the target action date of August 29, 2019 that it had assigned to our NDA under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), and has postponed product-specific advisory committee meetings for opioid analgesics, including one that was previously scheduled for NKTR-181 on August 21, 2019. We currently anticipate an advisory committee meeting for NKTR-181 will be formally scheduled to occur within the next several months.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA continues to consider a number of scientific and policy issues relating this class of drugs. While the results from the Phase 3 study of NKTR-181 were positive, and NKTR-181 has Fast Track designation, the regulatory pathway for NKTR-181 remains subject to substantial uncertainty including changing and evolving standards for approving new opioid-based drugs generally and the amount of data required to support an approval of NKTR-181. In addition, regulations concerning and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">controlling the access to opioid-based pharmaceuticals are strict and there is no guarantee which scheduling category will apply to NKTR-181 if regulatory approval is achieved.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The commercial potential of NKTR-181 remains difficult to predict due to factors that include, for example, the safety and efficacy compared to other available treatments, changing standards of care, third party payer reimbursement standards, scope and contents of the NKTR-181 label, constraints on marketing, patient and physician preferences, drug scheduling status, current and future litigation involving analgesic pharmaceuticals, perceived or actual resistance to the introduction of new controlled substances to the market, the availability of competitive alternatives that may emerge either during or after approval, the availability of generic versions of our NKTR-181, and the countries in which we receive regulatory approvals.&#160; If the market potential for NKTR-181 is lower than we anticipate, it could significantly and negatively impact the commercial potential and value of NKTR-181.&#160;</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the event that we commercialize and market NKTR-181, we would be required to build, either internally or through third-party contracts, a sales and marketing organization and infrastructure, which would require a significant investment, and we may not be successful in building this organization and infrastructure in a timely or efficient manner.  We intend to support any commercialization of NKTR-181 with one or more potential capital partners, but there is no guarantee we will be successful in finalizing a capital partnership for this purpose. An important objective of NKTR-181 drug development program is to create a unique opioid molecule that does not rapidly enter a patient&#8217;s central nervous system, thereby having the potential to be less susceptible to abuse than alternative opioid therapies. To date, we have conducted numerous experiments using laboratory and home-based chemistry techniques that have been unable to convert NKTR-181 into a rapidly-acting, more abusable form of opioid. In the future, an alternative chemistry technique, process or method of administration, or combination thereof, may be discovered to enable the conversion of NKTR-181 into a more abusable opioid.&#160;</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If NKTR-181 is approved by FDA, the ability to market and promote NKTR-181 will depend on the scope and content of the final FDA-approved labeling, which could have a material and adverse impact on the market potential of NKTR-181.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If NKTR-181 is approved by the FDA, the commercial success of NKTR-181 will be materially impacted by the FDA-approved label which will set forth the patient population covered by the approved indication in the label, the required warnings, a description of efficacy outcomes, and the human abuse potential profile of NKTR-181, among other matters, for healthcare providers and patients.&#160;&#160;FDA approval is required to make safety and efficacy claims regarding a product.&#160;&#160;As a result, there is substantial risk and uncertainty regarding the content of the final label and package insert for NKTR-181, if approved by FDA, which could materially and adversely impact the commercial potential of NKTR-181.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our results of operations and financial condition depend significantly on the ability of our collaboration partners to successfully develop and market drugs and they may fail to do so.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under our collaboration agreements with various pharmaceutical or biotechnology companies (other than the BMS Collaboration Agreement), our collaboration partner is generally solely responsible for:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">designing and conducting large scale clinical studies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">preparing and filing documents necessary to obtain government approvals to sell a given drug candidate; and/or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">marketing and selling the drugs when and if they are approved.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our reliance on collaboration partners poses a number of significant risks to our business, including risks that:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we have very little control over the timing and level of resources that our collaboration partners dedicate to commercial marketing efforts such as the amount of investment in sales and marketing personnel, general marketing campaigns, direct-to-consumer advertising, product sampling, pricing agreements and rebate strategies with government and private payers, manufacturing and supply of drug product, and other marketing and selling activities that need to be undertaken and well executed for a drug to have the potential to achieve commercial success;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">collaboration partners with commercial rights may choose to devote fewer resources to the marketing of our partnered drugs than they devote to their own drugs or other drugs that they have in-licensed;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we have very little control over the timing and amount of resources our partners devote to development programs in one or more major markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disagreements with partners could lead to delays in, or termination of, the research, development or commercialization of product candidates or to litigation or arbitration proceedings;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disputes may arise or escalate in the future with respect to the ownership of rights to technology or intellectual property developed with partners;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we do not have the ability to unilaterally terminate agreements (or partners may have extension or renewal rights) that we believe are not on commercially reasonable terms or consistent with our current business strategy;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partners may be unable to pay us as expected; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">partners may terminate their agreements with us unilaterally for any or no reason, in some cases with the payment of a termination fee penalty and in other cases with no termination fee penalty.</span></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Given these risks, the success of our current and future collaboration partnerships is highly unpredictable and can have a substantial negative impact on our business. If the approved drugs fail to achieve commercial success or the drugs in development fail to have positive late stage clinical outcomes sufficient to support regulatory approval in major markets, it could significantly impair our access to capital necessary to fund our research and development efforts for our proprietary drug candidates. If we are unable to obtain sufficient capital resources to advance our drug candidate pipeline, it would negatively impact the value of our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have substantial future capital requirements and there is a risk we may not have access to sufficient capital to meet our current business plan. If we do not receive substantial milestone or royalty payments from our existing collaboration agreements, execute new high value collaborations or other arrangements, or are unable to raise additional capital in one or more financing transactions, we would be unable to continue our current level of investment in research and development.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had cash and investments in marketable securities valued at approximately </span><span style="font-family:inherit;font-size:10pt;">$1.7 billion</span><span style="font-family:inherit;font-size:10pt;"> and had debt of $250.0 million in principal of senior secured notes. While we believe that our cash position will be sufficient to meet our liquidity requirements through at least the next 12 months, our future capital requirements will depend upon numerous unpredictable factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost, timing and outcomes of clinical studies and regulatory reviews of our proprietary drug candidates that we have licensed to our collaboration partners &#8212;important examples include NKTR-214 in collaboration with BMS and NKTR-358 licensed to Lilly;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the commercial launch and sales levels of products marketed by our collaboration partners for which we are entitled to royalties and sales milestones&#8212;importantly, the level of success in marketing and selling MOVANTIK</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> by AstraZeneca in the U.S. and ADYNOVATE</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> by Baxalta (a wholly-owned subsidiary of Takeda) globally, as well as MOVENTIG</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (the naloxegol brand name in the EU) by Kirin in the EU;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">if and when we receive potential milestone payments and royalties from our existing collaborations if the drug candidates subject to those collaborations achieve clinical, regulatory or commercial success;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the progress, timing, cost and results of our clinical development programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the success, progress, timing and costs of our efforts to implement new collaborations, licenses and other transactions that increase our current net cash, such as the sale of additional royalty interests held by us, term loan or other debt arrangements, and the issuance of securities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the number of patients, enrollment criteria, primary and secondary endpoints, and the number of clinical studies required by the regulatory authorities in order to consider for approval our drug candidates and those of our collaboration partners;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our general and administrative expenses, capital expenditures and other uses of cash; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disputes concerning patents, proprietary rights, or license and collaboration agreements that negatively impact our receipt of milestone payments or royalties or require us to make significant payments arising from licenses, settlements, adverse judgments or ongoing royalties.</span></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A significant multi-year capital commitment is required to advance our drug candidates through the various stages of research and development in order to generate sufficient data to enable high value collaboration partnerships with significant upfront payments or to successfully achieve regulatory approval. In the event we do not enter into any new collaboration partnerships with significant upfront payments and we choose to continue our later stage research and development programs, we may need to pursue financing alternatives, including dilutive equity-based financings, such as an offering of convertible debt or common stock, which would dilute the percentage ownership of our current common stockholders and could significantly lower the market value of our common stock. If sufficient capital is not available to us or is not available on commercially reasonable </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">terms, it could require us to delay or reduce one or more of our research and development programs. If we are unable to sufficiently advance our research and development programs, it could substantially impair the value of such programs and result in a material adverse effect on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The commercial potential of a drug candidate in development is difficult to predict. If the market size for a new drug is significantly smaller than we anticipate, it could significantly and negatively impact our revenue, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">It is very difficult to estimate the commercial potential of product candidates due to important factors such as safety and efficacy compared to other available treatments, including potential generic drug alternatives with similar efficacy profiles, changing standards of care, third party payer reimbursement standards, patient and physician preferences, drug scheduling status, the availability of competitive alternatives that may emerge either during the long drug development process or after commercial introduction, and the availability of generic versions of our product candidates following approval by regulatory authorities based on the expiration of regulatory exclusivity or our inability to prevent generic versions from coming to market by asserting our patents. If due to one or more of these risks the market potential for a drug candidate is lower than we anticipated, it could significantly and negatively impact the commercial potential of the drug candidate, the commercial terms of any collaboration partnership potential for such drug candidate, or if we have already entered into a collaboration for such drug candidate, the revenue potential from royalty and milestone payments could be significantly diminished and this would negatively impact our business, financial condition and results of operations. We also depend on our relationships with other companies for sales and marketing performance and the commercialization of product candidates. Poor performance by these companies, or disputes with these companies, could negatively impact our revenue and financial condition.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If government and private insurance programs do not provide payment or reimbursement for our partnered products or proprietary products, those products will not be widely accepted, which would have a negative impact on our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In both domestic and foreign markets, sales of our partnered and proprietary products that have received regulatory approval will depend in part on market acceptance among physicians and patients, pricing approvals by government authorities and the availability of coverage and payment or reimbursement from third-party payers, such as government programs, including Medicare and Medicaid, managed care providers, private health insurers and other organizations. However, eligibility for coverage does not necessarily signify that a drug candidate will be adequately reimbursed in all cases or at a rate that covers costs related to research, development, manufacture, sale, and distribution. Third-party payers are increasingly challenging the price and cost effectiveness of medical products and services. Therefore, significant uncertainty exists as to the coverage and pricing approvals for, and the payment or reimbursement status of, newly approved healthcare products.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Moreover, legislation and regulations affecting the pricing of pharmaceuticals may change before regulatory agencies approve our proposed products for marketing and could further limit coverage or pricing approvals for, and reimbursement of, our products from government authorities and third-party payers. For example, Congress passed the Affordable Care Act in 2010 which enacted a number of reforms to expand access to health insurance while also reducing or constraining the growth of healthcare spending, enhancing remedies against fraud and abuse, adding new transparency requirements for healthcare industries, and imposing new taxes on fees on healthcare industry participants, among other policy reforms. Federal agencies, Congress and state legislatures have continued to show interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system. In addition, in recent years, Congress has enacted various laws seeking to reduce the federal debt level and contain healthcare expenditures, and the Medicare and other healthcare programs are frequently identified as potential targets for spending cuts. New government legislation or regulations related to pricing or other fundamental changes to the healthcare delivery system as well as a government or third-party payer decision not to approve pricing for, or provide adequate coverage or reimbursement of, our products hold the potential to severely limit market opportunities of such products.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We intend to continue to seek partnerships with pharmaceutical and biotechnology partners to fund a portion of our research and development capital requirements. The timing of new collaboration partnerships is difficult to predict due to availability of clinical data, the outcomes from our clinical studies, the number of potential partners that need to complete due diligence and approval processes, the definitive agreement negotiation process and numerous other unpredictable factors that can delay, impede or prevent significant transactions. If we are unable to find suitable partners or negotiate collaboration arrangements with favorable commercial terms with respect to our existing and future drug candidates or the licensing of our </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">intellectual property, or if any arrangements we negotiate, or have negotiated, are terminated, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our revenue is exclusively derived from our collaboration agreements, which can result in significant fluctuation in our revenue from period to period, and our past revenue is therefore not necessarily indicative of our future revenue.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our revenue is exclusively derived from our collaboration agreements, from which we receive upfront fees, contract research payments, milestone and other contingent payments based on clinical progress, regulatory progress or net sales achievements, royalties and product sales. Significant variations in the timing of receipt of cash payments and our recognition of revenue can result from payments based on the execution of new collaboration agreements, the timing of clinical outcomes, regulatory approval, commercial launch or the achievement of certain annual sales thresholds. The amount of our revenue derived from collaboration agreements in any given period will depend on a number of unpredictable factors, including our ability to find and maintain suitable collaboration partners, the timing of the negotiation and conclusion of collaboration agreements with such partners, whether and when we or our collaboration partners achieve clinical, regulatory and sales milestones, the timing of regulatory approvals in one or more major markets, reimbursement levels by private and government payers, and the market introduction of new drugs or generic versions of the approved drug, as well as other factors. Our past revenue generated from collaboration agreements is not necessarily indicative of our future revenue. If any of our existing or future collaboration partners fails to develop, obtain regulatory approval for, manufacture or ultimately commercialize any product candidate under our collaboration agreement, our business, financial condition, and results of operations could be materially and adversely affected.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently derive, and expect to derive in the foreseeable future, substantially all of our revenue from collaboration agreements with biotechnology and pharmaceutical companies. These collaboration agreements contain complex commercial terms, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">clinical development and commercialization obligations that are based on certain commercial reasonableness performance standards that can often be difficult to enforce if disputes arise as to adequacy of our partner&#8217;s performance;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">research and development performance and reimbursement obligations for our personnel and other resources allocated to partnered drug candidate development programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">clinical and commercial manufacturing agreements, some of which are priced on an actual cost basis for products supplied by us to our partners with complicated cost allocation formulas and methodologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">intellectual property ownership allocation between us and our partners for improvements and new inventions developed during the course of the collaboration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">royalties on drug sales based on a number of complex variables, including net sales calculations, geography, scope of patent claim coverage, patent life, generic competitors, bundled pricing and other factors; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">indemnity obligations for intellectual property infringement, product liability and certain other claims.</span></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a party to numerous significant collaboration agreements and other strategic transaction agreements (e.g., financings and asset divestitures) that contain complex representations and warranties, covenants and indemnification obligations. If we are found to have materially breached such agreements, it could subject us to substantial liabilities and harm our financial condition.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, we are involved in litigation matters involving the interpretation and application of complex terms and conditions of our agreements. One or more disputes may arise or escalate in the future regarding our collaboration agreements, transaction documents, or third-party license agreements that may ultimately result in costly litigation and unfavorable interpretation of contract terms, which would have a material adverse effect on our business, financial condition and results of operations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we, or our partners through our collaborations, are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty commercializing our products, which would adversely affect our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To the extent we rely on other pharmaceutical or biotechnology companies with established sales, marketing and distribution systems to market our products, we will need to establish and maintain partnership arrangements, and we may not be able to enter into these arrangements on acceptable terms or at all. To the extent that we enter into co-promotion or other arrangements, any revenue we receive will depend upon the efforts of third parties, which may not be successful and over which we have little or no control&#8212;important examples of this risk include MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> partnered with AstraZeneca and ADYNOVATE</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (previously referred to as BAX 855) partnered with Baxalta (a wholly-owned subsidiary of Takeda). In the event that we market our products without a partner, we would be required to build, either internally or through third-party contracts, a sales and marketing organization and infrastructure, which would require a significant investment, and we may not be successful in building this organization and infrastructure in a timely or efficient manner.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to create robust sales, marketing and distribution capabilities or to enter into agreements with third parties to perform these functions, we will be unable to commercialize our product candidates successfully.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently have no sales or distribution capabilities. To commercialize any of our drugs that receive regulatory approval for commercialization, we must develop robust internal sales, marketing and distribution capabilities, and manage inventory, supply, labeling, storage, record keeping, and advertising and promotion capabilities, which would be expensive and time consuming, or enter into arrangements with third parties to perform these services. If we decide to market our products directly, we must commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and with supporting distribution, administration and compliance capabilities. Factors that may inhibit our efforts to commercialize our products directly or through partnerships include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the inability of sales personnel to obtain access to or successfully educate adequate numbers of physicians about the potential benefits associated with the use of, and to subsequently prescribe, our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the lack of complementary products or multiple product pricing arrangements may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">unforeseen costs and expenses associated with creating and sustaining an independent sales and marketing organization.</span></div></td></tr></table><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We depend on third parties to conduct the clinical trials for our proprietary product candidates and any failure of those parties to fulfill their obligations could harm our development and commercialization plans.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We depend on independent clinical investigators, contract research organizations and other third-party service providers to conduct clinical trials for our proprietary product candidates. We rely heavily on these parties for the successful execution of our clinical trials. Though we are ultimately responsible for the results of their activities, many aspects of their activities are beyond our control. For example, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trials, but the independent clinical investigators may prioritize other projects over ours or communicate issues regarding our products to us in an untimely manner. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The early termination of any of our clinical trial arrangements, the failure of third parties to comply with the regulations and requirements governing clinical trials or the failure of third parties to properly conduct our clinical trials could hinder or delay the development, approval and commercialization of our product candidates and would adversely affect our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We expect to continue to incur substantial losses and negative cash flow from operations and may not achieve or sustain profitability in the future.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we reported net loss of </span><span style="font-family:inherit;font-size:10pt;text-align:right;">$327.2 million</span><span style="font-family:inherit;font-size:10pt;">. If and when we achieve profitability depends upon a number of factors, including the timing and recognition of milestone and other contingent payments and royalties received, the timing of revenue under our collaboration agreements, the amount of investments we make in our proprietary product candidates and the regulatory approval and market success of our product candidates. We may not be able to achieve and sustain profitability.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other factors that will affect whether we achieve and sustain profitability include our ability, alone or together with our partners, to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">develop drugs utilizing our technologies, either independently or in collaboration with other pharmaceutical or biotechnology companies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">effectively estimate and manage clinical development costs, particularly the cost of the clinical studies for NKTR-214, NKTR-358, NKTR-262, NKTR-255, and ONZEALD</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">receive necessary regulatory and marketing approvals;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">maintain or expand manufacturing at necessary levels;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">achieve market acceptance of our partnered products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">receive royalties on products that have been approved, marketed or submitted for marketing approval with regulatory authorities; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">maintain sufficient funds to finance our activities.</span></div></td></tr></table><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant competition for our polymer conjugate chemistry technology platforms and our partnered and proprietary products and product candidates could make our technologies, products or product candidates obsolete or uncompetitive, which would negatively impact our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our advanced polymer conjugate chemistry platforms and our partnered and proprietary products and product candidates compete with various pharmaceutical and biotechnology companies. Competitors of our polymer conjugate chemistry technologies include Biogen Inc., Savient Pharmaceuticals, Inc., Dr.&#160;Reddy&#8217;s Laboratories Ltd., SunBio Corporation, Mountain View Pharmaceuticals, Inc., Novo Nordisk A/S (formerly assets held by Neose Technologies, Inc.), and NOF Corporation. Several other chemical, biotechnology and pharmaceutical companies may also be developing polymer conjugation technologies or technologies that have similar impact on target drug molecules. Some of these companies license or provide the technology to other companies, while others are developing the technology for internal use.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There are many competitors for our proprietary product candidates currently in development. For NKTR-214, there are numerous companies engaged in developing immunotherapies to be used alone, or in combination, to treat a wide range of oncology indications targeting both solid and liquid tumors. In particular, we expect to compete with therapies with tumor infiltrating lymphocytes, or TILS, chimeric antigen receptor-expressing T cells, or CAR-T, cytokine-based therapies, and checkpoint inhibitors. Potential competitors in the TIL and CAR-T space include Gilead Sciences, Inc. (through its acquisition of Kite Pharma, Inc.)/NCI, Apeiron Biologics, Philogen S.p.A., IRX Therapeutics, Anaveon AG, Adaptimmune LLC, and Novartis AG, Alkermes plc, Altor Bioscience, Roche, Synthorx, Inc., and Eli Lilly &amp; Co. (through its acquisition of Armo BioSciences) in the cytokine-based therapies space, and Tesaro, Inc., Macrogenics, Inc., Merck, Bristol-Myers Squibb Company, and Roche in the checkpoint inhibitor space. For NKTR-358, there are a number of competitors in various stages of clinical development that are working on programs which are designed to correct the underlying immune system imbalance in the body due to autoimmune disease. In particular, we expect to compete with therapies that could be cytokine-based therapies (Symbiotix, LLC and Tizona Therapeutics), regulatory T cell therapies (Targazyme, Inc., Caladrius BioSciences, Inc., and Tract Therapeutics, Inc.), or IL-2-based-therapies (Amgen Inc.). For MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, there are currently several alternative therapies used to address opioid-induced constipation (OIC) and opioid-induced bowel dysfunction (OBD), including RELISTOR</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (methylnaltrexone bromide), oral therapy AMITIZA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (lubiprostone), and oral and rectal over-the-counter laxatives and stool softeners such as docusate sodium, senna and milk of magnesia. For ADYNOVATE</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, there is substantial competition from Sanofi&#8217;s Fc fusion protein ELOCTATE</span><span style="font-family:inherit;font-size:9pt;">&#8482;</span><span style="font-family:inherit;font-size:10pt;"> for Hemophilia A treatment, JIVI</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (antihemophilic factor (recombinant) PEGylated-aucl), an extended half-life Factor VIII for Hemophilia A treatment, approved in the U.S. in August 2018, and marketed by Bayer Healthcare, and Novo Nordisk which is expected to launch an extended half-life product in 2020. In addition, technologies other than those based on Fc fusion and polymer conjugation approaches (such as gene therapy approaches being developed by BioMarin Pharmaceutical Inc. and others) are being pursued to treat patients with Hemophilia A. For NKTR-181, there are numerous companies developing pain therapies designed to have less abuse potential primarily through formulation technologies and techniques applied to existing pain therapies. Potential competitors include Acura Pharmaceuticals, Inc., Cara Therapeutics, Inc., Collegium Pharmaceutical, Inc., Zyla Life Sciences (formerly Egalet Ltd), Elite Pharmaceuticals, Inc., Endo Health Solutions Inc., KemPharm, Inc., Pfizer/Eli Lilly &amp; Co., Purdue Pharma L.P., and Regeneron Pharmaceuticals, Inc./Teva Pharmaceutical Industries Ltd. For ONZEALD</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> there are a number of chemotherapies and cancer therapies approved today and in various stages of clinical development for breast cancer, including, but not limited to: Abraxane</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (paclitaxel protein-bound particles for injectable suspension (albumin bound)), Xeloda</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (capecitabine), Afinitor</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (everolimus), Ellence</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (epirubicin), Gemzar</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (gemcitabine), Halaven</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (eribulin), Herceptin</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (trastuzumab), Ixempra</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (ixabepilone), Navelbine</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (vinolrebine), and Taxotere</span><span style="font-family:inherit;font-size:9pt;">&#174;</span><span style="font-family:inherit;font-size:10pt;"> (docetaxel). Major pharmaceutical or biotechnology companies with approved drugs or drugs in development for breast cancers include, but are not limited to, Bristol-</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">44</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Myers Squibb Company, Eli Lilly &amp; Co., Roche, GlaxoSmithKline plc, Pfizer Inc., Eisai Inc., and Sanofi Aventis S.A. There can be no assurance that we or our partners will successfully develop, obtain regulatory approvals for and commercialize next-generation or new products that will successfully compete with those of our competitors. Many of our competitors have greater financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies. As a result, our competitors may succeed in developing competing technologies, obtaining regulatory approval or gaining market acceptance for products before we do. These developments could make our products or technologies uncompetitive or obsolete.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to manage our growth effectively, which could adversely affect our operations and financial performance.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The ability to manage and operate our business as we execute our development and growth strategy will require effective planning. Significant rapid growth could strain our management and internal resources, and other problems may arise that could adversely affect our financial performance. We expect that our efforts to grow will place a significant strain on personnel, management systems, infrastructure and other resources. Our ability to effectively manage future growth will also require us to successfully attract, train, motivate, retain and manage new employees and continue to update and improve our operational, financial and management controls and procedures. If we do not manage our growth effectively, our operations and financial performance could be adversely affected.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our future depends on the proper management of our current and future business operations and their associated expenses.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our business strategy requires us to manage our business to provide for the continued development and potential commercialization of our proprietary and partnered drug candidates. Our strategy also calls for us to undertake increased research and development activities and to manage an increasing number of relationships with partners and other third parties, while simultaneously managing the capital necessary to support this strategy. If we are unable to manage effectively our current operations and any growth we may experience, our business, financial condition and results of operations may be adversely affected. If we are unable to effectively manage our expenses, we may find it necessary to reduce our personnel-related costs through reductions in our workforce, which could harm our operations, employee morale and impair our ability to retain and recruit talent. Furthermore, if adequate funds are not available, we may be required to obtain funds through arrangements with partners or other sources that may require us to relinquish rights to certain of our technologies, products or future economic rights that we would not otherwise relinquish or require us to enter into other financing arrangements on unfavorable terms.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Because competition for highly qualified technical personnel is intense, we may not be able to attract and retain the personnel we need to support our operations and growth.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We must attract and retain experts in the areas of clinical testing, manufacturing, research, regulatory and finance, and may need to attract and retain commercial, marketing and distribution experts and develop additional expertise in our existing personnel. We face intense competition from other biopharmaceutical companies, research and academic institutions and other organizations for qualified personnel. Many of the organizations with which we compete for qualified personnel have greater resources than we have. Because competition for skilled personnel in our industry is intense, companies such as ours sometimes experience high attrition rates with regard to their skilled employees. Further, in making employment decisions, job candidates often consider the value of the stock awards they are to receive in connection with their employment. Our equity incentive plan and employee benefit plans may not be effective in motivating or retaining our employees or attracting new employees, and significant volatility in the price of our stock may adversely affect our ability to attract or retain qualified personnel. If we fail to attract new personnel or to retain and motivate our current personnel, our business and future growth prospects could be severely harmed.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are dependent on our management team and key technical personnel, and the loss of any key manager or employee may impair our ability to develop our products effectively and may harm our business, operating results and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our success largely depends on the continued services of our executive officers and other key personnel. The loss of one or more members of our management team or other key employees could seriously harm our business, operating results and financial condition. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are also dependent on the continued services of our technical personnel because of </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the highly technical nature of our products and the regulatory approval process. Because our executive officers and key employees are not obligated to provide us with continued services, they could terminate their employment with us at any time without penalty. We do not have any post-employment noncompetition agreements with any of our employees and do not maintain key person life insurance policies on any of our executive officers or key employees.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The price of our common stock has, and may continue to fluctuate significantly, which could result in substantial losses for investors and securities class action litigation.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our stock price is volatile. During the three months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, based on closing prices on the NASDAQ Global Select Market, the closing price of our common stock ranged from </span><span style="font-family:inherit;font-size:10pt;">$16.91</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">$36.27</span><span style="font-family:inherit;font-size:10pt;"> per share. Plaintiffs&#8217; securities litigation firms have recently publicly announced that they are investigating a potential breach of fiduciary duty claim involving our board of directors. Additionally, on October 30, 2018, the Company and certain of its executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California, which complaint was subsequently amended on May 15, 2019.&#160;&#160;Also, on February 13, 2019, and February 18, 2019, shareholder derivative complaints were filed in the U.S. District Court for the District of Delaware naming the CEO, CFO and certain members of Nektar&#8217;s board. Both the class action and shareholder derivative actions assert, among other things, that for a period beginning at least from November 11, 2017 through October 2, 2018, the Company&#8217;s stock was inflated due to alleged misrepresentations about the efficacy and safety of NKTR-214. In addition, on August 19, 2019, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California, which complaint asserted, among other things, that for a period between February 15, 2019 and August 8, 2019, inclusive, our stock was inflated due to an alleged failure to disclose a NKTR-214 manufacturing issue. We expect our stock price to remain volatile. A variety of factors may have a significant effect on the market price of our common stock, including the risks described in this section titled &#8220;Risk Factors&#8221; and the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">announcements of data from, or material developments in, our clinical studies and those of our collaboration partners, including data regarding efficacy and safety, delays in clinical development, regulatory approval or commercial launch &#8211; in particular, data from clinical studies of NKTR-214 has had a significant impact on our stock price;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">announcements by collaboration partners as to their plans or expectations related to drug candidates and approved drugs in which we have a substantial economic interest;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">announcements regarding terminations or disputes under our collaboration agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fluctuations in our results of operations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">developments in patent or other proprietary rights, including intellectual property litigation or entering into intellectual property license agreements and the costs associated with those arrangements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">announcements of technological innovations or new therapeutic products that may compete with our approved products or products under development;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">announcements of changes in governmental regulation affecting us or our competitors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">litigation brought against us or third parties to whom we have indemnification obligations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">public concern as to the safety of drug formulations developed by us or others;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our financing needs and activities; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">general market conditions.</span></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At times, our stock price has been volatile even in the absence of significant news or developments. The stock prices of biotechnology companies and securities markets generally have been subject to dramatic price swings in recent years.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have implemented certain anti-takeover measures, which make it more difficult to acquire us, even though such acquisitions may be beneficial to our stockholders.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even though such acquisitions may be beneficial to our stockholders. These anti-takeover provisions include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">establishment of a classified board of directors such that not all members of the board may be elected at one time;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">lack of a provision for cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability of our board to authorize the issuance of &#8220;blank check&#8221; preferred stock to increase the number of outstanding shares and thwart a takeover attempt;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">prohibition on stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of stockholders;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon by stockholders at stockholder meetings; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limitations on who may call a special meeting of stockholders.</span></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, provisions of Delaware law relating to business combinations with interested stockholders may discourage, delay or prevent a third party from acquiring us. These provisions may also discourage, delay or prevent a third party from acquiring a large portion of our securities or initiating a tender offer or proxy contest, even if our stockholders might receive a premium for their shares in the acquisition over the then-current market prices. We also have a change of control severance benefit plan, which provides for certain cash severance, stock award acceleration and other benefits in the event our employees are terminated (or, in some cases, resign for specified reasons) following an acquisition. This severance plan could discourage a third party from acquiring us.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The indenture governing our 7.75% senior secured notes imposes significant operating and financial restrictions on us and our subsidiaries that may prevent us from pursuing certain business opportunities and restrict our ability to operate our business.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 5, 2015, we issued $250.0 million in aggregate principal amount of 7.75% senior secured notes due October 2020. The indenture governing the senior secured notes contains covenants that restrict our and our subsidiaries&#8217; ability to take various actions, including, among other things:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">incur or guarantee additional indebtedness or issue disqualified capital stock or cause certain of our subsidiaries to issue preferred stock;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">pay dividends or distributions, redeem equity interests or subordinated indebtedness or make certain types of investments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">create or incur liens;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">transfer, sell, lease or otherwise dispose of assets and issue or sell equity interests in certain of our subsidiaries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">incur restrictions on certain of our subsidiaries&#8217; ability to pay dividends or other distributions to the Company or to make intercompany loans, advances or asset transfers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">enter into transactions with affiliates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">engage in any business other than businesses which are the same, similar, ancillary or reasonably related to our business as of the date of the indenture; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">consummate a merger, consolidation, reorganization or business combination, sell, lease, convey or otherwise dispose of all or substantially all of our assets or other change of control transaction.</span></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This indenture also requires us to maintain a minimum cash and investments in marketable securities balance of $60.0 million. We have certain reporting obligations under the indenture regarding cash position and royalty revenue. The indenture specifies a number of events of default, some of which are subject to applicable grace or cure periods, including, among other things, non-payment defaults, covenant defaults, cross-defaults to other material indebtedness, bankruptcy and insolvency defaults, non-payment of material judgments, loss of any material business license, criminal indictment of the Company, and certain civil forfeiture proceedings involving material assets of the Company. Our ability to comply with these covenants will likely be affected by many factors, including events beyond our control, and we may not satisfy those requirements. Our failure to comply with our obligations could result in an event of default under our other indebtedness and the acceleration of our other indebtedness, in whole or in part, could result in an event of default under the indenture governing the senior secured notes.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The restrictions contained in the indenture governing the senior secured notes could also limit our ability to plan for or react to market conditions, meet capital needs or otherwise restrict our activities or business plans and adversely affect our ability to finance our operations, enter into acquisitions or to engage in other business activities that would be in our interest.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Preliminary and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, we publish preliminary or interim data from our clinical studies. Preliminary data remain subject to audit confirmation and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Interim data are also subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. As a result, preliminary and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data could significantly harm our business prospects.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially reasonable basis, if at all.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerous pending and issued U.S. and foreign patent rights and other proprietary rights owned by third parties relate to pharmaceutical compositions, methods of preparation and manufacturing, and methods of use and administration. We cannot predict with any certainty which, if any, patent references will be considered relevant to our or our collaboration partners&#8217; technology or drug candidates by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. In certain cases, we have existing licenses or cross-licenses with third parties; however, the scope and adequacy of these licenses is very uncertain and can change substantially during long development and commercialization cycles for biotechnology and pharmaceutical products. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternate technology. If we are required to enter into a license with a third party, our potential economic benefit for the products subject to the license will be diminished. If a license is not available on commercially reasonable terms or at all, we may be prevented from developing and commercializing the drug, which could significantly harm our business, results of operations, and financial condition.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues. We own more than 275 U.S. and 850 foreign patents and have a number of pending patent applications that cover various aspects of our technologies. There can be no assurance that patents that have issued will be held valid and enforceable in a court of law. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time consuming and costly.&#160;Additionally, issued patents can be subject to opposition, inter partes review or other proceedings that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially relevant and/or broad coverage).&#160;Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a patent is issued and enforceable, because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may expire early and provide only a short period of protection, if any, following the commercialization of products encompassed by our patents.&#160;We may have to participate in post grant or inter partes review before the U.S. Patent and Trademark Office, which could result in a loss of the patent and/or substantial cost to us.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have filed patent applications, and plan to file additional patent applications, covering various aspects of our PEGylation and advanced polymer conjugate technologies and our proprietary product candidates.&#160;There can be no assurance that the patent applications for which we apply would actually issue as patents, or do so with commercially relevant and/or broad coverage. The coverage claimed in a patent application can be significantly reduced before the patent is issued.&#160;The scope of our claim coverage can be critical to our ability to enter into licensing transactions with third parties and our right to receive royalties from our collaboration partnerships. Since publication of discoveries in scientific or patent literature often lags behind the date of such discoveries, we cannot be certain that we were the first inventor of inventions covered by our patents or patent applications.&#160;In addition, there is no guarantee that we will be the first to file a patent application directed to an invention.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">An adverse outcome in any judicial proceeding involving intellectual property, including patents, could subject us to significant liabilities to third parties, require disputed rights to be licensed from or to third parties or require us to cease using the technology in dispute.&#160;In those instances where we seek an intellectual property license from another, we may not be able to obtain the license on a commercially reasonable basis, if at all, thereby raising concerns on our ability to freely commercialize our technologies or products.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely on trade secret protection for our confidential and proprietary information. No assurance can be given that others will not independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our trade secrets. In addition, unpatented proprietary rights, including trade secrets and know-how, can be difficult to protect and may lose their value if they are independently developed by a third party or if their secrecy is lost. Any loss of trade secret protection or other unpatented proprietary rights could harm our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If product liability lawsuits are brought against us, we may incur substantial liabilities.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The manufacture, clinical testing, marketing and sale of medical products involve inherent product liability risks. If product liability costs exceed our product liability insurance coverage (or if we cannot secure product liability insurance), we may incur substantial liabilities that could have a severe negative impact on our financial position. Whether or not we are ultimately successful in any product liability litigation, such litigation would consume substantial amounts of our financial and managerial resources and might result in adverse publicity, all of which would impair our business. Additionally, we may not be able to maintain our clinical trial insurance or product liability insurance at an acceptable cost, if at all, and this insurance may not provide adequate coverage against potential claims or losses.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we or current or future collaborators or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions and civil or criminal penalties.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although we do not currently have any products on the market, once we begin commercializing our drug candidates, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal and state governments of the jurisdictions in which we conduct our business. Healthcare providers, physicians and third-party payers play a primary role in the recommendation and prescription of any drug candidates for which we obtain marketing approval. Our future arrangements with third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, or paying remuneration (a term interpreted broadly to include anything of value, including, for example, gifts, discounts, and credits), directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order, or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement or record material to payment of a false claim or avoiding, decreasing, or concealing an obligation to pay money owed to the federal government;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">provisions of the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal criminal statutes, referred to as the &#8220;HIPAA All-Payer Fraud Prohibition,&#8221; that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">federal transparency laws, including the federal Physician Payment Sunshine Act, which require manufacturers of certain drugs and biologics to track and disclose payments and other transfers of value they make to U.S. physicians and teaching hospitals as well as physician ownership and investment interests in the manufacturer, and that such information is subsequently made publicly available in a searchable format on a CMS website;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">provisions of HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, state transparency reporting and compliance laws; and state laws governing the privacy and security of health information in certain </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-left:78px;padding-top:8px;"><span style="font-family:inherit;font-size:10pt;">circumstances, many of which differ from each other in significant ways and which may not have the same effect, thus complicating compliance efforts.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ensuring that our future business arrangements with third-parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including civil or criminal penalties, monetary damages, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely affect financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, third parties have asserted, and may in the future assert, that we or our partners infringe their proprietary rights, such as patents and trade secrets, or have otherwise breached our obligations to them. A third party often bases its assertions on a claim that its patents cover our technology platform or drug candidates or that we have misappropriated its confidential or proprietary information. Similar assertions of infringement could be based on future patents that may issue to third parties. In certain of our agreements with our partners, we are obligated to indemnify and hold harmless our collaboration partners from intellectual property infringement, product liability and certain other claims, which could cause us to incur substantial costs and liability if we are called upon to defend ourselves and our partners against any claims. If a third party obtains injunctive or other equitable relief against us or our partners, they could effectively prevent us, or our partners, from developing or commercializing, or deriving revenue from, certain drugs or drug candidates in the U.S. and abroad. Costs associated with litigation, substantial damage claims, indemnification claims or royalties paid for licenses from third parties could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are involved in legal proceedings where we or other third parties are enforcing or seeking intellectual property rights, invalidating or limiting patent rights that have already been allowed or issued, or otherwise asserting proprietary rights through one or more potential legal remedies. For example, we are currently involved in German litigation proceedings whereby Bayer is seeking co-ownership rights in certain of our patent filings pending at the European Patent Office covering, among other things, PEGylated Factor VIII which we have exclusively licensed to Baxalta (a wholly-owned subsidiary of Takeda). The subject matter of our patent filings in this proceeding relates to Bayer&#8217;s PEGylated recombinant Factor VIII compound, BAY 94-9027, now commercially marketed as JIVI</span><span style="font-family:inherit;font-size:9pt;">&#174;</span><span style="font-family:inherit;font-size:10pt;">. We believe that Bayer&#8217;s claim to an ownership interest in these patent filings is without merit and are vigorously defending sole and exclusive ownership rights to this intellectual property. In addition, Nektar has filed claims in Germany seeking ownership rights of certain Bayer patent applications. In the U.S., Bayer filed a complaint against Baxalta and Nektar alleging the ADYNOVATE</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> product infringes a Bayer patent. Although the U.S. court dismissed all of Bayer&#8217;s claims against Nektar and Nektar was removed as a defendant, a jury found the Bayer patent was valid and infringed, and awarded Bayer damages, the responsibility of which are borne fully by Baxalta. This damages award does not impact our royalties from sales of ADYNOVATE</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> under our collaboration with Baxalta. In other U.S. proceedings, Nektar and Baxalta filed complaints against Bayer Healthcare alleging Bayer&#8217;s JIVI</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> product infringes several Nektar patents. In addition, in response to notices AstraZeneca and we received from the generic companies, Apotex (Apotex Inc. and Apotex Corp.) and MSN Laboratories Pvt. Ltd., alerting us that they had filed abbreviated new drug applications (ANDAs) with the FDA to market a generic version of MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (Paragraph IV Certifications), AstraZeneca and we together filed patent infringement suits against each of these generic companies in December 2018. Also, in a letter dated September 26, 2019, AstraZeneca and we received another Paragraph IV Certification from Aurobindo Pharma USA Inc.  In these Paragraph IV Certifications, all three generic companies only alleged one patent, U.S. Patent No. 9,012,469, is invalid, unenforceable and/or not infringed by the manufacture, use or sale of their respective generic products. At this time, none of the other five Orange Book listed patents associated with MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> are being challenged by these generics companies. In addition, we are currently named in putative securities class action lawsuits, and our CEO, CFO and certain members of our board are named in shareholder derivative complaints. We are also regularly involved in opposition proceedings at the European Patent Office and in inter partes review proceedings at the U.S. Patent and Trademark Office where third parties seek to invalidate or limit the scope of our allowed patent applications or issued patents covering (among other things) our drugs and platform technologies. The cost to us in initiating or defending any litigation or other proceeding, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts or result in financial implications either in terms of seeking license arrangements or payment of damages or royalties.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our internal computer systems, or those of our partners, vendors, CROs, CMOs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs or the theft of our confidential information or patient confidential information.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Despite the implementation of security measures, our internal computer systems and those of our partners, vendors, contract research organizations (CROs), contract manufacturing organizations (CMOs) and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such events could cause interruptions of our operations. For instance, the loss of preclinical data or data from any future clinical trial involving our product candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information of our company or clinical patients, we could suffer or be subject to reputational harm, monetary fines (such as those imposed by European Regulation 2016/679, known as the General Data Protection Regulation, or &#8220;GDPR&#8221; and, effective in 2020, the California Consumer Privacy Act, or &#8220;CCPA&#8221;), civil suits, civil penalties or criminal sanctions and requirements to disclose the breach, and other forms of&#160;liability, and the development of our product candidates could be delayed.  In addition, we continue to be subject to new and evolving data protection laws and regulations from a variety of jurisdictions, and there is a risk that our systems and processes for managing and protecting data may be found to be inadequate, which could expose us to fines and litigation. </span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The United Kingdom&#8217;s withdrawal from the European Union (EU) may have a negative effect on global economic conditions, access to patient markets, and regulatory certainty, which could adversely affect our operations.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the electorate in the United Kingdom voted to withdraw from the EU in a national referendum (Brexit). Although the United Kingdom and the EU continue to discuss the terms under which the United Kingdom will withdraw from the EU, no agreement has been reached.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to having a negative effect on global economic conditions, Brexit is expected to lead to a period of considerable uncertainty on regulatory processes in Europe and the European Economic Area. The lack of clarity about which EU rules and regulations the United Kingdom would replace or replicate in the event of Brexit, such as rules and regulations relating to trade (including the importation and exportation of pharmaceuticals), clinical research, and intellectual property, increases the risk that our clinical trials being carried out in United Kingdom are delayed or disrupted.&#160;&#160;Further, depending on which rules and regulations the United Kingdom ultimately adopts following a withdrawal from the EU, our business could be negatively affected.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Global economic conditions may negatively affect us and may magnify certain risks that affect our business.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operations and performance have been, and may continue to be, affected by global economic conditions. As a result of global economic conditions, some third-party payers may delay or be unable to satisfy their reimbursement obligations. Job losses or other economic hardships may also affect patients&#8217; ability to afford healthcare as a result of increased co-pay or deductible obligations, greater cost sensitivity to existing co-pay or deductible obligations, lost healthcare insurance coverage or for other reasons. We believe such conditions have led and could continue to lead to reduced demand for our and our collaboration partners&#8217; drug products, which could have a material adverse effect on our product sales, business and results of operations.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, rising international trade tensions, new or increased tariffs and changes in the U.S. trade policy may increase the costs of materials and products imported into the U.S. and may adversely affect our business. Tariffs, trade restrictions or sanctions imposed by the U.S. or other countries could increase the prices of our and our collaboration partners&#8217; drug products, affect our and our collaboration partners&#8217; ability to commercialize such drug products, or create adverse tax consequences in the U.S. or other countries. As a result, changes in international trade policy, changes in trade agreements and the imposition of tariffs or sanctions by the U.S. or other countries could materially adversely affect our results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:24px;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If earthquakes or other catastrophic events strike, our business may be harmed.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our corporate headquarters, including a substantial portion of our research and development operations, are located in the San Francisco Bay Area, a region known for seismic activity and a potential terrorist target. In addition, we own facilities for the manufacture of products using our advanced polymer conjugate technologies in Huntsville, Alabama and own and lease offices in Hyderabad, India. There are no backup facilities for our manufacturing operations located in Huntsville, Alabama. In the event of an earthquake or other natural disaster, political instability, or terrorist event in any of these locations, our ability to manufacture and supply materials for drug candidates in development and our ability to meet our manufacturing obligations to our customers would be significantly disrupted and our business, results of operations and financial condition would be harmed. Our collaborative partners may also be subject to catastrophic events, such as earthquakes, floods, hurricanes and tornadoes, any of </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">which could harm our business, results of operations and financial condition. We have not undertaken a systematic analysis of the potential consequences to our business, results of operations and financial condition from a major earthquake or other catastrophic event, such as a fire, sustained loss of power, terrorist activity or other disaster, and do not have a recovery plan for such disasters. In addition, our insurance coverage may not be sufficient to compensate us for actual losses from any interruption of our business that may occur.</span></div><div><a id="sBED438EF8A3B5DD2848898CD66C1093D"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;2.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unregistered Sales of Equity Securities and Use of Proceeds</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None, including no purchases of any class of our equity securities by us or any affiliate pursuant to any publicly announced repurchase plan in the three months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div><a id="s7E8A7191ECAB502E820B32C6AB5F4A4C"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;3.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Defaults Upon Senior Securities</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><a id="s6324675F70625C38B502D7D5512B9790"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;4.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Mine Safety Disclosures</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div><a id="sAAEA73AB93DB5C459F0093157FC75EE9"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;5.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Information</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB5BD69B42BB354B795D0E90DDF4CB75B"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;-sec-extract:summary;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;6.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibits</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Except as so indicated in Exhibit 32.1, the following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Description of Documents</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.1(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/906709/0001047469-98-031070.txt"><span style="font-family:inherit;font-size:10pt;">Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.2(2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/906709/000091205700037283/ex-3_3.txt"><span style="font-family:inherit;font-size:10pt;">Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.3(3)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/906709/000104746903002325/a2101294zex-3_1.htm"><span style="font-family:inherit;font-size:10pt;">Certificate of Ownership and Merger of Nektar Therapeutics.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.4(4)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/906709/000114420410011093/v176023_ex3-6.htm"><span style="font-family:inherit;font-size:10pt;">Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.5(5)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/906709/000119312519029550/d692256dex31.htm"><span style="font-family:inherit;font-size:10pt;">Amended and Restated Bylaws of Nektar Therapeutics.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1(6)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="nktr2019-09x30xexx101.htm"><span style="font-family:inherit;font-size:10pt;">Separation, Consulting and General Release Agreement ++</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.1(6)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="nktr2019-09x30xexx311.htm"><span style="font-family:inherit;font-size:10pt;">Certification of Nektar Therapeutics&#8217; principal executive officer required by Rule 13a-14(a) or Rule 15d-14(a).</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.2(6)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="nktr2019-09x30xexx312.htm"><span style="font-family:inherit;font-size:10pt;">Certification of Nektar Therapeutics&#8217; principal financial officer required by Rule 13a-14(a) or Rule 15d-14(a).</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.1*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="nktr2019-09x30xexx321.htm"><span style="font-family:inherit;font-size:10pt;">Section 1350 Certifications.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.SCH(6)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Schema Document.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.CAL(6)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.LAB(6)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.PRE(6)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101.DEF(6)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104(6)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).</span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">_____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q, for the quarter ended June 30, 1998.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Incorporated by reference to Exhibit 3.3 to Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q, for the quarter ended June 30, 2000.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Current Report on Form 8-K, filed with the SEC on January 23, 2003.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Incorporated by reference to Exhibit 3.6 to Nektar Therapeutics&#8217; Annual Report on Form 10-K, for the year ended December 31, 2009.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(5)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Current Report on Form 8-K, filed with the SEC on February 6, 2019.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(6)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Filed herewith.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exhibit 32.1 is being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise stated in such filing.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">++</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Management contract or compensatory plan or arrangement.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53</span></div></div><hr style="page-break-after:always"></hr><div><a id="sA7F65855E94059629F3D9913E034738C"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0D6175B8F89758B9AB40E630E36615D1"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;padding-top:16px;text-indent:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="line-height:120%;padding-top:8px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="3"></td></tr><tr><td style="width:43%;"></td><td style="width:5%;"></td><td style="width:52%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ GIL M. LABRUCHERIE</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gil M. Labrucherie</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior&#160;Vice&#160;President, Chief Operating Officer, and&#160;Chief&#160;Financial&#160;Officer</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date: November&#160;6, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ JILLIAN B. THOMSEN</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Jillian B. Thomsen</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior&#160;Vice&#160;President,&#160;Finance&#160;and&#160;Chief&#160;Accounting&#160;Officer</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date: November&#160;6, 2019</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">54</span></div></div>	</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>nktr2019-09x30xexx101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s179939418a7d4b0bad0b5e029e438ac3"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.1</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:24px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SEPARATION, CONSULTING AND GENERAL RELEASE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Separation, Consulting and General Release Agreement (&#8220;Agreement&#8221;) effective as of October 15, 2019 (the &#8220;Effective Date&#8221;) and is made by and between John Nicholson (&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Nicholson</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and Nektar Therapeutics (&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:inherit;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:10pt;">, Nicholson and Company entered into an Employee Agreement, dated December 1, 2008, regarding various nondisclosure, non-solicitation and invention assignment obligations (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employee Confidentiality Agreement</font><font style="font-family:inherit;font-size:10pt;">&#8221;);</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:10pt;">, Nicholson provided notice that he would step down from his current position as Senior Vice President and Chief Operating Officer effective October 1, 2019, and would remain an employee of the Company until his retirement effective October 15, 2019; </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:10pt;">, the parties desire that Nicholson be available for, and, as needed, perform requested consulting services through the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consulting Services Term</font><font style="font-family:inherit;font-size:10pt;">&#8221; (as defined below);</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NOW, THEREFORE</font><font style="font-family:inherit;font-size:10pt;">, in consideration of the mutual promises and respective agreements, representations, warranties, covenants, conditions contained in this Agreement, the parties hereby agree as follows:</font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Separation from Company and Severance Benefits</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;Separation</font><font style="font-family:inherit;font-size:10pt;">.  Effective on the October 15, 2019 (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Separation Date</font><font style="font-family:inherit;font-size:10pt;">&#8221;), Nicholson&#8217;s employment at the Company, as well as Nicholson&#8217;s employment in any other capacity for the Company or any of its affiliates, shall terminate.  In addition, with respect to stock options (&#8220;the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Options</font><font style="font-family:inherit;font-size:10pt;">&#8221;) and restricted stock units (&#8220;the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">RSUs</font><font style="font-family:inherit;font-size:10pt;">&#8221;) the Company previously granted to Nicholson, Nicholson acknowledges and agrees that any such Options and any such RSUs not vested by the Separation Date are forfeited in accordance with the terms of the stock option and restricted stock unit agreements and related stock option and related restricted stock unit notices and the applicable equity incentive plan of the Company.  Nicholson acknowledges and agrees that he has no further right or benefits under any agreement to receive or acquire any security or derivative security in or with respect to the Company or any of its affiliates or subsidiaries.  Following the Separation Date, Nicholson shall not be authorized to transact any business on behalf of the Company or any its affiliates or subsidiaries unless authorized to do so in writing by an officer of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;Severance Benefits</font><font style="font-family:inherit;font-size:10pt;">.  Provided that Nicholson complies with all of the terms of this Agreement, the Company shall provide Nicholson with the following severance benefits (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Severance Benefits</font><font style="font-family:inherit;font-size:10pt;">&#8221;): (a) a paid consulting arrangement as set forth in Section 3 below; and (b) Nicholson&#8217;s Options, to the extent outstanding and vested as of the Separation Date, will remain exercisable for an additional three (3) months following the conclusion of the Consulting Services Term (defined below); and (c) provided that Nicholson timely exercises his right to continue his health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;COBRA&#8221;), the Company will pay the monthly health insurance coverage fees for Nicholson and his eligible dependents for a period commencing on the Separation Date and ending on March 31, 2021, subject to the proviso that in all cases the Company&#8217;s obligation to pay the monthly health insurance coverage fees shall end on the date Nicholson becomes eligible to receive health insurance coverage from any subsequent employer.  Nicholson shall notify the Company promptly upon accepting employment with any other person or entity, but no later than three calendar days prior to commencing such employment, and at the same time, Nicholson shall notify the Company whether he is eligible to receive health coverage in connection with such employment.  Nicholson acknowledges that the Severance Benefits represent payments that he would not otherwise be entitled to receive, now or in the future, without entering into this Agreement, and constitutes valuable consideration for the promises and undertakings set forth in this Agreement.  </font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">2.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Payment of Salary and Expenses</font><font style="font-family:inherit;font-size:10pt;">.  On Nicholson&#8217;s Separation Date, the Company will pay Nicholson a total of (i) all accrued and unpaid salary, and (ii) an amount equaling his effective hourly rate multiplied by the number of hours of accrued, but unused, paid time off [collectively, (i) and (ii), the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Obligations</font><font style="font-family:inherit;font-size:10pt;">&#8221;].  In the event that Nicholson has a negative paid time off balance, Nicholson agrees that such amount will be deducted from the Company&#8217;s payment to him of his Accrued Obligations.  By signing below, Nicholson acknowledges and represents that, upon receiving the Accrued Obligations, he will have received all salary, wages, bonuses, accrued vacation and paid time off, and all other benefits and compensation due to him through the Separation Date.  </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="font-family:inherit;font-size:10pt;">Nicholson agrees that, by the Separation Date, he will submit his final documented expense reimbursement statement reflecting all business expenses he incurred through the Separation Date, if any, for which he seeks reimbursement.  The Company will reimburse Nicholson for these expenses pursuant to its regular business practice.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consulting Services</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)  </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consulting Services and Term</font><font style="font-family:inherit;font-size:10pt;">.  Immediately effective upon the Separation Date and through to March 31, 2021 (the &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consulting Services Term</font><font style="font-family:inherit;font-size:10pt;">&#8221;), Nicholson will serve as an independent contractor to the Company to perform such other tasks as may be reasonably requested by the Company&#8217;s Chief Executive Officer or his designee (the &#8220;Consulting Services&#8221;).  Unless requested to do so by Company&#8217;s Chief Executive Officer or his designee, Nicholson will not enter or visit Company&#8217;s premises and Nicholson is expected to provide Consulting Services from a location remote from any of Company&#8217;s premises.  Generally, during the Consulting Services Term, Nicholson is expected to be available for consultation by phone and email during regular business hours.  During the Consulting Services Term, Nicholson will have no authority to represent the Company to third parties or to bind the Company to any contractual obligations, whether written, oral or implied, or represent that Nicholson has such authority, unless authorized to do so in writing by an officer of the Company.  During the Consulting Services Term, Nicholson shall continue to abide by all of the Company&#8217;s policies and procedures in effect from time to time and perform duties requested of Nicholson in good faith to the best of his abilities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;Consideration and Fee Reimbursement during the Consulting Services Term</font><font style="font-family:inherit;font-size:10pt;">.  During the Consulting Services Term, Company will compensate Nicholson in accordance with the following Consulting Compensation Table.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Table 1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consulting Compensation Table</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For Each Period Within the Consulting Services Term</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:44.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:63%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:3px double #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:3px double #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 16-31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,134.14</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 1-30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,268.58</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 1-31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,268.58</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1-31, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,268.58</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 1-29, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,268.58</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 1-31, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,268.58</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 1-30, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,268.58</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 1-31, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,268.58</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 1-30, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,268.58</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">July 1-31, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,268.58</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 1-31, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,268.58</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">September 1-30, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,268.58</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October 1-31, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,268.58</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">November 1-30, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,268.58</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 1-31, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,268.58</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 1-31, 2021</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,268.58</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 1-28 2021</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,268.58</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 1-31, 2021</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,268.58</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">669,700.00</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The parties acknowledge and agree that the total compensation in accordance with Table 1 corresponds to one (1) year of Nicholson&#8217;s annual base salary.  Nicholson will also be reimbursed for reasonable out-of-pocket travel costs and other expenses that are approved in advance by email or writing by Company&#8217;s Chief Executive Officer of his designee.</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)  </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Invoices</font><font style="font-family:inherit;font-size:10pt;">.  During the Consulting Services Term and after a complete calendar month of Consulting Services, Nicholson shall provide to the Company on or before the seventh (7th) calendar day of the immediately following month an invoice for thirty-eight thousand, two hundred sixty-eight dollars and fifty-eight cents ($38,268.58).  For the incomplete month corresponding to the period of October 16-31, 2019, Nicholson shall provide the Company on or before November 7, 2019 an invoice for nineteen thousand, one hundred thirty-four dollars and fourteen cents ($19,134.14).  In </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">addition, Nicholson shall provide to the Company within seven (7) days at the end of each calendar month during the Consulting Services Term a true and correct invoice for any approved reasonable out-of-pocket travel costs and other expenses incurred during the prior month.  The Company shall pay each invoice within fifteen (15) business days of receiving such invoice from Nicholson.  Nicholson shall submit each invoice and direct all communications to the Company&#8217;s Senior Vice President, Human Resources (or such other person as delegated by Senior Vice President, Human Resources).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)  </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Independent Contractor Status</font><font style="font-family:inherit;font-size:10pt;">.  It is the express intention of Nicholson and the Company that, during the Consulting Services Term, Nicholson shall be an independent contractor, and shall be classified by Company as such for all purposes, and shall not be an officer, employee, agent, joint venturer, or partner of Company.  Accordingly, Nicholson shall not be entitled to earn or accrue during the Consulting Services Term and thereafter any rights, benefits, equity, or salary, or vest in any equity awards, under any employee benefit or compensation plan or program sponsored by Company or any of its parent, subsidiary or affiliated entities at any time, including, but not limited to health, dental, vision, 401(k), Change of Control Severance Benefit Plan, or other employee welfare benefits, and Nicholson shall be solely responsible for his insurance, taxes, fees, licenses, costs, equipment, expenses, and providing himself with office space, if necessary, to perform his duties as a consultant. Nothing in this Agreement shall be interpreted or construed as creating or establishing an employment relationship between Nicholson and Company at any time after the Separation Date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(e)  </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity Awards</font><font style="font-family:inherit;font-size:10pt;">.  Pursuant to the applicable Equity Incentive Plan (&#8220;Equity Plans&#8221;) and the equity award notices and agreements issued to Nicholson thereunder (collectively, the &#8220;Award Agreements&#8221;), Nicholson&#8217;s right to exercise any vested stock options shall end on the earlier of (i) three months following the conclusion of the Consulting Services Term, or (ii) the expiration of the term of Nicholson&#8217;s stock options.  Nicholson&#8217;s stock options and restricted stock units continue to remain subject to all other terms and conditions of the Award Agreements.  In the event of any conflict between the terms of the Equity Plans and Award Agreements and this Agreement, the terms of the Equity Plans and Award Agreements will control.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.  &#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employee Acknowledgements</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;Acknowledgements and Representations</font><font style="font-family:inherit;font-size:10pt;">.  Nicholson acknowledges: (a)&#160;receipt of all compensation and benefits due to him through the Effective Date as a result of services performed for the Company; (b)&#160;he has reported to the Company any and all work-related injuries incurred during employment; (c)&#160;the Company properly provided any leave of absence because of his or a family member&#8217;s health condition, and he has not been subjected to any improper treatment, conduct or actions due to a request for or taking such leave; (d) he has provided the Company with written notice of any and all concerns regarding suspected ethical and compliance issues or violations on the part of the Company or any Released Party; (e) he has not filed any complaints, claims, or actions against the Company or any Released Party; and (f) he has not raised a claim of sexual harassment or abuse with the Company. Nicholson further represents that he will not bring any action in the future in which he seeks to recover any damages from the Company relating to or arising from his employment or his separation from the Company, other than an action to enforce his rights under this Agreement.&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)  </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Confidential Information</font><font style="font-family:inherit;font-size:10pt;">. Nicholson shall continue to maintain the confidentiality of all confidential and proprietary information of Company and shall continue to comply with the continuing obligations of the Employee Confidentiality Agreement through the Transition Services Term, Consulting Services Term, and, as applicable, thereafter, including, without limitation, Section 4 of the Employee Confidentiality Agreement, which sets forth Nicholson&#8217;s confidentiality obligations with respect to Company&#8217;s Confidential Information (as defined in the Employee Confidentiality Agreement).</font></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Release Provisions</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:96px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">General Release</font><font style="font-family:inherit;font-size:10pt;">.  In exchange for the consideration described in Sections 1(b) and 3(b), Nicholson, personally and for Nicholson&#8217;s heirs, executors, administrators, successors and assigns, hereby generally and completely release the Company and its subsidiaries, successors, predecessors and affiliates, and its and their respective partners, members, directors, officers, employees, stockholders, shareholders, agents, attorneys, predecessors, insurers, affiliates and assigns (all of whom are referred to throughout this Agreement as &#8220;Released Parties&#8221;), from any and all claims, demands, actions, causes of action, suits, damages, losses, expenses, liabilities, and obligations, both known and unknown, individually or as part of a group action, that arise out of or are in any way related to events, acts, conduct, or omissions occurring at any time through the date Nicholson signs this Agreement (&#8220;Claims&#8221;).  This general release includes, but is not limited to, to all matters in law, equity, contract, tort, or pursuant to statute, including but not limited to any and all claims arising under the California Constitution, California statutory and common law; Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the California Fair </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="font-family:inherit;font-size:10pt;">Employment and Housing Act, the National Labor Relations Act; or any other federal, state or local statute, rule, ordinance, or regulation.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nicholson further agrees and acknowledges that the release provided for in this Section 5 shall apply to all unknown and unanticipated injuries and/or damages.  Nicholson acknowledges and understands that Section 1542 of the Civil Code of the State of California provides as follows:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A general release does not extend to claims THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS/HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM/HER, WOULD HAVE MATERIALLY AFFECTED HIS/HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.   </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nicholson intends these consequences even as to claims for damages that may exist as of the date this Agreement is executed that Nicholson does not know exist and which if known, would materially affect Nicholson&#8217;s decision to execute this Agreement, regardless of whether the lack of knowledge is the result of ignorance, oversight, error, negligence or any other cause.  Being aware of Section 1542 of the California Civil Code, Nicholson, by signing this Agreement, expressly waives the provisions of Section 1542 of the California Civil Code and any other similar provisions of law that may be applicable.</font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:96px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exclusions from General Release</font><font style="font-family:inherit;font-size:10pt;">.  The above release does not waive claims: (i)&#160;for unemployment or workers&#8217; compensation, (ii)&#160;for vested rights under ERISA-covered employee benefit plans as applicable on the date Nicholson signs this Agreement, (iii)&#160;that may arise after Nicholson signs this Agreement, (iv) for indemnification under California Labor Code section 2802, or (v) which cannot be released by private agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acknowledgement of Waiver of ADEA Claims</font><font style="font-family:inherit;font-size:10pt;">.  Nicholson acknowledges waiving and releasing any rights under the Age Discrimination in Employment Act of 1967 (&#8220;ADEA&#8221;) and that this waiver and release is knowing and voluntary.  Nicholson and the Company agree that this waiver and release does not apply to any rights or claims that may arise under the ADEA after the Effective Date of this Agreement.  Nicholson acknowledges that the consideration given for this waiver and Agreement is in addition to anything of value to which Nicholson was already entitled.  Nicholson further acknowledges notice by this writing that:</font></div><div style="line-height:120%;padding-left:48px;text-align:left;text-indent:96px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:inherit;font-size:10pt;">Nicholson should consult with an attorney prior to executing this Agreement;</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:96px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(b)</font><font style="font-family:inherit;font-size:10pt;">Nicholson has up to twenty-one (21) calendar days within which to consider this Agreement;</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:96px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(c)</font><font style="font-family:inherit;font-size:10pt;">Nicholson has seven (7) calendar days following Nicholson&#8217;s execution of this Agreement to revoke the Agreement; </font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:96px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(d)</font><font style="font-family:inherit;font-size:10pt;">the ADEA waiver in this Agreement shall not be effective until the seven (7) day revocation period has expired; and</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:96px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(e)</font><font style="font-family:inherit;font-size:10pt;">nothing in this Agreement prevents or precludes Nicholson from challenging or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties or costs for doing so, unless specifically authorized by federal law; and</font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:96px;"><font style="text-align:left;font-family:inherit;font-size:10pt;padding-right:48px;">(f)</font><font style="font-family:inherit;font-size:10pt;">in order to revoke this Agreement, Nicholson must deliver to Mark A. Wilson&#8217;s attention at the following address a written revocation before 12:00 a.m. (midnight) p.s.t. on the seventh calendar day following the date Nicholson signs the Agreement:</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mark A. Wilson, Esq. </font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nektar Therapeutics</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">455 Mission Bay Boulevard, South</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Suite 100</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">San Francisco, CA  94158</font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Email:  mwilson@nektar.com</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Confidentiality of this Agreement</font><font style="font-family:inherit;font-size:10pt;">.  The provisions of this Agreement shall be held in strictest confidence by Nicholson and shall not be publicized or disclosed in any manner whatsoever by Nicholson at any time to any person other than Nicholson&#8217;s lawyer or accountant, a governmental agency, or Nicholson&#8217;s immediate family without the prior written consent of an officer of the Company, except as necessary in any legal proceedings directly related to the provisions and terms of this Agreement, to prepare and file income tax forms, or as required by court order after reasonable notice to the Company.  Nothing in this Agreement shall prevent Nicholson from providing information to the NLRB upon request, nor shall this provision prevent Nicholson from exercising his rights under Section 7 of the National Labor Relations Act.  Nicholson and the Company specifically disclaim any intent to enter into this Agreement in exchange for a promise not to reveal to any government entity, including any court or agency, conduct that could be construed as a violation of federal law.  </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Proprietary Information</font><font style="font-family:inherit;font-size:10pt;">.  Nicholson acknowledges access to and receipt of confidential business and proprietary information regarding the Company and its clients while working.  This information may be in a variety of paper and electronic forms.  Nicholson agrees not to make any such information known to any member of the public and to comply with all applicable ethical responsibilities related to client confidences and secrets.  </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cooperation</font><font style="font-family:inherit;font-size:10pt;">.  Following the Effective Date, Nicholson agrees to reasonably cooperate with the Company in connection with: (a) any internal or governmental investigation or administrative, regulatory , arbitral or judicial proceeding involving the Company with respect to matters relating to Nicholson&#8217;s service to the Company or any inquiries related to facts or circumstances that Nicholson knows as a result of service to the Company (collectively, &#8220;Litigation&#8221;); and (b) any audit of the financial statements of the Company with respect to the period of time when Nicholson was employed by the Company (&#8220;Audit&#8221;).  Nicholson acknowledges that such cooperation may include, but shall not be limited to, Nicholson making himself available to the Company (or its respective attorneys or auditors) upon reasonable notice for: (i) interviews, factual investigations, and providing declarations or affidavits that provide truthful information in connection with any Litigation or Audit; (ii) appearing at the request of the Company to give testimony without requiring service of a subpoena or other legal process; (iii) volunteering to the Company pertinent information related to any Litigation or Audit; (iv) providing information and legal representations to the auditors of the Company, in a reasonable form and within a reasonable time frame, with respect to the Company's financial statements for the period in which Nicholson was employed by the Company; and (v) turning over to the Company any documents relevant to any Litigation or Audit that are or may come into Nicholson&#8217;s possession.  In addition, Nicholson agrees that he will not knowingly encourage, counsel, or assist any attorneys or their clients in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints by any third party against Company or any of its affiliates, unless under a subpoena or other court order to do so.  Nicholson agrees both to immediately notify Company upon receipt of any such subpoena or court order, and to furnish, within three (3) business days of its receipt, a copy of such subpoena or other court order.  If approached by anyone for counsel or assistance in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints against Company or any of its affiliates, Nicholson shall state no more than that he cannot provide counsel or assistance.  Notwithstanding anything to the contrary, nothing in this Agreement prevents Nicholson from providing truthful information to any governmental agency in connection with any governmental, regulatory or administrative agency proceeding.  Following the end of the Consulting Services Term, Nicholson shall receive: (i) an hourly fee for the cooperation described in this Section 9 at a rate of $250 per hour; and (ii) the reimbursement of reasonable travel and other expenses incurred by Nicholson in the course of providing such cooperation, provided, however, that all such travel and other expenses shall be reimbursed only if approved by Company in advance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.  &#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Voluntary Waiver and Release, Advice of Counsel, Consideration and Other Information</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;">Nicholson acknowledges and agrees that:  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)&#160;&#160;&#160;&#160;&#160;his waiver and release of rights under this Agreement are voluntary, and that he is acting of his own free will in executing this Agreement; </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) &#160;&#160;&#160;&#160;through this Agreement, he is releasing the Released Parties from any and all claims that he may have against any of the Released Parties; </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)&#160;&#160;&#160;&#160;&#160;his waiver and release, as set forth in this Agreement, do not apply to any rights or claims that may arise after the date he signs this Agreement; and</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;&#160;the Company hereby advises Nicholson that, before signing this Agreement, he should consult with an attorney, although he may choose voluntarily not to do so.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.  &#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tax Indemnification</font><font style="font-family:inherit;font-size:10pt;">.  Nicholson acknowledges and agrees that the Company has made no representations or Tax Indemnification warranties regarding the tax consequences of any amounts paid by the Company to Nicholson pursuant to this Agreement.  Nicholson agrees to pay all federal or state taxes owed by him, if any, which are required by law to be paid with respect to the payments herein.  Nicholson further agrees to indemnify and hold the Company harmless from any taxes owed by him, including interests or penalties owed by Nicholson, on account of this Agreement.  Nicholson further agrees to reimburse Company for any attorney&#8217;s fees and costs incurred by Company as a result of having to obtain indemnification under this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Return of Company Property</font><font style="font-family:inherit;font-size:10pt;">.  Nicholson agrees that, on or before the beginning of the Consulting Services Term and to the extent not already completed, Nicholson will return to the Company all Company documents (and all copies thereof whether in physical or electronic format) and, with the exception of a personal cell phone and computer, other Company property in Nicholson&#8217;s possession or control, including, but not limited to: Company files, email, electronic messages, notes, </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">memoranda, correspondence, agreements, draft documents, notebooks, logs, drawings, records, plans, proposals, reports, forecasts, financial information, sales and marketing information, research and development information, personnel information, specifications, computer-recorded information, tangible property and equipment, smart phones, cell phones, pagers, credit cards, entry cards, identification badges and keys; and any materials of any kind that contain or embody any proprietary or confidential information of the Company (and all reproductions thereof in whole or in part).  If Nicholson has used any personal computer, server, or electronic system to receive, store, review, prepare or transmit any Company confidential or proprietary data, materials or information, Nicholson agrees to provide the Company with a computer-useable copy of such information and then permanently delete and expunge such Company confidential or proprietary information from those systems.  Nicholson agrees to provide the Company access to his system as requested to verify that the necessary copying and/or deletion is completed.  Nicholson agrees not to retain any paper or electronic copies of any Company documents or data (including but not limited to email and electronic messages) other than this Release and other documents evidencing his employment relationship with the Company.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">No Interference with Rights</font><font style="font-family:inherit;font-size:10pt;">. &#160;Nothing in this Release, including but not limited to the release of claims, the non-disclosure of confidential and proprietary information, the acknowledgements and promise not to sue, or the confidentiality agreements, (a) limits or affects Nicholson&#8217;s right to challenge the validity of this release (b) prevents Nicholson from filing a charge or complaint with or from participating in an investigation or proceeding conducted by the EEOC, the National Labor Relations Board, the Securities and Exchange Commission, or any other federal, state or local agency charged with the enforcement of any laws, including providing documents or other information,&#160;or (c) prevents Nicholson from exercising his rights under Section 7 of the NLRA to engage in protected, concerted activity with other employees, although by signing this Agreement, Nicholson acknowledges waiving his right to recover any individual relief (including backpay, frontpay, reinstatement or other legal or equitable relief) in any charge, complaint, or lawsuit or other proceeding brought by Nicholson or on Nicholson&#8217;s behalf by any third party, except for any right Nicholson may have to receive a payment from a government agency (and not the Company) for information provided to the government agency or where otherwise prohibited.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Right to Testify</font><font style="font-family:inherit;font-size:10pt;">.  Nothing in this Agreement shall be construed as a waiver of Nicholson&#8217;s right to testify in an administrative, legislative, or judicial proceeding concerning alleged criminal conduct or alleged sexual harassment on the part of the Company, or on the part of the agents or employees of the Company, when Nicholson has been required or requested to attend such a proceeding pursuant to a court order, subpoena, or written request from an administrative agency or the legislature.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Entire Agreement; Modification</font><font style="font-family:inherit;font-size:10pt;">.  This Agreement is governed by California law.  This Agreement, the Award Agreements and Nicholson&#8217;s Employee Confidentiality Agreement constitute the complete and only agreements between Nicholson and the Company on these subjects.  In entering this Agreement, Nicholson is not relying on any promise or representation, written or oral, other than those expressly contained in this Agreement.  Any prior agreements between or directly involving Nicholson and the Company are superseded by this Agreement, except for the Employee Confidentiality Agreement with the Company, and the Award Agreements.  This Agreement may not be modified except in a writing signed by both Nicholson and a Senior Vice President of the Company.  This Agreement shall bind the heirs, personal representatives, successors and assigns of both Nicholson and the Company, and inure to the benefit of both Nicholson and the Released Parties, their heirs, successors and assigns.  Any determination that a provision of this Agreement is invalid or unenforceable, in whole or in part, will not affect any other provision of this Agreement, and the provision in question shall be modified by the court so as to be rendered enforceable in accordance with the intent of the parties to the extent possible.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">General</font><font style="font-family:inherit;font-size:10pt;">.  The headings in this Agreement are provided for reference only and shall not affect the substance of this Agreement.  This Agreement may be signed in counterparts.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Costs</font><font style="font-family:inherit;font-size:10pt;">.  The parties shall each bear their own attorneys&#8217; fees and other fees incurred in connection with this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Arbitration</font><font style="font-family:inherit;font-size:10pt;">.  The parties agree that any dispute regarding any aspect of this Agreement, including the confidentiality provisions, shall be submitted exclusively to final and binding arbitration before a mutually agreed upon arbitrator in accordance with the Federal Arbitration Act (&#8220;FAA&#8221;), 9 U.S.C. &#167;&#160;1, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">et seq</font><font style="font-family:inherit;font-size:10pt;">.  In the event the FAA does not apply for any reason, then the arbitration will proceed pursuant to the California Arbitration Act, California Code of Civil Procedure &#167;&#160;1280, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">et seq</font><font style="font-family:inherit;font-size:10pt;">.  The arbitrator shall be empowered to award any appropriate relief, including remedies at law, in equity or injunctive relief.  Arbitration proceedings shall be held in San Francisco, California, or at any other location mutually agreed upon by the parties.  The parties agree that this arbitration shall be the exclusive means of resolving any dispute under this Agreement and that no other action will be brought by them in any court or other forum.  If the parties cannot agree on an arbitrator, then an arbitrator will be selected using the alternate striking method from a list of five (5) neutral arbitrators </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provided by JAMS (Judicial Arbitration &amp; Mediation Services).  Employee will have the option of making the first strike.  Any dispute must be submitted to the other party in writing within thirty (30) days of when the party knew or should have known of the dispute.  Otherwise, the claim of such party shall be deemed waived to the maximum extent allowed by law.  Each party will pay the fees for their own counsel, subject to any remedies to which that party may later be entitled under applicable law.  However, in all cases where required by applicable law, the Company will pay the arbitrator&#8217;s fees and the arbitration costs.  If under applicable law the Company is not required to pay the arbitrator&#8217;s fees and the arbitration costs, then such fees and costs will be apportioned equally between each set of adverse parties.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Voluntary Execution of Agreement</font><font style="font-family:inherit;font-size:10pt;">.  This Agreement is executed voluntarily and without any duress or undue influence on the part or behalf of the parties hereto, with the full intent of releasing all claims.  The parties acknowledge that: (a) they have read this Agreement; (b) they understand the terms and consequences of this Agreement and of the releases it contains; and (c) they are fully aware of the legal and binding effect of this Agreement.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Counterparts</font><font style="font-family:inherit;font-size:10pt;">.  This Agreement may be executed in counterparts, and each counterpart shall have the same force and effect as an original and shall constitute an effective, binding agreement on the part of each of the undersigned.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In exchange for the promises contained in this Agreement, the Company promises to provide the benefits set forth in this Agreement.</font></div><div style="line-height:120%;padding-bottom:40px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nektar Therapeutics</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By: </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Dorian Hirth</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dorian Hirth</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SVP, Human Resources &amp; Facilities Operations</font></div><div style="line-height:120%;padding-bottom:32px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You have read and understood this Agreement, sign this Agreement knowing you could be waiving valuable rights, and acknowledge that this Agreement is final and binding.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">John Nicholson </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ John Nicholson</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>nktr2019-09x30xexx311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0CB8614841F454D09382CD876BC12A8F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATIONS</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Howard W. Robin, certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q for the period ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;of Nektar Therapeutics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)), for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:43%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: November&#160;6, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ HOWARD W. ROBIN</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Howard W. Robin</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chief Executive Officer, President and Director</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>nktr2019-09x30xexx312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF809379AFF2551EB9D494D4094829794"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Gil M. Labrucherie, certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q for the period ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;of Nektar Therapeutics;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)), for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:43%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: November&#160;6, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ GIL M. LABRUCHERIE</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gil M. Labrucherie</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Vice President, Chief Operating Officer,  and Chief Financial Officer</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>nktr2019-09x30xexx321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1DEE068A846F5F409AF64ADC04F0879D"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 1350 CERTIFICATIONS*</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Howard W. Robin, Chief Executive Officer, President and Director of Nektar Therapeutics (the &#8220;Company&#8221;), and Gil M. Labrucherie, Senior Vice President, Chief Operating Officer, and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Quarterly Report on Form 10-Q for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Exchange Act; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:40%;"></td><td style="width:17%;"></td><td style="width:43%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: November&#160;6, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ HOWARD W. ROBIN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ GIL M. LABRUCHERIE</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Howard W. Robin</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chief Executive Officer, President and Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gil M. Labrucherie</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Senior Vice President, Chief Operating Officer,  and Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">___________________________________________</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:60px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>nktr-20190930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.nektar.com/20190930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nktr="http://www.nektar.com/20190930" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20190930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20190930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20190930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20190930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CashAndInvestmentsInMarketableSecurities" roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecurities">
        <link:definition>2102100 - Disclosure - Cash and Investments in Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>2402403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail" roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail">
        <link:definition>2402402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail" roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail">
        <link:definition>2402404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsInMarketableSecuritiesTables" roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesTables">
        <link:definition>2302301 - Disclosure - Cash and Investments in Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.nektar.com/role/CommitmentsAndContingencies">
        <link:definition>2106100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>2406401 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss">
        <link:definition>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperations" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://www.nektar.com/role/CoverPage">
        <link:definition>0002000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.nektar.com/role/Inventory">
        <link:definition>2103100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryInventoryDetail" roleURI="http://www.nektar.com/role/InventoryInventoryDetail">
        <link:definition>2403402 - Disclosure - Inventory - Inventory (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.nektar.com/role/InventoryTables">
        <link:definition>2303301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.nektar.com/role/Leases">
        <link:definition>2104100 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/LeasesAdditionalInformationDetail">
        <link:definition>2404402 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail" roleURI="http://www.nektar.com/role/LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail">
        <link:definition>2404403 - Disclosure - Leases - Components of Lease Costs Included in Operating Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" roleURI="http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail">
        <link:definition>2404404 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.nektar.com/role/LeasesTables">
        <link:definition>2304301 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedToSaleOfFutureRoyalties" roleURI="http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyalties">
        <link:definition>2105100 - Disclosure - Liability Related to Sale of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail">
        <link:definition>2405401 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAndCollaborationAgreements" roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreements">
        <link:definition>2107100 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAndCollaborationAgreementsAdditionalInformationDetail" roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail">
        <link:definition>2407403 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAndCollaborationAgreementsChangesInDeferredRevenueBalanceFromCollaborationAgreementsDetail" roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreementsChangesInDeferredRevenueBalanceFromCollaborationAgreementsDetail">
        <link:definition>2407404 - Disclosure - License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail" roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail">
        <link:definition>2407402 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAndCollaborationAgreementsTables" roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreementsTables">
        <link:definition>2307301 - Disclosure - License and Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShare" roleURI="http://www.nektar.com/role/NetIncomeLossPerShare">
        <link:definition>2109100 - Disclosure - Net Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossPerShareAdditionalInformationDetail" roleURI="http://www.nektar.com/role/NetIncomeLossPerShareAdditionalInformationDetail">
        <link:definition>2409401 - Disclosure - Net Income (Loss) Per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2401402 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.nektar.com/role/StockBasedCompensation">
        <link:definition>2108100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationActivityDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail">
        <link:definition>2408403 - Disclosure - Stock-Based Compensation - Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail">
        <link:definition>2408402 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.nektar.com/role/StockBasedCompensationTables">
        <link:definition>2308301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="nktr_ARESanFranciscoNumberOneNineLLCMember" name="ARESanFranciscoNumberOneNineLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_AccruedClinicalTrialExpensesCurrent" name="AccruedClinicalTrialExpensesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="nktr_AccruedContractManufacturingExpenseCurrent" name="AccruedContractManufacturingExpenseCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="nktr_AdditionalSpaceRequiredToBeLeasedInFuture" name="AdditionalSpaceRequiredToBeLeasedInFuture" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="instant" />
  <xsd:element id="nktr_AdvancePaymentsToContractManufacturers" name="AdvancePaymentsToContractManufacturers" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="nktr_AggregateConsiderationReceivedFromAgreements" name="AggregateConsiderationReceivedFromAgreements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_AmgenIncMember" name="AmgenIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" name="AmountOfTransactionPriceAllocatedToPerformanceObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="nktr_AmountRecognizedForGrantingLicenses" name="AmountRecognizedForGrantingLicenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_AnnualSalesLevelMilestoneMember" name="AnnualSalesLevelMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_AreaOfLeasedSpace" name="AreaOfLeasedSpace" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="nktr_AstraZenecaAbMember" name="AstraZenecaAbMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_AstraZenecaAgreementWithKirinMember" name="AstraZenecaAgreementWithKirinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_BMSCollaborationAgreementMember" name="BMSCollaborationAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_BaxaltaIncorporatedOrTakedaPLCMember" name="BaxaltaIncorporatedOrTakedaPLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_BristolMyersSquibbCompanyMember" name="BristolMyersSquibbCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" name="CashAndInvestmentsInMarketableSecuritiesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_CashAndInvestmentsInMarketableSecuritiesTable" name="CashAndInvestmentsInMarketableSecuritiesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" name="CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="nktr_ClinicalTrialAgreementMember" name="ClinicalTrialAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_CollaborationPartnerMember" name="CollaborationPartnerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" name="CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement" name="CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum" name="CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="nktr_CostsIncurredShareOfExpenses" name="CostsIncurredShareOfExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="nktr_DebtInvestmentMaturityTerm" name="DebtInvestmentMaturityTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_DebtInvestmentMaximumMaturityPeriod" name="DebtInvestmentMaximumMaturityPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_DrugProductDevelopmentMember" name="DrugProductDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_EliLillyAndCompanyMember" name="EliLillyAndCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_EliLillyMember" name="EliLillyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" name="EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" name="EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_EstimatedFairValueOfShares" name="EstimatedFairValueOfShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="nktr_HemophiliaMember" name="HemophiliaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_KilroyRealtyFinancePartnershipLPMember" name="KilroyRealtyFinancePartnershipLPMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" name="LesseeOperatingLeaseLiabilityPaymentsDueYearSix" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" name="LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="nktr_LiabilitiesAndStockholdersEquityDeficitAbstract" name="LiabilitiesAndStockholdersEquityDeficitAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" name="LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" name="LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" name="LiabilityRelatedToSaleOfFutureRoyaltiesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_LicenseAndCollaborationAgreementsAbstract" name="LicenseAndCollaborationAgreementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_LicenseAndCollaborationAgreementsLineItems" name="LicenseAndCollaborationAgreementsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_LicenseAndCollaborationAgreementsTable" name="LicenseAndCollaborationAgreementsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_LicenseCollaborationAndOtherRevenueMember" name="LicenseCollaborationAndOtherRevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_LicenseCollaborationOtherRevenue" name="LicenseCollaborationOtherRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="nktr_LongTermInvestmentMaturityPeriod" name="LongTermInvestmentMaturityPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_MOVANTIKAndMOVENTIGMember" name="MOVANTIKAndMOVENTIGMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained" name="MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="nktr_MissionBayLeaseMember" name="MissionBayLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_NektarMember" name="NektarMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_NektarThreeFiveEightLicenseMember" name="NektarThreeFiveEightLicenseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_NektarThreeFiveEightMember" name="NektarThreeFiveEightMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_NektarTwoOneFourMember" name="NektarTwoOneFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_NeulastaMember" name="NeulastaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" name="NonCashInterestExpenseRelatedToSaleOfRoyalties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_NumberOfConsecutiveFiveYearTermsToExtendLease" name="NumberOfConsecutiveFiveYearTermsToExtendLease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_NumberOfLeasedSpacesDelivered" name="NumberOfLeasedSpacesDelivered" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_OpdivoAndYervoyMember" name="OpdivoAndYervoyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_OpdivoMember" name="OpdivoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_OrganizationPolicyTextBlock" name="OrganizationPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_OtherPartnerMember" name="OtherPartnerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" name="PaymentsReceivedUnderRightsToSublicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" name="PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" name="PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" name="PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner" name="PercentageOfOutOfPocketCostsToBeReimbursedByPartner" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_PercentageOfSharingInDevelopmentCosts" name="PercentageOfSharingInDevelopmentCosts" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" name="PercentageOfSharingInPhaseTwoDevelopmentCosts" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_PercentageOfSharingInProductionCosts" name="PercentageOfSharingInProductionCosts" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" name="PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" name="PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_PhaseOneClinicalDevelopmentMember" name="PhaseOneClinicalDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_PotentialDevelopmentAndRegulatoryMilestones" name="PotentialDevelopmentAndRegulatoryMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="nktr_PotentialDevelopmentMilestones" name="PotentialDevelopmentMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" name="PotentialDevelopmentRegulatoryAndSalesMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="nktr_PreferredStockShareDesignated" name="PreferredStockShareDesignated" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" name="ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" name="ProceedsFromSaleOfPotentialFutureRoyaltiesGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="nktr_ProfitsAndLossesSharingPercentage" name="ProfitsAndLossesSharingPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_ProspectiveInterestRatePercentage" name="ProspectiveInterestRatePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_PurchaseAndSaleAgreementMember" name="PurchaseAndSaleAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_ReimbursementOfExpenses" name="ReimbursementOfExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="nktr_RemainingAmountAllocatedToTransactionPrice" name="RemainingAmountAllocatedToTransactionPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="nktr_SaleOfStockConsiderationReceived" name="SaleOfStockConsiderationReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" name="SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_SharePurchaseAgreementMember" name="SharePurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_StockOptionsAndRestrictedStockUnitsMember" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nktr_ThirdStreetLeaseMember" name="ThirdStreetLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" name="UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" name="UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>nktr-20190930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecurities" xlink:href="nktr-20190930.xsd#CashAndInvestmentsInMarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:href="nktr-20190930.xsd#CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail" xlink:href="nktr-20190930.xsd#CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesTables" xlink:href="nktr-20190930.xsd#CashAndInvestmentsInMarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsAndContingencies" xlink:href="nktr-20190930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:href="nktr-20190930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="nktr-20190930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="nktr-20190930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="nktr-20190930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="nktr-20190930.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="nktr-20190930.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CoverPage" xlink:href="nktr-20190930.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:href="nktr-20190930.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryInventoryDetail" xlink:href="nktr-20190930.xsd#InventoryInventoryDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:href="nktr-20190930.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/Leases" xlink:href="nktr-20190930.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#LeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail" xlink:href="nktr-20190930.xsd#LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" xlink:href="nktr-20190930.xsd#LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesTables" xlink:href="nktr-20190930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyalties" xlink:href="nktr-20190930.xsd#LiabilityRelatedToSaleOfFutureRoyalties" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreements" xlink:href="nktr-20190930.xsd#LicenseAndCollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#LicenseAndCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreementsChangesInDeferredRevenueBalanceFromCollaborationAgreementsDetail" xlink:href="nktr-20190930.xsd#LicenseAndCollaborationAgreementsChangesInDeferredRevenueBalanceFromCollaborationAgreementsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail" xlink:href="nktr-20190930.xsd#LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreementsTables" xlink:href="nktr-20190930.xsd#LicenseAndCollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/NetIncomeLossPerShare" xlink:href="nktr-20190930.xsd#NetIncomeLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/NetIncomeLossPerShareAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#NetIncomeLossPerShareAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="nktr-20190930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nktr-20190930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:href="nktr-20190930.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:href="nktr-20190930.xsd#StockBasedCompensationActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:href="nktr-20190930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:href="nktr-20190930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecurities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_FF24C4EA114C56F1AACA7255CC3BC080" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_FC7B39397CC251AEA34D1BE79C36EC9C" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_FF24C4EA114C56F1AACA7255CC3BC080" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_FC7B39397CC251AEA34D1BE79C36EC9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_B9228CE2B6505CF6911E3179C7585D22" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_FF24C4EA114C56F1AACA7255CC3BC080" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_B9228CE2B6505CF6911E3179C7585D22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_A6D20C2DF49D5CA79E9EB51BCC2A99AD" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_FF24C4EA114C56F1AACA7255CC3BC080" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_A6D20C2DF49D5CA79E9EB51BCC2A99AD" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_10c00824-133a-511f-7095-1bb270a2d331" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_10c00824-133a-511f-7095-1bb270a2d331" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ab305fa-195a-59cf-c0de-4b5d05fc9de4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_a786ac72-7b36-d915-a262-d97f0559057f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_10c00824-133a-511f-7095-1bb270a2d331" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_a786ac72-7b36-d915-a262-d97f0559057f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_26692f67-d7fd-f2c2-da44-c5fe8f8327e2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_10c00824-133a-511f-7095-1bb270a2d331" xlink:to="loc_us-gaap_Cash_26692f67-d7fd-f2c2-da44-c5fe8f8327e2" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0e2721e-44a1-957d-5aaa-294b580a15e3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0e2721e-44a1-957d-5aaa-294b580a15e3" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AccruedContractManufacturingExpenseCurrent" xlink:label="loc_nktr_AccruedContractManufacturingExpenseCurrent_a0c783cd-e605-c3a0-879f-1bb270828a40" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_nktr_AccruedContractManufacturingExpenseCurrent_a0c783cd-e605-c3a0-879f-1bb270828a40" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AccruedClinicalTrialExpensesCurrent" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_b875fcdf-1684-c730-0bec-1bb270a23d7c" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_b875fcdf-1684-c730-0bec-1bb270a23d7c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d9354686-0832-bbe3-9389-140489c487e8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_84c97d53-d75c-0fec-d05e-498cb2460450" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_InterestPayableCurrent_84c97d53-d75c-0fec-d05e-498cb2460450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1beea529-7ff9-f264-77a3-b82530469f83" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1beea529-7ff9-f264-77a3-b82530469f83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="loc_us-gaap_SeniorLongTermNotes_8acf0381-d8d9-037c-de05-6aed90f2b185" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_SeniorLongTermNotes_8acf0381-d8d9-037c-de05-6aed90f2b185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_1ec96379-5fc8-530b-9f6b-1bb270537ea5" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_1ec96379-5fc8-530b-9f6b-1bb270537ea5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c575cd94-2e5c-db53-1e93-d54553800310" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c575cd94-2e5c-db53-1e93-d54553800310" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d32a2417-a96e-df92-8909-70df29d31528" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d32a2417-a96e-df92-8909-70df29d31528" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AdvancePaymentsToContractManufacturers" xlink:label="loc_nktr_AdvancePaymentsToContractManufacturers_4e9ff9db-6075-983f-b055-1bb26fb738fb" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_nktr_AdvancePaymentsToContractManufacturers_4e9ff9db-6075-983f-b055-1bb26fb738fb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_79aabdc0-b963-1fd1-4e81-8c0801b1ebca" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_OtherAssetsCurrent_79aabdc0-b963-1fd1-4e81-8c0801b1ebca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5be77b8d-fe95-a009-6655-0f33965794f2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5be77b8d-fe95-a009-6655-0f33965794f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52f5671e-53e6-6055-795e-6bd414fd86c2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_52f5671e-53e6-6055-795e-6bd414fd86c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_05b5e0d3-ebb5-73ce-e5cc-1bb26fb74522" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_05b5e0d3-ebb5-73ce-e5cc-1bb26fb74522" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_564fa4d6-c965-e4ab-4ab8-1bb270b16df7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_564fa4d6-c965-e4ab-4ab8-1bb270b16df7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a98081f0-fd09-95f3-a79b-8332c7cecd45" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a98081f0-fd09-95f3-a79b-8332c7cecd45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_97b88949-d4fc-dff4-be7f-d39018557f4e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DepreciationAndAmortization_97b88949-d4fc-dff4-be7f-d39018557f4e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_29b0a481-c653-23c1-27cf-114dadcce1af" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_29b0a481-c653-23c1-27cf-114dadcce1af" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d54a644c-3d3c-bcc1-da30-2f136651f90f" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d54a644c-3d3c-bcc1-da30-2f136651f90f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_bb8c0c41-60b6-6ad9-c835-6a671aae07c5" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_bb8c0c41-60b6-6ad9-c835-6a671aae07c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_eff09578-f037-1eb7-c0f0-39ba77f668a1" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_eff09578-f037-1eb7-c0f0-39ba77f668a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7d3f88de-7d0f-fe63-f176-2a8af9ecbcbd" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7d3f88de-7d0f-fe63-f176-2a8af9ecbcbd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a039d388-4db8-a076-4618-28899f6ce801" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a039d388-4db8-a076-4618-28899f6ce801" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5a6cca43-79c5-34f3-6172-5859b13486b1" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5a6cca43-79c5-34f3-6172-5859b13486b1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b2d1473c-d06a-7053-5039-5cb1510f932e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b2d1473c-d06a-7053-5039-5cb1510f932e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_33cd5d62-efc5-7725-6424-7800a10af341" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_33cd5d62-efc5-7725-6424-7800a10af341" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2e493320-ebb4-7df2-c1f0-2dc8298386c7" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2e493320-ebb4-7df2-c1f0-2dc8298386c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_696ef8d0-385f-266e-0f61-04b954a738e7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_696ef8d0-385f-266e-0f61-04b954a738e7" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="loc_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_01c58722-39a8-1ffa-4b06-1bb27034dcd9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_01c58722-39a8-1ffa-4b06-1bb27034dcd9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_714a30d1-878f-1497-8ad1-4b1e113da228" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_714a30d1-878f-1497-8ad1-4b1e113da228" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6ED5DA3E99B65442AB6578C79B554056" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0507ECD3CA905A33A0160C685A5F7703" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6ED5DA3E99B65442AB6578C79B554056" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0507ECD3CA905A33A0160C685A5F7703" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_CAC53B0EE3CD55C2A83FB9401F168791" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0507ECD3CA905A33A0160C685A5F7703" xlink:to="loc_us-gaap_OperatingIncomeLoss_CAC53B0EE3CD55C2A83FB9401F168791" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4B7DF0F7054651568FB8800A6A8CE1FA" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_CAC53B0EE3CD55C2A83FB9401F168791" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4B7DF0F7054651568FB8800A6A8CE1FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_A9483692CCF95E94AEEFF5603AF3D0C1" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_CAC53B0EE3CD55C2A83FB9401F168791" xlink:to="loc_us-gaap_CostsAndExpenses_A9483692CCF95E94AEEFF5603AF3D0C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1B3D36B082C654E99995E4E53950C86C" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_A9483692CCF95E94AEEFF5603AF3D0C1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1B3D36B082C654E99995E4E53950C86C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7ECBFE51C3A9535A82DC9B035CC1DABC" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_A9483692CCF95E94AEEFF5603AF3D0C1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7ECBFE51C3A9535A82DC9B035CC1DABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_765BC82A078256F59C02DCC3B8C4CDBD" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_A9483692CCF95E94AEEFF5603AF3D0C1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_765BC82A078256F59C02DCC3B8C4CDBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_A824EBBFDB305230995DABA1C09C9910" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0507ECD3CA905A33A0160C685A5F7703" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_A824EBBFDB305230995DABA1C09C9910" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7378A477BD1E5FB3B4B5C88093411B42" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_A824EBBFDB305230995DABA1C09C9910" xlink:to="loc_us-gaap_InterestExpense_7378A477BD1E5FB3B4B5C88093411B42" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_9F0640AF945D5F2980D6FFEA328499E9" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_A824EBBFDB305230995DABA1C09C9910" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_9F0640AF945D5F2980D6FFEA328499E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9D4EE4574A7958A28E228B46122AA99F" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_A824EBBFDB305230995DABA1C09C9910" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9D4EE4574A7958A28E228B46122AA99F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_CC48238F5DA05149AF7A19C59C746CBE" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6ED5DA3E99B65442AB6578C79B554056" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_CC48238F5DA05149AF7A19C59C746CBE" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/InventoryInventoryDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_9EA26FB8925A540C844E315C5DF5751B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_43DB8C61CCD253B9849A15D00839CB95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_9EA26FB8925A540C844E315C5DF5751B" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_43DB8C61CCD253B9849A15D00839CB95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_102502AB3A185E83BDF3E6662320DF63" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_9EA26FB8925A540C844E315C5DF5751B" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_102502AB3A185E83BDF3E6662320DF63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_116C0185AC8A524797619E1F02CE503F" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_9EA26FB8925A540C844E315C5DF5751B" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_116C0185AC8A524797619E1F02CE503F" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/Leases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/LeasesAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_61CD9C9BFACA50F7A778BA343E9606AD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_E511E502551D5C4CBE9F79AC4583F78E" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_61CD9C9BFACA50F7A778BA343E9606AD" xlink:to="loc_us-gaap_OperatingLeaseCost_E511E502551D5C4CBE9F79AC4583F78E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_740558EF2EBE544890C6F48916497542" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_61CD9C9BFACA50F7A778BA343E9606AD" xlink:to="loc_us-gaap_VariableLeaseCost_740558EF2EBE544890C6F48916497542" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d0e3c4ab-df94-52c6-3761-ce2ed0f2f507" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d0e3c4ab-df94-52c6-3761-ce2ed0f2f507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e0f20176-305e-e29f-ab09-584aea596901" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e0f20176-305e-e29f-ab09-584aea596901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8e35e675-3955-0e95-1b9c-d08dd410962e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8e35e675-3955-0e95-1b9c-d08dd410962e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_852d78fc-d4b9-e5fb-fd5a-9da7d3d49669" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_852d78fc-d4b9-e5fb-fd5a-9da7d3d49669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7a6864a2-d55e-24e7-17f1-75d5cad038ee" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7a6864a2-d55e-24e7-17f1-75d5cad038ee" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:label="loc_nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_130866fd-b703-417a-ec61-1bb27053a2ec" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_130866fd-b703-417a-ec61-1bb27053a2ec" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:label="loc_nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_730963af-71bf-d8fd-7002-1bb27053922e" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_730963af-71bf-d8fd-7002-1bb27053922e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyalties" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseAndCollaborationAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseAndCollaborationAgreementsChangesInDeferredRevenueBalanceFromCollaborationAgreementsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseAndCollaborationAgreementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/NetIncomeLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/NetIncomeLossPerShareAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>nktr-20190930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecurities" xlink:href="nktr-20190930.xsd#CashAndInvestmentsInMarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:href="nktr-20190930.xsd#CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail" xlink:href="nktr-20190930.xsd#CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesTables" xlink:href="nktr-20190930.xsd#CashAndInvestmentsInMarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsAndContingencies" xlink:href="nktr-20190930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:href="nktr-20190930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="nktr-20190930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="nktr-20190930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="nktr-20190930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="nktr-20190930.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="nktr-20190930.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CoverPage" xlink:href="nktr-20190930.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:href="nktr-20190930.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryInventoryDetail" xlink:href="nktr-20190930.xsd#InventoryInventoryDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:href="nktr-20190930.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/Leases" xlink:href="nktr-20190930.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#LeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail" xlink:href="nktr-20190930.xsd#LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" xlink:href="nktr-20190930.xsd#LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesTables" xlink:href="nktr-20190930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyalties" xlink:href="nktr-20190930.xsd#LiabilityRelatedToSaleOfFutureRoyalties" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreements" xlink:href="nktr-20190930.xsd#LicenseAndCollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#LicenseAndCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreementsChangesInDeferredRevenueBalanceFromCollaborationAgreementsDetail" xlink:href="nktr-20190930.xsd#LicenseAndCollaborationAgreementsChangesInDeferredRevenueBalanceFromCollaborationAgreementsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail" xlink:href="nktr-20190930.xsd#LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreementsTables" xlink:href="nktr-20190930.xsd#LicenseAndCollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/NetIncomeLossPerShare" xlink:href="nktr-20190930.xsd#NetIncomeLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/NetIncomeLossPerShareAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#NetIncomeLossPerShareAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="nktr-20190930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nktr-20190930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:href="nktr-20190930.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:href="nktr-20190930.xsd#StockBasedCompensationActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:href="nktr-20190930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:href="nktr-20190930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecurities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:type="locator" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_8190C288BC89181AFB8B23E8D9D1156C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:to="loc_srt_RangeAxis_8190C288BC89181AFB8B23E8D9D1156C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_7A0BE7B3B87AD16237FB23E8D9D1A068_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8190C288BC89181AFB8B23E8D9D1156C" xlink:to="loc_srt_RangeMember_7A0BE7B3B87AD16237FB23E8D9D1A068_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_7A0BE7B3B87AD16237FB23E8D9D1A068" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8190C288BC89181AFB8B23E8D9D1156C" xlink:to="loc_srt_RangeMember_7A0BE7B3B87AD16237FB23E8D9D1A068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9F78A9A835D1EFE726D523E8D9D26EB4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7A0BE7B3B87AD16237FB23E8D9D1A068" xlink:to="loc_srt_MinimumMember_9F78A9A835D1EFE726D523E8D9D26EB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_C25D258CF026702E573A23E8D9D2AAC6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7A0BE7B3B87AD16237FB23E8D9D1A068" xlink:to="loc_srt_MaximumMember_C25D258CF026702E573A23E8D9D2AAC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_64DAC4A00A1E4876632F23E8D9D26149" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_64DAC4A00A1E4876632F23E8D9D26149" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_80C31E842445DCABCF2023E8D9D2844D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_64DAC4A00A1E4876632F23E8D9D26149" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_80C31E842445DCABCF2023E8D9D2844D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_80C31E842445DCABCF2023E8D9D2844D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_64DAC4A00A1E4876632F23E8D9D26149" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_80C31E842445DCABCF2023E8D9D2844D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_EAD44DF971930F6549C923E8D9D21633" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_80C31E842445DCABCF2023E8D9D2844D" xlink:to="loc_us-gaap_SeniorNotesMember_EAD44DF971930F6549C923E8D9D21633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9E997F3B751E6C1142D923E8D9D3DB43" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:to="loc_us-gaap_DebtInstrumentAxis_9E997F3B751E6C1142D923E8D9D3DB43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_75CBA2196986279A737623E8D9D3B813_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9E997F3B751E6C1142D923E8D9D3DB43" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_75CBA2196986279A737623E8D9D3B813_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_75CBA2196986279A737623E8D9D3B813" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9E997F3B751E6C1142D923E8D9D3DB43" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_75CBA2196986279A737623E8D9D3B813" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:label="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_36E3F02852D342A49F6623E8D9D377BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_75CBA2196986279A737623E8D9D3B813" xlink:to="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_36E3F02852D342A49F6623E8D9D377BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C978F377BE631B55522923E8D9D4CC1B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C978F377BE631B55522923E8D9D4CC1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F031A566274288AB43FB23E8D9D471F4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C978F377BE631B55522923E8D9D4CC1B" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F031A566274288AB43FB23E8D9D471F4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F031A566274288AB43FB23E8D9D471F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C978F377BE631B55522923E8D9D4CC1B" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F031A566274288AB43FB23E8D9D471F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_EF1A1E10AB6E883510AC23E8D9D4E75C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F031A566274288AB43FB23E8D9D471F4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_EF1A1E10AB6E883510AC23E8D9D4E75C" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_DebtInvestmentMaximumMaturityPeriod" xlink:label="loc_nktr_DebtInvestmentMaximumMaturityPeriod_A986E8A4AE1D4BA2B63623E8D9D5DB1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_nktr_DebtInvestmentMaximumMaturityPeriod_A986E8A4AE1D4BA2B63623E8D9D5DB1C" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_DebtInvestmentMaturityTerm" xlink:label="loc_nktr_DebtInvestmentMaturityTerm_273C7BB023BB4A4C8E5323E8D9D59FA3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_nktr_DebtInvestmentMaturityTerm_273C7BB023BB4A4C8E5323E8D9D59FA3" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LongTermInvestmentMaturityPeriod" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_45AAA984A09DD83C8D7B23E8D9D5EE06" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_nktr_LongTermInvestmentMaturityPeriod_45AAA984A09DD83C8D7B23E8D9D5EE06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4322A3FF870345A5649D23E8D9D58D64" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4322A3FF870345A5649D23E8D9D58D64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2A43D0A897E7F2A2D07D23E8D9D5628C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2A43D0A897E7F2A2D07D23E8D9D5628C" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained" xlink:label="loc_nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained_CFD54470FE8192583A2823E8D9D65CB6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained_CFD54470FE8192583A2823E8D9D65CB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_241DC0FA2EEE8AC5719023E8D9D6C96C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_241DC0FA2EEE8AC5719023E8D9D6C96C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_564D64CCB5442273334D23E8D9D68734" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_564D64CCB5442273334D23E8D9D68734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_CA70854F06D105F6621E23E8D9D6E7E8" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_us-gaap_SeniorNotes_CA70854F06D105F6621E23E8D9D6E7E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_EC4FB48F771ADD545A6F23E8D9D66087" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_EC4FB48F771ADD545A6F23E8D9D66087" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E447DC42C4FE68BFE1B82BEEF230BAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E447DC42C4FE68BFE1B82BEEF230BAF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_2337E6D06E81E1CA268482BEEF24B4AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E447DC42C4FE68BFE1B82BEEF230BAF" xlink:to="loc_us-gaap_InvestmentTypeAxis_2337E6D06E81E1CA268482BEEF24B4AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_2337E6D06E81E1CA268482BEEF24B4AC" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_2337E6D06E81E1CA268482BEEF24B4AC" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_B55F1C4643D0A6D6196C82BEEF24E143" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_B55F1C4643D0A6D6196C82BEEF24E143" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_2F6EAA62463B41A549B182BEEF249D31" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:to="loc_us-gaap_CommercialPaperMember_2F6EAA62463B41A549B182BEEF249D31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CE66F0729B459DEE23B282BEEF25BB45" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CE66F0729B459DEE23B282BEEF25BB45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_E0CD7D6223DAF290623282BEEF25084F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:to="loc_us-gaap_MoneyMarketFundsMember_E0CD7D6223DAF290623282BEEF25084F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_9710AF4A595CBEB35E5F82BEEF25D8D5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:to="loc_us-gaap_CertificatesOfDepositMember_9710AF4A595CBEB35E5F82BEEF25D8D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A94701A6A0DBE18A63CB82BEEF25587A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E447DC42C4FE68BFE1B82BEEF230BAF" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A94701A6A0DBE18A63CB82BEEF25587A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92B3BBF7718A444EE8CD82BEEF2553EF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A94701A6A0DBE18A63CB82BEEF25587A" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92B3BBF7718A444EE8CD82BEEF2553EF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92B3BBF7718A444EE8CD82BEEF2553EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A94701A6A0DBE18A63CB82BEEF25587A" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92B3BBF7718A444EE8CD82BEEF2553EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2B95C6FAB7B7364CEB6182BEEF258FC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92B3BBF7718A444EE8CD82BEEF2553EF" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2B95C6FAB7B7364CEB6182BEEF258FC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_62ADA0F9EFA8A5DEB19782BEEF264C6B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92B3BBF7718A444EE8CD82BEEF2553EF" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_62ADA0F9EFA8A5DEB19782BEEF264C6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7DF762A12D792A1851CE82BEEF26C50D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7DF762A12D792A1851CE82BEEF26C50D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_A90B3EE80C26E7411DC182BEEF2698E5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_A90B3EE80C26E7411DC182BEEF2698E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_153638D619DBA448296F82BEEF260857" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269" xlink:to="loc_us-gaap_Cash_153638D619DBA448296F82BEEF260857" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_F8CDCE32CB93B9D3881A82BEEF274453" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_F8CDCE32CB93B9D3881A82BEEF274453" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_250606D9666A52CB95323EA0178E85D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_8C49DF3890B35CFDB78BFF5EBD886F9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_250606D9666A52CB95323EA0178E85D9" xlink:to="loc_us-gaap_LossContingenciesTable_8C49DF3890B35CFDB78BFF5EBD886F9A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1B29F6A06B40582A9719525F85AA96C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8C49DF3890B35CFDB78BFF5EBD886F9A" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1B29F6A06B40582A9719525F85AA96C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_873F61AA1399B43F6E131BB29EEA2E52_816E6A6178D4510B809C21B7FBAA8298" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1B29F6A06B40582A9719525F85AA96C4" xlink:to="loc_us-gaap_LossContingencyNatureDomain_873F61AA1399B43F6E131BB29EEA2E52_816E6A6178D4510B809C21B7FBAA8298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_5A462247FF245CF28184BB09362226CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1B29F6A06B40582A9719525F85AA96C4" xlink:to="loc_us-gaap_LossContingencyNatureDomain_5A462247FF245CF28184BB09362226CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_251F7F5535C852E7BD4F66085E2BB4A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_5A462247FF245CF28184BB09362226CE" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_251F7F5535C852E7BD4F66085E2BB4A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_653D712551105371AD6AF17345B306B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_250606D9666A52CB95323EA0178E85D9" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_653D712551105371AD6AF17345B306B1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0BAEC335589E53E997386830078442D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_StatementTable_0BAEC335589E53E997386830078442D1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2A036958EAEA5162904ABCA2EF945433" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0BAEC335589E53E997386830078442D1" xlink:to="loc_srt_ProductOrServiceAxis_2A036958EAEA5162904ABCA2EF945433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_8D2E5CF377D602A98DAD63C479E700D2_816E6A6178D4510B809C21B7FBAA8298" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2A036958EAEA5162904ABCA2EF945433" xlink:to="loc_srt_ProductsAndServicesDomain_8D2E5CF377D602A98DAD63C479E700D2_816E6A6178D4510B809C21B7FBAA8298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_10AF9F952A5A5A06902D8EA94D233396" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2A036958EAEA5162904ABCA2EF945433" xlink:to="loc_srt_ProductsAndServicesDomain_10AF9F952A5A5A06902D8EA94D233396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_1D4A9552E5E551BF98B5C55E83C1C823" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_10AF9F952A5A5A06902D8EA94D233396" xlink:to="loc_us-gaap_ProductMember_1D4A9552E5E551BF98B5C55E83C1C823" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_D6B58A0847525FE9AA6A9C37410478EE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_10AF9F952A5A5A06902D8EA94D233396" xlink:to="loc_us-gaap_RoyaltyMember_D6B58A0847525FE9AA6A9C37410478EE" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_8EA5AE0CFB865019B1CB01618DB26A59" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_10AF9F952A5A5A06902D8EA94D233396" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_8EA5AE0CFB865019B1CB01618DB26A59" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LicenseCollaborationAndOtherRevenueMember" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_DC41128EE69956898E30AA8E0678F650" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_10AF9F952A5A5A06902D8EA94D233396" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_DC41128EE69956898E30AA8E0678F650" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_6E0AF52A0A3F542C996F85637C63FD2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_RevenuesAbstract_6E0AF52A0A3F542C996F85637C63FD2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D8E4A552864A51A698A5758EBA1B22FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_6E0AF52A0A3F542C996F85637C63FD2D" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D8E4A552864A51A698A5758EBA1B22FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_FD57E25683765983A40F4DDFCF309891" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_FD57E25683765983A40F4DDFCF309891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_E7A39F64C59C5F45ACD94BB82007F0DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD57E25683765983A40F4DDFCF309891" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_E7A39F64C59C5F45ACD94BB82007F0DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_FD39389C831F53509B32D58081C8AD1A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD57E25683765983A40F4DDFCF309891" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_FD39389C831F53509B32D58081C8AD1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_E131000894E359D79ED4A414B7F9E9FF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD57E25683765983A40F4DDFCF309891" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_E131000894E359D79ED4A414B7F9E9FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_52D536CB56265B54A6878D17C7DF906D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD57E25683765983A40F4DDFCF309891" xlink:to="loc_us-gaap_CostsAndExpenses_52D536CB56265B54A6878D17C7DF906D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_E51F43ECAAD55055ABA1FAD77E318626" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_OperatingIncomeLoss_E51F43ECAAD55055ABA1FAD77E318626" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_649DE37034F659B8B2274D8D377F5091" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_649DE37034F659B8B2274D8D377F5091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_36FFD95C4C355287803D89B478397ED3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_649DE37034F659B8B2274D8D377F5091" xlink:to="loc_us-gaap_InterestExpense_36FFD95C4C355287803D89B478397ED3" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_162D21AD575F50BABB4F9AF0ACF5579A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_649DE37034F659B8B2274D8D377F5091" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_162D21AD575F50BABB4F9AF0ACF5579A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_E913B944A8FF5C7398F9CCE8E5A16ECE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_649DE37034F659B8B2274D8D377F5091" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_E913B944A8FF5C7398F9CCE8E5A16ECE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_AF90FBEEB9C85BF3829BF39CBD0A13F0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_649DE37034F659B8B2274D8D377F5091" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_AF90FBEEB9C85BF3829BF39CBD0A13F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1AF98EB0D65F57F18CB7D84EB54A2025" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1AF98EB0D65F57F18CB7D84EB54A2025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_CCB61A512DDC5FEA90240DD0ABCB0D52" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_CCB61A512DDC5FEA90240DD0ABCB0D52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A9246639E73B559EB7FC8436E9DBA858" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_NetIncomeLoss_A9246639E73B559EB7FC8436E9DBA858" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_2342D51E90A458CBA36D9DD8CDBEFA4D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_2342D51E90A458CBA36D9DD8CDBEFA4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_6118B14FC122583FA36712F3B085A3AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_2342D51E90A458CBA36D9DD8CDBEFA4D" xlink:to="loc_us-gaap_EarningsPerShareBasic_6118B14FC122583FA36712F3B085A3AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_277FB16BF07251239B3355A60D072AF9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_2342D51E90A458CBA36D9DD8CDBEFA4D" xlink:to="loc_us-gaap_EarningsPerShareDiluted_277FB16BF07251239B3355A60D072AF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_02369FB4737F5BED92E3CDA0F8193D13" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_02369FB4737F5BED92E3CDA0F8193D13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1787353FEE5D56F2B5C4D3F24E4DF833" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_02369FB4737F5BED92E3CDA0F8193D13" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1787353FEE5D56F2B5C4D3F24E4DF833" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_337AB3B54E715740973F5F594B8ACCA8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_02369FB4737F5BED92E3CDA0F8193D13" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_337AB3B54E715740973F5F594B8ACCA8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A7BFF0B2ED982F0DC17F4159E96E2B3A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_StatementTable_A7BFF0B2ED982F0DC17F4159E96E2B3A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_29D25CC0BCAB8EEC2C6F4159E96F290C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_A7BFF0B2ED982F0DC17F4159E96E2B3A" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_29D25CC0BCAB8EEC2C6F4159E96F290C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_29D25CC0BCAB8EEC2C6F4159E96F290C" xlink:to="loc_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_29D25CC0BCAB8EEC2C6F4159E96F290C" xlink:to="loc_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_21A726DEC7B03460C0A64159E970DA54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244" xlink:to="loc_us-gaap_CommonStockMember_21A726DEC7B03460C0A64159E970DA54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0060CBE67F7E90812CF84159E972439D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0060CBE67F7E90812CF84159E972439D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_73CBF5E38A4EBEC777CB4159E972D1F1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_73CBF5E38A4EBEC777CB4159E972D1F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_EDAC4CA29F71BC626EC14159E97225ED" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244" xlink:to="loc_us-gaap_RetainedEarningsMember_EDAC4CA29F71BC626EC14159E97225ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_D33E90989DB2BDB1FFCB4159E973CED8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_SharesOutstanding_D33E90989DB2BDB1FFCB4159E973CED8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2D546D39A77B788B8E544159E9738C99" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_StockholdersEquity_2D546D39A77B788B8E544159E9738C99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_2FE18273BD703B03D4D74159E974845F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_2FE18273BD703B03D4D74159E974845F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B0D3132270259EAA0734159E9749866" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B0D3132270259EAA0734159E9749866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_E1092F78F586D026B1244159E974E502" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_E1092F78F586D026B1244159E974E502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8DB7865EB653571D37A04159E9737B07" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8DB7865EB653571D37A04159E9737B07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9CAC59C63B4A517A49DA4159E973B664" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9CAC59C63B4A517A49DA4159E973B664" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_E42204E8221773FFD5894159E974FF2F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_E42204E8221773FFD5894159E974FF2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D90328FBA524AD2334044159E97449CE" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D90328FBA524AD2334044159E97449CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_AE305B6B5AEFEA03556F4159E9741B9F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_NetIncomeLoss_AE305B6B5AEFEA03556F4159E9741B9F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/InventoryInventoryDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/Leases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/LeasesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_51F77C2B1556DDFA0CB0424AFEA2C2B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_51F77C2B1556DDFA0CB0424AFEA2C2B2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_11120C4AD7E4394A1F78424AFEA2E977" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_51F77C2B1556DDFA0CB0424AFEA2C2B2" xlink:to="loc_srt_CounterpartyNameAxis_11120C4AD7E4394A1F78424AFEA2E977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65924A7B9773DE546D98424AFEA3A516_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_11120C4AD7E4394A1F78424AFEA2E977" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65924A7B9773DE546D98424AFEA3A516_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65924A7B9773DE546D98424AFEA3A516" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_11120C4AD7E4394A1F78424AFEA2E977" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65924A7B9773DE546D98424AFEA3A516" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ARESanFranciscoNumberOneNineLLCMember" xlink:label="loc_nktr_ARESanFranciscoNumberOneNineLLCMember_0B48C242A835C2D5DF55424AFEA318B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65924A7B9773DE546D98424AFEA3A516" xlink:to="loc_nktr_ARESanFranciscoNumberOneNineLLCMember_0B48C242A835C2D5DF55424AFEA318B1" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_KilroyRealtyFinancePartnershipLPMember" xlink:label="loc_nktr_KilroyRealtyFinancePartnershipLPMember_7339641D8AEC50C34779424AFEA33F26" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65924A7B9773DE546D98424AFEA3A516" xlink:to="loc_nktr_KilroyRealtyFinancePartnershipLPMember_7339641D8AEC50C34779424AFEA33F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_AC59AEEE5B3C91915BAF424AFEA4889A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_51F77C2B1556DDFA0CB0424AFEA2C2B2" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_AC59AEEE5B3C91915BAF424AFEA4889A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_040CB8AA2621012F08F3424AFEA40140_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_AC59AEEE5B3C91915BAF424AFEA4889A" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_040CB8AA2621012F08F3424AFEA40140_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_040CB8AA2621012F08F3424AFEA40140" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_AC59AEEE5B3C91915BAF424AFEA4889A" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_040CB8AA2621012F08F3424AFEA40140" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_MissionBayLeaseMember" xlink:label="loc_nktr_MissionBayLeaseMember_874C9B0A1396845904FB424AFEA481F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_040CB8AA2621012F08F3424AFEA40140" xlink:to="loc_nktr_MissionBayLeaseMember_874C9B0A1396845904FB424AFEA481F1" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ThirdStreetLeaseMember" xlink:label="loc_nktr_ThirdStreetLeaseMember_01CDFCF0BD694DE46985424AFEA55E16" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_040CB8AA2621012F08F3424AFEA40140" xlink:to="loc_nktr_ThirdStreetLeaseMember_01CDFCF0BD694DE46985424AFEA55E16" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AreaOfLeasedSpace" xlink:label="loc_nktr_AreaOfLeasedSpace_D7C8171BD5768B24E34C424AFEA5D026" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_nktr_AreaOfLeasedSpace_D7C8171BD5768B24E34C424AFEA5D026" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NumberOfConsecutiveFiveYearTermsToExtendLease" xlink:label="loc_nktr_NumberOfConsecutiveFiveYearTermsToExtendLease_53EED72BFD9E8887C6B7424AFEA62118" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_nktr_NumberOfConsecutiveFiveYearTermsToExtendLease_53EED72BFD9E8887C6B7424AFEA62118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_59F561A4D104D26ABB7A424AFEA67BDA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_59F561A4D104D26ABB7A424AFEA67BDA" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AdditionalSpaceRequiredToBeLeasedInFuture" xlink:label="loc_nktr_AdditionalSpaceRequiredToBeLeasedInFuture_027FD05D86E52949C946424AFEA69542" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_nktr_AdditionalSpaceRequiredToBeLeasedInFuture_027FD05D86E52949C946424AFEA69542" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_C39CA597D000298C4816424AFEA791E6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_C39CA597D000298C4816424AFEA791E6" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NumberOfLeasedSpacesDelivered" xlink:label="loc_nktr_NumberOfLeasedSpacesDelivered_85C94440E695D9CCDCC9424AFEA75263" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_nktr_NumberOfLeasedSpacesDelivered_85C94440E695D9CCDCC9424AFEA75263" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_99AB198EE8ABF8BA11B4424AFEA765F3" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_us-gaap_OperatingLeasePayments_99AB198EE8ABF8BA11B4424AFEA765F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_839864574398B3DA3CBC424AFEA70ABD" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_839864574398B3DA3CBC424AFEA70ABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7CD1971DB0B9E36EE911424AFEA8B43B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7CD1971DB0B9E36EE911424AFEA8B43B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/LeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyalties" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:type="locator" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_169703747E6954E289D686091163168B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_169703747E6954E289D686091163168B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1E752C12F05F5F508130A81B79C3A9AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_169703747E6954E289D686091163168B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1E752C12F05F5F508130A81B79C3A9AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2504FB0E0877A66DFE0444C1806E3B41_816E6A6178D4510B809C21B7FBAA8298" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1E752C12F05F5F508130A81B79C3A9AB" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2504FB0E0877A66DFE0444C1806E3B41_816E6A6178D4510B809C21B7FBAA8298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_639B9841668A5418973A43392C399310" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1E752C12F05F5F508130A81B79C3A9AB" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_639B9841668A5418973A43392C399310" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PurchaseAndSaleAgreementMember" xlink:label="loc_nktr_PurchaseAndSaleAgreementMember_E51327D7378357AEAFBFF5C0D10BAA19" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_639B9841668A5418973A43392C399310" xlink:to="loc_nktr_PurchaseAndSaleAgreementMember_E51327D7378357AEAFBFF5C0D10BAA19" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_D86C4AD555925CDDB626F26E46C316EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:to="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_D86C4AD555925CDDB626F26E46C316EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_1A983441232354488C6FF5C17356EF90" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_1A983441232354488C6FF5C17356EF90" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_EE273E50D651593DA1E52FD0ABFDC1F5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_EE273E50D651593DA1E52FD0ABFDC1F5" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_2DE06395B79B5198A0C6AB1AC0A729A8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_2DE06395B79B5198A0C6AB1AC0A729A8" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:label="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_2F9B0A549F435D4588862E6F07CF7099" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:to="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_2F9B0A549F435D4588862E6F07CF7099" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ProspectiveInterestRatePercentage" xlink:label="loc_nktr_ProspectiveInterestRatePercentage_E4E48FBF880951D196EFC997BAE361CF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:to="loc_nktr_ProspectiveInterestRatePercentage_E4E48FBF880951D196EFC997BAE361CF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseAndCollaborationAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_397E6B38CF89ACB8123A240DE8726478" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_dei_LegalEntityAxis_397E6B38CF89ACB8123A240DE8726478" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_397E6B38CF89ACB8123A240DE8726478" xlink:to="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_397E6B38CF89ACB8123A240DE8726478" xlink:to="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_6291CECEBAA65A81AA2B240DE87363D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:to="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_6291CECEBAA65A81AA2B240DE87363D6" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_BristolMyersSquibbCompanyMember" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_9DFB3F050C85858672CF240DE873F17A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_9DFB3F050C85858672CF240DE873F17A" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_EliLillyAndCompanyMember" xlink:label="loc_nktr_EliLillyAndCompanyMember_8F891E727F8372BC2FEA240DE8732FEB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:to="loc_nktr_EliLillyAndCompanyMember_8F891E727F8372BC2FEA240DE8732FEB" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_EliLillyMember" xlink:label="loc_nktr_EliLillyMember_8A33A80393F9424E53D6240DE8732535" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:to="loc_nktr_EliLillyMember_8A33A80393F9424E53D6240DE8732535" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AmgenIncMember" xlink:label="loc_nktr_AmgenIncMember_5363D8F1BE0B28C4183B240DE874DD68" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:to="loc_nktr_AmgenIncMember_5363D8F1BE0B28C4183B240DE874DD68" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AstraZenecaAbMember" xlink:label="loc_nktr_AstraZenecaAbMember_02406795D7E9A1251FC4240DE874D749" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:to="loc_nktr_AstraZenecaAbMember_02406795D7E9A1251FC4240DE874D749" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OtherPartnerMember" xlink:label="loc_nktr_OtherPartnerMember_6764A4830985DF7B3434240DE8748B83" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:to="loc_nktr_OtherPartnerMember_6764A4830985DF7B3434240DE8748B83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_37F37A313D75F40D656E240DE8744B43" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_37F37A313D75F40D656E240DE8744B43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_37F37A313D75F40D656E240DE8744B43" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_37F37A313D75F40D656E240DE8744B43" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_HemophiliaMember" xlink:label="loc_nktr_HemophiliaMember_0549D893244EBB27DABA240DE875BCD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:to="loc_nktr_HemophiliaMember_0549D893244EBB27DABA240DE875BCD0" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_BMSCollaborationAgreementMember" xlink:label="loc_nktr_BMSCollaborationAgreementMember_DDBAD6FF5B6C69CC9BC2240DE875FA5A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:to="loc_nktr_BMSCollaborationAgreementMember_DDBAD6FF5B6C69CC9BC2240DE875FA5A" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ClinicalTrialAgreementMember" xlink:label="loc_nktr_ClinicalTrialAgreementMember_E2277BADC346DF62A033240DE875E220" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:to="loc_nktr_ClinicalTrialAgreementMember_E2277BADC346DF62A033240DE875E220" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NektarThreeFiveEightMember" xlink:label="loc_nktr_NektarThreeFiveEightMember_EF2EF49B3BB01A1CAA69240DE8758D83" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:to="loc_nktr_NektarThreeFiveEightMember_EF2EF49B3BB01A1CAA69240DE8758D83" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PhaseOneClinicalDevelopmentMember" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_360AED5278179C31DDF3240DE8768B1A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:to="loc_nktr_PhaseOneClinicalDevelopmentMember_360AED5278179C31DDF3240DE8768B1A" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_DrugProductDevelopmentMember" xlink:label="loc_nktr_DrugProductDevelopmentMember_7CCCC632A5CAC9F3B483240DE876275E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:to="loc_nktr_DrugProductDevelopmentMember_7CCCC632A5CAC9F3B483240DE876275E" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_MOVANTIKAndMOVENTIGMember" xlink:label="loc_nktr_MOVANTIKAndMOVENTIGMember_DE5D9A0E7A9A3A3CCAA3240DE876CBB9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:to="loc_nktr_MOVANTIKAndMOVENTIGMember_DE5D9A0E7A9A3A3CCAA3240DE876CBB9" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AstraZenecaAgreementWithKirinMember" xlink:label="loc_nktr_AstraZenecaAgreementWithKirinMember_8020127879189B711ADD240DE876B323" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:to="loc_nktr_AstraZenecaAgreementWithKirinMember_8020127879189B711ADD240DE876B323" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NektarMember" xlink:label="loc_nktr_NektarMember_34CC8717FC84A52F2FEC240DE876DC29" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:to="loc_nktr_NektarMember_34CC8717FC84A52F2FEC240DE876DC29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_2221472B029E4CB8F6AD240DE87644C2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_srt_StatementGeographicalAxis_2221472B029E4CB8F6AD240DE87644C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_2952CB7755C4CACEA1F3240DE8763047_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2221472B029E4CB8F6AD240DE87644C2" xlink:to="loc_srt_SegmentGeographicalDomain_2952CB7755C4CACEA1F3240DE8763047_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_2952CB7755C4CACEA1F3240DE8763047" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2221472B029E4CB8F6AD240DE87644C2" xlink:to="loc_srt_SegmentGeographicalDomain_2952CB7755C4CACEA1F3240DE8763047" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_989EB8136EA244DC26AD240DE8779E26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2952CB7755C4CACEA1F3240DE8763047" xlink:to="loc_us-gaap_EuropeanUnionMember_989EB8136EA244DC26AD240DE8779E26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_92D1977C48E591CFA7F8240DE877AC03" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_srt_ProductOrServiceAxis_92D1977C48E591CFA7F8240DE877AC03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_9786066F0D173F846E7C240DE87746DE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_92D1977C48E591CFA7F8240DE877AC03" xlink:to="loc_srt_ProductsAndServicesDomain_9786066F0D173F846E7C240DE87746DE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_9786066F0D173F846E7C240DE87746DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_92D1977C48E591CFA7F8240DE877AC03" xlink:to="loc_srt_ProductsAndServicesDomain_9786066F0D173F846E7C240DE87746DE" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NektarTwoOneFourMember" xlink:label="loc_nktr_NektarTwoOneFourMember_E6580671CCD95B959A1E240DE87874A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9786066F0D173F846E7C240DE87746DE" xlink:to="loc_nktr_NektarTwoOneFourMember_E6580671CCD95B959A1E240DE87874A0" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NektarThreeFiveEightMember" xlink:label="loc_nktr_NektarThreeFiveEightMember_9DB84F7FC3D5A46A8E4F240DE87882A8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9786066F0D173F846E7C240DE87746DE" xlink:to="loc_nktr_NektarThreeFiveEightMember_9DB84F7FC3D5A46A8E4F240DE87882A8" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NektarThreeFiveEightLicenseMember" xlink:label="loc_nktr_NektarThreeFiveEightLicenseMember_00933A0E6E561A79C211240DE87836E3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9786066F0D173F846E7C240DE87746DE" xlink:to="loc_nktr_NektarThreeFiveEightLicenseMember_00933A0E6E561A79C211240DE87836E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_AFD0B26557058927F051240DE878BF1A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_srt_ConsolidatedEntitiesAxis_AFD0B26557058927F051240DE878BF1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_B7B8C7034CCDAF7DFAA3240DE878F02D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_AFD0B26557058927F051240DE878BF1A" xlink:to="loc_srt_ConsolidatedEntitiesDomain_B7B8C7034CCDAF7DFAA3240DE878F02D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_B7B8C7034CCDAF7DFAA3240DE878F02D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_AFD0B26557058927F051240DE878BF1A" xlink:to="loc_srt_ConsolidatedEntitiesDomain_B7B8C7034CCDAF7DFAA3240DE878F02D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ParentCompanyMember" xlink:label="loc_srt_ParentCompanyMember_A120878CDC8738704729240DE8793C3A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_B7B8C7034CCDAF7DFAA3240DE878F02D" xlink:to="loc_srt_ParentCompanyMember_A120878CDC8738704729240DE8793C3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_246716A12EF89B4FE888240DE879AF75" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_246716A12EF89B4FE888240DE879AF75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10CA257573A0B63ABB10240DE879670A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_246716A12EF89B4FE888240DE879AF75" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10CA257573A0B63ABB10240DE879670A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10CA257573A0B63ABB10240DE879670A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_246716A12EF89B4FE888240DE879AF75" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10CA257573A0B63ABB10240DE879670A" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OpdivoMember" xlink:label="loc_nktr_OpdivoMember_D05E10C1E0BCAB56A672240DE8795470" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10CA257573A0B63ABB10240DE879670A" xlink:to="loc_nktr_OpdivoMember_D05E10C1E0BCAB56A672240DE8795470" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OpdivoAndYervoyMember" xlink:label="loc_nktr_OpdivoAndYervoyMember_D0A252CBF8ED910D5C79240DE8798006" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10CA257573A0B63ABB10240DE879670A" xlink:to="loc_nktr_OpdivoAndYervoyMember_D0A252CBF8ED910D5C79240DE8798006" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9115477101444FF6B6DE240DE87ADF33" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_srt_RangeAxis_9115477101444FF6B6DE240DE87ADF33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_05ECB0B476A3320C2B6C240DE87A9196_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9115477101444FF6B6DE240DE87ADF33" xlink:to="loc_srt_RangeMember_05ECB0B476A3320C2B6C240DE87A9196_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_05ECB0B476A3320C2B6C240DE87A9196" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9115477101444FF6B6DE240DE87ADF33" xlink:to="loc_srt_RangeMember_05ECB0B476A3320C2B6C240DE87A9196" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_0F2C6D6426AAC6A29832240DE87A7F69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_05ECB0B476A3320C2B6C240DE87A9196" xlink:to="loc_srt_MaximumMember_0F2C6D6426AAC6A29832240DE87A7F69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_47E828B6EA4B8D502D59240DE87AB73C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_05ECB0B476A3320C2B6C240DE87A9196" xlink:to="loc_srt_MinimumMember_47E828B6EA4B8D502D59240DE87AB73C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_EC4258FED493CAFEE22B240DE87BA3FF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_EC4258FED493CAFEE22B240DE87BA3FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58EC923DA2FED0EE633F240DE87B1D02_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_EC4258FED493CAFEE22B240DE87BA3FF" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58EC923DA2FED0EE633F240DE87B1D02_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58EC923DA2FED0EE633F240DE87B1D02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_EC4258FED493CAFEE22B240DE87BA3FF" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58EC923DA2FED0EE633F240DE87B1D02" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_SharePurchaseAgreementMember" xlink:label="loc_nktr_SharePurchaseAgreementMember_9685DAB7E7773485C3C1240DE87B695F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58EC923DA2FED0EE633F240DE87B1D02" xlink:to="loc_nktr_SharePurchaseAgreementMember_9685DAB7E7773485C3C1240DE87B695F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_FB54A9D5B9D156E385C7240DE87B9913" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_FB54A9D5B9D156E385C7240DE87B9913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_23AE80A4420F7908F3D2240DE87B5105_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FB54A9D5B9D156E385C7240DE87B9913" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_23AE80A4420F7908F3D2240DE87B5105_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_23AE80A4420F7908F3D2240DE87B5105" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FB54A9D5B9D156E385C7240DE87B9913" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_23AE80A4420F7908F3D2240DE87B5105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1B7E70A7C05984BCD9EC240DE87C57E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_23AE80A4420F7908F3D2240DE87B5105" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1B7E70A7C05984BCD9EC240DE87C57E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23CD38861EF53B17CFA9240DE87C9584" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23CD38861EF53B17CFA9240DE87C9584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7152D14D2133911A324D240DE87C4E15_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23CD38861EF53B17CFA9240DE87C9584" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7152D14D2133911A324D240DE87C4E15_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7152D14D2133911A324D240DE87C4E15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23CD38861EF53B17CFA9240DE87C9584" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7152D14D2133911A324D240DE87C4E15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_6499D1A865B2EDB8719C240DE87C4CA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_7152D14D2133911A324D240DE87C4E15" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_6499D1A865B2EDB8719C240DE87C4CA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelAxis" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_C8DD08FD5057ED6C0FA6240DE87D2797" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_C8DD08FD5057ED6C0FA6240DE87D2797" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_909B6BA32EB1C837B8D6240DE87D8E87_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_C8DD08FD5057ED6C0FA6240DE87D2797" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_909B6BA32EB1C837B8D6240DE87D8E87_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_909B6BA32EB1C837B8D6240DE87D8E87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_C8DD08FD5057ED6C0FA6240DE87D2797" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_909B6BA32EB1C837B8D6240DE87D8E87" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AnnualSalesLevelMilestoneMember" xlink:label="loc_nktr_AnnualSalesLevelMilestoneMember_0D697836DE9B89B4F0D7240DE87DBCA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_909B6BA32EB1C837B8D6240DE87D8E87" xlink:to="loc_nktr_AnnualSalesLevelMilestoneMember_0D697836DE9B89B4F0D7240DE87DBCA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_A2BA62362F09AF30382D240DE87E7B09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_A2BA62362F09AF30382D240DE87E7B09" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_DC7232A4D0A29CA7FE5E240DE87EF743" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_DC7232A4D0A29CA7FE5E240DE87EF743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8AA9E9A25CAC9A582761240DE87EF2ED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8AA9E9A25CAC9A582761240DE87EF2ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1480C47463E4FC9CE328240DE87E0491" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1480C47463E4FC9CE328240DE87E0491" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_09F6F3CE020A9025806E240DE87E26D8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_09F6F3CE020A9025806E240DE87E26D8" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ProfitsAndLossesSharingPercentage" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage_DF4FDF60626EB0B28BA7240DE87E7853" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_ProfitsAndLossesSharingPercentage_DF4FDF60626EB0B28BA7240DE87E7853" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfSharingInDevelopmentCosts" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_8BE1B7EE5F89040F5EA3240DE87F0368" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_8BE1B7EE5F89040F5EA3240DE87F0368" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfSharingInProductionCosts" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_6412570336C7AE017C16240DE87F8169" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_6412570336C7AE017C16240DE87F8169" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner" xlink:label="loc_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_9181DEEA6BB046087B75240DE87F9736" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_9181DEEA6BB046087B75240DE87F9736" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_54756B666E5EC1BFB66C240DE87FEA62" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_54756B666E5EC1BFB66C240DE87FEA62" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_9F3BBF085044F7A82967240DE87F3018" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_9F3BBF085044F7A82967240DE87F3018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_8FAD0AFB4916DC060DDA240DE8801A12" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_us-gaap_SharesIssued_8FAD0AFB4916DC060DDA240DE8801A12" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_SaleOfStockConsiderationReceived" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_8DF12339BEE5840F4BC3240DE880525F" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_8DF12339BEE5840F4BC3240DE880525F" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ReimbursementOfExpenses" xlink:label="loc_nktr_ReimbursementOfExpenses_E3E3829DFC9F9E8A1792240DE880ADB3" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_ReimbursementOfExpenses_E3E3829DFC9F9E8A1792240DE880ADB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0CE450CA6F32087F649F240DE8802D89" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0CE450CA6F32087F649F240DE8802D89" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AggregateConsiderationReceivedFromAgreements" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements_4BDF4B8E260F86E1D94D240DE8816968" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_AggregateConsiderationReceivedFromAgreements_4BDF4B8E260F86E1D94D240DE8816968" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_EstimatedFairValueOfShares" xlink:label="loc_nktr_EstimatedFairValueOfShares_D633B6310C6488A63B09240DE881A842" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_EstimatedFairValueOfShares_D633B6310C6488A63B09240DE881A842" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_695FE58402791E1A4242240DE88147BC" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_695FE58402791E1A4242240DE88147BC" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_RemainingAmountAllocatedToTransactionPrice" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice_97FFE04CF388E3F4D3AB240DE881235C" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_RemainingAmountAllocatedToTransactionPrice_97FFE04CF388E3F4D3AB240DE881235C" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:label="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_DA8D39DD70374B279D71240DE8818AFE" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_DA8D39DD70374B279D71240DE8818AFE" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AmountRecognizedForGrantingLicenses" xlink:label="loc_nktr_AmountRecognizedForGrantingLicenses_E31501D36409EF5E4FC1240DE881F202" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_AmountRecognizedForGrantingLicenses_E31501D36409EF5E4FC1240DE881F202" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_491F316DFCC186BC92F7240DE882270E" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_491F316DFCC186BC92F7240DE882270E" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_A5AB6CDBC2F8535AB212240DE882030D" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_A5AB6CDBC2F8535AB212240DE882030D" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7BF4B4D5EAEB93BEC923240DE88280F1" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7BF4B4D5EAEB93BEC923240DE88280F1" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_4C324B5E4418944D0D10240DE8827216" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_4C324B5E4418944D0D10240DE8827216" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_C983344EA4B6D9AB50F0240DE882E4DD" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_C983344EA4B6D9AB50F0240DE882E4DD" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_75111105C95217A15F7F240DE8829787" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_75111105C95217A15F7F240DE8829787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3CC6917EE2AAE03832B7240DE8833CFF" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3CC6917EE2AAE03832B7240DE8833CFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4EB0EA3AC608A2E1AF00240DE8832F91" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4EB0EA3AC608A2E1AF00240DE8832F91" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:label="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_16C7E3C800209745E007240DE883CAF8" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_16C7E3C800209745E007240DE883CAF8" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_7B1B478D541FB1990FD3240DE883CF52" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_7B1B478D541FB1990FD3240DE883CF52" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_FA2463F8D4FF717D22FA240DE883BF25" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_FA2463F8D4FF717D22FA240DE883BF25" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement" xlink:label="loc_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement_06697B12EA0F0735B9DE240DE88358A3" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement_06697B12EA0F0735B9DE240DE88358A3" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum" xlink:label="loc_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum_E0FC436A576DBA1762A8240DE8847C5E" xlink:type="locator" />
    <link:definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum_E0FC436A576DBA1762A8240DE8847C5E" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CostsIncurredShareOfExpenses" xlink:label="loc_nktr_CostsIncurredShareOfExpenses_916CCB75CA22A8F07265240DE8846E82" xlink:type="locator" />
    <link:definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_CostsIncurredShareOfExpenses_916CCB75CA22A8F07265240DE8846E82" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PotentialDevelopmentMilestones" xlink:label="loc_nktr_PotentialDevelopmentMilestones_D026954A18145D13FC5A240DE8844A27" xlink:type="locator" />
    <link:definitionArc order="36" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PotentialDevelopmentMilestones_D026954A18145D13FC5A240DE8844A27" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseAndCollaborationAgreementsChangesInDeferredRevenueBalanceFromCollaborationAgreementsDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail" xlink:type="extended">
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LicenseAndCollaborationAgreementsLineItems" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems_2681DA383C6FA5200C3024067A6CF7D2" xlink:type="locator" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LicenseAndCollaborationAgreementsTable" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable_17D8E3CB27F988D7D57E24067A6800CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_2681DA383C6FA5200C3024067A6CF7D2" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsTable_17D8E3CB27F988D7D57E24067A6800CD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_F67B1A3028E555727BB024067A686948" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_17D8E3CB27F988D7D57E24067A6800CD" xlink:to="loc_dei_LegalEntityAxis_F67B1A3028E555727BB024067A686948" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1DED3D2A9C15E803030424067A69FFFA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_F67B1A3028E555727BB024067A686948" xlink:to="loc_dei_EntityDomain_1DED3D2A9C15E803030424067A69FFFA_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1DED3D2A9C15E803030424067A69FFFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_F67B1A3028E555727BB024067A686948" xlink:to="loc_dei_EntityDomain_1DED3D2A9C15E803030424067A69FFFA" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_BristolMyersSquibbCompanyMember" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_69A10847E970C593F5DF24067A69C488" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1DED3D2A9C15E803030424067A69FFFA" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_69A10847E970C593F5DF24067A69C488" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_EliLillyAndCompanyMember" xlink:label="loc_nktr_EliLillyAndCompanyMember_D70C36B2B9BE3F12D98F24067A695E92" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1DED3D2A9C15E803030424067A69FFFA" xlink:to="loc_nktr_EliLillyAndCompanyMember_D70C36B2B9BE3F12D98F24067A695E92" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AmgenIncMember" xlink:label="loc_nktr_AmgenIncMember_8EFE39DF8EAE0C509D6F24067A6A7E7C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1DED3D2A9C15E803030424067A69FFFA" xlink:to="loc_nktr_AmgenIncMember_8EFE39DF8EAE0C509D6F24067A6A7E7C" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OtherPartnerMember" xlink:label="loc_nktr_OtherPartnerMember_C2C1826CE89F77DE7CBA24067A6A6D19" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1DED3D2A9C15E803030424067A69FFFA" xlink:to="loc_nktr_OtherPartnerMember_C2C1826CE89F77DE7CBA24067A6A6D19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F50F36B92EEC82F2254224067A6A05E9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_17D8E3CB27F988D7D57E24067A6800CD" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F50F36B92EEC82F2254224067A6A05E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_155D7294020CB2CE9E6E24067A6B3956_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F50F36B92EEC82F2254224067A6A05E9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_155D7294020CB2CE9E6E24067A6B3956_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_155D7294020CB2CE9E6E24067A6B3956" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F50F36B92EEC82F2254224067A6A05E9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_155D7294020CB2CE9E6E24067A6B3956" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NektarTwoOneFourMember" xlink:label="loc_nktr_NektarTwoOneFourMember_8F502B7ED56FED3ACA2E24067A6B94A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_155D7294020CB2CE9E6E24067A6B3956" xlink:to="loc_nktr_NektarTwoOneFourMember_8F502B7ED56FED3ACA2E24067A6B94A3" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NektarThreeFiveEightMember" xlink:label="loc_nktr_NektarThreeFiveEightMember_E55A6D8A17B9A84192EE24067A6CB955" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_155D7294020CB2CE9E6E24067A6B3956" xlink:to="loc_nktr_NektarThreeFiveEightMember_E55A6D8A17B9A84192EE24067A6CB955" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NeulastaMember" xlink:label="loc_nktr_NeulastaMember_78124CA411E62E1EC49624067A6CBC35" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_155D7294020CB2CE9E6E24067A6B3956" xlink:to="loc_nktr_NeulastaMember_78124CA411E62E1EC49624067A6CBC35" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LicenseCollaborationOtherRevenue" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue_82CC4F2519B33E65A9BA24067A6C9B0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_2681DA383C6FA5200C3024067A6CF7D2" xlink:to="loc_nktr_LicenseCollaborationOtherRevenue_82CC4F2519B33E65A9BA24067A6C9B0F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseAndCollaborationAgreementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/NetIncomeLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/NetIncomeLossPerShareAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B62141538BA797E4CC841981655B2167" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13D74808B814D69A729319816559EB10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B62141538BA797E4CC841981655B2167" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13D74808B814D69A729319816559EB10" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_97BA751453A860F80CC91981655A08BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13D74808B814D69A729319816559EB10" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_97BA751453A860F80CC91981655A08BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_E99A0E103C9CD63411A71981655A54AA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_97BA751453A860F80CC91981655A08BC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_E99A0E103C9CD63411A71981655A54AA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_E99A0E103C9CD63411A71981655A54AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_97BA751453A860F80CC91981655A08BC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_E99A0E103C9CD63411A71981655A54AA" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_StockOptionsAndRestrictedStockUnitsMember" xlink:label="loc_nktr_StockOptionsAndRestrictedStockUnitsMember_4DB124B721755CCA734E1981655A4B54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_E99A0E103C9CD63411A71981655A54AA" xlink:to="loc_nktr_StockOptionsAndRestrictedStockUnitsMember_4DB124B721755CCA734E1981655A4B54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C8AEBB36AAC038B425A11981655B42BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B62141538BA797E4CC841981655B2167" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C8AEBB36AAC038B425A11981655B42BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C25CC2A12F34A7A2D22C1981655B4A83" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B62141538BA797E4CC841981655B2167" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C25CC2A12F34A7A2D22C1981655B4A83" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:type="locator" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_81F4282E6CDC1231F5CE2410C438D977" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF" xlink:to="loc_srt_CounterpartyNameAxis_81F4282E6CDC1231F5CE2410C438D977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3B6A2A47F21B983655EC2410C4390874_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_81F4282E6CDC1231F5CE2410C438D977" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3B6A2A47F21B983655EC2410C4390874_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3B6A2A47F21B983655EC2410C4390874" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_81F4282E6CDC1231F5CE2410C438D977" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3B6A2A47F21B983655EC2410C4390874" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CollaborationPartnerMember" xlink:label="loc_nktr_CollaborationPartnerMember_837C97215E35536B09D92410C4399D39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3B6A2A47F21B983655EC2410C4390874" xlink:to="loc_nktr_CollaborationPartnerMember_837C97215E35536B09D92410C4399D39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C66946791A3091079822410C439101A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C66946791A3091079822410C439101A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_F1B18BFA736F339DB1952410C4391A5E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C66946791A3091079822410C439101A" xlink:to="loc_us-gaap_TypeOfAdoptionMember_F1B18BFA736F339DB1952410C4391A5E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_F1B18BFA736F339DB1952410C4391A5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C66946791A3091079822410C439101A" xlink:to="loc_us-gaap_TypeOfAdoptionMember_F1B18BFA736F339DB1952410C4391A5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_63B7C2CB96727936AE4B2410C4393AA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_F1B18BFA736F339DB1952410C4391A5E" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_63B7C2CB96727936AE4B2410C4393AA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_6437864FB68F67C76FB02410C43A4985" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF" xlink:to="loc_srt_StatementGeographicalAxis_6437864FB68F67C76FB02410C43A4985" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_361C6B1197DB8DDE0CCD2410C43A8349_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6437864FB68F67C76FB02410C43A4985" xlink:to="loc_srt_SegmentGeographicalDomain_361C6B1197DB8DDE0CCD2410C43A8349_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_361C6B1197DB8DDE0CCD2410C43A8349" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6437864FB68F67C76FB02410C43A4985" xlink:to="loc_srt_SegmentGeographicalDomain_361C6B1197DB8DDE0CCD2410C43A8349" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_IN" xlink:label="loc_country_IN_1ECBF4BA13380F5C37FC2410C43AFDED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_361C6B1197DB8DDE0CCD2410C43A8349" xlink:to="loc_country_IN_1ECBF4BA13380F5C37FC2410C43AFDED" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_48FE25BBC82F48D53B082410C43B5516" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_48FE25BBC82F48D53B082410C43B5516" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_0AA4A5CF705DBCB92C6A2410C43BD303" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_us-gaap_SeniorNotes_0AA4A5CF705DBCB92C6A2410C43BD303" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_90A1ACB53471618FA1FF2410C43BBC85" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_us-gaap_NumberOfOperatingSegments_90A1ACB53471618FA1FF2410C43BBC85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9A1FB2B9C87A2994FF912410C43B3B25" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9A1FB2B9C87A2994FF912410C43B3B25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6F2D8DB33F2EE7DE36CC2410C43B7D20" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6F2D8DB33F2EE7DE36CC2410C43B7D20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_B463F2E97D9F7A3FDAC92410C43BE76E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_us-gaap_OperatingLeaseLiability_B463F2E97D9F7A3FDAC92410C43BE76E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_C72775C82149D11D70312410C43C503D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_C72775C82149D11D70312410C43C503D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5202C963CA09799790362410C43CD9DD" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5202C963CA09799790362410C43CD9DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_17263E115CD84E7011CE2410C43C1DF9" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_17263E115CD84E7011CE2410C43C1DF9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FD9F5D81C8D1FCACC3C13E2EDB9277D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FD9F5D81C8D1FCACC3C13E2EDB9277D0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7D0491AAA506A7B3B23E3E2EDB92F49D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FD9F5D81C8D1FCACC3C13E2EDB9277D0" xlink:to="loc_us-gaap_AwardTypeAxis_7D0491AAA506A7B3B23E3E2EDB92F49D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B64D9BC43AD5047A8FE3E2EDB936661_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7D0491AAA506A7B3B23E3E2EDB92F49D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B64D9BC43AD5047A8FE3E2EDB936661_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B64D9BC43AD5047A8FE3E2EDB936661" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7D0491AAA506A7B3B23E3E2EDB92F49D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B64D9BC43AD5047A8FE3E2EDB936661" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_479F34B0F5AED7883D273E2EDB94DE66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B64D9BC43AD5047A8FE3E2EDB936661" xlink:to="loc_us-gaap_EmployeeStockOptionMember_479F34B0F5AED7883D273E2EDB94DE66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5FB6AB3EF71BA5CDCF573E2EDB94C936" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B64D9BC43AD5047A8FE3E2EDB936661" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5FB6AB3EF71BA5CDCF573E2EDB94C936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9F4DFA840F13F40357543E2EDB9406B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9F4DFA840F13F40357543E2EDB9406B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FA86BA7F7EE2FBFE8243E2EDB95F583" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FA86BA7F7EE2FBFE8243E2EDB95F583" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18AD850A0C93C86E6CD93E2EDB95BEC3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18AD850A0C93C86E6CD93E2EDB95BEC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D228B40D5A7363DE0F7F3E2EDB959DB1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D228B40D5A7363DE0F7F3E2EDB959DB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_72EC530EFF06DF7085903E2EDB953060" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_72EC530EFF06DF7085903E2EDB953060" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2C49BE85D82F5F46ACDF0842B09D3FDB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790DB18DF9835F3193643A219CD6FEF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2C49BE85D82F5F46ACDF0842B09D3FDB" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790DB18DF9835F3193643A219CD6FEF9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_D7E19384712C56149EA6A0FBBDE84850" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790DB18DF9835F3193643A219CD6FEF9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_D7E19384712C56149EA6A0FBBDE84850" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_25024C778B091221A4851BB29F32428E_816E6A6178D4510B809C21B7FBAA8298" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D7E19384712C56149EA6A0FBBDE84850" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_25024C778B091221A4851BB29F32428E_816E6A6178D4510B809C21B7FBAA8298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E98871E9B8255E11BBA48525C5213593" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D7E19384712C56149EA6A0FBBDE84850" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_E98871E9B8255E11BBA48525C5213593" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_4EA448AE2F20555B8F4B4A099960F5D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E98871E9B8255E11BBA48525C5213593" xlink:to="loc_us-gaap_CostOfSalesMember_4EA448AE2F20555B8F4B4A099960F5D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_CEC5D9D7164D5A05AD3048F082E72921" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E98871E9B8255E11BBA48525C5213593" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_CEC5D9D7164D5A05AD3048F082E72921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_12D3063FD3985499A15318EEC7DA1695" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E98871E9B8255E11BBA48525C5213593" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_12D3063FD3985499A15318EEC7DA1695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3176C3E9D800561CB16D3469327BB98D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2C49BE85D82F5F46ACDF0842B09D3FDB" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3176C3E9D800561CB16D3469327BB98D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>nktr-20190930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_67F24EB21F061A61F20F6360C314D8E7_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_D57C921AC1E9565F8588C8F01D8421D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_D57C921AC1E9565F8588C8F01D8421D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_D57C921AC1E9565F8588C8F01D8421D6" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_D57C921AC1E9565F8588C8F01D8421D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5E04FE33BB40926F33676360C31535BE_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_6699E4AEEF475160B45EB5172BCACA3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5E04FE33BB40926F33676360C31535BE_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_6699E4AEEF475160B45EB5172BCACA3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6699E4AEEF475160B45EB5172BCACA3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6699E4AEEF475160B45EB5172BCACA3F" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_6699E4AEEF475160B45EB5172BCACA3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_03474EC3067D4BC4DA4282BEEF23D819_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_03474EC3067D4BC4DA4282BEEF23D819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_03474EC3067D4BC4DA4282BEEF23D819" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_03474EC3067D4BC4DA4282BEEF23D819" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_03474EC3067D4BC4DA4282BEEF23D819" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E447DC42C4FE68BFE1B82BEEF230BAF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E447DC42C4FE68BFE1B82BEEF230BAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E447DC42C4FE68BFE1B82BEEF230BAF_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E447DC42C4FE68BFE1B82BEEF230BAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E447DC42C4FE68BFE1B82BEEF230BAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E447DC42C4FE68BFE1B82BEEF230BAF" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E447DC42C4FE68BFE1B82BEEF230BAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_2337E6D06E81E1CA268482BEEF24B4AC_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_2337E6D06E81E1CA268482BEEF24B4AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_2337E6D06E81E1CA268482BEEF24B4AC_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_2337E6D06E81E1CA268482BEEF24B4AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_2337E6D06E81E1CA268482BEEF24B4AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_2337E6D06E81E1CA268482BEEF24B4AC" xlink:to="lab_us-gaap_InvestmentTypeAxis_2337E6D06E81E1CA268482BEEF24B4AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_B55F1C4643D0A6D6196C82BEEF24E143_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_B55F1C4643D0A6D6196C82BEEF24E143" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Notes and Bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_B55F1C4643D0A6D6196C82BEEF24E143_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_B55F1C4643D0A6D6196C82BEEF24E143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_B55F1C4643D0A6D6196C82BEEF24E143" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_B55F1C4643D0A6D6196C82BEEF24E143" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_B55F1C4643D0A6D6196C82BEEF24E143" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_2F6EAA62463B41A549B182BEEF249D31_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_2F6EAA62463B41A549B182BEEF249D31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_2F6EAA62463B41A549B182BEEF249D31_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_2F6EAA62463B41A549B182BEEF249D31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_2F6EAA62463B41A549B182BEEF249D31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_2F6EAA62463B41A549B182BEEF249D31" xlink:to="lab_us-gaap_CommercialPaperMember_2F6EAA62463B41A549B182BEEF249D31" xlink:type="arc" />
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CE66F0729B459DEE23B282BEEF25BB45_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CE66F0729B459DEE23B282BEEF25BB45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Obligations of U.S. Government Agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CE66F0729B459DEE23B282BEEF25BB45_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CE66F0729B459DEE23B282BEEF25BB45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CE66F0729B459DEE23B282BEEF25BB45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CE66F0729B459DEE23B282BEEF25BB45" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CE66F0729B459DEE23B282BEEF25BB45" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_E0CD7D6223DAF290623282BEEF25084F_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_E0CD7D6223DAF290623282BEEF25084F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_E0CD7D6223DAF290623282BEEF25084F_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_E0CD7D6223DAF290623282BEEF25084F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_E0CD7D6223DAF290623282BEEF25084F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_E0CD7D6223DAF290623282BEEF25084F" xlink:to="lab_us-gaap_MoneyMarketFundsMember_E0CD7D6223DAF290623282BEEF25084F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_9710AF4A595CBEB35E5F82BEEF25D8D5_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_9710AF4A595CBEB35E5F82BEEF25D8D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of Deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_9710AF4A595CBEB35E5F82BEEF25D8D5_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_9710AF4A595CBEB35E5F82BEEF25D8D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_9710AF4A595CBEB35E5F82BEEF25D8D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember_9710AF4A595CBEB35E5F82BEEF25D8D5" xlink:to="lab_us-gaap_CertificatesOfDepositMember_9710AF4A595CBEB35E5F82BEEF25D8D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A94701A6A0DBE18A63CB82BEEF25587A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A94701A6A0DBE18A63CB82BEEF25587A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A94701A6A0DBE18A63CB82BEEF25587A_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A94701A6A0DBE18A63CB82BEEF25587A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A94701A6A0DBE18A63CB82BEEF25587A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A94701A6A0DBE18A63CB82BEEF25587A" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A94701A6A0DBE18A63CB82BEEF25587A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92B3BBF7718A444EE8CD82BEEF2553EF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92B3BBF7718A444EE8CD82BEEF2553EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92B3BBF7718A444EE8CD82BEEF2553EF_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92B3BBF7718A444EE8CD82BEEF2553EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92B3BBF7718A444EE8CD82BEEF2553EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92B3BBF7718A444EE8CD82BEEF2553EF" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92B3BBF7718A444EE8CD82BEEF2553EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2B95C6FAB7B7364CEB6182BEEF258FC7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_2B95C6FAB7B7364CEB6182BEEF258FC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2B95C6FAB7B7364CEB6182BEEF258FC7_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_2B95C6FAB7B7364CEB6182BEEF258FC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2B95C6FAB7B7364CEB6182BEEF258FC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_2B95C6FAB7B7364CEB6182BEEF258FC7" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_2B95C6FAB7B7364CEB6182BEEF258FC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_62ADA0F9EFA8A5DEB19782BEEF264C6B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_62ADA0F9EFA8A5DEB19782BEEF264C6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_62ADA0F9EFA8A5DEB19782BEEF264C6B_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_62ADA0F9EFA8A5DEB19782BEEF264C6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_62ADA0F9EFA8A5DEB19782BEEF264C6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_62ADA0F9EFA8A5DEB19782BEEF264C6B" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_62ADA0F9EFA8A5DEB19782BEEF264C6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7DF762A12D792A1851CE82BEEF26C50D_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7DF762A12D792A1851CE82BEEF26C50D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7DF762A12D792A1851CE82BEEF26C50D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7DF762A12D792A1851CE82BEEF26C50D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7DF762A12D792A1851CE82BEEF26C50D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7DF762A12D792A1851CE82BEEF26C50D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7DF762A12D792A1851CE82BEEF26C50D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_A90B3EE80C26E7411DC182BEEF2698E5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_A90B3EE80C26E7411DC182BEEF2698E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_A90B3EE80C26E7411DC182BEEF2698E5_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_A90B3EE80C26E7411DC182BEEF2698E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_A90B3EE80C26E7411DC182BEEF2698E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_A90B3EE80C26E7411DC182BEEF2698E5" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_A90B3EE80C26E7411DC182BEEF2698E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_Cash_153638D619DBA448296F82BEEF260857_terseLabel_en-US" xlink:label="lab_us-gaap_Cash_153638D619DBA448296F82BEEF260857" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_153638D619DBA448296F82BEEF260857_label_en-US" xlink:label="lab_us-gaap_Cash_153638D619DBA448296F82BEEF260857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_153638D619DBA448296F82BEEF260857" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash_153638D619DBA448296F82BEEF260857" xlink:to="lab_us-gaap_Cash_153638D619DBA448296F82BEEF260857" xlink:type="arc" />
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_F8CDCE32CB93B9D3881A82BEEF274453_totalLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_F8CDCE32CB93B9D3881A82BEEF274453" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_F8CDCE32CB93B9D3881A82BEEF274453_label_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_F8CDCE32CB93B9D3881A82BEEF274453" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Restricted Cash Cash Equivalents And Available For Sale Investments</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_F8CDCE32CB93B9D3881A82BEEF274453_documentation_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_F8CDCE32CB93B9D3881A82BEEF274453" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, restricted cash, cash equivalents, and available for sale investments.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_F8CDCE32CB93B9D3881A82BEEF274453" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_F8CDCE32CB93B9D3881A82BEEF274453" xlink:to="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_F8CDCE32CB93B9D3881A82BEEF274453" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_476C1986628F5759FA583E2EDB923154_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_476C1986628F5759FA583E2EDB923154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_476C1986628F5759FA583E2EDB923154" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_476C1986628F5759FA583E2EDB923154" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_476C1986628F5759FA583E2EDB923154" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FD9F5D81C8D1FCACC3C13E2EDB9277D0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FD9F5D81C8D1FCACC3C13E2EDB9277D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FD9F5D81C8D1FCACC3C13E2EDB9277D0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FD9F5D81C8D1FCACC3C13E2EDB9277D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FD9F5D81C8D1FCACC3C13E2EDB9277D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FD9F5D81C8D1FCACC3C13E2EDB9277D0" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FD9F5D81C8D1FCACC3C13E2EDB9277D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_7D0491AAA506A7B3B23E3E2EDB92F49D_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_7D0491AAA506A7B3B23E3E2EDB92F49D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_7D0491AAA506A7B3B23E3E2EDB92F49D_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_7D0491AAA506A7B3B23E3E2EDB92F49D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7D0491AAA506A7B3B23E3E2EDB92F49D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_7D0491AAA506A7B3B23E3E2EDB92F49D" xlink:to="lab_us-gaap_AwardTypeAxis_7D0491AAA506A7B3B23E3E2EDB92F49D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B64D9BC43AD5047A8FE3E2EDB936661_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B64D9BC43AD5047A8FE3E2EDB936661" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B64D9BC43AD5047A8FE3E2EDB936661_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B64D9BC43AD5047A8FE3E2EDB936661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B64D9BC43AD5047A8FE3E2EDB936661" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B64D9BC43AD5047A8FE3E2EDB936661" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B64D9BC43AD5047A8FE3E2EDB936661" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_479F34B0F5AED7883D273E2EDB94DE66_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_479F34B0F5AED7883D273E2EDB94DE66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_479F34B0F5AED7883D273E2EDB94DE66_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_479F34B0F5AED7883D273E2EDB94DE66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_479F34B0F5AED7883D273E2EDB94DE66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_479F34B0F5AED7883D273E2EDB94DE66" xlink:to="lab_us-gaap_EmployeeStockOptionMember_479F34B0F5AED7883D273E2EDB94DE66" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_5FB6AB3EF71BA5CDCF573E2EDB94C936_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_5FB6AB3EF71BA5CDCF573E2EDB94C936" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSU)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_5FB6AB3EF71BA5CDCF573E2EDB94C936_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_5FB6AB3EF71BA5CDCF573E2EDB94C936" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5FB6AB3EF71BA5CDCF573E2EDB94C936" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_5FB6AB3EF71BA5CDCF573E2EDB94C936" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_5FB6AB3EF71BA5CDCF573E2EDB94C936" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9F4DFA840F13F40357543E2EDB9406B5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9F4DFA840F13F40357543E2EDB9406B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9F4DFA840F13F40357543E2EDB9406B5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9F4DFA840F13F40357543E2EDB9406B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9F4DFA840F13F40357543E2EDB9406B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9F4DFA840F13F40357543E2EDB9406B5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9F4DFA840F13F40357543E2EDB9406B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FA86BA7F7EE2FBFE8243E2EDB95F583_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FA86BA7F7EE2FBFE8243E2EDB95F583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value, options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FA86BA7F7EE2FBFE8243E2EDB95F583_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FA86BA7F7EE2FBFE8243E2EDB95F583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FA86BA7F7EE2FBFE8243E2EDB95F583" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FA86BA7F7EE2FBFE8243E2EDB95F583" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FA86BA7F7EE2FBFE8243E2EDB95F583" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18AD850A0C93C86E6CD93E2EDB95BEC3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18AD850A0C93C86E6CD93E2EDB95BEC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18AD850A0C93C86E6CD93E2EDB95BEC3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18AD850A0C93C86E6CD93E2EDB95BEC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18AD850A0C93C86E6CD93E2EDB95BEC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18AD850A0C93C86E6CD93E2EDB95BEC3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18AD850A0C93C86E6CD93E2EDB95BEC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D228B40D5A7363DE0F7F3E2EDB959DB1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D228B40D5A7363DE0F7F3E2EDB959DB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value, RSUs (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D228B40D5A7363DE0F7F3E2EDB959DB1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D228B40D5A7363DE0F7F3E2EDB959DB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D228B40D5A7363DE0F7F3E2EDB959DB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D228B40D5A7363DE0F7F3E2EDB959DB1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D228B40D5A7363DE0F7F3E2EDB959DB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_72EC530EFF06DF7085903E2EDB953060_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_72EC530EFF06DF7085903E2EDB953060" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under equity compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_72EC530EFF06DF7085903E2EDB953060_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_72EC530EFF06DF7085903E2EDB953060" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_72EC530EFF06DF7085903E2EDB953060" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_72EC530EFF06DF7085903E2EDB953060" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_72EC530EFF06DF7085903E2EDB953060" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_664A943C8930FA6C54046360C280AE40_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_E2F953D728955AA9875CE779DEA860DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_E2F953D728955AA9875CE779DEA860DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E2F953D728955AA9875CE779DEA860DC" xlink:to="lab_us-gaap_EarningsPerShareAbstract_E2F953D728955AA9875CE779DEA860DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_7B07958E14A548C116846360C280B222_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_F4C4E8E7EFD35379BFA203331AA6ED23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_7B07958E14A548C116846360C280B222_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_F4C4E8E7EFD35379BFA203331AA6ED23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_F4C4E8E7EFD35379BFA203331AA6ED23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_F4C4E8E7EFD35379BFA203331AA6ED23" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_F4C4E8E7EFD35379BFA203331AA6ED23" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7E56122B97E7A09217B644C180AFC6E1_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7E8DF451EFA65667A16D16FD085831D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7E56122B97E7A09217B644C180AFC6E1_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7E8DF451EFA65667A16D16FD085831D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7E8DF451EFA65667A16D16FD085831D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7E8DF451EFA65667A16D16FD085831D3" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7E8DF451EFA65667A16D16FD085831D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D1D1FCB705D0FA99D44044C180AF5A6D_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5915AD0B09B3540098CD0E7352237A58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D1D1FCB705D0FA99D44044C180AF5A6D_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5915AD0B09B3540098CD0E7352237A58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5915AD0B09B3540098CD0E7352237A58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5915AD0B09B3540098CD0E7352237A58" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5915AD0B09B3540098CD0E7352237A58" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_409D76272E1BC3960DF944C180B060D1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_198F69BAD91355A3996977681FD4C3EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_409D76272E1BC3960DF944C180B060D1_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_198F69BAD91355A3996977681FD4C3EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_198F69BAD91355A3996977681FD4C3EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_198F69BAD91355A3996977681FD4C3EA" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_198F69BAD91355A3996977681FD4C3EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_E12DEAF80623AE90DB9C44C180B01E7E_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_920E160CD9B8568E946EC8CA0C4B49F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_E12DEAF80623AE90DB9C44C180B01E7E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_920E160CD9B8568E946EC8CA0C4B49F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_920E160CD9B8568E946EC8CA0C4B49F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_920E160CD9B8568E946EC8CA0C4B49F4" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_920E160CD9B8568E946EC8CA0C4B49F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97BF5CDF081F5D76D5FA2410C43881FD_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97BF5CDF081F5D76D5FA2410C43881FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97BF5CDF081F5D76D5FA2410C43881FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97BF5CDF081F5D76D5FA2410C43881FD" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97BF5CDF081F5D76D5FA2410C43881FD" xlink:type="arc" />
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_81F4282E6CDC1231F5CE2410C438D977_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_81F4282E6CDC1231F5CE2410C438D977" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_81F4282E6CDC1231F5CE2410C438D977_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_81F4282E6CDC1231F5CE2410C438D977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_81F4282E6CDC1231F5CE2410C438D977" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_81F4282E6CDC1231F5CE2410C438D977" xlink:to="lab_srt_CounterpartyNameAxis_81F4282E6CDC1231F5CE2410C438D977" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_3B6A2A47F21B983655EC2410C4390874_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_3B6A2A47F21B983655EC2410C4390874" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_3B6A2A47F21B983655EC2410C4390874_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_3B6A2A47F21B983655EC2410C4390874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3B6A2A47F21B983655EC2410C4390874" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3B6A2A47F21B983655EC2410C4390874" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_3B6A2A47F21B983655EC2410C4390874" xlink:type="arc" />
    <link:label id="lab_nktr_CollaborationPartnerMember_837C97215E35536B09D92410C4399D39_terseLabel_en-US" xlink:label="lab_nktr_CollaborationPartnerMember_837C97215E35536B09D92410C4399D39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Partner</link:label>
    <link:label id="lab_nktr_CollaborationPartnerMember_837C97215E35536B09D92410C4399D39_label_en-US" xlink:label="lab_nktr_CollaborationPartnerMember_837C97215E35536B09D92410C4399D39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Partner [Member]</link:label>
    <link:label id="lab_nktr_CollaborationPartnerMember_837C97215E35536B09D92410C4399D39_documentation_en-US" xlink:label="lab_nktr_CollaborationPartnerMember_837C97215E35536B09D92410C4399D39" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration partner.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CollaborationPartnerMember" xlink:label="loc_nktr_CollaborationPartnerMember_837C97215E35536B09D92410C4399D39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborationPartnerMember_837C97215E35536B09D92410C4399D39" xlink:to="lab_nktr_CollaborationPartnerMember_837C97215E35536B09D92410C4399D39" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C66946791A3091079822410C439101A_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C66946791A3091079822410C439101A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C66946791A3091079822410C439101A_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C66946791A3091079822410C439101A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C66946791A3091079822410C439101A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C66946791A3091079822410C439101A" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C66946791A3091079822410C439101A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_F1B18BFA736F339DB1952410C4391A5E_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_F1B18BFA736F339DB1952410C4391A5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_F1B18BFA736F339DB1952410C4391A5E_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_F1B18BFA736F339DB1952410C4391A5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_F1B18BFA736F339DB1952410C4391A5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_F1B18BFA736F339DB1952410C4391A5E" xlink:to="lab_us-gaap_TypeOfAdoptionMember_F1B18BFA736F339DB1952410C4391A5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_63B7C2CB96727936AE4B2410C4393AA8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_63B7C2CB96727936AE4B2410C4393AA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 842</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_63B7C2CB96727936AE4B2410C4393AA8_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_63B7C2CB96727936AE4B2410C4393AA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_63B7C2CB96727936AE4B2410C4393AA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_63B7C2CB96727936AE4B2410C4393AA8" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_63B7C2CB96727936AE4B2410C4393AA8" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_6437864FB68F67C76FB02410C43A4985_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_6437864FB68F67C76FB02410C43A4985" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_6437864FB68F67C76FB02410C43A4985_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_6437864FB68F67C76FB02410C43A4985" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_6437864FB68F67C76FB02410C43A4985" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_6437864FB68F67C76FB02410C43A4985" xlink:to="lab_srt_StatementGeographicalAxis_6437864FB68F67C76FB02410C43A4985" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_361C6B1197DB8DDE0CCD2410C43A8349_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_361C6B1197DB8DDE0CCD2410C43A8349" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_361C6B1197DB8DDE0CCD2410C43A8349_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_361C6B1197DB8DDE0CCD2410C43A8349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_361C6B1197DB8DDE0CCD2410C43A8349" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_361C6B1197DB8DDE0CCD2410C43A8349" xlink:to="lab_srt_SegmentGeographicalDomain_361C6B1197DB8DDE0CCD2410C43A8349" xlink:type="arc" />
    <link:label id="lab_country_IN_1ECBF4BA13380F5C37FC2410C43AFDED_terseLabel_en-US" xlink:label="lab_country_IN_1ECBF4BA13380F5C37FC2410C43AFDED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">India</link:label>
    <link:label id="lab_country_IN_1ECBF4BA13380F5C37FC2410C43AFDED_label_en-US" xlink:label="lab_country_IN_1ECBF4BA13380F5C37FC2410C43AFDED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">INDIA</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_IN" xlink:label="loc_country_IN_1ECBF4BA13380F5C37FC2410C43AFDED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IN_1ECBF4BA13380F5C37FC2410C43AFDED" xlink:to="lab_country_IN_1ECBF4BA13380F5C37FC2410C43AFDED" xlink:type="arc" />
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:type="arc" />
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_48FE25BBC82F48D53B082410C43B5516_terseLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_48FE25BBC82F48D53B082410C43B5516" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and investments in marketable securities</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_48FE25BBC82F48D53B082410C43B5516" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_48FE25BBC82F48D53B082410C43B5516" xlink:to="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_48FE25BBC82F48D53B082410C43B5516" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorNotes_0AA4A5CF705DBCB92C6A2410C43BD303_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotes_0AA4A5CF705DBCB92C6A2410C43BD303" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior secured notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotes_0AA4A5CF705DBCB92C6A2410C43BD303_label_en-US" xlink:label="lab_us-gaap_SeniorNotes_0AA4A5CF705DBCB92C6A2410C43BD303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_0AA4A5CF705DBCB92C6A2410C43BD303" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotes_0AA4A5CF705DBCB92C6A2410C43BD303" xlink:to="lab_us-gaap_SeniorNotes_0AA4A5CF705DBCB92C6A2410C43BD303" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_90A1ACB53471618FA1FF2410C43BBC85_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_90A1ACB53471618FA1FF2410C43BBC85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of business segment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_90A1ACB53471618FA1FF2410C43BBC85_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_90A1ACB53471618FA1FF2410C43BBC85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_90A1ACB53471618FA1FF2410C43BBC85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_90A1ACB53471618FA1FF2410C43BBC85" xlink:to="lab_us-gaap_NumberOfOperatingSegments_90A1ACB53471618FA1FF2410C43BBC85" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9A1FB2B9C87A2994FF912410C43B3B25_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_9A1FB2B9C87A2994FF912410C43B3B25" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable for expense reimbursements from collaboration partner</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9A1FB2B9C87A2994FF912410C43B3B25_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_9A1FB2B9C87A2994FF912410C43B3B25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9A1FB2B9C87A2994FF912410C43B3B25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_9A1FB2B9C87A2994FF912410C43B3B25" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_9A1FB2B9C87A2994FF912410C43B3B25" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6F2D8DB33F2EE7DE36CC2410C43B7D20_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_6F2D8DB33F2EE7DE36CC2410C43B7D20" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6F2D8DB33F2EE7DE36CC2410C43B7D20_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_6F2D8DB33F2EE7DE36CC2410C43B7D20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6F2D8DB33F2EE7DE36CC2410C43B7D20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_6F2D8DB33F2EE7DE36CC2410C43B7D20" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_6F2D8DB33F2EE7DE36CC2410C43B7D20" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_B463F2E97D9F7A3FDAC92410C43BE76E_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_B463F2E97D9F7A3FDAC92410C43BE76E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_B463F2E97D9F7A3FDAC92410C43BE76E_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_B463F2E97D9F7A3FDAC92410C43BE76E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_B463F2E97D9F7A3FDAC92410C43BE76E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_B463F2E97D9F7A3FDAC92410C43BE76E" xlink:to="lab_us-gaap_OperatingLeaseLiability_B463F2E97D9F7A3FDAC92410C43BE76E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_C72775C82149D11D70312410C43C503D_verboseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_C72775C82149D11D70312410C43C503D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cumulative effect adjustment to accumulated deficit</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_C72775C82149D11D70312410C43C503D_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_C72775C82149D11D70312410C43C503D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect on Retained Earnings, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_C72775C82149D11D70312410C43C503D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_C72775C82149D11D70312410C43C503D" xlink:to="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_C72775C82149D11D70312410C43C503D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5202C963CA09799790362410C43CD9DD_positiveLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5202C963CA09799790362410C43CD9DD" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5202C963CA09799790362410C43CD9DD_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5202C963CA09799790362410C43CD9DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5202C963CA09799790362410C43CD9DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5202C963CA09799790362410C43CD9DD" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5202C963CA09799790362410C43CD9DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_17263E115CD84E7011CE2410C43C1DF9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_17263E115CD84E7011CE2410C43C1DF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax provision on unrealized gain on available-for-sale securities, offset by benefit in continuing operations</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_17263E115CD84E7011CE2410C43C1DF9_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_17263E115CD84E7011CE2410C43C1DF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_17263E115CD84E7011CE2410C43C1DF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_17263E115CD84E7011CE2410C43C1DF9" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax_17263E115CD84E7011CE2410C43C1DF9" xlink:type="arc" />
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_0E1B3CC0AA9A941705E7424AFF173870_terseLabel_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock_0E1B3CC0AA9A941705E7424AFF173870" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_0E1B3CC0AA9A941705E7424AFF173870_label_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock_0E1B3CC0AA9A941705E7424AFF173870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization Policy [Text Block]</link:label>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_0E1B3CC0AA9A941705E7424AFF173870_documentation_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock_0E1B3CC0AA9A941705E7424AFF173870" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OrganizationPolicyTextBlock" xlink:label="loc_nktr_OrganizationPolicyTextBlock_0E1B3CC0AA9A941705E7424AFF173870" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationPolicyTextBlock_0E1B3CC0AA9A941705E7424AFF173870" xlink:to="lab_nktr_OrganizationPolicyTextBlock_0E1B3CC0AA9A941705E7424AFF173870" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_8896FB7F238209726314424AFF1714B9_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_8896FB7F238209726314424AFF1714B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_8896FB7F238209726314424AFF1714B9_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_8896FB7F238209726314424AFF1714B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_8896FB7F238209726314424AFF1714B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_8896FB7F238209726314424AFF1714B9" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_8896FB7F238209726314424AFF1714B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_17BF6685D0A225E5D9B5424AFF17BD78_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_17BF6685D0A225E5D9B5424AFF17BD78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_17BF6685D0A225E5D9B5424AFF17BD78_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_17BF6685D0A225E5D9B5424AFF17BD78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_17BF6685D0A225E5D9B5424AFF17BD78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_17BF6685D0A225E5D9B5424AFF17BD78" xlink:to="lab_us-gaap_UseOfEstimates_17BF6685D0A225E5D9B5424AFF17BD78" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_47A5801472FD77BB35C8424AFF170DC4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_47A5801472FD77BB35C8424AFF170DC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_47A5801472FD77BB35C8424AFF170DC4_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_47A5801472FD77BB35C8424AFF170DC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_47A5801472FD77BB35C8424AFF170DC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_47A5801472FD77BB35C8424AFF170DC4" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_47A5801472FD77BB35C8424AFF170DC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_0C1FABB35F890327C4D8424AFF18E809_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_0C1FABB35F890327C4D8424AFF18E809" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Concentrations</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_0C1FABB35F890327C4D8424AFF18E809_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_0C1FABB35F890327C4D8424AFF18E809" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_0C1FABB35F890327C4D8424AFF18E809" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_0C1FABB35F890327C4D8424AFF18E809" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_0C1FABB35F890327C4D8424AFF18E809" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_5B3B158855D659163253424AFF18195D_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_5B3B158855D659163253424AFF18195D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_5B3B158855D659163253424AFF18195D_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_5B3B158855D659163253424AFF18195D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_5B3B158855D659163253424AFF18195D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_5B3B158855D659163253424AFF18195D" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_5B3B158855D659163253424AFF18195D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_8C1905C0335D8ADE27DB424AFF181668_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy_8C1905C0335D8ADE27DB424AFF181668" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_8C1905C0335D8ADE27DB424AFF181668_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy_8C1905C0335D8ADE27DB424AFF181668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_8C1905C0335D8ADE27DB424AFF181668" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy_8C1905C0335D8ADE27DB424AFF181668" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy_8C1905C0335D8ADE27DB424AFF181668" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_AB10BE4A9889CD772759424AFF186065_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_AB10BE4A9889CD772759424AFF186065" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_AB10BE4A9889CD772759424AFF186065_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_AB10BE4A9889CD772759424AFF186065" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_AB10BE4A9889CD772759424AFF186065" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_AB10BE4A9889CD772759424AFF186065" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_AB10BE4A9889CD772759424AFF186065" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_5F1196D9922BF85C83D1424AFF185FA1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_5F1196D9922BF85C83D1424AFF185FA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_5F1196D9922BF85C83D1424AFF185FA1_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_5F1196D9922BF85C83D1424AFF185FA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5F1196D9922BF85C83D1424AFF185FA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5F1196D9922BF85C83D1424AFF185FA1" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_5F1196D9922BF85C83D1424AFF185FA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_CFD359A26A66439BA4E2424AFF19AD23_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_CFD359A26A66439BA4E2424AFF19AD23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_CFD359A26A66439BA4E2424AFF19AD23_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_CFD359A26A66439BA4E2424AFF19AD23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_CFD359A26A66439BA4E2424AFF19AD23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_CFD359A26A66439BA4E2424AFF19AD23" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_CFD359A26A66439BA4E2424AFF19AD23" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D0611389F956C0CEB8DC424AFF19CB1A_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D0611389F956C0CEB8DC424AFF19CB1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D0611389F956C0CEB8DC424AFF19CB1A_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D0611389F956C0CEB8DC424AFF19CB1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D0611389F956C0CEB8DC424AFF19CB1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D0611389F956C0CEB8DC424AFF19CB1A" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D0611389F956C0CEB8DC424AFF19CB1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_5154BB08BE7D937798DD424AFF19B75B_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_5154BB08BE7D937798DD424AFF19B75B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_5154BB08BE7D937798DD424AFF19B75B_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_5154BB08BE7D937798DD424AFF19B75B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_5154BB08BE7D937798DD424AFF19B75B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_5154BB08BE7D937798DD424AFF19B75B" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_5154BB08BE7D937798DD424AFF19B75B" xlink:type="arc" />
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_1DF0C8BEE9321D700D54424AFF193CA6_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_1DF0C8BEE9321D700D54424AFF193CA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Related to Sale of Future Royalties</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_1DF0C8BEE9321D700D54424AFF193CA6_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_1DF0C8BEE9321D700D54424AFF193CA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Future Royalties Policy [Text Block]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_1DF0C8BEE9321D700D54424AFF193CA6_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_1DF0C8BEE9321D700D54424AFF193CA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_1DF0C8BEE9321D700D54424AFF193CA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_1DF0C8BEE9321D700D54424AFF193CA6" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_1DF0C8BEE9321D700D54424AFF193CA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C31DB47F65E66CEAD06A1BB29EE9DF97_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C3EC29BFB77C589398C43DC6889CAD5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C3EC29BFB77C589398C43DC6889CAD5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C3EC29BFB77C589398C43DC6889CAD5A" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C3EC29BFB77C589398C43DC6889CAD5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_24E239715BCE8BC807AA1BB29EE9C2AA_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_8C49DF3890B35CFDB78BFF5EBD886F9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_24E239715BCE8BC807AA1BB29EE9C2AA_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_8C49DF3890B35CFDB78BFF5EBD886F9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_8C49DF3890B35CFDB78BFF5EBD886F9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_8C49DF3890B35CFDB78BFF5EBD886F9A" xlink:to="lab_us-gaap_LossContingenciesTable_8C49DF3890B35CFDB78BFF5EBD886F9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_E98E7BA439986B150E881BB29EEA50D7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_1B29F6A06B40582A9719525F85AA96C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_E98E7BA439986B150E881BB29EEA50D7_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_1B29F6A06B40582A9719525F85AA96C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1B29F6A06B40582A9719525F85AA96C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1B29F6A06B40582A9719525F85AA96C4" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_1B29F6A06B40582A9719525F85AA96C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_873F61AA1399B43F6E131BB29EEA2E52_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_5A462247FF245CF28184BB09362226CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_873F61AA1399B43F6E131BB29EEA2E52_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_5A462247FF245CF28184BB09362226CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_5A462247FF245CF28184BB09362226CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain_5A462247FF245CF28184BB09362226CE" xlink:to="lab_us-gaap_LossContingencyNatureDomain_5A462247FF245CF28184BB09362226CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_4A31BC8A9B714A48C3401BB29EEA3D99_terseLabel_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember_251F7F5535C852E7BD4F66085E2BB4A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indemnification Obligation</link:label>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_4A31BC8A9B714A48C3401BB29EEA3D99_label_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember_251F7F5535C852E7BD4F66085E2BB4A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indemnification Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_251F7F5535C852E7BD4F66085E2BB4A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndemnificationGuaranteeMember_251F7F5535C852E7BD4F66085E2BB4A2" xlink:to="lab_us-gaap_IndemnificationGuaranteeMember_251F7F5535C852E7BD4F66085E2BB4A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_32A22E8FDF38C3DB3C9C1BB29EEB47D5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_250606D9666A52CB95323EA0178E85D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_32A22E8FDF38C3DB3C9C1BB29EEB47D5_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_250606D9666A52CB95323EA0178E85D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_250606D9666A52CB95323EA0178E85D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_250606D9666A52CB95323EA0178E85D9" xlink:to="lab_us-gaap_LossContingenciesLineItems_250606D9666A52CB95323EA0178E85D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_2FF41FB5DDF7FC1E0AC91BB29EEB784C_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_653D712551105371AD6AF17345B306B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation matters, liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_2FF41FB5DDF7FC1E0AC91BB29EEB784C_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_653D712551105371AD6AF17345B306B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_653D712551105371AD6AF17345B306B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue_653D712551105371AD6AF17345B306B1" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue_653D712551105371AD6AF17345B306B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_3127CBAD3B0860355DC91BB29E41BC95_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_07704BBE98095E67B7953227A42C1444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_07704BBE98095E67B7953227A42C1444" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_07704BBE98095E67B7953227A42C1444" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_07704BBE98095E67B7953227A42C1444" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_CADA8BC7DA37A48B7F671BB29E423E0D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F0CE0E7D90E156139E92EEA1EB063FD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_CADA8BC7DA37A48B7F671BB29E423E0D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F0CE0E7D90E156139E92EEA1EB063FD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F0CE0E7D90E156139E92EEA1EB063FD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F0CE0E7D90E156139E92EEA1EB063FD8" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F0CE0E7D90E156139E92EEA1EB063FD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_DF5FB81E7071DB0059321BB29EB4D041_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_3C98126956EA5184B8639D0E54D6E745" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_DF5FB81E7071DB0059321BB29EB4D041_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_3C98126956EA5184B8639D0E54D6E745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_3C98126956EA5184B8639D0E54D6E745" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_3C98126956EA5184B8639D0E54D6E745" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_3C98126956EA5184B8639D0E54D6E745" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_F18DDAB43016CA92C7A01BB29EED47BF_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4D8AA414F2B2543C913841E1BEE7CDD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_F18DDAB43016CA92C7A01BB29EED47BF_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4D8AA414F2B2543C913841E1BEE7CDD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4D8AA414F2B2543C913841E1BEE7CDD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4D8AA414F2B2543C913841E1BEE7CDD5" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4D8AA414F2B2543C913841E1BEE7CDD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_90C64499DBCAFE2376E01BB29F31D4EF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790DB18DF9835F3193643A219CD6FEF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_90C64499DBCAFE2376E01BB29F31D4EF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790DB18DF9835F3193643A219CD6FEF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790DB18DF9835F3193643A219CD6FEF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790DB18DF9835F3193643A219CD6FEF9" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790DB18DF9835F3193643A219CD6FEF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_970BF9266D6B31F68F811BB29F3284E4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_D7E19384712C56149EA6A0FBBDE84850" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_970BF9266D6B31F68F811BB29F3284E4_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_D7E19384712C56149EA6A0FBBDE84850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_D7E19384712C56149EA6A0FBBDE84850" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D7E19384712C56149EA6A0FBBDE84850" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_D7E19384712C56149EA6A0FBBDE84850" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_25024C778B091221A4851BB29F32428E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_E98871E9B8255E11BBA48525C5213593" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_25024C778B091221A4851BB29F32428E_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_E98871E9B8255E11BBA48525C5213593" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E98871E9B8255E11BBA48525C5213593" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E98871E9B8255E11BBA48525C5213593" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_E98871E9B8255E11BBA48525C5213593" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfSalesMember_5FA2A00EA8254FEEE7741BB29F32CFE9_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_4EA448AE2F20555B8F4B4A099960F5D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_5FA2A00EA8254FEEE7741BB29F32CFE9_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_4EA448AE2F20555B8F4B4A099960F5D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_4EA448AE2F20555B8F4B4A099960F5D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember_4EA448AE2F20555B8F4B4A099960F5D2" xlink:to="lab_us-gaap_CostOfSalesMember_4EA448AE2F20555B8F4B4A099960F5D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_64A0C2917AD141EEAC5A1BB29F32768D_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_CEC5D9D7164D5A05AD3048F082E72921" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_64A0C2917AD141EEAC5A1BB29F32768D_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_CEC5D9D7164D5A05AD3048F082E72921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_CEC5D9D7164D5A05AD3048F082E72921" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_CEC5D9D7164D5A05AD3048F082E72921" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_CEC5D9D7164D5A05AD3048F082E72921" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8E8C362E592871279EEF1BB29F33AC9F_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_12D3063FD3985499A15318EEC7DA1695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8E8C362E592871279EEF1BB29F33AC9F_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_12D3063FD3985499A15318EEC7DA1695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_12D3063FD3985499A15318EEC7DA1695" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_12D3063FD3985499A15318EEC7DA1695" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_12D3063FD3985499A15318EEC7DA1695" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0F417A0F8BD5520A922D1BB29F33B5DD_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2C49BE85D82F5F46ACDF0842B09D3FDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0F417A0F8BD5520A922D1BB29F33B5DD_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2C49BE85D82F5F46ACDF0842B09D3FDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2C49BE85D82F5F46ACDF0842B09D3FDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2C49BE85D82F5F46ACDF0842B09D3FDB" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2C49BE85D82F5F46ACDF0842B09D3FDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_C0C6991037C0A4D990F01BB29F33B3F1_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_3176C3E9D800561CB16D3469327BB98D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_C0C6991037C0A4D990F01BB29F33B3F1_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_3176C3E9D800561CB16D3469327BB98D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3176C3E9D800561CB16D3469327BB98D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_3176C3E9D800561CB16D3469327BB98D" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_3176C3E9D800561CB16D3469327BB98D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_B4F3CFE1990BA66C06171BB29EAB184C_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_CD022A443CE05E598B4F343899979AD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_CD022A443CE05E598B4F343899979AD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CD022A443CE05E598B4F343899979AD0" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_CD022A443CE05E598B4F343899979AD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8B379EB7C0FA9C2F01F01BB29EAC3FC2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0465659F2A95582F816A3DA840B76574" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8B379EB7C0FA9C2F01F01BB29EAC3FC2_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0465659F2A95582F816A3DA840B76574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0465659F2A95582F816A3DA840B76574" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0465659F2A95582F816A3DA840B76574" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0465659F2A95582F816A3DA840B76574" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_BC517EFFABCAFD1FE4251BB29EAC690D_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_12D9085B617A560B9BFBB5D4F6CDDF31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_BC517EFFABCAFD1FE4251BB29EAC690D_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_12D9085B617A560B9BFBB5D4F6CDDF31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_12D9085B617A560B9BFBB5D4F6CDDF31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_12D9085B617A560B9BFBB5D4F6CDDF31" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_12D9085B617A560B9BFBB5D4F6CDDF31" xlink:type="arc" />
    <link:label id="lab_nktr_PreferredStockShareDesignated_3C31190D59AB1BEE60DA1BB29EAC2D47_terseLabel_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated_5A5B081B773657FEA8B31196AB832A32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares designated (in shares)</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_3C31190D59AB1BEE60DA1BB29EAC2D47_label_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated_5A5B081B773657FEA8B31196AB832A32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Share Designated</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_3C31190D59AB1BEE60DA1BB29EAC2D47_documentation_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated_5A5B081B773657FEA8B31196AB832A32" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred stock, shares designated.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PreferredStockShareDesignated" xlink:label="loc_nktr_PreferredStockShareDesignated_5A5B081B773657FEA8B31196AB832A32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PreferredStockShareDesignated_5A5B081B773657FEA8B31196AB832A32" xlink:to="lab_nktr_PreferredStockShareDesignated_5A5B081B773657FEA8B31196AB832A32" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_C5B75CE6A7ED5B9307D41BB29EACDFD8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_165E120B35545C9A8335E25CAB7BE2DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_C5B75CE6A7ED5B9307D41BB29EACDFD8_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_165E120B35545C9A8335E25CAB7BE2DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_165E120B35545C9A8335E25CAB7BE2DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_165E120B35545C9A8335E25CAB7BE2DF" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_165E120B35545C9A8335E25CAB7BE2DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_628B5F26BD6943861BA91BB29EAC5353_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_2986D0E13A455F53AEB78065E0585C9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_628B5F26BD6943861BA91BB29EAC5353_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_2986D0E13A455F53AEB78065E0585C9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2986D0E13A455F53AEB78065E0585C9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_2986D0E13A455F53AEB78065E0585C9F" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_2986D0E13A455F53AEB78065E0585C9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_35299D492F75E96685741BB29EAD347F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_DDF53E32F5B25906BEAA46DD39016021" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_35299D492F75E96685741BB29EAD347F_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_DDF53E32F5B25906BEAA46DD39016021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_DDF53E32F5B25906BEAA46DD39016021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_DDF53E32F5B25906BEAA46DD39016021" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_DDF53E32F5B25906BEAA46DD39016021" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2134931EB71A644C5D471BB29EADBE18_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_797E6DDFA9575150B795E945C422A31A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2134931EB71A644C5D471BB29EADBE18_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_797E6DDFA9575150B795E945C422A31A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_797E6DDFA9575150B795E945C422A31A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_797E6DDFA9575150B795E945C422A31A" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_797E6DDFA9575150B795E945C422A31A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_F73DBC92FA52670ECBCA1BB29EA08D29_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_7C1BD88AB8BC5B278AF132D11DD0E81E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_F73DBC92FA52670ECBCA1BB29EA08D29_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_7C1BD88AB8BC5B278AF132D11DD0E81E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_7C1BD88AB8BC5B278AF132D11DD0E81E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_7C1BD88AB8BC5B278AF132D11DD0E81E" xlink:to="lab_us-gaap_ContractWithCustomerLiability_7C1BD88AB8BC5B278AF132D11DD0E81E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_CED5ADA7E9F7019BCAD31BB29EA097B4_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_649FC627CB92503C96C4A9EF121E5213" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Recognition of previously unearned revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_CED5ADA7E9F7019BCAD31BB29EA097B4_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_649FC627CB92503C96C4A9EF121E5213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_649FC627CB92503C96C4A9EF121E5213" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_649FC627CB92503C96C4A9EF121E5213" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_649FC627CB92503C96C4A9EF121E5213" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_8CEB6EA392DBEBA663EF1BB29EA0BAD1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_5EDBD04394FD5570AB171FDA6E5FDAD6" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5EDBD04394FD5570AB171FDA6E5FDAD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_5EDBD04394FD5570AB171FDA6E5FDAD6" xlink:to="lab_us-gaap_ContractWithCustomerLiability_5EDBD04394FD5570AB171FDA6E5FDAD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_D2D6E31B9743FD12B123424AFF30DB4B_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_D2D6E31B9743FD12B123424AFF30DB4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_D2D6E31B9743FD12B123424AFF30DB4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2D6E31B9743FD12B123424AFF30DB4B" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_D2D6E31B9743FD12B123424AFF30DB4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BB4D0132CF227BDD8E1B424AFF304D28_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BB4D0132CF227BDD8E1B424AFF304D28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BB4D0132CF227BDD8E1B424AFF304D28_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BB4D0132CF227BDD8E1B424AFF304D28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BB4D0132CF227BDD8E1B424AFF304D28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BB4D0132CF227BDD8E1B424AFF304D28" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BB4D0132CF227BDD8E1B424AFF304D28" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_800BF132AFE7DF476D56424AFF31BAF4_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_800BF132AFE7DF476D56424AFF31BAF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_800BF132AFE7DF476D56424AFF31BAF4_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_800BF132AFE7DF476D56424AFF31BAF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_800BF132AFE7DF476D56424AFF31BAF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_800BF132AFE7DF476D56424AFF31BAF4" xlink:to="lab_us-gaap_ProfitLoss_800BF132AFE7DF476D56424AFF31BAF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F8433F6EEE65AEF0F265424AFF31AD24_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F8433F6EEE65AEF0F265424AFF31AD24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F8433F6EEE65AEF0F265424AFF31AD24_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F8433F6EEE65AEF0F265424AFF31AD24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F8433F6EEE65AEF0F265424AFF31AD24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F8433F6EEE65AEF0F265424AFF31AD24" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F8433F6EEE65AEF0F265424AFF31AD24" xlink:type="arc" />
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_BFD8D8DDAC383C279E53424AFF31ED16_negatedLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_BFD8D8DDAC383C279E53424AFF31ED16" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_BFD8D8DDAC383C279E53424AFF31ED16_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_BFD8D8DDAC383C279E53424AFF31ED16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_BFD8D8DDAC383C279E53424AFF31ED16_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_BFD8D8DDAC383C279E53424AFF31ED16" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non cash royalty revenue related to sale future royalties.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_BFD8D8DDAC383C279E53424AFF31ED16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_BFD8D8DDAC383C279E53424AFF31ED16" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_BFD8D8DDAC383C279E53424AFF31ED16" xlink:type="arc" />
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_146BEFFAFA835E52BADD424AFF326CC3_terseLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_146BEFFAFA835E52BADD424AFF326CC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense on liability related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_146BEFFAFA835E52BADD424AFF326CC3_label_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_146BEFFAFA835E52BADD424AFF326CC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Interest Expense Related To Sale Of Royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_146BEFFAFA835E52BADD424AFF326CC3_documentation_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_146BEFFAFA835E52BADD424AFF326CC3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-cash interest expense related to sale of royalties.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_146BEFFAFA835E52BADD424AFF326CC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_146BEFFAFA835E52BADD424AFF326CC3" xlink:to="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_146BEFFAFA835E52BADD424AFF326CC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3F31BA4985A2984568D1424AFF3200BA_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_3F31BA4985A2984568D1424AFF3200BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3F31BA4985A2984568D1424AFF3200BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_3F31BA4985A2984568D1424AFF3200BA" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_3F31BA4985A2984568D1424AFF3200BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationAndAmortization_4217144F3DA0EE6062C4424AFF32FC95_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_4217144F3DA0EE6062C4424AFF32FC95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_4217144F3DA0EE6062C4424AFF32FC95_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_4217144F3DA0EE6062C4424AFF32FC95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_4217144F3DA0EE6062C4424AFF32FC95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization_4217144F3DA0EE6062C4424AFF32FC95" xlink:to="lab_us-gaap_DepreciationAndAmortization_4217144F3DA0EE6062C4424AFF32FC95" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_741852958252833A2E64424AFF32CD4D_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_741852958252833A2E64424AFF32CD4D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion of discounts, net and other non-cash transactions</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_741852958252833A2E64424AFF32CD4D_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_741852958252833A2E64424AFF32CD4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_741852958252833A2E64424AFF32CD4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_741852958252833A2E64424AFF32CD4D" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_741852958252833A2E64424AFF32CD4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AC6A6D5D0BDF15D348C3424AFF32F64E_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AC6A6D5D0BDF15D348C3424AFF32F64E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AC6A6D5D0BDF15D348C3424AFF32F64E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AC6A6D5D0BDF15D348C3424AFF32F64E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AC6A6D5D0BDF15D348C3424AFF32F64E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AC6A6D5D0BDF15D348C3424AFF32F64E" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AC6A6D5D0BDF15D348C3424AFF32F64E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B372960786EDA698A46D424AFF33A0D5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B372960786EDA698A46D424AFF33A0D5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B372960786EDA698A46D424AFF33A0D5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B372960786EDA698A46D424AFF33A0D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B372960786EDA698A46D424AFF33A0D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B372960786EDA698A46D424AFF33A0D5" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_B372960786EDA698A46D424AFF33A0D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_1B9080276CCC8B7CE112424AFF337544_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_1B9080276CCC8B7CE112424AFF337544" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_1B9080276CCC8B7CE112424AFF337544_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_1B9080276CCC8B7CE112424AFF337544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1B9080276CCC8B7CE112424AFF337544" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_1B9080276CCC8B7CE112424AFF337544" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_1B9080276CCC8B7CE112424AFF337544" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2E631BFE5367F9AA6101424AFF343246_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2E631BFE5367F9AA6101424AFF343246" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2E631BFE5367F9AA6101424AFF343246_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2E631BFE5367F9AA6101424AFF343246" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2E631BFE5367F9AA6101424AFF343246" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2E631BFE5367F9AA6101424AFF343246" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2E631BFE5367F9AA6101424AFF343246" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_AE4DF12507C1BF4527E9424AFF34C39A_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_AE4DF12507C1BF4527E9424AFF34C39A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_AE4DF12507C1BF4527E9424AFF34C39A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_AE4DF12507C1BF4527E9424AFF34C39A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_AE4DF12507C1BF4527E9424AFF34C39A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_AE4DF12507C1BF4527E9424AFF34C39A" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_AE4DF12507C1BF4527E9424AFF34C39A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8AED867BEABDFE57F77C424AFF34B3FB_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8AED867BEABDFE57F77C424AFF34B3FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8AED867BEABDFE57F77C424AFF34B3FB_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8AED867BEABDFE57F77C424AFF34B3FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8AED867BEABDFE57F77C424AFF34B3FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8AED867BEABDFE57F77C424AFF34B3FB" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8AED867BEABDFE57F77C424AFF34B3FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_E7DE61295B4772504931424AFF35B9B8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_E7DE61295B4772504931424AFF35B9B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_E7DE61295B4772504931424AFF35B9B8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_E7DE61295B4772504931424AFF35B9B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_E7DE61295B4772504931424AFF35B9B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_E7DE61295B4772504931424AFF35B9B8" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_E7DE61295B4772504931424AFF35B9B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_C9A2EB95718AFA52FDE4424AFF35DD98_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_C9A2EB95718AFA52FDE4424AFF35DD98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_C9A2EB95718AFA52FDE4424AFF35DD98_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_C9A2EB95718AFA52FDE4424AFF35DD98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_C9A2EB95718AFA52FDE4424AFF35DD98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_C9A2EB95718AFA52FDE4424AFF35DD98" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_C9A2EB95718AFA52FDE4424AFF35DD98" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0B64F80909C748982542424AFF35FB4E_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0B64F80909C748982542424AFF35FB4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0B64F80909C748982542424AFF35FB4E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0B64F80909C748982542424AFF35FB4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0B64F80909C748982542424AFF35FB4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0B64F80909C748982542424AFF35FB4E" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0B64F80909C748982542424AFF35FB4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_D97E520D146FDF8B5032424AFF358106_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_D97E520D146FDF8B5032424AFF358106" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_D97E520D146FDF8B5032424AFF358106_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_D97E520D146FDF8B5032424AFF358106" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_D97E520D146FDF8B5032424AFF358106" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_D97E520D146FDF8B5032424AFF358106" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_D97E520D146FDF8B5032424AFF358106" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_095380656426F371E04A424AFF357EB0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_095380656426F371E04A424AFF357EB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_095380656426F371E04A424AFF357EB0_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_095380656426F371E04A424AFF357EB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_095380656426F371E04A424AFF357EB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_095380656426F371E04A424AFF357EB0" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_095380656426F371E04A424AFF357EB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_09A3FB027AD85982A543424AFF3668F6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_09A3FB027AD85982A543424AFF3668F6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_09A3FB027AD85982A543424AFF3668F6_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_09A3FB027AD85982A543424AFF3668F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_09A3FB027AD85982A543424AFF3668F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_09A3FB027AD85982A543424AFF3668F6" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_09A3FB027AD85982A543424AFF3668F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F27DCD0859288DB2DEE9424AFF36EEA2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F27DCD0859288DB2DEE9424AFF36EEA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F27DCD0859288DB2DEE9424AFF36EEA2_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F27DCD0859288DB2DEE9424AFF36EEA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F27DCD0859288DB2DEE9424AFF36EEA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F27DCD0859288DB2DEE9424AFF36EEA2" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F27DCD0859288DB2DEE9424AFF36EEA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4953C98F2784547CA7A3424AFF376E4F_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4953C98F2784547CA7A3424AFF376E4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4953C98F2784547CA7A3424AFF376E4F_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4953C98F2784547CA7A3424AFF376E4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4953C98F2784547CA7A3424AFF376E4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4953C98F2784547CA7A3424AFF376E4F" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4953C98F2784547CA7A3424AFF376E4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FB9E3D3ADBEC70C48DB6424AFF37220B_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FB9E3D3ADBEC70C48DB6424AFF37220B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FB9E3D3ADBEC70C48DB6424AFF37220B_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FB9E3D3ADBEC70C48DB6424AFF37220B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FB9E3D3ADBEC70C48DB6424AFF37220B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FB9E3D3ADBEC70C48DB6424AFF37220B" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FB9E3D3ADBEC70C48DB6424AFF37220B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_13979D2D62E2A8F87390424AFF3751BA_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_13979D2D62E2A8F87390424AFF3751BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_13979D2D62E2A8F87390424AFF3751BA_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_13979D2D62E2A8F87390424AFF3751BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_13979D2D62E2A8F87390424AFF3751BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_13979D2D62E2A8F87390424AFF3751BA" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_13979D2D62E2A8F87390424AFF3751BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8267BA1F606A59A276C7424AFF374103_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8267BA1F606A59A276C7424AFF374103" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8267BA1F606A59A276C7424AFF374103_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8267BA1F606A59A276C7424AFF374103" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8267BA1F606A59A276C7424AFF374103" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8267BA1F606A59A276C7424AFF374103" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8267BA1F606A59A276C7424AFF374103" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F10F5A94C395CCCF024B424AFF377893_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F10F5A94C395CCCF024B424AFF377893" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F10F5A94C395CCCF024B424AFF377893_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F10F5A94C395CCCF024B424AFF377893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F10F5A94C395CCCF024B424AFF377893" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F10F5A94C395CCCF024B424AFF377893" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F10F5A94C395CCCF024B424AFF377893" xlink:type="arc" />
    <link:label id="lab_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_075F06A583B43632AFCD424AFF38DBAE_terseLabel_en-US" xlink:label="lab_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_075F06A583B43632AFCD424AFF38DBAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_075F06A583B43632AFCD424AFF38DBAE_label_en-US" xlink:label="lab_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_075F06A583B43632AFCD424AFF38DBAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Common Stock Net Of Issuance Costs</link:label>
    <link:label id="lab_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_075F06A583B43632AFCD424AFF38DBAE_documentation_en-US" xlink:label="lab_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_075F06A583B43632AFCD424AFF38DBAE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Common Stock Net Of Issuance Costs</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="loc_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_075F06A583B43632AFCD424AFF38DBAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_075F06A583B43632AFCD424AFF38DBAE" xlink:to="lab_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_075F06A583B43632AFCD424AFF38DBAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_5CA2A285063CC8BC1F28424AFF385283_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_5CA2A285063CC8BC1F28424AFF385283" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_5CA2A285063CC8BC1F28424AFF385283_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_5CA2A285063CC8BC1F28424AFF385283" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_5CA2A285063CC8BC1F28424AFF385283" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_5CA2A285063CC8BC1F28424AFF385283" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_5CA2A285063CC8BC1F28424AFF385283" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DB0FCAE2C931263B31FA424AFF38FFFA_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DB0FCAE2C931263B31FA424AFF38FFFA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DB0FCAE2C931263B31FA424AFF38FFFA_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DB0FCAE2C931263B31FA424AFF38FFFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DB0FCAE2C931263B31FA424AFF38FFFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DB0FCAE2C931263B31FA424AFF38FFFA" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_DB0FCAE2C931263B31FA424AFF38FFFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96BF74F3975FE6A27323424AFF394DD5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96BF74F3975FE6A27323424AFF394DD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96BF74F3975FE6A27323424AFF394DD5_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96BF74F3975FE6A27323424AFF394DD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96BF74F3975FE6A27323424AFF394DD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96BF74F3975FE6A27323424AFF394DD5" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96BF74F3975FE6A27323424AFF394DD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64546924E9FBD49C9CF4424AFF399F8B_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64546924E9FBD49C9CF4424AFF399F8B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64546924E9FBD49C9CF4424AFF399F8B_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64546924E9FBD49C9CF4424AFF399F8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64546924E9FBD49C9CF4424AFF399F8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64546924E9FBD49C9CF4424AFF399F8B" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64546924E9FBD49C9CF4424AFF399F8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17F7D94021A13BD2C141424AFF3956E5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17F7D94021A13BD2C141424AFF3956E5" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17F7D94021A13BD2C141424AFF3956E5_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17F7D94021A13BD2C141424AFF3956E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17F7D94021A13BD2C141424AFF3956E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17F7D94021A13BD2C141424AFF3956E5" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17F7D94021A13BD2C141424AFF3956E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DAC8DEE94A09137365DD424AFF392697_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DAC8DEE94A09137365DD424AFF392697" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DAC8DEE94A09137365DD424AFF392697" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DAC8DEE94A09137365DD424AFF392697" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DAC8DEE94A09137365DD424AFF392697" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_87FBE524F16A59045C77424AFF3AB05A_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_87FBE524F16A59045C77424AFF3AB05A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_87FBE524F16A59045C77424AFF3AB05A_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_87FBE524F16A59045C77424AFF3AB05A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_87FBE524F16A59045C77424AFF3AB05A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_87FBE524F16A59045C77424AFF3AB05A" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_87FBE524F16A59045C77424AFF3AB05A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_4C268AA9F98C1845DFF2424AFF3AB83C_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_4C268AA9F98C1845DFF2424AFF3AB83C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_4C268AA9F98C1845DFF2424AFF3AB83C_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_4C268AA9F98C1845DFF2424AFF3AB83C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_4C268AA9F98C1845DFF2424AFF3AB83C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_4C268AA9F98C1845DFF2424AFF3AB83C" xlink:to="lab_us-gaap_InterestPaidNet_4C268AA9F98C1845DFF2424AFF3AB83C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_CEA5BB9C985D29EA6707425049C69701_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_CEA5BB9C985D29EA6707425049C69701" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets recognized in exchange for lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_CEA5BB9C985D29EA6707425049C69701_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_CEA5BB9C985D29EA6707425049C69701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_CEA5BB9C985D29EA6707425049C69701" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_CEA5BB9C985D29EA6707425049C69701" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_CEA5BB9C985D29EA6707425049C69701" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_3C6BFEBB246BF332DD001BB29EAED0E3_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_FA02EA85C45A567690EB4191A2E220A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_FA02EA85C45A567690EB4191A2E220A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_FA02EA85C45A567690EB4191A2E220A4" xlink:to="lab_us-gaap_LeasesAbstract_FA02EA85C45A567690EB4191A2E220A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_5A1E86B072F335ADB93D1BB29EAF5E1A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_71466E51F22154F29C7467AC0F481386" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_5A1E86B072F335ADB93D1BB29EAF5E1A_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_71466E51F22154F29C7467AC0F481386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_71466E51F22154F29C7467AC0F481386" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_71466E51F22154F29C7467AC0F481386" xlink:to="lab_us-gaap_OperatingLeaseCost_71466E51F22154F29C7467AC0F481386" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableLeaseCost_148888381B38ED56D5941BB29EAF28AB_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_4F6246E1794757CDA75B8024C35750A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_148888381B38ED56D5941BB29EAF28AB_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_4F6246E1794757CDA75B8024C35750A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_4F6246E1794757CDA75B8024C35750A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost_4F6246E1794757CDA75B8024C35750A4" xlink:to="lab_us-gaap_VariableLeaseCost_4F6246E1794757CDA75B8024C35750A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCost_779773AA56011A2752E11BB29EAFB9EF_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost_A00832FD6BA254D2BB777BA9A29EAFAA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_779773AA56011A2752E11BB29EAFB9EF_label_en-US" xlink:label="lab_us-gaap_LeaseCost_A00832FD6BA254D2BB777BA9A29EAFAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_A00832FD6BA254D2BB777BA9A29EAFAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_A00832FD6BA254D2BB777BA9A29EAFAA" xlink:to="lab_us-gaap_LeaseCost_A00832FD6BA254D2BB777BA9A29EAFAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_38877A23FC98F83DD4CA1BB29EA2080C_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_70FAE1C57B22501BAF776AEB000A779F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_70FAE1C57B22501BAF776AEB000A779F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_70FAE1C57B22501BAF776AEB000A779F" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_70FAE1C57B22501BAF776AEB000A779F" xlink:type="arc" />
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_B57450889F82EA27D7C61BB29EA294E0_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_F2799B7050A2514484331CD273DA7525" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Related to Sale of Future Royalties</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_B57450889F82EA27D7C61BB29EA294E0_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_F2799B7050A2514484331CD273DA7525" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties [Text Block]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_B57450889F82EA27D7C61BB29EA294E0_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_F2799B7050A2514484331CD273DA7525" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability related to sale of potential future royalties.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_F2799B7050A2514484331CD273DA7525" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_F2799B7050A2514484331CD273DA7525" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_F2799B7050A2514484331CD273DA7525" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_BE9B9B33DA88FEFE032982BEEF042136_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_BE9B9B33DA88FEFE032982BEEF042136" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 (three months ended)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_BE9B9B33DA88FEFE032982BEEF042136_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_BE9B9B33DA88FEFE032982BEEF042136" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_BE9B9B33DA88FEFE032982BEEF042136" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_BE9B9B33DA88FEFE032982BEEF042136" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_BE9B9B33DA88FEFE032982BEEF042136" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4D33A98BF982658B72A382BEEF043F12_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4D33A98BF982658B72A382BEEF043F12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4D33A98BF982658B72A382BEEF043F12_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4D33A98BF982658B72A382BEEF043F12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4D33A98BF982658B72A382BEEF043F12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4D33A98BF982658B72A382BEEF043F12" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4D33A98BF982658B72A382BEEF043F12" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_87EEA5603B26C232290182BEEF048898_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_87EEA5603B26C232290182BEEF048898" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_87EEA5603B26C232290182BEEF048898_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_87EEA5603B26C232290182BEEF048898" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_87EEA5603B26C232290182BEEF048898" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_87EEA5603B26C232290182BEEF048898" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_87EEA5603B26C232290182BEEF048898" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_B43FB414364DF8D3F22982BEEF049E06_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_B43FB414364DF8D3F22982BEEF049E06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_B43FB414364DF8D3F22982BEEF049E06_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_B43FB414364DF8D3F22982BEEF049E06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_B43FB414364DF8D3F22982BEEF049E06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_B43FB414364DF8D3F22982BEEF049E06" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_B43FB414364DF8D3F22982BEEF049E06" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_E719A79A68B3FCF9A5D582BEEF0541DF_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_E719A79A68B3FCF9A5D582BEEF0541DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_E719A79A68B3FCF9A5D582BEEF0541DF_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_E719A79A68B3FCF9A5D582BEEF0541DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_E719A79A68B3FCF9A5D582BEEF0541DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_E719A79A68B3FCF9A5D582BEEF0541DF" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_E719A79A68B3FCF9A5D582BEEF0541DF" xlink:type="arc" />
    <link:label id="lab_nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_A5C1D6E5D426CB07673B82BEEF0539BF_terseLabel_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_A5C1D6E5D426CB07673B82BEEF0539BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_A5C1D6E5D426CB07673B82BEEF0539BF_label_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_A5C1D6E5D426CB07673B82BEEF0539BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Year Six</link:label>
    <link:label id="lab_nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_A5C1D6E5D426CB07673B82BEEF0539BF_documentation_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_A5C1D6E5D426CB07673B82BEEF0539BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee operating lease liability payments due year six.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:label="loc_nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_A5C1D6E5D426CB07673B82BEEF0539BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_A5C1D6E5D426CB07673B82BEEF0539BF" xlink:to="lab_nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_A5C1D6E5D426CB07673B82BEEF0539BF" xlink:type="arc" />
    <link:label id="lab_nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_28720D28A97AF073746C82BEEF05750D_terseLabel_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_28720D28A97AF073746C82BEEF05750D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 and thereafter</link:label>
    <link:label id="lab_nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_28720D28A97AF073746C82BEEF05750D_label_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_28720D28A97AF073746C82BEEF05750D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Year Six</link:label>
    <link:label id="lab_nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_28720D28A97AF073746C82BEEF05750D_documentation_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_28720D28A97AF073746C82BEEF05750D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee operating lease liability payments due after year six.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:label="loc_nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_28720D28A97AF073746C82BEEF05750D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_28720D28A97AF073746C82BEEF05750D" xlink:to="lab_nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_28720D28A97AF073746C82BEEF05750D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30401444F22C651CEE2282BEEF053A38_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30401444F22C651CEE2282BEEF053A38" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30401444F22C651CEE2282BEEF053A38_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30401444F22C651CEE2282BEEF053A38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30401444F22C651CEE2282BEEF053A38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30401444F22C651CEE2282BEEF053A38" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30401444F22C651CEE2282BEEF053A38" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_89768840027FFE6E1BAD82BEEF05F00E_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_89768840027FFE6E1BAD82BEEF05F00E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: portion representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_89768840027FFE6E1BAD82BEEF05F00E_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_89768840027FFE6E1BAD82BEEF05F00E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_89768840027FFE6E1BAD82BEEF05F00E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_89768840027FFE6E1BAD82BEEF05F00E" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_89768840027FFE6E1BAD82BEEF05F00E" xlink:type="arc" />
    <link:label id="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_DF90EF142FFC3379832382BEEF05AB43_negatedLabel_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_DF90EF142FFC3379832382BEEF05AB43" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: lease incentives</link:label>
    <link:label id="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_DF90EF142FFC3379832382BEEF05AB43_label_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_DF90EF142FFC3379832382BEEF05AB43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease Liability Tenant Improvement Reimbursements</link:label>
    <link:label id="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_DF90EF142FFC3379832382BEEF05AB43_documentation_en-US" xlink:label="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_DF90EF142FFC3379832382BEEF05AB43" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee operating lease liability tenant improvement reimbursements.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_DF90EF142FFC3379832382BEEF05AB43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_DF90EF142FFC3379832382BEEF05AB43" xlink:to="lab_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_DF90EF142FFC3379832382BEEF05AB43" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0DB810E58EBE584A000B82BEEF060022_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_0DB810E58EBE584A000B82BEEF060022" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_0DB810E58EBE584A000B82BEEF060022" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_0DB810E58EBE584A000B82BEEF060022" xlink:to="lab_us-gaap_OperatingLeaseLiability_0DB810E58EBE584A000B82BEEF060022" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_57635599FCB6D95C688882BEEF06B2F8_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_57635599FCB6D95C688882BEEF06B2F8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_57635599FCB6D95C688882BEEF06B2F8_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_57635599FCB6D95C688882BEEF06B2F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_57635599FCB6D95C688882BEEF06B2F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_57635599FCB6D95C688882BEEF06B2F8" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_57635599FCB6D95C688882BEEF06B2F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_DECCE17FEB695B51156082BEEF069C29_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_DECCE17FEB695B51156082BEEF069C29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_DECCE17FEB695B51156082BEEF069C29_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_DECCE17FEB695B51156082BEEF069C29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_DECCE17FEB695B51156082BEEF069C29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_DECCE17FEB695B51156082BEEF069C29" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_DECCE17FEB695B51156082BEEF069C29" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_61699188B8C8424C7D7D2406F8525D18_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_61699188B8C8424C7D7D2406F8525D18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_61699188B8C8424C7D7D2406F8525D18_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_61699188B8C8424C7D7D2406F8525D18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_61699188B8C8424C7D7D2406F8525D18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_61699188B8C8424C7D7D2406F8525D18" xlink:to="lab_us-gaap_AssetsAbstract_61699188B8C8424C7D7D2406F8525D18" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_7FB91D3DF97B156D87962406F852678E_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_7FB91D3DF97B156D87962406F852678E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_7FB91D3DF97B156D87962406F852678E_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_7FB91D3DF97B156D87962406F852678E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7FB91D3DF97B156D87962406F852678E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7FB91D3DF97B156D87962406F852678E" xlink:to="lab_us-gaap_AssetsCurrentAbstract_7FB91D3DF97B156D87962406F852678E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_C8FA445AA38FD79C08812406F853278B_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_C8FA445AA38FD79C08812406F853278B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_C8FA445AA38FD79C08812406F853278B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_C8FA445AA38FD79C08812406F853278B" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_C8FA445AA38FD79C08812406F853278B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_B2D9FD753FDB5E8508BD2406F85332D5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_B2D9FD753FDB5E8508BD2406F85332D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_B2D9FD753FDB5E8508BD2406F85332D5_label_en-US" xlink:label="lab_us-gaap_InventoryNet_B2D9FD753FDB5E8508BD2406F85332D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_B2D9FD753FDB5E8508BD2406F85332D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_B2D9FD753FDB5E8508BD2406F85332D5" xlink:to="lab_us-gaap_InventoryNet_B2D9FD753FDB5E8508BD2406F85332D5" xlink:type="arc" />
    <link:label id="lab_nktr_AdvancePaymentsToContractManufacturers_B5695156F4F61CF7F0482406F85444CE_terseLabel_en-US" xlink:label="lab_nktr_AdvancePaymentsToContractManufacturers_B5695156F4F61CF7F0482406F85444CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advance payments to contract manufacturers</link:label>
    <link:label id="lab_nktr_AdvancePaymentsToContractManufacturers_B5695156F4F61CF7F0482406F85444CE_label_en-US" xlink:label="lab_nktr_AdvancePaymentsToContractManufacturers_B5695156F4F61CF7F0482406F85444CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advance Payments To Contract Manufacturers</link:label>
    <link:label id="lab_nktr_AdvancePaymentsToContractManufacturers_B5695156F4F61CF7F0482406F85444CE_documentation_en-US" xlink:label="lab_nktr_AdvancePaymentsToContractManufacturers_B5695156F4F61CF7F0482406F85444CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of advance payments to contract manufacturers, net of amortization.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AdvancePaymentsToContractManufacturers" xlink:label="loc_nktr_AdvancePaymentsToContractManufacturers_B5695156F4F61CF7F0482406F85444CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AdvancePaymentsToContractManufacturers_B5695156F4F61CF7F0482406F85444CE" xlink:to="lab_nktr_AdvancePaymentsToContractManufacturers_B5695156F4F61CF7F0482406F85444CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_49EA0957F2F4AA71051C2406F854FB21_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_49EA0957F2F4AA71051C2406F854FB21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_49EA0957F2F4AA71051C2406F854FB21_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_49EA0957F2F4AA71051C2406F854FB21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_49EA0957F2F4AA71051C2406F854FB21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_49EA0957F2F4AA71051C2406F854FB21" xlink:to="lab_us-gaap_OtherAssetsCurrent_49EA0957F2F4AA71051C2406F854FB21" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_A930912AD8F9EED108992406F85488E1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_A930912AD8F9EED108992406F85488E1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_A930912AD8F9EED108992406F85488E1_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_A930912AD8F9EED108992406F85488E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_A930912AD8F9EED108992406F85488E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_A930912AD8F9EED108992406F85488E1" xlink:to="lab_us-gaap_AssetsCurrent_A930912AD8F9EED108992406F85488E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_BD41D0E3C264C7B1D4402406F854E029_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_BD41D0E3C264C7B1D4402406F854E029" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_BD41D0E3C264C7B1D4402406F854E029_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_BD41D0E3C264C7B1D4402406F854E029" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_BD41D0E3C264C7B1D4402406F854E029" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_BD41D0E3C264C7B1D4402406F854E029" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_BD41D0E3C264C7B1D4402406F854E029" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_D35CDBBCDBAAC592375A2406F8541804_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_D35CDBBCDBAAC592375A2406F8541804" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_D35CDBBCDBAAC592375A2406F8541804" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_D35CDBBCDBAAC592375A2406F8541804" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_D35CDBBCDBAAC592375A2406F8541804" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_B5F6C5B9D839572755C62406F8554512_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_B5F6C5B9D839572755C62406F8554512" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_B5F6C5B9D839572755C62406F8554512_label_en-US" xlink:label="lab_us-gaap_Goodwill_B5F6C5B9D839572755C62406F8554512" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_B5F6C5B9D839572755C62406F8554512" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_B5F6C5B9D839572755C62406F8554512" xlink:to="lab_us-gaap_Goodwill_B5F6C5B9D839572755C62406F8554512" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6242A9E7128A66D2956D2406F85585BB_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_6242A9E7128A66D2956D2406F85585BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6242A9E7128A66D2956D2406F85585BB_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_6242A9E7128A66D2956D2406F85585BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6242A9E7128A66D2956D2406F85585BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_6242A9E7128A66D2956D2406F85585BB" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_6242A9E7128A66D2956D2406F85585BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_F986F677FA2460531BC52406F8556EBD_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_F986F677FA2460531BC52406F8556EBD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_F986F677FA2460531BC52406F8556EBD_label_en-US" xlink:label="lab_us-gaap_Assets_F986F677FA2460531BC52406F8556EBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_F986F677FA2460531BC52406F8556EBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_F986F677FA2460531BC52406F8556EBD" xlink:to="lab_us-gaap_Assets_F986F677FA2460531BC52406F8556EBD" xlink:type="arc" />
    <link:label id="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9_terseLabel_en-US" xlink:label="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9_label_en-US" xlink:label="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities And Stockholders Equity Deficit [Abstract]</link:label>
    <link:label id="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9_documentation_en-US" xlink:label="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities and stock holders equity (deficit) abstract..</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LiabilitiesAndStockholdersEquityDeficitAbstract" xlink:label="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9" xlink:to="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4AB43B867A1E2F5B0A852406F855E30F_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_4AB43B867A1E2F5B0A852406F855E30F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4AB43B867A1E2F5B0A852406F855E30F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_4AB43B867A1E2F5B0A852406F855E30F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4AB43B867A1E2F5B0A852406F855E30F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4AB43B867A1E2F5B0A852406F855E30F" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_4AB43B867A1E2F5B0A852406F855E30F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_C5602C0921DCBA70EBE72406F8567624_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_C5602C0921DCBA70EBE72406F8567624" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_C5602C0921DCBA70EBE72406F8567624_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_C5602C0921DCBA70EBE72406F8567624" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_C5602C0921DCBA70EBE72406F8567624" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_C5602C0921DCBA70EBE72406F8567624" xlink:to="lab_us-gaap_AccountsPayableCurrent_C5602C0921DCBA70EBE72406F8567624" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_A831CBD2A6A03AF37D6E2406F8566DC8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_A831CBD2A6A03AF37D6E2406F8566DC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_A831CBD2A6A03AF37D6E2406F8566DC8_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_A831CBD2A6A03AF37D6E2406F8566DC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_A831CBD2A6A03AF37D6E2406F8566DC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_A831CBD2A6A03AF37D6E2406F8566DC8" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_A831CBD2A6A03AF37D6E2406F8566DC8" xlink:type="arc" />
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_2269EFDDCD413A9DFA772406F856BDA6_terseLabel_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent_2269EFDDCD413A9DFA772406F856BDA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_2269EFDDCD413A9DFA772406F856BDA6_label_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent_2269EFDDCD413A9DFA772406F856BDA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expenses Current</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_2269EFDDCD413A9DFA772406F856BDA6_documentation_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent_2269EFDDCD413A9DFA772406F856BDA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses current.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AccruedClinicalTrialExpensesCurrent" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_2269EFDDCD413A9DFA772406F856BDA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccruedClinicalTrialExpensesCurrent_2269EFDDCD413A9DFA772406F856BDA6" xlink:to="lab_nktr_AccruedClinicalTrialExpensesCurrent_2269EFDDCD413A9DFA772406F856BDA6" xlink:type="arc" />
    <link:label id="lab_nktr_AccruedContractManufacturingExpenseCurrent_12006C1B5A677F0E4B672406F8561FB1_terseLabel_en-US" xlink:label="lab_nktr_AccruedContractManufacturingExpenseCurrent_12006C1B5A677F0E4B672406F8561FB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued contract manufacturing expenses</link:label>
    <link:label id="lab_nktr_AccruedContractManufacturingExpenseCurrent_12006C1B5A677F0E4B672406F8561FB1_label_en-US" xlink:label="lab_nktr_AccruedContractManufacturingExpenseCurrent_12006C1B5A677F0E4B672406F8561FB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Contract Manufacturing Expense Current</link:label>
    <link:label id="lab_nktr_AccruedContractManufacturingExpenseCurrent_12006C1B5A677F0E4B672406F8561FB1_documentation_en-US" xlink:label="lab_nktr_AccruedContractManufacturingExpenseCurrent_12006C1B5A677F0E4B672406F8561FB1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued contract manufacturing expense current.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AccruedContractManufacturingExpenseCurrent" xlink:label="loc_nktr_AccruedContractManufacturingExpenseCurrent_12006C1B5A677F0E4B672406F8561FB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccruedContractManufacturingExpenseCurrent_12006C1B5A677F0E4B672406F8561FB1" xlink:to="lab_nktr_AccruedContractManufacturingExpenseCurrent_12006C1B5A677F0E4B672406F8561FB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_C19F86488776DEED85172406F8568187_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_C19F86488776DEED85172406F8568187" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_C19F86488776DEED85172406F8568187_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_C19F86488776DEED85172406F8568187" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_C19F86488776DEED85172406F8568187" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_C19F86488776DEED85172406F8568187" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_C19F86488776DEED85172406F8568187" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPayableCurrent_BCDDAEC3B74733516AAB2406F8577960_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_BCDDAEC3B74733516AAB2406F8577960" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_BCDDAEC3B74733516AAB2406F8577960_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_BCDDAEC3B74733516AAB2406F8577960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_BCDDAEC3B74733516AAB2406F8577960" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent_BCDDAEC3B74733516AAB2406F8577960" xlink:to="lab_us-gaap_InterestPayableCurrent_BCDDAEC3B74733516AAB2406F8577960" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_CD1E642AEB09255807C12406F857FC30_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_CD1E642AEB09255807C12406F857FC30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_CD1E642AEB09255807C12406F857FC30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_CD1E642AEB09255807C12406F857FC30" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_CD1E642AEB09255807C12406F857FC30" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_464BBB4FC417F4978C502406F8578F1D_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_464BBB4FC417F4978C502406F8578F1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_464BBB4FC417F4978C502406F8578F1D_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_464BBB4FC417F4978C502406F8578F1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_464BBB4FC417F4978C502406F8578F1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_464BBB4FC417F4978C502406F8578F1D" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_464BBB4FC417F4978C502406F8578F1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_06DDA38F76851AC089512406F857D069_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_06DDA38F76851AC089512406F857D069" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_06DDA38F76851AC089512406F857D069_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_06DDA38F76851AC089512406F857D069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_06DDA38F76851AC089512406F857D069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_06DDA38F76851AC089512406F857D069" xlink:to="lab_us-gaap_LiabilitiesCurrent_06DDA38F76851AC089512406F857D069" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorLongTermNotes_68AE14F1883F3C34F9EF2406F8570678_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorLongTermNotes_68AE14F1883F3C34F9EF2406F8570678" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior secured notes, net</link:label>
    <link:label id="lab_us-gaap_SeniorLongTermNotes_68AE14F1883F3C34F9EF2406F8570678_label_en-US" xlink:label="lab_us-gaap_SeniorLongTermNotes_68AE14F1883F3C34F9EF2406F8570678" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="loc_us-gaap_SeniorLongTermNotes_68AE14F1883F3C34F9EF2406F8570678" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorLongTermNotes_68AE14F1883F3C34F9EF2406F8570678" xlink:to="lab_us-gaap_SeniorLongTermNotes_68AE14F1883F3C34F9EF2406F8570678" xlink:type="arc" />
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_0607690B0013C45631A82406F858AF70_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_0607690B0013C45631A82406F858AF70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to the sale of future royalties, net</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_0607690B0013C45631A82406F858AF70_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_0607690B0013C45631A82406F858AF70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_0607690B0013C45631A82406F858AF70_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_0607690B0013C45631A82406F858AF70" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability related to sale of potential future royalties non current net of issuance costs.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_0607690B0013C45631A82406F858AF70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_0607690B0013C45631A82406F858AF70" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_0607690B0013C45631A82406F858AF70" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_75FF7808475A03286E8A2406F858F44A_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_75FF7808475A03286E8A2406F858F44A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, less current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_75FF7808475A03286E8A2406F858F44A_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_75FF7808475A03286E8A2406F858F44A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_75FF7808475A03286E8A2406F858F44A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_75FF7808475A03286E8A2406F858F44A" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_75FF7808475A03286E8A2406F858F44A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_541D780485DEE9F853172406F858F253_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_541D780485DEE9F853172406F858F253" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_541D780485DEE9F853172406F858F253_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_541D780485DEE9F853172406F858F253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_541D780485DEE9F853172406F858F253" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_541D780485DEE9F853172406F858F253" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_541D780485DEE9F853172406F858F253" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_3B7D6A034E1FEF99DC0D2406F858F21D_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_3B7D6A034E1FEF99DC0D2406F858F21D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_3B7D6A034E1FEF99DC0D2406F858F21D_label_en-US" xlink:label="lab_us-gaap_Liabilities_3B7D6A034E1FEF99DC0D2406F858F21D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_3B7D6A034E1FEF99DC0D2406F858F21D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_3B7D6A034E1FEF99DC0D2406F858F21D" xlink:to="lab_us-gaap_Liabilities_3B7D6A034E1FEF99DC0D2406F858F21D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_A88366453FF93AA995A62406F858C63A_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_A88366453FF93AA995A62406F858C63A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_A88366453FF93AA995A62406F858C63A_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_A88366453FF93AA995A62406F858C63A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_A88366453FF93AA995A62406F858C63A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_A88366453FF93AA995A62406F858C63A" xlink:to="lab_us-gaap_CommitmentsAndContingencies_A88366453FF93AA995A62406F858C63A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1871CE5C5B73388BF95C2406F859A3F4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_1871CE5C5B73388BF95C2406F859A3F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1871CE5C5B73388BF95C2406F859A3F4_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_1871CE5C5B73388BF95C2406F859A3F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1871CE5C5B73388BF95C2406F859A3F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1871CE5C5B73388BF95C2406F859A3F4" xlink:to="lab_us-gaap_StockholdersEquityAbstract_1871CE5C5B73388BF95C2406F859A3F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_40EB1177BC3C17C57D4D2406F8594FF2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_40EB1177BC3C17C57D4D2406F8594FF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at September 30, 2019 or December 31, 2018</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_40EB1177BC3C17C57D4D2406F8594FF2_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_40EB1177BC3C17C57D4D2406F8594FF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_40EB1177BC3C17C57D4D2406F8594FF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_40EB1177BC3C17C57D4D2406F8594FF2" xlink:to="lab_us-gaap_PreferredStockValue_40EB1177BC3C17C57D4D2406F8594FF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_49C90079D71379CEA9882406F859A0F3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_49C90079D71379CEA9882406F859A0F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 300,000 shares authorized; 175,786 shares and 173,530 shares outstanding at September 30, 2019 and December 31, 2018, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_49C90079D71379CEA9882406F859A0F3_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_49C90079D71379CEA9882406F859A0F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_49C90079D71379CEA9882406F859A0F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_49C90079D71379CEA9882406F859A0F3" xlink:to="lab_us-gaap_CommonStockValue_49C90079D71379CEA9882406F859A0F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8C6A5FC0C26249279C4E2406F85998AD_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8C6A5FC0C26249279C4E2406F85998AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital in excess of par value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8C6A5FC0C26249279C4E2406F85998AD_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8C6A5FC0C26249279C4E2406F85998AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8C6A5FC0C26249279C4E2406F85998AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8C6A5FC0C26249279C4E2406F85998AD" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8C6A5FC0C26249279C4E2406F85998AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3068B806132C2E056D3F2406F859A7CA_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3068B806132C2E056D3F2406F859A7CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3068B806132C2E056D3F2406F859A7CA_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3068B806132C2E056D3F2406F859A7CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3068B806132C2E056D3F2406F859A7CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3068B806132C2E056D3F2406F859A7CA" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3068B806132C2E056D3F2406F859A7CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_E957A83DDABCA602446C2406F85A69ED_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_E957A83DDABCA602446C2406F85A69ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_E957A83DDABCA602446C2406F85A69ED_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_E957A83DDABCA602446C2406F85A69ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_E957A83DDABCA602446C2406F85A69ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_E957A83DDABCA602446C2406F85A69ED" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_E957A83DDABCA602446C2406F85A69ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_2B9D03FC93F4F07267E62406F85A7EEC_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_2B9D03FC93F4F07267E62406F85A7EEC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2B9D03FC93F4F07267E62406F85A7EEC_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_2B9D03FC93F4F07267E62406F85A7EEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2B9D03FC93F4F07267E62406F85A7EEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_2B9D03FC93F4F07267E62406F85A7EEC" xlink:to="lab_us-gaap_StockholdersEquity_2B9D03FC93F4F07267E62406F85A7EEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_A0B364D46D1583746B6C2406F85A43B9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_A0B364D46D1583746B6C2406F85A43B9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_A0B364D46D1583746B6C2406F85A43B9_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_A0B364D46D1583746B6C2406F85A43B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_A0B364D46D1583746B6C2406F85A43B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_A0B364D46D1583746B6C2406F85A43B9" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_A0B364D46D1583746B6C2406F85A43B9" xlink:type="arc" />
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_E4653B88D75BF9319B5844C1806D1D96_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_169703747E6954E289D686091163168B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_E4653B88D75BF9319B5844C1806D1D96_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_169703747E6954E289D686091163168B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_E4653B88D75BF9319B5844C1806D1D96_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_169703747E6954E289D686091163168B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_169703747E6954E289D686091163168B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_169703747E6954E289D686091163168B" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_169703747E6954E289D686091163168B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_0FDB1837D2FDCBB8763A44C1806DFE82_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_1E752C12F05F5F508130A81B79C3A9AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_0FDB1837D2FDCBB8763A44C1806DFE82_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_1E752C12F05F5F508130A81B79C3A9AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1E752C12F05F5F508130A81B79C3A9AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1E752C12F05F5F508130A81B79C3A9AB" xlink:to="lab_us-gaap_TypeOfArrangementAxis_1E752C12F05F5F508130A81B79C3A9AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2504FB0E0877A66DFE0444C1806E3B41_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_639B9841668A5418973A43392C399310" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2504FB0E0877A66DFE0444C1806E3B41_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_639B9841668A5418973A43392C399310" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_639B9841668A5418973A43392C399310" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_639B9841668A5418973A43392C399310" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_639B9841668A5418973A43392C399310" xlink:type="arc" />
    <link:label id="lab_nktr_PurchaseAndSaleAgreementMember_48E7E3154B8EF48DD3E344C1806EB5C4_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreementMember_E51327D7378357AEAFBFF5C0D10BAA19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase and Sale Agreement with RPI</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreementMember_48E7E3154B8EF48DD3E344C1806EB5C4_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreementMember_E51327D7378357AEAFBFF5C0D10BAA19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase And Sale Agreement [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreementMember_48E7E3154B8EF48DD3E344C1806EB5C4_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreementMember_E51327D7378357AEAFBFF5C0D10BAA19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase and sale agreement.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PurchaseAndSaleAgreementMember" xlink:label="loc_nktr_PurchaseAndSaleAgreementMember_E51327D7378357AEAFBFF5C0D10BAA19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreementMember_E51327D7378357AEAFBFF5C0D10BAA19" xlink:to="lab_nktr_PurchaseAndSaleAgreementMember_E51327D7378357AEAFBFF5C0D10BAA19" xlink:type="arc" />
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_40CFA72A0430C124DBB044C1806EA30B_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Related to Sale of Future Royalties [Line Items]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_40CFA72A0430C124DBB044C1806EA30B_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Line Items]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_40CFA72A0430C124DBB044C1806EA30B_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:type="arc" />
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_763872B0CB18D59B826544C1806E5EED_terseLabel_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_D86C4AD555925CDDB626F26E46C316EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of royalty rights</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_763872B0CB18D59B826544C1806E5EED_label_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_D86C4AD555925CDDB626F26E46C316EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Sale Of Potential Future Royalties Gross</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_763872B0CB18D59B826544C1806E5EED_documentation_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_D86C4AD555925CDDB626F26E46C316EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from sale of potential future royalties gross.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_D86C4AD555925CDDB626F26E46C316EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_D86C4AD555925CDDB626F26E46C316EB" xlink:to="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_D86C4AD555925CDDB626F26E46C316EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_CA1F47C4058B2194832644C1806F034C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross_1A983441232354488C6FF5C17356EF90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs related to sale of potential future royalties</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_CA1F47C4058B2194832644C1806F034C_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross_1A983441232354488C6FF5C17356EF90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_1A983441232354488C6FF5C17356EF90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross_1A983441232354488C6FF5C17356EF90" xlink:to="lab_us-gaap_DeferredFinanceCostsGross_1A983441232354488C6FF5C17356EF90" xlink:type="arc" />
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_44F8B11EB563A63356F044C1806F2DC8_terseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_EE273E50D651593DA1E52FD0ABFDC1F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_EE273E50D651593DA1E52FD0ABFDC1F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_EE273E50D651593DA1E52FD0ABFDC1F5" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_EE273E50D651593DA1E52FD0ABFDC1F5" xlink:type="arc" />
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_CF069C47648881CBC3A744C1806FD91E_negatedTerseLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_2DE06395B79B5198A0C6AB1AC0A729A8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense on liability related to sale of future royalties</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_2DE06395B79B5198A0C6AB1AC0A729A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_2DE06395B79B5198A0C6AB1AC0A729A8" xlink:to="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_2DE06395B79B5198A0C6AB1AC0A729A8" xlink:type="arc" />
    <link:label id="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_74D5B118677A051EFFCE44C1806F032C_terseLabel_en-US" xlink:label="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_2F9B0A549F435D4588862E6F07CF7099" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual interest rate</link:label>
    <link:label id="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_74D5B118677A051EFFCE44C1806F032C_label_en-US" xlink:label="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_2F9B0A549F435D4588862E6F07CF7099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Annual Interest Rate Over Life Of Royalty Liability</link:label>
    <link:label id="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_74D5B118677A051EFFCE44C1806F032C_documentation_en-US" xlink:label="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_2F9B0A549F435D4588862E6F07CF7099" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated annual interest rate over life of royalty liability.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:label="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_2F9B0A549F435D4588862E6F07CF7099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_2F9B0A549F435D4588862E6F07CF7099" xlink:to="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_2F9B0A549F435D4588862E6F07CF7099" xlink:type="arc" />
    <link:label id="lab_nktr_ProspectiveInterestRatePercentage_A7C2C3FE007F9024E4CD44C1806F2871_terseLabel_en-US" xlink:label="lab_nktr_ProspectiveInterestRatePercentage_E4E48FBF880951D196EFC997BAE361CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prospective interest rate</link:label>
    <link:label id="lab_nktr_ProspectiveInterestRatePercentage_A7C2C3FE007F9024E4CD44C1806F2871_label_en-US" xlink:label="lab_nktr_ProspectiveInterestRatePercentage_E4E48FBF880951D196EFC997BAE361CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prospective Interest Rate Percentage</link:label>
    <link:label id="lab_nktr_ProspectiveInterestRatePercentage_A7C2C3FE007F9024E4CD44C1806F2871_documentation_en-US" xlink:label="lab_nktr_ProspectiveInterestRatePercentage_E4E48FBF880951D196EFC997BAE361CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prospective interest rate percentage.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ProspectiveInterestRatePercentage" xlink:label="loc_nktr_ProspectiveInterestRatePercentage_E4E48FBF880951D196EFC997BAE361CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProspectiveInterestRatePercentage_E4E48FBF880951D196EFC997BAE361CF" xlink:to="lab_nktr_ProspectiveInterestRatePercentage_E4E48FBF880951D196EFC997BAE361CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_51F77C2B1556DDFA0CB0424AFEA2C2B2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_51F77C2B1556DDFA0CB0424AFEA2C2B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_51F77C2B1556DDFA0CB0424AFEA2C2B2_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_51F77C2B1556DDFA0CB0424AFEA2C2B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_51F77C2B1556DDFA0CB0424AFEA2C2B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_51F77C2B1556DDFA0CB0424AFEA2C2B2" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_51F77C2B1556DDFA0CB0424AFEA2C2B2" xlink:type="arc" />
    <link:label id="lab_nktr_ARESanFranciscoNumberOneNineLLCMember_0B48C242A835C2D5DF55424AFEA318B1_terseLabel_en-US" xlink:label="lab_nktr_ARESanFranciscoNumberOneNineLLCMember_0B48C242A835C2D5DF55424AFEA318B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ARE-San Francisco No. 19, LLC</link:label>
    <link:label id="lab_nktr_ARESanFranciscoNumberOneNineLLCMember_0B48C242A835C2D5DF55424AFEA318B1_label_en-US" xlink:label="lab_nktr_ARESanFranciscoNumberOneNineLLCMember_0B48C242A835C2D5DF55424AFEA318B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">A R E San Francisco Number One Nine L L C [Member]</link:label>
    <link:label id="lab_nktr_ARESanFranciscoNumberOneNineLLCMember_0B48C242A835C2D5DF55424AFEA318B1_documentation_en-US" xlink:label="lab_nktr_ARESanFranciscoNumberOneNineLLCMember_0B48C242A835C2D5DF55424AFEA318B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ARE San Francisco Number 19 LLC.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ARESanFranciscoNumberOneNineLLCMember" xlink:label="loc_nktr_ARESanFranciscoNumberOneNineLLCMember_0B48C242A835C2D5DF55424AFEA318B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ARESanFranciscoNumberOneNineLLCMember_0B48C242A835C2D5DF55424AFEA318B1" xlink:to="lab_nktr_ARESanFranciscoNumberOneNineLLCMember_0B48C242A835C2D5DF55424AFEA318B1" xlink:type="arc" />
    <link:label id="lab_nktr_KilroyRealtyFinancePartnershipLPMember_7339641D8AEC50C34779424AFEA33F26_terseLabel_en-US" xlink:label="lab_nktr_KilroyRealtyFinancePartnershipLPMember_7339641D8AEC50C34779424AFEA33F26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kilroy Realty Finance Partnership, L.P</link:label>
    <link:label id="lab_nktr_KilroyRealtyFinancePartnershipLPMember_7339641D8AEC50C34779424AFEA33F26_label_en-US" xlink:label="lab_nktr_KilroyRealtyFinancePartnershipLPMember_7339641D8AEC50C34779424AFEA33F26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kilroy Realty Finance Partnership L P [Member]</link:label>
    <link:label id="lab_nktr_KilroyRealtyFinancePartnershipLPMember_7339641D8AEC50C34779424AFEA33F26_documentation_en-US" xlink:label="lab_nktr_KilroyRealtyFinancePartnershipLPMember_7339641D8AEC50C34779424AFEA33F26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kilroy Realty Finance Partnership, L.P.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_KilroyRealtyFinancePartnershipLPMember" xlink:label="loc_nktr_KilroyRealtyFinancePartnershipLPMember_7339641D8AEC50C34779424AFEA33F26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_KilroyRealtyFinancePartnershipLPMember_7339641D8AEC50C34779424AFEA33F26" xlink:to="lab_nktr_KilroyRealtyFinancePartnershipLPMember_7339641D8AEC50C34779424AFEA33F26" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_AC59AEEE5B3C91915BAF424AFEA4889A_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_AC59AEEE5B3C91915BAF424AFEA4889A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_AC59AEEE5B3C91915BAF424AFEA4889A_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_AC59AEEE5B3C91915BAF424AFEA4889A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_AC59AEEE5B3C91915BAF424AFEA4889A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_AC59AEEE5B3C91915BAF424AFEA4889A" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis_AC59AEEE5B3C91915BAF424AFEA4889A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_040CB8AA2621012F08F3424AFEA40140_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_040CB8AA2621012F08F3424AFEA40140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_040CB8AA2621012F08F3424AFEA40140_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_040CB8AA2621012F08F3424AFEA40140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_040CB8AA2621012F08F3424AFEA40140" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_040CB8AA2621012F08F3424AFEA40140" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain_040CB8AA2621012F08F3424AFEA40140" xlink:type="arc" />
    <link:label id="lab_nktr_MissionBayLeaseMember_874C9B0A1396845904FB424AFEA481F1_terseLabel_en-US" xlink:label="lab_nktr_MissionBayLeaseMember_874C9B0A1396845904FB424AFEA481F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mission Bay Lease</link:label>
    <link:label id="lab_nktr_MissionBayLeaseMember_874C9B0A1396845904FB424AFEA481F1_label_en-US" xlink:label="lab_nktr_MissionBayLeaseMember_874C9B0A1396845904FB424AFEA481F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mission Bay Lease [Member]</link:label>
    <link:label id="lab_nktr_MissionBayLeaseMember_874C9B0A1396845904FB424AFEA481F1_documentation_en-US" xlink:label="lab_nktr_MissionBayLeaseMember_874C9B0A1396845904FB424AFEA481F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mission bay lease.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_MissionBayLeaseMember" xlink:label="loc_nktr_MissionBayLeaseMember_874C9B0A1396845904FB424AFEA481F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MissionBayLeaseMember_874C9B0A1396845904FB424AFEA481F1" xlink:to="lab_nktr_MissionBayLeaseMember_874C9B0A1396845904FB424AFEA481F1" xlink:type="arc" />
    <link:label id="lab_nktr_ThirdStreetLeaseMember_01CDFCF0BD694DE46985424AFEA55E16_terseLabel_en-US" xlink:label="lab_nktr_ThirdStreetLeaseMember_01CDFCF0BD694DE46985424AFEA55E16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Third Street Lease</link:label>
    <link:label id="lab_nktr_ThirdStreetLeaseMember_01CDFCF0BD694DE46985424AFEA55E16_label_en-US" xlink:label="lab_nktr_ThirdStreetLeaseMember_01CDFCF0BD694DE46985424AFEA55E16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third Street Lease [Member]</link:label>
    <link:label id="lab_nktr_ThirdStreetLeaseMember_01CDFCF0BD694DE46985424AFEA55E16_documentation_en-US" xlink:label="lab_nktr_ThirdStreetLeaseMember_01CDFCF0BD694DE46985424AFEA55E16" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Third street lease.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ThirdStreetLeaseMember" xlink:label="loc_nktr_ThirdStreetLeaseMember_01CDFCF0BD694DE46985424AFEA55E16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ThirdStreetLeaseMember_01CDFCF0BD694DE46985424AFEA55E16" xlink:to="lab_nktr_ThirdStreetLeaseMember_01CDFCF0BD694DE46985424AFEA55E16" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:type="arc" />
    <link:label id="lab_nktr_AreaOfLeasedSpace_D7C8171BD5768B24E34C424AFEA5D026_terseLabel_en-US" xlink:label="lab_nktr_AreaOfLeasedSpace_D7C8171BD5768B24E34C424AFEA5D026" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease space (in sq. feet)</link:label>
    <link:label id="lab_nktr_AreaOfLeasedSpace_D7C8171BD5768B24E34C424AFEA5D026_label_en-US" xlink:label="lab_nktr_AreaOfLeasedSpace_D7C8171BD5768B24E34C424AFEA5D026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area Of Leased Space</link:label>
    <link:label id="lab_nktr_AreaOfLeasedSpace_D7C8171BD5768B24E34C424AFEA5D026_documentation_en-US" xlink:label="lab_nktr_AreaOfLeasedSpace_D7C8171BD5768B24E34C424AFEA5D026" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Area of leased space.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AreaOfLeasedSpace" xlink:label="loc_nktr_AreaOfLeasedSpace_D7C8171BD5768B24E34C424AFEA5D026" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AreaOfLeasedSpace_D7C8171BD5768B24E34C424AFEA5D026" xlink:to="lab_nktr_AreaOfLeasedSpace_D7C8171BD5768B24E34C424AFEA5D026" xlink:type="arc" />
    <link:label id="lab_nktr_NumberOfConsecutiveFiveYearTermsToExtendLease_53EED72BFD9E8887C6B7424AFEA62118_terseLabel_en-US" xlink:label="lab_nktr_NumberOfConsecutiveFiveYearTermsToExtendLease_53EED72BFD9E8887C6B7424AFEA62118" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of consecutive 5 year terms to extend lease</link:label>
    <link:label id="lab_nktr_NumberOfConsecutiveFiveYearTermsToExtendLease_53EED72BFD9E8887C6B7424AFEA62118_label_en-US" xlink:label="lab_nktr_NumberOfConsecutiveFiveYearTermsToExtendLease_53EED72BFD9E8887C6B7424AFEA62118" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Consecutive Five Year Terms To Extend Lease</link:label>
    <link:label id="lab_nktr_NumberOfConsecutiveFiveYearTermsToExtendLease_53EED72BFD9E8887C6B7424AFEA62118_documentation_en-US" xlink:label="lab_nktr_NumberOfConsecutiveFiveYearTermsToExtendLease_53EED72BFD9E8887C6B7424AFEA62118" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of consecutive five year terms to extend lease.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NumberOfConsecutiveFiveYearTermsToExtendLease" xlink:label="loc_nktr_NumberOfConsecutiveFiveYearTermsToExtendLease_53EED72BFD9E8887C6B7424AFEA62118" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NumberOfConsecutiveFiveYearTermsToExtendLease_53EED72BFD9E8887C6B7424AFEA62118" xlink:to="lab_nktr_NumberOfConsecutiveFiveYearTermsToExtendLease_53EED72BFD9E8887C6B7424AFEA62118" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_59F561A4D104D26ABB7A424AFEA67BDA_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_59F561A4D104D26ABB7A424AFEA67BDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease extension term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_59F561A4D104D26ABB7A424AFEA67BDA_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_59F561A4D104D26ABB7A424AFEA67BDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_59F561A4D104D26ABB7A424AFEA67BDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_59F561A4D104D26ABB7A424AFEA67BDA" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_59F561A4D104D26ABB7A424AFEA67BDA" xlink:type="arc" />
    <link:label id="lab_nktr_AdditionalSpaceRequiredToBeLeasedInFuture_027FD05D86E52949C946424AFEA69542_terseLabel_en-US" xlink:label="lab_nktr_AdditionalSpaceRequiredToBeLeasedInFuture_027FD05D86E52949C946424AFEA69542" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional space required to be leased in the future (in sqft)</link:label>
    <link:label id="lab_nktr_AdditionalSpaceRequiredToBeLeasedInFuture_027FD05D86E52949C946424AFEA69542_label_en-US" xlink:label="lab_nktr_AdditionalSpaceRequiredToBeLeasedInFuture_027FD05D86E52949C946424AFEA69542" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Space Required To Be Leased In Future</link:label>
    <link:label id="lab_nktr_AdditionalSpaceRequiredToBeLeasedInFuture_027FD05D86E52949C946424AFEA69542_documentation_en-US" xlink:label="lab_nktr_AdditionalSpaceRequiredToBeLeasedInFuture_027FD05D86E52949C946424AFEA69542" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional space required to be leased in future.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AdditionalSpaceRequiredToBeLeasedInFuture" xlink:label="loc_nktr_AdditionalSpaceRequiredToBeLeasedInFuture_027FD05D86E52949C946424AFEA69542" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AdditionalSpaceRequiredToBeLeasedInFuture_027FD05D86E52949C946424AFEA69542" xlink:to="lab_nktr_AdditionalSpaceRequiredToBeLeasedInFuture_027FD05D86E52949C946424AFEA69542" xlink:type="arc" />
    <link:label id="lab_nktr_NumberOfLeasedSpacesDelivered_85C94440E695D9CCDCC9424AFEA75263_terseLabel_en-US" xlink:label="lab_nktr_NumberOfLeasedSpacesDelivered_85C94440E695D9CCDCC9424AFEA75263" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional spaces delivered</link:label>
    <link:label id="lab_nktr_NumberOfLeasedSpacesDelivered_85C94440E695D9CCDCC9424AFEA75263_label_en-US" xlink:label="lab_nktr_NumberOfLeasedSpacesDelivered_85C94440E695D9CCDCC9424AFEA75263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Leased Spaces Delivered</link:label>
    <link:label id="lab_nktr_NumberOfLeasedSpacesDelivered_85C94440E695D9CCDCC9424AFEA75263_documentation_en-US" xlink:label="lab_nktr_NumberOfLeasedSpacesDelivered_85C94440E695D9CCDCC9424AFEA75263" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of leased spaces delivered.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NumberOfLeasedSpacesDelivered" xlink:label="loc_nktr_NumberOfLeasedSpacesDelivered_85C94440E695D9CCDCC9424AFEA75263" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NumberOfLeasedSpacesDelivered_85C94440E695D9CCDCC9424AFEA75263" xlink:to="lab_nktr_NumberOfLeasedSpacesDelivered_85C94440E695D9CCDCC9424AFEA75263" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_99AB198EE8ABF8BA11B4424AFEA765F3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_99AB198EE8ABF8BA11B4424AFEA765F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_99AB198EE8ABF8BA11B4424AFEA765F3_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_99AB198EE8ABF8BA11B4424AFEA765F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_99AB198EE8ABF8BA11B4424AFEA765F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_99AB198EE8ABF8BA11B4424AFEA765F3" xlink:to="lab_us-gaap_OperatingLeasePayments_99AB198EE8ABF8BA11B4424AFEA765F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_839864574398B3DA3CBC424AFEA70ABD_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_839864574398B3DA3CBC424AFEA70ABD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_839864574398B3DA3CBC424AFEA70ABD_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_839864574398B3DA3CBC424AFEA70ABD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_839864574398B3DA3CBC424AFEA70ABD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_839864574398B3DA3CBC424AFEA70ABD" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_839864574398B3DA3CBC424AFEA70ABD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7CD1971DB0B9E36EE911424AFEA8B43B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7CD1971DB0B9E36EE911424AFEA8B43B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, weighted-average discount rate, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7CD1971DB0B9E36EE911424AFEA8B43B_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7CD1971DB0B9E36EE911424AFEA8B43B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7CD1971DB0B9E36EE911424AFEA8B43B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7CD1971DB0B9E36EE911424AFEA8B43B" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7CD1971DB0B9E36EE911424AFEA8B43B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_C9E6534393533B5E252D1BB29EB17B01_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_B09F0C56E9E55257866E8B17E9FCFD88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Investments in Marketable Securities, Including Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_C9E6534393533B5E252D1BB29EB17B01_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_B09F0C56E9E55257866E8B17E9FCFD88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_B09F0C56E9E55257866E8B17E9FCFD88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_B09F0C56E9E55257866E8B17E9FCFD88" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_B09F0C56E9E55257866E8B17E9FCFD88" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_10514E37749144649D191BB29EB1C914_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_7E4C8DD08AA05C46A5086383760F8A3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portfolio of Cash and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_10514E37749144649D191BB29EB1C914_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_7E4C8DD08AA05C46A5086383760F8A3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_7E4C8DD08AA05C46A5086383760F8A3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_7E4C8DD08AA05C46A5086383760F8A3C" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_7E4C8DD08AA05C46A5086383760F8A3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C3AA6E09BA4C782176101BB29E4968D6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C991D684E23F5D75B7721D7BEF69D4AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C3AA6E09BA4C782176101BB29E4968D6_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C991D684E23F5D75B7721D7BEF69D4AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C991D684E23F5D75B7721D7BEF69D4AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C991D684E23F5D75B7721D7BEF69D4AD" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C991D684E23F5D75B7721D7BEF69D4AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_9602EDCF2188562721621BB29EDBDD5D_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_26E5A3174E66511F82C4D274CFC81F42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_9602EDCF2188562721621BB29EDBDD5D_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_26E5A3174E66511F82C4D274CFC81F42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_26E5A3174E66511F82C4D274CFC81F42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_26E5A3174E66511F82C4D274CFC81F42" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_26E5A3174E66511F82C4D274CFC81F42" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_84E003BA75C4598F9C7323C003C9A158_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_84E003BA75C4598F9C7323C003C9A158" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_84E003BA75C4598F9C7323C003C9A158_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_84E003BA75C4598F9C7323C003C9A158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_84E003BA75C4598F9C7323C003C9A158" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_84E003BA75C4598F9C7323C003C9A158" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_84E003BA75C4598F9C7323C003C9A158" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_9E128A7493B899C1EF2223DA4092F3CB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_9E128A7493B899C1EF2223DA4092F3CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_9E128A7493B899C1EF2223DA4092F3CB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_9E128A7493B899C1EF2223DA4092F3CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_9E128A7493B899C1EF2223DA4092F3CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_9E128A7493B899C1EF2223DA4092F3CB" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_9E128A7493B899C1EF2223DA4092F3CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_E3D89497297700EB3F044159E96C3B3D_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_E3D89497297700EB3F044159E96C3B3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_E3D89497297700EB3F044159E96C3B3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_E3D89497297700EB3F044159E96C3B3D" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_E3D89497297700EB3F044159E96C3B3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_A7BFF0B2ED982F0DC17F4159E96E2B3A_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_A7BFF0B2ED982F0DC17F4159E96E2B3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_A7BFF0B2ED982F0DC17F4159E96E2B3A_label_en-US" xlink:label="lab_us-gaap_StatementTable_A7BFF0B2ED982F0DC17F4159E96E2B3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A7BFF0B2ED982F0DC17F4159E96E2B3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_A7BFF0B2ED982F0DC17F4159E96E2B3A" xlink:to="lab_us-gaap_StatementTable_A7BFF0B2ED982F0DC17F4159E96E2B3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_29D25CC0BCAB8EEC2C6F4159E96F290C_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_29D25CC0BCAB8EEC2C6F4159E96F290C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_29D25CC0BCAB8EEC2C6F4159E96F290C_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_29D25CC0BCAB8EEC2C6F4159E96F290C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_29D25CC0BCAB8EEC2C6F4159E96F290C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_29D25CC0BCAB8EEC2C6F4159E96F290C" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_29D25CC0BCAB8EEC2C6F4159E96F290C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244" xlink:to="lab_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_21A726DEC7B03460C0A64159E970DA54_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_21A726DEC7B03460C0A64159E970DA54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_21A726DEC7B03460C0A64159E970DA54_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_21A726DEC7B03460C0A64159E970DA54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_21A726DEC7B03460C0A64159E970DA54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_21A726DEC7B03460C0A64159E970DA54" xlink:to="lab_us-gaap_CommonStockMember_21A726DEC7B03460C0A64159E970DA54" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_0060CBE67F7E90812CF84159E972439D_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0060CBE67F7E90812CF84159E972439D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital in Excess of Par Value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_0060CBE67F7E90812CF84159E972439D_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0060CBE67F7E90812CF84159E972439D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0060CBE67F7E90812CF84159E972439D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_0060CBE67F7E90812CF84159E972439D" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0060CBE67F7E90812CF84159E972439D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_73CBF5E38A4EBEC777CB4159E972D1F1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_73CBF5E38A4EBEC777CB4159E972D1F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_73CBF5E38A4EBEC777CB4159E972D1F1_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_73CBF5E38A4EBEC777CB4159E972D1F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_73CBF5E38A4EBEC777CB4159E972D1F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_73CBF5E38A4EBEC777CB4159E972D1F1" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_73CBF5E38A4EBEC777CB4159E972D1F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_EDAC4CA29F71BC626EC14159E97225ED_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_EDAC4CA29F71BC626EC14159E97225ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_EDAC4CA29F71BC626EC14159E97225ED_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_EDAC4CA29F71BC626EC14159E97225ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_EDAC4CA29F71BC626EC14159E97225ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_EDAC4CA29F71BC626EC14159E97225ED" xlink:to="lab_us-gaap_RetainedEarningsMember_EDAC4CA29F71BC626EC14159E97225ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="lab_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_D33E90989DB2BDB1FFCB4159E973CED8_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_D33E90989DB2BDB1FFCB4159E973CED8" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_D33E90989DB2BDB1FFCB4159E973CED8_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_D33E90989DB2BDB1FFCB4159E973CED8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_D33E90989DB2BDB1FFCB4159E973CED8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_D33E90989DB2BDB1FFCB4159E973CED8" xlink:to="lab_us-gaap_SharesOutstanding_D33E90989DB2BDB1FFCB4159E973CED8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_2D546D39A77B788B8E544159E9738C99_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_2D546D39A77B788B8E544159E9738C99" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2D546D39A77B788B8E544159E9738C99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_2D546D39A77B788B8E544159E9738C99" xlink:to="lab_us-gaap_StockholdersEquity_2D546D39A77B788B8E544159E9738C99" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_2FE18273BD703B03D4D74159E974845F_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_2FE18273BD703B03D4D74159E974845F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of new accounting standards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_2FE18273BD703B03D4D74159E974845F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_2FE18273BD703B03D4D74159E974845F" xlink:to="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_2FE18273BD703B03D4D74159E974845F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B0D3132270259EAA0734159E9749866_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B0D3132270259EAA0734159E9749866" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock to Bristol-Myers Squibb (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B0D3132270259EAA0734159E9749866_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B0D3132270259EAA0734159E9749866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B0D3132270259EAA0734159E9749866" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B0D3132270259EAA0734159E9749866" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B0D3132270259EAA0734159E9749866" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_E1092F78F586D026B1244159E974E502_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_E1092F78F586D026B1244159E974E502" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock to Bristol-Myers Squibb</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_E1092F78F586D026B1244159E974E502_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_E1092F78F586D026B1244159E974E502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_E1092F78F586D026B1244159E974E502" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_E1092F78F586D026B1244159E974E502" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_E1092F78F586D026B1244159E974E502" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9CAC59C63B4A517A49DA4159E973B664_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9CAC59C63B4A517A49DA4159E973B664" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9CAC59C63B4A517A49DA4159E973B664_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9CAC59C63B4A517A49DA4159E973B664" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9CAC59C63B4A517A49DA4159E973B664" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9CAC59C63B4A517A49DA4159E973B664" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9CAC59C63B4A517A49DA4159E973B664" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_E42204E8221773FFD5894159E974FF2F_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_E42204E8221773FFD5894159E974FF2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_E42204E8221773FFD5894159E974FF2F_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_E42204E8221773FFD5894159E974FF2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_E42204E8221773FFD5894159E974FF2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_E42204E8221773FFD5894159E974FF2F" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_E42204E8221773FFD5894159E974FF2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D90328FBA524AD2334044159E97449CE_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D90328FBA524AD2334044159E97449CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D90328FBA524AD2334044159E97449CE_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D90328FBA524AD2334044159E97449CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D90328FBA524AD2334044159E97449CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D90328FBA524AD2334044159E97449CE" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D90328FBA524AD2334044159E97449CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_AE305B6B5AEFEA03556F4159E9741B9F_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_AE305B6B5AEFEA03556F4159E9741B9F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_AE305B6B5AEFEA03556F4159E9741B9F_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_AE305B6B5AEFEA03556F4159E9741B9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_AE305B6B5AEFEA03556F4159E9741B9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_AE305B6B5AEFEA03556F4159E9741B9F" xlink:to="lab_us-gaap_NetIncomeLoss_AE305B6B5AEFEA03556F4159E9741B9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_7D7CA183D918092E14394159E975EABD_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_7D7CA183D918092E14394159E975EABD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_7D7CA183D918092E14394159E975EABD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_7D7CA183D918092E14394159E975EABD" xlink:to="lab_us-gaap_SharesOutstanding_7D7CA183D918092E14394159E975EABD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_2715E909ED092AE9C80D4159E975A5F4_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_2715E909ED092AE9C80D4159E975A5F4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2715E909ED092AE9C80D4159E975A5F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_2715E909ED092AE9C80D4159E975A5F4" xlink:to="lab_us-gaap_StockholdersEquity_2715E909ED092AE9C80D4159E975A5F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3BBBE07097CAA67FE0551BB29ECAB4A2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_24903EEB4C585DA9BE616D3A4BAAC0C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, Collaboration and Other Revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3BBBE07097CAA67FE0551BB29ECAB4A2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_24903EEB4C585DA9BE616D3A4BAAC0C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_24903EEB4C585DA9BE616D3A4BAAC0C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_24903EEB4C585DA9BE616D3A4BAAC0C9" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_24903EEB4C585DA9BE616D3A4BAAC0C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_87DB636FDABDE02305F21BB29ECA9071_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_C2FE5195D8F357858545A9D40576B73A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Deferred Revenue Balance from Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_87DB636FDABDE02305F21BB29ECA9071_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_C2FE5195D8F357858545A9D40576B73A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_C2FE5195D8F357858545A9D40576B73A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_C2FE5195D8F357858545A9D40576B73A" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_C2FE5195D8F357858545A9D40576B73A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13D74808B814D69A729319816559EB10_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13D74808B814D69A729319816559EB10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13D74808B814D69A729319816559EB10_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13D74808B814D69A729319816559EB10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13D74808B814D69A729319816559EB10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13D74808B814D69A729319816559EB10" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13D74808B814D69A729319816559EB10" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_97BA751453A860F80CC91981655A08BC_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_97BA751453A860F80CC91981655A08BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_97BA751453A860F80CC91981655A08BC_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_97BA751453A860F80CC91981655A08BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_97BA751453A860F80CC91981655A08BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_97BA751453A860F80CC91981655A08BC" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_97BA751453A860F80CC91981655A08BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_E99A0E103C9CD63411A71981655A54AA_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_E99A0E103C9CD63411A71981655A54AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_E99A0E103C9CD63411A71981655A54AA_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_E99A0E103C9CD63411A71981655A54AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_E99A0E103C9CD63411A71981655A54AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_E99A0E103C9CD63411A71981655A54AA" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_E99A0E103C9CD63411A71981655A54AA" xlink:type="arc" />
    <link:label id="lab_nktr_StockOptionsAndRestrictedStockUnitsMember_4DB124B721755CCA734E1981655A4B54_terseLabel_en-US" xlink:label="lab_nktr_StockOptionsAndRestrictedStockUnitsMember_4DB124B721755CCA734E1981655A4B54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options and Restricted Stock Units</link:label>
    <link:label id="lab_nktr_StockOptionsAndRestrictedStockUnitsMember_4DB124B721755CCA734E1981655A4B54_label_en-US" xlink:label="lab_nktr_StockOptionsAndRestrictedStockUnitsMember_4DB124B721755CCA734E1981655A4B54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_nktr_StockOptionsAndRestrictedStockUnitsMember_4DB124B721755CCA734E1981655A4B54_documentation_en-US" xlink:label="lab_nktr_StockOptionsAndRestrictedStockUnitsMember_4DB124B721755CCA734E1981655A4B54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options and restricted stock units.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_StockOptionsAndRestrictedStockUnitsMember" xlink:label="loc_nktr_StockOptionsAndRestrictedStockUnitsMember_4DB124B721755CCA734E1981655A4B54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_StockOptionsAndRestrictedStockUnitsMember_4DB124B721755CCA734E1981655A4B54" xlink:to="lab_nktr_StockOptionsAndRestrictedStockUnitsMember_4DB124B721755CCA734E1981655A4B54" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B62141538BA797E4CC841981655B2167_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B62141538BA797E4CC841981655B2167" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B62141538BA797E4CC841981655B2167_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B62141538BA797E4CC841981655B2167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B62141538BA797E4CC841981655B2167" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B62141538BA797E4CC841981655B2167" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B62141538BA797E4CC841981655B2167" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C8AEBB36AAC038B425A11981655B42BC_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C8AEBB36AAC038B425A11981655B42BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C8AEBB36AAC038B425A11981655B42BC_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C8AEBB36AAC038B425A11981655B42BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C8AEBB36AAC038B425A11981655B42BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C8AEBB36AAC038B425A11981655B42BC" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C8AEBB36AAC038B425A11981655B42BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C25CC2A12F34A7A2D22C1981655B4A83_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C25CC2A12F34A7A2D22C1981655B4A83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average potentially dilutive securities included in calculation of diluted securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C25CC2A12F34A7A2D22C1981655B4A83_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C25CC2A12F34A7A2D22C1981655B4A83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C25CC2A12F34A7A2D22C1981655B4A83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C25CC2A12F34A7A2D22C1981655B4A83" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C25CC2A12F34A7A2D22C1981655B4A83" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51_label_en-US" xlink:label="lab_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="lab_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_96E1ACCF6BEB06A54E4B378CF646E3EF_verboseLabel_en-US" xlink:label="lab_dei_DocumentType_96E1ACCF6BEB06A54E4B378CF646E3EF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_96E1ACCF6BEB06A54E4B378CF646E3EF_label_en-US" xlink:label="lab_dei_DocumentType_96E1ACCF6BEB06A54E4B378CF646E3EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_96E1ACCF6BEB06A54E4B378CF646E3EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_96E1ACCF6BEB06A54E4B378CF646E3EF" xlink:to="lab_dei_DocumentType_96E1ACCF6BEB06A54E4B378CF646E3EF" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_797E23DB47E4A976E3FC378CF647CE00_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_797E23DB47E4A976E3FC378CF647CE00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_797E23DB47E4A976E3FC378CF647CE00_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_797E23DB47E4A976E3FC378CF647CE00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_797E23DB47E4A976E3FC378CF647CE00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_797E23DB47E4A976E3FC378CF647CE00" xlink:to="lab_dei_DocumentQuarterlyReport_797E23DB47E4A976E3FC378CF647CE00" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_646584C8A0B249227C36378CF647D002_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_646584C8A0B249227C36378CF647D002" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_646584C8A0B249227C36378CF647D002_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_646584C8A0B249227C36378CF647D002" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_646584C8A0B249227C36378CF647D002" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_646584C8A0B249227C36378CF647D002" xlink:to="lab_dei_DocumentPeriodEndDate_646584C8A0B249227C36378CF647D002" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_5B552CA3799B04FDBC8F378CF648999E_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_5B552CA3799B04FDBC8F378CF648999E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_5B552CA3799B04FDBC8F378CF648999E_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_5B552CA3799B04FDBC8F378CF648999E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_5B552CA3799B04FDBC8F378CF648999E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_5B552CA3799B04FDBC8F378CF648999E" xlink:to="lab_dei_DocumentTransitionReport_5B552CA3799B04FDBC8F378CF648999E" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_C5976D16DC0441EB8798378CF648FD71_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_C5976D16DC0441EB8798378CF648FD71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_C5976D16DC0441EB8798378CF648FD71_label_en-US" xlink:label="lab_dei_EntityFileNumber_C5976D16DC0441EB8798378CF648FD71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_C5976D16DC0441EB8798378CF648FD71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_C5976D16DC0441EB8798378CF648FD71" xlink:to="lab_dei_EntityFileNumber_C5976D16DC0441EB8798378CF648FD71" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_C1A284BDBA9B214A882C378CF6480CA1_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_C1A284BDBA9B214A882C378CF6480CA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_C1A284BDBA9B214A882C378CF6480CA1_label_en-US" xlink:label="lab_dei_EntityRegistrantName_C1A284BDBA9B214A882C378CF6480CA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_C1A284BDBA9B214A882C378CF6480CA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_C1A284BDBA9B214A882C378CF6480CA1" xlink:to="lab_dei_EntityRegistrantName_C1A284BDBA9B214A882C378CF6480CA1" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_DF4B44190056986107F8378CF6486F81_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_DF4B44190056986107F8378CF6486F81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_DF4B44190056986107F8378CF6486F81_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_DF4B44190056986107F8378CF6486F81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_DF4B44190056986107F8378CF6486F81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_DF4B44190056986107F8378CF6486F81" xlink:to="lab_dei_EntityIncorporationStateCountryCode_DF4B44190056986107F8378CF6486F81" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_28E6224DE1DDA87CDADD378CF64848C5_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_28E6224DE1DDA87CDADD378CF64848C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_28E6224DE1DDA87CDADD378CF64848C5_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_28E6224DE1DDA87CDADD378CF64848C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_28E6224DE1DDA87CDADD378CF64848C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_28E6224DE1DDA87CDADD378CF64848C5" xlink:to="lab_dei_EntityTaxIdentificationNumber_28E6224DE1DDA87CDADD378CF64848C5" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_0CD0FB10244FD9B199C8378CF648C121_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_0CD0FB10244FD9B199C8378CF648C121" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_0CD0FB10244FD9B199C8378CF648C121_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_0CD0FB10244FD9B199C8378CF648C121" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_0CD0FB10244FD9B199C8378CF648C121" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_0CD0FB10244FD9B199C8378CF648C121" xlink:to="lab_dei_EntityAddressAddressLine1_0CD0FB10244FD9B199C8378CF648C121" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_3A481A7D89AF40B4AB16378CF649A317_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_3A481A7D89AF40B4AB16378CF649A317" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_3A481A7D89AF40B4AB16378CF649A317_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_3A481A7D89AF40B4AB16378CF649A317" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_3A481A7D89AF40B4AB16378CF649A317" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_3A481A7D89AF40B4AB16378CF649A317" xlink:to="lab_dei_EntityAddressCityOrTown_3A481A7D89AF40B4AB16378CF649A317" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_E0024BECB963893CCA4F378CF6494380_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_E0024BECB963893CCA4F378CF6494380" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_E0024BECB963893CCA4F378CF6494380_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_E0024BECB963893CCA4F378CF6494380" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_E0024BECB963893CCA4F378CF6494380" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_E0024BECB963893CCA4F378CF6494380" xlink:to="lab_dei_EntityAddressStateOrProvince_E0024BECB963893CCA4F378CF6494380" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_C3EFE3E8029B590B5303378CF64956B6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_C3EFE3E8029B590B5303378CF64956B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_C3EFE3E8029B590B5303378CF64956B6_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_C3EFE3E8029B590B5303378CF64956B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_C3EFE3E8029B590B5303378CF64956B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_C3EFE3E8029B590B5303378CF64956B6" xlink:to="lab_dei_EntityAddressPostalZipCode_C3EFE3E8029B590B5303378CF64956B6" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_AF3461CD6E3E04B54B16378CF649B710_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_AF3461CD6E3E04B54B16378CF649B710" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_AF3461CD6E3E04B54B16378CF649B710_label_en-US" xlink:label="lab_dei_CityAreaCode_AF3461CD6E3E04B54B16378CF649B710" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_AF3461CD6E3E04B54B16378CF649B710" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_AF3461CD6E3E04B54B16378CF649B710" xlink:to="lab_dei_CityAreaCode_AF3461CD6E3E04B54B16378CF649B710" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_C540963D56F50042ACAB378CF649D7F0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_C540963D56F50042ACAB378CF649D7F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_C540963D56F50042ACAB378CF649D7F0_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_C540963D56F50042ACAB378CF649D7F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_C540963D56F50042ACAB378CF649D7F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_C540963D56F50042ACAB378CF649D7F0" xlink:to="lab_dei_LocalPhoneNumber_C540963D56F50042ACAB378CF649D7F0" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_40E69B98F85593B4187B378CF6496DD3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_40E69B98F85593B4187B378CF6496DD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_40E69B98F85593B4187B378CF6496DD3_label_en-US" xlink:label="lab_dei_Security12bTitle_40E69B98F85593B4187B378CF6496DD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_40E69B98F85593B4187B378CF6496DD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_40E69B98F85593B4187B378CF6496DD3" xlink:to="lab_dei_Security12bTitle_40E69B98F85593B4187B378CF6496DD3" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_D81FEB5DD7B213FFABFD378CF64A0EB9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_D81FEB5DD7B213FFABFD378CF64A0EB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_D81FEB5DD7B213FFABFD378CF64A0EB9_label_en-US" xlink:label="lab_dei_TradingSymbol_D81FEB5DD7B213FFABFD378CF64A0EB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_D81FEB5DD7B213FFABFD378CF64A0EB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_D81FEB5DD7B213FFABFD378CF64A0EB9" xlink:to="lab_dei_TradingSymbol_D81FEB5DD7B213FFABFD378CF64A0EB9" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_1B2FE3ECB8F49BEF2984378CF64ADE71_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_1B2FE3ECB8F49BEF2984378CF64ADE71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_1B2FE3ECB8F49BEF2984378CF64ADE71_label_en-US" xlink:label="lab_dei_SecurityExchangeName_1B2FE3ECB8F49BEF2984378CF64ADE71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_1B2FE3ECB8F49BEF2984378CF64ADE71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_1B2FE3ECB8F49BEF2984378CF64ADE71" xlink:to="lab_dei_SecurityExchangeName_1B2FE3ECB8F49BEF2984378CF64ADE71" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_56B395048433D97D9A55378CF64A3274_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_56B395048433D97D9A55378CF64A3274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_56B395048433D97D9A55378CF64A3274_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_56B395048433D97D9A55378CF64A3274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_56B395048433D97D9A55378CF64A3274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_56B395048433D97D9A55378CF64A3274" xlink:to="lab_dei_EntityCurrentReportingStatus_56B395048433D97D9A55378CF64A3274" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_C2C475937E3925A03104378CF64A2D55_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_C2C475937E3925A03104378CF64A2D55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_C2C475937E3925A03104378CF64A2D55_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_C2C475937E3925A03104378CF64A2D55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_C2C475937E3925A03104378CF64A2D55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_C2C475937E3925A03104378CF64A2D55" xlink:to="lab_dei_EntityInteractiveDataCurrent_C2C475937E3925A03104378CF64A2D55" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_B37CA5F192B655C5FE2A378CF64A57D3_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_B37CA5F192B655C5FE2A378CF64A57D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_B37CA5F192B655C5FE2A378CF64A57D3_label_en-US" xlink:label="lab_dei_EntityFilerCategory_B37CA5F192B655C5FE2A378CF64A57D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_B37CA5F192B655C5FE2A378CF64A57D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_B37CA5F192B655C5FE2A378CF64A57D3" xlink:to="lab_dei_EntityFilerCategory_B37CA5F192B655C5FE2A378CF64A57D3" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_159E786F3B0064BABB0F378CF64AFB93_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_159E786F3B0064BABB0F378CF64AFB93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_159E786F3B0064BABB0F378CF64AFB93_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_159E786F3B0064BABB0F378CF64AFB93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_159E786F3B0064BABB0F378CF64AFB93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_159E786F3B0064BABB0F378CF64AFB93" xlink:to="lab_dei_EntitySmallBusiness_159E786F3B0064BABB0F378CF64AFB93" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8206823920B7940A3C2B378CF64A486D_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_8206823920B7940A3C2B378CF64A486D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8206823920B7940A3C2B378CF64A486D_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_8206823920B7940A3C2B378CF64A486D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_8206823920B7940A3C2B378CF64A486D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_8206823920B7940A3C2B378CF64A486D" xlink:to="lab_dei_EntityEmergingGrowthCompany_8206823920B7940A3C2B378CF64A486D" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_E64F799CEF874DFE6460378CF64BADB5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_E64F799CEF874DFE6460378CF64BADB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_E64F799CEF874DFE6460378CF64BADB5_label_en-US" xlink:label="lab_dei_EntityShellCompany_E64F799CEF874DFE6460378CF64BADB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_E64F799CEF874DFE6460378CF64BADB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_E64F799CEF874DFE6460378CF64BADB5" xlink:to="lab_dei_EntityShellCompany_E64F799CEF874DFE6460378CF64BADB5" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_F641CB10B18970CF24CF378CF64F456D_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_F641CB10B18970CF24CF378CF64F456D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_F641CB10B18970CF24CF378CF64F456D_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_F641CB10B18970CF24CF378CF64F456D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_F641CB10B18970CF24CF378CF64F456D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_F641CB10B18970CF24CF378CF64F456D" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_F641CB10B18970CF24CF378CF64F456D" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_D4C76A4F2960AFDF8E98378CF64F259E_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_D4C76A4F2960AFDF8E98378CF64F259E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_D4C76A4F2960AFDF8E98378CF64F259E_label_en-US" xlink:label="lab_dei_AmendmentFlag_D4C76A4F2960AFDF8E98378CF64F259E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_D4C76A4F2960AFDF8E98378CF64F259E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_D4C76A4F2960AFDF8E98378CF64F259E" xlink:to="lab_dei_AmendmentFlag_D4C76A4F2960AFDF8E98378CF64F259E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_220C1C4CF82F3DBB5E40378CF650D563_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_220C1C4CF82F3DBB5E40378CF650D563" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_220C1C4CF82F3DBB5E40378CF650D563_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_220C1C4CF82F3DBB5E40378CF650D563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_220C1C4CF82F3DBB5E40378CF650D563" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_220C1C4CF82F3DBB5E40378CF650D563" xlink:to="lab_dei_DocumentFiscalYearFocus_220C1C4CF82F3DBB5E40378CF650D563" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_11DDFB426FEC150F52D1378CF651FD59_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_11DDFB426FEC150F52D1378CF651FD59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_11DDFB426FEC150F52D1378CF651FD59_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_11DDFB426FEC150F52D1378CF651FD59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_11DDFB426FEC150F52D1378CF651FD59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_11DDFB426FEC150F52D1378CF651FD59" xlink:to="lab_dei_DocumentFiscalPeriodFocus_11DDFB426FEC150F52D1378CF651FD59" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_0F863D874ABD6B9CC420378CF6514616_verboseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_0F863D874ABD6B9CC420378CF6514616" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_0F863D874ABD6B9CC420378CF6514616_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_0F863D874ABD6B9CC420378CF6514616" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_0F863D874ABD6B9CC420378CF6514616" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_0F863D874ABD6B9CC420378CF6514616" xlink:to="lab_dei_EntityCentralIndexKey_0F863D874ABD6B9CC420378CF6514616" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_F4268A76F20AB6939BB0378CF651FE17_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_F4268A76F20AB6939BB0378CF651FE17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_F4268A76F20AB6939BB0378CF651FE17_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_F4268A76F20AB6939BB0378CF651FE17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_F4268A76F20AB6939BB0378CF651FE17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_F4268A76F20AB6939BB0378CF651FE17" xlink:to="lab_dei_CurrentFiscalYearEndDate_F4268A76F20AB6939BB0378CF651FE17" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_1529D54C5C5CBFF6A7AD1BB29EEF0EEA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_800A8D8176D75D4F860CB10B44A65ED6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_1529D54C5C5CBFF6A7AD1BB29EEF0EEA_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_800A8D8176D75D4F860CB10B44A65ED6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_800A8D8176D75D4F860CB10B44A65ED6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_800A8D8176D75D4F860CB10B44A65ED6" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_800A8D8176D75D4F860CB10B44A65ED6" xlink:type="arc" />
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F_terseLabel_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash And Investments In Marketable Securities [Table]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F_label_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Investments In Marketable Securities [Table]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F_documentation_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and Investments in Marketable Securities [Table]</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:to="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_8190C288BC89181AFB8B23E8D9D1156C_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_8190C288BC89181AFB8B23E8D9D1156C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_8190C288BC89181AFB8B23E8D9D1156C_label_en-US" xlink:label="lab_srt_RangeAxis_8190C288BC89181AFB8B23E8D9D1156C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_8190C288BC89181AFB8B23E8D9D1156C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_8190C288BC89181AFB8B23E8D9D1156C" xlink:to="lab_srt_RangeAxis_8190C288BC89181AFB8B23E8D9D1156C" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_7A0BE7B3B87AD16237FB23E8D9D1A068_terseLabel_en-US" xlink:label="lab_srt_RangeMember_7A0BE7B3B87AD16237FB23E8D9D1A068" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_7A0BE7B3B87AD16237FB23E8D9D1A068_label_en-US" xlink:label="lab_srt_RangeMember_7A0BE7B3B87AD16237FB23E8D9D1A068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_7A0BE7B3B87AD16237FB23E8D9D1A068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_7A0BE7B3B87AD16237FB23E8D9D1A068" xlink:to="lab_srt_RangeMember_7A0BE7B3B87AD16237FB23E8D9D1A068" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_9F78A9A835D1EFE726D523E8D9D26EB4_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_9F78A9A835D1EFE726D523E8D9D26EB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_9F78A9A835D1EFE726D523E8D9D26EB4_label_en-US" xlink:label="lab_srt_MinimumMember_9F78A9A835D1EFE726D523E8D9D26EB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9F78A9A835D1EFE726D523E8D9D26EB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_9F78A9A835D1EFE726D523E8D9D26EB4" xlink:to="lab_srt_MinimumMember_9F78A9A835D1EFE726D523E8D9D26EB4" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_C25D258CF026702E573A23E8D9D2AAC6_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_C25D258CF026702E573A23E8D9D2AAC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_C25D258CF026702E573A23E8D9D2AAC6_label_en-US" xlink:label="lab_srt_MaximumMember_C25D258CF026702E573A23E8D9D2AAC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_C25D258CF026702E573A23E8D9D2AAC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_C25D258CF026702E573A23E8D9D2AAC6" xlink:to="lab_srt_MaximumMember_C25D258CF026702E573A23E8D9D2AAC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_64DAC4A00A1E4876632F23E8D9D26149_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_64DAC4A00A1E4876632F23E8D9D26149" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_64DAC4A00A1E4876632F23E8D9D26149_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_64DAC4A00A1E4876632F23E8D9D26149" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_64DAC4A00A1E4876632F23E8D9D26149" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_64DAC4A00A1E4876632F23E8D9D26149" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_64DAC4A00A1E4876632F23E8D9D26149" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_80C31E842445DCABCF2023E8D9D2844D_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_80C31E842445DCABCF2023E8D9D2844D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_80C31E842445DCABCF2023E8D9D2844D_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_80C31E842445DCABCF2023E8D9D2844D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_80C31E842445DCABCF2023E8D9D2844D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_80C31E842445DCABCF2023E8D9D2844D" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_80C31E842445DCABCF2023E8D9D2844D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorNotesMember_EAD44DF971930F6549C923E8D9D21633_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_EAD44DF971930F6549C923E8D9D21633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_EAD44DF971930F6549C923E8D9D21633_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_EAD44DF971930F6549C923E8D9D21633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_EAD44DF971930F6549C923E8D9D21633" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember_EAD44DF971930F6549C923E8D9D21633" xlink:to="lab_us-gaap_SeniorNotesMember_EAD44DF971930F6549C923E8D9D21633" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_9E997F3B751E6C1142D923E8D9D3DB43_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_9E997F3B751E6C1142D923E8D9D3DB43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_9E997F3B751E6C1142D923E8D9D3DB43_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_9E997F3B751E6C1142D923E8D9D3DB43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9E997F3B751E6C1142D923E8D9D3DB43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_9E997F3B751E6C1142D923E8D9D3DB43" xlink:to="lab_us-gaap_DebtInstrumentAxis_9E997F3B751E6C1142D923E8D9D3DB43" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_75CBA2196986279A737623E8D9D3B813_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_75CBA2196986279A737623E8D9D3B813" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_75CBA2196986279A737623E8D9D3B813_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_75CBA2196986279A737623E8D9D3B813" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_75CBA2196986279A737623E8D9D3B813" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_75CBA2196986279A737623E8D9D3B813" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_75CBA2196986279A737623E8D9D3B813" xlink:type="arc" />
    <link:label id="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_36E3F02852D342A49F6623E8D9D377BD_terseLabel_en-US" xlink:label="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_36E3F02852D342A49F6623E8D9D377BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">7.75% Senior Secured Notes Due October 2020</link:label>
    <link:label id="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_36E3F02852D342A49F6623E8D9D377BD_label_en-US" xlink:label="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_36E3F02852D342A49F6623E8D9D377BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seven Point Seven Five Percent Senior Secured Notes Due October Two Thousand And Twenty [Member]</link:label>
    <link:label id="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_36E3F02852D342A49F6623E8D9D377BD_documentation_en-US" xlink:label="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_36E3F02852D342A49F6623E8D9D377BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Seven point seven five percent senior secured notes due October two thousand and twenty.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:label="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_36E3F02852D342A49F6623E8D9D377BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_36E3F02852D342A49F6623E8D9D377BD" xlink:to="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_36E3F02852D342A49F6623E8D9D377BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_EF1A1E10AB6E883510AC23E8D9D4E75C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_EF1A1E10AB6E883510AC23E8D9D4E75C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_EF1A1E10AB6E883510AC23E8D9D4E75C_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_EF1A1E10AB6E883510AC23E8D9D4E75C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_EF1A1E10AB6E883510AC23E8D9D4E75C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_EF1A1E10AB6E883510AC23E8D9D4E75C" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_EF1A1E10AB6E883510AC23E8D9D4E75C" xlink:type="arc" />
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC_terseLabel_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC_label_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Investments In Marketable Securities [Line Items]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC_documentation_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:type="arc" />
    <link:label id="lab_nktr_DebtInvestmentMaximumMaturityPeriod_A986E8A4AE1D4BA2B63623E8D9D5DB1C_terseLabel_en-US" xlink:label="lab_nktr_DebtInvestmentMaximumMaturityPeriod_A986E8A4AE1D4BA2B63623E8D9D5DB1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum maturity term for debt securities investment</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaximumMaturityPeriod_A986E8A4AE1D4BA2B63623E8D9D5DB1C_label_en-US" xlink:label="lab_nktr_DebtInvestmentMaximumMaturityPeriod_A986E8A4AE1D4BA2B63623E8D9D5DB1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Investment Maximum Maturity Period</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaximumMaturityPeriod_A986E8A4AE1D4BA2B63623E8D9D5DB1C_documentation_en-US" xlink:label="lab_nktr_DebtInvestmentMaximumMaturityPeriod_A986E8A4AE1D4BA2B63623E8D9D5DB1C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt investment maximum maturity period.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_DebtInvestmentMaximumMaturityPeriod" xlink:label="loc_nktr_DebtInvestmentMaximumMaturityPeriod_A986E8A4AE1D4BA2B63623E8D9D5DB1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DebtInvestmentMaximumMaturityPeriod_A986E8A4AE1D4BA2B63623E8D9D5DB1C" xlink:to="lab_nktr_DebtInvestmentMaximumMaturityPeriod_A986E8A4AE1D4BA2B63623E8D9D5DB1C" xlink:type="arc" />
    <link:label id="lab_nktr_DebtInvestmentMaturityTerm_273C7BB023BB4A4C8E5323E8D9D59FA3_terseLabel_en-US" xlink:label="lab_nktr_DebtInvestmentMaturityTerm_273C7BB023BB4A4C8E5323E8D9D59FA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average maturity term for debt securities investment (or less)</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaturityTerm_273C7BB023BB4A4C8E5323E8D9D59FA3_label_en-US" xlink:label="lab_nktr_DebtInvestmentMaturityTerm_273C7BB023BB4A4C8E5323E8D9D59FA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Investment Maturity Term</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaturityTerm_273C7BB023BB4A4C8E5323E8D9D59FA3_documentation_en-US" xlink:label="lab_nktr_DebtInvestmentMaturityTerm_273C7BB023BB4A4C8E5323E8D9D59FA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt investment maturity date description.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_DebtInvestmentMaturityTerm" xlink:label="loc_nktr_DebtInvestmentMaturityTerm_273C7BB023BB4A4C8E5323E8D9D59FA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DebtInvestmentMaturityTerm_273C7BB023BB4A4C8E5323E8D9D59FA3" xlink:to="lab_nktr_DebtInvestmentMaturityTerm_273C7BB023BB4A4C8E5323E8D9D59FA3" xlink:type="arc" />
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_45AAA984A09DD83C8D7B23E8D9D5EE06_terseLabel_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod_45AAA984A09DD83C8D7B23E8D9D5EE06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long term investment maturity period</link:label>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_45AAA984A09DD83C8D7B23E8D9D5EE06_label_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod_45AAA984A09DD83C8D7B23E8D9D5EE06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Investment Maturity Period</link:label>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_45AAA984A09DD83C8D7B23E8D9D5EE06_documentation_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod_45AAA984A09DD83C8D7B23E8D9D5EE06" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long term investment maturity period.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LongTermInvestmentMaturityPeriod" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_45AAA984A09DD83C8D7B23E8D9D5EE06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LongTermInvestmentMaturityPeriod_45AAA984A09DD83C8D7B23E8D9D5EE06" xlink:to="lab_nktr_LongTermInvestmentMaturityPeriod_45AAA984A09DD83C8D7B23E8D9D5EE06" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4322A3FF870345A5649D23E8D9D58D64_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4322A3FF870345A5649D23E8D9D58D64" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4322A3FF870345A5649D23E8D9D58D64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4322A3FF870345A5649D23E8D9D58D64" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4322A3FF870345A5649D23E8D9D58D64" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_2A43D0A897E7F2A2D07D23E8D9D5628C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_2A43D0A897E7F2A2D07D23E8D9D5628C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior secured notes, interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_2A43D0A897E7F2A2D07D23E8D9D5628C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_2A43D0A897E7F2A2D07D23E8D9D5628C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2A43D0A897E7F2A2D07D23E8D9D5628C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2A43D0A897E7F2A2D07D23E8D9D5628C" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_2A43D0A897E7F2A2D07D23E8D9D5628C" xlink:type="arc" />
    <link:label id="lab_nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained_CFD54470FE8192583A2823E8D9D65CB6_terseLabel_en-US" xlink:label="lab_nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained_CFD54470FE8192583A2823E8D9D65CB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum cash and investments in marketable securities to be maintained</link:label>
    <link:label id="lab_nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained_CFD54470FE8192583A2823E8D9D65CB6_label_en-US" xlink:label="lab_nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained_CFD54470FE8192583A2823E8D9D65CB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Cash And Investments In Marketable Securities To Be Maintained</link:label>
    <link:label id="lab_nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained_CFD54470FE8192583A2823E8D9D65CB6_documentation_en-US" xlink:label="lab_nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained_CFD54470FE8192583A2823E8D9D65CB6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum cash and investments in marketable securities to be maintained.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained" xlink:label="loc_nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained_CFD54470FE8192583A2823E8D9D65CB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained_CFD54470FE8192583A2823E8D9D65CB6" xlink:to="lab_nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained_CFD54470FE8192583A2823E8D9D65CB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_241DC0FA2EEE8AC5719023E8D9D6C96C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_241DC0FA2EEE8AC5719023E8D9D6C96C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1 to level 2 transfers</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_241DC0FA2EEE8AC5719023E8D9D6C96C_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_241DC0FA2EEE8AC5719023E8D9D6C96C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_241DC0FA2EEE8AC5719023E8D9D6C96C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_241DC0FA2EEE8AC5719023E8D9D6C96C" xlink:to="lab_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_241DC0FA2EEE8AC5719023E8D9D6C96C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_564D64CCB5442273334D23E8D9D68734_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_564D64CCB5442273334D23E8D9D68734" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2 to level 1 transfers</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_564D64CCB5442273334D23E8D9D68734_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_564D64CCB5442273334D23E8D9D68734" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_564D64CCB5442273334D23E8D9D68734" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_564D64CCB5442273334D23E8D9D68734" xlink:to="lab_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_564D64CCB5442273334D23E8D9D68734" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorNotes_CA70854F06D105F6621E23E8D9D6E7E8_verboseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotes_CA70854F06D105F6621E23E8D9D6E7E8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Senior secured notes, principal amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_CA70854F06D105F6621E23E8D9D6E7E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotes_CA70854F06D105F6621E23E8D9D6E7E8" xlink:to="lab_us-gaap_SeniorNotes_CA70854F06D105F6621E23E8D9D6E7E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_EC4FB48F771ADD545A6F23E8D9D66087_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_EC4FB48F771ADD545A6F23E8D9D66087" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior notes, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_EC4FB48F771ADD545A6F23E8D9D66087_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_EC4FB48F771ADD545A6F23E8D9D66087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_EC4FB48F771ADD545A6F23E8D9D66087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_EC4FB48F771ADD545A6F23E8D9D66087" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_EC4FB48F771ADD545A6F23E8D9D66087" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_2B2D9BAC4B4745CB635763C479E44057_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_3D5DFD9E3A975274BE34EC3E94431490" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_3D5DFD9E3A975274BE34EC3E94431490" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_3D5DFD9E3A975274BE34EC3E94431490" xlink:to="lab_us-gaap_IncomeStatementAbstract_3D5DFD9E3A975274BE34EC3E94431490" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_1BC4162942DF5ADA050763C479E74239_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_2A036958EAEA5162904ABCA2EF945433" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_1BC4162942DF5ADA050763C479E74239_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_2A036958EAEA5162904ABCA2EF945433" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2A036958EAEA5162904ABCA2EF945433" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_2A036958EAEA5162904ABCA2EF945433" xlink:to="lab_srt_ProductOrServiceAxis_2A036958EAEA5162904ABCA2EF945433" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_8D2E5CF377D602A98DAD63C479E700D2_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_10AF9F952A5A5A06902D8EA94D233396" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_8D2E5CF377D602A98DAD63C479E700D2_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_10AF9F952A5A5A06902D8EA94D233396" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_10AF9F952A5A5A06902D8EA94D233396" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_10AF9F952A5A5A06902D8EA94D233396" xlink:to="lab_srt_ProductsAndServicesDomain_10AF9F952A5A5A06902D8EA94D233396" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_165ED2A72140C46E044663C479E7DACC_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_1D4A9552E5E551BF98B5C55E83C1C823" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_165ED2A72140C46E044663C479E7DACC_label_en-US" xlink:label="lab_us-gaap_ProductMember_1D4A9552E5E551BF98B5C55E83C1C823" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_1D4A9552E5E551BF98B5C55E83C1C823" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_1D4A9552E5E551BF98B5C55E83C1C823" xlink:to="lab_us-gaap_ProductMember_1D4A9552E5E551BF98B5C55E83C1C823" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyMember_13A77C324F584CB4E9F963C479E9E849_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember_D6B58A0847525FE9AA6A9C37410478EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_13A77C324F584CB4E9F963C479E9E849_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember_D6B58A0847525FE9AA6A9C37410478EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_D6B58A0847525FE9AA6A9C37410478EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember_D6B58A0847525FE9AA6A9C37410478EE" xlink:to="lab_us-gaap_RoyaltyMember_D6B58A0847525FE9AA6A9C37410478EE" xlink:type="arc" />
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_B9F8D8186B380094E0AE63C479EA9A7B_terseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_8EA5AE0CFB865019B1CB01618DB26A59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_B9F8D8186B380094E0AE63C479EA9A7B_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_8EA5AE0CFB865019B1CB01618DB26A59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_B9F8D8186B380094E0AE63C479EA9A7B_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_8EA5AE0CFB865019B1CB01618DB26A59" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_8EA5AE0CFB865019B1CB01618DB26A59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_8EA5AE0CFB865019B1CB01618DB26A59" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_8EA5AE0CFB865019B1CB01618DB26A59" xlink:type="arc" />
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_C6B3BF09F0EAA2DDCB6163C479EA3877_terseLabel_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember_DC41128EE69956898E30AA8E0678F650" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, collaboration and other revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_C6B3BF09F0EAA2DDCB6163C479EA3877_label_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember_DC41128EE69956898E30AA8E0678F650" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Collaboration And Other Revenue [Member]</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_C6B3BF09F0EAA2DDCB6163C479EA3877_documentation_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember_DC41128EE69956898E30AA8E0678F650" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License collaboration and other revenue.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LicenseCollaborationAndOtherRevenueMember" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_DC41128EE69956898E30AA8E0678F650" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseCollaborationAndOtherRevenueMember_DC41128EE69956898E30AA8E0678F650" xlink:to="lab_nktr_LicenseCollaborationAndOtherRevenueMember_DC41128EE69956898E30AA8E0678F650" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_BF2F2F68C80646989D8063C479EADACC_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_6E0AF52A0A3F542C996F85637C63FD2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_BF2F2F68C80646989D8063C479EADACC_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_6E0AF52A0A3F542C996F85637C63FD2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_6E0AF52A0A3F542C996F85637C63FD2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_6E0AF52A0A3F542C996F85637C63FD2D" xlink:to="lab_us-gaap_RevenuesAbstract_6E0AF52A0A3F542C996F85637C63FD2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12F88A5C6865FC6F04CC63C479EABC95_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D8E4A552864A51A698A5758EBA1B22FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12F88A5C6865FC6F04CC63C479EABC95_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D8E4A552864A51A698A5758EBA1B22FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D8E4A552864A51A698A5758EBA1B22FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D8E4A552864A51A698A5758EBA1B22FF" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D8E4A552864A51A698A5758EBA1B22FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_CD988CD3FFB690A21F8563C479EB0666_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_FD57E25683765983A40F4DDFCF309891" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_CD988CD3FFB690A21F8563C479EB0666_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_FD57E25683765983A40F4DDFCF309891" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_FD57E25683765983A40F4DDFCF309891" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD57E25683765983A40F4DDFCF309891" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_FD57E25683765983A40F4DDFCF309891" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_CA4F5BCBFABB576E417063C479EBAAAE_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_E7A39F64C59C5F45ACD94BB82007F0DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_CA4F5BCBFABB576E417063C479EBAAAE_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_E7A39F64C59C5F45ACD94BB82007F0DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_E7A39F64C59C5F45ACD94BB82007F0DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_E7A39F64C59C5F45ACD94BB82007F0DE" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_E7A39F64C59C5F45ACD94BB82007F0DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_070CBD91F6E2F812049463C479EB7BF3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_FD39389C831F53509B32D58081C8AD1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_070CBD91F6E2F812049463C479EB7BF3_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_FD39389C831F53509B32D58081C8AD1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_FD39389C831F53509B32D58081C8AD1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_FD39389C831F53509B32D58081C8AD1A" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_FD39389C831F53509B32D58081C8AD1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_0641B6B249F2746BC44263C479EB8A3C_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_E131000894E359D79ED4A414B7F9E9FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_0641B6B249F2746BC44263C479EB8A3C_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_E131000894E359D79ED4A414B7F9E9FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_E131000894E359D79ED4A414B7F9E9FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_E131000894E359D79ED4A414B7F9E9FF" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_E131000894E359D79ED4A414B7F9E9FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_DFE4462E1526D15CC35D63C479EBB92F_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_52D536CB56265B54A6878D17C7DF906D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_DFE4462E1526D15CC35D63C479EBB92F_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_52D536CB56265B54A6878D17C7DF906D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_52D536CB56265B54A6878D17C7DF906D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_52D536CB56265B54A6878D17C7DF906D" xlink:to="lab_us-gaap_CostsAndExpenses_52D536CB56265B54A6878D17C7DF906D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3C12267052BE5C0881B663C479EB387D_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_E51F43ECAAD55055ABA1FAD77E318626" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3C12267052BE5C0881B663C479EB387D_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_E51F43ECAAD55055ABA1FAD77E318626" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_E51F43ECAAD55055ABA1FAD77E318626" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_E51F43ECAAD55055ABA1FAD77E318626" xlink:to="lab_us-gaap_OperatingIncomeLoss_E51F43ECAAD55055ABA1FAD77E318626" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_37DBD65033FBFBE2604F63C479EC026E_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_649DE37034F659B8B2274D8D377F5091" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-operating income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_37DBD65033FBFBE2604F63C479EC026E_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_649DE37034F659B8B2274D8D377F5091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_649DE37034F659B8B2274D8D377F5091" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_649DE37034F659B8B2274D8D377F5091" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_649DE37034F659B8B2274D8D377F5091" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_C6CAE03DAE8F82D5EA4563C479EC615D_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_36FFD95C4C355287803D89B478397ED3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_C6CAE03DAE8F82D5EA4563C479EC615D_label_en-US" xlink:label="lab_us-gaap_InterestExpense_36FFD95C4C355287803D89B478397ED3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_36FFD95C4C355287803D89B478397ED3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_36FFD95C4C355287803D89B478397ED3" xlink:to="lab_us-gaap_InterestExpense_36FFD95C4C355287803D89B478397ED3" xlink:type="arc" />
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_965DA0563B446E67481F63C479EC477F_negatedLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_162D21AD575F50BABB4F9AF0ACF5579A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense on liability related to sale of future royalties</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_162D21AD575F50BABB4F9AF0ACF5579A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_162D21AD575F50BABB4F9AF0ACF5579A" xlink:to="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_162D21AD575F50BABB4F9AF0ACF5579A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_920E5D710432F5AB089F63C479EC8179_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_E913B944A8FF5C7398F9CCE8E5A16ECE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income and other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_920E5D710432F5AB089F63C479EC8179_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_E913B944A8FF5C7398F9CCE8E5A16ECE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_E913B944A8FF5C7398F9CCE8E5A16ECE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_E913B944A8FF5C7398F9CCE8E5A16ECE" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_E913B944A8FF5C7398F9CCE8E5A16ECE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_FB26780E0FEA62E5C7C363C479EC8D46_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_AF90FBEEB9C85BF3829BF39CBD0A13F0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-operating income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_FB26780E0FEA62E5C7C363C479EC8D46_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_AF90FBEEB9C85BF3829BF39CBD0A13F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_AF90FBEEB9C85BF3829BF39CBD0A13F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_AF90FBEEB9C85BF3829BF39CBD0A13F0" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_AF90FBEEB9C85BF3829BF39CBD0A13F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_223BA24C7C28FA4426DE63C479ED6A8A_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1AF98EB0D65F57F18CB7D84EB54A2025" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_223BA24C7C28FA4426DE63C479ED6A8A_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1AF98EB0D65F57F18CB7D84EB54A2025" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1AF98EB0D65F57F18CB7D84EB54A2025" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1AF98EB0D65F57F18CB7D84EB54A2025" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1AF98EB0D65F57F18CB7D84EB54A2025" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_532EB079A49DC8B4058363C479EDB8BB_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_CCB61A512DDC5FEA90240DD0ABCB0D52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision (benefit) for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_532EB079A49DC8B4058363C479EDB8BB_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_CCB61A512DDC5FEA90240DD0ABCB0D52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_CCB61A512DDC5FEA90240DD0ABCB0D52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_CCB61A512DDC5FEA90240DD0ABCB0D52" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_CCB61A512DDC5FEA90240DD0ABCB0D52" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_E000ADC743B39A72088763C479ED60F7_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_A9246639E73B559EB7FC8436E9DBA858" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A9246639E73B559EB7FC8436E9DBA858" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_A9246639E73B559EB7FC8436E9DBA858" xlink:to="lab_us-gaap_NetIncomeLoss_A9246639E73B559EB7FC8436E9DBA858" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_EEE362D2832F39E2959863C479ED0FE7_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_2342D51E90A458CBA36D9DD8CDBEFA4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_EEE362D2832F39E2959863C479ED0FE7_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_2342D51E90A458CBA36D9DD8CDBEFA4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_2342D51E90A458CBA36D9DD8CDBEFA4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_2342D51E90A458CBA36D9DD8CDBEFA4D" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_2342D51E90A458CBA36D9DD8CDBEFA4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_C76D39CAF33B60DC628063C479ED9CFB_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_6118B14FC122583FA36712F3B085A3AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_C76D39CAF33B60DC628063C479ED9CFB_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_6118B14FC122583FA36712F3B085A3AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_6118B14FC122583FA36712F3B085A3AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_6118B14FC122583FA36712F3B085A3AE" xlink:to="lab_us-gaap_EarningsPerShareBasic_6118B14FC122583FA36712F3B085A3AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_259081E4BD8B0AE8FCD563C479EE87DF_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_277FB16BF07251239B3355A60D072AF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_259081E4BD8B0AE8FCD563C479EE87DF_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_277FB16BF07251239B3355A60D072AF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_277FB16BF07251239B3355A60D072AF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_277FB16BF07251239B3355A60D072AF9" xlink:to="lab_us-gaap_EarningsPerShareDiluted_277FB16BF07251239B3355A60D072AF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1952CE8111927B728B0463C479EEBCEF_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_02369FB4737F5BED92E3CDA0F8193D13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding used in computing net income (loss) per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1952CE8111927B728B0463C479EEBCEF_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_02369FB4737F5BED92E3CDA0F8193D13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_02369FB4737F5BED92E3CDA0F8193D13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_02369FB4737F5BED92E3CDA0F8193D13" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_02369FB4737F5BED92E3CDA0F8193D13" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F9FD05636612315C243963C479EEEF57_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1787353FEE5D56F2B5C4D3F24E4DF833" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F9FD05636612315C243963C479EEEF57_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1787353FEE5D56F2B5C4D3F24E4DF833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1787353FEE5D56F2B5C4D3F24E4DF833" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1787353FEE5D56F2B5C4D3F24E4DF833" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1787353FEE5D56F2B5C4D3F24E4DF833" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73835300093F3AA3483B63C479EE4E66_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_337AB3B54E715740973F5F594B8ACCA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_73835300093F3AA3483B63C479EE4E66_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_337AB3B54E715740973F5F594B8ACCA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_337AB3B54E715740973F5F594B8ACCA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_337AB3B54E715740973F5F594B8ACCA8" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_337AB3B54E715740973F5F594B8ACCA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0DDED6197A354238E30B1BB29E144F07_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_F411070828EB593A8E0FFB30BA997075" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0DDED6197A354238E30B1BB29E144F07_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_F411070828EB593A8E0FFB30BA997075" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_F411070828EB593A8E0FFB30BA997075" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_F411070828EB593A8E0FFB30BA997075" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_F411070828EB593A8E0FFB30BA997075" xlink:type="arc" />
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_DBA2BCF8A45543B7B3DB240DE8727F54_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract_DBA2BCF8A45543B7B3DB240DE8727F54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Abstract]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_DBA2BCF8A45543B7B3DB240DE8727F54_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract_DBA2BCF8A45543B7B3DB240DE8727F54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LicenseAndCollaborationAgreementsAbstract" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract_DBA2BCF8A45543B7B3DB240DE8727F54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract_DBA2BCF8A45543B7B3DB240DE8727F54" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsAbstract_DBA2BCF8A45543B7B3DB240DE8727F54" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_397E6B38CF89ACB8123A240DE8726478_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_397E6B38CF89ACB8123A240DE8726478" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_397E6B38CF89ACB8123A240DE8726478_label_en-US" xlink:label="lab_dei_LegalEntityAxis_397E6B38CF89ACB8123A240DE8726478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_397E6B38CF89ACB8123A240DE8726478" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_397E6B38CF89ACB8123A240DE8726478" xlink:to="lab_dei_LegalEntityAxis_397E6B38CF89ACB8123A240DE8726478" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882_label_en-US" xlink:label="lab_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:to="lab_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:type="arc" />
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_6291CECEBAA65A81AA2B240DE87363D6_terseLabel_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_6291CECEBAA65A81AA2B240DE87363D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Baxalta Incorporated/Takeda</link:label>
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_6291CECEBAA65A81AA2B240DE87363D6_label_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_6291CECEBAA65A81AA2B240DE87363D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Baxalta Incorporated Or Takeda P L C [Member]</link:label>
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_6291CECEBAA65A81AA2B240DE87363D6_documentation_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_6291CECEBAA65A81AA2B240DE87363D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Baxalta Incorporated or takeda PLC.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_6291CECEBAA65A81AA2B240DE87363D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_6291CECEBAA65A81AA2B240DE87363D6" xlink:to="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_6291CECEBAA65A81AA2B240DE87363D6" xlink:type="arc" />
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_9DFB3F050C85858672CF240DE873F17A_terseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember_9DFB3F050C85858672CF240DE873F17A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb Company</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_9DFB3F050C85858672CF240DE873F17A_label_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember_9DFB3F050C85858672CF240DE873F17A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bristol Myers Squibb Company [Member]</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_9DFB3F050C85858672CF240DE873F17A_documentation_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember_9DFB3F050C85858672CF240DE873F17A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb Company.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_BristolMyersSquibbCompanyMember" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_9DFB3F050C85858672CF240DE873F17A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BristolMyersSquibbCompanyMember_9DFB3F050C85858672CF240DE873F17A" xlink:to="lab_nktr_BristolMyersSquibbCompanyMember_9DFB3F050C85858672CF240DE873F17A" xlink:type="arc" />
    <link:label id="lab_nktr_EliLillyAndCompanyMember_8F891E727F8372BC2FEA240DE8732FEB_terseLabel_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember_8F891E727F8372BC2FEA240DE8732FEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eli Lilly and Company</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_8F891E727F8372BC2FEA240DE8732FEB_label_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember_8F891E727F8372BC2FEA240DE8732FEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eli Lilly And Company [Member]</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_8F891E727F8372BC2FEA240DE8732FEB_documentation_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember_8F891E727F8372BC2FEA240DE8732FEB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eli Lilly and Company.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_EliLillyAndCompanyMember" xlink:label="loc_nktr_EliLillyAndCompanyMember_8F891E727F8372BC2FEA240DE8732FEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyAndCompanyMember_8F891E727F8372BC2FEA240DE8732FEB" xlink:to="lab_nktr_EliLillyAndCompanyMember_8F891E727F8372BC2FEA240DE8732FEB" xlink:type="arc" />
    <link:label id="lab_nktr_EliLillyMember_8A33A80393F9424E53D6240DE8732535_terseLabel_en-US" xlink:label="lab_nktr_EliLillyMember_8A33A80393F9424E53D6240DE8732535" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eli Lilly</link:label>
    <link:label id="lab_nktr_EliLillyMember_8A33A80393F9424E53D6240DE8732535_label_en-US" xlink:label="lab_nktr_EliLillyMember_8A33A80393F9424E53D6240DE8732535" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eli Lilly [Member]</link:label>
    <link:label id="lab_nktr_EliLillyMember_8A33A80393F9424E53D6240DE8732535_documentation_en-US" xlink:label="lab_nktr_EliLillyMember_8A33A80393F9424E53D6240DE8732535" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eli Lilly.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_EliLillyMember" xlink:label="loc_nktr_EliLillyMember_8A33A80393F9424E53D6240DE8732535" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyMember_8A33A80393F9424E53D6240DE8732535" xlink:to="lab_nktr_EliLillyMember_8A33A80393F9424E53D6240DE8732535" xlink:type="arc" />
    <link:label id="lab_nktr_AmgenIncMember_5363D8F1BE0B28C4183B240DE874DD68_terseLabel_en-US" xlink:label="lab_nktr_AmgenIncMember_5363D8F1BE0B28C4183B240DE874DD68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amgen, Inc.</link:label>
    <link:label id="lab_nktr_AmgenIncMember_5363D8F1BE0B28C4183B240DE874DD68_label_en-US" xlink:label="lab_nktr_AmgenIncMember_5363D8F1BE0B28C4183B240DE874DD68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amgen Inc [Member]</link:label>
    <link:label id="lab_nktr_AmgenIncMember_5363D8F1BE0B28C4183B240DE874DD68_documentation_en-US" xlink:label="lab_nktr_AmgenIncMember_5363D8F1BE0B28C4183B240DE874DD68" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amgen Inc.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AmgenIncMember" xlink:label="loc_nktr_AmgenIncMember_5363D8F1BE0B28C4183B240DE874DD68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AmgenIncMember_5363D8F1BE0B28C4183B240DE874DD68" xlink:to="lab_nktr_AmgenIncMember_5363D8F1BE0B28C4183B240DE874DD68" xlink:type="arc" />
    <link:label id="lab_nktr_AstraZenecaAbMember_02406795D7E9A1251FC4240DE874D749_terseLabel_en-US" xlink:label="lab_nktr_AstraZenecaAbMember_02406795D7E9A1251FC4240DE874D749" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AstraZeneca AB</link:label>
    <link:label id="lab_nktr_AstraZenecaAbMember_02406795D7E9A1251FC4240DE874D749_label_en-US" xlink:label="lab_nktr_AstraZenecaAbMember_02406795D7E9A1251FC4240DE874D749" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Astra Zeneca Ab [Member]</link:label>
    <link:label id="lab_nktr_AstraZenecaAbMember_02406795D7E9A1251FC4240DE874D749_documentation_en-US" xlink:label="lab_nktr_AstraZenecaAbMember_02406795D7E9A1251FC4240DE874D749" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AstraZeneca AB.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AstraZenecaAbMember" xlink:label="loc_nktr_AstraZenecaAbMember_02406795D7E9A1251FC4240DE874D749" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AstraZenecaAbMember_02406795D7E9A1251FC4240DE874D749" xlink:to="lab_nktr_AstraZenecaAbMember_02406795D7E9A1251FC4240DE874D749" xlink:type="arc" />
    <link:label id="lab_nktr_OtherPartnerMember_6764A4830985DF7B3434240DE8748B83_terseLabel_en-US" xlink:label="lab_nktr_OtherPartnerMember_6764A4830985DF7B3434240DE8748B83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Baxalta Inc. / Takeda Pharmaceutical Company Ltd. and other</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_6764A4830985DF7B3434240DE8748B83_label_en-US" xlink:label="lab_nktr_OtherPartnerMember_6764A4830985DF7B3434240DE8748B83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Partner [Member]</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_6764A4830985DF7B3434240DE8748B83_documentation_en-US" xlink:label="lab_nktr_OtherPartnerMember_6764A4830985DF7B3434240DE8748B83" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OtherPartnerMember" xlink:label="loc_nktr_OtherPartnerMember_6764A4830985DF7B3434240DE8748B83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OtherPartnerMember_6764A4830985DF7B3434240DE8748B83" xlink:to="lab_nktr_OtherPartnerMember_6764A4830985DF7B3434240DE8748B83" xlink:type="arc" />
    <link:label id="lab_nktr_HemophiliaMember_0549D893244EBB27DABA240DE875BCD0_terseLabel_en-US" xlink:label="lab_nktr_HemophiliaMember_0549D893244EBB27DABA240DE875BCD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hemophilia</link:label>
    <link:label id="lab_nktr_HemophiliaMember_0549D893244EBB27DABA240DE875BCD0_label_en-US" xlink:label="lab_nktr_HemophiliaMember_0549D893244EBB27DABA240DE875BCD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hemophilia [Member]</link:label>
    <link:label id="lab_nktr_HemophiliaMember_0549D893244EBB27DABA240DE875BCD0_documentation_en-US" xlink:label="lab_nktr_HemophiliaMember_0549D893244EBB27DABA240DE875BCD0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hemophilia.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_HemophiliaMember" xlink:label="loc_nktr_HemophiliaMember_0549D893244EBB27DABA240DE875BCD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_HemophiliaMember_0549D893244EBB27DABA240DE875BCD0" xlink:to="lab_nktr_HemophiliaMember_0549D893244EBB27DABA240DE875BCD0" xlink:type="arc" />
    <link:label id="lab_nktr_BMSCollaborationAgreementMember_DDBAD6FF5B6C69CC9BC2240DE875FA5A_terseLabel_en-US" xlink:label="lab_nktr_BMSCollaborationAgreementMember_DDBAD6FF5B6C69CC9BC2240DE875FA5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BMS Collaboration Agreement</link:label>
    <link:label id="lab_nktr_BMSCollaborationAgreementMember_DDBAD6FF5B6C69CC9BC2240DE875FA5A_label_en-US" xlink:label="lab_nktr_BMSCollaborationAgreementMember_DDBAD6FF5B6C69CC9BC2240DE875FA5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">B M S Collaboration Agreement [Member]</link:label>
    <link:label id="lab_nktr_BMSCollaborationAgreementMember_DDBAD6FF5B6C69CC9BC2240DE875FA5A_documentation_en-US" xlink:label="lab_nktr_BMSCollaborationAgreementMember_DDBAD6FF5B6C69CC9BC2240DE875FA5A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BMS collaboration agreement.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_BMSCollaborationAgreementMember" xlink:label="loc_nktr_BMSCollaborationAgreementMember_DDBAD6FF5B6C69CC9BC2240DE875FA5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BMSCollaborationAgreementMember_DDBAD6FF5B6C69CC9BC2240DE875FA5A" xlink:to="lab_nktr_BMSCollaborationAgreementMember_DDBAD6FF5B6C69CC9BC2240DE875FA5A" xlink:type="arc" />
    <link:label id="lab_nktr_ClinicalTrialAgreementMember_E2277BADC346DF62A033240DE875E220_terseLabel_en-US" xlink:label="lab_nktr_ClinicalTrialAgreementMember_E2277BADC346DF62A033240DE875E220" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Trial Agreement</link:label>
    <link:label id="lab_nktr_ClinicalTrialAgreementMember_E2277BADC346DF62A033240DE875E220_label_en-US" xlink:label="lab_nktr_ClinicalTrialAgreementMember_E2277BADC346DF62A033240DE875E220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trial Agreement [Member]</link:label>
    <link:label id="lab_nktr_ClinicalTrialAgreementMember_E2277BADC346DF62A033240DE875E220_documentation_en-US" xlink:label="lab_nktr_ClinicalTrialAgreementMember_E2277BADC346DF62A033240DE875E220" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical trial agreement.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ClinicalTrialAgreementMember" xlink:label="loc_nktr_ClinicalTrialAgreementMember_E2277BADC346DF62A033240DE875E220" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ClinicalTrialAgreementMember_E2277BADC346DF62A033240DE875E220" xlink:to="lab_nktr_ClinicalTrialAgreementMember_E2277BADC346DF62A033240DE875E220" xlink:type="arc" />
    <link:label id="lab_nktr_NektarThreeFiveEightMember_EF2EF49B3BB01A1CAA69240DE8758D83_terseLabel_en-US" xlink:label="lab_nktr_NektarThreeFiveEightMember_EF2EF49B3BB01A1CAA69240DE8758D83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NKTR-358</link:label>
    <link:label id="lab_nktr_NektarThreeFiveEightMember_EF2EF49B3BB01A1CAA69240DE8758D83_label_en-US" xlink:label="lab_nktr_NektarThreeFiveEightMember_EF2EF49B3BB01A1CAA69240DE8758D83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nektar Three Five Eight [Member]</link:label>
    <link:label id="lab_nktr_NektarThreeFiveEightMember_EF2EF49B3BB01A1CAA69240DE8758D83_documentation_en-US" xlink:label="lab_nktr_NektarThreeFiveEightMember_EF2EF49B3BB01A1CAA69240DE8758D83" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nektar three five eight.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NektarThreeFiveEightMember" xlink:label="loc_nktr_NektarThreeFiveEightMember_EF2EF49B3BB01A1CAA69240DE8758D83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NektarThreeFiveEightMember_EF2EF49B3BB01A1CAA69240DE8758D83" xlink:to="lab_nktr_NektarThreeFiveEightMember_EF2EF49B3BB01A1CAA69240DE8758D83" xlink:type="arc" />
    <link:label id="lab_nktr_PhaseOneClinicalDevelopmentMember_360AED5278179C31DDF3240DE8768B1A_terseLabel_en-US" xlink:label="lab_nktr_PhaseOneClinicalDevelopmentMember_360AED5278179C31DDF3240DE8768B1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phase 1 Clinical Development</link:label>
    <link:label id="lab_nktr_PhaseOneClinicalDevelopmentMember_360AED5278179C31DDF3240DE8768B1A_label_en-US" xlink:label="lab_nktr_PhaseOneClinicalDevelopmentMember_360AED5278179C31DDF3240DE8768B1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phase One Clinical Development [Member]</link:label>
    <link:label id="lab_nktr_PhaseOneClinicalDevelopmentMember_360AED5278179C31DDF3240DE8768B1A_documentation_en-US" xlink:label="lab_nktr_PhaseOneClinicalDevelopmentMember_360AED5278179C31DDF3240DE8768B1A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phase 1 clinical development.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PhaseOneClinicalDevelopmentMember" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_360AED5278179C31DDF3240DE8768B1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PhaseOneClinicalDevelopmentMember_360AED5278179C31DDF3240DE8768B1A" xlink:to="lab_nktr_PhaseOneClinicalDevelopmentMember_360AED5278179C31DDF3240DE8768B1A" xlink:type="arc" />
    <link:label id="lab_nktr_DrugProductDevelopmentMember_7CCCC632A5CAC9F3B483240DE876275E_terseLabel_en-US" xlink:label="lab_nktr_DrugProductDevelopmentMember_7CCCC632A5CAC9F3B483240DE876275E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Drug Product Development</link:label>
    <link:label id="lab_nktr_DrugProductDevelopmentMember_7CCCC632A5CAC9F3B483240DE876275E_label_en-US" xlink:label="lab_nktr_DrugProductDevelopmentMember_7CCCC632A5CAC9F3B483240DE876275E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Drug Product Development [Member]</link:label>
    <link:label id="lab_nktr_DrugProductDevelopmentMember_7CCCC632A5CAC9F3B483240DE876275E_documentation_en-US" xlink:label="lab_nktr_DrugProductDevelopmentMember_7CCCC632A5CAC9F3B483240DE876275E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Drug product development.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_DrugProductDevelopmentMember" xlink:label="loc_nktr_DrugProductDevelopmentMember_7CCCC632A5CAC9F3B483240DE876275E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DrugProductDevelopmentMember_7CCCC632A5CAC9F3B483240DE876275E" xlink:to="lab_nktr_DrugProductDevelopmentMember_7CCCC632A5CAC9F3B483240DE876275E" xlink:type="arc" />
    <link:label id="lab_nktr_MOVANTIKAndMOVENTIGMember_DE5D9A0E7A9A3A3CCAA3240DE876CBB9_terseLabel_en-US" xlink:label="lab_nktr_MOVANTIKAndMOVENTIGMember_DE5D9A0E7A9A3A3CCAA3240DE876CBB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MOVANTIK and MOVENTIG</link:label>
    <link:label id="lab_nktr_MOVANTIKAndMOVENTIGMember_DE5D9A0E7A9A3A3CCAA3240DE876CBB9_label_en-US" xlink:label="lab_nktr_MOVANTIKAndMOVENTIGMember_DE5D9A0E7A9A3A3CCAA3240DE876CBB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">M O V A N T I K And M O V E N T I G [Member]</link:label>
    <link:label id="lab_nktr_MOVANTIKAndMOVENTIGMember_DE5D9A0E7A9A3A3CCAA3240DE876CBB9_documentation_en-US" xlink:label="lab_nktr_MOVANTIKAndMOVENTIGMember_DE5D9A0E7A9A3A3CCAA3240DE876CBB9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MOVANTIK and MOVENTIG.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_MOVANTIKAndMOVENTIGMember" xlink:label="loc_nktr_MOVANTIKAndMOVENTIGMember_DE5D9A0E7A9A3A3CCAA3240DE876CBB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MOVANTIKAndMOVENTIGMember_DE5D9A0E7A9A3A3CCAA3240DE876CBB9" xlink:to="lab_nktr_MOVANTIKAndMOVENTIGMember_DE5D9A0E7A9A3A3CCAA3240DE876CBB9" xlink:type="arc" />
    <link:label id="lab_nktr_AstraZenecaAgreementWithKirinMember_8020127879189B711ADD240DE876B323_terseLabel_en-US" xlink:label="lab_nktr_AstraZenecaAgreementWithKirinMember_8020127879189B711ADD240DE876B323" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AstraZeneca-Kirin</link:label>
    <link:label id="lab_nktr_AstraZenecaAgreementWithKirinMember_8020127879189B711ADD240DE876B323_label_en-US" xlink:label="lab_nktr_AstraZenecaAgreementWithKirinMember_8020127879189B711ADD240DE876B323" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Astra Zeneca Agreement With Kirin [Member]</link:label>
    <link:label id="lab_nktr_AstraZenecaAgreementWithKirinMember_8020127879189B711ADD240DE876B323_documentation_en-US" xlink:label="lab_nktr_AstraZenecaAgreementWithKirinMember_8020127879189B711ADD240DE876B323" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AstraZeneca agreement with Kirin.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AstraZenecaAgreementWithKirinMember" xlink:label="loc_nktr_AstraZenecaAgreementWithKirinMember_8020127879189B711ADD240DE876B323" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AstraZenecaAgreementWithKirinMember_8020127879189B711ADD240DE876B323" xlink:to="lab_nktr_AstraZenecaAgreementWithKirinMember_8020127879189B711ADD240DE876B323" xlink:type="arc" />
    <link:label id="lab_nktr_NektarMember_34CC8717FC84A52F2FEC240DE876DC29_terseLabel_en-US" xlink:label="lab_nktr_NektarMember_34CC8717FC84A52F2FEC240DE876DC29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nektar</link:label>
    <link:label id="lab_nktr_NektarMember_34CC8717FC84A52F2FEC240DE876DC29_label_en-US" xlink:label="lab_nktr_NektarMember_34CC8717FC84A52F2FEC240DE876DC29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nektar [Member]</link:label>
    <link:label id="lab_nktr_NektarMember_34CC8717FC84A52F2FEC240DE876DC29_documentation_en-US" xlink:label="lab_nktr_NektarMember_34CC8717FC84A52F2FEC240DE876DC29" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nektar [Member]</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NektarMember" xlink:label="loc_nktr_NektarMember_34CC8717FC84A52F2FEC240DE876DC29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NektarMember_34CC8717FC84A52F2FEC240DE876DC29" xlink:to="lab_nktr_NektarMember_34CC8717FC84A52F2FEC240DE876DC29" xlink:type="arc" />
    <link:label id="lab_us-gaap_EuropeanUnionMember_989EB8136EA244DC26AD240DE8779E26_terseLabel_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember_989EB8136EA244DC26AD240DE8779E26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">European Union</link:label>
    <link:label id="lab_us-gaap_EuropeanUnionMember_989EB8136EA244DC26AD240DE8779E26_label_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember_989EB8136EA244DC26AD240DE8779E26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">European Union [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_989EB8136EA244DC26AD240DE8779E26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeanUnionMember_989EB8136EA244DC26AD240DE8779E26" xlink:to="lab_us-gaap_EuropeanUnionMember_989EB8136EA244DC26AD240DE8779E26" xlink:type="arc" />
    <link:label id="lab_nktr_NektarTwoOneFourMember_E6580671CCD95B959A1E240DE87874A0_terseLabel_en-US" xlink:label="lab_nktr_NektarTwoOneFourMember_E6580671CCD95B959A1E240DE87874A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NKTR-214</link:label>
    <link:label id="lab_nktr_NektarTwoOneFourMember_E6580671CCD95B959A1E240DE87874A0_label_en-US" xlink:label="lab_nktr_NektarTwoOneFourMember_E6580671CCD95B959A1E240DE87874A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nektar Two One Four [Member]</link:label>
    <link:label id="lab_nktr_NektarTwoOneFourMember_E6580671CCD95B959A1E240DE87874A0_documentation_en-US" xlink:label="lab_nktr_NektarTwoOneFourMember_E6580671CCD95B959A1E240DE87874A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nektar two one four.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NektarTwoOneFourMember" xlink:label="loc_nktr_NektarTwoOneFourMember_E6580671CCD95B959A1E240DE87874A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NektarTwoOneFourMember_E6580671CCD95B959A1E240DE87874A0" xlink:to="lab_nktr_NektarTwoOneFourMember_E6580671CCD95B959A1E240DE87874A0" xlink:type="arc" />
    <link:label id="lab_nktr_NektarThreeFiveEightLicenseMember_00933A0E6E561A79C211240DE87836E3_terseLabel_en-US" xlink:label="lab_nktr_NektarThreeFiveEightLicenseMember_00933A0E6E561A79C211240DE87836E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NKTR-358 License</link:label>
    <link:label id="lab_nktr_NektarThreeFiveEightLicenseMember_00933A0E6E561A79C211240DE87836E3_label_en-US" xlink:label="lab_nktr_NektarThreeFiveEightLicenseMember_00933A0E6E561A79C211240DE87836E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nektar Three Five Eight License [Member]</link:label>
    <link:label id="lab_nktr_NektarThreeFiveEightLicenseMember_00933A0E6E561A79C211240DE87836E3_documentation_en-US" xlink:label="lab_nktr_NektarThreeFiveEightLicenseMember_00933A0E6E561A79C211240DE87836E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nektar three five eight license.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NektarThreeFiveEightLicenseMember" xlink:label="loc_nktr_NektarThreeFiveEightLicenseMember_00933A0E6E561A79C211240DE87836E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NektarThreeFiveEightLicenseMember_00933A0E6E561A79C211240DE87836E3" xlink:to="lab_nktr_NektarThreeFiveEightLicenseMember_00933A0E6E561A79C211240DE87836E3" xlink:type="arc" />
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_AFD0B26557058927F051240DE878BF1A_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis_AFD0B26557058927F051240DE878BF1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_AFD0B26557058927F051240DE878BF1A_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis_AFD0B26557058927F051240DE878BF1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_AFD0B26557058927F051240DE878BF1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis_AFD0B26557058927F051240DE878BF1A" xlink:to="lab_srt_ConsolidatedEntitiesAxis_AFD0B26557058927F051240DE878BF1A" xlink:type="arc" />
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_B7B8C7034CCDAF7DFAA3240DE878F02D_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain_B7B8C7034CCDAF7DFAA3240DE878F02D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_B7B8C7034CCDAF7DFAA3240DE878F02D_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain_B7B8C7034CCDAF7DFAA3240DE878F02D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_B7B8C7034CCDAF7DFAA3240DE878F02D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain_B7B8C7034CCDAF7DFAA3240DE878F02D" xlink:to="lab_srt_ConsolidatedEntitiesDomain_B7B8C7034CCDAF7DFAA3240DE878F02D" xlink:type="arc" />
    <link:label id="lab_srt_ParentCompanyMember_A120878CDC8738704729240DE8793C3A_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember_A120878CDC8738704729240DE8793C3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nektar's</link:label>
    <link:label id="lab_srt_ParentCompanyMember_A120878CDC8738704729240DE8793C3A_label_en-US" xlink:label="lab_srt_ParentCompanyMember_A120878CDC8738704729240DE8793C3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ParentCompanyMember" xlink:label="loc_srt_ParentCompanyMember_A120878CDC8738704729240DE8793C3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember_A120878CDC8738704729240DE8793C3A" xlink:to="lab_srt_ParentCompanyMember_A120878CDC8738704729240DE8793C3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_246716A12EF89B4FE888240DE879AF75_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_246716A12EF89B4FE888240DE879AF75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_246716A12EF89B4FE888240DE879AF75_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_246716A12EF89B4FE888240DE879AF75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_246716A12EF89B4FE888240DE879AF75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_246716A12EF89B4FE888240DE879AF75" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_246716A12EF89B4FE888240DE879AF75" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10CA257573A0B63ABB10240DE879670A_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10CA257573A0B63ABB10240DE879670A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10CA257573A0B63ABB10240DE879670A_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10CA257573A0B63ABB10240DE879670A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10CA257573A0B63ABB10240DE879670A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10CA257573A0B63ABB10240DE879670A" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10CA257573A0B63ABB10240DE879670A" xlink:type="arc" />
    <link:label id="lab_nktr_OpdivoMember_D05E10C1E0BCAB56A672240DE8795470_terseLabel_en-US" xlink:label="lab_nktr_OpdivoMember_D05E10C1E0BCAB56A672240DE8795470" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Opdivo</link:label>
    <link:label id="lab_nktr_OpdivoMember_D05E10C1E0BCAB56A672240DE8795470_label_en-US" xlink:label="lab_nktr_OpdivoMember_D05E10C1E0BCAB56A672240DE8795470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Opdivo [Member]</link:label>
    <link:label id="lab_nktr_OpdivoMember_D05E10C1E0BCAB56A672240DE8795470_documentation_en-US" xlink:label="lab_nktr_OpdivoMember_D05E10C1E0BCAB56A672240DE8795470" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Opdivo.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OpdivoMember" xlink:label="loc_nktr_OpdivoMember_D05E10C1E0BCAB56A672240DE8795470" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OpdivoMember_D05E10C1E0BCAB56A672240DE8795470" xlink:to="lab_nktr_OpdivoMember_D05E10C1E0BCAB56A672240DE8795470" xlink:type="arc" />
    <link:label id="lab_nktr_OpdivoAndYervoyMember_D0A252CBF8ED910D5C79240DE8798006_terseLabel_en-US" xlink:label="lab_nktr_OpdivoAndYervoyMember_D0A252CBF8ED910D5C79240DE8798006" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Opdivo and Yervoy</link:label>
    <link:label id="lab_nktr_OpdivoAndYervoyMember_D0A252CBF8ED910D5C79240DE8798006_label_en-US" xlink:label="lab_nktr_OpdivoAndYervoyMember_D0A252CBF8ED910D5C79240DE8798006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Opdivo And Yervoy [Member]</link:label>
    <link:label id="lab_nktr_OpdivoAndYervoyMember_D0A252CBF8ED910D5C79240DE8798006_documentation_en-US" xlink:label="lab_nktr_OpdivoAndYervoyMember_D0A252CBF8ED910D5C79240DE8798006" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Opdivo and yervoy.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OpdivoAndYervoyMember" xlink:label="loc_nktr_OpdivoAndYervoyMember_D0A252CBF8ED910D5C79240DE8798006" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OpdivoAndYervoyMember_D0A252CBF8ED910D5C79240DE8798006" xlink:to="lab_nktr_OpdivoAndYervoyMember_D0A252CBF8ED910D5C79240DE8798006" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_EC4258FED493CAFEE22B240DE87BA3FF_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_EC4258FED493CAFEE22B240DE87BA3FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_EC4258FED493CAFEE22B240DE87BA3FF_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_EC4258FED493CAFEE22B240DE87BA3FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_EC4258FED493CAFEE22B240DE87BA3FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_EC4258FED493CAFEE22B240DE87BA3FF" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_EC4258FED493CAFEE22B240DE87BA3FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_58EC923DA2FED0EE633F240DE87B1D02_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_58EC923DA2FED0EE633F240DE87B1D02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_58EC923DA2FED0EE633F240DE87B1D02_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_58EC923DA2FED0EE633F240DE87B1D02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58EC923DA2FED0EE633F240DE87B1D02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58EC923DA2FED0EE633F240DE87B1D02" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_58EC923DA2FED0EE633F240DE87B1D02" xlink:type="arc" />
    <link:label id="lab_nktr_SharePurchaseAgreementMember_9685DAB7E7773485C3C1240DE87B695F_terseLabel_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember_9685DAB7E7773485C3C1240DE87B695F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_9685DAB7E7773485C3C1240DE87B695F_label_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember_9685DAB7E7773485C3C1240DE87B695F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_9685DAB7E7773485C3C1240DE87B695F_documentation_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember_9685DAB7E7773485C3C1240DE87B695F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share purchase agreement.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_SharePurchaseAgreementMember" xlink:label="loc_nktr_SharePurchaseAgreementMember_9685DAB7E7773485C3C1240DE87B695F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SharePurchaseAgreementMember_9685DAB7E7773485C3C1240DE87B695F" xlink:to="lab_nktr_SharePurchaseAgreementMember_9685DAB7E7773485C3C1240DE87B695F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1B7E70A7C05984BCD9EC240DE87C57E3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1B7E70A7C05984BCD9EC240DE87C57E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1B7E70A7C05984BCD9EC240DE87C57E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1B7E70A7C05984BCD9EC240DE87C57E3" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1B7E70A7C05984BCD9EC240DE87C57E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_6499D1A865B2EDB8719C240DE87C4CA1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_6499D1A865B2EDB8719C240DE87C4CA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASC 606</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_6499D1A865B2EDB8719C240DE87C4CA1_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_6499D1A865B2EDB8719C240DE87C4CA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_6499D1A865B2EDB8719C240DE87C4CA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member_6499D1A865B2EDB8719C240DE87C4CA1" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member_6499D1A865B2EDB8719C240DE87C4CA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_C8DD08FD5057ED6C0FA6240DE87D2797_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis_C8DD08FD5057ED6C0FA6240DE87D2797" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Sales Channel</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_C8DD08FD5057ED6C0FA6240DE87D2797_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis_C8DD08FD5057ED6C0FA6240DE87D2797" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Sales Channel [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelAxis" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_C8DD08FD5057ED6C0FA6240DE87D2797" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_C8DD08FD5057ED6C0FA6240DE87D2797" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelAxis_C8DD08FD5057ED6C0FA6240DE87D2797" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_909B6BA32EB1C837B8D6240DE87D8E87_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain_909B6BA32EB1C837B8D6240DE87D8E87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Sales Channel</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_909B6BA32EB1C837B8D6240DE87D8E87_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain_909B6BA32EB1C837B8D6240DE87D8E87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Sales Channel [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_909B6BA32EB1C837B8D6240DE87D8E87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_909B6BA32EB1C837B8D6240DE87D8E87" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelDomain_909B6BA32EB1C837B8D6240DE87D8E87" xlink:type="arc" />
    <link:label id="lab_nktr_AnnualSalesLevelMilestoneMember_0D697836DE9B89B4F0D7240DE87DBCA6_terseLabel_en-US" xlink:label="lab_nktr_AnnualSalesLevelMilestoneMember_0D697836DE9B89B4F0D7240DE87DBCA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Sales Level Milestone</link:label>
    <link:label id="lab_nktr_AnnualSalesLevelMilestoneMember_0D697836DE9B89B4F0D7240DE87DBCA6_label_en-US" xlink:label="lab_nktr_AnnualSalesLevelMilestoneMember_0D697836DE9B89B4F0D7240DE87DBCA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Sales Level Milestone [Member]</link:label>
    <link:label id="lab_nktr_AnnualSalesLevelMilestoneMember_0D697836DE9B89B4F0D7240DE87DBCA6_documentation_en-US" xlink:label="lab_nktr_AnnualSalesLevelMilestoneMember_0D697836DE9B89B4F0D7240DE87DBCA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual sales level milestone.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AnnualSalesLevelMilestoneMember" xlink:label="loc_nktr_AnnualSalesLevelMilestoneMember_0D697836DE9B89B4F0D7240DE87DBCA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AnnualSalesLevelMilestoneMember_0D697836DE9B89B4F0D7240DE87DBCA6" xlink:to="lab_nktr_AnnualSalesLevelMilestoneMember_0D697836DE9B89B4F0D7240DE87DBCA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_A2BA62362F09AF30382D240DE87E7B09_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_A2BA62362F09AF30382D240DE87E7B09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized in period related to performance in prior periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_A2BA62362F09AF30382D240DE87E7B09_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_A2BA62362F09AF30382D240DE87E7B09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_A2BA62362F09AF30382D240DE87E7B09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_A2BA62362F09AF30382D240DE87E7B09" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_A2BA62362F09AF30382D240DE87E7B09" xlink:type="arc" />
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_DC7232A4D0A29CA7FE5E240DE87EF743_verboseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_DC7232A4D0A29CA7FE5E240DE87EF743" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments received from license agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_DC7232A4D0A29CA7FE5E240DE87EF743_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_DC7232A4D0A29CA7FE5E240DE87EF743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments Received From License Agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_DC7232A4D0A29CA7FE5E240DE87EF743_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_DC7232A4D0A29CA7FE5E240DE87EF743" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments received from license agreements.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_DC7232A4D0A29CA7FE5E240DE87EF743" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_DC7232A4D0A29CA7FE5E240DE87EF743" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_DC7232A4D0A29CA7FE5E240DE87EF743" xlink:type="arc" />
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_09F6F3CE020A9025806E240DE87E26D8_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_09F6F3CE020A9025806E240DE87E26D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential future additional development and regulatory milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_09F6F3CE020A9025806E240DE87E26D8_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_09F6F3CE020A9025806E240DE87E26D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Development And Regulatory Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_09F6F3CE020A9025806E240DE87E26D8_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_09F6F3CE020A9025806E240DE87E26D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential development and regulatory milestones.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_09F6F3CE020A9025806E240DE87E26D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_09F6F3CE020A9025806E240DE87E26D8" xlink:to="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_09F6F3CE020A9025806E240DE87E26D8" xlink:type="arc" />
    <link:label id="lab_nktr_ProfitsAndLossesSharingPercentage_DF4FDF60626EB0B28BA7240DE87E7853_terseLabel_en-US" xlink:label="lab_nktr_ProfitsAndLossesSharingPercentage_DF4FDF60626EB0B28BA7240DE87E7853" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global commercialization profits and losses sharing percentage</link:label>
    <link:label id="lab_nktr_ProfitsAndLossesSharingPercentage_DF4FDF60626EB0B28BA7240DE87E7853_label_en-US" xlink:label="lab_nktr_ProfitsAndLossesSharingPercentage_DF4FDF60626EB0B28BA7240DE87E7853" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profits And Losses Sharing Percentage</link:label>
    <link:label id="lab_nktr_ProfitsAndLossesSharingPercentage_DF4FDF60626EB0B28BA7240DE87E7853_documentation_en-US" xlink:label="lab_nktr_ProfitsAndLossesSharingPercentage_DF4FDF60626EB0B28BA7240DE87E7853" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profits and losses sharing percentage.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ProfitsAndLossesSharingPercentage" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage_DF4FDF60626EB0B28BA7240DE87E7853" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProfitsAndLossesSharingPercentage_DF4FDF60626EB0B28BA7240DE87E7853" xlink:to="lab_nktr_ProfitsAndLossesSharingPercentage_DF4FDF60626EB0B28BA7240DE87E7853" xlink:type="arc" />
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_8BE1B7EE5F89040F5EA3240DE87F0368_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts_8BE1B7EE5F89040F5EA3240DE87F0368" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of sharing development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_8BE1B7EE5F89040F5EA3240DE87F0368_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts_8BE1B7EE5F89040F5EA3240DE87F0368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Sharing In Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_8BE1B7EE5F89040F5EA3240DE87F0368_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts_8BE1B7EE5F89040F5EA3240DE87F0368" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of sharing in development costs.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfSharingInDevelopmentCosts" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_8BE1B7EE5F89040F5EA3240DE87F0368" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInDevelopmentCosts_8BE1B7EE5F89040F5EA3240DE87F0368" xlink:to="lab_nktr_PercentageOfSharingInDevelopmentCosts_8BE1B7EE5F89040F5EA3240DE87F0368" xlink:type="arc" />
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_6412570336C7AE017C16240DE87F8169_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts_6412570336C7AE017C16240DE87F8169" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of sharing production costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_6412570336C7AE017C16240DE87F8169_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts_6412570336C7AE017C16240DE87F8169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Sharing In Production Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_6412570336C7AE017C16240DE87F8169_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts_6412570336C7AE017C16240DE87F8169" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of sharing in production costs.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfSharingInProductionCosts" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_6412570336C7AE017C16240DE87F8169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInProductionCosts_6412570336C7AE017C16240DE87F8169" xlink:to="lab_nktr_PercentageOfSharingInProductionCosts_6412570336C7AE017C16240DE87F8169" xlink:type="arc" />
    <link:label id="lab_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_9181DEEA6BB046087B75240DE87F9736_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_9181DEEA6BB046087B75240DE87F9736" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of out-of-pocket costs to be reimbursed by partner</link:label>
    <link:label id="lab_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_9181DEEA6BB046087B75240DE87F9736_label_en-US" xlink:label="lab_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_9181DEEA6BB046087B75240DE87F9736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Out Of Pocket Costs To Be Reimbursed By Partner</link:label>
    <link:label id="lab_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_9181DEEA6BB046087B75240DE87F9736_documentation_en-US" xlink:label="lab_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_9181DEEA6BB046087B75240DE87F9736" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of out of pocket costs to be reimbursed by partner.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner" xlink:label="loc_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_9181DEEA6BB046087B75240DE87F9736" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_9181DEEA6BB046087B75240DE87F9736" xlink:to="lab_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_9181DEEA6BB046087B75240DE87F9736" xlink:type="arc" />
    <link:label id="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_54756B666E5EC1BFB66C240DE87FEA62_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_54756B666E5EC1BFB66C240DE87FEA62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_54756B666E5EC1BFB66C240DE87FEA62_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_54756B666E5EC1BFB66C240DE87FEA62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements Maximum Aggregate Additional Cash Payments Receivable Upon Achievement Of Development And Regulatory Milestones</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_54756B666E5EC1BFB66C240DE87FEA62_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_54756B666E5EC1BFB66C240DE87FEA62" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_54756B666E5EC1BFB66C240DE87FEA62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_54756B666E5EC1BFB66C240DE87FEA62" xlink:to="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_54756B666E5EC1BFB66C240DE87FEA62" xlink:type="arc" />
    <link:label id="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_9F3BBF085044F7A82967240DE87F3018_terseLabel_en-US" xlink:label="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_9F3BBF085044F7A82967240DE87F3018" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eligible additional cash payments receivable upon achievement of certain sales milestones</link:label>
    <link:label id="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_9F3BBF085044F7A82967240DE87F3018_label_en-US" xlink:label="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_9F3BBF085044F7A82967240DE87F3018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eligible Additional Cash Payments Receivable Upon Achievement Of Certain Sales Milestones</link:label>
    <link:label id="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_9F3BBF085044F7A82967240DE87F3018_documentation_en-US" xlink:label="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_9F3BBF085044F7A82967240DE87F3018" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eligible additional cash payments receivable upon achievement of certain sales milestones.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_9F3BBF085044F7A82967240DE87F3018" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_9F3BBF085044F7A82967240DE87F3018" xlink:to="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_9F3BBF085044F7A82967240DE87F3018" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_8FAD0AFB4916DC060DDA240DE8801A12_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_8FAD0AFB4916DC060DDA240DE8801A12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_8FAD0AFB4916DC060DDA240DE8801A12_label_en-US" xlink:label="lab_us-gaap_SharesIssued_8FAD0AFB4916DC060DDA240DE8801A12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_8FAD0AFB4916DC060DDA240DE8801A12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_8FAD0AFB4916DC060DDA240DE8801A12" xlink:to="lab_us-gaap_SharesIssued_8FAD0AFB4916DC060DDA240DE8801A12" xlink:type="arc" />
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_8DF12339BEE5840F4BC3240DE880525F_terseLabel_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived_8DF12339BEE5840F4BC3240DE880525F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock consideration received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_8DF12339BEE5840F4BC3240DE880525F_label_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived_8DF12339BEE5840F4BC3240DE880525F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock Consideration Received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_8DF12339BEE5840F4BC3240DE880525F_documentation_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived_8DF12339BEE5840F4BC3240DE880525F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of stock consideration received.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_SaleOfStockConsiderationReceived" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_8DF12339BEE5840F4BC3240DE880525F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SaleOfStockConsiderationReceived_8DF12339BEE5840F4BC3240DE880525F" xlink:to="lab_nktr_SaleOfStockConsiderationReceived_8DF12339BEE5840F4BC3240DE880525F" xlink:type="arc" />
    <link:label id="lab_nktr_ReimbursementOfExpenses_E3E3829DFC9F9E8A1792240DE880ADB3_terseLabel_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses_E3E3829DFC9F9E8A1792240DE880ADB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement of expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_E3E3829DFC9F9E8A1792240DE880ADB3_label_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses_E3E3829DFC9F9E8A1792240DE880ADB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Of Expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_E3E3829DFC9F9E8A1792240DE880ADB3_documentation_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses_E3E3829DFC9F9E8A1792240DE880ADB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement of expenses.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ReimbursementOfExpenses" xlink:label="loc_nktr_ReimbursementOfExpenses_E3E3829DFC9F9E8A1792240DE880ADB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ReimbursementOfExpenses_E3E3829DFC9F9E8A1792240DE880ADB3" xlink:to="lab_nktr_ReimbursementOfExpenses_E3E3829DFC9F9E8A1792240DE880ADB3" xlink:type="arc" />
    <link:label id="lab_nktr_AggregateConsiderationReceivedFromAgreements_4BDF4B8E260F86E1D94D240DE8816968_terseLabel_en-US" xlink:label="lab_nktr_AggregateConsiderationReceivedFromAgreements_4BDF4B8E260F86E1D94D240DE8816968" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total consideration received under agreements</link:label>
    <link:label id="lab_nktr_AggregateConsiderationReceivedFromAgreements_4BDF4B8E260F86E1D94D240DE8816968_label_en-US" xlink:label="lab_nktr_AggregateConsiderationReceivedFromAgreements_4BDF4B8E260F86E1D94D240DE8816968" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Consideration Received From Agreements</link:label>
    <link:label id="lab_nktr_AggregateConsiderationReceivedFromAgreements_4BDF4B8E260F86E1D94D240DE8816968_documentation_en-US" xlink:label="lab_nktr_AggregateConsiderationReceivedFromAgreements_4BDF4B8E260F86E1D94D240DE8816968" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate consideration received from agreements.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AggregateConsiderationReceivedFromAgreements" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements_4BDF4B8E260F86E1D94D240DE8816968" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AggregateConsiderationReceivedFromAgreements_4BDF4B8E260F86E1D94D240DE8816968" xlink:to="lab_nktr_AggregateConsiderationReceivedFromAgreements_4BDF4B8E260F86E1D94D240DE8816968" xlink:type="arc" />
    <link:label id="lab_nktr_EstimatedFairValueOfShares_D633B6310C6488A63B09240DE881A842_terseLabel_en-US" xlink:label="lab_nktr_EstimatedFairValueOfShares_D633B6310C6488A63B09240DE881A842" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value of shares</link:label>
    <link:label id="lab_nktr_EstimatedFairValueOfShares_D633B6310C6488A63B09240DE881A842_label_en-US" xlink:label="lab_nktr_EstimatedFairValueOfShares_D633B6310C6488A63B09240DE881A842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Fair Value Of Shares</link:label>
    <link:label id="lab_nktr_EstimatedFairValueOfShares_D633B6310C6488A63B09240DE881A842_documentation_en-US" xlink:label="lab_nktr_EstimatedFairValueOfShares_D633B6310C6488A63B09240DE881A842" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated fair value of shares.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_EstimatedFairValueOfShares" xlink:label="loc_nktr_EstimatedFairValueOfShares_D633B6310C6488A63B09240DE881A842" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EstimatedFairValueOfShares_D633B6310C6488A63B09240DE881A842" xlink:to="lab_nktr_EstimatedFairValueOfShares_D633B6310C6488A63B09240DE881A842" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_695FE58402791E1A4242240DE88147BC_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_695FE58402791E1A4242240DE88147BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Closing date price of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_695FE58402791E1A4242240DE88147BC_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_695FE58402791E1A4242240DE88147BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_695FE58402791E1A4242240DE88147BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_695FE58402791E1A4242240DE88147BC" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_695FE58402791E1A4242240DE88147BC" xlink:type="arc" />
    <link:label id="lab_nktr_RemainingAmountAllocatedToTransactionPrice_97FFE04CF388E3F4D3AB240DE881235C_terseLabel_en-US" xlink:label="lab_nktr_RemainingAmountAllocatedToTransactionPrice_97FFE04CF388E3F4D3AB240DE881235C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining amount allocated to transaction price</link:label>
    <link:label id="lab_nktr_RemainingAmountAllocatedToTransactionPrice_97FFE04CF388E3F4D3AB240DE881235C_label_en-US" xlink:label="lab_nktr_RemainingAmountAllocatedToTransactionPrice_97FFE04CF388E3F4D3AB240DE881235C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining Amount Allocated To Transaction Price</link:label>
    <link:label id="lab_nktr_RemainingAmountAllocatedToTransactionPrice_97FFE04CF388E3F4D3AB240DE881235C_documentation_en-US" xlink:label="lab_nktr_RemainingAmountAllocatedToTransactionPrice_97FFE04CF388E3F4D3AB240DE881235C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remaining amount allocated to transaction price.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_RemainingAmountAllocatedToTransactionPrice" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice_97FFE04CF388E3F4D3AB240DE881235C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RemainingAmountAllocatedToTransactionPrice_97FFE04CF388E3F4D3AB240DE881235C" xlink:to="lab_nktr_RemainingAmountAllocatedToTransactionPrice_97FFE04CF388E3F4D3AB240DE881235C" xlink:type="arc" />
    <link:label id="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_DA8D39DD70374B279D71240DE8818AFE_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_DA8D39DD70374B279D71240DE8818AFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential future development, regulatory and sales milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_DA8D39DD70374B279D71240DE8818AFE_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_DA8D39DD70374B279D71240DE8818AFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Development Regulatory And Sales Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_DA8D39DD70374B279D71240DE8818AFE_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_DA8D39DD70374B279D71240DE8818AFE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential development regulatory and sales milestones.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:label="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_DA8D39DD70374B279D71240DE8818AFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_DA8D39DD70374B279D71240DE8818AFE" xlink:to="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_DA8D39DD70374B279D71240DE8818AFE" xlink:type="arc" />
    <link:label id="lab_nktr_AmountRecognizedForGrantingLicenses_E31501D36409EF5E4FC1240DE881F202_terseLabel_en-US" xlink:label="lab_nktr_AmountRecognizedForGrantingLicenses_E31501D36409EF5E4FC1240DE881F202" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount recognized for granting licenses</link:label>
    <link:label id="lab_nktr_AmountRecognizedForGrantingLicenses_E31501D36409EF5E4FC1240DE881F202_label_en-US" xlink:label="lab_nktr_AmountRecognizedForGrantingLicenses_E31501D36409EF5E4FC1240DE881F202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount Recognized For Granting Licenses</link:label>
    <link:label id="lab_nktr_AmountRecognizedForGrantingLicenses_E31501D36409EF5E4FC1240DE881F202_documentation_en-US" xlink:label="lab_nktr_AmountRecognizedForGrantingLicenses_E31501D36409EF5E4FC1240DE881F202" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount recognized for granting licenses.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AmountRecognizedForGrantingLicenses" xlink:label="loc_nktr_AmountRecognizedForGrantingLicenses_E31501D36409EF5E4FC1240DE881F202" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AmountRecognizedForGrantingLicenses_E31501D36409EF5E4FC1240DE881F202" xlink:to="lab_nktr_AmountRecognizedForGrantingLicenses_E31501D36409EF5E4FC1240DE881F202" xlink:type="arc" />
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_491F316DFCC186BC92F7240DE882270E_terseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_491F316DFCC186BC92F7240DE882270E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Received upfront and milestone payment</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_491F316DFCC186BC92F7240DE882270E_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_491F316DFCC186BC92F7240DE882270E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments Received Under License Agreement</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_491F316DFCC186BC92F7240DE882270E_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_491F316DFCC186BC92F7240DE882270E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront and milestone payments received under license agreement.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_491F316DFCC186BC92F7240DE882270E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_491F316DFCC186BC92F7240DE882270E" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_491F316DFCC186BC92F7240DE882270E" xlink:type="arc" />
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_A5AB6CDBC2F8535AB212240DE882030D_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_A5AB6CDBC2F8535AB212240DE882030D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of sharing in Phase 2 development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_A5AB6CDBC2F8535AB212240DE882030D_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_A5AB6CDBC2F8535AB212240DE882030D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Sharing In Phase Two Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_A5AB6CDBC2F8535AB212240DE882030D_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_A5AB6CDBC2F8535AB212240DE882030D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of sharing in Phase 2 development costs.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_A5AB6CDBC2F8535AB212240DE882030D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_A5AB6CDBC2F8535AB212240DE882030D" xlink:to="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_A5AB6CDBC2F8535AB212240DE882030D" xlink:type="arc" />
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7BF4B4D5EAEB93BEC923240DE88280F1_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7BF4B4D5EAEB93BEC923240DE88280F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of funding phase 3 development costs on an indication by indication basis borne</link:label>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7BF4B4D5EAEB93BEC923240DE88280F1_label_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7BF4B4D5EAEB93BEC923240DE88280F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne</link:label>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7BF4B4D5EAEB93BEC923240DE88280F1_documentation_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7BF4B4D5EAEB93BEC923240DE88280F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of funding Phase three development costs on an indication by indication basis borne.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7BF4B4D5EAEB93BEC923240DE88280F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7BF4B4D5EAEB93BEC923240DE88280F1" xlink:to="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7BF4B4D5EAEB93BEC923240DE88280F1" xlink:type="arc" />
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_4C324B5E4418944D0D10240DE8827216_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_4C324B5E4418944D0D10240DE8827216" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of regulatory milestones payments will be reduced under certain conditions</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_4C324B5E4418944D0D10240DE8827216_label_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_4C324B5E4418944D0D10240DE8827216" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Development Milestones Payments To Be Received Under Certain Conditions</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_4C324B5E4418944D0D10240DE8827216_documentation_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_4C324B5E4418944D0D10240DE8827216" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of development milestones payments, to be received under certain conditions.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_4C324B5E4418944D0D10240DE8827216" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_4C324B5E4418944D0D10240DE8827216" xlink:to="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_4C324B5E4418944D0D10240DE8827216" xlink:type="arc" />
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_C983344EA4B6D9AB50F0240DE882E4DD_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_C983344EA4B6D9AB50F0240DE882E4DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of regulatory milestones payments will be reduced if conditions occur</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_C983344EA4B6D9AB50F0240DE882E4DD_label_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_C983344EA4B6D9AB50F0240DE882E4DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Development Milestones Payments To Be Received If Conditions Occur</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_C983344EA4B6D9AB50F0240DE882E4DD_documentation_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_C983344EA4B6D9AB50F0240DE882E4DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of development milestones payments, to be received, if conditions occur.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_C983344EA4B6D9AB50F0240DE882E4DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_C983344EA4B6D9AB50F0240DE882E4DD" xlink:to="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_C983344EA4B6D9AB50F0240DE882E4DD" xlink:type="arc" />
    <link:label id="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_75111105C95217A15F7F240DE8829787_terseLabel_en-US" xlink:label="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_75111105C95217A15F7F240DE8829787" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of transaction price allocated to performance obligation</link:label>
    <link:label id="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_75111105C95217A15F7F240DE8829787_label_en-US" xlink:label="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_75111105C95217A15F7F240DE8829787" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount Of Transaction Price Allocated To Performance Obligation</link:label>
    <link:label id="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_75111105C95217A15F7F240DE8829787_documentation_en-US" xlink:label="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_75111105C95217A15F7F240DE8829787" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of transaction price allocated to performance obligation.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_75111105C95217A15F7F240DE8829787" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_75111105C95217A15F7F240DE8829787" xlink:to="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_75111105C95217A15F7F240DE8829787" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3CC6917EE2AAE03832B7240DE8833CFF_positiveLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3CC6917EE2AAE03832B7240DE8833CFF" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized from contracts with customers</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3CC6917EE2AAE03832B7240DE8833CFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3CC6917EE2AAE03832B7240DE8833CFF" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3CC6917EE2AAE03832B7240DE8833CFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_4EB0EA3AC608A2E1AF00240DE8832F91_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_4EB0EA3AC608A2E1AF00240DE8832F91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4EB0EA3AC608A2E1AF00240DE8832F91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_4EB0EA3AC608A2E1AF00240DE8832F91" xlink:to="lab_us-gaap_ContractWithCustomerLiability_4EB0EA3AC608A2E1AF00240DE8832F91" xlink:type="arc" />
    <link:label id="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_16C7E3C800209745E007240DE883CAF8_terseLabel_en-US" xlink:label="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_16C7E3C800209745E007240DE883CAF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Received under right to sublicense agreement</link:label>
    <link:label id="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_16C7E3C800209745E007240DE883CAF8_label_en-US" xlink:label="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_16C7E3C800209745E007240DE883CAF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Received Under Rights To Sublicense Agreement</link:label>
    <link:label id="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_16C7E3C800209745E007240DE883CAF8_documentation_en-US" xlink:label="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_16C7E3C800209745E007240DE883CAF8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments received under rights to sublicense agreement.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:label="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_16C7E3C800209745E007240DE883CAF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_16C7E3C800209745E007240DE883CAF8" xlink:to="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_16C7E3C800209745E007240DE883CAF8" xlink:type="arc" />
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_7B1B478D541FB1990FD3240DE883CF52_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_7B1B478D541FB1990FD3240DE883CF52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments from sublicense agreement retained by our collaboration partner</link:label>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_7B1B478D541FB1990FD3240DE883CF52_label_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_7B1B478D541FB1990FD3240DE883CF52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Upfront Payment Market Access Milestone Payments Royalties And Sales Milestone Payments From Sublicense Agreement Retained By Our Collaboration Partner</link:label>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_7B1B478D541FB1990FD3240DE883CF52_documentation_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_7B1B478D541FB1990FD3240DE883CF52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of upfront payment market access milestone payments royalties and sales milestone payments from sublicense agreement retained by our collaboration partner.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_7B1B478D541FB1990FD3240DE883CF52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_7B1B478D541FB1990FD3240DE883CF52" xlink:to="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_7B1B478D541FB1990FD3240DE883CF52" xlink:type="arc" />
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_FA2463F8D4FF717D22FA240DE883BF25_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_FA2463F8D4FF717D22FA240DE883BF25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of upfront payment, market access milestones, royalties and sales milestones</link:label>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_FA2463F8D4FF717D22FA240DE883BF25_label_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_FA2463F8D4FF717D22FA240DE883BF25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Upfront Payment Market Access Milestone Payments Royalties And Sales Milestone Payments</link:label>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_FA2463F8D4FF717D22FA240DE883BF25_documentation_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_FA2463F8D4FF717D22FA240DE883BF25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_FA2463F8D4FF717D22FA240DE883BF25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_FA2463F8D4FF717D22FA240DE883BF25" xlink:to="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_FA2463F8D4FF717D22FA240DE883BF25" xlink:type="arc" />
    <link:label id="lab_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement_06697B12EA0F0735B9DE240DE88358A3_terseLabel_en-US" xlink:label="lab_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement_06697B12EA0F0735B9DE240DE88358A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of post approval study expenses eligible for reimbursement</link:label>
    <link:label id="lab_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement_06697B12EA0F0735B9DE240DE88358A3_label_en-US" xlink:label="lab_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement_06697B12EA0F0735B9DE240DE88358A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs Incurred, Amount Of Post Approval Study Expenses Eligible For Reimbursement</link:label>
    <link:label id="lab_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement_06697B12EA0F0735B9DE240DE88358A3_documentation_en-US" xlink:label="lab_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement_06697B12EA0F0735B9DE240DE88358A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Costs Incurred, Amount Of Post Approval Study Expenses Eligible For Reimbursement</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement" xlink:label="loc_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement_06697B12EA0F0735B9DE240DE88358A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement_06697B12EA0F0735B9DE240DE88358A3" xlink:to="lab_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement_06697B12EA0F0735B9DE240DE88358A3" xlink:type="arc" />
    <link:label id="lab_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum_E0FC436A576DBA1762A8240DE8847C5E_terseLabel_en-US" xlink:label="lab_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum_E0FC436A576DBA1762A8240DE8847C5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of post approval study expenses eligible for reimbursement, maximum</link:label>
    <link:label id="lab_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum_E0FC436A576DBA1762A8240DE8847C5E_label_en-US" xlink:label="lab_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum_E0FC436A576DBA1762A8240DE8847C5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs Incurred, Amount Of Post Approval Study Expenses Eligible For Reimbursement, Maximum</link:label>
    <link:label id="lab_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum_E0FC436A576DBA1762A8240DE8847C5E_documentation_en-US" xlink:label="lab_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum_E0FC436A576DBA1762A8240DE8847C5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Costs Incurred, Amount Of Post Approval Study Expenses Eligible For Reimbursement, Maximum</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum" xlink:label="loc_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum_E0FC436A576DBA1762A8240DE8847C5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum_E0FC436A576DBA1762A8240DE8847C5E" xlink:to="lab_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum_E0FC436A576DBA1762A8240DE8847C5E" xlink:type="arc" />
    <link:label id="lab_nktr_CostsIncurredShareOfExpenses_916CCB75CA22A8F07265240DE8846E82_terseLabel_en-US" xlink:label="lab_nktr_CostsIncurredShareOfExpenses_916CCB75CA22A8F07265240DE8846E82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of expenses</link:label>
    <link:label id="lab_nktr_CostsIncurredShareOfExpenses_916CCB75CA22A8F07265240DE8846E82_label_en-US" xlink:label="lab_nktr_CostsIncurredShareOfExpenses_916CCB75CA22A8F07265240DE8846E82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs Incurred, Share Of Expenses</link:label>
    <link:label id="lab_nktr_CostsIncurredShareOfExpenses_916CCB75CA22A8F07265240DE8846E82_documentation_en-US" xlink:label="lab_nktr_CostsIncurredShareOfExpenses_916CCB75CA22A8F07265240DE8846E82" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Costs Incurred, Share Of Expenses</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CostsIncurredShareOfExpenses" xlink:label="loc_nktr_CostsIncurredShareOfExpenses_916CCB75CA22A8F07265240DE8846E82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CostsIncurredShareOfExpenses_916CCB75CA22A8F07265240DE8846E82" xlink:to="lab_nktr_CostsIncurredShareOfExpenses_916CCB75CA22A8F07265240DE8846E82" xlink:type="arc" />
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_D026954A18145D13FC5A240DE8844A27_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones_D026954A18145D13FC5A240DE8844A27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential future additional payments for development milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_D026954A18145D13FC5A240DE8844A27_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones_D026954A18145D13FC5A240DE8844A27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Development Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_D026954A18145D13FC5A240DE8844A27_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones_D026954A18145D13FC5A240DE8844A27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential development milestones.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PotentialDevelopmentMilestones" xlink:label="loc_nktr_PotentialDevelopmentMilestones_D026954A18145D13FC5A240DE8844A27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentMilestones_D026954A18145D13FC5A240DE8844A27" xlink:to="lab_nktr_PotentialDevelopmentMilestones_D026954A18145D13FC5A240DE8844A27" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_C6CA142F05E49CB9BD291BB29ED9E157_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_150BE860EF315CB88965F0D448799666" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_C6CA142F05E49CB9BD291BB29ED9E157_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_150BE860EF315CB88965F0D448799666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_150BE860EF315CB88965F0D448799666" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_150BE860EF315CB88965F0D448799666" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_150BE860EF315CB88965F0D448799666" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_A4350C46083F1CA6B1491BB29E1C53B3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_58DB24C310245FF2810A08FA396666DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_A4350C46083F1CA6B1491BB29E1C53B3_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_58DB24C310245FF2810A08FA396666DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_58DB24C310245FF2810A08FA396666DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_58DB24C310245FF2810A08FA396666DC" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_58DB24C310245FF2810A08FA396666DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_CC293EC297B9C87EA6451BB29E1C541E_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_1A406F6558685807B72B0246866DF19F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_CC293EC297B9C87EA6451BB29E1C541E_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_1A406F6558685807B72B0246866DF19F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_1A406F6558685807B72B0246866DF19F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_1A406F6558685807B72B0246866DF19F" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_1A406F6558685807B72B0246866DF19F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_6AB57ED851DFCA9C1EA01BB29E1C856E_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_844634B379AD5C5EAE15E18C35F86FC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_6AB57ED851DFCA9C1EA01BB29E1C856E_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_844634B379AD5C5EAE15E18C35F86FC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_844634B379AD5C5EAE15E18C35F86FC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_844634B379AD5C5EAE15E18C35F86FC1" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_844634B379AD5C5EAE15E18C35F86FC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_C9BEAF72641A5F4BB50A1BB29E1CE276_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_5D2CC14518055515A1435FA28FFBAA17" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_5D2CC14518055515A1435FA28FFBAA17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_5D2CC14518055515A1435FA28FFBAA17" xlink:to="lab_us-gaap_InventoryNet_5D2CC14518055515A1435FA28FFBAA17" xlink:type="arc" />
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_17D8E3CB27F988D7D57E24067A6800CD_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable_17D8E3CB27F988D7D57E24067A6800CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_17D8E3CB27F988D7D57E24067A6800CD_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable_17D8E3CB27F988D7D57E24067A6800CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_17D8E3CB27F988D7D57E24067A6800CD_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable_17D8E3CB27F988D7D57E24067A6800CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LicenseAndCollaborationAgreementsTable" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable_17D8E3CB27F988D7D57E24067A6800CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_17D8E3CB27F988D7D57E24067A6800CD" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsTable_17D8E3CB27F988D7D57E24067A6800CD" xlink:type="arc" />
    <link:label id="lab_nktr_NeulastaMember_78124CA411E62E1EC49624067A6CBC35_terseLabel_en-US" xlink:label="lab_nktr_NeulastaMember_78124CA411E62E1EC49624067A6CBC35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neulasta</link:label>
    <link:label id="lab_nktr_NeulastaMember_78124CA411E62E1EC49624067A6CBC35_label_en-US" xlink:label="lab_nktr_NeulastaMember_78124CA411E62E1EC49624067A6CBC35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neulasta [Member]</link:label>
    <link:label id="lab_nktr_NeulastaMember_78124CA411E62E1EC49624067A6CBC35_documentation_en-US" xlink:label="lab_nktr_NeulastaMember_78124CA411E62E1EC49624067A6CBC35" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neulasta.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NeulastaMember" xlink:label="loc_nktr_NeulastaMember_78124CA411E62E1EC49624067A6CBC35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NeulastaMember_78124CA411E62E1EC49624067A6CBC35" xlink:to="lab_nktr_NeulastaMember_78124CA411E62E1EC49624067A6CBC35" xlink:type="arc" />
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_2681DA383C6FA5200C3024067A6CF7D2_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems_2681DA383C6FA5200C3024067A6CF7D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_2681DA383C6FA5200C3024067A6CF7D2_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems_2681DA383C6FA5200C3024067A6CF7D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_2681DA383C6FA5200C3024067A6CF7D2_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems_2681DA383C6FA5200C3024067A6CF7D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LicenseAndCollaborationAgreementsLineItems" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems_2681DA383C6FA5200C3024067A6CF7D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_2681DA383C6FA5200C3024067A6CF7D2" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsLineItems_2681DA383C6FA5200C3024067A6CF7D2" xlink:type="arc" />
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_82CC4F2519B33E65A9BA24067A6C9B0F_terseLabel_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue_82CC4F2519B33E65A9BA24067A6C9B0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, collaboration and other revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_82CC4F2519B33E65A9BA24067A6C9B0F_label_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue_82CC4F2519B33E65A9BA24067A6C9B0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Collaboration Other Revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_82CC4F2519B33E65A9BA24067A6C9B0F_documentation_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue_82CC4F2519B33E65A9BA24067A6C9B0F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</link:label>
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LicenseCollaborationOtherRevenue" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue_82CC4F2519B33E65A9BA24067A6C9B0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseCollaborationOtherRevenue_82CC4F2519B33E65A9BA24067A6C9B0F" xlink:to="lab_nktr_LicenseCollaborationOtherRevenue_82CC4F2519B33E65A9BA24067A6C9B0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_A65D8581B6D6BE80377D1BB29F041160_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_3BB1A3EFAB045FBCAE292775709FB620" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Lease Costs Included in Operating Expenses</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_A65D8581B6D6BE80377D1BB29F041160_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_3BB1A3EFAB045FBCAE292775709FB620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_3BB1A3EFAB045FBCAE292775709FB620" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_3BB1A3EFAB045FBCAE292775709FB620" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_3BB1A3EFAB045FBCAE292775709FB620" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_63C288B03BF54711FAF31BB29F052F7C_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6744BD2E841A56B69330A353C2B4F021" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_63C288B03BF54711FAF31BB29F052F7C_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6744BD2E841A56B69330A353C2B4F021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6744BD2E841A56B69330A353C2B4F021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6744BD2E841A56B69330A353C2B4F021" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6744BD2E841A56B69330A353C2B4F021" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>nktr-20190930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecurities" xlink:href="nktr-20190930.xsd#CashAndInvestmentsInMarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:href="nktr-20190930.xsd#CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail" xlink:href="nktr-20190930.xsd#CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesTables" xlink:href="nktr-20190930.xsd#CashAndInvestmentsInMarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsAndContingencies" xlink:href="nktr-20190930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:href="nktr-20190930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="nktr-20190930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="nktr-20190930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="nktr-20190930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="nktr-20190930.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="nktr-20190930.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/CoverPage" xlink:href="nktr-20190930.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:href="nktr-20190930.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryInventoryDetail" xlink:href="nktr-20190930.xsd#InventoryInventoryDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:href="nktr-20190930.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/Leases" xlink:href="nktr-20190930.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#LeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail" xlink:href="nktr-20190930.xsd#LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" xlink:href="nktr-20190930.xsd#LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LeasesTables" xlink:href="nktr-20190930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyalties" xlink:href="nktr-20190930.xsd#LiabilityRelatedToSaleOfFutureRoyalties" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreements" xlink:href="nktr-20190930.xsd#LicenseAndCollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#LicenseAndCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreementsChangesInDeferredRevenueBalanceFromCollaborationAgreementsDetail" xlink:href="nktr-20190930.xsd#LicenseAndCollaborationAgreementsChangesInDeferredRevenueBalanceFromCollaborationAgreementsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail" xlink:href="nktr-20190930.xsd#LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseAndCollaborationAgreementsTables" xlink:href="nktr-20190930.xsd#LicenseAndCollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/NetIncomeLossPerShare" xlink:href="nktr-20190930.xsd#NetIncomeLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/NetIncomeLossPerShareAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#NetIncomeLossPerShareAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="nktr-20190930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="nktr-20190930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nktr-20190930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:href="nktr-20190930.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:href="nktr-20190930.xsd#StockBasedCompensationActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:href="nktr-20190930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:href="nktr-20190930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecurities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_39EB54EED2DF5C93B423F95016F2111D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_800A8D8176D75D4F860CB10B44A65ED6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_39EB54EED2DF5C93B423F95016F2111D" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_800A8D8176D75D4F860CB10B44A65ED6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7FD9EC0C12DD0F8322E123E8D9D04478" xlink:type="locator" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7FD9EC0C12DD0F8322E123E8D9D04478" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_8190C288BC89181AFB8B23E8D9D1156C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:to="loc_srt_RangeAxis_8190C288BC89181AFB8B23E8D9D1156C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_7A0BE7B3B87AD16237FB23E8D9D1A068" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8190C288BC89181AFB8B23E8D9D1156C" xlink:to="loc_srt_RangeMember_7A0BE7B3B87AD16237FB23E8D9D1A068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9F78A9A835D1EFE726D523E8D9D26EB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7A0BE7B3B87AD16237FB23E8D9D1A068" xlink:to="loc_srt_MinimumMember_9F78A9A835D1EFE726D523E8D9D26EB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_C25D258CF026702E573A23E8D9D2AAC6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7A0BE7B3B87AD16237FB23E8D9D1A068" xlink:to="loc_srt_MaximumMember_C25D258CF026702E573A23E8D9D2AAC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_64DAC4A00A1E4876632F23E8D9D26149" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_64DAC4A00A1E4876632F23E8D9D26149" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_80C31E842445DCABCF2023E8D9D2844D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_64DAC4A00A1E4876632F23E8D9D26149" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_80C31E842445DCABCF2023E8D9D2844D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_EAD44DF971930F6549C923E8D9D21633" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_80C31E842445DCABCF2023E8D9D2844D" xlink:to="loc_us-gaap_SeniorNotesMember_EAD44DF971930F6549C923E8D9D21633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9E997F3B751E6C1142D923E8D9D3DB43" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:to="loc_us-gaap_DebtInstrumentAxis_9E997F3B751E6C1142D923E8D9D3DB43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_75CBA2196986279A737623E8D9D3B813" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9E997F3B751E6C1142D923E8D9D3DB43" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_75CBA2196986279A737623E8D9D3B813" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:label="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_36E3F02852D342A49F6623E8D9D377BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_75CBA2196986279A737623E8D9D3B813" xlink:to="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_36E3F02852D342A49F6623E8D9D377BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C978F377BE631B55522923E8D9D4CC1B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C978F377BE631B55522923E8D9D4CC1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F031A566274288AB43FB23E8D9D471F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_C978F377BE631B55522923E8D9D4CC1B" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F031A566274288AB43FB23E8D9D471F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_EF1A1E10AB6E883510AC23E8D9D4E75C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F031A566274288AB43FB23E8D9D471F4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_EF1A1E10AB6E883510AC23E8D9D4E75C" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_2CACA5BF40941BE549C223E8D9D1547F" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_DebtInvestmentMaximumMaturityPeriod" xlink:label="loc_nktr_DebtInvestmentMaximumMaturityPeriod_A986E8A4AE1D4BA2B63623E8D9D5DB1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_nktr_DebtInvestmentMaximumMaturityPeriod_A986E8A4AE1D4BA2B63623E8D9D5DB1C" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_DebtInvestmentMaturityTerm" xlink:label="loc_nktr_DebtInvestmentMaturityTerm_273C7BB023BB4A4C8E5323E8D9D59FA3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_nktr_DebtInvestmentMaturityTerm_273C7BB023BB4A4C8E5323E8D9D59FA3" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LongTermInvestmentMaturityPeriod" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_45AAA984A09DD83C8D7B23E8D9D5EE06" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_nktr_LongTermInvestmentMaturityPeriod_45AAA984A09DD83C8D7B23E8D9D5EE06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4322A3FF870345A5649D23E8D9D58D64" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4322A3FF870345A5649D23E8D9D58D64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2A43D0A897E7F2A2D07D23E8D9D5628C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2A43D0A897E7F2A2D07D23E8D9D5628C" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained" xlink:label="loc_nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained_CFD54470FE8192583A2823E8D9D65CB6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained_CFD54470FE8192583A2823E8D9D65CB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_241DC0FA2EEE8AC5719023E8D9D6C96C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_241DC0FA2EEE8AC5719023E8D9D6C96C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_564D64CCB5442273334D23E8D9D68734" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_564D64CCB5442273334D23E8D9D68734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_CA70854F06D105F6621E23E8D9D6E7E8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_us-gaap_SeniorNotes_CA70854F06D105F6621E23E8D9D6E7E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_EC4FB48F771ADD545A6F23E8D9D66087" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_88DE3423B372A69E403823E8D9D5C1DC" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_EC4FB48F771ADD545A6F23E8D9D66087" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_54CF12012BF551AA8A6A4597E167DE76" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7E8DF451EFA65667A16D16FD085831D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_54CF12012BF551AA8A6A4597E167DE76" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7E8DF451EFA65667A16D16FD085831D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5915AD0B09B3540098CD0E7352237A58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7E8DF451EFA65667A16D16FD085831D3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5915AD0B09B3540098CD0E7352237A58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_198F69BAD91355A3996977681FD4C3EA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7E8DF451EFA65667A16D16FD085831D3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_198F69BAD91355A3996977681FD4C3EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_920E160CD9B8568E946EC8CA0C4B49F4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7E8DF451EFA65667A16D16FD085831D3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_920E160CD9B8568E946EC8CA0C4B49F4" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_93845BB3C7A25A62AE53D25844A5ADCD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_7E8DF451EFA65667A16D16FD085831D3" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_93845BB3C7A25A62AE53D25844A5ADCD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_03474EC3067D4BC4DA4282BEEF23D819" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E447DC42C4FE68BFE1B82BEEF230BAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_03474EC3067D4BC4DA4282BEEF23D819" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E447DC42C4FE68BFE1B82BEEF230BAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_2337E6D06E81E1CA268482BEEF24B4AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E447DC42C4FE68BFE1B82BEEF230BAF" xlink:to="loc_us-gaap_InvestmentTypeAxis_2337E6D06E81E1CA268482BEEF24B4AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_2337E6D06E81E1CA268482BEEF24B4AC" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_B55F1C4643D0A6D6196C82BEEF24E143" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_B55F1C4643D0A6D6196C82BEEF24E143" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_2F6EAA62463B41A549B182BEEF249D31" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:to="loc_us-gaap_CommercialPaperMember_2F6EAA62463B41A549B182BEEF249D31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CE66F0729B459DEE23B282BEEF25BB45" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CE66F0729B459DEE23B282BEEF25BB45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_E0CD7D6223DAF290623282BEEF25084F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:to="loc_us-gaap_MoneyMarketFundsMember_E0CD7D6223DAF290623282BEEF25084F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_9710AF4A595CBEB35E5F82BEEF25D8D5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1C05816935930D7012D082BEEF24E075" xlink:to="loc_us-gaap_CertificatesOfDepositMember_9710AF4A595CBEB35E5F82BEEF25D8D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A94701A6A0DBE18A63CB82BEEF25587A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E447DC42C4FE68BFE1B82BEEF230BAF" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A94701A6A0DBE18A63CB82BEEF25587A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92B3BBF7718A444EE8CD82BEEF2553EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A94701A6A0DBE18A63CB82BEEF25587A" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92B3BBF7718A444EE8CD82BEEF2553EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2B95C6FAB7B7364CEB6182BEEF258FC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92B3BBF7718A444EE8CD82BEEF2553EF" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2B95C6FAB7B7364CEB6182BEEF258FC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_62ADA0F9EFA8A5DEB19782BEEF264C6B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92B3BBF7718A444EE8CD82BEEF2553EF" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_62ADA0F9EFA8A5DEB19782BEEF264C6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6E447DC42C4FE68BFE1B82BEEF230BAF" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7DF762A12D792A1851CE82BEEF26C50D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7DF762A12D792A1851CE82BEEF26C50D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_A90B3EE80C26E7411DC182BEEF2698E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_A90B3EE80C26E7411DC182BEEF2698E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_153638D619DBA448296F82BEEF260857" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269" xlink:to="loc_us-gaap_Cash_153638D619DBA448296F82BEEF260857" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_F8CDCE32CB93B9D3881A82BEEF274453" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC1A2979D502C47C507B82BEEF26F269" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_F8CDCE32CB93B9D3881A82BEEF274453" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_A13E11B440C75A509196FE0FA5F0359C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_B09F0C56E9E55257866E8B17E9FCFD88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_A13E11B440C75A509196FE0FA5F0359C" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_B09F0C56E9E55257866E8B17E9FCFD88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_7E4C8DD08AA05C46A5086383760F8A3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_A13E11B440C75A509196FE0FA5F0359C" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_7E4C8DD08AA05C46A5086383760F8A3C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_355572F733B750B7B9E56BF42E6DBEA3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C991D684E23F5D75B7721D7BEF69D4AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_355572F733B750B7B9E56BF42E6DBEA3" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C991D684E23F5D75B7721D7BEF69D4AD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C3EC29BFB77C589398C43DC6889CAD5A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_8C49DF3890B35CFDB78BFF5EBD886F9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C3EC29BFB77C589398C43DC6889CAD5A" xlink:to="loc_us-gaap_LossContingenciesTable_8C49DF3890B35CFDB78BFF5EBD886F9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1B29F6A06B40582A9719525F85AA96C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8C49DF3890B35CFDB78BFF5EBD886F9A" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1B29F6A06B40582A9719525F85AA96C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_5A462247FF245CF28184BB09362226CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_1B29F6A06B40582A9719525F85AA96C4" xlink:to="loc_us-gaap_LossContingencyNatureDomain_5A462247FF245CF28184BB09362226CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndemnificationGuaranteeMember" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_251F7F5535C852E7BD4F66085E2BB4A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_5A462247FF245CF28184BB09362226CE" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_251F7F5535C852E7BD4F66085E2BB4A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_250606D9666A52CB95323EA0178E85D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8C49DF3890B35CFDB78BFF5EBD886F9A" xlink:to="loc_us-gaap_LossContingenciesLineItems_250606D9666A52CB95323EA0178E85D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_653D712551105371AD6AF17345B306B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_250606D9666A52CB95323EA0178E85D9" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_653D712551105371AD6AF17345B306B1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_89A56A31A0C350F937452406F8527855" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_61699188B8C8424C7D7D2406F8525D18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_89A56A31A0C350F937452406F8527855" xlink:to="loc_us-gaap_AssetsAbstract_61699188B8C8424C7D7D2406F8525D18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7FB91D3DF97B156D87962406F852678E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_61699188B8C8424C7D7D2406F8525D18" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7FB91D3DF97B156D87962406F852678E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_62105159FD05C712D1252406F8534E7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7FB91D3DF97B156D87962406F852678E" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_62105159FD05C712D1252406F8534E7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_25DD1B28143E69578DA92406F853289D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7FB91D3DF97B156D87962406F852678E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_25DD1B28143E69578DA92406F853289D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_C8FA445AA38FD79C08812406F853278B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7FB91D3DF97B156D87962406F852678E" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_C8FA445AA38FD79C08812406F853278B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_B2D9FD753FDB5E8508BD2406F85332D5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7FB91D3DF97B156D87962406F852678E" xlink:to="loc_us-gaap_InventoryNet_B2D9FD753FDB5E8508BD2406F85332D5" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AdvancePaymentsToContractManufacturers" xlink:label="loc_nktr_AdvancePaymentsToContractManufacturers_B5695156F4F61CF7F0482406F85444CE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7FB91D3DF97B156D87962406F852678E" xlink:to="loc_nktr_AdvancePaymentsToContractManufacturers_B5695156F4F61CF7F0482406F85444CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_49EA0957F2F4AA71051C2406F854FB21" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7FB91D3DF97B156D87962406F852678E" xlink:to="loc_us-gaap_OtherAssetsCurrent_49EA0957F2F4AA71051C2406F854FB21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_A930912AD8F9EED108992406F85488E1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7FB91D3DF97B156D87962406F852678E" xlink:to="loc_us-gaap_AssetsCurrent_A930912AD8F9EED108992406F85488E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_513AAEEB0010EFBD40A02406F854701D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_61699188B8C8424C7D7D2406F8525D18" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_513AAEEB0010EFBD40A02406F854701D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_BD41D0E3C264C7B1D4402406F854E029" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_61699188B8C8424C7D7D2406F8525D18" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_BD41D0E3C264C7B1D4402406F854E029" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_D35CDBBCDBAAC592375A2406F8541804" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_61699188B8C8424C7D7D2406F8525D18" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_D35CDBBCDBAAC592375A2406F8541804" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_B5F6C5B9D839572755C62406F8554512" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_61699188B8C8424C7D7D2406F8525D18" xlink:to="loc_us-gaap_Goodwill_B5F6C5B9D839572755C62406F8554512" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6242A9E7128A66D2956D2406F85585BB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_61699188B8C8424C7D7D2406F8525D18" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6242A9E7128A66D2956D2406F85585BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_F986F677FA2460531BC52406F8556EBD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_61699188B8C8424C7D7D2406F8525D18" xlink:to="loc_us-gaap_Assets_F986F677FA2460531BC52406F8556EBD" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LiabilitiesAndStockholdersEquityDeficitAbstract" xlink:label="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_89A56A31A0C350F937452406F8527855" xlink:to="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4AB43B867A1E2F5B0A852406F855E30F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4AB43B867A1E2F5B0A852406F855E30F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_C5602C0921DCBA70EBE72406F8567624" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4AB43B867A1E2F5B0A852406F855E30F" xlink:to="loc_us-gaap_AccountsPayableCurrent_C5602C0921DCBA70EBE72406F8567624" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_A831CBD2A6A03AF37D6E2406F8566DC8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4AB43B867A1E2F5B0A852406F855E30F" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_A831CBD2A6A03AF37D6E2406F8566DC8" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AccruedClinicalTrialExpensesCurrent" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_2269EFDDCD413A9DFA772406F856BDA6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4AB43B867A1E2F5B0A852406F855E30F" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_2269EFDDCD413A9DFA772406F856BDA6" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AccruedContractManufacturingExpenseCurrent" xlink:label="loc_nktr_AccruedContractManufacturingExpenseCurrent_12006C1B5A677F0E4B672406F8561FB1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4AB43B867A1E2F5B0A852406F855E30F" xlink:to="loc_nktr_AccruedContractManufacturingExpenseCurrent_12006C1B5A677F0E4B672406F8561FB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_C19F86488776DEED85172406F8568187" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4AB43B867A1E2F5B0A852406F855E30F" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_C19F86488776DEED85172406F8568187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_BCDDAEC3B74733516AAB2406F8577960" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4AB43B867A1E2F5B0A852406F855E30F" xlink:to="loc_us-gaap_InterestPayableCurrent_BCDDAEC3B74733516AAB2406F8577960" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_CD1E642AEB09255807C12406F857FC30" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4AB43B867A1E2F5B0A852406F855E30F" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_CD1E642AEB09255807C12406F857FC30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_464BBB4FC417F4978C502406F8578F1D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4AB43B867A1E2F5B0A852406F855E30F" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_464BBB4FC417F4978C502406F8578F1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_06DDA38F76851AC089512406F857D069" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4AB43B867A1E2F5B0A852406F855E30F" xlink:to="loc_us-gaap_LiabilitiesCurrent_06DDA38F76851AC089512406F857D069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="loc_us-gaap_SeniorLongTermNotes_68AE14F1883F3C34F9EF2406F8570678" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9" xlink:to="loc_us-gaap_SeniorLongTermNotes_68AE14F1883F3C34F9EF2406F8570678" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0BFDCFA6F061B5F461422406F85883DA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0BFDCFA6F061B5F461422406F85883DA" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_0607690B0013C45631A82406F858AF70" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_0607690B0013C45631A82406F858AF70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_75FF7808475A03286E8A2406F858F44A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_75FF7808475A03286E8A2406F858F44A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_541D780485DEE9F853172406F858F253" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_541D780485DEE9F853172406F858F253" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_3B7D6A034E1FEF99DC0D2406F858F21D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9" xlink:to="loc_us-gaap_Liabilities_3B7D6A034E1FEF99DC0D2406F858F21D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_A88366453FF93AA995A62406F858C63A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_A88366453FF93AA995A62406F858C63A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1871CE5C5B73388BF95C2406F859A3F4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1871CE5C5B73388BF95C2406F859A3F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_40EB1177BC3C17C57D4D2406F8594FF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1871CE5C5B73388BF95C2406F859A3F4" xlink:to="loc_us-gaap_PreferredStockValue_40EB1177BC3C17C57D4D2406F8594FF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_49C90079D71379CEA9882406F859A0F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1871CE5C5B73388BF95C2406F859A3F4" xlink:to="loc_us-gaap_CommonStockValue_49C90079D71379CEA9882406F859A0F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8C6A5FC0C26249279C4E2406F85998AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1871CE5C5B73388BF95C2406F859A3F4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8C6A5FC0C26249279C4E2406F85998AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3068B806132C2E056D3F2406F859A7CA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1871CE5C5B73388BF95C2406F859A3F4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3068B806132C2E056D3F2406F859A7CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_E957A83DDABCA602446C2406F85A69ED" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1871CE5C5B73388BF95C2406F859A3F4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_E957A83DDABCA602446C2406F85A69ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2B9D03FC93F4F07267E62406F85A7EEC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1871CE5C5B73388BF95C2406F859A3F4" xlink:to="loc_us-gaap_StockholdersEquity_2B9D03FC93F4F07267E62406F85A7EEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_A0B364D46D1583746B6C2406F85A43B9" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_336346C4835A324E15D92406F855FFF9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_A0B364D46D1583746B6C2406F85A43B9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_CD022A443CE05E598B4F343899979AD0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0465659F2A95582F816A3DA840B76574" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CD022A443CE05E598B4F343899979AD0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0465659F2A95582F816A3DA840B76574" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_12D9085B617A560B9BFBB5D4F6CDDF31" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CD022A443CE05E598B4F343899979AD0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_12D9085B617A560B9BFBB5D4F6CDDF31" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PreferredStockShareDesignated" xlink:label="loc_nktr_PreferredStockShareDesignated_5A5B081B773657FEA8B31196AB832A32" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CD022A443CE05E598B4F343899979AD0" xlink:to="loc_nktr_PreferredStockShareDesignated_5A5B081B773657FEA8B31196AB832A32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_165E120B35545C9A8335E25CAB7BE2DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CD022A443CE05E598B4F343899979AD0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_165E120B35545C9A8335E25CAB7BE2DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2986D0E13A455F53AEB78065E0585C9F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CD022A443CE05E598B4F343899979AD0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2986D0E13A455F53AEB78065E0585C9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_DDF53E32F5B25906BEAA46DD39016021" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CD022A443CE05E598B4F343899979AD0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_DDF53E32F5B25906BEAA46DD39016021" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_797E6DDFA9575150B795E945C422A31A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CD022A443CE05E598B4F343899979AD0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_797E6DDFA9575150B795E945C422A31A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_D2D6E31B9743FD12B123424AFF30DB4B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BB4D0132CF227BDD8E1B424AFF304D28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2D6E31B9743FD12B123424AFF30DB4B" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BB4D0132CF227BDD8E1B424AFF304D28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_800BF132AFE7DF476D56424AFF31BAF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BB4D0132CF227BDD8E1B424AFF304D28" xlink:to="loc_us-gaap_ProfitLoss_800BF132AFE7DF476D56424AFF31BAF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F8433F6EEE65AEF0F265424AFF31AD24" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BB4D0132CF227BDD8E1B424AFF304D28" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F8433F6EEE65AEF0F265424AFF31AD24" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_BFD8D8DDAC383C279E53424AFF31ED16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F8433F6EEE65AEF0F265424AFF31AD24" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_BFD8D8DDAC383C279E53424AFF31ED16" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_146BEFFAFA835E52BADD424AFF326CC3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F8433F6EEE65AEF0F265424AFF31AD24" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_146BEFFAFA835E52BADD424AFF326CC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3F31BA4985A2984568D1424AFF3200BA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F8433F6EEE65AEF0F265424AFF31AD24" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3F31BA4985A2984568D1424AFF3200BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_4217144F3DA0EE6062C4424AFF32FC95" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F8433F6EEE65AEF0F265424AFF31AD24" xlink:to="loc_us-gaap_DepreciationAndAmortization_4217144F3DA0EE6062C4424AFF32FC95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_741852958252833A2E64424AFF32CD4D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F8433F6EEE65AEF0F265424AFF31AD24" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_741852958252833A2E64424AFF32CD4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AC6A6D5D0BDF15D348C3424AFF32F64E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F8433F6EEE65AEF0F265424AFF31AD24" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AC6A6D5D0BDF15D348C3424AFF32F64E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B372960786EDA698A46D424AFF33A0D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AC6A6D5D0BDF15D348C3424AFF32F64E" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_B372960786EDA698A46D424AFF33A0D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1B9080276CCC8B7CE112424AFF337544" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AC6A6D5D0BDF15D348C3424AFF32F64E" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1B9080276CCC8B7CE112424AFF337544" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2E631BFE5367F9AA6101424AFF343246" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AC6A6D5D0BDF15D348C3424AFF32F64E" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2E631BFE5367F9AA6101424AFF343246" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_AE4DF12507C1BF4527E9424AFF34C39A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AC6A6D5D0BDF15D348C3424AFF32F64E" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_AE4DF12507C1BF4527E9424AFF34C39A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8AED867BEABDFE57F77C424AFF34B3FB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AC6A6D5D0BDF15D348C3424AFF32F64E" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8AED867BEABDFE57F77C424AFF34B3FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_E7DE61295B4772504931424AFF35B9B8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AC6A6D5D0BDF15D348C3424AFF32F64E" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_E7DE61295B4772504931424AFF35B9B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_C9A2EB95718AFA52FDE4424AFF35DD98" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AC6A6D5D0BDF15D348C3424AFF32F64E" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_C9A2EB95718AFA52FDE4424AFF35DD98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0B64F80909C748982542424AFF35FB4E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AC6A6D5D0BDF15D348C3424AFF32F64E" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0B64F80909C748982542424AFF35FB4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_D97E520D146FDF8B5032424AFF358106" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_BB4D0132CF227BDD8E1B424AFF304D28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_D97E520D146FDF8B5032424AFF358106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_095380656426F371E04A424AFF357EB0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2D6E31B9743FD12B123424AFF30DB4B" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_095380656426F371E04A424AFF357EB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_09A3FB027AD85982A543424AFF3668F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_095380656426F371E04A424AFF357EB0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_09A3FB027AD85982A543424AFF3668F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F27DCD0859288DB2DEE9424AFF36EEA2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_095380656426F371E04A424AFF357EB0" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_F27DCD0859288DB2DEE9424AFF36EEA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4953C98F2784547CA7A3424AFF376E4F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_095380656426F371E04A424AFF357EB0" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4953C98F2784547CA7A3424AFF376E4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FB9E3D3ADBEC70C48DB6424AFF37220B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_095380656426F371E04A424AFF357EB0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FB9E3D3ADBEC70C48DB6424AFF37220B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_13979D2D62E2A8F87390424AFF3751BA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_095380656426F371E04A424AFF357EB0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_13979D2D62E2A8F87390424AFF3751BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8267BA1F606A59A276C7424AFF374103" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_095380656426F371E04A424AFF357EB0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8267BA1F606A59A276C7424AFF374103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F10F5A94C395CCCF024B424AFF377893" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2D6E31B9743FD12B123424AFF30DB4B" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F10F5A94C395CCCF024B424AFF377893" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="loc_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_075F06A583B43632AFCD424AFF38DBAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F10F5A94C395CCCF024B424AFF377893" xlink:to="loc_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_075F06A583B43632AFCD424AFF38DBAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_5CA2A285063CC8BC1F28424AFF385283" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F10F5A94C395CCCF024B424AFF377893" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_5CA2A285063CC8BC1F28424AFF385283" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DB0FCAE2C931263B31FA424AFF38FFFA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_F10F5A94C395CCCF024B424AFF377893" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_DB0FCAE2C931263B31FA424AFF38FFFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96BF74F3975FE6A27323424AFF394DD5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2D6E31B9743FD12B123424AFF30DB4B" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96BF74F3975FE6A27323424AFF394DD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64546924E9FBD49C9CF4424AFF399F8B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2D6E31B9743FD12B123424AFF30DB4B" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64546924E9FBD49C9CF4424AFF399F8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17F7D94021A13BD2C141424AFF3956E5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2D6E31B9743FD12B123424AFF30DB4B" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17F7D94021A13BD2C141424AFF3956E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DAC8DEE94A09137365DD424AFF392697" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2D6E31B9743FD12B123424AFF30DB4B" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DAC8DEE94A09137365DD424AFF392697" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_87FBE524F16A59045C77424AFF3AB05A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2D6E31B9743FD12B123424AFF30DB4B" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_87FBE524F16A59045C77424AFF3AB05A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_4C268AA9F98C1845DFF2424AFF3AB83C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_87FBE524F16A59045C77424AFF3AB05A" xlink:to="loc_us-gaap_InterestPaidNet_4C268AA9F98C1845DFF2424AFF3AB83C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_CEA5BB9C985D29EA6707425049C69701" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_87FBE524F16A59045C77424AFF3AB05A" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_CEA5BB9C985D29EA6707425049C69701" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_D57C921AC1E9565F8588C8F01D8421D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6699E4AEEF475160B45EB5172BCACA3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_D57C921AC1E9565F8588C8F01D8421D6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6699E4AEEF475160B45EB5172BCACA3F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_3D5DFD9E3A975274BE34EC3E94431490" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0BAEC335589E53E997386830078442D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3D5DFD9E3A975274BE34EC3E94431490" xlink:to="loc_us-gaap_StatementTable_0BAEC335589E53E997386830078442D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2A036958EAEA5162904ABCA2EF945433" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0BAEC335589E53E997386830078442D1" xlink:to="loc_srt_ProductOrServiceAxis_2A036958EAEA5162904ABCA2EF945433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_10AF9F952A5A5A06902D8EA94D233396" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2A036958EAEA5162904ABCA2EF945433" xlink:to="loc_srt_ProductsAndServicesDomain_10AF9F952A5A5A06902D8EA94D233396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_1D4A9552E5E551BF98B5C55E83C1C823" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_10AF9F952A5A5A06902D8EA94D233396" xlink:to="loc_us-gaap_ProductMember_1D4A9552E5E551BF98B5C55E83C1C823" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_D6B58A0847525FE9AA6A9C37410478EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_10AF9F952A5A5A06902D8EA94D233396" xlink:to="loc_us-gaap_RoyaltyMember_D6B58A0847525FE9AA6A9C37410478EE" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_8EA5AE0CFB865019B1CB01618DB26A59" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_10AF9F952A5A5A06902D8EA94D233396" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_8EA5AE0CFB865019B1CB01618DB26A59" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LicenseCollaborationAndOtherRevenueMember" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_DC41128EE69956898E30AA8E0678F650" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_10AF9F952A5A5A06902D8EA94D233396" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_DC41128EE69956898E30AA8E0678F650" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0BAEC335589E53E997386830078442D1" xlink:to="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_6E0AF52A0A3F542C996F85637C63FD2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_RevenuesAbstract_6E0AF52A0A3F542C996F85637C63FD2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D8E4A552864A51A698A5758EBA1B22FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_6E0AF52A0A3F542C996F85637C63FD2D" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D8E4A552864A51A698A5758EBA1B22FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_FD57E25683765983A40F4DDFCF309891" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_FD57E25683765983A40F4DDFCF309891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_E7A39F64C59C5F45ACD94BB82007F0DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD57E25683765983A40F4DDFCF309891" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_E7A39F64C59C5F45ACD94BB82007F0DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_FD39389C831F53509B32D58081C8AD1A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD57E25683765983A40F4DDFCF309891" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_FD39389C831F53509B32D58081C8AD1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_E131000894E359D79ED4A414B7F9E9FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD57E25683765983A40F4DDFCF309891" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_E131000894E359D79ED4A414B7F9E9FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_52D536CB56265B54A6878D17C7DF906D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FD57E25683765983A40F4DDFCF309891" xlink:to="loc_us-gaap_CostsAndExpenses_52D536CB56265B54A6878D17C7DF906D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_E51F43ECAAD55055ABA1FAD77E318626" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_OperatingIncomeLoss_E51F43ECAAD55055ABA1FAD77E318626" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_649DE37034F659B8B2274D8D377F5091" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_649DE37034F659B8B2274D8D377F5091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_36FFD95C4C355287803D89B478397ED3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_649DE37034F659B8B2274D8D377F5091" xlink:to="loc_us-gaap_InterestExpense_36FFD95C4C355287803D89B478397ED3" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_162D21AD575F50BABB4F9AF0ACF5579A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_649DE37034F659B8B2274D8D377F5091" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_162D21AD575F50BABB4F9AF0ACF5579A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_E913B944A8FF5C7398F9CCE8E5A16ECE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_649DE37034F659B8B2274D8D377F5091" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_E913B944A8FF5C7398F9CCE8E5A16ECE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_AF90FBEEB9C85BF3829BF39CBD0A13F0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_649DE37034F659B8B2274D8D377F5091" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_AF90FBEEB9C85BF3829BF39CBD0A13F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1AF98EB0D65F57F18CB7D84EB54A2025" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1AF98EB0D65F57F18CB7D84EB54A2025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_CCB61A512DDC5FEA90240DD0ABCB0D52" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_CCB61A512DDC5FEA90240DD0ABCB0D52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_A9246639E73B559EB7FC8436E9DBA858" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_NetIncomeLoss_A9246639E73B559EB7FC8436E9DBA858" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_2342D51E90A458CBA36D9DD8CDBEFA4D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_2342D51E90A458CBA36D9DD8CDBEFA4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_6118B14FC122583FA36712F3B085A3AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_2342D51E90A458CBA36D9DD8CDBEFA4D" xlink:to="loc_us-gaap_EarningsPerShareBasic_6118B14FC122583FA36712F3B085A3AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_277FB16BF07251239B3355A60D072AF9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_2342D51E90A458CBA36D9DD8CDBEFA4D" xlink:to="loc_us-gaap_EarningsPerShareDiluted_277FB16BF07251239B3355A60D072AF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_02369FB4737F5BED92E3CDA0F8193D13" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_792E7D0F91D552488EE7439FCBB18CCD" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_02369FB4737F5BED92E3CDA0F8193D13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1787353FEE5D56F2B5C4D3F24E4DF833" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_02369FB4737F5BED92E3CDA0F8193D13" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1787353FEE5D56F2B5C4D3F24E4DF833" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_337AB3B54E715740973F5F594B8ACCA8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_02369FB4737F5BED92E3CDA0F8193D13" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_337AB3B54E715740973F5F594B8ACCA8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_E3D89497297700EB3F044159E96C3B3D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A7BFF0B2ED982F0DC17F4159E96E2B3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_E3D89497297700EB3F044159E96C3B3D" xlink:to="loc_us-gaap_StatementTable_A7BFF0B2ED982F0DC17F4159E96E2B3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_29D25CC0BCAB8EEC2C6F4159E96F290C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A7BFF0B2ED982F0DC17F4159E96E2B3A" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_29D25CC0BCAB8EEC2C6F4159E96F290C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_29D25CC0BCAB8EEC2C6F4159E96F290C" xlink:to="loc_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_21A726DEC7B03460C0A64159E970DA54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244" xlink:to="loc_us-gaap_CommonStockMember_21A726DEC7B03460C0A64159E970DA54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0060CBE67F7E90812CF84159E972439D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0060CBE67F7E90812CF84159E972439D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_73CBF5E38A4EBEC777CB4159E972D1F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_73CBF5E38A4EBEC777CB4159E972D1F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_EDAC4CA29F71BC626EC14159E97225ED" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_45B5AD949E31D6846EEC4159E96F7244" xlink:to="loc_us-gaap_RetainedEarningsMember_EDAC4CA29F71BC626EC14159E97225ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A7BFF0B2ED982F0DC17F4159E96E2B3A" xlink:to="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_D33E90989DB2BDB1FFCB4159E973CED8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_SharesOutstanding_D33E90989DB2BDB1FFCB4159E973CED8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2D546D39A77B788B8E544159E9738C99" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_StockholdersEquity_2D546D39A77B788B8E544159E9738C99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_2FE18273BD703B03D4D74159E974845F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_2FE18273BD703B03D4D74159E974845F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B0D3132270259EAA0734159E9749866" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9B0D3132270259EAA0734159E9749866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_E1092F78F586D026B1244159E974E502" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_E1092F78F586D026B1244159E974E502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8DB7865EB653571D37A04159E9737B07" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8DB7865EB653571D37A04159E9737B07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9CAC59C63B4A517A49DA4159E973B664" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9CAC59C63B4A517A49DA4159E973B664" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_E42204E8221773FFD5894159E974FF2F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_E42204E8221773FFD5894159E974FF2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D90328FBA524AD2334044159E97449CE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D90328FBA524AD2334044159E97449CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_AE305B6B5AEFEA03556F4159E9741B9F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_NetIncomeLoss_AE305B6B5AEFEA03556F4159E9741B9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_7D7CA183D918092E14394159E975EABD" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_SharesOutstanding_7D7CA183D918092E14394159E975EABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2715E909ED092AE9C80D4159E975A5F4" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2CF8FD34FEBCE0CED1B34159E9735556" xlink:to="loc_us-gaap_StockholdersEquity_2715E909ED092AE9C80D4159E975A5F4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_96E1ACCF6BEB06A54E4B378CF646E3EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_DocumentType_96E1ACCF6BEB06A54E4B378CF646E3EF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_797E23DB47E4A976E3FC378CF647CE00" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_DocumentQuarterlyReport_797E23DB47E4A976E3FC378CF647CE00" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_646584C8A0B249227C36378CF647D002" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_DocumentPeriodEndDate_646584C8A0B249227C36378CF647D002" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_5B552CA3799B04FDBC8F378CF648999E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_DocumentTransitionReport_5B552CA3799B04FDBC8F378CF648999E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_C5976D16DC0441EB8798378CF648FD71" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_EntityFileNumber_C5976D16DC0441EB8798378CF648FD71" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_C1A284BDBA9B214A882C378CF6480CA1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_EntityRegistrantName_C1A284BDBA9B214A882C378CF6480CA1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_DF4B44190056986107F8378CF6486F81" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_EntityIncorporationStateCountryCode_DF4B44190056986107F8378CF6486F81" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_28E6224DE1DDA87CDADD378CF64848C5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_EntityTaxIdentificationNumber_28E6224DE1DDA87CDADD378CF64848C5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_0CD0FB10244FD9B199C8378CF648C121" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_EntityAddressAddressLine1_0CD0FB10244FD9B199C8378CF648C121" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_3A481A7D89AF40B4AB16378CF649A317" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_EntityAddressCityOrTown_3A481A7D89AF40B4AB16378CF649A317" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_E0024BECB963893CCA4F378CF6494380" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_EntityAddressStateOrProvince_E0024BECB963893CCA4F378CF6494380" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_C3EFE3E8029B590B5303378CF64956B6" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_EntityAddressPostalZipCode_C3EFE3E8029B590B5303378CF64956B6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_AF3461CD6E3E04B54B16378CF649B710" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_CityAreaCode_AF3461CD6E3E04B54B16378CF649B710" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_C540963D56F50042ACAB378CF649D7F0" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_LocalPhoneNumber_C540963D56F50042ACAB378CF649D7F0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_40E69B98F85593B4187B378CF6496DD3" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_Security12bTitle_40E69B98F85593B4187B378CF6496DD3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_D81FEB5DD7B213FFABFD378CF64A0EB9" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_TradingSymbol_D81FEB5DD7B213FFABFD378CF64A0EB9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_1B2FE3ECB8F49BEF2984378CF64ADE71" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_SecurityExchangeName_1B2FE3ECB8F49BEF2984378CF64ADE71" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_56B395048433D97D9A55378CF64A3274" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_EntityCurrentReportingStatus_56B395048433D97D9A55378CF64A3274" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_C2C475937E3925A03104378CF64A2D55" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_EntityInteractiveDataCurrent_C2C475937E3925A03104378CF64A2D55" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_B37CA5F192B655C5FE2A378CF64A57D3" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_EntityFilerCategory_B37CA5F192B655C5FE2A378CF64A57D3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_159E786F3B0064BABB0F378CF64AFB93" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_EntitySmallBusiness_159E786F3B0064BABB0F378CF64AFB93" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_8206823920B7940A3C2B378CF64A486D" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_EntityEmergingGrowthCompany_8206823920B7940A3C2B378CF64A486D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_E64F799CEF874DFE6460378CF64BADB5" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_EntityShellCompany_E64F799CEF874DFE6460378CF64BADB5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_F641CB10B18970CF24CF378CF64F456D" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_F641CB10B18970CF24CF378CF64F456D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_D4C76A4F2960AFDF8E98378CF64F259E" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_AmendmentFlag_D4C76A4F2960AFDF8E98378CF64F259E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_220C1C4CF82F3DBB5E40378CF650D563" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_DocumentFiscalYearFocus_220C1C4CF82F3DBB5E40378CF650D563" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_11DDFB426FEC150F52D1378CF651FD59" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_DocumentFiscalPeriodFocus_11DDFB426FEC150F52D1378CF651FD59" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_0F863D874ABD6B9CC420378CF6514616" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_EntityCentralIndexKey_0F863D874ABD6B9CC420378CF6514616" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_F4268A76F20AB6939BB0378CF651FE17" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FFE4E452702AE4CBEA6C378CF644FA51" xlink:to="loc_dei_CurrentFiscalYearEndDate_F4268A76F20AB6939BB0378CF651FE17" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_9DFA0F1F042B54E3ABA80A75DC0ADDC2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_3C98126956EA5184B8639D0E54D6E745" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9DFA0F1F042B54E3ABA80A75DC0ADDC2" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_3C98126956EA5184B8639D0E54D6E745" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/InventoryInventoryDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_F2D16B239F7E512988BE81C8780FE7C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_58DB24C310245FF2810A08FA396666DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_F2D16B239F7E512988BE81C8780FE7C8" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_58DB24C310245FF2810A08FA396666DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_1A406F6558685807B72B0246866DF19F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_F2D16B239F7E512988BE81C8780FE7C8" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_1A406F6558685807B72B0246866DF19F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_844634B379AD5C5EAE15E18C35F86FC1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_F2D16B239F7E512988BE81C8780FE7C8" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_844634B379AD5C5EAE15E18C35F86FC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_5D2CC14518055515A1435FA28FFBAA17" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_F2D16B239F7E512988BE81C8780FE7C8" xlink:to="loc_us-gaap_InventoryNet_5D2CC14518055515A1435FA28FFBAA17" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_07704BBE98095E67B7953227A42C1444" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F0CE0E7D90E156139E92EEA1EB063FD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_07704BBE98095E67B7953227A42C1444" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_F0CE0E7D90E156139E92EEA1EB063FD8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/Leases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_CFFA2D2D7B4255E3B9DEFC9A27E8B91D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_26E5A3174E66511F82C4D274CFC81F42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_CFFA2D2D7B4255E3B9DEFC9A27E8B91D" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_26E5A3174E66511F82C4D274CFC81F42" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LeasesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_90E5BC7B2EE6ABBDB594424AFEA15F7E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_51F77C2B1556DDFA0CB0424AFEA2C2B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90E5BC7B2EE6ABBDB594424AFEA15F7E" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_51F77C2B1556DDFA0CB0424AFEA2C2B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_11120C4AD7E4394A1F78424AFEA2E977" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_51F77C2B1556DDFA0CB0424AFEA2C2B2" xlink:to="loc_srt_CounterpartyNameAxis_11120C4AD7E4394A1F78424AFEA2E977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65924A7B9773DE546D98424AFEA3A516" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_11120C4AD7E4394A1F78424AFEA2E977" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65924A7B9773DE546D98424AFEA3A516" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ARESanFranciscoNumberOneNineLLCMember" xlink:label="loc_nktr_ARESanFranciscoNumberOneNineLLCMember_0B48C242A835C2D5DF55424AFEA318B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65924A7B9773DE546D98424AFEA3A516" xlink:to="loc_nktr_ARESanFranciscoNumberOneNineLLCMember_0B48C242A835C2D5DF55424AFEA318B1" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_KilroyRealtyFinancePartnershipLPMember" xlink:label="loc_nktr_KilroyRealtyFinancePartnershipLPMember_7339641D8AEC50C34779424AFEA33F26" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_65924A7B9773DE546D98424AFEA3A516" xlink:to="loc_nktr_KilroyRealtyFinancePartnershipLPMember_7339641D8AEC50C34779424AFEA33F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_AC59AEEE5B3C91915BAF424AFEA4889A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_51F77C2B1556DDFA0CB0424AFEA2C2B2" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_AC59AEEE5B3C91915BAF424AFEA4889A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_040CB8AA2621012F08F3424AFEA40140" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_AC59AEEE5B3C91915BAF424AFEA4889A" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_040CB8AA2621012F08F3424AFEA40140" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_MissionBayLeaseMember" xlink:label="loc_nktr_MissionBayLeaseMember_874C9B0A1396845904FB424AFEA481F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_040CB8AA2621012F08F3424AFEA40140" xlink:to="loc_nktr_MissionBayLeaseMember_874C9B0A1396845904FB424AFEA481F1" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ThirdStreetLeaseMember" xlink:label="loc_nktr_ThirdStreetLeaseMember_01CDFCF0BD694DE46985424AFEA55E16" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_040CB8AA2621012F08F3424AFEA40140" xlink:to="loc_nktr_ThirdStreetLeaseMember_01CDFCF0BD694DE46985424AFEA55E16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_51F77C2B1556DDFA0CB0424AFEA2C2B2" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AreaOfLeasedSpace" xlink:label="loc_nktr_AreaOfLeasedSpace_D7C8171BD5768B24E34C424AFEA5D026" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_nktr_AreaOfLeasedSpace_D7C8171BD5768B24E34C424AFEA5D026" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NumberOfConsecutiveFiveYearTermsToExtendLease" xlink:label="loc_nktr_NumberOfConsecutiveFiveYearTermsToExtendLease_53EED72BFD9E8887C6B7424AFEA62118" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_nktr_NumberOfConsecutiveFiveYearTermsToExtendLease_53EED72BFD9E8887C6B7424AFEA62118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_59F561A4D104D26ABB7A424AFEA67BDA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_59F561A4D104D26ABB7A424AFEA67BDA" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AdditionalSpaceRequiredToBeLeasedInFuture" xlink:label="loc_nktr_AdditionalSpaceRequiredToBeLeasedInFuture_027FD05D86E52949C946424AFEA69542" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_nktr_AdditionalSpaceRequiredToBeLeasedInFuture_027FD05D86E52949C946424AFEA69542" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_C39CA597D000298C4816424AFEA791E6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_C39CA597D000298C4816424AFEA791E6" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NumberOfLeasedSpacesDelivered" xlink:label="loc_nktr_NumberOfLeasedSpacesDelivered_85C94440E695D9CCDCC9424AFEA75263" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_nktr_NumberOfLeasedSpacesDelivered_85C94440E695D9CCDCC9424AFEA75263" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_99AB198EE8ABF8BA11B4424AFEA765F3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_us-gaap_OperatingLeasePayments_99AB198EE8ABF8BA11B4424AFEA765F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_839864574398B3DA3CBC424AFEA70ABD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_839864574398B3DA3CBC424AFEA70ABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7CD1971DB0B9E36EE911424AFEA8B43B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DE1C169351E4F5544E5D424AFEA51275" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7CD1971DB0B9E36EE911424AFEA8B43B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_FA02EA85C45A567690EB4191A2E220A4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_71466E51F22154F29C7467AC0F481386" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_FA02EA85C45A567690EB4191A2E220A4" xlink:to="loc_us-gaap_OperatingLeaseCost_71466E51F22154F29C7467AC0F481386" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_4F6246E1794757CDA75B8024C35750A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_FA02EA85C45A567690EB4191A2E220A4" xlink:to="loc_us-gaap_VariableLeaseCost_4F6246E1794757CDA75B8024C35750A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_A00832FD6BA254D2BB777BA9A29EAFAA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_FA02EA85C45A567690EB4191A2E220A4" xlink:to="loc_us-gaap_LeaseCost_A00832FD6BA254D2BB777BA9A29EAFAA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_7808A20FB6528EEB358F82BEEF047560" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_BE9B9B33DA88FEFE032982BEEF042136" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7808A20FB6528EEB358F82BEEF047560" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_BE9B9B33DA88FEFE032982BEEF042136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4D33A98BF982658B72A382BEEF043F12" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7808A20FB6528EEB358F82BEEF047560" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4D33A98BF982658B72A382BEEF043F12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_87EEA5603B26C232290182BEEF048898" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7808A20FB6528EEB358F82BEEF047560" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_87EEA5603B26C232290182BEEF048898" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_B43FB414364DF8D3F22982BEEF049E06" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7808A20FB6528EEB358F82BEEF047560" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_B43FB414364DF8D3F22982BEEF049E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_E719A79A68B3FCF9A5D582BEEF0541DF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7808A20FB6528EEB358F82BEEF047560" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_E719A79A68B3FCF9A5D582BEEF0541DF" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:label="loc_nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_A5C1D6E5D426CB07673B82BEEF0539BF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7808A20FB6528EEB358F82BEEF047560" xlink:to="loc_nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_A5C1D6E5D426CB07673B82BEEF0539BF" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix" xlink:label="loc_nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_28720D28A97AF073746C82BEEF05750D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7808A20FB6528EEB358F82BEEF047560" xlink:to="loc_nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix_28720D28A97AF073746C82BEEF05750D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30401444F22C651CEE2282BEEF053A38" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7808A20FB6528EEB358F82BEEF047560" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30401444F22C651CEE2282BEEF053A38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_89768840027FFE6E1BAD82BEEF05F00E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7808A20FB6528EEB358F82BEEF047560" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_89768840027FFE6E1BAD82BEEF05F00E" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_DF90EF142FFC3379832382BEEF05AB43" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7808A20FB6528EEB358F82BEEF047560" xlink:to="loc_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_DF90EF142FFC3379832382BEEF05AB43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_0DB810E58EBE584A000B82BEEF060022" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7808A20FB6528EEB358F82BEEF047560" xlink:to="loc_us-gaap_OperatingLeaseLiability_0DB810E58EBE584A000B82BEEF060022" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_57635599FCB6D95C688882BEEF06B2F8" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7808A20FB6528EEB358F82BEEF047560" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_57635599FCB6D95C688882BEEF06B2F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_DECCE17FEB695B51156082BEEF069C29" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7808A20FB6528EEB358F82BEEF047560" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_DECCE17FEB695B51156082BEEF069C29" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_00B22F2DCA9F5C5388F4C243D9409E1F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_3BB1A3EFAB045FBCAE292775709FB620" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_00B22F2DCA9F5C5388F4C243D9409E1F" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_3BB1A3EFAB045FBCAE292775709FB620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6744BD2E841A56B69330A353C2B4F021" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_00B22F2DCA9F5C5388F4C243D9409E1F" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6744BD2E841A56B69330A353C2B4F021" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyalties" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_70FAE1C57B22501BAF776AEB000A779F" xlink:type="locator" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_F2799B7050A2514484331CD273DA7525" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_70FAE1C57B22501BAF776AEB000A779F" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_F2799B7050A2514484331CD273DA7525" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_FF2F11F235125F63B51A29C452548FC4" xlink:type="locator" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_169703747E6954E289D686091163168B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_FF2F11F235125F63B51A29C452548FC4" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_169703747E6954E289D686091163168B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1E752C12F05F5F508130A81B79C3A9AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_169703747E6954E289D686091163168B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1E752C12F05F5F508130A81B79C3A9AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_639B9841668A5418973A43392C399310" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1E752C12F05F5F508130A81B79C3A9AB" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_639B9841668A5418973A43392C399310" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PurchaseAndSaleAgreementMember" xlink:label="loc_nktr_PurchaseAndSaleAgreementMember_E51327D7378357AEAFBFF5C0D10BAA19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_639B9841668A5418973A43392C399310" xlink:to="loc_nktr_PurchaseAndSaleAgreementMember_E51327D7378357AEAFBFF5C0D10BAA19" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_169703747E6954E289D686091163168B" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_D86C4AD555925CDDB626F26E46C316EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:to="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_D86C4AD555925CDDB626F26E46C316EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_1A983441232354488C6FF5C17356EF90" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_1A983441232354488C6FF5C17356EF90" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_EE273E50D651593DA1E52FD0ABFDC1F5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_EE273E50D651593DA1E52FD0ABFDC1F5" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_2DE06395B79B5198A0C6AB1AC0A729A8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_2DE06395B79B5198A0C6AB1AC0A729A8" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:label="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_2F9B0A549F435D4588862E6F07CF7099" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:to="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_2F9B0A549F435D4588862E6F07CF7099" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ProspectiveInterestRatePercentage" xlink:label="loc_nktr_ProspectiveInterestRatePercentage_E4E48FBF880951D196EFC997BAE361CF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_3B4C3B3CBD8E5B2C936DA695AE12A38F" xlink:to="loc_nktr_ProspectiveInterestRatePercentage_E4E48FBF880951D196EFC997BAE361CF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseAndCollaborationAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9EACC51A4B82575B8CC746F09E337EE9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4D8AA414F2B2543C913841E1BEE7CDD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9EACC51A4B82575B8CC746F09E337EE9" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4D8AA414F2B2543C913841E1BEE7CDD5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0107F999B6F4EBA9C17F240DE87164F2" xlink:type="locator" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LicenseAndCollaborationAgreementsAbstract" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract_DBA2BCF8A45543B7B3DB240DE8727F54" xlink:type="locator" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0107F999B6F4EBA9C17F240DE87164F2" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsAbstract_DBA2BCF8A45543B7B3DB240DE8727F54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract_DBA2BCF8A45543B7B3DB240DE8727F54" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_397E6B38CF89ACB8123A240DE8726478" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_dei_LegalEntityAxis_397E6B38CF89ACB8123A240DE8726478" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_397E6B38CF89ACB8123A240DE8726478" xlink:to="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_6291CECEBAA65A81AA2B240DE87363D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:to="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_6291CECEBAA65A81AA2B240DE87363D6" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_BristolMyersSquibbCompanyMember" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_9DFB3F050C85858672CF240DE873F17A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_9DFB3F050C85858672CF240DE873F17A" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_EliLillyAndCompanyMember" xlink:label="loc_nktr_EliLillyAndCompanyMember_8F891E727F8372BC2FEA240DE8732FEB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:to="loc_nktr_EliLillyAndCompanyMember_8F891E727F8372BC2FEA240DE8732FEB" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_EliLillyMember" xlink:label="loc_nktr_EliLillyMember_8A33A80393F9424E53D6240DE8732535" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:to="loc_nktr_EliLillyMember_8A33A80393F9424E53D6240DE8732535" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AmgenIncMember" xlink:label="loc_nktr_AmgenIncMember_5363D8F1BE0B28C4183B240DE874DD68" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:to="loc_nktr_AmgenIncMember_5363D8F1BE0B28C4183B240DE874DD68" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AstraZenecaAbMember" xlink:label="loc_nktr_AstraZenecaAbMember_02406795D7E9A1251FC4240DE874D749" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:to="loc_nktr_AstraZenecaAbMember_02406795D7E9A1251FC4240DE874D749" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OtherPartnerMember" xlink:label="loc_nktr_OtherPartnerMember_6764A4830985DF7B3434240DE8748B83" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9574A31D3B388A3255BE240DE8738882" xlink:to="loc_nktr_OtherPartnerMember_6764A4830985DF7B3434240DE8748B83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_37F37A313D75F40D656E240DE8744B43" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_37F37A313D75F40D656E240DE8744B43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_37F37A313D75F40D656E240DE8744B43" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_HemophiliaMember" xlink:label="loc_nktr_HemophiliaMember_0549D893244EBB27DABA240DE875BCD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:to="loc_nktr_HemophiliaMember_0549D893244EBB27DABA240DE875BCD0" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_BMSCollaborationAgreementMember" xlink:label="loc_nktr_BMSCollaborationAgreementMember_DDBAD6FF5B6C69CC9BC2240DE875FA5A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:to="loc_nktr_BMSCollaborationAgreementMember_DDBAD6FF5B6C69CC9BC2240DE875FA5A" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ClinicalTrialAgreementMember" xlink:label="loc_nktr_ClinicalTrialAgreementMember_E2277BADC346DF62A033240DE875E220" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:to="loc_nktr_ClinicalTrialAgreementMember_E2277BADC346DF62A033240DE875E220" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NektarThreeFiveEightMember" xlink:label="loc_nktr_NektarThreeFiveEightMember_EF2EF49B3BB01A1CAA69240DE8758D83" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:to="loc_nktr_NektarThreeFiveEightMember_EF2EF49B3BB01A1CAA69240DE8758D83" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PhaseOneClinicalDevelopmentMember" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_360AED5278179C31DDF3240DE8768B1A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:to="loc_nktr_PhaseOneClinicalDevelopmentMember_360AED5278179C31DDF3240DE8768B1A" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_DrugProductDevelopmentMember" xlink:label="loc_nktr_DrugProductDevelopmentMember_7CCCC632A5CAC9F3B483240DE876275E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:to="loc_nktr_DrugProductDevelopmentMember_7CCCC632A5CAC9F3B483240DE876275E" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_MOVANTIKAndMOVENTIGMember" xlink:label="loc_nktr_MOVANTIKAndMOVENTIGMember_DE5D9A0E7A9A3A3CCAA3240DE876CBB9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:to="loc_nktr_MOVANTIKAndMOVENTIGMember_DE5D9A0E7A9A3A3CCAA3240DE876CBB9" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AstraZenecaAgreementWithKirinMember" xlink:label="loc_nktr_AstraZenecaAgreementWithKirinMember_8020127879189B711ADD240DE876B323" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:to="loc_nktr_AstraZenecaAgreementWithKirinMember_8020127879189B711ADD240DE876B323" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NektarMember" xlink:label="loc_nktr_NektarMember_34CC8717FC84A52F2FEC240DE876DC29" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77BDB8C89ED484C36B6F240DE8746B2C" xlink:to="loc_nktr_NektarMember_34CC8717FC84A52F2FEC240DE876DC29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_2221472B029E4CB8F6AD240DE87644C2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_srt_StatementGeographicalAxis_2221472B029E4CB8F6AD240DE87644C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_2952CB7755C4CACEA1F3240DE8763047" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2221472B029E4CB8F6AD240DE87644C2" xlink:to="loc_srt_SegmentGeographicalDomain_2952CB7755C4CACEA1F3240DE8763047" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_989EB8136EA244DC26AD240DE8779E26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2952CB7755C4CACEA1F3240DE8763047" xlink:to="loc_us-gaap_EuropeanUnionMember_989EB8136EA244DC26AD240DE8779E26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_92D1977C48E591CFA7F8240DE877AC03" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_srt_ProductOrServiceAxis_92D1977C48E591CFA7F8240DE877AC03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_9786066F0D173F846E7C240DE87746DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_92D1977C48E591CFA7F8240DE877AC03" xlink:to="loc_srt_ProductsAndServicesDomain_9786066F0D173F846E7C240DE87746DE" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NektarTwoOneFourMember" xlink:label="loc_nktr_NektarTwoOneFourMember_E6580671CCD95B959A1E240DE87874A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9786066F0D173F846E7C240DE87746DE" xlink:to="loc_nktr_NektarTwoOneFourMember_E6580671CCD95B959A1E240DE87874A0" xlink:type="arc" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9786066F0D173F846E7C240DE87746DE" xlink:to="loc_nktr_NektarThreeFiveEightMember_EF2EF49B3BB01A1CAA69240DE8758D83" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NektarThreeFiveEightLicenseMember" xlink:label="loc_nktr_NektarThreeFiveEightLicenseMember_00933A0E6E561A79C211240DE87836E3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9786066F0D173F846E7C240DE87746DE" xlink:to="loc_nktr_NektarThreeFiveEightLicenseMember_00933A0E6E561A79C211240DE87836E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_AFD0B26557058927F051240DE878BF1A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_srt_ConsolidatedEntitiesAxis_AFD0B26557058927F051240DE878BF1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_B7B8C7034CCDAF7DFAA3240DE878F02D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_AFD0B26557058927F051240DE878BF1A" xlink:to="loc_srt_ConsolidatedEntitiesDomain_B7B8C7034CCDAF7DFAA3240DE878F02D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ParentCompanyMember" xlink:label="loc_srt_ParentCompanyMember_A120878CDC8738704729240DE8793C3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_B7B8C7034CCDAF7DFAA3240DE878F02D" xlink:to="loc_srt_ParentCompanyMember_A120878CDC8738704729240DE8793C3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_246716A12EF89B4FE888240DE879AF75" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_246716A12EF89B4FE888240DE879AF75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10CA257573A0B63ABB10240DE879670A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_246716A12EF89B4FE888240DE879AF75" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10CA257573A0B63ABB10240DE879670A" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OpdivoMember" xlink:label="loc_nktr_OpdivoMember_D05E10C1E0BCAB56A672240DE8795470" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10CA257573A0B63ABB10240DE879670A" xlink:to="loc_nktr_OpdivoMember_D05E10C1E0BCAB56A672240DE8795470" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OpdivoAndYervoyMember" xlink:label="loc_nktr_OpdivoAndYervoyMember_D0A252CBF8ED910D5C79240DE8798006" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10CA257573A0B63ABB10240DE879670A" xlink:to="loc_nktr_OpdivoAndYervoyMember_D0A252CBF8ED910D5C79240DE8798006" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9115477101444FF6B6DE240DE87ADF33" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_srt_RangeAxis_9115477101444FF6B6DE240DE87ADF33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_05ECB0B476A3320C2B6C240DE87A9196" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9115477101444FF6B6DE240DE87ADF33" xlink:to="loc_srt_RangeMember_05ECB0B476A3320C2B6C240DE87A9196" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_0F2C6D6426AAC6A29832240DE87A7F69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_05ECB0B476A3320C2B6C240DE87A9196" xlink:to="loc_srt_MaximumMember_0F2C6D6426AAC6A29832240DE87A7F69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_47E828B6EA4B8D502D59240DE87AB73C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_05ECB0B476A3320C2B6C240DE87A9196" xlink:to="loc_srt_MinimumMember_47E828B6EA4B8D502D59240DE87AB73C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_EC4258FED493CAFEE22B240DE87BA3FF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_EC4258FED493CAFEE22B240DE87BA3FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58EC923DA2FED0EE633F240DE87B1D02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_EC4258FED493CAFEE22B240DE87BA3FF" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58EC923DA2FED0EE633F240DE87B1D02" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_SharePurchaseAgreementMember" xlink:label="loc_nktr_SharePurchaseAgreementMember_9685DAB7E7773485C3C1240DE87B695F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58EC923DA2FED0EE633F240DE87B1D02" xlink:to="loc_nktr_SharePurchaseAgreementMember_9685DAB7E7773485C3C1240DE87B695F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_FB54A9D5B9D156E385C7240DE87B9913" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_FB54A9D5B9D156E385C7240DE87B9913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_23AE80A4420F7908F3D2240DE87B5105" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FB54A9D5B9D156E385C7240DE87B9913" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_23AE80A4420F7908F3D2240DE87B5105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1B7E70A7C05984BCD9EC240DE87C57E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_23AE80A4420F7908F3D2240DE87B5105" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1B7E70A7C05984BCD9EC240DE87C57E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23CD38861EF53B17CFA9240DE87C9584" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23CD38861EF53B17CFA9240DE87C9584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7152D14D2133911A324D240DE87C4E15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23CD38861EF53B17CFA9240DE87C9584" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7152D14D2133911A324D240DE87C4E15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_6499D1A865B2EDB8719C240DE87C4CA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_7152D14D2133911A324D240DE87C4E15" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_6499D1A865B2EDB8719C240DE87C4CA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelAxis" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_C8DD08FD5057ED6C0FA6240DE87D2797" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_C8DD08FD5057ED6C0FA6240DE87D2797" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_909B6BA32EB1C837B8D6240DE87D8E87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_C8DD08FD5057ED6C0FA6240DE87D2797" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_909B6BA32EB1C837B8D6240DE87D8E87" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AnnualSalesLevelMilestoneMember" xlink:label="loc_nktr_AnnualSalesLevelMilestoneMember_0D697836DE9B89B4F0D7240DE87DBCA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_909B6BA32EB1C837B8D6240DE87D8E87" xlink:to="loc_nktr_AnnualSalesLevelMilestoneMember_0D697836DE9B89B4F0D7240DE87DBCA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A12F5D434258F6725FF0240DE87212D4" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_A2BA62362F09AF30382D240DE87E7B09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_A2BA62362F09AF30382D240DE87E7B09" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_DC7232A4D0A29CA7FE5E240DE87EF743" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_DC7232A4D0A29CA7FE5E240DE87EF743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8AA9E9A25CAC9A582761240DE87EF2ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8AA9E9A25CAC9A582761240DE87EF2ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1480C47463E4FC9CE328240DE87E0491" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1480C47463E4FC9CE328240DE87E0491" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_09F6F3CE020A9025806E240DE87E26D8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_09F6F3CE020A9025806E240DE87E26D8" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ProfitsAndLossesSharingPercentage" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage_DF4FDF60626EB0B28BA7240DE87E7853" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_ProfitsAndLossesSharingPercentage_DF4FDF60626EB0B28BA7240DE87E7853" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfSharingInDevelopmentCosts" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_8BE1B7EE5F89040F5EA3240DE87F0368" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_8BE1B7EE5F89040F5EA3240DE87F0368" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfSharingInProductionCosts" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_6412570336C7AE017C16240DE87F8169" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_6412570336C7AE017C16240DE87F8169" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner" xlink:label="loc_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_9181DEEA6BB046087B75240DE87F9736" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner_9181DEEA6BB046087B75240DE87F9736" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_54756B666E5EC1BFB66C240DE87FEA62" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_54756B666E5EC1BFB66C240DE87FEA62" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_9F3BBF085044F7A82967240DE87F3018" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_9F3BBF085044F7A82967240DE87F3018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_8FAD0AFB4916DC060DDA240DE8801A12" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_us-gaap_SharesIssued_8FAD0AFB4916DC060DDA240DE8801A12" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_SaleOfStockConsiderationReceived" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_8DF12339BEE5840F4BC3240DE880525F" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_8DF12339BEE5840F4BC3240DE880525F" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_ReimbursementOfExpenses" xlink:label="loc_nktr_ReimbursementOfExpenses_E3E3829DFC9F9E8A1792240DE880ADB3" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_ReimbursementOfExpenses_E3E3829DFC9F9E8A1792240DE880ADB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0CE450CA6F32087F649F240DE8802D89" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0CE450CA6F32087F649F240DE8802D89" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AggregateConsiderationReceivedFromAgreements" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements_4BDF4B8E260F86E1D94D240DE8816968" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_AggregateConsiderationReceivedFromAgreements_4BDF4B8E260F86E1D94D240DE8816968" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_EstimatedFairValueOfShares" xlink:label="loc_nktr_EstimatedFairValueOfShares_D633B6310C6488A63B09240DE881A842" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_EstimatedFairValueOfShares_D633B6310C6488A63B09240DE881A842" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_695FE58402791E1A4242240DE88147BC" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_695FE58402791E1A4242240DE88147BC" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_RemainingAmountAllocatedToTransactionPrice" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice_97FFE04CF388E3F4D3AB240DE881235C" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_RemainingAmountAllocatedToTransactionPrice_97FFE04CF388E3F4D3AB240DE881235C" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:label="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_DA8D39DD70374B279D71240DE8818AFE" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_DA8D39DD70374B279D71240DE8818AFE" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AmountRecognizedForGrantingLicenses" xlink:label="loc_nktr_AmountRecognizedForGrantingLicenses_E31501D36409EF5E4FC1240DE881F202" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_AmountRecognizedForGrantingLicenses_E31501D36409EF5E4FC1240DE881F202" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_491F316DFCC186BC92F7240DE882270E" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_491F316DFCC186BC92F7240DE882270E" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_A5AB6CDBC2F8535AB212240DE882030D" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_A5AB6CDBC2F8535AB212240DE882030D" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7BF4B4D5EAEB93BEC923240DE88280F1" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_7BF4B4D5EAEB93BEC923240DE88280F1" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_4C324B5E4418944D0D10240DE8827216" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_4C324B5E4418944D0D10240DE8827216" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_C983344EA4B6D9AB50F0240DE882E4DD" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_C983344EA4B6D9AB50F0240DE882E4DD" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_75111105C95217A15F7F240DE8829787" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_75111105C95217A15F7F240DE8829787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3CC6917EE2AAE03832B7240DE8833CFF" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3CC6917EE2AAE03832B7240DE8833CFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4EB0EA3AC608A2E1AF00240DE8832F91" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4EB0EA3AC608A2E1AF00240DE8832F91" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:label="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_16C7E3C800209745E007240DE883CAF8" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_16C7E3C800209745E007240DE883CAF8" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_7B1B478D541FB1990FD3240DE883CF52" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_7B1B478D541FB1990FD3240DE883CF52" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_FA2463F8D4FF717D22FA240DE883BF25" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_FA2463F8D4FF717D22FA240DE883BF25" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement" xlink:label="loc_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement_06697B12EA0F0735B9DE240DE88358A3" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement_06697B12EA0F0735B9DE240DE88358A3" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum" xlink:label="loc_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum_E0FC436A576DBA1762A8240DE8847C5E" xlink:type="locator" />
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum_E0FC436A576DBA1762A8240DE8847C5E" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CostsIncurredShareOfExpenses" xlink:label="loc_nktr_CostsIncurredShareOfExpenses_916CCB75CA22A8F07265240DE8846E82" xlink:type="locator" />
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_CostsIncurredShareOfExpenses_916CCB75CA22A8F07265240DE8846E82" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_PotentialDevelopmentMilestones" xlink:label="loc_nktr_PotentialDevelopmentMilestones_D026954A18145D13FC5A240DE8844A27" xlink:type="locator" />
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5D3A85B388E5700DB612240DE87DF224" xlink:to="loc_nktr_PotentialDevelopmentMilestones_D026954A18145D13FC5A240DE8844A27" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseAndCollaborationAgreementsChangesInDeferredRevenueBalanceFromCollaborationAgreementsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2603E12B98C854409562DF33D4AB3BCD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_7C1BD88AB8BC5B278AF132D11DD0E81E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2603E12B98C854409562DF33D4AB3BCD" xlink:to="loc_us-gaap_ContractWithCustomerLiability_7C1BD88AB8BC5B278AF132D11DD0E81E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_649FC627CB92503C96C4A9EF121E5213" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2603E12B98C854409562DF33D4AB3BCD" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_649FC627CB92503C96C4A9EF121E5213" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5EDBD04394FD5570AB171FDA6E5FDAD6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2603E12B98C854409562DF33D4AB3BCD" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5EDBD04394FD5570AB171FDA6E5FDAD6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8A1E7DE4B23A8288BE2C24067A672E54" xlink:type="locator" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LicenseAndCollaborationAgreementsTable" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable_17D8E3CB27F988D7D57E24067A6800CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8A1E7DE4B23A8288BE2C24067A672E54" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsTable_17D8E3CB27F988D7D57E24067A6800CD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_F67B1A3028E555727BB024067A686948" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_17D8E3CB27F988D7D57E24067A6800CD" xlink:to="loc_dei_LegalEntityAxis_F67B1A3028E555727BB024067A686948" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1DED3D2A9C15E803030424067A69FFFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_F67B1A3028E555727BB024067A686948" xlink:to="loc_dei_EntityDomain_1DED3D2A9C15E803030424067A69FFFA" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_BristolMyersSquibbCompanyMember" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_69A10847E970C593F5DF24067A69C488" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1DED3D2A9C15E803030424067A69FFFA" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_69A10847E970C593F5DF24067A69C488" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_EliLillyAndCompanyMember" xlink:label="loc_nktr_EliLillyAndCompanyMember_D70C36B2B9BE3F12D98F24067A695E92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1DED3D2A9C15E803030424067A69FFFA" xlink:to="loc_nktr_EliLillyAndCompanyMember_D70C36B2B9BE3F12D98F24067A695E92" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_AmgenIncMember" xlink:label="loc_nktr_AmgenIncMember_8EFE39DF8EAE0C509D6F24067A6A7E7C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1DED3D2A9C15E803030424067A69FFFA" xlink:to="loc_nktr_AmgenIncMember_8EFE39DF8EAE0C509D6F24067A6A7E7C" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OtherPartnerMember" xlink:label="loc_nktr_OtherPartnerMember_C2C1826CE89F77DE7CBA24067A6A6D19" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1DED3D2A9C15E803030424067A69FFFA" xlink:to="loc_nktr_OtherPartnerMember_C2C1826CE89F77DE7CBA24067A6A6D19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F50F36B92EEC82F2254224067A6A05E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_17D8E3CB27F988D7D57E24067A6800CD" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F50F36B92EEC82F2254224067A6A05E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_155D7294020CB2CE9E6E24067A6B3956" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F50F36B92EEC82F2254224067A6A05E9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_155D7294020CB2CE9E6E24067A6B3956" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NektarTwoOneFourMember" xlink:label="loc_nktr_NektarTwoOneFourMember_8F502B7ED56FED3ACA2E24067A6B94A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_155D7294020CB2CE9E6E24067A6B3956" xlink:to="loc_nktr_NektarTwoOneFourMember_8F502B7ED56FED3ACA2E24067A6B94A3" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NektarThreeFiveEightMember" xlink:label="loc_nktr_NektarThreeFiveEightMember_E55A6D8A17B9A84192EE24067A6CB955" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_155D7294020CB2CE9E6E24067A6B3956" xlink:to="loc_nktr_NektarThreeFiveEightMember_E55A6D8A17B9A84192EE24067A6CB955" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_NeulastaMember" xlink:label="loc_nktr_NeulastaMember_78124CA411E62E1EC49624067A6CBC35" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_155D7294020CB2CE9E6E24067A6B3956" xlink:to="loc_nktr_NeulastaMember_78124CA411E62E1EC49624067A6CBC35" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LicenseAndCollaborationAgreementsLineItems" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems_2681DA383C6FA5200C3024067A6CF7D2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_17D8E3CB27F988D7D57E24067A6800CD" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsLineItems_2681DA383C6FA5200C3024067A6CF7D2" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LicenseCollaborationOtherRevenue" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue_82CC4F2519B33E65A9BA24067A6C9B0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_2681DA383C6FA5200C3024067A6CF7D2" xlink:to="loc_nktr_LicenseCollaborationOtherRevenue_82CC4F2519B33E65A9BA24067A6C9B0F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseAndCollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0B003CEA64965A9E9436230CA7C99F88" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_24903EEB4C585DA9BE616D3A4BAAC0C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0B003CEA64965A9E9436230CA7C99F88" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_24903EEB4C585DA9BE616D3A4BAAC0C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_C2FE5195D8F357858545A9D40576B73A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0B003CEA64965A9E9436230CA7C99F88" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_C2FE5195D8F357858545A9D40576B73A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/NetIncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_E2F953D728955AA9875CE779DEA860DC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_F4C4E8E7EFD35379BFA203331AA6ED23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E2F953D728955AA9875CE779DEA860DC" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_F4C4E8E7EFD35379BFA203331AA6ED23" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/NetIncomeLossPerShareAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6A5E0DDB238231628DDB1981654A96F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13D74808B814D69A729319816559EB10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6A5E0DDB238231628DDB1981654A96F1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13D74808B814D69A729319816559EB10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_97BA751453A860F80CC91981655A08BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13D74808B814D69A729319816559EB10" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_97BA751453A860F80CC91981655A08BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_E99A0E103C9CD63411A71981655A54AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_97BA751453A860F80CC91981655A08BC" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_E99A0E103C9CD63411A71981655A54AA" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_StockOptionsAndRestrictedStockUnitsMember" xlink:label="loc_nktr_StockOptionsAndRestrictedStockUnitsMember_4DB124B721755CCA734E1981655A4B54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_E99A0E103C9CD63411A71981655A54AA" xlink:to="loc_nktr_StockOptionsAndRestrictedStockUnitsMember_4DB124B721755CCA734E1981655A4B54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B62141538BA797E4CC841981655B2167" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_13D74808B814D69A729319816559EB10" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B62141538BA797E4CC841981655B2167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C8AEBB36AAC038B425A11981655B42BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B62141538BA797E4CC841981655B2167" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C8AEBB36AAC038B425A11981655B42BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C25CC2A12F34A7A2D22C1981655B4A83" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B62141538BA797E4CC841981655B2167" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C25CC2A12F34A7A2D22C1981655B4A83" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_763044C644775EB182E8827DF87145D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_150BE860EF315CB88965F0D448799666" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_763044C644775EB182E8827DF87145D8" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_150BE860EF315CB88965F0D448799666" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97BF5CDF081F5D76D5FA2410C43881FD" xlink:type="locator" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_97BF5CDF081F5D76D5FA2410C43881FD" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_81F4282E6CDC1231F5CE2410C438D977" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF" xlink:to="loc_srt_CounterpartyNameAxis_81F4282E6CDC1231F5CE2410C438D977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3B6A2A47F21B983655EC2410C4390874" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_81F4282E6CDC1231F5CE2410C438D977" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3B6A2A47F21B983655EC2410C4390874" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CollaborationPartnerMember" xlink:label="loc_nktr_CollaborationPartnerMember_837C97215E35536B09D92410C4399D39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3B6A2A47F21B983655EC2410C4390874" xlink:to="loc_nktr_CollaborationPartnerMember_837C97215E35536B09D92410C4399D39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C66946791A3091079822410C439101A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C66946791A3091079822410C439101A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_F1B18BFA736F339DB1952410C4391A5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C66946791A3091079822410C439101A" xlink:to="loc_us-gaap_TypeOfAdoptionMember_F1B18BFA736F339DB1952410C4391A5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_63B7C2CB96727936AE4B2410C4393AA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_F1B18BFA736F339DB1952410C4391A5E" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_63B7C2CB96727936AE4B2410C4393AA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_6437864FB68F67C76FB02410C43A4985" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF" xlink:to="loc_srt_StatementGeographicalAxis_6437864FB68F67C76FB02410C43A4985" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_361C6B1197DB8DDE0CCD2410C43A8349" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6437864FB68F67C76FB02410C43A4985" xlink:to="loc_srt_SegmentGeographicalDomain_361C6B1197DB8DDE0CCD2410C43A8349" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_IN" xlink:label="loc_country_IN_1ECBF4BA13380F5C37FC2410C43AFDED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_361C6B1197DB8DDE0CCD2410C43A8349" xlink:to="loc_country_IN_1ECBF4BA13380F5C37FC2410C43AFDED" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5BF3B0CEE3F703A03CB32410C438D8EF" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_48FE25BBC82F48D53B082410C43B5516" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_48FE25BBC82F48D53B082410C43B5516" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotes" xlink:label="loc_us-gaap_SeniorNotes_0AA4A5CF705DBCB92C6A2410C43BD303" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_us-gaap_SeniorNotes_0AA4A5CF705DBCB92C6A2410C43BD303" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_90A1ACB53471618FA1FF2410C43BBC85" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_us-gaap_NumberOfOperatingSegments_90A1ACB53471618FA1FF2410C43BBC85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9A1FB2B9C87A2994FF912410C43B3B25" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9A1FB2B9C87A2994FF912410C43B3B25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6F2D8DB33F2EE7DE36CC2410C43B7D20" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6F2D8DB33F2EE7DE36CC2410C43B7D20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_B463F2E97D9F7A3FDAC92410C43BE76E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_us-gaap_OperatingLeaseLiability_B463F2E97D9F7A3FDAC92410C43BE76E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_C72775C82149D11D70312410C43C503D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_C72775C82149D11D70312410C43C503D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5202C963CA09799790362410C43CD9DD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5202C963CA09799790362410C43CD9DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_17263E115CD84E7011CE2410C43C1DF9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_C031C4C2F71C48609B8B2410C43B4EAC" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_17263E115CD84E7011CE2410C43C1DF9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F64614386D0A19EA15D424AFF164112" xlink:type="locator" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_OrganizationPolicyTextBlock" xlink:label="loc_nktr_OrganizationPolicyTextBlock_0E1B3CC0AA9A941705E7424AFF173870" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F64614386D0A19EA15D424AFF164112" xlink:to="loc_nktr_OrganizationPolicyTextBlock_0E1B3CC0AA9A941705E7424AFF173870" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_8896FB7F238209726314424AFF1714B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F64614386D0A19EA15D424AFF164112" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_8896FB7F238209726314424AFF1714B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_17BF6685D0A225E5D9B5424AFF17BD78" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F64614386D0A19EA15D424AFF164112" xlink:to="loc_us-gaap_UseOfEstimates_17BF6685D0A225E5D9B5424AFF17BD78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_47A5801472FD77BB35C8424AFF170DC4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F64614386D0A19EA15D424AFF164112" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_47A5801472FD77BB35C8424AFF170DC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_0C1FABB35F890327C4D8424AFF18E809" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F64614386D0A19EA15D424AFF164112" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_0C1FABB35F890327C4D8424AFF18E809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_5B3B158855D659163253424AFF18195D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F64614386D0A19EA15D424AFF164112" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_5B3B158855D659163253424AFF18195D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_8C1905C0335D8ADE27DB424AFF181668" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F64614386D0A19EA15D424AFF164112" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_8C1905C0335D8ADE27DB424AFF181668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_AB10BE4A9889CD772759424AFF186065" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F64614386D0A19EA15D424AFF164112" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_AB10BE4A9889CD772759424AFF186065" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5F1196D9922BF85C83D1424AFF185FA1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F64614386D0A19EA15D424AFF164112" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5F1196D9922BF85C83D1424AFF185FA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_CFD359A26A66439BA4E2424AFF19AD23" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F64614386D0A19EA15D424AFF164112" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_CFD359A26A66439BA4E2424AFF19AD23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D0611389F956C0CEB8DC424AFF19CB1A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F64614386D0A19EA15D424AFF164112" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_D0611389F956C0CEB8DC424AFF19CB1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_5154BB08BE7D937798DD424AFF19B75B" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F64614386D0A19EA15D424AFF164112" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_5154BB08BE7D937798DD424AFF19B75B" xlink:type="arc" />
    <link:loc xlink:href="nktr-20190930.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_1DF0C8BEE9321D700D54424AFF193CA6" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F64614386D0A19EA15D424AFF164112" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_1DF0C8BEE9321D700D54424AFF193CA6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_754FDE5A36EF5D3CB41A12FE3F757733" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_F411070828EB593A8E0FFB30BA997075" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_754FDE5A36EF5D3CB41A12FE3F757733" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_F411070828EB593A8E0FFB30BA997075" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_476C1986628F5759FA583E2EDB923154" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FD9F5D81C8D1FCACC3C13E2EDB9277D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_476C1986628F5759FA583E2EDB923154" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FD9F5D81C8D1FCACC3C13E2EDB9277D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7D0491AAA506A7B3B23E3E2EDB92F49D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FD9F5D81C8D1FCACC3C13E2EDB9277D0" xlink:to="loc_us-gaap_AwardTypeAxis_7D0491AAA506A7B3B23E3E2EDB92F49D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B64D9BC43AD5047A8FE3E2EDB936661" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7D0491AAA506A7B3B23E3E2EDB92F49D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B64D9BC43AD5047A8FE3E2EDB936661" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_479F34B0F5AED7883D273E2EDB94DE66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B64D9BC43AD5047A8FE3E2EDB936661" xlink:to="loc_us-gaap_EmployeeStockOptionMember_479F34B0F5AED7883D273E2EDB94DE66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5FB6AB3EF71BA5CDCF573E2EDB94C936" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B64D9BC43AD5047A8FE3E2EDB936661" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5FB6AB3EF71BA5CDCF573E2EDB94C936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FD9F5D81C8D1FCACC3C13E2EDB9277D0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9F4DFA840F13F40357543E2EDB9406B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9F4DFA840F13F40357543E2EDB9406B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FA86BA7F7EE2FBFE8243E2EDB95F583" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3FA86BA7F7EE2FBFE8243E2EDB95F583" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18AD850A0C93C86E6CD93E2EDB95BEC3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_18AD850A0C93C86E6CD93E2EDB95BEC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D228B40D5A7363DE0F7F3E2EDB959DB1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_D228B40D5A7363DE0F7F3E2EDB959DB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_72EC530EFF06DF7085903E2EDB953060" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4050D00B9133B50D14BB3E2EDB946C61" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_72EC530EFF06DF7085903E2EDB953060" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_814754801F825932A6B2792C25AFD187" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790DB18DF9835F3193643A219CD6FEF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_814754801F825932A6B2792C25AFD187" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790DB18DF9835F3193643A219CD6FEF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_D7E19384712C56149EA6A0FBBDE84850" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790DB18DF9835F3193643A219CD6FEF9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_D7E19384712C56149EA6A0FBBDE84850" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E98871E9B8255E11BBA48525C5213593" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D7E19384712C56149EA6A0FBBDE84850" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_E98871E9B8255E11BBA48525C5213593" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_4EA448AE2F20555B8F4B4A099960F5D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E98871E9B8255E11BBA48525C5213593" xlink:to="loc_us-gaap_CostOfSalesMember_4EA448AE2F20555B8F4B4A099960F5D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_CEC5D9D7164D5A05AD3048F082E72921" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E98871E9B8255E11BBA48525C5213593" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_CEC5D9D7164D5A05AD3048F082E72921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_12D3063FD3985499A15318EEC7DA1695" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E98871E9B8255E11BBA48525C5213593" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_12D3063FD3985499A15318EEC7DA1695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2C49BE85D82F5F46ACDF0842B09D3FDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_790DB18DF9835F3193643A219CD6FEF9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2C49BE85D82F5F46ACDF0842B09D3FDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3176C3E9D800561CB16D3469327BB98D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2C49BE85D82F5F46ACDF0842B09D3FDB" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3176C3E9D800561CB16D3469327BB98D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_78D2A4A04DFCCF96EBD123C003C9C913" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_84E003BA75C4598F9C7323C003C9A158" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_78D2A4A04DFCCF96EBD123C003C9C913" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_84E003BA75C4598F9C7323C003C9A158" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_9E128A7493B899C1EF2223DA4092F3CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_78D2A4A04DFCCF96EBD123C003C9C913" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_9E128A7493B899C1EF2223DA4092F3CB" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812031360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Matters</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 30, 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California, which complaint was subsequently amended on May 15, 2019.&#160;&#160;Also, on February 13, 2019, and February 18, 2019, shareholder derivative complaints were filed in the U.S. District Court for the District of Delaware naming the CEO, CFO and certain members of Nektar&#8217;s board. Both the class action and shareholder derivative actions assert, among other things, that for a period beginning at least from November 11, 2017 through October 2, 2018, our stock was inflated due to alleged misrepresentations about the efficacy and safety of NKTR-214. In addition, on August 19, 2019, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California, which complaint asserted, among other things, that for a period between February 15, 2019 and August 8, 2019, inclusive, our stock was inflated due to an alleged failure to disclose a NKTR-214 manufacturing issue. All of these cases are in the early stages. Accordingly, we cannot reasonably estimate any range of potential future charges, and we have not recorded any accrual for a contingent liability associated with these legal proceedings. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Indemnifications in Connection with Commercial Agreements</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual any time after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants, including our obligation to RPI described in Note 5. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification obligations, representations or warranties. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> liabilities for these obligations in our Condensed Consolidated Balance Sheets at either </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6840435264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Organization</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes treatments for cancer, autoimmune disease and chronic pain.</span></div>Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our consolidated financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries:  Inheris Biopharma, Inc., Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our comprehensive income (loss) consists of our net income (loss) plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities, neither of which were significant during the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. In addition, there were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> filed with the SEC on March 1, 2019. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We operate in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> business segment by our Chief Executive Officer.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Significant Concentrations</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant Concentrations</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones, other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, our accounts receivable includes </span><span style="font-family:inherit;font-size:10pt;"><span>$27.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$24.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, for net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS). </span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2019, we adopted Accounting Standards Codification (ASC) 842, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (ASC 842). ASC 842 supersedes the guidance in ASC 840, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (ASC 840). Under ASC 842, an entity recognizes a right-of-use asset and a corresponding lease liability, measured as the present value of the lease payments. In our adoption, we used the package of practical expedients, which, among other things, allowed us to carry forward our historical lease classification of those leases in effect as of January 1, 2019. We present results for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> under ASC 842. We have not restated the results for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and our financial position as of December 31, 2018, and continue to report them under ASC 840.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. However, in determining the present value of our lease payments for leases in effect when we adopted ASC 842, we used our incremental borrowing rate as of January 1, 2019. </span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our real estate leases, and elected the short-term lease recognition exemption for our short-term leases, which allows us not to recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term.</span></div>We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts. For leases in effect as of January 1, 2019, we recognized our lease incentives as part of our transition adjustment.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:inherit;font-size:10pt;"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Sales</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Royalty Revenue</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Generally, we are entitled to royalties from our collaboration partners based on the net sales of their approved drugs that are marketed and sold in one or more countries where we hold royalty rights. For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">License, Collaboration and other Revenue</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">License Grants</span><span style="font-family:inherit;font-size:10pt;">:&#160;For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Milestone Payments</span><span style="font-family:inherit;font-size:10pt;">:&#160;At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">a clinical study or filing for or receipt of regulatory approval, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. Our partners generally pay development milestones</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">subsequent to</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">achievement of the triggering event.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Services</span><span style="font-family:inherit;font-size:10pt;">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expense</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a clinical joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined to be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best </span></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we recorded an income tax provision for our Nektar India operations at an effective tax rate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>33%</span></span><span style="font-family:inherit;font-size:10pt;">. Due to our net loss and unrealized gain on available-for-sale securities in the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we recorded a tax provision against such unrealized gain with an offsetting tax benefit in continuing operations of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. For the three months ended September 30, 2019, however, since we had a loss on our available-for-sale securities, we recorded a benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> against our unrealized loss in available-for-sale securities with an offsetting expense in continuing operations. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is effective in the first quarter of 2020 and should be applied retrospectively to January 1, 2018, when we adopted ASC 606. Early adoption is permitted. We are evaluating the effect of adoption, but we do not expect a material effect on our revenue.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#8220;incurred loss&#8221; model with an &#8220;expected loss&#8221; model. Accordingly, we will present these financial assets at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. ASU 2016-13 is effective in the first quarter of 2020. Early adoption is permitted. We are currently evaluating the impact of adoption of this ASU, but we do not anticipate that adoption will have a material effect on our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">nventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock', window );">Liability Related to Sale of Future Royalties</a></td>
<td class="text">We periodically assess the estimated royalty payments to RPI from UCB and Roche, and, to the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different from our original estimates, we will prospectively adjust the amortization of the Royalty Obligation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6824523280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Cash and Investments in Marketable Securities</a></td>
<td class="text">Cash and Investments in Marketable Securities<div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value at</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,224</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194,905</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,414,448</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,140,445</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>231,082</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>582,889</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash and investments in marketable securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,726,754</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,918,239</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, all of our long-term investments had maturities between </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross unrealized gains and losses were not significant at either </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">. During the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the three months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, we sold </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> available-for-sale securities. During the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, we sold available-for-sale securities totaling&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$12.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, and  gross realized gains and losses on those </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> sales were not significant.&#160;The cost of securities sold is based on the specific identification method.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of our </span><span style="font-family:inherit;font-size:10pt;"><span>7.75%</span></span><span style="font-family:inherit;font-size:10pt;"> senior secured notes due </span><span style="font-family:inherit;font-size:10pt;">October 2020</span><span style="font-family:inherit;font-size:10pt;">, we are required to maintain a minimum cash and investments in marketable securities balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our portfolio of cash and investments in marketable securities includes (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:59%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value at</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hierarchy</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate notes and bonds</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,163,575</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,288,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>482,468</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>498,048</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Obligations of U.S. government agencies</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,646,043</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,800,011</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,674</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,656</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificate of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">N/A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,871</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,760</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">N/A</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,166</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,812</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash and investments in marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,726,754</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,918,239</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">____________________________</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;1&#160;&#8212;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Quoted prices in active markets for identical assets or liabilities.</span></div></td></tr></table><div style="line-height:120%;padding-left:84px;text-indent:-84px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;2&#160;&#8212;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div></td></tr></table><div style="line-height:120%;padding-left:84px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-left:84px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We use a market approach to value our Level 2 investments. The disclosed fair value related to our investments is based on market prices from a variety of industry standard data providers and generally represents quoted prices for similar assets in active markets or has been derived from observable market data. </span></div><div style="line-height:120%;padding-left:84px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-left:84px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> transfers between Level 1 and Level 2 of the fair value hierarchy.</span></div><div style="line-height:120%;padding-left:84px;text-indent:-84px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level&#160;3&#160;&#8212;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, based on a discounted cash flow analysis using Level 3 inputs including financial discount rates, we believe the fair value of the </span><span style="font-family:inherit;font-size:10pt;"><span>$250.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in principal amount of our </span><span style="font-family:inherit;font-size:10pt;"><span>7.75%</span></span><span style="font-family:inherit;font-size:10pt;"> senior secured notes due </span><span style="font-family:inherit;font-size:10pt;">October 2020</span><span style="font-family:inherit;font-size:10pt;"> is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$252.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. We may redeem some or all of these notes at a redemption price equal to the principal amount of the notes plus accrued and unpaid interest to the redemption date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812066624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Additional Information (Detail) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average potentially dilutive securities included in calculation of diluted securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsAndRestrictedStockUnitsMember', window );">Stock Options and Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6853233184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">76 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2018</div></th>
<th class="th"><div>Aug. 23, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized in period related to performance in prior periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,500,000<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,600,000<span></span>
</td>
<td class="nump">$ 64,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,892,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,392,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,392,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, less current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,744,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,779,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,779,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentAndRegulatoryMilestones', window );">Potential future additional development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,218,000<span></span>
</td>
<td class="nump">27,762,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,755,000<span></span>
</td>
<td class="nump">1,153,497,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,636,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,171,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,171,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NektarThreeFiveEightMember', window );">NKTR-358 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement | NKTR-214 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements', window );">Upfront and milestone payments received from license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProfitsAndLossesSharingPercentage', window );">Global commercialization profits and losses sharing percentage</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones', window );">Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement | NKTR-214 | Nektar's | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones', window );">Eligible additional cash payments receivable upon achievement of certain sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement | NKTR-214 | Nektar's | Opdivo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement | NKTR-214 | Nektar's | Opdivo and Yervoy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember', window );">NKTR-358 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_NektarMember', window );">Nektar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments', window );">Percentage of upfront payment, market access milestones, royalties and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember', window );">Baxalta Incorporated/Takeda | Hemophilia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement', window );">Received under right to sublicense agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember', window );">Baxalta Incorporated/Takeda | Hemophilia | Annual Sales Level Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember', window );">Baxalta Incorporated/Takeda | Hemophilia | European Union</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements', window );">Upfront and milestone payments received from license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,284,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SaleOfStockConsiderationReceived', window );">Sale of stock consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | NKTR-214 | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ReimbursementOfExpenses', window );">Reimbursement of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,300,000<span></span>
</td>
<td class="nump">$ 18,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,400,000<span></span>
</td>
<td class="nump">42,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | BMS Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | BMS Collaboration Agreement | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AggregateConsiderationReceivedFromAgreements', window );">Total consideration received under agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EstimatedFairValueOfShares', window );">Estimated fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 790,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Closing date price of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RemainingAmountAllocatedToTransactionPrice', window );">Remaining amount allocated to transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,059,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones', window );">Potential future development, regulatory and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | BMS Collaboration Agreement | NKTR-214</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProfitsAndLossesSharingPercentage', window );">Global commercialization profits and losses sharing percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountRecognizedForGrantingLicenses', window );">Amount recognized for granting licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,059,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | BMS Collaboration Agreement | NKTR-214 | Opdivo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">67.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | BMS Collaboration Agreement | NKTR-214 | Opdivo and Yervoy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">78.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Clinical Trial Agreement | NKTR-214</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner', window );">Percentage of out-of-pocket costs to be reimbursed by partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358 | ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358 License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation', window );">Amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentAndRegulatoryMilestones', window );">Potential future additional development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions', window );">Percentage of regulatory milestones payments will be reduced under certain conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur', window );">Percentage of regulatory milestones payments will be reduced if conditions occur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358 | Nektar's | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne', window );">Percentage of funding phase 3 development costs on an indication by indication basis borne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358 | Nektar's | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne', window );">Percentage of funding phase 3 development costs on an indication by indication basis borne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Phase 1 Clinical Development | NKTR-358 License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation', window );">Amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Drug Product Development | NKTR-358 License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation', window );">Amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyMember', window );">Eli Lilly | NKTR-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AmgenIncMember', window );">Amgen, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AmgenIncMember', window );">Amgen, Inc. | ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB | MOVANTIK and MOVENTIG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 385,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement', window );">Amount of post approval study expenses eligible for reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum', window );">Amount of post approval study expenses eligible for reimbursement, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CostsIncurredShareOfExpenses', window );">Share of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB | AstraZeneca-Kirin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner', window );">Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments from sublicense agreement retained by our collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Baxalta Inc. / Takeda Pharmaceutical Company Ltd. and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AggregateConsiderationReceivedFromAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate consideration received from agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AggregateConsiderationReceivedFromAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AmountRecognizedForGrantingLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for granting licenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AmountRecognizedForGrantingLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs Incurred, Amount Of Post Approval Study Expenses Eligible For Reimbursement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs Incurred, Amount Of Post Approval Study Expenses Eligible For Reimbursement, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CostsIncurredShareOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs Incurred, Share Of Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CostsIncurredShareOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible additional cash payments receivable upon achievement of certain sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EstimatedFairValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EstimatedFairValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments received under rights to sublicense agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentsReceivedUnderRightsToSublicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received, if conditions occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received under certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of funding Phase three development costs on an indication by indication basis borne.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of out of pocket costs to be reimbursed by partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in Phase 2 development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInProductionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in production costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInProductionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of upfront payment market access milestone payments royalties and sales milestone payments from sublicense agreement retained by our collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development regulatory and sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentRegulatoryAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProfitsAndLossesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profits and losses sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProfitsAndLossesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ReimbursementOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ReimbursementOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RemainingAmountAllocatedToTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amount allocated to transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RemainingAmountAllocatedToTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SaleOfStockConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SaleOfStockConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received from license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NektarThreeFiveEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NektarThreeFiveEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NektarTwoOneFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NektarTwoOneFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoAndYervoyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoAndYervoyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NektarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NektarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=nktr_AnnualSalesLevelMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=nktr_AnnualSalesLevelMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_ClinicalTrialAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_ClinicalTrialAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NektarThreeFiveEightLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NektarThreeFiveEightLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PhaseOneClinicalDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PhaseOneClinicalDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_DrugProductDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_DrugProductDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AstraZenecaAbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKAndMOVENTIGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKAndMOVENTIGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_AstraZenecaAgreementWithKirinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_AstraZenecaAgreementWithKirinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6659842336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (99,206)<span></span>
</td>
<td class="num">$ (97,519)<span></span>
</td>
<td class="num">$ (322,099)<span></span>
</td>
<td class="nump">$ 776,258<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6838036320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Nov. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEKTAR THERAPEUTICS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3134940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">455 Mission Bay Boulevard South<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">482-5300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NKTR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,922,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000906709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6837767360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Maturities of Operating Lease Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2019 (three months ended)</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">15,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">19,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">19,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">20,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix', window );">2024</a></td>
<td class="nump">20,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix', window );">2025 and thereafter</a></td>
<td class="nump">116,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">214,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: portion representing interest</a></td>
<td class="num">(56,621)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements', window );">Less: lease incentives</a></td>
<td class="num">(3,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">154,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(9,318)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">$ 145,099<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year six.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due year six.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability tenant improvement reimbursements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nktr2019-09x30x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "contextCount": 209,
   "dts": {
    "calculationLink": {
     "local": [
      "nktr-20190930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nktr-20190930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml",
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "nktr2019-09x30x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nktr-20190930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nktr-20190930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "nktr-20190930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd"
     ]
    }
   },
   "elementCount": 402,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2018-01-31": 21,
    "http://www.nektar.com/20190930": 7,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 33
   },
   "keyCustom": 55,
   "keyStandard": 256,
   "memberCustom": 33,
   "memberStandard": 28,
   "nsprefix": "nktr",
   "nsuri": "http://www.nektar.com/20190930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0002000 - Document - Cover Page",
     "role": "http://www.nektar.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Inventory",
     "role": "http://www.nektar.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Leases",
     "role": "http://www.nektar.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105100 - Disclosure - Liability Related to Sale of Future Royalties",
     "role": "http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyalties",
     "shortName": "Liability Related to Sale of Future Royalties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Commitments and Contingencies",
     "role": "http://www.nektar.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - License and Collaboration Agreements",
     "role": "http://www.nektar.com/role/LicenseAndCollaborationAgreements",
     "shortName": "License and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Stock-Based Compensation",
     "role": "http://www.nektar.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109100 - Disclosure - Net Income (Loss) Per Share",
     "role": "http://www.nektar.com/role/NetIncomeLossPerShare",
     "shortName": "Net Income (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302301 - Disclosure - Cash and Investments in Marketable Securities (Tables)",
     "role": "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesTables",
     "shortName": "Cash and Investments in Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Inventory (Tables)",
     "role": "http://www.nektar.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "lang": null,
      "name": "nktr:AdvancePaymentsToContractManufacturers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Leases (Tables)",
     "role": "http://www.nektar.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - License and Collaboration Agreements (Tables)",
     "role": "http://www.nektar.com/role/LicenseAndCollaborationAgreementsTables",
     "shortName": "License and Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.nektar.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401402 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Organization and Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_nktrSegment",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)",
     "role": "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail",
     "shortName": "Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail",
     "shortName": "Cash and Investments in Marketable Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "I2015Q4Oct5_us-gaap_DebtInstrumentAxis_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)",
     "role": "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail",
     "shortName": "Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - Inventory - Inventory (Detail)",
     "role": "http://www.nektar.com/role/InventoryInventoryDetail",
     "shortName": "Inventory - Inventory (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/LeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404403 - Disclosure - Leases - Components of Lease Costs Included in Operating Expenses (Detail)",
     "role": "http://www.nektar.com/role/LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail",
     "shortName": "Leases - Components of Lease Costs Included in Operating Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404404 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities (Detail)",
     "role": "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail",
     "shortName": "Leases - Summary of Maturities of Operating Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail",
     "shortName": "Liability Related to Sale of Future Royalties - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2018Q4QTD",
      "decimals": "3",
      "lang": null,
      "name": "nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FI2019Q3_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_IndemnificationGuaranteeMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406401 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FI2019Q3_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_IndemnificationGuaranteeMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nktr:LicenseCollaborationOtherRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)",
     "role": "http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail",
     "shortName": "License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nktr:LicenseCollaborationOtherRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
     "shortName": "License and Collaboration Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)",
     "role": "http://www.nektar.com/role/LicenseAndCollaborationAgreementsChangesInDeferredRevenueBalanceFromCollaborationAgreementsDetail",
     "shortName": "License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "role": "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Stock-Based Compensation - Activity (Detail)",
     "role": "http://www.nektar.com/role/StockBasedCompensationActivityDetail",
     "shortName": "Stock-Based Compensation - Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2018Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409401 - Disclosure - Net Income (Loss) Per Share - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/NetIncomeLossPerShareAdditionalInformationDetail",
     "shortName": "Net Income (Loss) Per Share - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2018Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Cash and Investments in Marketable Securities",
     "role": "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecurities",
     "shortName": "Cash and Investments in Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr2019-09x30x10q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 63,
   "tag": {
    "country_IN": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "INDIA",
        "terseLabel": "India"
       }
      }
     },
     "localname": "IN",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nktr_ARESanFranciscoNumberOneNineLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ARE San Francisco Number 19 LLC.",
        "label": "A R E San Francisco Number One Nine L L C [Member]",
        "terseLabel": "ARE-San Francisco No. 19, LLC"
       }
      }
     },
     "localname": "ARESanFranciscoNumberOneNineLLCMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AccruedClinicalTrialExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued clinical trial expenses current.",
        "label": "Accrued Clinical Trial Expenses Current",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpensesCurrent",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AccruedContractManufacturingExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued contract manufacturing expense current.",
        "label": "Accrued Contract Manufacturing Expense Current",
        "terseLabel": "Accrued contract manufacturing expenses"
       }
      }
     },
     "localname": "AccruedContractManufacturingExpenseCurrent",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AdditionalSpaceRequiredToBeLeasedInFuture": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional space required to be leased in future.",
        "label": "Additional Space Required To Be Leased In Future",
        "terseLabel": "Additional space required to be leased in the future (in sqft)"
       }
      }
     },
     "localname": "AdditionalSpaceRequiredToBeLeasedInFuture",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "nktr_AdvancePaymentsToContractManufacturers": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of advance payments to contract manufacturers, net of amortization.",
        "label": "Advance Payments To Contract Manufacturers",
        "terseLabel": "Advance payments to contract manufacturers"
       }
      }
     },
     "localname": "AdvancePaymentsToContractManufacturers",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AggregateConsiderationReceivedFromAgreements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate consideration received from agreements.",
        "label": "Aggregate Consideration Received From Agreements",
        "terseLabel": "Total consideration received under agreements"
       }
      }
     },
     "localname": "AggregateConsiderationReceivedFromAgreements",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AmgenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amgen Inc.",
        "label": "Amgen Inc [Member]",
        "terseLabel": "Amgen, Inc."
       }
      }
     },
     "localname": "AmgenIncMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation.",
        "label": "Amount Of Transaction Price Allocated To Performance Obligation",
        "terseLabel": "Amount of transaction price allocated to performance obligation"
       }
      }
     },
     "localname": "AmountOfTransactionPriceAllocatedToPerformanceObligation",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AmountRecognizedForGrantingLicenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for granting licenses.",
        "label": "Amount Recognized For Granting Licenses",
        "terseLabel": "Amount recognized for granting licenses"
       }
      }
     },
     "localname": "AmountRecognizedForGrantingLicenses",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AnnualSalesLevelMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Annual sales level milestone.",
        "label": "Annual Sales Level Milestone [Member]",
        "terseLabel": "Annual Sales Level Milestone"
       }
      }
     },
     "localname": "AnnualSalesLevelMilestoneMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AreaOfLeasedSpace": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of leased space.",
        "label": "Area Of Leased Space",
        "terseLabel": "Lease space (in sq. feet)"
       }
      }
     },
     "localname": "AreaOfLeasedSpace",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "nktr_AstraZenecaAbMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AstraZeneca AB.",
        "label": "Astra Zeneca Ab [Member]",
        "terseLabel": "AstraZeneca AB"
       }
      }
     },
     "localname": "AstraZenecaAbMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AstraZenecaAgreementWithKirinMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AstraZeneca agreement with Kirin.",
        "label": "Astra Zeneca Agreement With Kirin [Member]",
        "terseLabel": "AstraZeneca-Kirin"
       }
      }
     },
     "localname": "AstraZenecaAgreementWithKirinMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BMSCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BMS collaboration agreement.",
        "label": "B M S Collaboration Agreement [Member]",
        "terseLabel": "BMS Collaboration Agreement"
       }
      }
     },
     "localname": "BMSCollaborationAgreementMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BaxaltaIncorporatedOrTakedaPLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Baxalta Incorporated or takeda PLC.",
        "label": "Baxalta Incorporated Or Takeda P L C [Member]",
        "terseLabel": "Baxalta Incorporated/Takeda"
       }
      }
     },
     "localname": "BaxaltaIncorporatedOrTakedaPLCMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BristolMyersSquibbCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bristol-Myers Squibb Company.",
        "label": "Bristol Myers Squibb Company [Member]",
        "terseLabel": "Bristol-Myers Squibb Company"
       }
      }
     },
     "localname": "BristolMyersSquibbCompanyMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CashAndInvestmentsInMarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash and Investments in Marketable Securities [Line Items]",
        "label": "Cash And Investments In Marketable Securities [Line Items]",
        "terseLabel": "Cash and Investments in Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "CashAndInvestmentsInMarketableSecuritiesLineItems",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_CashAndInvestmentsInMarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash and Investments in Marketable Securities [Table]",
        "label": "Cash And Investments In Marketable Securities [Table]",
        "terseLabel": "Cash And Investments In Marketable Securities [Table]"
       }
      }
     },
     "localname": "CashAndInvestmentsInMarketableSecuritiesTable",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, restricted cash, cash equivalents, and available for sale investments.",
        "label": "Cash Restricted Cash Cash Equivalents And Available For Sale Investments",
        "terseLabel": "Cash and investments in marketable securities",
        "totalLabel": "Total cash and investments in marketable securities"
       }
      }
     },
     "localname": "CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail",
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ClinicalTrialAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinical trial agreement.",
        "label": "Clinical Trial Agreement [Member]",
        "terseLabel": "Clinical Trial Agreement"
       }
      }
     },
     "localname": "ClinicalTrialAgreementMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CollaborationPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration partner.",
        "label": "Collaboration Partner [Member]",
        "terseLabel": "Collaboration Partner"
       }
      }
     },
     "localname": "CollaborationPartnerMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones.",
        "label": "Collaborative Arrangements Maximum Aggregate Additional Cash Payments Receivable Upon Achievement Of Development And Regulatory Milestones",
        "terseLabel": "Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Costs Incurred, Amount Of Post Approval Study Expenses Eligible For Reimbursement",
        "label": "Costs Incurred, Amount Of Post Approval Study Expenses Eligible For Reimbursement",
        "terseLabel": "Amount of post approval study expenses eligible for reimbursement"
       }
      }
     },
     "localname": "CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Costs Incurred, Amount Of Post Approval Study Expenses Eligible For Reimbursement, Maximum",
        "label": "Costs Incurred, Amount Of Post Approval Study Expenses Eligible For Reimbursement, Maximum",
        "terseLabel": "Amount of post approval study expenses eligible for reimbursement, maximum"
       }
      }
     },
     "localname": "CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CostsIncurredShareOfExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Costs Incurred, Share Of Expenses",
        "label": "Costs Incurred, Share Of Expenses",
        "terseLabel": "Share of expenses"
       }
      }
     },
     "localname": "CostsIncurredShareOfExpenses",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DebtInvestmentMaturityTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt investment maturity date description.",
        "label": "Debt Investment Maturity Term",
        "terseLabel": "Weighted average maturity term for debt securities investment (or less)"
       }
      }
     },
     "localname": "DebtInvestmentMaturityTerm",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_DebtInvestmentMaximumMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt investment maximum maturity period.",
        "label": "Debt Investment Maximum Maturity Period",
        "terseLabel": "Maximum maturity term for debt securities investment"
       }
      }
     },
     "localname": "DebtInvestmentMaximumMaturityPeriod",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_DrugProductDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Drug product development.",
        "label": "Drug Product Development [Member]",
        "terseLabel": "Drug Product Development"
       }
      }
     },
     "localname": "DrugProductDevelopmentMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EliLillyAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eli Lilly and Company.",
        "label": "Eli Lilly And Company [Member]",
        "terseLabel": "Eli Lilly and Company"
       }
      }
     },
     "localname": "EliLillyAndCompanyMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EliLillyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eli Lilly.",
        "label": "Eli Lilly [Member]",
        "terseLabel": "Eli Lilly"
       }
      }
     },
     "localname": "EliLillyMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eligible additional cash payments receivable upon achievement of certain sales milestones.",
        "label": "Eligible Additional Cash Payments Receivable Upon Achievement Of Certain Sales Milestones",
        "terseLabel": "Eligible additional cash payments receivable upon achievement of certain sales milestones"
       }
      }
     },
     "localname": "EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated annual interest rate over life of royalty liability.",
        "label": "Estimated Annual Interest Rate Over Life Of Royalty Liability",
        "terseLabel": "Annual interest rate"
       }
      }
     },
     "localname": "EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_EstimatedFairValueOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated fair value of shares.",
        "label": "Estimated Fair Value Of Shares",
        "terseLabel": "Estimated fair value of shares"
       }
      }
     },
     "localname": "EstimatedFairValueOfShares",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_HemophiliaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hemophilia.",
        "label": "Hemophilia [Member]",
        "terseLabel": "Hemophilia"
       }
      }
     },
     "localname": "HemophiliaMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_KilroyRealtyFinancePartnershipLPMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Kilroy Realty Finance Partnership, L.P.",
        "label": "Kilroy Realty Finance Partnership L P [Member]",
        "terseLabel": "Kilroy Realty Finance Partnership, L.P"
       }
      }
     },
     "localname": "KilroyRealtyFinancePartnershipLPMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after year six.",
        "label": "Lessee Operating Lease Liability Payments Due After Year Six",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LesseeOperatingLeaseLiabilityPaymentsDueYearSix": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee operating lease liability payments due year six.",
        "label": "Lessee Operating Lease Liability Payments Due Year Six",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearSix",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee operating lease liability tenant improvement reimbursements.",
        "label": "Lessee Operating Lease Liability Tenant Improvement Reimbursements",
        "negatedLabel": "Less: lease incentives"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementReimbursements",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilitiesAndStockholdersEquityDeficitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liabilities and stock holders equity (deficit) abstract..",
        "label": "Liabilities And Stockholders Equity Deficit [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityDeficitAbstract",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties [Line Items]",
        "terseLabel": "Liability Related to Sale of Future Royalties [Line Items]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesLineItems",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties Policy [Text Block]",
        "terseLabel": "Liability Related to Sale of Future Royalties"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties [Table]",
        "terseLabel": "Liability Related To Sale Of Future Royalties [Table]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesTable",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties non current net of issuance costs.",
        "label": "Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs",
        "terseLabel": "Liability related to the sale of future royalties, net"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties.",
        "label": "Liability Related To Sale Of Potential Future Royalties [Text Block]",
        "terseLabel": "Liability Related to Sale of Future Royalties"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyalties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsAbstract",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Line Items]",
        "terseLabel": "License And Collaboration Agreements [Line Items]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsLineItems",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Table]",
        "terseLabel": "License And Collaboration Agreements [Table]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsTable",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseCollaborationAndOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License collaboration and other revenue.",
        "label": "License Collaboration And Other Revenue [Member]",
        "terseLabel": "License, collaboration and other revenue"
       }
      }
     },
     "localname": "LicenseCollaborationAndOtherRevenueMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LicenseCollaborationOtherRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.",
        "label": "License Collaboration Other Revenue",
        "terseLabel": "License, collaboration and other revenue"
       }
      }
     },
     "localname": "LicenseCollaborationOtherRevenue",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LongTermInvestmentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term investment maturity period.",
        "label": "Long Term Investment Maturity Period",
        "terseLabel": "Long term investment maturity period"
       }
      }
     },
     "localname": "LongTermInvestmentMaturityPeriod",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_MOVANTIKAndMOVENTIGMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "MOVANTIK and MOVENTIG.",
        "label": "M O V A N T I K And M O V E N T I G [Member]",
        "terseLabel": "MOVANTIK and MOVENTIG"
       }
      }
     },
     "localname": "MOVANTIKAndMOVENTIGMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum cash and investments in marketable securities to be maintained.",
        "label": "Minimum Cash And Investments In Marketable Securities To Be Maintained",
        "terseLabel": "Minimum cash and investments in marketable securities to be maintained"
       }
      }
     },
     "localname": "MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_MissionBayLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mission bay lease.",
        "label": "Mission Bay Lease [Member]",
        "terseLabel": "Mission Bay Lease"
       }
      }
     },
     "localname": "MissionBayLeaseMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NektarMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nektar [Member]",
        "label": "Nektar [Member]",
        "terseLabel": "Nektar"
       }
      }
     },
     "localname": "NektarMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NektarThreeFiveEightLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nektar three five eight license.",
        "label": "Nektar Three Five Eight License [Member]",
        "terseLabel": "NKTR-358 License"
       }
      }
     },
     "localname": "NektarThreeFiveEightLicenseMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NektarThreeFiveEightMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nektar three five eight.",
        "label": "Nektar Three Five Eight [Member]",
        "terseLabel": "NKTR-358"
       }
      }
     },
     "localname": "NektarThreeFiveEightMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NektarTwoOneFourMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nektar two one four.",
        "label": "Nektar Two One Four [Member]",
        "terseLabel": "NKTR-214"
       }
      }
     },
     "localname": "NektarTwoOneFourMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NeulastaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Neulasta.",
        "label": "Neulasta [Member]",
        "terseLabel": "Neulasta"
       }
      }
     },
     "localname": "NeulastaMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-cash interest expense related to sale of royalties.",
        "label": "Non Cash Interest Expense Related To Sale Of Royalties",
        "negatedLabel": "Non-cash interest expense on liability related to sale of future royalties",
        "negatedTerseLabel": "Non-cash interest expense on liability related to sale of future royalties",
        "terseLabel": "Non-cash interest expense on liability related to sale of future royalties"
       }
      }
     },
     "localname": "NonCashInterestExpenseRelatedToSaleOfRoyalties",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non cash royalty revenue related to sale future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties",
        "negatedLabel": "Non-cash royalty revenue related to sale of future royalties",
        "terseLabel": "Non-cash royalty revenue related to sale of future royalties"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-cash royalty revenue related to sale of future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]",
        "terseLabel": "Non-cash royalty revenue related to sale of future royalties"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NumberOfConsecutiveFiveYearTermsToExtendLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of consecutive five year terms to extend lease.",
        "label": "Number Of Consecutive Five Year Terms To Extend Lease",
        "terseLabel": "Number of consecutive 5 year terms to extend lease"
       }
      }
     },
     "localname": "NumberOfConsecutiveFiveYearTermsToExtendLease",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "nktr_NumberOfLeasedSpacesDelivered": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of leased spaces delivered.",
        "label": "Number Of Leased Spaces Delivered",
        "terseLabel": "Number of additional spaces delivered"
       }
      }
     },
     "localname": "NumberOfLeasedSpacesDelivered",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "nktr_OpdivoAndYervoyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Opdivo and yervoy.",
        "label": "Opdivo And Yervoy [Member]",
        "terseLabel": "Opdivo and Yervoy"
       }
      }
     },
     "localname": "OpdivoAndYervoyMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_OpdivoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Opdivo.",
        "label": "Opdivo [Member]",
        "terseLabel": "Opdivo"
       }
      }
     },
     "localname": "OpdivoMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization.",
        "label": "Organization Policy [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_OtherPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other.",
        "label": "Other Partner [Member]",
        "terseLabel": "Baxalta Inc. / Takeda Pharmaceutical Company Ltd. and other"
       }
      }
     },
     "localname": "OtherPartnerMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PaymentsReceivedUnderRightsToSublicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments received under rights to sublicense agreement.",
        "label": "Payments Received Under Rights To Sublicense Agreement",
        "terseLabel": "Received under right to sublicense agreement"
       }
      }
     },
     "localname": "PaymentsReceivedUnderRightsToSublicenseAgreement",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of development milestones payments, to be received, if conditions occur.",
        "label": "Percentage Of Development Milestones Payments To Be Received If Conditions Occur",
        "terseLabel": "Percentage of regulatory milestones payments will be reduced if conditions occur"
       }
      }
     },
     "localname": "PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of development milestones payments, to be received under certain conditions.",
        "label": "Percentage Of Development Milestones Payments To Be Received Under Certain Conditions",
        "terseLabel": "Percentage of regulatory milestones payments will be reduced under certain conditions"
       }
      }
     },
     "localname": "PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of funding Phase three development costs on an indication by indication basis borne.",
        "label": "Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne",
        "terseLabel": "Percentage of funding phase 3 development costs on an indication by indication basis borne"
       }
      }
     },
     "localname": "PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of out of pocket costs to be reimbursed by partner.",
        "label": "Percentage Of Out Of Pocket Costs To Be Reimbursed By Partner",
        "terseLabel": "Percentage of out-of-pocket costs to be reimbursed by partner"
       }
      }
     },
     "localname": "PercentageOfOutOfPocketCostsToBeReimbursedByPartner",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of sharing in development costs.",
        "label": "Percentage Of Sharing In Development Costs",
        "terseLabel": "Percentage of sharing development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of sharing in Phase 2 development costs.",
        "label": "Percentage Of Sharing In Phase Two Development Costs",
        "terseLabel": "Percentage of sharing in Phase 2 development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInPhaseTwoDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInProductionCosts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of sharing in production costs.",
        "label": "Percentage Of Sharing In Production Costs",
        "terseLabel": "Percentage of sharing production costs"
       }
      }
     },
     "localname": "PercentageOfSharingInProductionCosts",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments.",
        "label": "Percentage Of Upfront Payment Market Access Milestone Payments Royalties And Sales Milestone Payments",
        "terseLabel": "Percentage of upfront payment, market access milestones, royalties and sales milestones"
       }
      }
     },
     "localname": "PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of upfront payment market access milestone payments royalties and sales milestone payments from sublicense agreement retained by our collaboration partner.",
        "label": "Percentage Of Upfront Payment Market Access Milestone Payments Royalties And Sales Milestone Payments From Sublicense Agreement Retained By Our Collaboration Partner",
        "terseLabel": "Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments from sublicense agreement retained by our collaboration partner"
       }
      }
     },
     "localname": "PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PhaseOneClinicalDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Phase 1 clinical development.",
        "label": "Phase One Clinical Development [Member]",
        "terseLabel": "Phase 1 Clinical Development"
       }
      }
     },
     "localname": "PhaseOneClinicalDevelopmentMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PotentialDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential development and regulatory milestones.",
        "label": "Potential Development And Regulatory Milestones",
        "terseLabel": "Potential future additional development and regulatory milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PotentialDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential development milestones.",
        "label": "Potential Development Milestones",
        "terseLabel": "Potential future additional payments for development milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentMilestones",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PotentialDevelopmentRegulatoryAndSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential development regulatory and sales milestones.",
        "label": "Potential Development Regulatory And Sales Milestones",
        "terseLabel": "Potential future development, regulatory and sales milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentRegulatoryAndSalesMilestones",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PreferredStockShareDesignated": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred stock, shares designated.",
        "label": "Preferred Stock Share Designated",
        "terseLabel": "Preferred stock, shares designated (in shares)"
       }
      }
     },
     "localname": "PreferredStockShareDesignated",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Issuance Of Common Stock Net Of Issuance Costs",
        "label": "Proceeds From Issuance Of Common Stock Net Of Issuance Costs",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds from sale of potential future royalties gross.",
        "label": "Proceeds From Sale Of Potential Future Royalties Gross",
        "terseLabel": "Proceeds from sale of royalty rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPotentialFutureRoyaltiesGross",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ProfitsAndLossesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Profits and losses sharing percentage.",
        "label": "Profits And Losses Sharing Percentage",
        "terseLabel": "Global commercialization profits and losses sharing percentage"
       }
      }
     },
     "localname": "ProfitsAndLossesSharingPercentage",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_ProspectiveInterestRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prospective interest rate percentage.",
        "label": "Prospective Interest Rate Percentage",
        "terseLabel": "Prospective interest rate"
       }
      }
     },
     "localname": "ProspectiveInterestRatePercentage",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PurchaseAndSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase and sale agreement.",
        "label": "Purchase And Sale Agreement [Member]",
        "terseLabel": "Purchase and Sale Agreement with RPI"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreementMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ReimbursementOfExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reimbursement of expenses.",
        "label": "Reimbursement Of Expenses",
        "terseLabel": "Reimbursement of expenses"
       }
      }
     },
     "localname": "ReimbursementOfExpenses",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_RemainingAmountAllocatedToTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amount allocated to transaction price.",
        "label": "Remaining Amount Allocated To Transaction Price",
        "terseLabel": "Remaining amount allocated to transaction price"
       }
      }
     },
     "localname": "RemainingAmountAllocatedToTransactionPrice",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SaleOfStockConsiderationReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of stock consideration received.",
        "label": "Sale Of Stock Consideration Received",
        "terseLabel": "Sale of stock consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceived",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Seven point seven five percent senior secured notes due October two thousand and twenty.",
        "label": "Seven Point Seven Five Percent Senior Secured Notes Due October Two Thousand And Twenty [Member]",
        "terseLabel": "7.75% Senior Secured Notes Due October 2020"
       }
      }
     },
     "localname": "SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share purchase agreement.",
        "label": "Share Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_StockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock options and restricted stock units.",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "terseLabel": "Stock Options and Restricted Stock Units"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/NetIncomeLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ThirdStreetLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Third street lease.",
        "label": "Third Street Lease [Member]",
        "terseLabel": "Third Street Lease"
       }
      }
     },
     "localname": "ThirdStreetLeaseMember",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront and milestone payments received from license agreements.",
        "label": "Upfront And Milestone Payments Received From License Agreements",
        "verboseLabel": "Upfront and milestone payments received from license agreements"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront and milestone payments received under license agreement.",
        "label": "Upfront And Milestone Payments Received Under License Agreement",
        "terseLabel": "Received upfront and milestone payment"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement",
     "nsuri": "http://www.nektar.com/20190930",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r44",
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Parent Company [Member]",
        "terseLabel": "Nektar's"
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r120",
      "r161",
      "r164",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r121",
      "r161",
      "r165",
      "r279",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "ASC 606"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASC 842"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r16",
      "r162"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable",
        "verboseLabel": "Accounts receivable for expense reimbursements from collaboration partner"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r46",
      "r48",
      "r49"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r45",
      "r49",
      "r50",
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Capital in excess of par value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Capital in Excess of Par Value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r172",
      "r174",
      "r189",
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r174",
      "r185",
      "r188"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Weighted average antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetIncomeLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetIncomeLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetIncomeLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetIncomeLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r118",
      "r251",
      "r265"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r43"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r123",
      "r126"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r176",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by award type pertaining to equity-based compensation.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r28",
      "r82"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 1.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r76",
      "r82",
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r76",
      "r226"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r85",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Corporate Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r38",
      "r138",
      "r257",
      "r269"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r137",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 300,000 shares authorized; 175,786 shares and 173,530 shares outstanding at September 30, 2019 and December 31, 2018, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r53",
      "r55",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r109",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Significant Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r210",
      "r216",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contract balances and changes in contract balances.",
        "label": "Contract with Customer, Asset and Liability [Table Text Block]",
        "terseLabel": "Changes in Deferred Revenue Balance from Collaboration Agreements"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r155",
      "r156",
      "r162"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Deferred revenue, Ending balance",
        "periodStartLabel": "Deferred revenue, Beginning balance",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsChangesInDeferredRevenueBalanceFromCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r155",
      "r156",
      "r162"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r155",
      "r156",
      "r162"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, less current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedLabel": "Recognition of previously unearned revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsChangesInDeferredRevenueBalanceFromCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenue recognized in period related to performance in prior periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerSalesChannelAxis": {
     "auth_ref": [
      "r161",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by sales channel for delivery of good or service in contract with customer.",
        "label": "Contract with Customer, Sales Channel [Axis]",
        "terseLabel": "Contract with Customer, Sales Channel"
       }
      }
     },
     "localname": "ContractWithCustomerSalesChannelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerSalesChannelDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.",
        "label": "Contract with Customer, Sales Channel [Domain]",
        "terseLabel": "Contract with Customer, Sales Channel"
       }
      }
     },
     "localname": "ContractWithCustomerSalesChannelDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r169",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Notes and Bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cumulative effect on retained earnings net of related income tax effect.",
        "label": "Cumulative Effect on Retained Earnings, Net of Tax",
        "terseLabel": "Adoption of new accounting standards",
        "verboseLabel": "Cumulative effect adjustment to accumulated deficit"
       }
      }
     },
     "localname": "CumulativeEffectOnRetainedEarningsNetOfTax1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r252",
      "r253",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Senior secured notes, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Transaction costs related to sale of potential future royalties"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r80",
      "r134"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r154",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r61",
      "r93",
      "r97",
      "r99",
      "r100",
      "r101",
      "r104",
      "r260",
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r61",
      "r93",
      "r97",
      "r99",
      "r100",
      "r101",
      "r104",
      "r260",
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetIncomeLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r226"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r90",
      "r197",
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "positiveLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EuropeanUnionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Economic and political union of member states, located primarily in Europe.",
        "label": "European Union [Member]",
        "terseLabel": "European Union"
       }
      }
     },
     "localname": "EuropeanUnionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Level 1 to level 2 transfers"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Level 2 to level 1 transfers"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r219",
      "r220",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Portfolio of Cash and Investments in Marketable Securities"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r221",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Cash and Investments in Marketable Securities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r221",
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value Hierarchy Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r221",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value Hierarchy Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r221",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r132",
      "r133"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r59",
      "r93",
      "r250",
      "r258",
      "r273"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r117",
      "r203"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision (benefit) for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r195",
      "r196",
      "r199",
      "r200",
      "r201",
      "r205",
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r98",
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Weighted average potentially dilutive securities included in calculation of diluted securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetIncomeLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndemnificationGuaranteeMember": {
     "auth_ref": [
      "r146",
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor.",
        "label": "Indemnification Agreement [Member]",
        "terseLabel": "Indemnification Obligation"
       }
      }
     },
     "localname": "IndemnificationGuaranteeMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r58",
      "r116",
      "r227",
      "r228",
      "r261"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r74",
      "r77",
      "r83"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r33"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r22",
      "r130"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryInventoryDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r40",
      "r127"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/InventoryInventoryDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/InventoryInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r41",
      "r86",
      "r106",
      "r128",
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r24",
      "r130"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryInventoryDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r23",
      "r130"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryInventoryDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryInventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Axis]",
        "terseLabel": "Lease Arrangement, Type"
       }
      }
     },
     "localname": "LeaseArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Domain]",
        "terseLabel": "Lease Arrangement, Type"
       }
      }
     },
     "localname": "LeaseArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r242",
      "r244"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Costs Included in Operating Expenses"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "2019 (three months ended)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: portion representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease extension term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r254",
      "r267"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r36",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r147",
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r147",
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Litigation matters, liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r147",
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r76",
      "r78",
      "r81"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r51",
      "r54",
      "r60",
      "r81",
      "r103",
      "r259",
      "r271"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Net income (loss) per share"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total non-operating income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Non-operating income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "terseLabel": "Senior notes, fair value"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r236",
      "r244"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Operating lease liabilities",
        "verboseLabel": "Operating lease, lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail",
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r232",
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease, right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r241",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease liability, weighted-average discount rate, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r240",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease liability, weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r91",
      "r115",
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r33"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r52",
      "r55",
      "r57",
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r47",
      "r202",
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "terseLabel": "Tax provision on unrealized gain on available-for-sale securities, offset by benefit in continuing operations"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Accretion of discounts, net and other non-cash transactions"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest income and other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r68",
      "r71",
      "r124"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at September 30, 2019 or December 31, 2018"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r73",
      "r187"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based compensation arrangement, excluding stock option exercises.",
        "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options",
        "terseLabel": "Proceeds from shares issued under equity compensation plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r68",
      "r69",
      "r124"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r68",
      "r69",
      "r124"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Sales of investments",
        "verboseLabel": "Available-for-sale securities, sold"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Sales of property, plant and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r51",
      "r54",
      "r75",
      "r118",
      "r119",
      "r209",
      "r211",
      "r212",
      "r214",
      "r215"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r135",
      "r268"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r192",
      "r283"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r86",
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSU)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r153",
      "r266"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r157",
      "r160",
      "r161"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "positiveLabel": "Revenue recognized from contracts with customers",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r239",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets recognized in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.nektar.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "verboseLabel": "Royalty revenue"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Closing date price of common stock (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetIncomeLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Cash and Investments in Marketable Securities, Including Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]",
        "terseLabel": "License, Collaboration and Other Revenue"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r174",
      "r184",
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that sets forth the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r174",
      "r184",
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r8",
      "r25",
      "r26",
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r179",
      "r181",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for share-based compensation plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Activity [Table Text Block]",
        "terseLabel": "Share-based Compensation, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r176",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorLongTermNotes": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.",
        "label": "Senior Notes, Noncurrent",
        "terseLabel": "Senior secured notes, net"
       }
      }
     },
     "localname": "SeniorLongTermNotes",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotes": {
     "auth_ref": [
      "r256",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.",
        "label": "Senior Notes",
        "terseLabel": "Senior secured notes",
        "verboseLabel": "Senior secured notes, principal amount"
       }
      }
     },
     "localname": "SeniorNotes",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value, RSUs (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted stock options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value, options (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r173",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity-based compensation award.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r39",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r152",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Sale of stock to Bristol-Myers Squibb (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r152",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Shares issued under equity compensation plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r152",
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Sale of stock to Bristol-Myers Squibb"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r153",
      "r175",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Shares issued under equity compensation plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r122"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r169",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Obligations of U.S. Government Agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r107",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r237",
      "r244"
     ],
     "calculation": {
      "http://www.nektar.com/role/LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r96",
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r95",
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Weighted average shares outstanding used in computing net income (loss) per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e543-108305"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14615-108349"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14394-108349"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14453-108349"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14472-108349"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=99404985&loc=d3e10037-110241"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12053-110248"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=82913499&loc=d3e13051-110250"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208855"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL108322424-203045"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.16)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=50488274&loc=d3e64164-112818"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r284": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r285": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r286": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r287": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r288": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r289": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e640-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1500-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812004192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">License, Collaboration and Other Revenue</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.42528735632183%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Partner</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Drug or Drug Candidate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Bristol-Myers Squibb Company</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NKTR-214</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,059,768</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Eli Lilly and Company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NKTR-358</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,221</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,200</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,627</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amgen, Inc.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Neulasta</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Baxalta Inc. / Takeda Pharmaceutical Company Ltd. and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ADYNOVATE</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>371</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>404</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>910</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,703</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License, collaboration and other revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,121</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,860</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,082,848</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Changes in Deferred Revenue Balance from Collaboration Agreements</a></td>
<td class="text"><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the changes in our deferred revenue balance from our collaboration agreements during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended <br/>September 30,<br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue&#8212;December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,636</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of previously unearned revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,465</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue&#8212;September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,171</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6821819648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 05, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtInvestmentMaximumMaturityPeriod', window );">Maximum maturity term for debt securities investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtInvestmentMaturityTerm', window );">Weighted average maturity term for debt securities investment (or less)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Available-for-sale securities, sold</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11,963,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Level 1 to level 2 transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Level 2 to level 1 transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior secured notes, principal amount</a></td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 7.75% Senior Secured Notes Due October 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior secured notes, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained', window );">Minimum cash and investments in marketable securities to be maintained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 7.75% Senior Secured Notes Due October 2020 | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior secured notes, interest rate</a></td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior secured notes, principal amount</a></td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Senior notes, fair value</a></td>
<td class="nump">$ 252,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LongTermInvestmentMaturityPeriod', window );">Long term investment maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LongTermInvestmentMaturityPeriod', window );">Long term investment maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Investments in Marketable Securities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashAndInvestmentsInMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtInvestmentMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt investment maturity date description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DebtInvestmentMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtInvestmentMaximumMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt investment maximum maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DebtInvestmentMaximumMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LongTermInvestmentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term investment maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LongTermInvestmentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum cash and investments in marketable securities to be maintained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812017904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Costs Included in Operating Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 4,116<span></span>
</td>
<td class="nump">$ 1,927<span></span>
</td>
<td class="nump">$ 10,030<span></span>
</td>
<td class="nump">$ 5,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,485<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">4,539<span></span>
</td>
<td class="nump">3,371<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 5,601<span></span>
</td>
<td class="nump">$ 3,023<span></span>
</td>
<td class="nump">$ 14,569<span></span>
</td>
<td class="nump">$ 9,022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6841260368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>ft&#178; </div>
<div>space</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>ft&#178; </div>
<div>extension_period</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets recognized in exchange for lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,025<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease liability, weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease liability, weighted-average discount rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_ARESanFranciscoNumberOneNineLLCMember', window );">ARE-San Francisco No. 19, LLC | Mission Bay Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AreaOfLeasedSpace', window );">Lease space (in sq. feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,085<span></span>
</td>
<td class="nump">10,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NumberOfConsecutiveFiveYearTermsToExtendLease', window );">Number of consecutive 5 year terms to extend lease | extension_period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AdditionalSpaceRequiredToBeLeasedInFuture', window );">Additional space required to be leased in the future (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets recognized in exchange for lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_KilroyRealtyFinancePartnershipLPMember', window );">Kilroy Realty Finance Partnership, L.P | Third Street Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AreaOfLeasedSpace', window );">Lease space (in sq. feet) | ft&#178;</a></td>
<td class="nump">67,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,105<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
<td class="nump">135,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets recognized in exchange for lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NumberOfLeasedSpacesDelivered', window );">Number of additional spaces delivered | space</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AdditionalSpaceRequiredToBeLeasedInFuture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional space required to be leased in future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AdditionalSpaceRequiredToBeLeasedInFuture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AreaOfLeasedSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of leased space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AreaOfLeasedSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NumberOfConsecutiveFiveYearTermsToExtendLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive five year terms to extend lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NumberOfConsecutiveFiveYearTermsToExtendLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NumberOfLeasedSpacesDelivered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of leased spaces delivered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NumberOfLeasedSpacesDelivered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_ARESanFranciscoNumberOneNineLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_ARESanFranciscoNumberOneNineLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=nktr_MissionBayLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=nktr_MissionBayLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_KilroyRealtyFinancePartnershipLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_KilroyRealtyFinancePartnershipLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=nktr_ThirdStreetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=nktr_ThirdStreetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812058208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Costs Included in Operating Expenses</a></td>
<td class="text"><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of lease costs, which we include in operating expenses in our Condensed Consolidated Statements of Operations, were as follows (in thousands):</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80842911877394%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,116</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,927</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,030</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,651</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,485</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,096</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,539</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,601</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,569</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,022</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the maturities of our operating lease liabilities were as follows (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:88%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year ended December&#160;31,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">2019 (Three months ended)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,400</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,283</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,026</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,633</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,899</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116,881</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>214,379</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: portion representing interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56,621</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: lease incentives</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154,417</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: current portion</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,318</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities, less current portion</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,099</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6821049872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 81,224<span></span>
</td>
<td class="nump">$ 194,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">1,414,448<span></span>
</td>
<td class="nump">1,140,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">231,082<span></span>
</td>
<td class="nump">582,889<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">$ 1,726,754<span></span>
</td>
<td class="nump">$ 1,918,239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6830935360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock', window );">Liability Related to Sale of Future Royalties</a></td>
<td class="text">Liability Related to Sale of Future Royalties<div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February&#160;24, 2012, we entered into a Purchase and Sale Agreement (the Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the Royalty Entitlement) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$124.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the Royalty Entitlement.&#160;As part of this sale, we incurred approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$4.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> in transaction costs, which are amortized to interest expense over the estimated life of the Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from the CIMZIA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and MIRCERA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the </span><span style="font-family:inherit;font-size:10pt;"><span>$124.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in proceeds from this transaction as a liability (Royalty Obligation) that is amortized using the interest method over the estimated life of the Purchase and Sale Agreement as royalties from the CIMZIA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and MIRCERA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> products are remitted directly to RPI. During the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, we recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$27.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$24.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in non-cash royalty revenue from net sales of CIMZIA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and MIRCERA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, and we recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$17.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$14.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of related non-cash interest expense.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We periodically assess the estimated royalty payments to RPI from UCB and Roche, and, to the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different from our original estimates, we will prospectively adjust the amortization of the Royalty Obligation. From inception through </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, our estimate of the total interest expense on the Royalty Obligation resulted in an effective annual interest rate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>17%</span></span><span style="font-family:inherit;font-size:10pt;">. During the three months ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">, our estimate of the effective annual interest rate over the life of the agreement increased to </span><span style="font-family:inherit;font-size:10pt;"><span>17.6%</span></span><span style="font-family:inherit;font-size:10pt;">, which resulted in a prospective interest rate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>21%</span></span><span style="font-family:inherit;font-size:10pt;">.&#160;&#160;During the three months ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, primarily </span></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">as a result of increases in the forecasted sales of MIRCERA</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, our estimate of the effective annual interest rate over the life of the agreement increased to </span><span style="font-family:inherit;font-size:10pt;"><span>18.7%</span></span><span style="font-family:inherit;font-size:10pt;">, which results in a prospective interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span>29%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Purchase and Sale Agreement grants RPI the right to receive certain reports and other information relating to the Royalty Entitlement and contains other representations and warranties, covenants and indemnification obligations that are customary for a transaction of this nature. To our knowledge, we are currently in compliance with these provisions of the Purchase and Sale Agreement; however, if we were to breach our obligations, we could be required to pay damages to RPI that are not limited to the purchase price we received in the sale transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6830780608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text">Net Income (Loss) Per Share<div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We calculate basic net income (loss) per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net income (loss) per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, our net income (loss) available to common stockholders equals the reported net income (loss). </span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the three months ended September 30, 2018, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. During the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the three months ended September 30, 2018, potentially dilutive securities consisted of the weighted-average common shares underlying outstanding stock options and RSUs, which totaled </span><span style="font-family:inherit;font-size:10pt;"><span>17.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>18.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>17.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares, respectively.</span></div><span style="font-family:inherit;font-size:10pt;">For the computation of diluted earnings per share for nine months ended September 30, 2018, we included approximately </span><span style="font-family:inherit;font-size:10pt;"><span>11.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> weighted-average common shares underlying stock options and RSUs under the treasury stock method and excluded approximately </span><span style="font-family:inherit;font-size:10pt;"><span>3.2 million</span></span> of shares of common stock underlying stock options because their effect was antidilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6841381072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 29,218<span></span>
</td>
<td class="nump">$ 27,762<span></span>
</td>
<td class="nump">$ 80,755<span></span>
</td>
<td class="nump">$ 1,153,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">4,927<span></span>
</td>
<td class="nump">4,783<span></span>
</td>
<td class="nump">15,385<span></span>
</td>
<td class="nump">16,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">99,048<span></span>
</td>
<td class="nump">102,895<span></span>
</td>
<td class="nump">324,197<span></span>
</td>
<td class="nump">290,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">23,983<span></span>
</td>
<td class="nump">18,718<span></span>
</td>
<td class="nump">71,570<span></span>
</td>
<td class="nump">57,666<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">127,958<span></span>
</td>
<td class="nump">126,396<span></span>
</td>
<td class="nump">411,152<span></span>
</td>
<td class="nump">365,270<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(98,740)<span></span>
</td>
<td class="num">(98,634)<span></span>
</td>
<td class="num">(330,397)<span></span>
</td>
<td class="nump">788,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(5,425)<span></span>
</td>
<td class="num">(5,442)<span></span>
</td>
<td class="num">(15,882)<span></span>
</td>
<td class="num">(16,167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
<td class="num">(5,813)<span></span>
</td>
<td class="num">(4,814)<span></span>
</td>
<td class="num">(17,853)<span></span>
</td>
<td class="num">(14,808)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income and other income (expense), net</a></td>
<td class="nump">11,492<span></span>
</td>
<td class="nump">11,847<span></span>
</td>
<td class="nump">35,964<span></span>
</td>
<td class="nump">25,523<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating income (expense), net</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">1,591<span></span>
</td>
<td class="nump">2,229<span></span>
</td>
<td class="num">(5,452)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before provision for income taxes</a></td>
<td class="num">(98,486)<span></span>
</td>
<td class="num">(97,043)<span></span>
</td>
<td class="num">(328,168)<span></span>
</td>
<td class="nump">782,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">322<span></span>
</td>
<td class="num">(900)<span></span>
</td>
<td class="num">(939)<span></span>
</td>
<td class="nump">3,250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (98,808)<span></span>
</td>
<td class="num">$ (96,143)<span></span>
</td>
<td class="num">$ (327,229)<span></span>
</td>
<td class="nump">$ 779,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Net income (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (1.87)<span></span>
</td>
<td class="nump">$ 4.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (1.87)<span></span>
</td>
<td class="nump">$ 4.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted average shares outstanding used in computing net income (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">175,402<span></span>
</td>
<td class="nump">172,698<span></span>
</td>
<td class="nump">174,609<span></span>
</td>
<td class="nump">168,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">175,402<span></span>
</td>
<td class="nump">172,698<span></span>
</td>
<td class="nump">174,609<span></span>
</td>
<td class="nump">179,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 5,558<span></span>
</td>
<td class="nump">$ 4,256<span></span>
</td>
<td class="nump">$ 14,302<span></span>
</td>
<td class="nump">$ 16,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">10,275<span></span>
</td>
<td class="nump">10,259<span></span>
</td>
<td class="nump">29,008<span></span>
</td>
<td class="nump">29,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">10,264<span></span>
</td>
<td class="nump">8,372<span></span>
</td>
<td class="nump">27,585<span></span>
</td>
<td class="nump">24,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 3,121<span></span>
</td>
<td class="nump">$ 4,875<span></span>
</td>
<td class="nump">$ 9,860<span></span>
</td>
<td class="nump">$ 1,082,848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6811983888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, Beginning balance</a></td>
<td class="nump">$ 24,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of previously unearned revenue</a></td>
<td class="num">(9,465)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, Ending balance</a></td>
<td class="nump">$ 15,171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6841258352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">70 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 24, 2012</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,585<span></span>
</td>
<td class="nump">$ 24,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,813)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,814)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17,853)<span></span>
</td>
<td class="num">$ (14,808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability', window );">Annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProspectiveInterestRatePercentage', window );">Prospective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember', window );">Purchase and Sale Agreement with RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross', window );">Proceeds from sale of royalty rights</a></td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Transaction costs related to sale of potential future royalties</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated annual interest rate over life of royalty liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of potential future royalties gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProspectiveInterestRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prospective interest rate percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProspectiveInterestRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812034480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">Organization and Summary of Significant Accounting Policies<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Organization</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes treatments for cancer, autoimmune disease and chronic pain.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. At </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in cash and investments in marketable securities and debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$250.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in principal of senior secured notes due in </span><span style="font-family:inherit;font-size:10pt;">October 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our consolidated financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries:  Inheris Biopharma, Inc., Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our comprehensive income (loss) consists of our net income (loss) plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities, neither of which were significant during the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. In addition, there were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;"> filed with the SEC on March 1, 2019. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We operate in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> business segment by our Chief Executive Officer.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant Concentrations</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones, other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</span><span style="font-family:inherit;font-size:10pt;">, our accounts receivable includes </span><span style="font-family:inherit;font-size:10pt;"><span>$27.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$24.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, for net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS). </span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2019, we adopted Accounting Standards Codification (ASC) 842, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (ASC 842). ASC 842 supersedes the guidance in ASC 840, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (ASC 840). Under ASC 842, an entity recognizes a right-of-use asset and a corresponding lease liability, measured as the present value of the lease payments. In our adoption, we used the package of practical expedients, which, among other things, allowed us to carry forward our historical lease classification of those leases in effect as of January 1, 2019. We present results for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> under ASC 842. We have not restated the results for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and our financial position as of December 31, 2018, and continue to report them under ASC 840.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. However, in determining the present value of our lease payments for leases in effect when we adopted ASC 842, we used our incremental borrowing rate as of January 1, 2019. </span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our real estate leases, and elected the short-term lease recognition exemption for our short-term leases, which allows us not to recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts. For leases in effect as of January 1, 2019, we recognized our lease incentives as part of our transition adjustment. </span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of our adoption of ASC 842, we recorded right-of-use assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$83.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$96.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for our facilities operating leases, with </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> effect on our opening balance of accumulated deficit. Please see Note 4 for additional information regarding our leases.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</span><span style="font-family:inherit;font-size:10pt;"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Sales</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Royalty Revenue</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Generally, we are entitled to royalties from our collaboration partners based on the net sales of their approved drugs that are marketed and sold in one or more countries where we hold royalty rights. For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">License, Collaboration and other Revenue</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">License Grants</span><span style="font-family:inherit;font-size:10pt;">:&#160;For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Milestone Payments</span><span style="font-family:inherit;font-size:10pt;">:&#160;At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">a clinical study or filing for or receipt of regulatory approval, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. Our partners generally pay development milestones</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">subsequent to</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">achievement of the triggering event.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Services</span><span style="font-family:inherit;font-size:10pt;">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expense</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a clinical joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined to be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best </span></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we recorded an income tax provision for our Nektar India operations at an effective tax rate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>33%</span></span><span style="font-family:inherit;font-size:10pt;">. Due to our net loss and unrealized gain on available-for-sale securities in the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we recorded a tax provision against such unrealized gain with an offsetting tax benefit in continuing operations of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. For the three months ended September 30, 2019, however, since we had a loss on our available-for-sale securities, we recorded a benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> against our unrealized loss in available-for-sale securities with an offsetting expense in continuing operations. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, as a result of taxable income in India and the U.S., resulting primarily from income recognized from the upfront payment from BMS, we recorded a global income tax provision at an effective tax rate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>0.4%</span></span><span style="font-family:inherit;font-size:10pt;">. The income tax benefit for the three months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> reflects our pre-tax loss for that period. Our income resulted in tax liabilities in certain states where we did not have sufficient net operating losses to offset our estimated apportioned taxable income. Our effective tax rate was based on certain assumptions and other estimates regarding the apportionment of taxable income and the states in which we had nexus in 2018. Our apportionment of taxable income included estimates of the apportionment of the BMS upfront payment based on estimates of activities to be carried out under the collaboration agreement with BMS, as well as estimates of the apportionment of other sources of income. Our effective tax rate reflected the release of the valuation allowance of net operating loss carryforwards and other tax credits to offset U.S. federal and state taxable income. </span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is effective in the first quarter of 2020 and should be applied retrospectively to January 1, 2018, when we adopted ASC 606. Early adoption is permitted. We are evaluating the effect of adoption, but we do not expect a material effect on our revenue.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#8220;incurred loss&#8221; model with an &#8220;expected loss&#8221; model. Accordingly, we will present these financial assets at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. ASU 2016-13 is effective in the first quarter of 2020. Early adoption is permitted. We are currently evaluating the impact of adoption of this ASU, but we do not anticipate that adoption will have a material effect on our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>209</ContextCount>
  <ElementCount>311</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0002000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Cash and Investments in Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashAndInvestmentsInMarketableSecurities</Role>
      <ShortName>Cash and Investments in Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Liability Related to Sale of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyalties</Role>
      <ShortName>Liability Related to Sale of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseAndCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Net Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/NetIncomeLossPerShare</Role>
      <ShortName>Net Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2302301 - Disclosure - Cash and Investments in Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesTables</Role>
      <ShortName>Cash and Investments in Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CashAndInvestmentsInMarketableSecurities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/Inventory</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/Leases</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - License and Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseAndCollaborationAgreementsTables</Role>
      <ShortName>License and Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/LicenseAndCollaborationAgreements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/StockBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesCashAndInvestmentsInMarketableSecuritiesIncludingCashEquivalentsDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashAndInvestmentsInMarketableSecuritiesPortfolioOfCashAndInvestmentsInMarketableSecuritiesDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Inventory - Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/InventoryInventoryDetail</Role>
      <ShortName>Inventory - Inventory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Leases - Components of Lease Costs Included in Operating Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LeasesComponentsOfLeaseCostsIncludedInOperatingExpensesDetail</Role>
      <ShortName>Leases - Components of Lease Costs Included in Operating Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Summary of Maturities of Operating Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetail</Role>
      <ShortName>Liability Related to Sale of Future Royalties - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseAndCollaborationAgreementsLicenseCollaborationAndOtherRevenueDetail</Role>
      <ShortName>License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseAndCollaborationAgreementsAdditionalInformationDetail</Role>
      <ShortName>License and Collaboration Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseAndCollaborationAgreementsChangesInDeferredRevenueBalanceFromCollaborationAgreementsDetail</Role>
      <ShortName>License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Stock-Based Compensation - Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nktr2019-09x30x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2409401 - Disclosure - Net Income (Loss) Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/NetIncomeLossPerShareAdditionalInformationDetail</Role>
      <ShortName>Net Income (Loss) Per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/NetIncomeLossPerShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="nktr2019-09x30x10q.htm">nktr2019-09x30x10q.htm</File>
    <File>nktr-20190930.xsd</File>
    <File>nktr-20190930_cal.xml</File>
    <File>nktr-20190930_def.xml</File>
    <File>nktr-20190930_lab.xml</File>
    <File>nktr-20190930_pre.xml</File>
    <File>nktr2019-09x30xexx101.htm</File>
    <File>nktr2019-09x30xexx311.htm</File>
    <File>nktr2019-09x30xexx312.htm</File>
    <File>nktr2019-09x30xexx321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6842653888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80842911877394%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,119</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,208</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,470</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,680</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,449</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,081</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,746</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,030</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,976</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,880</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,287</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,787</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,895</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Share-based Compensation, Activity</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options granted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>131</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>190</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>246</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>929</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average grant-date fair value of options granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39.28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSUs granted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>712</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>558</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average grant-date fair value of RSUs granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.00</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57.27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54.49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares issued under equity compensation plans</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>820</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>642</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,256</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,248</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for share-based compensation plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6841088288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">$ 1,646,043<span></span>
</td>
<td class="nump">$ 1,800,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">28,166<span></span>
</td>
<td class="nump">5,812<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">1,726,754<span></span>
</td>
<td class="nump">1,918,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Notes and Bonds | Fair Value Hierarchy Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">1,163,575<span></span>
</td>
<td class="nump">1,288,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Corporate Commercial Paper | Fair Value Hierarchy Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">482,468<span></span>
</td>
<td class="nump">498,048<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Obligations of U.S. Government Agencies | Fair Value Hierarchy Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Fair Value Hierarchy Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">45,674<span></span>
</td>
<td class="nump">105,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">$ 6,871<span></span>
</td>
<td class="nump">$ 6,760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>37
<FILENAME>0000906709-19-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000906709-19-000010-xbrl.zip
M4$L#!!0    ( &F=9D\Q0#,?UA   ,NR   1    ;FMT<BTR,#$Y,#DS,"YX
M<V3M7>MSVS82_]Z_@J<OEYNI(CM.VCI3Y\;/GJ:VI;&</NY+!R)7$L84H(*@
M;/6OOP7XIOBF4C%GS>2#3.XN]H==+!8+$/GQWR]+VUB#<"AG9[WCMT<] YC)
M+<KF9[W/D_[YY'(X[/W[TS<__J/?_^WBX=:XXJ:[!":-2P%$@F4\4[DP?K7
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M3=44PJFI!7]W0W@%4'I[(XVJ1J?D\>\]Y'O7A#OF F?C3]_\#U!+ P04
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M7<<FEVKAG\F6[@+-T[%H>]KQ@PBUO9DLS[7#CA,D<2Z1M-X@IUF5'TXJ8FW
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MPU@-;6)>J?]C#&H(;4^K^)UO*-\C4^].[I-UX#1;TA-7[3%7Z7F+*;S"Q>H
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MH( 0SY5 DI6JK<< UE<(:[@OO!AY/B\3>@M1C&%5\[?S^3([='/TN%DBO+)
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MG-4W7K>>_'TX,E(7O;ZDPRQOE]-5\GMW=96-%A>SLF)5Z8$;%L2+J\_I=WA
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M$.9W3U</QXAX09L&<W9>T1D.OPK4=]QEXF-Y9WK+MWE=\J_KL@GLGUIN'TF
M(N<91T1G0# *<XQ5T=IF*27(53O"69RNH 1D]765.0^A@Z4GQ.LQ3N+CS,\1
M10K/[_EE*H)/5<P>Z9$Z*.P5\R_5N@G#/AA[JW+=EB^GD!2,9  KB#',1<HD
MZZPQ"9ES:F" C>BB=8 L::%Y+!6'L.>P6!^).%]Q>H&SUU\V"$N>QSIZ)!+[
MK9,?DWFW13=T!7S<XV,KW  <36 %&\*+*FS/\=R6O_[?]^W>LJ[6[\O?#Q;
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M78&HCV53?NAS95\QN+S1]YO[=?FQ>I@O[77QITB U&EA<"@&,UL$)96XNX?
M8,'=7Q&)9#_VT9(.==+"MD6<+'![@'X+/=EA][A;&:LU3@O=5!K"3P.?M\'G
MM@TNG[?!P#NOL=K%XSKL!-JGWTW9?3NM]V.E;L?*S;:=UAW\H5=I^['TPAPU
M!N<3N( ;V\-JO![L>S+I]G:Q?:>'KZZW16R^EBO[?)=<U%?+JC:8^)>ZV=B:
M%1!(@8C.L<KS0G$3_',@1,8,*JD9<3XYXV=4%1D36A!28,H@HP6"LLCM#AJ7
M..(R^@!GL]_Q"&FRAYK\O0,[^HD9#R)/'IN)T2#3"$LC^?;L $T\!IW/.E=U
M_<CR9UOU:)8AE4%& !:%HJ*@*>&[05MDW"OS>,2$@6_&/Z0LM3=-M!2$"JVQ
M$I+27+/8^46+ZLG@_'L#S#&V&4J@F^J-P)UGY.A/6YPSSB\2<^IX\S FIZ%+
M0YUX>J@Y!">]E48\O)_;Z.7R9O_Q _]C4<\4HXH(CB!C-!< IXK2=O!PG$HR
M2'V.FP7&@LYYF@N48IIQ,WP9SK"FF'.61[\ ^V1H/21;G /E: #+/25J'(('
MR5;'K0G"#*YS2]=1PGSD;#CK$Y6X (Z])GNAN.LGA:UQ6=W.%ZL9)5#GP 0+
M9E@*9'ZM .Q&9:9PUE_['MO!'.599M9E.D-&Y#,*J,V/,F@^S<PZ;62QNPB@
M=IY$]I&W>!P.T[.+G:!MH9U5TAZ1Y*QA_:B=HFCU].2D2@UAQWT#];J\W=Y4
MMUG*O][/U_/5IBQ_*>T;B3/$S?@I*&>" ,01+2!*NP$%)?.ZK?^*J0P#333&
MM@0!SDR4(I'.\Y1BE0F!>!9],_41NN3RRW+QM4=%DJ&$NNZQCL:E[T[K8QKY
MUW79' M(_K[%-OHVZRFB3FZV!F%X&EH5RIEG&Z\!.>J]IGRW6)5O-^5M/8,9
MSS)%M5W(%E *6+"B'5P"$>EUW^N$F0RG>9I+EN<YQUDA&(895#P%A"J*9>S2
M(B^E8RRXI$$W-)7EP6;/M6(<(H>GM%PX'&=QN&/(9S'H3^LTM"F$(Z\M]OIR
MTW-QQZ^NUO?S)=\4\_7ZP7SXK_/E?3G+M$9 "RRED<4"J)07K!M0A*)BP#+O
MB,4<0TE AC$ *88$<)ES6[T780'-^C;VW:IWBTT;0R6W\XW]@HO^+PT&XKC7
M"G $>@?FMEJ$9UT"OLR2^V)P(,M3E+/!/IU>( 9AS/NL[0L;E1!DI!!<0I'2
M/(48RV[8(;/<8:ZQPBD3*2&I6? J1E.&54X$L=J=$8ZR B 4,9&\0S6%K?P3
M%+D<'1U [#3&5Q!/CAT@'<R.<SW8JV_E];T]S;.SW;[7WFS''=Q*XI)341#)
MH3%)!=$Y:0>6B5M2K]ICSD9U6JC4GIE-%< Y@$RQ3"D.E$ASJ&7L0C\]S[6'
MX]1-K,Y"IY]R=1#MT<&#,_ MS'87_XQ581T9/"%LP1MA&BH7WJVGY6'C\#8@
MECBX*J2Q%A0HDA(@19IB>Y*Q&9\"R11Y5: X:0@6C((L9SA7'-MT.LTADZG"
M2.:*H-A%>H;>W^G%7>] + YM(2*Q\]_A>8$EOV#,G]QIZ%085UX/Q_KR,[3P
MXDL(-*!2<H%@"O*"LZP@O-O"D8@(':+VXDMVD:2<(X!T)C*,# \ 4@04$$J1
M0LK8:O5N<66K=+0'G'>P#_=X A5B[$6ZFZZ=BV\_F3M:CG$:LN=!X@D5C-$4
MTQ#%*)XY%F(<SI[_$E;=WBVKA[+\5*Z_&Y'X]&V^+L6\+J_M Y]&,QJ5X,NF
M6<RO+F_:JH3_**\_E.M%97ZNWK3G4%E:Y @Q)D7!M<H@R=5VG&L()%)>XAH'
M(6&I%$:--*,0&U0,Y@CR#+!"YEI%?\GX<$G7N96T?B6-8V^^6,^20]<NDKUS
M]B_NW4NV_B6-@_U.PY^I(_@NTJ?:!_JOZ$=O_LA)@( MY)0Q.$>/F,8,=68.
MCN8BSM<B?G7D/FWFFV:Z?=<B:0X.,Y(*S;(\E[F 0.=44]!*5D:1\GJ^ZY0=
M293QAB("L@+G #'%<YYJ(:2BB.+8#TFW!=)VV)(.7)_2<CV9=,UBC$.B;Q+C
M"']GN9EP@J.3*8SAS$Y#"H-X\F*-N1#L#)2E]NAPAM,,%810D3*098 ;0]UP
M0AE5 82IM:08I00H)FB&L;)CUMK*<($S #$;J=!E)&ER97.0.$4@,I@\G>6>
MP4F>_"7*D]])BY2O+VXRU8LA]T1KO;F\L84LZO:4,-8\XVFJN+&#M%**$-0-
MIT(KSP<!GWX[4APARE6FLQ1C+*A& O&4,9:G&LO8MPHL(+OB^EI5UW525\MK
MWQ2I-UVNB="83/FF.[<D-6C.=$_@&1\G,Y=]N9N&F@S _RP+.8R)(.\6M)9S
M8Z;(&"!< @24X@7FW< @.96S[^7Z2Q7DY8+68J$*+)DD($<2\Q1S"5-$=4HS
M13*6>1W_/ 3G/' >%=F_WL,,^&:!*[ENJC,VJWXZ]-J;!6>2)@?23HA52,JG
M(5]!/?)YH* 76ZX2]]=R5:[G2V.87]\N5HMZL]W;>6R;*EK /%.8928XRPA3
M2K?C$/*">6V/N%D$F7'/GO2!C&+$& <8 JJ4/3X'<A9[U[D%V0S)^2.8?B(7
MB%XWF1N?63^A.R3U,<(S2YT3<2?$+BSQTY"[P#Y5,;NJG^2%R?:_V]WM2C4R
M 4JJJ9 89REG62:[T6MO!/F(8VAL68&8L#?,:*:Q1CDOI)DQ4"92)@VOL4N%
M']L9?'2XY,O#HQW$#_.'YF/^^WQ]??'XKS5+MOZW3D=O>3?=GG*C>VX3GZV]
MH\P+@1OFQ QRKBXPC;GF;-Y7TQB(?O-7"Z"\?AE?.X7.BK3(&0,I)$7*D60L
MU>E.G* &?HD)1Z,0D+R BDF:IC@'A0"YA"AG9KDN!*/21WIZY28^5QL38=:;
MZNJW5E^N#F#Z31>AB':;!<[ L)^X[P >/?#SZN.5453:C;@3XAN8^6EH:FBG
MJJB]U?,,:+=W='FC%ZOYZFHQ7WZHZN:]Z=T-2H$T++0"9CP*GN=%FH/VNAT7
MP/U*OI.M0J99QA&"A4JQ6<93:QQ!RA@CC,N(ISKV^Z7V28L.8-(A/-M]81?:
M3IV6"\GZ- 9D6)>>GF4+SY?K8/Q@>DVY7ALEL)/NA_GZ<MV@N6Z* IBXJ%&(
M&160,"7,'*DY*S(S1;:SI.(%U(57L4E'DRG*<8Z9SCC#V(1@%.0<2DY1*DB.
M2>PBNSN4VW#D(KF;KY/O%F'RTV*57-NC].LZN2O726WQ_MDO.@G%NYL,GH%R
M/R'<L_UIR[;!: ;U]D#)==+ M,>.M\'+N&+H1MX).0S,_C0$,;135=0>.T04
M&TLUO]]\J]9VL3@3!09$:<WM+0,)M$(9[@9ESOS**[QB"F22I10+$_UPG*?"
M/NL@L"V)5TBI8>Q:3,]$L)&Z.IGO$#9BN/UTD +ZD]Q'^:+R.U#QMMB2/;AS
MJMQ3HIS5K3?#4U2U_LZ<5+.!'#D].?B"15G6BZ\KJZ$S6$  S"#"S*RFA%)Y
M*GDWN#*)G-Y-<#"#.18I!8(0:,18*V["&6,WYX+"C,/8Y^B.J=?U#J&_>H4@
M][1RC<SK(-7:BE:RAS8>B1ZO^HU'9K_'^U[OIT-?[#O)P O:'I"V";R_%\B1
M*GB7&AZ57MYOZLU\=;U8?9T56!!<J)P3);$P[4\DZH:,U)(.#4L/;8$<*Y#9
M9W\PP@7C%$*L,EQP083*I#Z3LE=[B&$#4R^>^T>FL2@.$YH>H#M_;'H QC,X
M[4/R=*/37MXXA*?]6?)Y';1:G5[?YQD56&>YD#E#D.9 <-:--0PQ]+OG\;J]
MC-%<I@I CC#6&'); #@U[J>8&L]CZ]H68IR,8Q"ZW:1M;*;]Y*TE>7J)1@?:
M3DA=2-*G(7=!/7KA2=6P;/60O6>) (@SQB1BF298L3RGF'2AA82(>%8).VY'
M2N..@IG&(L,LS87B'.520I:"//6[+C%8Y@+F% =QZZUM46D=HFEG3B6>H,A-
MOWH3.SG=ZN_)<;T:R$YOG3J,"#, $8/ ""+@.4(%EJ@[GB&% EYKS9.&""/*
MN*(YPP0#G-I*VHJ9*!1E9B4-8C_^_*)2!5EE#J.WIU;%8G:X6%V<;W5YBB4?
MO>I#[D0%JY<KKRE6?W[<)6O5G)7YVV+SK;@W@_:V7+]KGXYYF&D"I2C,_,]Q
MEI-4%:+H4LHIE1F;W36G@$TDN-ZX*M<I>Z0 ]B%L+J@HC#(3RC6 F01 FJ"2
M J]'/Y]"<QYKLDOEK,OOY>J^O$A$^76Q6EGM^C(W/WKE>2=N(,>NPC46L;[*
MM<65_&Z )1VRBV2';6SE.D'32>D*0>]4M"N(+\_$*QQ#0=3KXW;X[J\LS HE
M,9><**9)"I@9:!)V0XT1@6:K\JM=TP:0LN?&<\1TD=OG>UB&4UC8)ZXY4QID
M0-E2+TY#D&V'X"%.YY'88NF*4]X9>5M4]_7R(;E?E?/U:J]X >6M1R,$T+M(
M[,<1P(NDA7M0+W1"HOB,R[XJV;]1?@#9'."<CXX.Y3!,6$@+)7+%(<O,TLK>
M-8#M]7TSA 67H T+U2J$DLZPDD*F"#*D)<8DY0(0H"7/%3;_EKE_4-@!&Q 2
MJNU:]K5X\ >*85QI_@$&H[LO7C&,'T,][O84\_J;7E:_U[L;##*3N3+3(R,(
M:@DR 3*(,L2UAJD42/C?Z?&W$6]J?'27QP)+&F13N,/SC*83XRH(N],85F%<
M.7Y79R@_KH/J?;FQICZLJ^^+Z_)://Q:E]=O5Y=&_^?V44]^M5E\;Q['W5^?
MLP\W 5O<+\N(D)(J(#H@2&9>^=D(YF-G;>WHNVE&G^T52=5!3>8[K/_DMRZ(
MT09N<G=F^OU$T(#=:E\'U]:+^,DB3A:K/R<[T,D>]=D$TI_8$[(9L96F(:8Q
M':Q&Z_&^)RZKF\7&/I\\HVDJ;)*':T6D1B27.&\- ,&U5YE^CZ^-+)1VN"ZV
MI9M_6AH\WB<EW?EQ$[M(U/B+6%O0^B<+Y<\7]K?+^V:1]*%:;VOB;#;KQ9?[
M3?,8ZJ9*WIMA9 /N:KFT/_9V99JCK(]7U8QT4+*C[^292&^.IR%!?8 _.^G8
MTW?G\B[7_]LLM9IW[3Y7-K.QNEHL2].CMAW*6OY<^:J;I@A"G2NE<LR53G66
MXPXJEYF7^)P%8&09._#)#L5UYU6R>JIO]H_MAU<V1KD[C%'NNQ@E0+!XGD[@
MIK"3;W\_K7[2]#N'DF<B;O_X1PE-8S32B1GAK'UB&G/+>2EX6I[G_.WA=,G4
MQ#P6Q<?J8;X\2.<O[7;>Y\I6>+^\T?>;^W6Y_1$#9R:TI-(^RUI "@M;+1=W
M*1*@),C=MBVCF8^^<6E OVEFG_46=I>%-_]M@%N9JN?;M_IN&O#M3QKT'K<K
MHS3-Z1GFO&W2+]*W52IM8[1X#S8OMXWQN6H>F$@N;Y(MZN3C5!K#XP+LN1NE
MW[58VSA.(^7I,!EZ6[8'72],KM&9G\#-VJCN52/U8/\)KUO<MW7RGN#8(P H
M%[:$B>848H4SP:5L$61Y43C=7HMA-W96J9OB%BW>I&P+Q)L1O>QV(.-,>,&:
MQGVN.T>K])SF.JB[BOTOS',#)KA@Y/O/;>=HA-[3VI'1\<* "#VG.=+TRG06
MFNSIS&3!/7MA$HO#7N#ZT[#)@B)&,<\813BG$G3&TU1PKY1C&).19ZU/OE6G
M?^QRR(YD3R0[$]BIGN60O3AS'9"RO%N75XMM=?K5-;^U&TS_V,Y\* ,$(*2A
MY*FM@91G!>HLZH)AGU$XQ$[DH7<(;?MHTP$XO]3[(#;=,NAC$>D7XQVBNDC,
M[Y;ECLY#B!=VI_)N75W?7XVO;B>H.R%I(0B?AHX%\:0*WQW]%.MR\ZU<V_WN
M)IBQ&>E.(0D"%&<,TPQG%$*>J7QGKY!(^MU)Z6\G>A:77UVMR^[RR?6BOJKN
M5YOZHME;M".NLM"351?J;]9S,Y<T \YQ616 :S<UBTQR+RUK,"4MJ-TN7HOK
M^!F5*))UE)\3@C6<TVG(50 _JM"]S4^JC(UU:>(Y66[_>[!%5LSO%IOY<K<_
MQHN<YQ++5$@-L(2(%G"GE3E2/K%60+.QC\I^LR][U<EB=7CPH:[+3=T(69>N
M\S\$$9)Z-RD[$^M^VM:!3'[J8/[9DK\_?M!"/=O9 W<63RA@A*:8AB3&<*R*
MWHV'BJ8)=YH YV-Y52Z^VR./,P%)QO*4T%Q)GC-J*\ZTIB%/)?8+]8*8'"/J
M:S#9$V8MJ*&:V(?9OFH8B]*0.KBC^./K%(\D?\]I\Q*^ :Q/5?*&N/2JV WF
MJ[_,O5U]+U>&ZB;[+EA*TXSD15%000H%0-;9)!AYEE<89BNZL'5@CM<OB<%@
M7QT+3EU( 3L =V[A.H#BI5A]^)VJ5/7RY56-ZL_0@(6K73KO#W@V2[29625#
M(+3",">:<9Z#M-N20#!#CJ<I QN-+E?;_-!VE3IX4=J+UMX+TFA\!EV,-OP>
MG(@_S?18R] 7N/-;@@XA?ZH"-\RIUY>>PSD;ONS\,']HXD"ND%GG9CBU!;@T
MPAE1K+-;0.9U*&&XM<B9N=U*Z&Z+)]1*TYG,H<O,&#R&76-^>(79D1>8+9Q>
MJTM?LJ<J9[W]<5Y7]F.JOXBIV[ME]5!VY[S>[1/J,\J5I#D1B@MIU)1H0HH.
M@H!:#-.S 8;C2]OZWO68U0@T]U6ZD1@.(GH=UMV1WP.TYQ; XSQZ:6& YIBJ
M+(9P[56%#,;?P$5N*P^']A61*@<9PP(18C3;5D=O[6/!A%<]HW!6(\MDN\QM
MQ;(])1YFP=N'XD%KWLCL!ESV=I/3A/3Q"(/^B]\!K3!591SLE]L2>#!S_37Q
M=!W'@O%,"88)H-Q67==2=>=FL)1LH#(.LQW]V/#C0J9#E7$@T7WU<3R.@ZCD
MQ&K@>_+II9EA6F:JRAG(NU?U,R2+H;9/#G4\%3G2-&4I*PBBC&:V+$:+0(O!
M!_]ZVQTENEPZ1#GQ&0ZSG1*+W"A[*E,++U]B<<#N2I^VF*I0!O#,<Y^E/WOA
M:PK/)",*9ZD$*-=24X%3N - 09K/-M5FOG33QX!FO>1QA]!Y&+_WKQ(7JZ+P
MZRW@II]G(M]//GM4$)YJV> 3\AFA*::AGC$<ZUT>V).[@=II#P751XJOI0Q#
M^W1PCK)<0P)4BG@'A"B1!JC'/L1\Y%#S:3WV10<U>#WV06TP2$7'HC^HFNY
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M6O1@.=ZBFX0JM5C\Q<F7XDEKE+<S;E+5CZ.!BO7>,-':E:HH%"!:B9QA@0'
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MO/4DN;Q)=KXD6V>2G3=6;7?7I8Q#]J<[EY+&I\FV;8_;N)-KXV%7=1\-TFZ
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MM\JI=GG+:3'3;Y-<10>65:OZ4;9FX?FU_%&N;"N 7+1C#<\3?Y$^M3QX/'C
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MQ#LBX\2)J<Q\*U>+:OU;M2TW;8Q44*&^)O,LR6$L4WVZD'?M)"DTNG/D_O7
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MA$ WM0B%5MOH[[55)#")XYCDJ( X%ZH)@2A*$,MD7N1V.S .2M7"JV?9] 5
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M39 XH8G=JTDV'P[LWALLT:(&$_U%S^GZ3_YJ^5:2%5?GW6MPFNS<8P/C*FJ
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M"#91:7%4"DT\)EA(*;E4MM8=?1>^H2B1B]F2HM'2RKPL9A^OHY1JNXNV#1
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MF+.*29&N'M>48P6>UW _,_.]#83L!6&V$$X'OW?3KY&K42H[DV7L[!>@ED
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MT AE84YT7]_WI<8AU22GNT+5/XII,1M,4OV^T<UX.DXL2&\I]^-J3\_@((8
M "&)PU1:+ITEBD"BN9=.9FE3??4]M8:L9GE]*OWI +TIT+@V,#.:,L2HID0Q
MP86%W'#K)6 YIM_A?J9N'R:U<M1E,+<KN&QB U]&T[V"F%=:!T>A)]@9I:):
M"2A5*=&+LIP[#$6DM=,MYT2OV?*5['S.=O9VOIR63R>[AGB=)#G[^@9&I'68
M TQ\7&Y:1$N4$RLLYMS'XSO'9.NKJ[L%-#7-YZX?.NQ7A)ZU#)AY;R4UQ.#D
MTN "8"ND)EQ@R9WMYHK_9(D1FQ/WED<.Q[$Y]S;WV;<_N_W;W/OMN<*M.4J
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M\5!.B<VJQ*SCX0ZXO=H^, B%AL0;B! 5V$?:.$0>:R"HPF>8,KI=!#S/\=@
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M4$T<$M(RP8"$D&'(1,[[NC/8%&I+OLZFT #_N])44Q; BR^/T@+NR>+[:OL
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M$ =9V^"/BX8&7K<T(;:&(\E20LE/?Y59X8O;!@F**LV,U09Y07'\"ZKX*!#
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M'5[?_6.]7#T7A2H7'XN_7TS%BW(>/]YN-@!' CI.Z2<@PY@DC,N4YTI"P*5
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MP6 P66GC%[5^>;I)D=NY/)GC<3+6/X)TD^H)G,T4IQ0 *]=3.-(CE&%3FI0
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MJ],^&WRYMFN4W9[-?:-+!JJU1\VM \8B2:HN"1"L"%^7P?*U]QW5&#8#W*-
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M^!C@<S)^WA]QW-/W^;0&Y +V!)AA#UNFC3"@W :">I1;&#J>ZSD4Z*+78L&
MG)!U:ZK*9!T*CMM8W"OH[:MN.TK@(3 %GF" >T(XU)0>Q:YCV1!+BR(;(L!,
M;T'I+0%>,U[:"0#OZ+RT/(>TS1U=@3HR0QU%C'+D<)MS0@7A$ICZWG%F<4#T
M7>1+<MA>8Z.N@WFC1ROV-8NM=>). WET5I5)(&HS&SM 2D%=+#FR,3"EWD5
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MGI1QG$M[[TROUAG%20/9, <-0CP#H7 \AA#D+O$$=1CAGFTJ5T]?,&=Y-E@
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MZR>1FE\ZMR9.L22OH7M-"CNHT5L_7\P)^R\H6C^XE0AU$F$^?L4\8-H *GL
M4":XH)P!Z$CN4-L6B#4B$1K6_K!#$.D VFAUE^.7"$=Z<"^M3<_<LG XVJ-'
M@O$Y^6!RCW@0,\ZH[7K"XR8'0%JF^L4D"_'M^619-U^%[>W-=@CG';/9(D^K
MQ,!>GE%JG?06M5#,'4=R;(=9-N.0$DD]T^(.IPX!-@.6BUUGH2+&6JAM:'M8
M(=;L4+/1</=!HO9D3A8N'+#/,Z,VU=L;< !6B]R+Q[>#X&6PKZ/[;OGIW[=!
MGY4\=N#B4<FOV74EW)$>1X SQY*42Y,S0=6OT%56#8)\03S.G:>64>\531S4
M <K$0:+)4E_/9X7]%*-[)3WWZ?15*Q-;F;A")N+9I154(L>E4')FJ_\(P*6#
M'4<P:%/@N=)N0"8V=)-,!U+0@>;V[B4]?)F8FY;O,E]-8?IY_G-N.(,P"L[Z
M02[(( +_\8BKH:+!;W,#[@9J+9-&C,%^8/A=G2OA1P\Z=SZ_9<WP$_6QXE#U
MFOM$68LC/\ET(F+6#]) ,8T_[H5Z)T@QE9*K:?%;3NU\@^@NC/RH&^;A(/5!
M?I[[[6/"Y#\*>CTEQ>)$WRPG50-T($^6+?_93R;/&/GWP=EM$OC?SOP[-:+W
M_N"'_Y#J\^/]I)R,GP,ZA50!VN28>/JP&Y"6)ZD41"*+*R/'!OH[_B,J;#8U
M?Y-Y&?U$@_O?4N P:%*+>UR8E.L[X0AP&08N9@Q2!SZ+=S1#:Z[0Y_3U$D]I
MZ"^P>=U:+TQX"UR>__FC>,>M$HKJ$1?NWV[DE7'S5_=*?G:_WIS;UPOLN>,A
MVI<7CGMQ[3J&^NWZ\N.Y(V_4']<WZC^?W(N;:^/2,RX_JPG<G*L.^S;\7\XC
M)2WB<:J<R[23YS*/,F,4),6!'25:"J6B-,6O>S?VKQ,!U_#0YK[_R-H#$_$>
M:G%:_#W_@DB3:O!8)8#"VLVUBM$-!H.R]2]OP)O\;S7P[N3O"G+<A$,EZ"^"
M'\95//07;..AG]R'43$\?YS%DP\*4SO_Y$?8R_JJMYI\J7>5,A[XHS1X/_GE
MMZ=:]LTTQC(-(4+VICX$4[R#FO_QVYL%XZ%\?WT3?]:WGM=TVN_::9&17<6^
MS1W$OFMMV 69PS>=.J\6AC?*A B,H6KHIT:@Y%/O\>'*$]\ .0TFN%#*:#,>
M.$F)L*HJS3:889$6SW."M\8[.OQZXD*BY8MJOJ@IG-/RQ8GSQ>[DQ0:T:)EF
MOYBF2IB<S*;^57%'VTM+(&Z9#/N+KOUACKT5*RUKM*S1LD;+&BUKK*30T>7V
M?T[BWKB;Y1>RUYRC;]PXW\LLE3TZ6%2;3D*)8#Q@9';"&$)70!M)R"U.B>4*
MC$UL,DX\Q*''%HX-E-:DE\3#JKLUW9_=P5A/6Z9IH/[?6SQE[!1)=U]NG#_3
M)/NSY)_+Y#I(OH?=0/X,TS_+MTT:/^7AQ"8N'NI0RH^AZM4)A$):J;%G4H/-
M+F^@PH)$-0CDV=0%PG*011S/I, U7?7I=J0&WY'4(!U$FRQBT$J-5FJ<C-3@
M9';8"4,E'ASB28M2SW&DAPCEKDMLU[2XN9"YVIBM\8]=2 U(.A@TF?O:BHU6
M;)R*V##!3&R8P$3ZU)G-A$D=CKA'"%;0-AU34!M45#YHR-C8C=A@'0*;/$:T
MV]SV!G=8]C<&<A4_^(/LP4@*SFMK?B[B&8K9):E,:7L7(X =0%W7X@S;C'#;
M16Y>]'.W(8=R+9O#,^B@9L]0[UW)T#;<?:JHQG,W0T#,@(<$X-2AC%'N8& 1
M!7+5DPJ^)52O&Q+8!JJI:%'=HOH(44UG]4E<@"S/1!YQ'4D1E))06WH2(N!Z
M GD+EU>\KLO>-*J1Z #0Y/Y B^H6U?N":G,.U:8PN64Z'O D-1$3DEJ4<&X"
MKEH V:U'O054<W'<J#ZZK(*+.#KK^FG?2!Z[UNJ_1:'A+,XS#O09X[MQ-DZ"
MLF=8EX1P%,7#5V%<S# .3(_8EN"< D AMKF@K@<] #VDBXEO3W,OM<>C;UGR
MIUI<6ZUMB?/RQ5?%PM[$UVI9+^^\?%&O)FO:J.'.CB*\=@)1^5/ +(=S=[$"
MB+F 2.E@O94N.80>=2U@(AL0AA>NWW@='WKGF.4=W&@1F1:R+61?!%D\RX2Q
M"+/TW>6F:Q.*$! ($@H<R_9<"CG=TN;4*@=YYY!%9H?R)J/>+69;S+X(LW2&
M6<*)2Y6.M2U"J(VA$%@QJ\< $M@#SI;R4%:YO[O'+.E@W-X)>U [SQ\5]T1I
MT#'RLCJW<9*73<K+]A9WW36T)7V,UV^LDACF3&*8#@#2\X3P'$@= 2V78&68
M6P1)#U!O2P&SM9SID@/L^?6747']5SF,QB0$[D"T%W=Y[*TUT(;/3U5:B%G"
M&@<VE*;I A< RKERZ1T,F>O8TA28P.W9%_LE+4B'O^[E :VT.$AI<8320$ \
MLQV@(UQ3I[AA3B5S+69:'M='9P!W;+"ELS)K10A>4QJ(#F\OM&_1?I1HQS.T
M.P2I_S'N"<^EV&5<6(ASBU L"5!_[#"V\)IHAQW 48>3=MM]:T'"K=W_TTS(
MX#E3WN^[&$JPTSFP>\J>=ZD++:Y4.Z3"]%R+4RA=QV&J_S;# LTDQB#8*$+W
M\HZ%-H)_ J@T9Y=&$1-+C]N4<<"H)2R+>9XC!?$DA8Y)MKJ+WLS6F<FV<&=*
MB\H6E:^-2C&[MD@B)B%'@#D>H0!CR1ESL&U1RR.6S;::2=Y$#@KHF'0+T:P6
ME2TJ7QF5$, Y6$J;2.6LVJ9G46)ZT@8,.4PPT[$P@-XV_=5&_$Q(<8>()K>M
M]Q.9)U.O]G(4Z-A$=*_8)LV**VB#GR,=NDCWO(CM3N7:R4Z\7?UV]=O5/\V)
MMZM_=$>_;*7U];&N^SCNI=KZZIUNUBJ$<QO)C -+0-MDD&/J("@PP*94'25S
M('#I4U-=$_+R[@]-1GWQ;[$=E%XK@FXSJ$PZ AU%$FGK"A\)A/ L-,R(*YDD
M-E,^+O60Y (!$YNNJ3J9KK=P6F,C"#46 28=D^,60BV$]@9"=!8P@L+TB!0
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M.#^(%A8),Q)F[-YQT/ ]8N*$-DQ+9C$U2"@$/'<2>$0XP6:S^1$;@,9KS(]
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MB?B)U3$27?$L\L:@7:@T$E0HCK2C F*MJ !2<6R\LW UTK7>S #4C48X<6:
M9&TVYGR46#8[^-=6G5/TX"@!(/!YH]<WA<0BP3Q05#&KF HO,"$!I!APO&%C
MNS81H!/# !+G)\X_ ,YOM+2$%%JGN"52$>H,U+&/KI<6.:LY(RNJ_)8X_Y&<
M]Q:[_",(>N'^$Q@D,#@J,'C2L!>T1@/$ @8 B0)"6*J\D81B$HP!3(WUPC[<
M?&,+:/ :[?NYV DX;.1'>%U$28-$$YJLC2:-"4*:6.,UB+UX.07 *LPE1]
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M9PJ/&6. &&8ME<8)H(BWWG#O*<9^)26S#<Y,3'6,F=2/N2.J)-^L/YG,BLM
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MRTY+F^S+7O3<XHVQQ%A1RBW!V%,8F!,+ UR0[AIA1!D28K.Q([@;#7H@QSU
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MT%*?_7OE 5WGX<!O;\>C/\(638NP11O_7N4>^J_O^(<8)@5NN*0%)T8A((E
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M)U=7_:#$;L-H#?I0U#\K(^93?_*[&1>78=_"HP=%D$ >(DNE<) RPI7&U'F
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M.;>G<UHZ32_SRFD:F!92%89NE:2B4Y8[:(?H(%2EQ1FFS*->KHWJJA]W903
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MFJ:;&L!YE8Y,"[BJ UQWG_$]0]TXODMI/;6OB[]UYYAE,NLKX9W"5'= ;IO
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M?ASC>N!_(U!<WQ"U:UZJZ>@+MFW]"I*ZLTJ:!^[<=<^+N P8\QTN.(^4"&#
MOA>%/E$^S*2SZ_"=\&2H(IL'/.:^%#*FC+$X5K;G!\'.+O:A/-2&;K(^W5RW
M=-,]*^O TN&-:;NZ ZWS=)6':8'[D]:@^:*$IY=OW]W??%XVEU=GV;F[7B.\
M\AU96B3\W'W\%*/"DW[.&EX#CS13'::32?6K[DZ&GV'8P_KSFI7]FF'2U8?T
MQOJ<7R?3Y='>9*/Y%?P)\[K0 *1GVK>;E>F[^H^5">-P0"7-T9+$UT__\XU
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M3:^M,K_6+@583)6)4#9=Z\"9T)==SS1=Z?B@E?YK ?*]\BK6"7S\WCQ@-EG
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MW7T!9]#>N+QF>&M_R_0L325:]LBTYT_ B,/;.S-OXX"*D#O$CXCD7/G*=VC
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MI1WX4>OMU^ZWL?AZI(T_&%&C(?70 ]$A!;1X:C]FG7RJ&!QW0<O(;VFQ@7E
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M"#%SW'![E0SJ%()&H>_X@1*,1!%7-I-4N20,% T<5WIB!6[OOM;,/_8C@\A
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M2QZZCH@#SQ6.K\+8CP.B[LG'@=F6@[&S'-C8S.FDL$\*>XW"'L!797D_V?
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MA1](3$]&,NW9B4]L$8(I0,) P<^A(+%P"1,1YUX<JFC/)+,YB=XX ]H7,*[
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M=,;(FZ9FXS3[&;O2PR9YBD;O_!@7P;5O^25L&!:Y%0#DS31K!5,=W[>JRL8
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M=W-L9++T5B"Q9]F:)VF.K\JN[R@NA<%@EJ=J2]8&,H'JSX33('9)/F'&.KL
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M9MO9,!WC-48$M3F[ML:2#"/$:9-Y4U/OME1"*]S&:&I5O[(AX\GD*]@&F@P
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M^0&F!IC:!5/[*%H#/)V09G1\&*)*T?)3]G-VDMBIF\W?47V ?,[+.-2R6KM
M4]4#K*I"515\>&K<RVFI)LB4]?6*)8.V?&ID]US!TQPIQF#+&:"SG] IC4QK
M@,Y3A\YS@LB-OE"#I?&$+8V_L.X/H_5RAW5]A,.8()\UD>5P1O61).]E5W]@
MM[VEP6= :D_<VJ2.S,$H/H#4(4'JE30RM'WT[W[RYM>7"82G"'C*/J;SGD+=
M11L[/U'SE7M%P6\0B!00B*9IB94$GB+_G5A TT-'T.^()]D:R7MEONR_[]Z*
M-)=KJ7A6-#[!B.)CXO@+AQS+QLC0][)$[GTH0U#R0!UZ"AP#=5AW4ZC[)20,
MQ.%"B,-I.3GV,<$-/HYC "VO22?KRX-4]NQ1AGMO]GU)>QWN^/SW.MSQ^>_U
MF8M4]&/?O6+,SW7!)UTC\]%UA:C^\5 :<Z@VM:,$'^J;K5)X^'$H%3F4BFR5
MBD20>!*\7"1WN53*,I0PO.2KOW1V,90PO)"+'DH87D)XTE#"\&F.R1/V.ZJ'
MKL0T^!7[1LP'U#U/U-5'JG30M/ !=2\7=<\..Y\A/%\>2=)!>6<_ QWV21BY
M6*0\L3B=5](%9",_+??D1'2X2RAY*%LC4=S']M9;X>4,R.'IPY1I#3 UP-0A
MN:IIB>>3N7F9('B*8+>/+-=3H+OH=.&A-N*CN;<QTLR#)AOTEJV?LTI]MN"I
MCA3%&,!S ,]>@J<RDM6#-C ;H+-ODNJ)0>0EF"-[FC@X%$=\7E"W1J:^CY5@
M*(YX H) /T%.&HFF/#+WXOD#6 U@M;M HFC((\M\2EATOWCT8/0\&>"SGI*'
MT3.HNVBKYU D\>D!4Z==)-$41X:VES5W*))X-FQF*(/V@CC^TC'-(TE31JJU
ME\E\*(4V$(B!0)PW@>"JIJ$^;R75O=2%EX6<(6K[?+TDKZP+<)/L5H9_+ +
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MS?V7#/BT .8 <#H%YHSD-H:;*QMF48D,''YWR!\-6@!78,1\3=BH[@_(>4Q
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M+7@-"QKJJNXH;EK+,52GM&A$H?PQ\@FA!]Q&)>JL7147B&K9>>]U_B";UXH
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M/[FM^4J;L'VWV,5[=V?\OINS#=W[AW=TCY[<$L?%)FS?>'2_Y]']X4[GW1_
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M0+UD!>\A%@I;/$*DHVX!@L!>;[U50?8 #^H]674A.7YJ,C97E.0J=:>+T2#
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ML/#HS"1?_5MDJ-71ATB+<5$(J$,:A@0=0&D%["G0ME,T*DI!TQ]9$Y8D*(G
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MGW=_?LRB><:16[,L"Z]6-8Z=8J8XJTNF,Y/6.VDQD2(,K1!%-*?@Z4\#/8P
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MYSB2.<VS4YVV-Z<DB[R>H\K7%I\,G7;2\BO>MYZ95>1W,H/0DH'O;E5HXW#
M)#>FH95NB%F^$2 YW;B66K 9)3C(:V&9L%(6._:99EATR"8MG:#H8V\#*#:5
MHC"L<XZ\0QB'L/?)\(9LJCGENI$X$;O0I-]L09N1>QGF(EUU#E_CT?'@;I;T
M5#8]9\B@":Y#7:/28!^*5$]&X6K>(5PK<>S($AT(!%U^PO>LPYY-#[UI4X1^
M@P4K21YSG$V?)\;N^]%?">^%V2C)%G:',S&?%!;A01SG/'O4:Q6<@TXG7$:@
M*["[K*V5F)==ZC0VRW,>9BY3;MW6D5%9NW/A5N$>&:==W.-+]5!7CCLCLT]
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MQIV"" KS!Q6-\R1;.+!$K+_.LWD:NR22]I]0+G#2%K,\-?A #\7AW-'(E_"
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M!'Z K4H*1:J%RS^PR]H&;+:&6#5U-I5X_,'(J7YWWIB&_R&])=CSEHSC:9N
M'F[2U)+6H8!.0._SR:_X8*!Z]MQ:2GC*]H;28T3>%O:EAEJGE MUTB!C*/E
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M%W,Y[L.52)!/LID9)$R>IHQQ"^*$L@%T\"7/P7*WL@7ZB.JM2H(PSX<I>B[
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M^2&(@@LB-HCZ05 1Z&44SQ<B2H,LELIW,9,/E7\,D@2(9FW:YS[S=RGV5YS
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MV\6U%1>6Y_+P00H^P&6LQ,,O'/RCYTH<HVP"&?AB=,0 0B+Z D1C8=Q?%.7
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M4Q&/E&A=L[Q.(M0P8$6LAO.4N7E5'W17,ODD!(MOG8OEL6^89NV1YFK$76A
M$<" )K^6\^PE]:F)#L!.Y)+=@7[-$K<3E)VBP,RDS)S#5I'_O<7R23_%8=V&
M=+<9:H$XD+Z/E7A*C.,J+9-GV$S\[JY,,K30TZ7!7"@EA]&:P==Z)S-GMX02
ME#$<U]A^&FA.#3$,_6C^#<34=V W+W,XW^"+Q.C%X;U$.QH344'/F)IY%DP;
M+V=V'_,(V+N"I[?.VGYT#$@!!<O9:871 LH9:&Z5!(:6TQPXYNG!!GGW,;C2
M31^;<&3<=W':J,H5C!0"(';A+Z$PMJ8X3^CK]T_716L @S&+1Y(4*]![-,\J
M&]%\*:=C]]GV+J=.P$.8&X&N+XE\A359<;AI$4\IANB"![?C__>ACOUT#S.Y
M.S%BY!6?D#(IN^7@S>! L?6Y_#@QG0".4T6R539JU8GY@!$''!XLM[  YI:Y
MDBE/UV_,OJ?.;$;H.PE(6AP<,UYB\V82( B;!6B:)W56=8NGNJFSK<JN_N>Z
M ]\HO\T*,6^/I7;GZ'A+QSUH,NXZ(7$2#*V8V$)T.Y6][<@[CU&#D)*:U@I:
MF@'5<W'<6=; "8H P%0G'+SA\^>5FB%32<!$C2Y<4FT+/F=E^'!*P)@&32-
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M[S[91K9,#Q1.:QLMN0;8-OG-%PC<A_2R#J0MQZ.KD<?GD9GF]JBK"@6N7B(
MJ&;HQ+1U:-0^%!-0%K[=N5B][MUY!IB*1TUW5:_57].*^Z_4GVU95N#.]KWT
M5OK=YAO:]$ONU4,YA($ZB*R:]MH*U=>M+#Z\^IC(9"DNDN^J$/V2HA]/']F_
MZXJ.NR NUREIT<\%2:7(J!;W12&-SR6P!DWNZYC27+'NE3,WJ>'0#"6*$66.
MO,L+$@@?(G[!>EZ$VJ8:MQT(820U"<G(T[O%SXMJGAV:4=D>:Y*5K'^(TM'W
ML >)V/!&A$NM5$I325^3.74G0$WYVLG2378T);Y@CDQ/I<$-4YR^.::CKV#:
MMQ"E#0*(^[ALI;!QCV?),EI4E82(NSS-&/8O01_"^=@2.;P T]0LMXG9?FEL
MGN_+I;NS<R_"_$Q_48?M:I:["%>T!6#+58"YGJF.R'[I>DW@'/4 "*>U*+ *
MUY2=Z 6&?ULUA[:76XIA<NRK$,_Y"UO-6R>M5K*+JQ6<<QJ[]2-3M8%%#..2
M-49]FD%DL8([CE-JKTR^'O:V<&>+)CI-=6\TZH:@['6*Z@MVJ.#AB;/^ @4'
MFBU28LZ/#3HZ>"]2<@TX =$'L@O DJ_1E))ZVF1TSCJV!8[XL'D)7ZGYF ?9
MF0D.2C>+08ZU\P&-;+$W)Y3Z=H[7L=UW<H.0L_W@AM0FK+^*JP/PR@ZY/NO:
MO8=PU(E!_Z/?INTC]8ZL+I;$OQIV%<P/"!J:\SC+1#>]S'=@/5SD:OA".1.D
M-$BMD>W[$_D^!E)O"UY?UZ^:).[WQK^ZUO2JG,1<HEL8KPX9:'TROB@IZHEM
MUMN16%VM<^\X%U/C;![KW'(-D51H,.%EC"XSV[2HIM9R;/:WVXE69,Y?YKR5
M7O#8S/@K#?KW&WX0)]1S!U/] G\E*68=D5<-;L5_5LD=WV=RQQ(@3TV*!?.1
M#KPY5X8*Z)OF[*"@%X#5YI@P90SS_#,U;SKG*] 16 ;44Y2F5U"-,3F]@%!U
M0E]A(UX,L<'I#S7-66CB*IXK,\ !&2*54EU\-E4G/H3/*@U-'*49.V9JDGR2
M=H)0M@-99KI/M]E8MD65G+\-!I[<B][EE<[.:8J$.X^4AM%,B"A3;#-%YQF?
MY@XW+A\H$UMTA2!2XTJ%/-D#[BHN[!^<9>*$YU [3>^SN2A?N%I_VV+!*6.?
M8VODX^'75-L !WJ81QSG\!-5F$,T&2V=#IVML*IE@JA$YI@7QH$WX844Y<H3
MBB\A/X2EKW-(H%-^5TJ/W8;K.3:',4@9V>)QGO*BK$PJC6D-I0V4H*Q0]@ &
M9P.7K8BN86SLB1.7\!46]-82.;S@, !V(I"YA\2BO<N]2FG/X#:VCQJ:@762
MZ[@50.G&,BL,NP,B4HV14LP!-#1CC@CIRZ3&S#ZZ\2HK\1\N#7;1'F/T]:8#
M+5A*D_Q$;7L9_9+KR4T%X"O8*%1]G;G1Y*7BBJ5VFEKVX)(HO%TVXOB2Y"00
MS%I26SFYJ4T-(H*%UN=E-;4\J;1:N[0Y&4^A[*1-61&W[J<'D[IJVU,V+OCF
MA69*&4PV4W313)7Y1LX/T->SLW</FN=1#@8I'"$)\C'FN*?;+51/AK*;;>S<
MZI=2B]_="G, )<Y(9)]G&Y*67G.'F*MV0.;[=5]C_DX:;UES0[&^MLN^/,9T
M+(+:IIZ8T(\6S@\\L86,IK\TT2X97:>+@H\8-*7:1PZZMD*N,@*ID# ENCBI
MKY=L  ^S;.>'>=E>DGS<)$@,!L>OO]*Y[55.Y4K4S<N P2J#J@"E YLH#<=/
M>C,&5^OQ)B%.7E_D*?'<F=Q&"RD57\]*GY2\O""?/^5B-#2DP,2)O4O"Q:B^
M7DKZ^Y,#SAX_U^<49P=@*FJJ'TC+?40M!@"FN.>\594_6:OT7'R7-##Z2DL/
M!VJWLWS3EA,)#0?^^BP;GC71%]11-*OH-_3(N"2;;F(2R@AL7DDBEQ^W;@LD
M>.>"ABYIXW&OZMA[D$=Z0PH'5.V8+E[89V\-#9RB44\2B:O:L#X61H.?T":1
M@4:U06N0G5#B-O*S]H4221$CUM!($]LVI]$ FG$,S+_FGX-%**B\\?IG,;?N
M&\=#9'O?F[?V\7VX/"R9GAGJ[7TK1\?7I[9UZBAFKM?.)1R[8LB$?7:S:>$L
MQ&4B?RQ(HI5Q&\2T@?DC2Y->.DEK%HA\US.:8N&8C4#.2/=K;EG,5HBPEKD[
M.PFH:"G0#!/GP:6&FI[^2>75$6O'VE^@[V+6[6PHF[\4V/GCE7$E0M9-NR##
M1<2OQ3#(^I7G\@;'^,D]'.,!*$=%JX'(ASQ:2O3E;*Y+(G-5<8LW[<FX_.FL
M6U<WGI^)IEK#*MV!O\(XB]#V2S:B&,I\<K)1, ?(FZ/7/]"QE?A.QQ;-11X:
M),/:J/CL<JDO[:5!Z)+5EV?6R4 J;%YT@DZ!.W@T5 @5KI:UA29KTQ-1/!A>
M9I<?ZCC(;+>CGK52O:@40C:5 Y<T\,)P:(U>"1-9I;/;JM&)\^IJ(T>Z1E_@
MWMHS&Z]#7:@=2#Y\2O2+'?L8 LI7MMVP4"]C>"F#M+U W3_JN<-^YU\N0BH6
M:*4;OW/9^%LZ;;?*5WZK>7A-#U!S"(DSM)U$47&S;!?>V\V:""1W6*#LAT7(
MI=VBA?/LO&K0^2IF*L,BTTAQ/T96^WG\2X_3*VA2H:7C:6-B7/*>AC*:B^")
M))KBW)MBZVA!K"(6<&4NG5\I%Q!- IK4ZT EDJ&!Q]J9U'BWE)G:$B]):6G'
M4S"@@'[.A^FQN(_.B=(F]+;5]&.CN8![7FE$YM3JJTTS&[AK;9;X(Y0\PJ,6
M,?504JW[8L4]+&=H+$>A[.":1@L#790/H$OFSOTT52AOY8CBQ@ERTF2@K 8E
M=FBT+8*@7NBV-L+V>G4!>>NN\+./>S*Y;QQG_V:[=Q\EQ =<8WA[3;#90Z_S
MIU>HX&7.<*X$)9KT\/W&Z='GWVMZ-@3>)/-ZF*(.10H!-BS&^D&J\R SCN9I
MQE)HT*S7QM>U2NN*IZ$0Z!'7E=@K693U"8NWDH/CX9"ZK=J*P+<'!\THF.?J
MM\W3S=?L>'TJ^[@3W&KZ'5V^'U> FA#VP< #S']N.=R(!!UU@* E'AQTV[0Z
M[PV5 P0<LR&SUD,#R7PQ0CM)3JU>W1W4!>T!*#R+@/MY?\2'1:@7M1"X^VS[
M.\/AF8<*UV0#^Q*FDWQF9*P03_FF@S!A?[BNK*/./P*%P>(G/%05CZ3!+&0>
MVTQT^6>=<44GWXI*G8=1OPG*7/>9;M<EAWCV _MZ6F)[L?4>%%&\Y/@O9@9T
MT'TB<2!)#@B?7)4:S:HRJ-1BI?A\I#^MVX9XLUQ@UF%#B/ *SX4)7Z?.%VI;
M?(@0R8LZY2BMK_])41.O)6=7D]MA.0&MS]QK2PJG(:9<PK1.J#@<5H+]?ZB$
M-S5@YT76PYG$7+$Z0F2L/5E7F:FI#+QY?KG*-OE&V29WX+IR>BS0YJ\''T[5
MVJ_63^D?YG_I=/)"?:!:2'].)V85.-.;Z(Y]Z$!JN4NJDEIQKI ORHIISU@C
M4(X6=7)LR5/AV&*N:4FRLJ:VJYZ,\8NUO>UU5S8YLU*!;_J<F1GEJG(2-4'(
MO37LU T& 0 ZMMYW=A U0X'1L\E/<XPCPN,?L:O8 9OJ+W%:I]9<TUA]YU)>
M$5G:/8C%E&8&1AKD*/>53E>G*UX@EW9OV;)K[<W5[/10M!JPJKL@KB_-O6U!
M;-,6A(%Y9TO<D"%A1IW&['2.0_C9NNT;@TZJA;>*ADG,IZYVI32ELC*[ZP.O
M]1+GUA*8)!?Y1J\4EDD[VLFKM8P3(,D+O,-0"A$)'>O)(O, 2R4PS!CA!)-&
M^MQ8K7_<,<CO3\V_CV8J30W=P.\XO:3&=PMGY?BU#[:Y +99('E>4\]7<B+A
MA/4X&R6U6/!>R*2P <6.3P9/"/;#<-KXJ*8B+>N_\<8FN!JDKF[2Q&<5U\EA
MQ@ \2\*0F#([5RF#P7^ZI)FJQ:4 U#V.";E=$-"CJLA:)*& FAJ+9U<2V3#N
M36]!1P>N[*(9N2-QEXYAPVVO>[T:#SPP<Q^'<'?[7CPEC?=HB0=.O%3NT'7\
M5.Q))9[I?2PRU*D*I4ZIECR49#MQU2)%PQF,SYTA[0:3VV +7.!:K@>-G>W
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M67H?9C?,GXJS=TW_;UU>>F #]NG\\NBBYZ^\G1^?GMVU&7TOJ+^DM_XZOQ>
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M MQ#32ZE3#/O.*9-3AL[$W#^ 7:9IM(Y@!LBZ4"C1*1Z(=$_W\D:D@P#EZ7
MB/\I>9ON#/!G(=%]OPL46>Q/!->?SQW^C^<.APK3 >Q0(@_H%(I.M6()B-I2
M?,WR_S'P"U)3(3WP>LHG-OZKG.G!\KVX4*;JX21P12C@ AM:F$6":WE3ID/8
M!,&/64L]2#J+>LX6:<H-3MA/IHS *X_@]]FS4OM_'@P<HB ;&MQLZXA(\"$"
M,>V_%"S!7P]Z1F8CK49 HB;CY^5WFZ:,*I#F2D\ :\>)#G&$+U +J? @BN]6
M.7.?Y5M2!-Y 9@+GYLO+ZUOI_M;6U?$S8II:O#I4XNI>M+J)1E>\G9(&)S[
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MG'[1C>BV^,'+KK_&?O W4$L#!!0    ( &F=9D\^C$E"( 8  ($?   9
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M8>%B#PC& M].EM7>7O'4YJ]XRB#O+'W\6F@24=RC(":!N94(I:)&#@EUKCA
MHPNS9G%;QR"IO-=EBAO.&W,OJ<!TPN?\->'@:,&8H!$+[;44<V/N]>>TNI:N
M0Y_K9O9%VS&WT9V7;7M-WOD/4$L! A0#%     @ :9UF3S% ,Q_6$   R[(
M !$              ( !     &YK='(M,C Q.3 Y,S N>'-D4$L! A0#%
M  @ :9UF3_3:ILZ4&0  2@D! !4              ( !!1$  &YK='(M,C Q
M.3 Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( &F=9D_QKUDK8#X  *:[ @ 5
M          "  <PJ  !N:W1R+3(P,3DP.3,P7V1E9BYX;6Q02P$"% ,4
M" !IG69/,XP5=#:Q  "7B@@ %0              @ %?:0  ;FMT<BTR,#$Y
M,#DS,%]L86(N>&UL4$L! A0#%     @ :9UF3^R#R4 I8@  <*8$ !4
M         ( !R!H! &YK='(M,C Q.3 Y,S!?<')E+GAM;%!+ 0(4 Q0    (
M &F=9D^RZ$1]K@L" '8<%@ 6              "  21] 0!N:W1R,C Q.2TP
M.7@S,'@Q,'$N:'1M4$L! A0#%     @ :9UF3W"C[*F9,   4RP! !D
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#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6841859024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Capital in Excess of Par Value</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,524,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 87,828<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 2,207,865<span></span>
</td>
<td class="num">$ (2,111)<span></span>
</td>
<td class="num">$ (2,117,941)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1', window );">Adoption of new accounting standards</a></td>
<td class="nump">12,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,855,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">34,406<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">34,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">19,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(95,792)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95,792)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,379,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2018</a></td>
<td class="nump">58,283<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">2,262,219<span></span>
</td>
<td class="num">(2,796)<span></span>
</td>
<td class="num">(2,201,156)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,524,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 87,828<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">2,207,865<span></span>
</td>
<td class="num">(2,111)<span></span>
</td>
<td class="num">(2,117,941)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">5,248,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 779,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,057,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="nump">1,790,122<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,121,322<span></span>
</td>
<td class="num">(5,378)<span></span>
</td>
<td class="num">(1,325,839)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,379,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2018</a></td>
<td class="nump">58,283<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">2,262,219<span></span>
</td>
<td class="num">(2,796)<span></span>
</td>
<td class="num">(2,201,156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of stock to Bristol-Myers Squibb (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of stock to Bristol-Myers Squibb</a></td>
<td class="nump">790,231<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">790,230<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,751,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">20,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">20,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(1,206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">971,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">971,460<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,415,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="nump">$ 1,860,414<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,094,095<span></span>
</td>
<td class="num">(4,002)<span></span>
</td>
<td class="num">(1,229,696)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">642,000<span></span>
</td>
<td class="nump">642,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">$ 3,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">23,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(1,376)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,376)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(96,143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,143)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,057,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="nump">1,790,122<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,121,322<span></span>
</td>
<td class="num">(5,378)<span></span>
</td>
<td class="num">(1,325,839)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">1,717,575<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,147,925<span></span>
</td>
<td class="num">(6,316)<span></span>
</td>
<td class="num">(1,424,051)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">698,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">5,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">25,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(118,512)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118,512)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">1,633,511<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,178,773<span></span>
</td>
<td class="num">(2,716)<span></span>
</td>
<td class="num">(1,542,563)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 1,717,575<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,147,925<span></span>
</td>
<td class="num">(6,316)<span></span>
</td>
<td class="num">(1,424,051)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">2,256,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (327,229)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,786,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">1,488,711<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,241,160<span></span>
</td>
<td class="num">(1,186)<span></span>
</td>
<td class="num">(1,751,280)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">1,633,511<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,178,773<span></span>
</td>
<td class="num">(2,716)<span></span>
</td>
<td class="num">(1,542,563)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">7,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">24,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">1,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(109,909)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(109,909)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,966,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">$ 1,557,155<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,210,398<span></span>
</td>
<td class="num">(788)<span></span>
</td>
<td class="num">(1,652,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">820,000<span></span>
</td>
<td class="nump">820,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">$ 5,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">24,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(398)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(398)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(98,808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(98,808)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,786,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">$ 1,488,711<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 3,241,160<span></span>
</td>
<td class="num">$ (1,186)<span></span>
</td>
<td class="num">$ (1,751,280)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cumulative effect on retained earnings net of related income tax effect.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109228884&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6829948144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Activity (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">820,000<span></span>
</td>
<td class="nump">642,000<span></span>
</td>
<td class="nump">2,256,000<span></span>
</td>
<td class="nump">5,248,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted stock options (in shares)</a></td>
<td class="nump">131,000<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
<td class="nump">246,000<span></span>
</td>
<td class="nump">929,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, options (in dollars per share)</a></td>
<td class="nump">$ 13.43<span></span>
</td>
<td class="nump">$ 30.52<span></span>
</td>
<td class="nump">$ 15.81<span></span>
</td>
<td class="nump">$ 39.28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="nump">316,000<span></span>
</td>
<td class="nump">152,000<span></span>
</td>
<td class="nump">712,000<span></span>
</td>
<td class="nump">558,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, RSUs (in dollars per share)</a></td>
<td class="nump">$ 28.00<span></span>
</td>
<td class="nump">$ 57.27<span></span>
</td>
<td class="nump">$ 31.80<span></span>
</td>
<td class="nump">$ 54.49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6841256480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">$ 3,121<span></span>
</td>
<td class="nump">$ 4,875<span></span>
</td>
<td class="nump">$ 9,860<span></span>
</td>
<td class="nump">$ 1,082,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | NKTR-214</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,059,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">3,221<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">8,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AmgenIncMember', window );">Amgen, Inc. | Neulasta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Baxalta Inc. / Takeda Pharmaceutical Company Ltd. and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">$ 371<span></span>
</td>
<td class="nump">$ 404<span></span>
</td>
<td class="nump">$ 910<span></span>
</td>
<td class="nump">$ 10,703<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseCollaborationOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseCollaborationOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NektarTwoOneFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NektarTwoOneFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NeulastaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NeulastaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6840626048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 81,224<span></span>
</td>
<td class="nump">$ 194,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">1,414,448<span></span>
</td>
<td class="nump">1,140,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">41,205<span></span>
</td>
<td class="nump">43,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">13,720<span></span>
</td>
<td class="nump">11,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AdvancePaymentsToContractManufacturers', window );">Advance payments to contract manufacturers</a></td>
<td class="nump">13,015<span></span>
</td>
<td class="nump">26,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">15,212<span></span>
</td>
<td class="nump">21,293<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,578,824<span></span>
</td>
<td class="nump">1,437,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">231,082<span></span>
</td>
<td class="nump">582,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">64,614<span></span>
</td>
<td class="nump">48,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">134,888<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">76,501<span></span>
</td>
<td class="nump">76,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,385<span></span>
</td>
<td class="nump">4,244<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,088,294<span></span>
</td>
<td class="nump">2,150,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">21,963<span></span>
</td>
<td class="nump">5,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">23,101<span></span>
</td>
<td class="nump">9,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AccruedClinicalTrialExpensesCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">38,338<span></span>
</td>
<td class="nump">14,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AccruedContractManufacturingExpenseCurrent', window );">Accrued contract manufacturing expenses</a></td>
<td class="nump">8,646<span></span>
</td>
<td class="nump">23,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">11,394<span></span>
</td>
<td class="nump">9,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">4,198<span></span>
</td>
<td class="nump">4,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">9,318<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">8,392<span></span>
</td>
<td class="nump">13,892<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">125,350<span></span>
</td>
<td class="nump">82,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior secured notes, net</a></td>
<td class="nump">248,257<span></span>
</td>
<td class="nump">246,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">145,099<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liability related to the sale of future royalties, net</a></td>
<td class="nump">73,455<span></span>
</td>
<td class="nump">82,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, less current portion</a></td>
<td class="nump">6,779<span></span>
</td>
<td class="nump">10,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">643<span></span>
</td>
<td class="nump">9,990<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">599,583<span></span>
</td>
<td class="nump">432,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at September 30, 2019 or December 31, 2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000 shares authorized; 175,786 shares and 173,530 shares outstanding at September 30, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Capital in excess of par value</a></td>
<td class="nump">3,241,160<span></span>
</td>
<td class="nump">3,147,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,186)<span></span>
</td>
<td class="num">(6,316)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,751,280)<span></span>
</td>
<td class="num">(1,424,051)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,488,711<span></span>
</td>
<td class="nump">1,717,575<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 2,088,294<span></span>
</td>
<td class="nump">$ 2,150,172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccruedClinicalTrialExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccruedClinicalTrialExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccruedContractManufacturingExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued contract manufacturing expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccruedContractManufacturingExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AdvancePaymentsToContractManufacturers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of advance payments to contract manufacturers, net of amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AdvancePaymentsToContractManufacturers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties non current net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812034480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory consists of the following (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,586</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,846</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,961</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,403</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,132</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,720</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,381</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased. Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6830780608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text">License and Collaboration Agreements<div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. Our partners may generally cancel our collaboration agreements without significant financial penalty. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606. </span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.42528735632183%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Partner</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Drug or Drug Candidate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Bristol-Myers Squibb Company</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NKTR-214</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,059,768</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Eli Lilly and Company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NKTR-358</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,221</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,200</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,627</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amgen, Inc.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Neulasta</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Baxalta Inc. / Takeda Pharmaceutical Company Ltd. and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ADYNOVATE</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>371</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>404</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>910</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,703</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License, collaboration and other revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,121</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,860</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,082,848</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$20.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$56.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> of revenue for performance obligations that we had satisfied in prior periods, respectively. This amount includes all of our royalty revenue and non-cash royalty revenue because these royalties substantially relate to the licenses that we had previously granted. </span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the three and nine months ended September 30, 2018, we recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$18.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$64.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of revenue for performance obligations that we had satisfied in prior periods. This amount includes all of our royalty revenue and non-cash royalty revenue because these royalties substantially relate to the licenses that we had previously granted. This amount also includes the </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> development milestone payment earned and received from Baxalta Inc. in the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> described below.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the changes in our deferred revenue balance from our collaboration agreements during the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended <br/>September 30,<br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue&#8212;December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,636</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognition of previously unearned revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,465</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue&#8212;September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,171</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our balance of deferred revenue contains the transaction price from our collaboration agreements allocated to performance obligations which are partially unsatisfied. We expect to recognize approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$8.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of our deferred revenue over the next twelve months and recognize the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$6.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> over several years.&#160;</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, our collaboration agreements with partners included potential future payments for development and regulatory milestones totaling approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 billion</span></span><span style="font-family:inherit;font-size:10pt;">, including amounts from our agreements with BMS and Eli Lilly and Company described below. In addition, under our collaboration agreements we are entitled to receive contingent sales milestone payments, other contingent payments and royalty payments, as described below.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have been no material changes to our collaboration agreements in the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, except as described below.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Bristol-Myers Squibb Company (BMS)</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Bempegaldesleukin, also referred to as NKTR-214 </span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 13, 2018, we entered into a Strategic Collaboration Agreement (BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to these agreements, we and BMS are </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">jointly developing NKTR-214, including, without limitation, in combination with BMS&#8217;s Opdivo</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (nivolumab) and Opdivo</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> plus Yervoy</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (ipilimumab), and other compounds of BMS, us or any third party. The parties have agreed to jointly commercialize NKTR-214 on a worldwide basis. We retained the right to record all worldwide sales for NKTR-214. We will share global commercialization profits and losses with BMS for NKTR-214, with Nektar sharing </span><span style="font-family:inherit;font-size:10pt;"><span>65%</span></span><span style="font-family:inherit;font-size:10pt;"> and BMS sharing </span><span style="font-family:inherit;font-size:10pt;"><span>35%</span></span><span style="font-family:inherit;font-size:10pt;"> of the net profits and losses. The parties will share the internal and external development costs for NKTR-214 in combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties will share development costs for&#160;NKTR-214&#160;in combination with&#160;Opdivo</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>67.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of costs to BMS and </span><span style="font-family:inherit;font-size:10pt;"><span>32.5%</span></span><span style="font-family:inherit;font-size:10pt;"> to Nektar, and for&#160;NKTR-214&#160;in a triplet combination with&#160;Opdivo</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;and&#160;Yervoy</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>78%</span></span><span style="font-family:inherit;font-size:10pt;"> of costs to BMS and </span><span style="font-family:inherit;font-size:10pt;"><span>22%</span></span><span style="font-family:inherit;font-size:10pt;"> to Nektar.&#160;The parties will share costs for the manufacturing of NKTR-214, </span><span style="font-family:inherit;font-size:10pt;"><span>35%</span></span><span style="font-family:inherit;font-size:10pt;"> of costs to BMS and </span><span style="font-family:inherit;font-size:10pt;"><span>65%</span></span><span style="font-family:inherit;font-size:10pt;"> to Nektar.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The BMS Collaboration Agreement superseded and replaced the Clinical Trial Agreement we entered into with BMS in September 2016 to develop NKTR-214 in combination with Opdivo</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. Under the Clinical Trial Agreement, we acted as the sponsor of each Combination Therapy Trial and BMS was responsible for </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> of all out-of-pocket costs reasonably incurred in connection with third party contract research organizations, laboratories, clinical sites and institutional review boards. We recorded cost reimbursement payments to us from BMS as a reduction to research and development expense. Each party was otherwise responsible for its own internal costs, including internal personnel costs, incurred in connection with each Combination Therapy Trial.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:inherit;font-size:10pt;">. We are eligible to receive additional cash payments up to a total of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> upon the achievement of certain development and regulatory milestones and up to a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$350.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the achievement of certain sales milestones. In April 2018, BMS also purchased </span><span style="font-family:inherit;font-size:10pt;"><span>8,284,600</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$850.0 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808, and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#8217; reimbursement of our costs as a reduction of research and development expense and our reimbursement of BMS&#8217; costs as research and development expense. During the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$28.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$81.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, as a reduction of research and development expense for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses.&#160;During the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;">, we recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$18.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;text-align:right;"><span>$42.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, as a reduction of research and development expense for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have recorded a receivable of </span><span style="font-family:inherit;font-size:10pt;"><span>$27.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> from BMS in accounts receivable in our Condensed Consolidated Balance Sheet.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We analogized to ASC 606 for the accounting for our two performance obligations, consisting of the delivery of the licenses to develop and commercialize NKTR-214 and our participation on joint steering and other collaboration committees. We determined that our committee participation is not material.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We aggregated the total consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.85 billion</span></span><span style="font-family:inherit;font-size:10pt;"> received under the agreements and allocated it between the stock purchase and the revenue-generating elements, because we and BMS negotiated the agreements together and the effective date of the BMS Collaboration Agreement was dependent upon the effective date of the Share Purchase Agreement. We recorded the estimated fair value of the shares of </span><span style="font-family:inherit;font-size:10pt;"><span>$790.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in stockholders&#8217; equity based on the closing date price of our common stock of </span><span style="font-family:inherit;font-size:10pt;"><span>$99.36</span></span><span style="font-family:inherit;font-size:10pt;">, adjusted for a discount for lack of marketability reflecting the unregistered nature of the shares. We allocated the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$1,059.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the transaction price of the collaboration agreement. We consider the future potential development, regulatory and sales milestones of up to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 billion</span></span><span style="font-family:inherit;font-size:10pt;"> to be variable consideration. We excluded these milestones from the transaction price during 2018 and as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;"> due to the significant uncertainties involved with clinical development and regulatory approval. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accordingly, we allocated the entire transaction price of </span><span style="font-family:inherit;font-size:10pt;"><span>$1,059.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the granting of the licenses and therefore recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$1,059.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the nine months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> as license, collaboration and other revenue.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Eli Lilly and Company (Lilly</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">): NKTR-358 </span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), which became effective on August 23, 2017, to co-develop NKTR-358, a novel immunological drug candidate that we invented. Under the terms of the agreement, we (i) received an initial payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in September 2017 and are eligible for up to </span><span style="font-family:inherit;font-size:10pt;"><span>$250.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in additional development milestones, (ii) will co-develop NKTR-358 with Lilly, for which we are responsible for completing </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Phase 1 clinical development and certain drug product development and supply activities, (iii) will share with Lilly Phase 2 development costs with </span><span style="font-family:inherit;font-size:10pt;"><span>75%</span></span><span style="font-family:inherit;font-size:10pt;"> of those costs borne by Lilly and </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> of the costs borne by us, (iv) will have the option to contribute funding to Phase 3 development on an indication-by-indication basis ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> of development costs, and (v) will have the opportunity to receive up to double-digit sales royalty rates that escalate based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by </span><span style="font-family:inherit;font-size:10pt;"><span>75%</span></span><span style="font-family:inherit;font-size:10pt;"> if both conditions occur.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We identified our license grant to Lilly, our ongoing Phase 1 clinical development obligation and our drug product development obligation as the significant performance obligations in the arrangement. The valuation of each performance obligation involves significant estimates and assumptions, including but not limited to, expected market opportunity and pricing, assumed royalty rates, clinical trial costs, timelines and likelihood of success; in each case these estimates and assumptions covering long time periods. We determined the selling price for the license based on a discounted cash flow analysis of projected revenues from NKTR-358 and development and commercial costs using a discount rate based on a market participant&#8217;s weighted-average cost of capital adjusted for forecasting risk. We determined the selling prices for our Phase 1 clinical development and drug product development deliverables based on the nature of the services to be performed and estimates of the associated efforts and third-party rates for similar services.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although we are entitled to significant development milestones under this arrangement, through </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We have therefore determined the transaction price to consist of the upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in September 2017. Based on our estimates of the standalone selling prices of the performance obligations, we allocated the </span><span style="font-family:inherit;font-size:10pt;"><span>$150.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment as </span><span style="font-family:inherit;font-size:10pt;"><span>$125.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the license, </span><span style="font-family:inherit;font-size:10pt;"><span>$17.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the Phase 1 clinical development and </span><span style="font-family:inherit;font-size:10pt;"><span>$6.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the drug product development.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognized the </span><span style="font-family:inherit;font-size:10pt;"><span>$125.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of revenue allocated to the license upon the effective date of the license agreement in August 2017, since we determined that the license was a right to use our intellectual property, for which, as of the effective date, we had provided all necessary information to Lilly to benefit from the license and the license term had begun. We recognize revenue for the Phase 1 clinical development and drug product development using an input method, using costs incurred, as this method depicts our progress towards providing Lilly with the results of clinical trials and drug production processes. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have deferred revenue of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to this agreement, which we expect to recognize through early 2020, the estimated end of our performance obligations under this agreement.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Baxalta Inc. / Takeda Pharmaceutical Company Ltd</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Hemophilia</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a party to an exclusive research, development, license and manufacturing and supply agreement with Baxalta Inc. (Baxalta), a subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), entered into in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology. Under the terms of the agreement, we are entitled to research and development funding for our active programs, which are now complete for Factor VIII, and are responsible for supplying Takeda with its requirements for our proprietary materials. Takeda is responsible for all clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This Hemophilia A program includes ADYNOVATE</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, which was approved by the United States Food and Drug Administration (FDA) in November 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A, and is now marketed in the U.S., the European Union, and many other countries. As a result of the marketing authorization in the EU in January 2018, we earned a </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> development milestone, which we received in March 2018. We updated the transaction price for this milestone in January 2018 since we had previously excluded it due to the significant uncertainty from regulatory approval. Based on the terms of this milestone, we allocated the entire milestone to the license grant and research and development services, and therefore recognized the entire </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</span><span style="font-family:inherit;font-size:10pt;"> as we had previously satisfied those performance obligations. In </span><span style="font-family:inherit;font-size:10pt;">December 2018</span><span style="font-family:inherit;font-size:10pt;">, we earned an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone for annual sales of ADYNOVATE</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">/ADYNOVI</span><span style="font-family:inherit;font-size:9pt;">&#8482;</span><span style="font-family:inherit;font-size:10pt;"> reaching a certain specified amount.&#160;In addition, we are entitled to an additional </span></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">sales milestone upon achievement of an annual worldwide net sales target and royalties based on worldwide net sales of products resulting from this agreement.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents that were previously exclusively licensed to Baxalta under our 2005 agreement. Under the right to sublicense agreement, Baxalta paid us </span><span style="font-family:inherit;font-size:10pt;"><span>$12.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in November 2017 and agreed to pay us single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our remaining unsatisfied performance obligation consists of our ongoing supply of PEGylation materials at a price less than the standalone selling price of these materials. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, our deferred revenue from this arrangement is not significant.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Amgen, Inc</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.: Neulasta</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup>&#160;</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2010, we amended and restated an existing supply and license agreement by entering into a supply, dedicated suite and manufacturing guarantee agreement (the Amended and Restated Agreement) and a license agreement with Amgen, Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of the Amended and Restated Agreement, we received a </span><span style="font-family:inherit;font-size:10pt;"><span>$50.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> payment in the fourth quarter of 2010 in return for our guaranteeing the supply of certain quantities of our proprietary PEGylation materials to Amgen.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determined that our obligation to manufacture and supply our PEGylation materials and to maintain the dedicated manufacturing suite solely for the production of such materials for Amgen represented an obligation to stand ready to manufacture such materials. We concluded that we should recognize revenue based on the passage of time as this method depicts the satisfaction of Amgen&#8217;s right to require production of PEGylation materials at any time. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have deferred revenue of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$5.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to this agreement, which we expect to recognize through October 2020, the estimated end of our obligations under this agreement.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">AstraZeneca AB</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(naloxegol oxalate), previously referred to as naloxegol and NKTR-118 </span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2009, we entered into an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our patents and other intellectual property to develop, market, and sell MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. AstraZeneca is responsible for all research, development and commercialization costs and related decisions for MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. In September 2014 and December 2014, MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> /MOVENTIG</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> was approved in the US and EU, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have received a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$385.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of upfront and contingent milestone payments from this agreement, all of which was received in or before 2015. In addition, we are entitled to significant and escalating double-digit royalty payments and sales milestone payments based on annual worldwide net sales of MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2016, AstraZeneca announced that it had entered into an agreement with ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd. (Kirin), granting Kirin exclusive marketing rights to MOVENTIG</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in the EU, Iceland, Liechtenstein, Norway and Switzerland. Under our license agreement with AstraZeneca, we and AstraZeneca will share the upfront payment, market access milestone payments, royalties and sales milestone payments made by Kirin to AstraZeneca with AstraZeneca receiving </span><span style="font-family:inherit;font-size:10pt;"><span>60%</span></span><span style="font-family:inherit;font-size:10pt;"> and Nektar receiving </span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we do not have deferred revenue related to our agreement with AstraZeneca.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of its approval of MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, the FDA required AstraZeneca to perform a post-marketing, observational epidemiological study comparing MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> to other treatments of opioid-induced constipation in patients with chronic, non-cancer pain. As a result, the royalty rate payable to us from net sales of MOVANTIK</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in the U.S. by AstraZeneca can be reduced by up to two percentage points to fund </span><span style="font-family:inherit;font-size:10pt;"><span>33%</span></span><span style="font-family:inherit;font-size:10pt;"> of the external costs incurred by AstraZeneca to fund such post approval study, subject to a </span><span style="font-family:inherit;font-size:10pt;"><span>$35.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate cap. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, our cumulative share of the post-approval study expenses since 2015 totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. AstraZeneca may only recover costs incurred by the reduction of the royalty payable to us. In no case can amounts be recovered by the reduction of a contingent payment due from AstraZeneca to us or through a payment from us to AstraZeneca.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other</span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, as of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have a number of other collaboration agreements, including with our collaboration partners UCB Pharma and Halozyme Therapeutics, Inc., under which we are entitled to up to a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$45.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of development milestone payments upon achievement of certain development objectives, as well as sales milestones upon </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration agreements, we cannot estimate the probability or timing of achieving these milestones and, therefore, have excluded all development milestones from the respective transaction prices for these agreements. As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have deferred revenue of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$6.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to these other collaboration agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6824815376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash and Investments in Marketable Securities, Including Cash Equivalents</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value at</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,224</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194,905</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,414,448</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,140,445</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>231,082</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>582,889</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash and investments in marketable securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,726,754</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,918,239</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Portfolio of Cash and Investments in Marketable Securities</a></td>
<td class="text"><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our portfolio of cash and investments in marketable securities includes (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:59%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated Fair Value at</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Hierarchy</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate notes and bonds</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,163,575</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,288,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>482,468</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>498,048</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Obligations of U.S. government agencies</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,646,043</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,800,011</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,674</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,656</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certificate of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">N/A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,871</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,760</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">N/A</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,166</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,812</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash and investments in marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,726,754</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,918,239</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6829982240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 24,880<span></span>
</td>
<td class="nump">$ 23,287<span></span>
</td>
<td class="nump">$ 74,787<span></span>
</td>
<td class="nump">$ 63,895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">1,119<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
<td class="nump">3,208<span></span>
</td>
<td class="nump">3,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">15,680<span></span>
</td>
<td class="nump">15,365<span></span>
</td>
<td class="nump">47,549<span></span>
</td>
<td class="nump">40,449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 8,081<span></span>
</td>
<td class="nump">$ 6,746<span></span>
</td>
<td class="nump">$ 24,030<span></span>
</td>
<td class="nump">$ 19,976<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6841684128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (327,229)<span></span>
</td>
<td class="nump">$ 779,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
<td class="num">(27,585)<span></span>
</td>
<td class="num">(24,337)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
<td class="nump">17,853<span></span>
</td>
<td class="nump">14,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">74,787<span></span>
</td>
<td class="nump">63,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">9,582<span></span>
</td>
<td class="nump">7,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Accretion of discounts, net and other non-cash transactions</a></td>
<td class="num">(10,421)<span></span>
</td>
<td class="num">(8,136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">2,008<span></span>
</td>
<td class="num">(16,179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(2,339)<span></span>
</td>
<td class="num">(2,570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">18,127<span></span>
</td>
<td class="num">(22,087)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">16,109<span></span>
</td>
<td class="nump">2,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">13,164<span></span>
</td>
<td class="nump">19,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued expenses</a></td>
<td class="nump">10,019<span></span>
</td>
<td class="nump">26,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(9,465)<span></span>
</td>
<td class="num">(10,931)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">11,932<span></span>
</td>
<td class="nump">5,104<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(203,458)<span></span>
</td>
<td class="nump">835,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(1,028,883)<span></span>
</td>
<td class="num">(1,944,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">1,122,902<span></span>
</td>
<td class="nump">467,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(22,614)<span></span>
</td>
<td class="num">(5,552)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sales of property, plant and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,633<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">71,405<span></span>
</td>
<td class="num">(1,467,476)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">790,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from shares issued under equity compensation plans</a></td>
<td class="nump">18,449<span></span>
</td>
<td class="nump">59,067<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">18,449<span></span>
</td>
<td class="nump">849,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash and cash equivalents</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(113,681)<span></span>
</td>
<td class="nump">217,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">194,905<span></span>
</td>
<td class="nump">4,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">81,224<span></span>
</td>
<td class="nump">222,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">14,229<span></span>
</td>
<td class="nump">14,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets recognized in exchange for lease liabilities</a></td>
<td class="nump">$ 56,025<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock Net Of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based compensation arrangement, excluding stock option exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6823215216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PreferredStockShareDesignated', window );">Preferred stock, shares designated (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">175,786,000<span></span>
</td>
<td class="nump">173,530,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PreferredStockShareDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, shares designated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PreferredStockShareDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6838071104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember', window );">Indemnification Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Litigation matters, liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812093856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory consists of the following (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,586</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,846</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,961</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,403</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,132</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,720</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,381</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812003280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2017, we entered into a Lease Agreement (the Mission Bay Lease) with ARE-San Francisco No. </span><span style="font-family:inherit;font-size:10pt;">19</span><span style="font-family:inherit;font-size:10pt;">, LLC (ARE) and terminated our sublease with Pfizer, Inc., effectively extending our lease term from </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">2030</span><span style="font-family:inherit;font-size:10pt;"> for our </span><span style="font-family:inherit;font-size:10pt;"><span>145,085</span></span><span style="font-family:inherit;font-size:10pt;"> square foot corporate office and R&amp;D facility located at 455 Mission Bay Boulevard, San Francisco, California (the Mission Bay Facility). The term of the Mission Bay Lease commenced on </span><span style="font-family:inherit;font-size:10pt;">September&#160;1, 2017</span><span style="font-family:inherit;font-size:10pt;">, and will expire on </span><span style="font-family:inherit;font-size:10pt;">January&#160;31, 2030</span><span style="font-family:inherit;font-size:10pt;">, subject to our right to extend the term of the lease for </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year periods, which we have excluded from our determination of the lease term. The monthly base rent for the Mission Bay Facility will escalate over the term of the lease at various intervals. During the term of the Mission Bay Lease, we are responsible for paying our share of operating expenses specified in the lease, including utilities, common area maintenance, insurance and taxes. The Mission Bay Lease also obligates us to rent from ARE a total of an additional approximately </span><span style="font-family:inherit;font-size:10pt;"><span>8,000</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of space at the Mission Bay Facility. During the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, ARE delivered </span><span style="font-family:inherit;font-size:10pt;"><span>10,729</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of space, and therefore we recognized right-of-use assets and lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the space. The Mission Bay Lease includes various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2018, we entered into a Lease Agreement (the Third Street Lease) with Kilroy Realty Finance Partnership, L.P. (Kilroy) to lease </span><span style="font-family:inherit;font-size:10pt;"><span>135,936</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of space located at 360 Third Street, San Francisco, California (the Third Street Facility) from June 2018 to </span><span style="font-family:inherit;font-size:10pt;">January&#160;31, 2030</span><span style="font-family:inherit;font-size:10pt;">, subject to our right to extend the term for a consecutive </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year period, which we have excluded from our determination of the lease term. Kilroy delivered an initial </span><span style="font-family:inherit;font-size:10pt;"><span>1,726</span></span><span style="font-family:inherit;font-size:10pt;"> square feet in June 2018, a total of </span><span style="font-family:inherit;font-size:10pt;"><span>67,105</span></span><span style="font-family:inherit;font-size:10pt;"> square feet for </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> additional spaces in December 2018, and the final </span><span style="font-family:inherit;font-size:10pt;"><span>67,105</span></span><span style="font-family:inherit;font-size:10pt;"> square feet for four spaces in August 2019. As a result of the delivery of the final spaces during the nine months ended September 30, 2019, we recognized an additional right-of-use asset and lease liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$51.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Third Street Lease provides us additional facilities to support our San Francisco-based R&amp;D activities. Our fixed monthly base rent on an industrial gross lease basis includes certain expenses and property taxes paid directly by the landlord and will escalate each year over the term at specified intervals. We have a one-time right of first offer with respect to certain additional rental space at the Third Street Facility. The Third Street Lease includes various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of lease costs, which we include in operating expenses in our Condensed Consolidated Statements of Operations, were as follows (in thousands):</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80842911877394%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,116</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,927</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,030</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,651</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,485</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,096</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,539</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,371</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,601</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,023</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,569</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,022</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we paid </span><span style="font-family:inherit;font-size:10pt;"><span>$5.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for amounts included in the measurement of lease liabilities, which we include in net cash provided by (used in) operating activities in our Condensed Consolidated Statement of Cash Flows.</span></div><div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the maturities of our operating lease liabilities were as follows (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:88%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Year ended December&#160;31,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">2019 (Three months ended)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,400</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,283</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,026</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,633</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,899</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>116,881</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>214,379</span></span></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: portion representing interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56,621</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: lease incentives</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154,417</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: current portion</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,318</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities, less current portion</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,099</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;"> As of </span><span style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the weighted-average remaining lease term is </span><span style="font-family:inherit;font-size:10pt;"><span>10.3 years</span></span><span style="font-family:inherit;font-size:10pt;"> and the weighted-average discount rate used to determine the operating lease liability was </span><span style="font-family:inherit;font-size:10pt;"><span>5.9%</span></span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6830895264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80842911877394%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,119</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,176</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,208</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,470</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,680</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,449</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,081</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,746</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,030</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,976</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,880</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,287</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,787</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,895</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three months ended September&#160;30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine months ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options granted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>131</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>190</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>246</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>929</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average grant-date fair value of options granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39.28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RSUs granted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>316</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>712</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>558</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average grant-date fair value of RSUs granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.00</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57.27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54.49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares issued under equity compensation plans</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>820</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>642</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,256</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,248</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_O"["3MO[,'^8^.KH&SAUUW(+U!+ P04    " !HG69/F5R<(Q &  "<)P
M$P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03
M<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS
M[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#
MW(*+"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S
M^!7+5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4
MPL3 :F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:
MX./Q>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;
M:)P*C5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ
M$A6UY4#3( !8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&
M<IV0!0X -\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD
M,WJ=?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z
M'&="?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S
M(M>41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(
MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU
M+,76>)7 \:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/
M:;,CIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:
MK<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1
MDEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*
MY \FIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_
MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R
MS<C'5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;
M)0G+5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R
M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ
MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR
MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2
M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE
ML<%5'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_
M13.V$I<8O./FQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7G
MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5
M' 86%S+D4.Z2D 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2
M)1(4BK ,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%
MV^)4S;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODR
MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\
MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS
MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!
M4$L#!!0    ( &B=9D^B1 K$- ,  #L/   8    >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL=5=A;YLP%/PKB!\P\+-)TBJ)U&::-FF3JD[;/M/$25 !9T"2
M[M_/&,HRO_.7 L[=.YOSF;[EU32O[5'K+GJKRKI=Q<>N.]TG2;L]ZBIO/YB3
MKNTO>]-4>6<?FT/2GAJ=[QRI*A-*TUE2Y44=KY=N[*E9+\VY*XM:/S51>ZZJ
MO/GSJ$MS7<4B?A]X+@['KA](ULM3?M#?=??C]-38IV2JLBLJ7;>%J:-&[U?Q
M@[C?2.H)#O&ST-?VYC[JE_)BS&O_\&6WBM-^1KK4VZXOD=O+16]T6?:5[#Q^
MCT7C2;,GWMZ_5__D%F\7\Y*W>F/*7\6N.Z[B11SM]#X_E]VSN7[6XX*R.!I7
M_U5?=&GA_4RLQM:4K?L;;<]M9ZJQBIU*E;\-UZ)VU^OPBU(C#1-H)-!$&%Y.
MD"!'@IP(PBDDP\S<4C_F7;Y>-N8:-8-;I[S?%.)>VI>Y[0?=NW._V=6V=O2R
M3I?)I2\S(AX'!-T@Q(1(;.U)@)# (S$Z_2^PX0B)!21<@71T>4-7F*X@73FZ
MNJ%GW@O@B!D6R*! QNAS3X C%EA@!@5FC'[G"7"$2+'"'"K,.5]X$@!"6&(!
M)1:<+ST)  DX?0<E[CC?MQI  EZ+%,<IY15\NQ$F8+@(A%;P"K[G $,!TP5,
M[H,@7L&W'6$"O@L<7R%Y!=]YA E8+W#*!0\Q^>8C3,A]''7!DTS,?8 )N8_S
M+GB<B;G/,3+D/LZ\X(F6S'V ";F/8R]XJ"5S'V!"[N/D"YYKR=P'F(#[A+-/
M/-?2=Q]A NX3SC[Q7$O??8!1 ?<)9Y]XKI7O/L*$5'#VB>=:D:\",('_#PAG
MGWBNE?)5.";T_2*<?>*Y5OX> YB@"LX^\5RKF:\"/O<A%9Q]XKE6WD[>C)C,
M8>KQ2Y?=$5$:B@T^ HC'6RW\)8%O?VA)^ @@'F_%8L,Q66!#2WP$2![OS(\-
MP@36(O$1('F\,__01)C H2GQ$2!YO#-_0R.,[WYRTXI4NCFXKJV-MN9<NY;Q
M9G3J#!]<[Y/\@P]MY;>\.11U&[V8SC9$KFW9&]-I.Y7T@]V)1]O)3@^EWG?]
M[=S>-T,[-SQTYC2VJLG4+Z__ E!+ P04    " !HG69/M$&\&=,$  #H%P
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M1*0*O/%YH9LQJADCS0 S<Y84U]T8,,8X9D?1@<F-2?@I5#^%],/>WZH0_1C
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M^U[..??#]DT;+EYE :"\=T8KN? +I>HY0C(O@!'YP&NH])\#%XPH;8HCDK4
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MPE[; ^<*=/;!@WX(A1Z5G4'AH,QVJO>B'1BMH7CM9B'J!G+V#U!+ P04
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MMA@*:A^.'_!LIS&;#&_Z^0>QY1L7OP%02P,$%     @ :)UF3WD,K[*U 0
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M@MJ'XSV>[31DD^%-/_\?MGSBXB]02P,$%     @ :)UF3PE]3AZS 0  T@,
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M?S;SF,V&TT/Z063YQM4?4$L#!!0    ( &B=9D^[<D5(M $  -(#   9
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M]K]&=."E[&[\"+7^@RV&@MJ%XT=_-M.838;#?OY!;/G&Q2]02P,$%     @
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MUV8N^[;9+[1HARL!&N\E^5]02P,$%     @ :)UF3X3)^E3$ 0  -P0  !D
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M(P@U9'B%WP./O&ZL#Y \[5@-O\#^[D[:K<BL4G()K>&J11JJ#-^M#L>MQP?
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M_.',(*#(F)9I4%\,;G* N%PTXF& FQCX_S$EN)? ##-9:]#M)@@IF]H%N /
M# M8@]G9D4^FDN&=#3-:>PUF;X]D(7A3$Z1?(S)"@?<K@?FK2$9>9+#V&OZ=
M:5#OW[EQ,:/I9R.W&-)#%\NY>5NMCT#?XO*8Y)7U*J1Z\6U>3P]"2*Y8W3NU
M^"=UZNH&*3_(^C90]V5[]&@'4A3Z6.5T9[O57U!+ P04    " !HG69/S-+
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MQLSE<"\,@1;=>.6AZ=XM_P)02P,$%     @ :)UF3R@;"@M# P  $P\  !D
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MR9E0!=>5J!P%H\+\>L5)2%;W*JJ4&K]W8]68\=+K7VEN0M03HH&@<C\BP)X
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M$DPY4I,Z2#R79L33(9%5YJ'5R"3MN&E$G6E!](<=2>*A1 $Q26'>0)$C#9$
M)_,(9Z1/&T(BUA")1A*%HRPA!4'!G'F")"K(/"P8&7$=BK"IQ/"1HPB;2N9V
MJ 27FT9T.G*T[75;L20OQ]@H2>H@T"D]PFT"G<JS**.2J?,-%!&Z%2%3 3*5
M(740VI0;X3 !20%&<H>1R)*&"$@*@40F#$7@4''$6H# H<'$I9)T\WTCZH3$
M_H&M"4<:<92NBZ&(^44(TH@@$C@T6RB-($@3@C2 0R>!XR,4$=PU(4@#@C09
M4)H0I$<0I E!&L"AD^7_KXVH,Z!4[W@B&&F D29Q0Q.,] B,#,'(H/PO6V\"
MC'HI,H0B P#1)  9 H@9L9%@"" &Y75)/G77B.QPK]F*'E"2/N-W!BSJX>KR
MSN2K]3-V$?(,(H_D58:09T:09PAY!I&7Q-8;DR]+@PK&4:<)> :!ER:"C>BT
M,T+_O&$(HP;D@9J$<TL8M2/R0$O(LX \DVVZR'R=&C3:/;-YQBA#1$LQ4&=H
MDNID7 -E-7OV/'-+(H0%4Z@ALY(E$<*.F$(MX=[FW*?;-W.;PZR\AP]R@+)K
M%MNF ]@;,N%:@KT=@;TEV%N O4DFW!N;8R_/H&@)^1:0;])%M,W)]U'T;>-:
M0KX%Y!N;-G<4A9/F8GS%@K C <*!2=PDN?"-0Y.XC7V .1),' HF:<!V*$3T
M+Z8= =HAH,EH<P1H-P)H1X!V:")/MT60R)"([PBB#NWWI-LB2$0;8AO?8 _'
MIH&Y$8T:.81Y!YBW)#0[PK$+(WJ2P.D G-ER&8DL"92>H.D!FI;L,7B"FQ^Q
MO^H)0AXM*U.'D<B218DGG'F06EN2XGO"F1^Q9>H)0A[089.8^!L4D6--3Q#R
M""%F+#OG\2,<)ECX 0<N'WP^O4EE8P_)GA#D$1PD^@0"1QB1V 8"1P!SD4LB
MV/N0IY9GW Z$HP 0<22 !8)(&#$5!8)(0%-1XO;;D*\I57_N% A- 8#B2"@,
M!)0P(F<,!)0 Y@^G4[?1)$.H#NST$M#D3-H0$I%8%PA' 7#D2/X7"4=Q!$>1
M<!011^D&)Q*Q#<Y("(J((%8'(2B.("@2@B(@*'<8B4B4BX2="-CQ[(R9L!-'
ML!,).Q&QDT;*"-9;WO5$C$@ BH -3P)E9$?K(S8XI: GW" %R_QN59WK.[;'
M;RG8:;@ D'AVI"[8>;@8L<TI!3N_%B ;RXXMH(K%,2G8.;< K'AV6"[82;>P
M8_QFY]<")&7IZ="G5M6YV]5_VBO8.;8 <'F2.DO!#JG%B*6-%.SH60RXDC)O
M5:>D6[0O=]LJ78\RN2?"4$2W33P;:/RZR9C[)O3"";AQD@V1SZVJ<S3>[C^Q
M%AF,Z#:)SZYK I6*M"T&HT0P^JRM/$'49YQCW*(K*CYD#8(+@'U[F)+>4$&W
M3SR9F26]?B)'++PDO5L"+I< X,#MD@RU7DUB#<,?73U)K?F(561^ENR&BE0Y
MT#HRH-D=%:E&72"C-\B&72'+KX8Y=,QV.T296,; 5P#\D)X$M*I3&(U%=Y=O
M!TF/MLU.OAQ0?]GH]\7VVW*SFWPI]_MR?5E_&>"A+/=%5:UX5;GZ6"SN7]ZL
MBH=]_;+>)MD>O^-S?+,OGRZ/7V":O7R+ZNI?4$L#!!0    ( &B=9D_R:4D;
MY $  *0$   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;&U4VVZ<,!#]
M%<1[X\5<-ET!4C91U$JMM$J5]MD+PT6Q,;7-DOY]?6$IW?@%>\9GSIEC;.<S
M%V^R U#!.Z.#+,).J?& D*PZ8$3>\1$&O=)PP8C2H6B1' 60VA8QBO!NER%&
M^B$L<YL[B3+GDZ+] "<1R(DQ(OX<@?*Y"*/PFGCIVTZ9!"KSD;3P ]3K>!(Z
M0BM+W3,89,^'0$!3A _1X9@9O 7\[&&6FWE@G)PY?S/!U[H(=Z8AH% IPT#T
M<(%'H-00Z39^+YSA*FD*M_,K^[/UKKV<B81'3G_UM>J*\#X,:FC(1-4+G[_
MXB<-@\7\-[@ U7#3B=:H.)7V&U235)PM++H51M[=V ]VG!?^:YF_ "\%>"W
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M:^>^HUPXBAC7HA\;;98JCU.5FE9,Q9BDZO)! $BT>'6-J<G,+!?F]'")"-G
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M'0Y M[GH_'"J+L>:&7Z(]MN+"-^)MCLQ*K92&GVD;V>=5TK):0Y4AW F%*4
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M8/H!ZWTXKG.?I:%.S%TI/<JBNS T9_W02R[/Y+FV^G<]5/5R\8"EK@X-,Y5
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M6MDL)@_?X'/]-9A/MHIM&:,DW[XR'-Q<*X:(W!]F4$^A%N:<9:5D"\=#^[I
M+TD=]Y,S^ 6Y4@U7&%GH$Q"4(,,R"8R"C"[%]R7]!YV/G#_"T9J,M327P>F+
M6*D$3@?R02R7#^ WQ[>#!AE@E\&@ZUL06@WS,(_C4/7S+[>I?_8-+>S<J/D8
M9_ZP)LOUH>P6SRV^:IW?PX%0M!K53P4:Z\<[:?*Y/?^#.N>8+D>,U^7]\V[[
M[?0M<;J>2 1(; .D#HBX<XN4'$]%#MBEAK9-G%'68?,A9BU1>TPT.S<=?T1T
M%G'%XGY2]E3\'*Y8[:L3^,0)=7OV"CA"0G'?(1]HQIS#H!+N5QD+W*PH=/63
MGU5Z9X:1:> BV"W3= Z4+G8'D9@F*@<6J!&MO\E*/AUH!_=RGFV9@3TNC0+R
M@\@<*3R3"$D;VYX1C6K?'(#X$7_C #7%:Y,6#1=I\I)EQD?B&]0.%X.=P\')
M+XY[8UJ^P^*/)\8M3ET-$XA7;K6+>N10>^WB'ECY%T+R@E[S)]=!NCV1/VD>
M%G>I5M#-OV[+ ,PT/V ;E$D'9\L2F^BJVB,0?[-=.X57R=6?&N0V[.FJB!6V
M]QB&]+Y2[TVF;9(;)F]0O\;[K+*"M;&<$9!%V*O.\U1R1@:J4KT@6%G&Y/CJ
M8J/Z52[O=:7E3@'8+AGL7P&X^7ZSIM+2^C]S&.FEEI'N^SLC%9->Z83K(:H[
M/D1MI392A8>JE*IBC5&67 ?$_BIU5NF\K'=N+ W&(H.C VZ=+WN:;*S%1&7[
MWN&OV(+0P\F_:VZVHXH+:AMF&@-$G5HKOW];F.68/NJB*^/KE+2FA,. &HL"
M=K!V^8W+1V5VU2Z( $YW6'/.JY:@XL9)?U7_HJ(K4!=V+J[!U:TX>Y%[U6LX
M,VXB[S5RTT0#2-GHCJ2>^*^).B2(6K=%C?#D#K:B'9?+[XC87OL/'_ (*G$L
M_S@4AJ \TA08E !^G-G_;37?JL*@)7&$GMAV0-B"0L9]BCP<K!>Y#U5X;.05
M(X5+2_)AGU #G]N416R_C)C8V)2!HN[>>;T)8 -<H+B=0>Y*7T'/>%R+=YSJ
MX4#C3/$R>: =]GAI",I5,.7EUZ*N2E>OS<CF1MU8/@H#8 RWKFV]X03HJ_LB
M!VZD'<.3]]B3/*_;YVN4(."[F!HC6LOA3[(ZJDOEMB_ T9DM']X<T5N@#N71
MI/B0\4SE<_0CL<:'>[B'&K!>82#OA/BY;:7(1-&% *IM<EQ+' 3AD[#)MI1_
MP!H7N7E+ N\!%))IN7A@TY(BRI]0Q%P!_6LT,[.[5V4;Y..0T'Z0ONJ$?BKU
MK5T J>(Z"W%5"7A@=!9XM$,46?(\YQXB-H #;OI:#$E:S &-48SG4]$T!>.!
M"@"*O-9&GX(?;W+L:](&! 4 K.F'J#R O8::ZL"<&]6:I0+0U+GIM2[U!*@H
M&S/<?3>ZW=8[1(:) YK*FER;%F+]0JF%3 TL2@ I3(?-DIP\*TS!G:,UA=?*
M5 V@]@1?(MF6ZA7B?L1TP623U!NQS!YS DTD/:S>KAUP)P(Z$6J_T(BL.L*C
MY9N0>VPBXW'6ZFG_)NV5.ZK'(,G>M:@VAAGJ=7#T!0$:6)2KWZ 3O4D B RV
M=H];] PW!(LHA:QB1K!47U2T:T;YN*82+,PRN*H6OHWPT>7UU7$R.QNEB0QY
M1#C@9R.@:OG)]Y;@V./=MF (+(32H$<&\=L#5QPD8Z14-87^=J,8.$P-;,Z
MU<^DQDD!T[RJ.<>>6^>2)]Q1.C X"MCDKF>$@IP'<+/\EK([(G$.,W HB/9J
M2Y6#5*$R_R(5*FN\+43&R#(6A219":3'"A&6)"L5:T<;2E"O'O*%)/C-@=V3
M6P_3.NB+]\A":AJ1YQ0:]SQ?U-Z6O(WH86.Z85,W.F1U$=.*E6!NOR_LN[7'
MY'W9W#9::K>L[?)=GV$8J#Y?9K<UGSJ>24!O#&6/AB2IHG;:@[ \B[/P@FI
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M[]A(?C *LEOJR>.O..UH-]H=MQ1/U3-XNUV"P58#M>B#BG;I0L741UD*?#0
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M^T)/_OK_:0O[7[8M;.OH3:=@>_0IXL%36D#'X?^?OK+_/^TK^VL:#IX8U+
M+__H!=BNQ;+%E?Z8E:?)0#3;S]<ODJ-G;<Z5KT_=8?<\\Q8[<2AO?L(X@NW?
MZL*=S_<.%^S3I=FG]_OWZ7^^0;I^#83<M/KO/LE=UUYC65!(=D[N8'*[M!K\
MNC:W+7#]?R0]&W+9 :!.D"D[,- [\05:NQAJZFD7>N;>=UI*?FM/?9F? B&[
M9"L!,W5=D# I=UZT=N"E";>X5"#T4\4/#D[/!K]OZ41!4@TA"3XMI2>5+!+T
M\._+KVE;$XLBBW\Y'@-7:<U3(&1W8&G"1#]T'^73W. G3W.%[G)X.^X"@\IE
M!?8((WU241-/M3,(G-J$$FD+%':+^KFNMFOJN-'?/OL[O'B_=B/W\%R_*_&'
M0#*]9=GZ$F5KZYYAB'4P(2[84BJ>-LE=#.]M]JU8;5?J0GGD@LQ;2C<,X[!^
M,^,Q1M3HJ+63*G,3E;E/^49R)'&J]K[1UUIW9_?]136S[99$7_H061"G:HY<
M-6MK+6_T 7UVV/]LEQA(M8$E*J04B^YYZQWYZO^1G)^>3WZ?R"^O92C^(R8J
M G54G(\U&ASV?><+ZF*;]+46:8#*C*3Q-*>XU/)@77Z&]16_W3KA:3Z&<<^8
MLE*OS_6LJ'6XV 0@"E)Y8N50;<^]^;7<X_O#4]_!=UU *1462Q\S;E?-WZ%X
M^D??^[3$(RE],U3N+[R+K>P.\73M6EOJ:2CJG0M?/:?PU3]VA<8ZI*>.<^5#
M6A\HI/6T@;K"73_[<->EAKN>-BH'MOB$DU?;O>MK^2)>?X^,\Y$RZ== H;+^
ML-1)8H)83Z6[( C5$A)A#*I#5S!AJ&YQ[R)1/7&G_3)Z]_R'.^5T8*W<;M")
M./NI66?S%O>YW-ZY)\_U24K70+WT?W7SF2Z[2=_=]6R?X60G<=$WT!^WI1^H
M[Z&WV6-KW>T3 #Z32T>9%.BLF=<%9R7MM<+662'YM))N&H,IK<)DP[UV2%]<
M@C+C(O< #)MQDP@/A]^BBP'K/<E8G23#&>':_9H/!WB3*0J?>8?&-3F]Z# ?
M/KX\N<[*Y%6->C0, YSS%!U;R9LW5\!5WDI'\.?9(Q](YWU)B';)%=C\#3/>
M\\TQO-QWPMZ>Q="U-H2;<.M++DWS;1%X^?](]A']&VEJ($]U[OZD6^DT5YT7
M8FM];B3DZ4A(*GAXL;<[%_I+L:PK!/RCA"0V5G*UQA!I$+;Y] ,,\(E*A:\W
M-1HMG?OL]RR+9FLJ)&&D3B[BF-KWALV?SL"[HLSQ,QTQY6YN;4+)O4O[GI#Q
MTY?%08EVT4N+9W8IV1C>[?A=2[YCN+?C=V<=OXO#O[OV3Z/ 70QW3S"X^Y4X
M(GPH#^O@LYWAX79P5B&=/_K$2\3'Q6-^Q=?RHP,^?(*9O4\)SF].T8F/8JMU
M6%:6G_^Z&>]4CAG0=:=%-IR=GK=9_/#\=-KYVPYOT@>?:+G[4Z.+KM='P\Y!
M%8.7?-.X>!>*Y$CYQP^O.R8RS_.%."8;V;$0>+1%ZP:8C--.3'ZN#N'AO;56
M5K>_(\5H56Q\<?65-ODXS''>[\1Y#0QC5?KF;]Y(:!N931-]=Q>-O('YW#ET
MY VUM-EUYPY)E#C9A< 9I$0\_5[I!"YW36#7@G>F'_S#)2"T/,.=60;_<'D&
MK;MGT@O^X1(,6I/Y_H2"[SR9[Z9 8FC#,>OAG=K^:-S-T"[7M=?R.V-#JMZW
M%)CJJWNS-:RU0MK?M#;0KC>G;7/#!YE:?[2,NR6J[1_;GM3^]C#B]CB9]SV2
M?+*U:+N(6Z^51;DLM=+:<#:+N%<0)&.E/>-;-^Y#S/V,,GE0TZ,#)AG TTAA
MGT/!;E&%IO;\0VJR_T?KD>=OK_LN@;GC.P;XO+N] 0?(=.**')OU9LO\O*QN
MJ#N$;^J5*3J+ _23JB4,HDLW>%22P%B+1YM..D6F>YXJ*704CP33J0NK7YYS
M/VP;)K:-@P5[F-0>W+'OHH<G'Q;:F-UN4>#2=P4A1/S*A40=LWZ3.;]?+XJO
MU6''UH**C%\;CTXG;1KX_FG1<?TEK[]6+??6:-1%;A_U"NSL!'+8:F'#/Y"V
M-]J_\%$G\?-Z=G^MU;)-TOPSPL@+VI][*'0JS-U##&>#KBD9V:ZNX<4/(N'_
MD?PA7U7K>]"R6CJ!WUA*\W#M8IOM38O1?.\WX1]B''"K$/;Y.MSH7S$L=[?/
MRN1SV:&<[E&^G-9_V;? ,!&&_"GTFW8>B.CNG*048DLK]_Y.U1!^?#I.K(7)
M1 REGMJ"/5/8<;]_NY$..@B)@'?NJZ*:]HI#7XH4YD3Q6;94)Q",#H?<]7@*
MDM"0$!:XFIH*7WF@%DU\=,Y6*=,-0>%CC.J]BE#0B<QB=!_ ,W[5\?09*>-.
MWGC)B[7JEK;UY/9X\]^8%,.[TBWVIN>=\NLW_>8.F78^ZV39NS]_I=B3GZBT
M^9 3"250M:6DIS60;/[_M'8UK0W#,/2OY+##!BUEC.TX2"&44=;!O@Z[=5DZ
M ETIM(7MW\^2;$>N9<=N<TQI+-NQ%$G1>S(4T)0NMJ55Q/@GU][<BN^9OL@4
M;#UQ0F3?J6/*P($"Z)C'Z^ZHE,R/?L("PNY>WYTA!]]],'*S5M:!Q'#A0&<D
M8]^Z1H4;<C:'%=*NV,A$O>^=8E'?,W8EO+7NU $):2EUBQN!R1RS.] LRF2H
M/O^<*_R2K]36=RXRIRN75F1I!OF:UYT^\S=X__$/#8O8%]-T[=0ADS)*\613
M0-M+J&7[:#9-O2S**6SETWNY>'V8XS+41:4N9F%=WR(3G&X_H9M66#1C8P*O
M%=(+,F]G\ '!;Q>/+/J&,>?*VP'VPWC>JE!DF ""$=M& XFCSK.2@P\40%C>
M9(BDD^IM[T1UB"5R'!9)N2?%B0G'LY%'J>43QW";43%MOML-^GL:;"2$6HFH
MGGYA%5G(@*0@,&=<]&%V\G/D(2B(DU-4YXG_3_,Y%R7 /T;N;8BDB:4=XVB6
MC+TP4!6^YHMB$@@,SEYG=%$X38,S\1)Z&KA!X8>!D$3B4:](502&C)RA4B(:
M9<':FG!7,!,5=8/&/+^\^14Y!.PQD),!YHH0EK2)+I29U)2=E_"%ZJI0II4>
M3-)'"8TLZ@!&C\3=Z-MX9>&^VC65A[ JQNI7URIH6_.S/>PM!4RE=!TKOKM)
MQ4Z&MS]++I35J#:.T-H5VABA=M>RGHG]*(G4.+YL7L6D?)SZL+:2\>]P>%F1
M9R23PO6 V(#$4]?=-]GM]O?_4$L#!!0    ( &F=9D\FP#T.2 (  +P*   -
M    >&PO<W1Y;&5S+GAM;-56VVK;0!#]E6532@(EDIS8H8TD: .!0EL"\4/?
MPEH:20M[45<KU\[7=R^ZV"KIQ4U+[0?OS)F=,V<O]FS<Z"V#^PI HPUGHDEP
MI77])@B:K ).FG-9@S"10BI.M'%5&32U I(W-HFS8!:&BX 3*G :BY;?<MV@
M3+9")_AR@)#/OY$Y)/CA].675NKK%\B/)Z].3L*'L^LI?NH"9QAYCO=Y@J/%
M)0Y^G?0\-)\GF5UT0C__3?H?D4^H%T]0=],-4Y\Y2;RRB4&WMVE<2#%N\07V
M@&$F'-":L 3?$$97BMJL@G#*MAZ>62"33"JDS=F:RI%%FD<?CKQGC[WCX51(
MY6K["OY[U4V?!'K/"J2,#0)GV -I7!.M08E;X[C)#OPNA#I[N:V-PE*1;32;
MXS'!#:;(2JH<U% FPCV4Q@P**T?1LK*CEG5@@UI+;HR<DE(*XC3T&9UA:#-@
M[-[^)CX7>]R; ODY]DA"C*R*WC2K[LSQU$(G>9?-<^_2A@?QHIJNI7[7FN4(
MY]M+!W<*"KIQ_J88!!AV4M=L^Y;14G#PB_EIP>C @FE,^CJHDHH^&CY[53(#
M@,)H#4K3;!?YJDB]A(WNK].F.%3S[ @U/_<^ER! $;8KVMS]_WF7_['BBZL_
ME^S^5::"GU&C[7!'(')^#"(7QR#R;]_)H&L[.[UMK[,-*%JUE&DJ.KD5S7/P
M>NS3(L&?[)N%[?67L<$9>DU6YBFYQV]R<RA(R_2=7:(+)GBT/UCAT6*8M1PH
M$CS:'R&G+7_M"H[OU?0;4$L#!!0    ( &F=9D] =MU2BP,  . 9   /
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M'NJS[J? [ M02P$"% ,4    " !HG69/'R// \     3 @  "P
M    @ $     7W)E;',O+G)E;'-02P$"% ,4    " !HG69/)^B'#H(   "Q
M    $               @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( &B=9D]XU6IE[@   "L"   1              "  9D!  !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( &B=9D^97)PC$ 8  )PG   3
M      "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ :)UF
M3Z)$"L0T P  .P\  !@              ( !]P@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( &B=9D^T0;P9TP0  .@7   8
M      "  6$,  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" !HG69/;+M%LRH"   K!P  &               @ %J$0  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ :)UF3QRGV_Q'!0  61H  !@
M             ( !RA,  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( &B=9D^YX?P%% (  )P%   8              "  4<9  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !HG69/5GJL^8X'  "E
M+   &               @ &1&P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ :)UF3Z$^_=^M!   $18  !@              ( !52,
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( &B=9D^GD'2.
ML $  -(#   8              "  3@H  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " !HG69/$6Q&T[4!  #2 P  &
M@ $>*@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ :)UF
M3WD,K[*U 0  T ,  !D              ( !"2P  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " !HG69/"7U.'K,!  #2 P  &0
M        @ 'U+0  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( &B=9D^[<D5(M $  -(#   9              "  =\O  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ :)UF3S2O/!2U 0  T@,
M !D              ( !RC$  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " !HG69/<,!.S; !  #2 P  &0              @ &V,P
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( &B=9D_BY$?U
MLP$  -(#   9              "  9TU  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ :)UF3[A$C+:S 0  T@,  !D
M ( !AS<  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !H
MG69/X<_$>UH"  "C"   &0              @ %Q.0  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( &B=9D^$R?I4Q $  #<$   9
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M970R,BYX;6Q02P$"% ,4    " !HG69/)<@S)B<#  #G#0  &0
M    @ '>10  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M &B=9D_,TL"\!P(  (,%   9              "  3Q)  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ :)UF3R@;"@M# P  $P\  !D
M             ( !>DL  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " !HG69/0$N;-;0"  !@"@  &0              @ 'T3@  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( &B=9D^";+7:_@$
M '4%   9              "  =]1  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ :)UF3R%EL9,> P  S P  !D              ( !
M%%0  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !HG69/
MN,?)T%P"   _!P  &0              @ %I5P  >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( &B=9D\ANL9?A@(  -X(   9
M      "  ?Q9  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ :)UF3W"V.9Y^ @  -0D  !D              ( !N5P  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !HG69/(-)5KK@!   -!
M&0              @ %N7P  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( &B=9D^0I8;[T0(   4+   9              "  5UA  !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ :)UF3PTCKY<A
M"   434  !D              ( !960  'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    " !HG69/\FE)&^0!  "D!   &0
M@ &];   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( &B=
M9D]&SI,HKP(  +,)   9              "  =AN  !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ :)UF3P;SY(G/ @  & H  !D
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M='EL97,N>&UL4$L! A0#%     @ :9UF3T!VW5*+ P  X!D   \
M     ( !E?$  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( &F=9D^MHL>-
MF $  +<7   :              "  4WU  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( &F=9D_)4^7XH@$  !P8   3
M  "  1WW  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     O "\ NPP  /#X
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6838148288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Cash and investments in marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,726,754,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,726,754,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,918,239,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior secured notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable for expense reimbursements from collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,213,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,888,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,888,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,417,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,417,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1', window );">Cumulative effect adjustment to accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,577,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision on unrealized gain on available-for-sale securities, offset by benefit in continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IN', window );">India</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use assets</a></td>
<td class="nump">$ 83,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, lease liabilities</a></td>
<td class="nump">96,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1', window );">Cumulative effect adjustment to accumulated deficit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_CollaborationPartnerMember', window );">Collaboration Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable for expense reimbursements from collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cumulative effect on retained earnings net of related income tax effect.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_CollaborationPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_CollaborationPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>nktr2019-09x30x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nktr="http://www.nektar.com/20190930"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:utreg="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nktr-20190930.xsd" xlink:type="simple"/>
    <context id="FD2019Q3YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="I2019Q3Nov01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_nktr_LicenseCollaborationAndOtherRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_nktr_LicenseCollaborationAndOtherRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_nktr_LicenseCollaborationAndOtherRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_nktr_LicenseCollaborationAndOtherRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2017Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_CounterpartyNameAxis_nktr_CollaborationPartnerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:CollaborationPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_StatementGeographicalAxis_country_IN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_srt_CounterpartyNameAxis_nktr_CollaborationPartnerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:CollaborationPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="D2019Q1Jan1-Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_StatementGeographicalAxis_country_IN">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_DebtInstrumentAxis_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="I2015Q4Oct5_us-gaap_DebtInstrumentAxis_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-05</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:ARESanFranciscoNumberOneNineLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:KilroyRealtyFinancePartnershipLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:KilroyRealtyFinancePartnershipLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="I2017Q3Aug31_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:ARESanFranciscoNumberOneNineLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="D2017Q3Aug01-Aug31_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:ARESanFranciscoNumberOneNineLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="FI2019Q3_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:ARESanFranciscoNumberOneNineLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:MissionBayLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q2_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:KilroyRealtyFinancePartnershipLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="I2018Q2May31_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:KilroyRealtyFinancePartnershipLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="D2018Q4Dec1-Dec31_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:KilroyRealtyFinancePartnershipLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q3Aug31_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:KilroyRealtyFinancePartnershipLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">nktr:ThirdStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="FD2017Q4QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="D2012Q4Feb23-Dec31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2012-02-23</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="I2012Q1Feb24_us-gaap_TypeOfArrangementAxis_nktr_PurchaseAndSaleAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-02-24</instant>
        </period>
    </context>
    <context id="FD2018Q4QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="D2012Q1Feb23-Feb24_us-gaap_TypeOfArrangementAxis_nktr_PurchaseAndSaleAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-02-23</startDate>
            <endDate>2012-02-24</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_IndemnificationGuaranteeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_IndemnificationGuaranteeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="D2017Q3Sep1-Sep30_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightLicenseMember_us-gaap_TypeOfArrangementAxis_nktr_PhaseOneClinicalDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarThreeFiveEightLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PhaseOneClinicalDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="D2017Q3Aug22-Aug23_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="D2017Q3Aug22-Aug23_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="D2018Q2Apr1-Apr30_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="I2018Q2Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="D2010Q4Oct1-Dec31_dei_LegalEntityAxis_nktr_AmgenIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-10-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q4Dec1-Dec31_dei_LegalEntityAxis_nktr_BaxaltaIncorporatedOrTakedaPLCMember_us-gaap_ContractWithCustomerSalesChannelAxis_nktr_AnnualSalesLevelMilestoneMember_us-gaap_TypeOfArrangementAxis_nktr_HemophiliaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">nktr:AnnualSalesLevelMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="D2016Q3Sep1-Sep30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_ClinicalTrialAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:ClinicalTrialAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="D2015Q4Sep01-Dec31_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_MOVANTIKAndMOVENTIGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MOVANTIKAndMOVENTIGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-09-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q1Feb13-Feb13_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-13</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="D2017Q3Sep1-Sep30_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightLicenseMember_us-gaap_TypeOfArrangementAxis_nktr_DrugProductDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarThreeFiveEightLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:DrugProductDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="D2017Q3Aug01-Aug31_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BaxaltaIncorporatedOrTakedaPLCMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_TypeOfArrangementAxis_nktr_HemophiliaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="D2018Q2Apr1-Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="I2017Q3Aug23_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-23</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="D2018Q1Feb13-Feb13_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nktr_OpdivoAndYervoyMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoAndYervoyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-13</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="D2018Q2Apr1-Apr30_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="D2017Q3Aug22-Aug23_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="D2018Q2Apr1-Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_MOVANTIKAndMOVENTIGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MOVANTIKAndMOVENTIGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="D2017Q3Sep1-Sep30_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="D2017Q3Sep1-Sep30_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarThreeFiveEightLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="I2018Q2Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="D2018Q1Feb13-Feb13_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nktr_OpdivoMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-13</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="FI2019Q3_dei_LegalEntityAxis_nktr_OtherPartnerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="D2017Q4Nov1-Nov30_dei_LegalEntityAxis_nktr_BaxaltaIncorporatedOrTakedaPLCMember_us-gaap_TypeOfArrangementAxis_nktr_HemophiliaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="D2018Q1Feb13-Feb13_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-13</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="D2018Q1Feb13-Feb13_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nktr_OpdivoMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-13</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="D2018Q1Feb13-Feb13_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nktr_OpdivoAndYervoyMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoAndYervoyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-13</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="D2017Q3Aug22-Aug23_dei_LegalEntityAxis_nktr_EliLillyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="FI2019Q3_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="D2016Q1Mar1-Mar31_us-gaap_TypeOfArrangementAxis_nktr_NektarMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="D2017Q3Aug22-Aug23_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="D2016Q1Mar1-Mar31_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_AstraZenecaAgreementWithKirinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:AstraZenecaAgreementWithKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="D2018Q1Jan1-Jan31_dei_LegalEntityAxis_nktr_BaxaltaIncorporatedOrTakedaPLCMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_TypeOfArrangementAxis_nktr_HemophiliaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarTwoOneFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_TypeOfArrangementAxis_nktr_NeulastaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_TypeOfArrangementAxis_nktr_NeulastaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_dei_LegalEntityAxis_nktr_OtherPartnerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarTwoOneFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarTwoOneFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_TypeOfArrangementAxis_nktr_NeulastaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarTwoOneFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_dei_LegalEntityAxis_nktr_OtherPartnerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_dei_LegalEntityAxis_nktr_OtherPartnerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_TypeOfArrangementAxis_nktr_NeulastaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_dei_LegalEntityAxis_nktr_OtherPartnerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2019Q3_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_AstraZenecaAgreementWithKirinMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:AstraZenecaAgreementWithKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_nktr_StockOptionsAndRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_nktr_StockOptionsAndRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="sqft">
        <measure>utreg:sqft</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="space">
        <measure>nktr:space</measure>
    </unit>
    <unit id="extension_period">
        <measure>nktr:extension_period</measure>
    </unit>
    <unit id="U_nktrSegment">
        <measure>nktr:Segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2019Q3YTD"
      id="Fact-B0D20C8E345A5631AB6C49D63D57F5DB-wk-Fact-B0D20C8E345A5631AB6C49D63D57F5DB">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2019Q3YTD"
      id="Fact-533BD43F066A5135A05BCD3AA48F08AE-wk-Fact-533BD43F066A5135A05BCD3AA48F08AE">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2019Q3YTD"
      id="Fact-7A269BD6D8585750BBB03CFD638B424B-wk-Fact-7A269BD6D8585750BBB03CFD638B424B">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2019Q3YTD"
      id="Fact-082CE4F299C057DE9D171D7C15E08BCE-wk-Fact-082CE4F299C057DE9D171D7C15E08BCE">2019</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2019Q3YTD"
      id="Fact-6304204534DD5D168146B978135EBFE0-wk-Fact-6304204534DD5D168146B978135EBFE0">0000906709</dei:EntityCentralIndexKey>
    <nktr:DebtInvestmentMaturityTerm
      contextRef="FD2019Q3YTD"
      id="Fact-3300F5555CD55F0E8AEE0FCEC178AD92-wk-Fact-3300F5555CD55F0E8AEE0FCEC178AD92">P1Y</nktr:DebtInvestmentMaturityTerm>
    <nktr:DebtInvestmentMaximumMaturityPeriod
      contextRef="FD2019Q3YTD"
      id="Fact-15CC8E82CF845D3E92066C0186569019-wk-Fact-15CC8E82CF845D3E92066C0186569019">P2Y</nktr:DebtInvestmentMaximumMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember"
      id="Fact-3CDAD09CC02D55D69A953713156AE21A-wk-Fact-3CDAD09CC02D55D69A953713156AE21A">P2Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember"
      id="Fact-C4A5CA3EAE785A66A3C30BC698FADDA5-wk-Fact-C4A5CA3EAE785A66A3C30BC698FADDA5">P1Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember"
      id="Fact-4264FF26E213558789474D50350C021F-wk-Fact-4264FF26E213558789474D50350C021F">P1Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:PreferredStockShareDesignated
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-6192F77A09E456869C31CA9F6F151007-wk-Fact-6192F77A09E456869C31CA9F6F151007"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <nktr:PreferredStockShareDesignated
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-488ADC777EBE5AE4A4E3EB162D58F320-wk-Fact-488ADC777EBE5AE4A4E3EB162D58F320"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-83B31E4667575151887915C26CAD1166-wk-Fact-83B31E4667575151887915C26CAD1166"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-A63FDA3BC192573288B147B00C0C2394-wk-Fact-A63FDA3BC192573288B147B00C0C2394"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-10E775F26115557584EA084D31CAA47C-wk-Fact-10E775F26115557584EA084D31CAA47C"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-89A2A28AE7E7586CAEB6A6265404780C-wk-Fact-89A2A28AE7E7586CAEB6A6265404780C"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4"
      decimals="-3"
      id="Fact-C3C4F2BFC64958AEA38ABE45A16EF814-wk-Fact-C3C4F2BFC64958AEA38ABE45A16EF814"
      unitRef="shares">173530000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q3"
      decimals="-3"
      id="Fact-45DA1ACA13A05B69A0014F2C99604777-wk-Fact-45DA1ACA13A05B69A0014F2C99604777"
      unitRef="shares">175786000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q3_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_AstraZenecaAgreementWithKirinMember"
      decimals="INF"
      id="Fact-219113E2F6A553F7B8DA56018CF632A1-wk-Fact-219113E2F6A553F7B8DA56018CF632A1"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q3QTD_srt_StatementGeographicalAxis_country_IN"
      decimals="2"
      id="Fact-59EBC93BD4E853D8978C47703D3C9FDF-wk-Fact-59EBC93BD4E853D8978C47703D3C9FDF"
      unitRef="number">0.33</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="FI2018Q3"
      decimals="INF"
      id="Fact-EB8FFACF6B4D577C85C844522A7596E7-wk-Fact-EB8FFACF6B4D577C85C844522A7596E7"
      unitRef="usd">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="FI2018Q3"
      decimals="INF"
      id="Fact-ED5EC0CC5A39509C8A9052C801074BE6-wk-Fact-ED5EC0CC5A39509C8A9052C801074BE6"
      unitRef="usd">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-0D6116EAF65E5891B65532B12B27C1F7-wk-Fact-0D6116EAF65E5891B65532B12B27C1F7"
      unitRef="usd">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="I2017Q3Aug31_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember"
      id="Fact-EDD77977837FE55891FE23E0EDD2F2B9-wk-Fact-EDD77977837FE55891FE23E0EDD2F2B9">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="I2018Q2May31_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember"
      id="Fact-A05785C5043B8E5BAFEC23E2D9F3D18B-wk-Fact-A05785C5043B8E5BAFEC23E2D9F3D18B">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="FI2018Q4_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_IndemnificationGuaranteeMember"
      decimals="INF"
      id="Fact-F8882BCB7E345390AF7C9BFD35050391-wk-Fact-F8882BCB7E345390AF7C9BFD35050391"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-3F48871C692F5BD08A37AA4CBC3F0B00-wk-Fact-3F48871C692F5BD08A37AA4CBC3F0B00"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-1D7CCB56C3FE5C53A08E4B3233210C1E-wk-Fact-1D7CCB56C3FE5C53A08E4B3233210C1E"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-54DECBE6527B595EB1427D9B464D3D33-wk-Fact-54DECBE6527B595EB1427D9B464D3D33"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-D9EEEF08CBD65F3ABF20BCD1348DEC84-wk-Fact-D9EEEF08CBD65F3ABF20BCD1348DEC84"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-898509888A53595698C32F4A1084D381-wk-Fact-898509888A53595698C32F4A1084D381"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-8CDB806E33E05237BFDF292D38D19C04-wk-Fact-8CDB806E33E05237BFDF292D38D19C04"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="Fact-677F8523088553D1A6836AF6C286DC18-wk-Fact-677F8523088553D1A6836AF6C286DC18"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <dei:DocumentType
      contextRef="FD2019Q3YTD"
      id="d103432234e380-wk-Fact-016CC5E3EB1C5CC582D4F8A3E2217E16">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2019Q3YTD"
      id="d103432234e400-wk-Fact-B41605800C3159D6BEF39BE1DBE3B9AA">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2019Q3YTD"
      id="d103432234e410-wk-Fact-498D261A5EA55D02AB052CDA9AC9EE54">2019-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2019Q3YTD"
      id="d103432234e429-wk-Fact-D4D6DFAADD315054A60300034310AD82">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2019Q3YTD"
      id="d103432234e443-wk-Fact-A7019E720CF25E6DA3D0354EF9864C31">0-24006</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2019Q3YTD"
      id="d103432234e452-wk-Fact-59B3A1601D53521481DF35608E57F619">NEKTAR THERAPEUTICS</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2019Q3YTD"
      id="d103432234e476-wk-Fact-A6A2E7E4A2A750D1AAD6FFE9DE6A6326">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2019Q3YTD"
      id="d103432234e486-wk-Fact-0A8D70C5BA7B592282C19A5415777632">94-3134940</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2019Q3YTD"
      id="d103432234e511-wk-Fact-249A866EF31259CBBABEFBCB69460ECD">455 Mission Bay Boulevard South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2019Q3YTD"
      id="d103432234e517-wk-Fact-D60F683170935CF1B61A1AE6AA9E6044">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2019Q3YTD"
      id="d103432234e522-wk-Fact-E68B2485FF34537A8CDD70495AEC492E">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2019Q3YTD"
      id="d103432234e527-wk-Fact-ED034A4351435E5D8096B0A9A0034508">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2019Q3YTD"
      id="d103432234e536-wk-Fact-EA9CF9118B6D5665890101B58486934D">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2019Q3YTD"
      id="d103432234e541-wk-Fact-6469CB420D19566A8BA8E233DF7F1C55">482-5300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2019Q3YTD"
      id="d103432234e622-wk-Fact-D005A59520075B9A8A8267AA294C540C">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2019Q3YTD"
      id="d103432234e627-wk-Fact-32B2B23AA24C59ABBBF1440E18C36150">NKTR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2019Q3YTD"
      id="d103432234e632-wk-Fact-C791CC8F4C54571FABD94C073B255682">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2019Q3YTD"
      id="d103432234e644-wk-Fact-E633A65D7A105825A01FF5FB331CAF00">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2019Q3YTD"
      id="d103432234e655-wk-Fact-F8C894E9F22B515CB9C2176D8FD156BF">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2019Q3YTD"
      id="d103432234e683-wk-Fact-072652D474BA51CEB89E6D3797A2B0AE">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2019Q3YTD"
      id="d103432234e785-wk-Fact-6156413FB4EE5380AE5C048EF7B955A7">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2019Q3YTD"
      id="d103432234e837-wk-Fact-FE702BF31349579685582690504AA137">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2019Q3YTD"
      id="d103432234e867-wk-Fact-A9030AE9DAF45637A7540B603F46D7AB">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2019Q3Nov01"
      decimals="INF"
      id="d103432234e877-wk-Fact-FB8EF0887A5DBA74105A378D24AC4F7B"
      unitRef="shares">175922206</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e515-wk-Fact-C7A2AE7C68775A439814DA049308CCE0"
      unitRef="usd">81224000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e534-wk-Fact-0A046CD4CFDD5C44AB78FE4E6C5314BD"
      unitRef="usd">194905000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e549-wk-Fact-0AEF18E786665F2FAEBCBCB3D5386580"
      unitRef="usd">1414448000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e568-wk-Fact-D62AACC5E6A9595AA4AC531814DAB31B"
      unitRef="usd">1140445000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e588-wk-Fact-3EF320A72A825C11B68E939CF863BF03"
      unitRef="usd">41205000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e607-wk-Fact-FBC3973AE8EF5B379365CA7B557C76BC"
      unitRef="usd">43213000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e627-wk-Fact-D3F1F8DC7AB6516098B11FCDFB3E6D69"
      unitRef="usd">13720000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e646-wk-Fact-59492ABDF60153D4BA438B78B7470CB8"
      unitRef="usd">11381000</us-gaap:InventoryNet>
    <nktr:AdvancePaymentsToContractManufacturers
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e666-wk-Fact-B3A5D118EDD456F09241ABE722D70281"
      unitRef="usd">13015000</nktr:AdvancePaymentsToContractManufacturers>
    <nktr:AdvancePaymentsToContractManufacturers
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e685-wk-Fact-7361B8702F295AD581A123CF3E50012A"
      unitRef="usd">26450000</nktr:AdvancePaymentsToContractManufacturers>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e705-wk-Fact-831834B3A2AD5B20B2EDBADF6012D9B5"
      unitRef="usd">15212000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e724-wk-Fact-882D4B407D09569ABE9B90D81D5CDFD3"
      unitRef="usd">21293000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e744-wk-Fact-FE269227A18D55A1AE7EF202A520CC5D"
      unitRef="usd">1578824000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e763-wk-Fact-B25258D7E527528795B6250B8F0C3917"
      unitRef="usd">1437687000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e783-wk-Fact-0D4AE566CE7B54188DDCDEB656199CE3"
      unitRef="usd">231082000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e802-wk-Fact-326539B35D8A5187AE1F3CF50F026C2B"
      unitRef="usd">582889000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e823-wk-Fact-B2B086AC613F5C7EA4E28ED4C14E7425"
      unitRef="usd">64614000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e842-wk-Fact-0390508D6FA25DDD8A666AC3DD17EF1C"
      unitRef="usd">48851000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e862-wk-Fact-D5C3E1AD1AB45A32A92F8FB0BA74FF51"
      unitRef="usd">134888000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e881-wk-Fact-1EE83566912E56768BAD761839C55ED1"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e901-wk-Fact-3B7C23058C095F58B31DFEFD50B1A19C"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e920-wk-Fact-9608F99D57AF53EDBC13AB52C12067F1"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e940-wk-Fact-526582D8C8845948A070DDF6B804354B"
      unitRef="usd">2385000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e959-wk-Fact-925C6C3D0AA95E3A82C307A613F25683"
      unitRef="usd">4244000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e984-wk-Fact-90D4416F9A4C5B7CAC99584E45363966"
      unitRef="usd">2088294000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1003-wk-Fact-EB1B162E76DD560A8906F93D8C4E4680"
      unitRef="usd">2150172000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1105-wk-Fact-6AEFC54F4D635E7AAEB30A6C47E1E630"
      unitRef="usd">21963000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1124-wk-Fact-742A036C446E56C38FB621E2B50A080F"
      unitRef="usd">5854000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1139-wk-Fact-22CE95B5217A53DDB2CFF07D9B7C378F"
      unitRef="usd">23101000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1158-wk-Fact-0C66579A3CF1516C991B560A286E09B1"
      unitRef="usd">9937000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1178-wk-Fact-6FE3131A439D59AF9BE063B789CB12E9"
      unitRef="usd">38338000</nktr:AccruedClinicalTrialExpensesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1197-wk-Fact-4A0F4EF911F95240A07BCDFA53E03E9E"
      unitRef="usd">14700000</nktr:AccruedClinicalTrialExpensesCurrent>
    <nktr:AccruedContractManufacturingExpenseCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1217-wk-Fact-37C54E554B9350DF8E069EF198DF1858"
      unitRef="usd">8646000</nktr:AccruedContractManufacturingExpenseCurrent>
    <nktr:AccruedContractManufacturingExpenseCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1236-wk-Fact-C2625AC6F20B5BF7A8946AD454F9CAF6"
      unitRef="usd">23841000</nktr:AccruedContractManufacturingExpenseCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1257-wk-Fact-CB466845BB9C5C30B79B74460F5CB7D3"
      unitRef="usd">11394000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1276-wk-Fact-101BDB992E685B1BB3199823DE366260"
      unitRef="usd">9580000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1296-wk-Fact-91DD95E2EBAA5A179EAD892D2BC0C7D3"
      unitRef="usd">4198000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1315-wk-Fact-D65856DCFC6654C0B2B2AF803C0DAB7A"
      unitRef="usd">4198000</us-gaap:InterestPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1335-wk-Fact-9DF62218E4F95D648FC7684BADFBFC0A"
      unitRef="usd">9318000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1354-wk-Fact-78A37B4E6EA453CB9A472759D024D73F"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1374-wk-Fact-C52BCEB748C958139CBD9D2B1B5CB2F8"
      unitRef="usd">8392000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1393-wk-Fact-98380AAF04255AE7AAD65125EF70D144"
      unitRef="usd">13892000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1413-wk-Fact-06B8DAC6B8EE51B6AAD9E5D59B359F68"
      unitRef="usd">125350000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1432-wk-Fact-17309742D02956C5A46653F28CDC6802"
      unitRef="usd">82002000</us-gaap:LiabilitiesCurrent>
    <us-gaap:SeniorLongTermNotes
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1452-wk-Fact-D0354DF713665B9ABC2848BA5FD89FC1"
      unitRef="usd">248257000</us-gaap:SeniorLongTermNotes>
    <us-gaap:SeniorLongTermNotes
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1471-wk-Fact-2C4BDAFD72F45EDAAE886835361FB0C5"
      unitRef="usd">246950000</us-gaap:SeniorLongTermNotes>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1491-wk-Fact-4DC14A4ACA6254F9876DFB66F2EAAF81"
      unitRef="usd">145099000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1510-wk-Fact-829D1B5642A053288961708823B39E71"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1530-wk-Fact-9C9124555FEF58B6B80CE556C226F8B7"
      unitRef="usd">73455000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1549-wk-Fact-BC2D7EFF1FE657C3AF72B3165ACC0889"
      unitRef="usd">82911000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1569-wk-Fact-C013E6C1FDEC59BFBADAA04E4A3CCA89"
      unitRef="usd">6779000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1588-wk-Fact-E54AD2E930585241986DDF62B126DD3E"
      unitRef="usd">10744000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1608-wk-Fact-9D5C3BE5298C531C9C10C7924FD6B95B"
      unitRef="usd">643000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1627-wk-Fact-99F7DF085455533E9A19A50C146BB947"
      unitRef="usd">9990000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1647-wk-Fact-BAAF447486D45880AE72DC4144D16F00"
      unitRef="usd">599583000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1666-wk-Fact-3DBDDCF4DE0159C1822E2FD7EFA0FF47"
      unitRef="usd">432597000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q3"
      id="d103445858e1687-wk-Fact-C84CBC818ECD51EC842A832640B003D8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2018Q4"
      id="d103445858e1705-wk-Fact-0D46FAC9EB0F5EF6B7257CCAC8552FB7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1767-wk-Fact-6451D4857CB5535BA4C915ABCDE880F1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1786-wk-Fact-567D5A1E73EF5D4F8E3B2D6D7C233372"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1808-wk-Fact-94D779EF54B55C908162ABA3EC6BEB5E"
      unitRef="usd">17000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1827-wk-Fact-7449D344F6F8509FA48BC008BDFB4DAE"
      unitRef="usd">17000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1847-wk-Fact-B5909FB2D63B58EA8BD42F42248D1133"
      unitRef="usd">3241160000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1866-wk-Fact-6F3FECBFBF2159D282771E8E63B1010A"
      unitRef="usd">3147925000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1886-wk-Fact-B1EC96FE5F0352FC848067011F2590E7"
      unitRef="usd">-1186000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1906-wk-Fact-A597B561E8DA55AEB814BD94DE2F8D20"
      unitRef="usd">-6316000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1927-wk-Fact-75A4343331915634B80610E6C9B7CC25"
      unitRef="usd">-1751280000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1947-wk-Fact-B6F07C017B505698958601DA8D5CC926"
      unitRef="usd">-1424051000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e1968-wk-Fact-B678F4F136865CEF9F87800AB7F87743"
      unitRef="usd">1488711000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e1987-wk-Fact-DCD6BC68154A5F7B8D85D40C60BE3EDB"
      unitRef="usd">1717575000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103445858e2012-wk-Fact-8DAF82086DBA58A78695DBA1EB7F218B"
      unitRef="usd">2088294000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103445858e2031-wk-Fact-5A2DE51A86CE51908AD3DD961C50FEAC"
      unitRef="usd">2150172000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d103454968e646-wk-Fact-11E91C2A18B854BE933737684F281F63"
      unitRef="usd">5558000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d103454968e665-wk-Fact-59B1434592FC5E09BD2B4DF750E7E592"
      unitRef="usd">4256000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d103454968e684-wk-Fact-D31E7ED4FAB55FDDAF2458EE4CE7B87C"
      unitRef="usd">14302000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d103454968e704-wk-Fact-70728217C6975D828F443FD27D795C06"
      unitRef="usd">16414000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-3"
      id="d103454968e719-wk-Fact-367B8E3203D05EEB863C648CE2E3B101"
      unitRef="usd">10275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-3"
      id="d103454968e738-wk-Fact-91360F29085D56658D30B42034965981"
      unitRef="usd">10259000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-3"
      id="d103454968e757-wk-Fact-E02BF72F4EDA521AA45CAFA120EF92FE"
      unitRef="usd">29008000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember"
      decimals="-3"
      id="d103454968e777-wk-Fact-E7978B7DF0FA57269A5B548870879704"
      unitRef="usd">29898000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"
      decimals="-3"
      id="d103454968e797-wk-Fact-07F4CB988500513C895EF1F01F28DA5E"
      unitRef="usd">10264000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"
      decimals="-3"
      id="d103454968e816-wk-Fact-50138912970750EA811F5EB072C04637"
      unitRef="usd">8372000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"
      decimals="-3"
      id="d103454968e835-wk-Fact-B46B7CB57EC45220921450DBCFE51856"
      unitRef="usd">27585000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"
      decimals="-3"
      id="d103454968e855-wk-Fact-484E5970CB445C31993585F60293F0DC"
      unitRef="usd">24337000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_nktr_LicenseCollaborationAndOtherRevenueMember"
      decimals="-3"
      id="d103454968e875-wk-Fact-7D00AFF99FD15D91BE435EBB42AF05F4"
      unitRef="usd">3121000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_nktr_LicenseCollaborationAndOtherRevenueMember"
      decimals="-3"
      id="d103454968e894-wk-Fact-80C1A77E0E00588389D316EDCA79341C"
      unitRef="usd">4875000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_nktr_LicenseCollaborationAndOtherRevenueMember"
      decimals="-3"
      id="d103454968e913-wk-Fact-71D9E73C64385A6EB67BF8592F08DC02"
      unitRef="usd">9860000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q3YTD_srt_ProductOrServiceAxis_nktr_LicenseCollaborationAndOtherRevenueMember"
      decimals="-3"
      id="d103454968e933-wk-Fact-D4242468F9FE53E689B288B453A4089B"
      unitRef="usd">1082848000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103454968e953-wk-Fact-DF934E5E1B885A1597FEB851AEDD6454"
      unitRef="usd">29218000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103454968e972-wk-Fact-473AF8C568065B9BB6FFDA94FA51D747"
      unitRef="usd">27762000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103454968e991-wk-Fact-A26A18206DF45033A866D3CB5BF4BC6E"
      unitRef="usd">80755000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103454968e1011-wk-Fact-AAC4AF9FC7FB547FAC062D6967DB301F"
      unitRef="usd">1153497000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103454968e1113-wk-Fact-680B91C761835D2193037A549A6D10E5"
      unitRef="usd">4927000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103454968e1132-wk-Fact-64EA6A4C662D5F2A8920737E71327EF6"
      unitRef="usd">4783000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103454968e1151-wk-Fact-197F4A9007C65828859A42360506B032"
      unitRef="usd">15385000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103454968e1171-wk-Fact-C8092FC0721D51E2AE3EDF6497CFF4FA"
      unitRef="usd">16951000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103454968e1191-wk-Fact-C69216BDDBB355AE8A2A3EBB7D109B8B"
      unitRef="usd">99048000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103454968e1210-wk-Fact-BBBBA6CE21EF51A2A173A21FFA7E2F08"
      unitRef="usd">102895000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103454968e1229-wk-Fact-2239742565255586AE31C703938A53B0"
      unitRef="usd">324197000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103454968e1249-wk-Fact-DFE47604C70D546CBEE0C362E368DD68"
      unitRef="usd">290653000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103454968e1270-wk-Fact-692AF676F6595E97B2C5092AABABAEB7"
      unitRef="usd">23983000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103454968e1289-wk-Fact-E4F4407B25485D70A533213A9491A2D7"
      unitRef="usd">18718000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103454968e1308-wk-Fact-FAED8DD3A6DD566D80863F977AC9EF02"
      unitRef="usd">71570000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103454968e1328-wk-Fact-86CD37D81CF759D0A27823E5934F7C4A"
      unitRef="usd">57666000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103454968e1348-wk-Fact-9ED1991307A05268AD61123A0D3A8507"
      unitRef="usd">127958000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103454968e1367-wk-Fact-E86C60AAF8FF5E848B915CCA051C3C90"
      unitRef="usd">126396000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103454968e1386-wk-Fact-89C470974F4B54AC86489111651001D4"
      unitRef="usd">411152000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103454968e1406-wk-Fact-96A2EA34A9FC5646ADEB07AE12D13A02"
      unitRef="usd">365270000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103454968e1426-wk-Fact-F28A571EA9A556B189C76DAA5816B0E3"
      unitRef="usd">-98740000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103454968e1446-wk-Fact-0295221CD3E85EE4917DAC4973709D0E"
      unitRef="usd">-98634000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103454968e1466-wk-Fact-654252F668A95C1BB31855477C2F26A6"
      unitRef="usd">-330397000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103454968e1487-wk-Fact-1BC57A2830785FC48822967A10137C18"
      unitRef="usd">788227000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103454968e1589-wk-Fact-D2984EB146CF53A0A3D945CD9F6C484C"
      unitRef="usd">5425000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103454968e1609-wk-Fact-89E81FFBA1F359A3804311A524ED9638"
      unitRef="usd">5442000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103454968e1629-wk-Fact-E8729B69FC6B5DB98EB9E0772B1B6E42"
      unitRef="usd">15882000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103454968e1650-wk-Fact-90A3020EC53153A39B2EEBC5ADE7E243"
      unitRef="usd">16167000</us-gaap:InterestExpense>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103454968e1671-wk-Fact-F7BC5B5CFD2C510582E628BD7AE75A83"
      unitRef="usd">5813000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103454968e1691-wk-Fact-0BA0B4AE955153EA84EB12424A57BC40"
      unitRef="usd">4814000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103454968e1711-wk-Fact-1259198267AB52A0ADD3A2BBBAEFD915"
      unitRef="usd">17853000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103454968e1732-wk-Fact-790B3066DF1D58ABA7DFD64D6C7CF71C"
      unitRef="usd">14808000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103454968e1753-wk-Fact-1B686D885EE85A91A4B49036ECB3A97C"
      unitRef="usd">11492000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103454968e1772-wk-Fact-19523F84434E55D597D1B771668E721A"
      unitRef="usd">11847000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103454968e1791-wk-Fact-0D57A1B063D756A38C4F1D9BB05FF4BD"
      unitRef="usd">35964000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103454968e1811-wk-Fact-16253954A07D54349C114A4480075116"
      unitRef="usd">25523000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103454968e1831-wk-Fact-0A2BC7BC8ACC5AC29E8BDF8856CC05AC"
      unitRef="usd">254000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103454968e1850-wk-Fact-CA6B8053EFFF5FDC96521AB72B349F91"
      unitRef="usd">1591000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103454968e1869-wk-Fact-00680C506E63565ABD274A4D74ECF6ED"
      unitRef="usd">2229000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103454968e1889-wk-Fact-FC38F4D8FB1C553CB81FC65EC5549874"
      unitRef="usd">-5452000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103454968e1910-wk-Fact-0D821D81FFF05400AAD5EFE802AAD6A0"
      unitRef="usd">-98486000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103454968e1930-wk-Fact-60BB42A8992B5DF998DE60794D5DA4E8"
      unitRef="usd">-97043000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103454968e1950-wk-Fact-7A8E714FDFB953AE87870CB99E6FAF39"
      unitRef="usd">-328168000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103454968e1971-wk-Fact-3B7A5A9EB8735E8AAA57F26946D95565"
      unitRef="usd">782775000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103454968e1991-wk-Fact-2C701C642FCC5010B2A0051ADBA279D0"
      unitRef="usd">322000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103454968e2010-wk-Fact-75F7502996AF58A3BC9872E7D44EEE75"
      unitRef="usd">-900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103454968e2030-wk-Fact-A1E1407F13B35D9CAFA734E23F33A5FE"
      unitRef="usd">-939000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103454968e2051-wk-Fact-77F3102C78CD5D48A9534FE23DC2890F"
      unitRef="usd">3250000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103454968e2076-wk-Fact-96FE79C957FC5199AFAE69FD1F6EB6B0"
      unitRef="usd">-98808000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103454968e2096-wk-Fact-3CF3ED7F676A50F88B47DC66A978B759"
      unitRef="usd">-96143000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103454968e2116-wk-Fact-3ACDCA10646F5B9E86C244BF888CF7C6"
      unitRef="usd">-327229000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103454968e2137-wk-Fact-621CD3A72F9C55B69FC8DC281DF4A682"
      unitRef="usd">779525000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q3QTD"
      decimals="2"
      id="d103454968e2322-wk-Fact-2B4FA178B0E85A918823DA71E31CC318"
      unitRef="usdPerShare">-0.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q3QTD"
      decimals="2"
      id="d103454968e2342-wk-Fact-12F03FA832E25759BB4166B07348C42A"
      unitRef="usdPerShare">-0.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d103454968e2362-wk-Fact-FA86278E7DF956348A12695AAB4E0039"
      unitRef="usdPerShare">-1.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q3YTD"
      decimals="2"
      id="d103454968e2383-wk-Fact-72BF57175E5A5595A068738551CB2202"
      unitRef="usdPerShare">4.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q3QTD"
      decimals="2"
      id="d103454968e2403-wk-Fact-A7BCEE5C4EB9548FAFABBBFC6F3D644A"
      unitRef="usdPerShare">-0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q3QTD"
      decimals="2"
      id="d103454968e2423-wk-Fact-382D09C09AB75B2293D6EE9DC8BE3124"
      unitRef="usdPerShare">-0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d103454968e2443-wk-Fact-EB2D6943BD9F5B8B89BEE30D92071DEE"
      unitRef="usdPerShare">-1.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q3YTD"
      decimals="2"
      id="d103454968e2464-wk-Fact-6A969138F90F591A9A269DC3B74FE915"
      unitRef="usdPerShare">4.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103454968e2561-wk-Fact-4E3BA6614B3254898B020C181B05D89C"
      unitRef="shares">175402000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103454968e2580-wk-Fact-D1BECD626E1655A59E869A3926B49834"
      unitRef="shares">172698000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103454968e2599-wk-Fact-32954A9782F65EF6AF8C9B1C14D7E6C5"
      unitRef="shares">174609000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103454968e2619-wk-Fact-5B7F965C19555DE79A4611B68C056ABA"
      unitRef="shares">168363000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103454968e2639-wk-Fact-7266EDB4F0E95917B90B5A3E12C8D4EC"
      unitRef="shares">175402000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103454968e2658-wk-Fact-B9469E1891B45E3BA1E0B780D3F0A438"
      unitRef="shares">172698000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103454968e2677-wk-Fact-722EAC3DDB1858D3B9A28AABB4E1835D"
      unitRef="shares">174609000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103454968e2697-wk-Fact-EE8CC40D7AB351179347901C87AD0FA6"
      unitRef="shares">179619000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103444155e568-wk-Fact-4AEE8CAB47425CC99B15CF03C14A0DD4"
      unitRef="usd">-99206000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103444155e588-wk-Fact-2BE5910257E5586A8F486115BD622862"
      unitRef="usd">-97519000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103444155e608-wk-Fact-6CDF04BD3D545CB8B6029DC0D4377362"
      unitRef="usd">-322099000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103444155e629-wk-Fact-2A1F956172FD548BA22C5CB9797F07D5"
      unitRef="usd">776258000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e670-wk-Fact-DADC43442816590BB46C918ED2DC3B7B"
      unitRef="shares">173530000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e689-wk-Fact-337BEE240C83595A8C7817A72C6F98E4"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e708-wk-Fact-C1B0777DB6235649BFAECD51334A5102"
      unitRef="usd">3147925000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d103439808e728-wk-Fact-A21E86AF7C97576E88EC51BF25061539"
      unitRef="usd">-6316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d103439808e748-wk-Fact-84A89777B3F752889D42D0B3A2FB51C6"
      unitRef="usd">-1424051000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103439808e768-wk-Fact-DCD6BC68154A5F7B8D85D40C60BE3EDB"
      unitRef="usd">1717575000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e784-wk-Fact-8EDD12D513235E2498D7F96DD32728F9"
      unitRef="shares">698000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e817-wk-Fact-96F941EB0B885127AA692E82E3990F04"
      unitRef="usd">5463000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d103439808e875-wk-Fact-6FBF023C1AE3599E9857463058158D02"
      unitRef="usd">5463000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e929-wk-Fact-6624CA703D16558C82FB6A74DA355969"
      unitRef="usd">25385000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d103439808e987-wk-Fact-69B17CFF90F15944950C7E0EFA78AAA7"
      unitRef="usd">25385000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d103439808e1061-wk-Fact-F1DDFC6004E05E3AAC9864C52D1FEAEB"
      unitRef="usd">3600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d103439808e1099-wk-Fact-EDD8FA9E41B154D6B77CD7804209B062"
      unitRef="usd">3600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d103439808e1192-wk-Fact-77A9FC586F9956BC95ED8C2C55460830"
      unitRef="usd">-118512000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d103439808e1212-wk-Fact-0A2BA8FD84315DA482DA33A1FB51AF9F"
      unitRef="usd">-118512000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e1234-wk-Fact-7AB6A532E06F50ABA7614185B1B9F6A8"
      unitRef="shares">174228000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e1253-wk-Fact-4AA0A2B0A60F51269E34350DB74AE487"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e1272-wk-Fact-371ABB72350B5EF3AE7B400195F85F11"
      unitRef="usd">3178773000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d103439808e1292-wk-Fact-34E8BC6B96D35C28A20F7E90F24743C9"
      unitRef="usd">-2716000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d103439808e1312-wk-Fact-C35431C4D2CC5DFBAA4D303E4993F260"
      unitRef="usd">-1542563000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1"
      decimals="-3"
      id="d103439808e1332-wk-Fact-5EBD765E2D20500F850624417C076789"
      unitRef="usd">1633511000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e1348-wk-Fact-C2F1DC0135BF51D48E3CC80A8A828DC5"
      unitRef="shares">738000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e1381-wk-Fact-FF453767F7375077908C4406313DDD0E"
      unitRef="usd">7103000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d103439808e1439-wk-Fact-7DE98755F11C5671B5B348458F201402"
      unitRef="usd">7103000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e1493-wk-Fact-CD83B3C884A35221A9BFBCE7A55EDBD6"
      unitRef="usd">24522000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d103439808e1551-wk-Fact-1D781EC4D88D56B48C71A71B63DEE5C5"
      unitRef="usd">24522000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d103439808e1625-wk-Fact-DFCAE5AA3634546DB37AE079BB349788"
      unitRef="usd">1928000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d103439808e1663-wk-Fact-2C072DDAE4AA5282AF39C2839E0F2FB0"
      unitRef="usd">1928000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d103439808e1757-wk-Fact-D5C4484D791F531185E23067C8CA469C"
      unitRef="usd">-109909000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d103439808e1777-wk-Fact-92AA5D47DBB158FBBAC38851B72A95BF"
      unitRef="usd">-109909000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e1799-wk-Fact-1AB2858A72BE5813BA5809A73CFED188"
      unitRef="shares">174966000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e1813-wk-Fact-37514D286F0A5A6DA6A5146890153073"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e1832-wk-Fact-151DEA7D49A45EC1B431CF9D2EDB764F"
      unitRef="usd">3210398000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d103439808e1852-wk-Fact-265EC092832D5AFC94534A5835CDF8D2"
      unitRef="usd">-788000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d103439808e1872-wk-Fact-B4DCFB0C2F17500DA379721C006AC509"
      unitRef="usd">-1652472000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2"
      decimals="-3"
      id="d103439808e1892-wk-Fact-602A1B167F9A580B9FA1755F9189FBF6"
      unitRef="usd">1557155000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e1913-wk-Fact-B2435ABDCB14F364722722D7AF411B02"
      unitRef="shares">820000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e1946-wk-Fact-4ACD4394C2E388A7DAA822D7B1A14F5A"
      unitRef="usd">5882000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103439808e2004-wk-Fact-70FEB0FE24696AD6CD8D22D7B51A18E2"
      unitRef="usd">5882000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e2058-wk-Fact-A03CDACA440B26602B7422D7DF4020FB"
      unitRef="usd">24880000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103439808e2116-wk-Fact-E47D157598F7D40575A622D7E2988E40"
      unitRef="usd">24880000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d103439808e2190-wk-Fact-3BAC4B80BD61036AA96122D80450A2C3"
      unitRef="usd">-398000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103439808e2229-wk-Fact-3FDFE5CC340F457B326922D806B87310"
      unitRef="usd">-398000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d103439808e2323-wk-Fact-FDC4F322AF8AFBE09D2F22D83CF432E0"
      unitRef="usd">-98808000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103439808e2343-wk-Fact-96FE79C957FC5199AFAE69FD1F6EB6B0"
      unitRef="usd">-98808000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e2365-wk-Fact-C6AB9F278020E0FE744822D862D93A02"
      unitRef="shares">175786000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e2384-wk-Fact-6F2FBE86BCD15BF7CBC422D864592216"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e2403-wk-Fact-63582AB361457D84F5AC22D865CEBADB"
      unitRef="usd">3241160000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d103439808e2423-wk-Fact-396D0A7C0558B66098EC22D8674A9BB0"
      unitRef="usd">-1186000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d103439808e2443-wk-Fact-1E6B98DA44402D0F461322D868BA8977"
      unitRef="usd">-1751280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103439808e2463-wk-Fact-B678F4F136865CEF9F87800AB7F87743"
      unitRef="usd">1488711000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e2795-wk-Fact-4FF61FDBB1D559569EE84AC171B0C95C"
      unitRef="shares">159524000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e2814-wk-Fact-D08E4A0AB8E2516E87D720DA7D681531"
      unitRef="usd">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e2833-wk-Fact-BF6A637C186958C1BA99A1FAE176EC29"
      unitRef="usd">2207865000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d103439808e2853-wk-Fact-FB51F14B67AB5AA68B98B039194B7CC1"
      unitRef="usd">-2111000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d103439808e2873-wk-Fact-52A90500FDAD5AE9A1617C2424C67AE6"
      unitRef="usd">-2117941000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4"
      decimals="-3"
      id="d103439808e2893-wk-Fact-638D017E13EC5A578CA023A0F84DCF0B"
      unitRef="usd">87828000</us-gaap:StockholdersEquity>
    <us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1
      contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d103439808e2981-wk-Fact-2D128BFABB3E5ED3A5F6CFAB5260160B"
      unitRef="usd">12577000</us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1>
    <us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1
      contextRef="FD2018Q1QTD"
      decimals="-3"
      id="d103439808e3000-wk-Fact-8F366604C6DD59CE80A4FDFC7FF533FC"
      unitRef="usd">12577000</us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e3021-wk-Fact-847BBF041F6B5F889ABC3D215F6AA79B"
      unitRef="shares">2855000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e3035-wk-Fact-6BEB9F0E29815354A8C35EE742AD6599"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e3054-wk-Fact-2CA2D4B452405BC09EF06EADB9ABDA40"
      unitRef="usd">34405000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q1QTD"
      decimals="-3"
      id="d103439808e3112-wk-Fact-3A8EF5B7A8E35DC8A43C303BBCB241CD"
      unitRef="usd">34406000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e3166-wk-Fact-96DE997E90BE513DB28D178F048B6310"
      unitRef="usd">19949000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q1QTD"
      decimals="-3"
      id="d103439808e3224-wk-Fact-CC3EC7108A7653198197561C3344C215"
      unitRef="usd">19949000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d103439808e3298-wk-Fact-2CB0284F62C4560AB4BC42E09F0C2838"
      unitRef="usd">-685000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q1QTD"
      decimals="-3"
      id="d103439808e3337-wk-Fact-95ACA4FA92F25875B3D9B7BDED2C04A0"
      unitRef="usd">-685000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d103439808e3431-wk-Fact-0487349609C25432A3190C8796223524"
      unitRef="usd">-95792000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q1QTD"
      decimals="-3"
      id="d103439808e3451-wk-Fact-E166094F0C5150DDA10E89E1F2ED9B7C"
      unitRef="usd">-95792000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e3473-wk-Fact-7BA3BA0A6A565D7B91A339CAFF7A5487"
      unitRef="shares">162379000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e3492-wk-Fact-4827443C64635C4EB4AE8355A8AA74D6"
      unitRef="usd">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e3511-wk-Fact-8C576092484B5A889E541F7456E0C0A8"
      unitRef="usd">2262219000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d103439808e3531-wk-Fact-8949F78DBAE85C509F256D8D507A01F5"
      unitRef="usd">-2796000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d103439808e3551-wk-Fact-82F5143336EB55238B9E61650879F609"
      unitRef="usd">-2201156000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q1"
      decimals="-3"
      id="d103439808e3571-wk-Fact-4DF65A5733645C7E83B086D65E716558"
      unitRef="usd">58283000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e3587-wk-Fact-BE80ABAFC2D55DE0BAA00C1C1C2FC6CF"
      unitRef="shares">8285000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e3601-wk-Fact-F72A3A6626765FDEB62E13E66B9CA525"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e3620-wk-Fact-152176BF66855D08B5A79F7C91820D5F"
      unitRef="usd">790230000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d103439808e3640-wk-Fact-FCF20C03087A56ABAB297DF149EFBE17"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d103439808e3659-wk-Fact-997EEEC21A8251428EADDBAF6D72BCD4"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d103439808e3678-wk-Fact-353804B17BEF5E5ABC798AF14DC7D019"
      unitRef="usd">790231000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e3699-wk-Fact-6307FC334BEA576C997F7D4A5ADE72AF"
      unitRef="shares">1751000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e3732-wk-Fact-3AB85DB5D5375CE2ABF3A50CC20A47DF"
      unitRef="usd">20987000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d103439808e3790-wk-Fact-4CAF59FD16DA5FC5B6E968F90BC26D9F"
      unitRef="usd">20987000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e3845-wk-Fact-ACA07E8F0D72593087760D3E024ACEFD"
      unitRef="usd">20659000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d103439808e3903-wk-Fact-A61FC157974353EE8BDAD4937D9D6E4F"
      unitRef="usd">20659000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d103439808e3977-wk-Fact-713109E16D7D52BBBC2805048634FF19"
      unitRef="usd">-1206000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d103439808e4016-wk-Fact-C1BBCFBDD58A58BD9E86D138E86D82FD"
      unitRef="usd">-1206000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d103439808e4110-wk-Fact-0326D9D848945591A761D1AF6B3668E2"
      unitRef="usd">971460000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q2QTD"
      decimals="-3"
      id="d103439808e4129-wk-Fact-25BD7E955FD050B5BC61F5DAE33D628B"
      unitRef="usd">971460000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e4150-wk-Fact-E16E6243F056524BB1733030A58810D7"
      unitRef="shares">172415000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e4169-wk-Fact-1D9B32EC5BB95A5CB475900CC1BC964F"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e4188-wk-Fact-36FC07465D29511F8F94B3C0895CDD3D"
      unitRef="usd">3094095000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d103439808e4208-wk-Fact-E5CAE93A4C3B59CEA8516F77684C7E2E"
      unitRef="usd">-4002000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d103439808e4228-wk-Fact-13AAE89FBFE25FBBB974938B4807F0D2"
      unitRef="usd">-1229696000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q2"
      decimals="-3"
      id="d103439808e4248-wk-Fact-9371B22AAEAD589292A93A208F0E0907"
      unitRef="usd">1860414000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e4264-wk-Fact-05F6934A99355EF801B822DA91D6CC1A"
      unitRef="shares">642000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e4297-wk-Fact-9B2656E9F1723D64216822DA943D72A0"
      unitRef="usd">3940000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103439808e4355-wk-Fact-42D663229332FE9E626322DA97B0AF19"
      unitRef="usd">3940000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e4409-wk-Fact-5AA1B3568F0D8BEEFA2C22DAB79761A0"
      unitRef="usd">23287000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103439808e4467-wk-Fact-92F309E5E28AFFDC189822DABB004EEB"
      unitRef="usd">23287000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d103439808e4541-wk-Fact-1BFE179C58E21EB8DD6B22DADDCFE06D"
      unitRef="usd">-1376000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103439808e4580-wk-Fact-C42CD8A49EB313E66DCC22DAE0BE0ECE"
      unitRef="usd">-1376000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d103439808e4674-wk-Fact-A2B92CA573ACA30FDDD422DAFD564CF1"
      unitRef="usd">-96143000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103439808e4694-wk-Fact-3CF3ED7F676A50F88B47DC66A978B759"
      unitRef="usd">-96143000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e4716-wk-Fact-3A557D433F51FD238C0E22DB23256288"
      unitRef="shares">173057000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d103439808e4735-wk-Fact-94B3734880AD761CB87722DB24A2FE8D"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d103439808e4754-wk-Fact-A8AD28537FBC654E296722DB2612CFF6"
      unitRef="usd">3121322000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d103439808e4774-wk-Fact-36E76DAFD8DC22AFED4D22DB27928FBE"
      unitRef="usd">-5378000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d103439808e4794-wk-Fact-6F335128C8807470598622DB29008B6A"
      unitRef="usd">-1325839000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q3"
      decimals="-3"
      id="d103439808e4814-wk-Fact-B51E314B44FE14BCB07B22DB2A80B4CE"
      unitRef="usd">1790122000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e517-wk-Fact-2DAAF8D96463574CA92936C4E8414737"
      unitRef="usd">-327229000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e537-wk-Fact-20963A7CECAF5EFFB84B4E886DE55486"
      unitRef="usd">779525000</us-gaap:ProfitLoss>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e593-wk-Fact-68485AE8AC8756DBBFE076B40A0D5B21"
      unitRef="usd">27585000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e613-wk-Fact-ECCC1D73CC045BFB8D6A26176917A7FA"
      unitRef="usd">24337000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e634-wk-Fact-1259198267AB52A0ADD3A2BBBAEFD915"
      unitRef="usd">17853000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e653-wk-Fact-790B3066DF1D58ABA7DFD64D6C7CF71C"
      unitRef="usd">14808000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e673-wk-Fact-B1BCA189DB1959319F6A8B4FBCF38A2E"
      unitRef="usd">74787000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e692-wk-Fact-3BC234129E875B5891EA667CAB9217B1"
      unitRef="usd">63895000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e712-wk-Fact-CE06CB6A565853BCB452202AD1B852A2"
      unitRef="usd">9582000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e731-wk-Fact-F85CEDD8C8B151E5AC969C63012B8189"
      unitRef="usd">7799000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e751-wk-Fact-F917255C50D85B37AE0D89B210210C49"
      unitRef="usd">10421000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e771-wk-Fact-838C560380CB55718FC670E30176ABE3"
      unitRef="usd">8136000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e834-wk-Fact-FB611C18F1565CC2A08BAC1220C6A9AE"
      unitRef="usd">-2008000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e853-wk-Fact-F6A882D16FD05CA99B232F321682BAAA"
      unitRef="usd">16179000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e874-wk-Fact-334AC6E8E72758C4ADE8B35486D58BCD"
      unitRef="usd">2339000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e894-wk-Fact-A96D5BD742F158838B0C0216AF69ECF0"
      unitRef="usd">2570000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e915-wk-Fact-FFDEFCDF517D5E018BBAB60018898DBB"
      unitRef="usd">-18127000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e934-wk-Fact-F9BB4AFA211E529BB0FF29369A492BD2"
      unitRef="usd">22087000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e955-wk-Fact-34C6600EFFA65763A04300E92A947713"
      unitRef="usd">16109000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e974-wk-Fact-000C0CF9D6F55FECBAD8262AFE2A03C2"
      unitRef="usd">2611000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e994-wk-Fact-ED3B34C4B6F55373AA84A137BEF2FA37"
      unitRef="usd">13164000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e1013-wk-Fact-14BD1F10905250A49857CBD8EF4EFD16"
      unitRef="usd">19659000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e1033-wk-Fact-C34F14BC11175744AB543A4E6497A0D6"
      unitRef="usd">10019000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e1052-wk-Fact-FE2E63C5737D5A219CA4BB69A9B64DE0"
      unitRef="usd">26603000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e1072-wk-Fact-1D7EC5A95AA95CF39084C20853523AEF"
      unitRef="usd">-9465000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e1092-wk-Fact-D6CB98B2133C5B16A38BC851F5796880"
      unitRef="usd">-10931000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e1113-wk-Fact-FE068176AE2D5A3E908BAFB841486D8F"
      unitRef="usd">11932000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e1132-wk-Fact-CDCD1E92E8C15DA79DE34E46A644C287"
      unitRef="usd">5104000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e1157-wk-Fact-8155047C6E535DF4B3C6833AAFEA4E82"
      unitRef="usd">-203458000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e1177-wk-Fact-C8A9638096FB5476B3F33448BAD63B8E"
      unitRef="usd">835764000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e1233-wk-Fact-3BF9113144855AEE86D9E97A1314E623"
      unitRef="usd">1028883000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e1253-wk-Fact-74A6CBDF5F1255A9AFDFE74117DCD58B"
      unitRef="usd">1944178000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e1275-wk-Fact-7AABCE1BEB5E5367856075C8FD344826"
      unitRef="usd">1122902000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e1294-wk-Fact-8C079234461B5C64B91863539C87EFF4"
      unitRef="usd">467658000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e1314-wk-Fact-26ED553E8D36563EAC8CA5D45436AB3B"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e1333-wk-Fact-8D05DD808FE4505890C549F59C59D6AF"
      unitRef="usd">11963000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e1353-wk-Fact-5E1D9B86CB4D58F590206C38DDD6C90C"
      unitRef="usd">22614000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e1373-wk-Fact-A23D09F3C0E35F36B0C5F947624F70FA"
      unitRef="usd">5552000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e1394-wk-Fact-BADC636209AD568F83548A4E7CD9FECC"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e1413-wk-Fact-39C3DAF22F17559CB5077609175DF1E5"
      unitRef="usd">2633000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e1438-wk-Fact-FE92A87BD60B5147AE57ED4CDB208E3A"
      unitRef="usd">71405000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e1457-wk-Fact-74BD4D36F8F158ACBB06E6EE5A65B575"
      unitRef="usd">-1467476000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e1514-wk-Fact-E1F6B23408E55A5C8013B4A37CF65ABB"
      unitRef="usd">0</nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e1533-wk-Fact-88EBE07AFAC254F19551C24BA75E0533"
      unitRef="usd">790231000</nktr:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e1553-wk-Fact-30F702F0C9A9541EA577CA8978A68705"
      unitRef="usd">18449000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e1572-wk-Fact-F5C28F62628A55BC9D216B08718D4016"
      unitRef="usd">59067000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e1597-wk-Fact-AB48D4722C17547CA9CF801184D5DDC7"
      unitRef="usd">18449000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e1616-wk-Fact-3FBA5CC68E2256B9864F4E87AFD47958"
      unitRef="usd">849298000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e1631-wk-Fact-3CCDCA85E1FB57F79AA08D2597659E60"
      unitRef="usd">-77000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e1651-wk-Fact-5D422788DEC25542B4DAC6AB7CE2F356"
      unitRef="usd">-87000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e1677-wk-Fact-E85E3C5F14EC59539D4C72A52FA68AF7"
      unitRef="usd">-113681000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e1697-wk-Fact-905A02AD6B8A5903A10F6E6F05AD84A6"
      unitRef="usd">217499000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103434252e1713-wk-Fact-5DBAF7AD834C50418F1605E1820A2C56"
      unitRef="usd">194905000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2017Q4"
      decimals="-3"
      id="d103434252e1732-wk-Fact-EB6571B361DE5BA79BC94F06D047001B"
      unitRef="usd">4762000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103434252e1757-wk-Fact-8FDF80523DC7573BA5267FF6D33529BD"
      unitRef="usd">81224000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q3"
      decimals="-3"
      id="d103434252e1776-wk-Fact-F682FB2FC7C151E0A4657211F14CF402"
      unitRef="usd">222261000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e1837-wk-Fact-1CB5FBC8391E5EC3B7D0EB6655C10693"
      unitRef="usd">14229000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e1856-wk-Fact-0CD9A21F3C315F6F8B29FEADD49BAC41"
      unitRef="usd">14701000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103434252e1876-wk-Fact-1AD12742B8FAF4B4E9BE42504430ECB4"
      unitRef="usd">56025000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103434252e1895-wk-Fact-4045D05D733B3F00D1864250447892C1"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-9F10E181172155F081E82E7D18805DD2-0-wk-Fact-BE3B4B882A8357D4815343ACD8A7ADF8">Organization and Summary of Significant Accounting Policies&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes treatments for cancer, autoimmune disease and chronic pain.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we had approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in cash and investments in marketable securities and debt of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$250.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in principal of senior secured notes due in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our consolidated financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries:  Inheris Biopharma, Inc., Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#x2019; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our comprehensive income (loss) consists of our net income (loss) plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities, neither of which were significant during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In addition, there were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; filed with the SEC on March 1, 2019. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We operate in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; business segment by our Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Significant Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones, other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, our accounts receivable includes &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$27.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$24.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, for net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS). &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On January 1, 2019, we adopted Accounting Standards Codification (ASC) 842, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (ASC 842). ASC 842 supersedes the guidance in ASC 840, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (ASC 840). Under ASC 842, an entity recognizes a right-of-use asset and a corresponding lease liability, measured as the present value of the lease payments. In our adoption, we used the package of practical expedients, which, among other things, allowed us to carry forward our historical lease classification of those leases in effect as of January 1, 2019. We present results for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; under ASC 842. We have not restated the results for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and our financial position as of December 31, 2018, and continue to report them under ASC 840.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. However, in determining the present value of our lease payments for leases in effect when we adopted ASC 842, we used our incremental borrowing rate as of January 1, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our real estate leases, and elected the short-term lease recognition exemption for our short-term leases, which allows us not to recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts. For leases in effect as of January 1, 2019, we recognized our lease incentives as part of our transition adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As a result of our adoption of ASC 842, we recorded right-of-use assets of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$83.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and lease liabilities of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$96.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for our facilities operating leases, with &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; effect on our opening balance of accumulated deficit. Please see Note 4 for additional information regarding our leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#x2019; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#x2019;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Royalty Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Generally, we are entitled to royalties from our collaboration partners based on the net sales of their approved drugs that are marketed and sold in one or more countries where we hold royalty rights. For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;License, Collaboration and other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;License Grants&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&#160;For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Milestone Payments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&#160;At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;a clinical study or filing for or receipt of regulatory approval, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. Our partners generally pay development milestones&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;subsequent to&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;achievement of the triggering event.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and Development Services&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a clinical joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined to be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#x2019;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we recorded an income tax provision for our Nektar India operations at an effective tax rate of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Due to our net loss and unrealized gain on available-for-sale securities in the nine months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we recorded a tax provision against such unrealized gain with an offsetting tax benefit in continuing operations of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. For the three months ended September 30, 2019, however, since we had a loss on our available-for-sale securities, we recorded a benefit of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; against our unrealized loss in available-for-sale securities with an offsetting expense in continuing operations. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the nine months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, as a result of taxable income in India and the U.S., resulting primarily from income recognized from the upfront payment from BMS, we recorded a global income tax provision at an effective tax rate of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.4%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The income tax benefit for the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reflects our pre-tax loss for that period. Our income resulted in tax liabilities in certain states where we did not have sufficient net operating losses to offset our estimated apportioned taxable income. Our effective tax rate was based on certain assumptions and other estimates regarding the apportionment of taxable income and the states in which we had nexus in 2018. Our apportionment of taxable income included estimates of the apportionment of the BMS upfront payment based on estimates of activities to be carried out under the collaboration agreement with BMS, as well as estimates of the apportionment of other sources of income. Our effective tax rate reflected the release of the valuation allowance of net operating loss carryforwards and other tax credits to offset U.S. federal and state taxable income. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is effective in the first quarter of 2020 and should be applied retrospectively to January 1, 2018, when we adopted ASC 606. Early adoption is permitted. We are evaluating the effect of adoption, but we do not expect a material effect on our revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the FASB issued ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#x201c;incurred loss&#x201d; model with an &#x201c;expected loss&#x201d; model. Accordingly, we will present these financial assets at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. ASU 2016-13 is effective in the first quarter of 2020. Early adoption is permitted. We are currently evaluating the impact of adoption of this ASU, but we do not anticipate that adoption will have a material effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <nktr:OrganizationPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-41B1447C37BD50E790B98EF5435826C4-0-wk-Fact-580B7C6DAE105FB49B643D9D9131733A">&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes treatments for cancer, autoimmune disease and chronic pain.&lt;/span&gt;&lt;/div&gt;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</nktr:OrganizationPolicyTextBlock>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="FI2019Q3"
      decimals="-8"
      id="d103434634e376-wk-Fact-874CA20948255B3FA3DDADAF3CC44BA5"
      unitRef="usd">1700000000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:SeniorNotes
      contextRef="FI2019Q3"
      decimals="-5"
      id="d103434634e380-wk-Fact-DA055AF3B6A658AE91A44C5F4073DE16"
      unitRef="usd">250000000.0</us-gaap:SeniorNotes>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-9B467C3B9E1D5C6E8C58E9CA9194E3C3-0-wk-Fact-546AB5A36E355CB9BD5545BABF32A9AE">&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our consolidated financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries:  Inheris Biopharma, Inc., Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#x2019; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our comprehensive income (loss) consists of our net income (loss) plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities, neither of which were significant during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In addition, there were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; filed with the SEC on March 1, 2019. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="FD2019Q3YTD"
      id="TextSelection-04AF13CBF1925D75A2910A32CC997337-0-wk-Fact-F136220799515852ADB8515F8A39E7DA">&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-6B92C60D8D185E90AF6BDCC4D193576F-0-wk-Fact-88CD074AF4BD5418BE65C2527C4EA426">&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We operate in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; business segment by our Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d103434634e476-wk-Fact-E2E68A2CBE8F5220B3B1ADDE3571CA61"
      unitRef="U_nktrSegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d103434634e480-wk-Fact-E2E68A2CBE8F5220B3B1ADDE3571CA61"
      unitRef="U_nktrSegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="FD2019Q3YTD"
      id="TextSelection-682F12D598E15647AB35EF0280D925FF-0-wk-Fact-169774DFD9E85C0BB39B816FDB4420D2">&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Significant Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones, other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, our accounts receivable includes &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$27.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$24.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, for net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS). &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q3_srt_CounterpartyNameAxis_nktr_CollaborationPartnerMember"
      decimals="-5"
      id="d103434634e502-wk-Fact-3DC0219196A65CF29AEA8E8D49BEF29C"
      unitRef="usd">27700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2018Q4_srt_CounterpartyNameAxis_nktr_CollaborationPartnerMember"
      decimals="-5"
      id="d103434634e506-wk-Fact-E9B861B8067B58BABC4CAF4AFAFB3127"
      unitRef="usd">24200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-965090F40245504B8199C57DBFF72EFE-0-wk-Fact-890AF05245A95C34A174C36F023BD747">&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On January 1, 2019, we adopted Accounting Standards Codification (ASC) 842, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (ASC 842). ASC 842 supersedes the guidance in ASC 840, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (ASC 840). Under ASC 842, an entity recognizes a right-of-use asset and a corresponding lease liability, measured as the present value of the lease payments. In our adoption, we used the package of practical expedients, which, among other things, allowed us to carry forward our historical lease classification of those leases in effect as of January 1, 2019. We present results for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; under ASC 842. We have not restated the results for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and our financial position as of December 31, 2018, and continue to report them under ASC 840.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We determine if an arrangement contains a lease at the inception of the arrangement. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. We recognize operating lease right-of-use assets and liabilities at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date. However, in determining the present value of our lease payments for leases in effect when we adopted ASC 842, we used our incremental borrowing rate as of January 1, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We elected the practical expedient to account for the lease and non-lease components, such as common area maintenance charges, as a single lease component for our real estate leases, and elected the short-term lease recognition exemption for our short-term leases, which allows us not to recognize lease liabilities and right-of-use assets for leases with an original term of twelve months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise any such options. We recognize lease expense for our operating leases on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/div&gt;We have elected to recognize lease incentives, such as tenant improvement allowances, at the lease commencement date as a reduction of the right-of-use asset and lease liability until paid to us by the lessor to the extent that the lease provides a specified fixed or maximum level of reimbursement and we are reasonably certain to incur reimbursable costs at least equaling such amounts. For leases in effect as of January 1, 2019, we recognized our lease incentives as part of our transition adjustment.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="d103434634e567-wk-Fact-5C187D19796574065CA222E16FA392ED"
      unitRef="usd">83500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="d103434634e571-wk-Fact-843518803F3FAA95112D22E1AA321B74"
      unitRef="usd">96200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1
      contextRef="D2019Q1Jan1-Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="INF"
      id="d103434634e575-wk-Fact-7519867B8CBEFAF2BD5423ED7409E613"
      unitRef="usd">0</us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="FD2019Q3YTD"
      id="TextSelection-FD8CF47F19F054068F966E87407AFE39-0-wk-Fact-F74B435CA8875637B94E2C9DFD7860A5">&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#x2019; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-9FA6AF816D2E505C912EEB43978588E8-0-wk-Fact-A91CEEFEC6BB54E6B8063093D0C53FDD">&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#x2019;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Royalty Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Generally, we are entitled to royalties from our collaboration partners based on the net sales of their approved drugs that are marketed and sold in one or more countries where we hold royalty rights. For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;License, Collaboration and other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;License Grants&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&#160;For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Milestone Payments&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&#160;At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;a clinical study or filing for or receipt of regulatory approval, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. Our partners generally pay development milestones&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;subsequent to&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;achievement of the triggering event.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and Development Services&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="FD2019Q3YTD"
      id="TextSelection-D562C6FC70A15B1CA23FE285D4CB883C-0-wk-Fact-4A2FCF1A6D7655E59044C25B3B270966">&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a clinical joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined to be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#x2019;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-E3D24D29990850B3B283F2CF9605548F-0-wk-Fact-247824AB65E05E8A86D5A5875484D9EB">&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we recorded an income tax provision for our Nektar India operations at an effective tax rate of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Due to our net loss and unrealized gain on available-for-sale securities in the nine months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we recorded a tax provision against such unrealized gain with an offsetting tax benefit in continuing operations of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. For the three months ended September 30, 2019, however, since we had a loss on our available-for-sale securities, we recorded a benefit of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; against our unrealized loss in available-for-sale securities with an offsetting expense in continuing operations. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q3YTD_srt_StatementGeographicalAxis_country_IN"
      decimals="2"
      id="d103434634e705-wk-Fact-812330CC110755E5BE87422BDFC1128D"
      unitRef="number">0.33</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d103434634e713-wk-Fact-415803F94B8856AA8A621A12A6FC5561"
      unitRef="usd">1300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d103434634e718-wk-Fact-8264B6782CC0450A7EB51986A15F286D"
      unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2018Q3YTD"
      decimals="3"
      id="d103434634e731-wk-Fact-383B1D05F26C50ACB1215E7FE25CA54E"
      unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-390FCB32C82A5A6C86DC6394905DC0B6-0-wk-Fact-9EE86353D1825AA8B538FE60AC7843AB">&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is effective in the first quarter of 2020 and should be applied retrospectively to January 1, 2018, when we adopted ASC 606. Early adoption is permitted. We are evaluating the effect of adoption, but we do not expect a material effect on our revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the FASB issued ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#x201c;incurred loss&#x201d; model with an &#x201c;expected loss&#x201d; model. Accordingly, we will present these financial assets at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. ASU 2016-13 is effective in the first quarter of 2020. Early adoption is permitted. We are currently evaluating the impact of adoption of this ASU, but we do not anticipate that adoption will have a material effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-3592237DF8FF555A9324FCCD34254E8D-0-wk-Fact-C44B908FDD9650BCA339BB55F9BDAA78">Cash and Investments in Marketable Securities&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;81,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;194,905&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,414,448&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,140,445&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;231,082&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;582,889&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,726,754&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,918,239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, all of our long-term investments had maturities between &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross unrealized gains and losses were not significant at either &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we sold &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; available-for-sale securities. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we sold available-for-sale securities totaling&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and  gross realized gains and losses on those &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; sales were not significant.&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Under the terms of our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.75%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; senior secured notes due &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we are required to maintain a minimum cash and investments in marketable securities balance of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$60.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,163,575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,288,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;482,468&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;498,048&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,646,043&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,800,011&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45,674&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;105,656&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificate of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,871&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,760&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28,166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,812&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,726,754&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,918,239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;____________________________&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:84px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Level&#160;1&#160;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:84px;text-indent:-84px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:84px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Level&#160;2&#160;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:84px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:84px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We use a market approach to value our Level 2 investments. The disclosed fair value related to our investments is based on market prices from a variety of industry standard data providers and generally represents quoted prices for similar assets in active markets or has been derived from observable market data. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:84px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:84px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; transfers between Level 1 and Level 2 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:84px;text-indent:-84px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:84px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Level&#160;3&#160;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Additionally, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, based on a discounted cash flow analysis using Level 3 inputs including financial discount rates, we believe the fair value of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$250.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in principal amount of our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7.75%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; senior secured notes due &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;October 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$252.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. We may redeem some or all of these notes at a redemption price equal to the principal amount of the notes plus accrued and unpaid interest to the redemption date.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-77E59C22B45855EA8C324B7EDB0AB223-0-wk-Fact-EDB879DAE35C5F5B989F1222FFA37BCC">&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;81,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;194,905&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,414,448&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,140,445&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;231,082&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;582,889&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,726,754&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,918,239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103443569e473-wk-Fact-C7A2AE7C68775A439814DA049308CCE0"
      unitRef="usd">81224000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103443569e492-wk-Fact-0A046CD4CFDD5C44AB78FE4E6C5314BD"
      unitRef="usd">194905000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103443569e507-wk-Fact-0AEF18E786665F2FAEBCBCB3D5386580"
      unitRef="usd">1414448000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103443569e526-wk-Fact-D62AACC5E6A9595AA4AC531814DAB31B"
      unitRef="usd">1140445000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103443569e546-wk-Fact-0D4AE566CE7B54188DDCDEB656199CE3"
      unitRef="usd">231082000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103443569e565-wk-Fact-326539B35D8A5187AE1F3CF50F026C2B"
      unitRef="usd">582889000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103443569e590-wk-Fact-452068453D9854C3A344E31FEA012C2C"
      unitRef="usd">1726754000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103443569e609-wk-Fact-BC24C8C3E6CB5CDD97DFE80E883AC03B"
      unitRef="usd">1918239000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember"
      id="d103443569e633-wk-Fact-54B56E3EC0E552E391CD042272F07229">P2Y</nktr:LongTermInvestmentMaturityPeriod>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103443569e661-wk-Fact-EDD865A6822A5D0DA3A0A430EE25EBBE"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d103443569e673-wk-Fact-35E565DFCA33574A83F4A171CC060DA0"
      unitRef="usd">12000000.0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2015Q4Oct5_us-gaap_DebtInstrumentAxis_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d103443569e684-wk-Fact-C747187FE4075737A0C77A757CC065AB"
      unitRef="number">0.0775</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <nktr:MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained
      contextRef="I2015Q4Oct5_us-gaap_DebtInstrumentAxis_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d103443569e692-wk-Fact-2502601DF59758C88DED2B4948938804"
      unitRef="usd">60000000.0</nktr:MinimumCashAndInvestmentsInMarketableSecuritiesToBeMaintained>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-693315B671E55D158B9A10FC0C1BFE1A-0-wk-Fact-510731A5AE4B5C3C8EEBE3E0A6B027ED">&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,163,575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,288,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;482,468&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;498,048&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Obligations of U.S. government agencies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,646,043&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,800,011&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45,674&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;105,656&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Certificate of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,871&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,760&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;N/A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28,166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,812&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,726,754&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,918,239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d103443569e849-wk-Fact-C4DEA3487976526CBF8B57CACFA41208"
      unitRef="usd">1163575000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d103443569e868-wk-Fact-578814FE32865973943583F6DE0CFA5F"
      unitRef="usd">1288986000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d103443569e893-wk-Fact-B6B8E77E09C25EC6AB028617608B8531"
      unitRef="usd">482468000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d103443569e912-wk-Fact-2890B0589C675C4292AD933AEDD49963"
      unitRef="usd">498048000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d103443569e942-wk-Fact-C90B144A80615D0BBDD8413BA7505171"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="d103443569e961-wk-Fact-CC653838F4065AF891B90490D6AD82EB"
      unitRef="usd">12977000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103443569e991-wk-Fact-4D582123064C5C1BB4908253D108A499"
      unitRef="usd">1646043000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103443569e1010-wk-Fact-060C748118A05634A54DDA9E0AB061D4"
      unitRef="usd">1800011000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d103443569e1040-wk-Fact-D180B1300ABD5654A115E1907ACF69C5"
      unitRef="usd">45674000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d103443569e1059-wk-Fact-1C0803938E5D5BA9AF966C2C078A97A5"
      unitRef="usd">105656000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d103443569e1089-wk-Fact-57009B04F7E65B4DB21FF8CC0DA6691A"
      unitRef="usd">6871000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d103443569e1108-wk-Fact-88090A1967EB518292A8F4CA17199479"
      unitRef="usd">6760000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:Cash
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103443569e1138-wk-Fact-3258BF2B60BC5FBB9DF50CFF657DD474"
      unitRef="usd">28166000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103443569e1157-wk-Fact-3A4507E3EC105EA690067B38AB5E175F"
      unitRef="usd">5812000</us-gaap:Cash>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103443569e1192-wk-Fact-452068453D9854C3A344E31FEA012C2C"
      unitRef="usd">1726754000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103443569e1211-wk-Fact-BC24C8C3E6CB5CDD97DFE80E883AC03B"
      unitRef="usd">1918239000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="FI2019Q3"
      decimals="INF"
      id="d103443569e1266-wk-Fact-AD8E00F6814C57708C4F385FB1153096"
      unitRef="usd">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:SeniorNotes
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-5"
      id="d103443569e1286-wk-Fact-2E52C9AF45265AA7A4FA0FD8998C6248"
      unitRef="usd">250000000.0</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d103443569e1290-wk-Fact-0EFEA024259A5F32B12116BFED63536D"
      unitRef="number">0.0775</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-5"
      id="d103443569e1298-wk-Fact-30030661BAA05A9C8AA2F945CA59F815"
      unitRef="usd">252500000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-C3C7CCBEA9F554589F0EF07A8310C415-0-wk-Fact-AB930819968754D882F414F40751A274">Inventory&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,846&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,961&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,173&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,132&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,720&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,381&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased. Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-E620C21816F2526FBDBDDB0A51935D81-0-wk-Fact-31042DCB06C950789E1F2A4F571ECBDA">&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,846&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,961&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,173&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,132&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13,720&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,381&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103456137e433-wk-Fact-8C17B3DE2C4B5039B91373D1C61F8A83"
      unitRef="usd">1586000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103456137e452-wk-Fact-4371DF8B88085AFEBB352CDEE956E9B3"
      unitRef="usd">1846000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103456137e467-wk-Fact-B53AD903DF40589C983E4EC254D7ACEC"
      unitRef="usd">7961000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103456137e486-wk-Fact-D3E285C1776E582B88C9267973DB9B32"
      unitRef="usd">6403000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103456137e506-wk-Fact-5EE919FAF3ED51AC9B34F615CD20ACEE"
      unitRef="usd">4173000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103456137e525-wk-Fact-9CBC70D89D3F59C08DE240ECF986A900"
      unitRef="usd">3132000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103456137e550-wk-Fact-D3F1F8DC7AB6516098B11FCDFB3E6D69"
      unitRef="usd">13720000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103456137e569-wk-Fact-59492ABDF60153D4BA438B78B7470CB8"
      unitRef="usd">11381000</us-gaap:InventoryNet>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-FC18D540BE0955ABAB41C5B954E9B767-0-wk-Fact-A9F3A57B280858258B2499F2D70E99A0">nventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-EE714ED2BE2F50249C54A8D80A3A67E4-0-wk-Fact-8C9C421130195E47B87AE7E349E64947">Leases&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In August 2017, we entered into a Lease Agreement (the Mission Bay Lease) with ARE-San Francisco No. &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;19&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, LLC (ARE) and terminated our sublease with Pfizer, Inc., effectively extending our lease term from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2030&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for our &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;145,085&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square foot corporate office and R&amp;amp;D facility located at 455 Mission Bay Boulevard, San Francisco, California (the Mission Bay Facility). The term of the Mission Bay Lease commenced on &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;1, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and will expire on &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;January&#160;31, 2030&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, subject to our right to extend the term of the lease for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consecutive &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;five&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year periods, which we have excluded from our determination of the lease term. The monthly base rent for the Mission Bay Facility will escalate over the term of the lease at various intervals. During the term of the Mission Bay Lease, we are responsible for paying our share of operating expenses specified in the lease, including utilities, common area maintenance, insurance and taxes. The Mission Bay Lease also obligates us to rent from ARE a total of an additional approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet of space at the Mission Bay Facility. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, ARE delivered &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,729&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet of space, and therefore we recognized right-of-use assets and lease liabilities of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the space. The Mission Bay Lease includes various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2018, we entered into a Lease Agreement (the Third Street Lease) with Kilroy Realty Finance Partnership, L.P. (Kilroy) to lease &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;135,936&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet of space located at 360 Third Street, San Francisco, California (the Third Street Facility) from June 2018 to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;January&#160;31, 2030&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, subject to our right to extend the term for a consecutive &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;five&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;-year period, which we have excluded from our determination of the lease term. Kilroy delivered an initial &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,726&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet in June 2018, a total of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;67,105&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; additional spaces in December 2018, and the final &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;67,105&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; square feet for four spaces in August 2019. As a result of the delivery of the final spaces during the nine months ended September 30, 2019, we recognized an additional right-of-use asset and lease liability of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$51.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Third Street Lease provides us additional facilities to support our San Francisco-based R&amp;amp;D activities. Our fixed monthly base rent on an industrial gross lease basis includes certain expenses and property taxes paid directly by the landlord and will escalate each year over the term at specified intervals. We have a one-time right of first offer with respect to certain additional rental space at the Third Street Facility. The Third Street Lease includes various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for lease transactions of this nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The components of lease costs, which we include in operating expenses in our Condensed Consolidated Statements of Operations, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80842911877394%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,927&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,030&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,651&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,485&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,096&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,539&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,569&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we paid &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for amounts included in the measurement of lease liabilities, which we include in net cash provided by (used in) operating activities in our Condensed Consolidated Statement of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the maturities of our operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:88%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Year ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Times_New_Roman;font-size:10pt;"&gt;2019 (Three months ended)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,026&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,633&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,899&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2025 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;116,881&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;214,379&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: portion representing interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(56,621&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: lease incentives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,341&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;154,417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9,318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;145,099&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the weighted-average remaining lease term is &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10.3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and the weighted-average discount rate used to determine the operating lease liability was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.9%&lt;/span&gt;&lt;/span&gt;.</us-gaap:LesseeOperatingLeasesTextBlock>
    <nktr:AreaOfLeasedSpace
      contextRef="I2017Q3Aug31_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember"
      decimals="0"
      id="d103440843e373-wk-Fact-008C65BF8D075B55AEF8B097DC044382"
      unitRef="sqft">145085</nktr:AreaOfLeasedSpace>
    <nktr:NumberOfConsecutiveFiveYearTermsToExtendLease
      contextRef="D2017Q3Aug01-Aug31_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember"
      decimals="INF"
      id="d103440843e386-wk-Fact-881048915EAF570B8699A110BF53E6D0"
      unitRef="extension_period">2</nktr:NumberOfConsecutiveFiveYearTermsToExtendLease>
    <nktr:AdditionalSpaceRequiredToBeLeasedInFuture
      contextRef="I2017Q3Aug31_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember"
      decimals="-3"
      id="d103440843e394-wk-Fact-C70CF1BDD37C5AEE8371A706ADFE963C"
      unitRef="sqft">8000</nktr:AdditionalSpaceRequiredToBeLeasedInFuture>
    <nktr:AreaOfLeasedSpace
      contextRef="FI2019Q3_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember"
      decimals="0"
      id="d103440843e407-wk-Fact-B7908C13394B53A4A0A8932C9420F583"
      unitRef="sqft">10729</nktr:AreaOfLeasedSpace>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2019Q3YTD_srt_CounterpartyNameAxis_nktr_ARESanFranciscoNumberOneNineLLCMember_us-gaap_LeaseArrangementTypeAxis_nktr_MissionBayLeaseMember"
      decimals="-5"
      id="d103440843e411-wk-Fact-F47A040E17685F49B1E9C6EFF5E9EFFF"
      unitRef="usd">5000000.0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <nktr:AreaOfLeasedSpace
      contextRef="I2018Q2May31_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember"
      decimals="0"
      id="d103440843e418-wk-Fact-6B83716C9F86548DB279E6A56CAC0F2F"
      unitRef="sqft">135936</nktr:AreaOfLeasedSpace>
    <nktr:AreaOfLeasedSpace
      contextRef="FI2018Q2_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember"
      decimals="0"
      id="d103440843e430-wk-Fact-3AEC16750D2051F68DD8DFC231721B3D"
      unitRef="sqft">1726</nktr:AreaOfLeasedSpace>
    <nktr:AreaOfLeasedSpace
      contextRef="FI2018Q4_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember"
      decimals="0"
      id="d103440843e434-wk-Fact-CD744E2EEF6D5E9BB316143029EFFB03"
      unitRef="sqft">67105</nktr:AreaOfLeasedSpace>
    <nktr:NumberOfLeasedSpacesDelivered
      contextRef="D2018Q4Dec1-Dec31_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember"
      decimals="INF"
      id="d103440843e439-wk-Fact-3F12AE63FDCD53C4A18B37112104ABCF"
      unitRef="space">2</nktr:NumberOfLeasedSpacesDelivered>
    <nktr:AreaOfLeasedSpace
      contextRef="I2019Q3Aug31_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember"
      decimals="0"
      id="d103440843e443-wk-Fact-63230AED80CB37233214239723E714C3"
      unitRef="sqft">67105</nktr:AreaOfLeasedSpace>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2019Q3YTD_srt_CounterpartyNameAxis_nktr_KilroyRealtyFinancePartnershipLPMember_us-gaap_LeaseArrangementTypeAxis_nktr_ThirdStreetLeaseMember"
      decimals="-5"
      id="d103440843e447-wk-Fact-285D09B136852E2BC27F2398A8B5E8FA"
      unitRef="usd">51000000.0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-DD6EA6A203F35E99B03B7BFCC4757768-0-wk-Fact-5777A52251A559A29F22ACDCABB9B0C3">&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The components of lease costs, which we include in operating expenses in our Condensed Consolidated Statements of Operations, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80842911877394%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,927&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,030&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,651&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,485&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,096&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,539&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,569&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103440843e656-wk-Fact-5962E9FB825F5FD68503ECB1E1E081B7"
      unitRef="usd">4116000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103440843e675-wk-Fact-7F7764E1040652829496577575856B71"
      unitRef="usd">1927000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103440843e694-wk-Fact-EDB4BCA820EE5A3291A60DCA1C469788"
      unitRef="usd">10030000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103440843e714-wk-Fact-1AACE147EAA853D0AE76241409FB807F"
      unitRef="usd">5651000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103440843e729-wk-Fact-3FDAFB0917ED5CF581D7038EF66C01A6"
      unitRef="usd">1485000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103440843e748-wk-Fact-F6B3B80738BC5D28B2E411FEACF4B1CF"
      unitRef="usd">1096000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103440843e767-wk-Fact-3C9517648E5B544AA09FE2C3F8B621E0"
      unitRef="usd">4539000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103440843e787-wk-Fact-42531FA67F1B5C4CA67CC5C822B019B6"
      unitRef="usd">3371000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103440843e812-wk-Fact-C0A5E2A13CF6530E9F003066ED480188"
      unitRef="usd">5601000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103440843e831-wk-Fact-734F048FD1FE54F2964D29C2D8E7D9D3"
      unitRef="usd">3023000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103440843e850-wk-Fact-7C0D117FE2855F25BB0CDFF860D53776"
      unitRef="usd">14569000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103440843e870-wk-Fact-58B94252FA8558419A0A7BF9C3995F6D"
      unitRef="usd">9022000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d103440843e890-wk-Fact-E748631121585B86AD96285AEBF58721"
      unitRef="usd">5100000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-8C893C1C71B759FAA5D0CF6C70DD38BA-0-wk-Fact-D63C5CA1104B5BDA93EA980EEB5F928D">&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the maturities of our operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:88%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Year ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Times_New_Roman;font-size:10pt;"&gt;2019 (Three months ended)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,400&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,026&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,633&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,899&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2025 and thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;116,881&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;214,379&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: portion representing interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(56,621&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: lease incentives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3,341&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;154,417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9,318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;145,099&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103440843e949-wk-Fact-4857ACA474A55146ABFC2935C0129749"
      unitRef="usd">2400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103440843e964-wk-Fact-56DD175A00355961B599A217199CC69B"
      unitRef="usd">15283000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103440843e984-wk-Fact-A235C401ECD95479A78B6B8482C3FCEF"
      unitRef="usd">19026000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103440843e1004-wk-Fact-776A34B72EF65269AF2E7587B43D2666"
      unitRef="usd">19633000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103440843e1024-wk-Fact-75FD17CF06F75FB58EDCECA15517D206"
      unitRef="usd">20257000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <nktr:LesseeOperatingLeaseLiabilityPaymentsDueYearSix
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103440843e1044-wk-Fact-967E2CD90AED5930B42B7106D70F83B7"
      unitRef="usd">20899000</nktr:LesseeOperatingLeaseLiabilityPaymentsDueYearSix>
    <nktr:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103440843e1064-wk-Fact-977C4B7863CE5907B1FDA70E1357FDE6"
      unitRef="usd">116881000</nktr:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103440843e1084-wk-Fact-9D2B53C824805F7EABD7F58189C71A52"
      unitRef="usd">214379000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103440843e1104-wk-Fact-333505C2379457AAA97191E24EDE0E64"
      unitRef="usd">56621000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <nktr:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103440843e1125-wk-Fact-E52953FAB1B15E58A3AC9AC61A0D4429"
      unitRef="usd">3341000</nktr:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103440843e1147-wk-Fact-B0A07921E12252CE9DD043CB2188E81B"
      unitRef="usd">154417000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103440843e1167-wk-Fact-9DF62218E4F95D648FC7684BADFBFC0A"
      unitRef="usd">9318000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103440843e1193-wk-Fact-4DC14A4ACA6254F9876DFB66F2EAAF81"
      unitRef="usd">145099000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="FI2019Q3"
      id="d103440843e1209-wk-Fact-0AF0B2D52CA45A0090A6279E63B6AFFC">P10Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2019Q3"
      decimals="3"
      id="d103440843e1213-wk-Fact-26B9302C971A5BDF90946A3100B42D5F"
      unitRef="number">0.059</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-DD0137CEB54F50E5A3DA2AA225D426B8-0-wk-Fact-FC85B41CAD6F5B37800B2B4AD10C92B5">Liability Related to Sale of Future Royalties&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On February&#160;24, 2012, we entered into a Purchase and Sale Agreement (the Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the Royalty Entitlement) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$124.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the Royalty Entitlement.&#160;As part of this sale, we incurred approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$4.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in transaction costs, which are amortized to interest expense over the estimated life of the Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from the CIMZIA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and MIRCERA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$124.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in proceeds from this transaction as a liability (Royalty Obligation) that is amortized using the interest method over the estimated life of the Purchase and Sale Agreement as royalties from the CIMZIA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and MIRCERA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; products are remitted directly to RPI. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we recognized &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$27.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$24.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, in non-cash royalty revenue from net sales of CIMZIA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and MIRCERA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and we recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$17.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$14.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, of related non-cash interest expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We periodically assess the estimated royalty payments to RPI from UCB and Roche, and, to the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different from our original estimates, we will prospectively adjust the amortization of the Royalty Obligation. From inception through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, our estimate of the total interest expense on the Royalty Obligation resulted in an effective annual interest rate of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. During the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, our estimate of the effective annual interest rate over the life of the agreement increased to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.6%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which resulted in a prospective interest rate of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&#160;&#160;During the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, primarily &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;as a result of increases in the forecasted sales of MIRCERA&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, our estimate of the effective annual interest rate over the life of the agreement increased to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.7%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which results in a prospective interest rate of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Purchase and Sale Agreement grants RPI the right to receive certain reports and other information relating to the Royalty Entitlement and contains other representations and warranties, covenants and indemnification obligations that are customary for a transaction of this nature. To our knowledge, we are currently in compliance with these provisions of the Purchase and Sale Agreement; however, if we were to breach our obligations, we could be required to pay damages to RPI that are not limited to the purchase price we received in the sale transaction.&lt;/span&gt;&lt;/div&gt;</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="D2012Q1Feb23-Feb24_us-gaap_TypeOfArrangementAxis_nktr_PurchaseAndSaleAgreementMember"
      decimals="-5"
      id="d103442172e369-wk-Fact-B9FE5E408E0B53E993840FA707CC6443"
      unitRef="usd">124000000.0</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="I2012Q1Feb24_us-gaap_TypeOfArrangementAxis_nktr_PurchaseAndSaleAgreementMember"
      decimals="-5"
      id="d103442172e373-wk-Fact-4612CBCEDC845D16979AB281456671F2"
      unitRef="usd">4400000</us-gaap:DeferredFinanceCostsGross>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="D2012Q1Feb23-Feb24_us-gaap_TypeOfArrangementAxis_nktr_PurchaseAndSaleAgreementMember"
      decimals="-5"
      id="d103442172e386-wk-Fact-B9FE5E408E0B53E993840FA707CC6443"
      unitRef="usd">124000000.0</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d103442172e411-wk-Fact-CECA3421CBAA5EFA9ED156A9DB12AEE0"
      unitRef="usd">27600000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d103442172e415-wk-Fact-88D8E1E2AE975C8288293F1DF1579747"
      unitRef="usd">24300000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d103442172e428-wk-Fact-FD5B6128CF1152C681F230977954AE2C"
      unitRef="usd">17900000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d103442172e432-wk-Fact-7DE8976D395D56E69482BA4F1E5675E0"
      unitRef="usd">14800000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-D25874D9328E5A1E9C0FC77EF5C500F0-0-wk-Fact-6A2D74E99AE3581995CC976FE13AAED6">We periodically assess the estimated royalty payments to RPI from UCB and Roche, and, to the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different from our original estimates, we will prospectively adjust the amortization of the Royalty Obligation.</nktr:LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock>
    <nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
      contextRef="D2012Q4Feb23-Dec31"
      decimals="2"
      id="d103442172e448-wk-Fact-99B07B7962C951148396D6C6975F6AEB"
      unitRef="number">0.17</nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability>
    <nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
      contextRef="FD2017Q4QTD"
      decimals="3"
      id="d103442172e456-wk-Fact-B26C46A1500C5013AE605E400A6D3A34"
      unitRef="number">0.176</nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability>
    <nktr:ProspectiveInterestRatePercentage
      contextRef="FD2017Q4QTD"
      decimals="2"
      id="d103442172e460-wk-Fact-F35A3981408C5EAEAA2C2E8334021E6D"
      unitRef="number">0.21</nktr:ProspectiveInterestRatePercentage>
    <nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
      contextRef="FD2018Q4QTD"
      decimals="3"
      id="d103442172e476-wk-Fact-F99891C017465AABAC5F3FC02D39B577"
      unitRef="number">0.187</nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability>
    <nktr:ProspectiveInterestRatePercentage
      contextRef="FD2018Q4QTD"
      decimals="2"
      id="d103442172e480-wk-Fact-428520AC777651BABEE74026D6AB45DC"
      unitRef="number">0.29</nktr:ProspectiveInterestRatePercentage>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-CA7F0F1D64A55A8AA72451E9B3F11423-0-wk-Fact-B90B9FE7EE0A5D7A8E980875B117EFF0">Commitments and Contingencies&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On October 30, 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California, which complaint was subsequently amended on May 15, 2019.&#160;&#160;Also, on February 13, 2019, and February 18, 2019, shareholder derivative complaints were filed in the U.S. District Court for the District of Delaware naming the CEO, CFO and certain members of Nektar&#x2019;s board. Both the class action and shareholder derivative actions assert, among other things, that for a period beginning at least from November 11, 2017 through October 2, 2018, our stock was inflated due to alleged misrepresentations about the efficacy and safety of NKTR-214. In addition, on August 19, 2019, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California, which complaint asserted, among other things, that for a period between February 15, 2019 and August 8, 2019, inclusive, our stock was inflated due to an alleged failure to disclose a NKTR-214 manufacturing issue. All of these cases are in the early stages. Accordingly, we cannot reasonably estimate any range of potential future charges, and we have not recorded any accrual for a contingent liability associated with these legal proceedings. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Indemnifications in Connection with Commercial Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual any time after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants, including our obligation to RPI described in Note 5. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification obligations, representations or warranties. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; liabilities for these obligations in our Condensed Consolidated Balance Sheets at either &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="FI2019Q3_us-gaap_LossContingenciesByNatureOfContingencyAxis_us-gaap_IndemnificationGuaranteeMember"
      decimals="INF"
      id="d103439949e379-wk-Fact-0A145EC93D3356ED8E5579DE68227FB5"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-171960C5AAAB5E17A5ED068B0C510F1E-0-wk-Fact-53B00E16930B506D80A45DCDF5D085D7">License and Collaboration Agreements&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. Our partners may generally cancel our collaboration agreements without significant financial penalty. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.42528735632183%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Drug or Drug Candidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Bristol-Myers Squibb Company&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;NKTR-214&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,059,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Eli Lilly and Company&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;NKTR-358&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,627&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amgen, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Neulasta&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Baxalta Inc. / Takeda Pharmaceutical Company Ltd. and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ADYNOVATE&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;404&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;910&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,875&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,860&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,082,848&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we recognized &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$20.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$56.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of revenue for performance obligations that we had satisfied in prior periods, respectively. This amount includes all of our royalty revenue and non-cash royalty revenue because these royalties substantially relate to the licenses that we had previously granted. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the three and nine months ended September 30, 2018, we recognized &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$18.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$64.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of revenue for performance obligations that we had satisfied in prior periods. This amount includes all of our royalty revenue and non-cash royalty revenue because these royalties substantially relate to the licenses that we had previously granted. This amount also includes the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; development milestone payment earned and received from Baxalta Inc. in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the changes in our deferred revenue balance from our collaboration agreements during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine months ended &lt;br/&gt;September 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&#x2014;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Recognition of previously unearned revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9,465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&#x2014;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,171&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our balance of deferred revenue contains the transaction price from our collaboration agreements allocated to performance obligations which are partially unsatisfied. We expect to recognize approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of our deferred revenue over the next twelve months and recognize the remaining &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; over several years.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, our collaboration agreements with partners included potential future payments for development and regulatory milestones totaling approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, including amounts from our agreements with BMS and Eli Lilly and Company described below. In addition, under our collaboration agreements we are entitled to receive contingent sales milestone payments, other contingent payments and royalty payments, as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;There have been no material changes to our collaboration agreements in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, except as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Bristol-Myers Squibb Company (BMS)&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;: Bempegaldesleukin, also referred to as NKTR-214 &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On February 13, 2018, we entered into a Strategic Collaboration Agreement (BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. Pursuant to these agreements, we and BMS are &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;jointly developing NKTR-214, including, without limitation, in combination with BMS&#x2019;s Opdivo&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (nivolumab) and Opdivo&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; plus Yervoy&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (ipilimumab), and other compounds of BMS, us or any third party. The parties have agreed to jointly commercialize NKTR-214 on a worldwide basis. We retained the right to record all worldwide sales for NKTR-214. We will share global commercialization profits and losses with BMS for NKTR-214, with Nektar sharing &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and BMS sharing &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the net profits and losses. The parties will share the internal and external development costs for NKTR-214 in combination regimens based on each party&#x2019;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties will share development costs for&#160;NKTR-214&#160;in combination with&#160;Opdivo&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;67.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of costs to BMS and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;32.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to Nektar, and for&#160;NKTR-214&#160;in a triplet combination with&#160;Opdivo&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;and&#160;Yervoy&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;78%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of costs to BMS and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to Nektar.&#160;The parties will share costs for the manufacturing of NKTR-214, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of costs to BMS and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to Nektar.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The BMS Collaboration Agreement superseded and replaced the Clinical Trial Agreement we entered into with BMS in September 2016 to develop NKTR-214 in combination with Opdivo&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Under the Clinical Trial Agreement, we acted as the sponsor of each Combination Therapy Trial and BMS was responsible for &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of all out-of-pocket costs reasonably incurred in connection with third party contract research organizations, laboratories, clinical sites and institutional review boards. We recorded cost reimbursement payments to us from BMS as a reduction to research and development expense. Each party was otherwise responsible for its own internal costs, including internal personnel costs, incurred in connection with each Combination Therapy Trial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. We are eligible to receive additional cash payments up to a total of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upon the achievement of certain development and regulatory milestones and up to a total of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$350.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upon the achievement of certain sales milestones. In April 2018, BMS also purchased &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,284,600&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$850.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We determined that the BMS Collaboration Agreement falls within the scope of ASC 808. As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808, and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#x2019; reimbursement of our costs as a reduction of research and development expense and our reimbursement of BMS&#x2019; costs as research and development expense. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$28.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$81.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, as a reduction of research and development expense for BMS&#x2019; share of our expenses, net of our share of BMS&#x2019; expenses.&#160;During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we recorded &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$18.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;text-align:right;"&gt;&lt;span&gt;$42.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, as a reduction of research and development expense for BMS&#x2019; share of our expenses, net of our share of BMS&#x2019; expenses. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we have recorded a receivable of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$27.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; from BMS in accounts receivable in our Condensed Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We analogized to ASC 606 for the accounting for our two performance obligations, consisting of the delivery of the licenses to develop and commercialize NKTR-214 and our participation on joint steering and other collaboration committees. We determined that our committee participation is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We aggregated the total consideration of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.85 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; received under the agreements and allocated it between the stock purchase and the revenue-generating elements, because we and BMS negotiated the agreements together and the effective date of the BMS Collaboration Agreement was dependent upon the effective date of the Share Purchase Agreement. We recorded the estimated fair value of the shares of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$790.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in stockholders&#x2019; equity based on the closing date price of our common stock of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$99.36&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, adjusted for a discount for lack of marketability reflecting the unregistered nature of the shares. We allocated the remaining &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1,059.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to the transaction price of the collaboration agreement. We consider the future potential development, regulatory and sales milestones of up to approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to be variable consideration. We excluded these milestones from the transaction price during 2018 and as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; due to the significant uncertainties involved with clinical development and regulatory approval. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accordingly, we allocated the entire transaction price of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1,059.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to the granting of the licenses and therefore recognized &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1,059.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; during the nine months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as license, collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Eli Lilly and Company (Lilly&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;): NKTR-358 &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), which became effective on August 23, 2017, to co-develop NKTR-358, a novel immunological drug candidate that we invented. Under the terms of the agreement, we (i) received an initial payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$150.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in September 2017 and are eligible for up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$250.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in additional development milestones, (ii) will co-develop NKTR-358 with Lilly, for which we are responsible for completing &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Phase 1 clinical development and certain drug product development and supply activities, (iii) will share with Lilly Phase 2 development costs with &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of those costs borne by Lilly and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the costs borne by us, (iv) will have the option to contribute funding to Phase 3 development on an indication-by-indication basis ranging from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;zero&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of development costs, and (v) will have the opportunity to receive up to double-digit sales royalty rates that escalate based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; if both conditions occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We identified our license grant to Lilly, our ongoing Phase 1 clinical development obligation and our drug product development obligation as the significant performance obligations in the arrangement. The valuation of each performance obligation involves significant estimates and assumptions, including but not limited to, expected market opportunity and pricing, assumed royalty rates, clinical trial costs, timelines and likelihood of success; in each case these estimates and assumptions covering long time periods. We determined the selling price for the license based on a discounted cash flow analysis of projected revenues from NKTR-358 and development and commercial costs using a discount rate based on a market participant&#x2019;s weighted-average cost of capital adjusted for forecasting risk. We determined the selling prices for our Phase 1 clinical development and drug product development deliverables based on the nature of the services to be performed and estimates of the associated efforts and third-party rates for similar services.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Although we are entitled to significant development milestones under this arrangement, through &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We have therefore determined the transaction price to consist of the upfront payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$150.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in September 2017. Based on our estimates of the standalone selling prices of the performance obligations, we allocated the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$150.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; upfront payment as &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$125.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to the license, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$17.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to the Phase 1 clinical development and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to the drug product development.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We recognized the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$125.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of revenue allocated to the license upon the effective date of the license agreement in August 2017, since we determined that the license was a right to use our intellectual property, for which, as of the effective date, we had provided all necessary information to Lilly to benefit from the license and the license term had begun. We recognize revenue for the Phase 1 clinical development and drug product development using an input method, using costs incurred, as this method depicts our progress towards providing Lilly with the results of clinical trials and drug production processes. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we have deferred revenue of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; related to this agreement, which we expect to recognize through early 2020, the estimated end of our performance obligations under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Baxalta Inc. / Takeda Pharmaceutical Company Ltd&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;: Hemophilia&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We are a party to an exclusive research, development, license and manufacturing and supply agreement with Baxalta Inc. (Baxalta), a subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), entered into in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology. Under the terms of the agreement, we are entitled to research and development funding for our active programs, which are now complete for Factor VIII, and are responsible for supplying Takeda with its requirements for our proprietary materials. Takeda is responsible for all clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;This Hemophilia A program includes ADYNOVATE&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which was approved by the United States Food and Drug Administration (FDA) in November 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A, and is now marketed in the U.S., the European Union, and many other countries. As a result of the marketing authorization in the EU in January 2018, we earned a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; development milestone, which we received in March 2018. We updated the transaction price for this milestone in January 2018 since we had previously excluded it due to the significant uncertainty from regulatory approval. Based on the terms of this milestone, we allocated the entire milestone to the license grant and research and development services, and therefore recognized the entire &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as we had previously satisfied those performance obligations. In &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December 2018&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we earned an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; milestone for annual sales of ADYNOVATE&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;/ADYNOVI&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&#x2122;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reaching a certain specified amount.&#160;In addition, we are entitled to an additional &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;sales milestone upon achievement of an annual worldwide net sales target and royalties based on worldwide net sales of products resulting from this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents that were previously exclusively licensed to Baxalta under our 2005 agreement. Under the right to sublicense agreement, Baxalta paid us &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in November 2017 and agreed to pay us single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Our remaining unsatisfied performance obligation consists of our ongoing supply of PEGylation materials at a price less than the standalone selling price of these materials. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, our deferred revenue from this arrangement is not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Amgen, Inc&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;.: Neulasta&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In October 2010, we amended and restated an existing supply and license agreement by entering into a supply, dedicated suite and manufacturing guarantee agreement (the Amended and Restated Agreement) and a license agreement with Amgen, Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of the Amended and Restated Agreement, we received a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$50.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; payment in the fourth quarter of 2010 in return for our guaranteeing the supply of certain quantities of our proprietary PEGylation materials to Amgen.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We determined that our obligation to manufacture and supply our PEGylation materials and to maintain the dedicated manufacturing suite solely for the production of such materials for Amgen represented an obligation to stand ready to manufacture such materials. We concluded that we should recognize revenue based on the passage of time as this method depicts the satisfaction of Amgen&#x2019;s right to require production of PEGylation materials at any time. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we have deferred revenue of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; related to this agreement, which we expect to recognize through October 2020, the estimated end of our obligations under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;AstraZeneca AB&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;: MOVANTIK&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;(naloxegol oxalate), previously referred to as naloxegol and NKTR-118 &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In September 2009, we entered into an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our patents and other intellectual property to develop, market, and sell MOVANTIK&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. AstraZeneca is responsible for all research, development and commercialization costs and related decisions for MOVANTIK&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In September 2014 and December 2014, MOVANTIK&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; /MOVENTIG&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was approved in the US and EU, respectively. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we have received a total of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$385.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of upfront and contingent milestone payments from this agreement, all of which was received in or before 2015. In addition, we are entitled to significant and escalating double-digit royalty payments and sales milestone payments based on annual worldwide net sales of MOVANTIK&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March 2016, AstraZeneca announced that it had entered into an agreement with ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd. (Kirin), granting Kirin exclusive marketing rights to MOVENTIG&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in the EU, Iceland, Liechtenstein, Norway and Switzerland. Under our license agreement with AstraZeneca, we and AstraZeneca will share the upfront payment, market access milestone payments, royalties and sales milestone payments made by Kirin to AstraZeneca with AstraZeneca receiving &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and Nektar receiving &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we do not have deferred revenue related to our agreement with AstraZeneca.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As part of its approval of MOVANTIK&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the FDA required AstraZeneca to perform a post-marketing, observational epidemiological study comparing MOVANTIK&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to other treatments of opioid-induced constipation in patients with chronic, non-cancer pain. As a result, the royalty rate payable to us from net sales of MOVANTIK&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in the U.S. by AstraZeneca can be reduced by up to two percentage points to fund &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the external costs incurred by AstraZeneca to fund such post approval study, subject to a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$35.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; aggregate cap. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, our cumulative share of the post-approval study expenses since 2015 totaled &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. AstraZeneca may only recover costs incurred by the reduction of the royalty payable to us. In no case can amounts be recovered by the reduction of a contingent payment due from AstraZeneca to us or through a payment from us to AstraZeneca.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In addition, as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we have a number of other collaboration agreements, including with our collaboration partners UCB Pharma and Halozyme Therapeutics, Inc., under which we are entitled to up to a total of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$45.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of development milestone payments upon achievement of certain development objectives, as well as sales milestones upon &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration agreements, we cannot estimate the probability or timing of achieving these milestones and, therefore, have excluded all development milestones from the respective transaction prices for these agreements. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, we have deferred revenue of approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$6.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; related to these other collaboration agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-4A9F0B0B4BD652CBA812877DBF1DEB24-0-wk-Fact-4B23EDAB839E535B927568D4A477EC4C">&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.42528735632183%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:33%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Drug or Drug Candidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Bristol-Myers Squibb Company&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;NKTR-214&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,059,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Eli Lilly and Company&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;NKTR-358&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,627&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amgen, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Neulasta&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Baxalta Inc. / Takeda Pharmaceutical Company Ltd. and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;ADYNOVATE&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;404&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;910&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,875&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,860&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,082,848&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2019Q3QTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarTwoOneFourMember"
      decimals="-3"
      id="d103457909e614-wk-Fact-4B9DEE19AB395E54ABC136D1BABF99B6"
      unitRef="usd">0</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2018Q3QTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarTwoOneFourMember"
      decimals="-3"
      id="d103457909e633-wk-Fact-6DE55BDD66AC549E805BF1B9943F2DBF"
      unitRef="usd">0</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2019Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarTwoOneFourMember"
      decimals="-3"
      id="d103457909e653-wk-Fact-A72D0DB259C15B85821690F4A6A6C40B"
      unitRef="usd">0</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarTwoOneFourMember"
      decimals="-3"
      id="d103457909e672-wk-Fact-0C2D44BEE5995DD78939968A91BC3463"
      unitRef="usd">1059768000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2019Q3QTD_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember"
      decimals="-3"
      id="d103457909e702-wk-Fact-B1C32D09154554549D1D284A5200BC32"
      unitRef="usd">1500000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2018Q3QTD_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember"
      decimals="-3"
      id="d103457909e721-wk-Fact-BF3B39BD05BF5B53A969975519F5AE3A"
      unitRef="usd">3221000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2019Q3YTD_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember"
      decimals="-3"
      id="d103457909e741-wk-Fact-5F19ECD6FE015F1FBA4982E6BC43D3F4"
      unitRef="usd">5200000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2018Q3YTD_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember"
      decimals="-3"
      id="d103457909e760-wk-Fact-C9C3B54F1F2B52B5B808D15DE3D391CF"
      unitRef="usd">8627000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2019Q3QTD_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_TypeOfArrangementAxis_nktr_NeulastaMember"
      decimals="-3"
      id="d103457909e797-wk-Fact-D24262B5DC4D5542A81CA88D0F88E47D"
      unitRef="usd">1250000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2018Q3QTD_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_TypeOfArrangementAxis_nktr_NeulastaMember"
      decimals="-3"
      id="d103457909e816-wk-Fact-091C7F5C1F0F507D9CB8432312B17255"
      unitRef="usd">1250000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2019Q3YTD_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_TypeOfArrangementAxis_nktr_NeulastaMember"
      decimals="-3"
      id="d103457909e836-wk-Fact-CA7722ACB7F154BB94A731996B7A8180"
      unitRef="usd">3750000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2018Q3YTD_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_TypeOfArrangementAxis_nktr_NeulastaMember"
      decimals="-3"
      id="d103457909e855-wk-Fact-935174F3D2725488843277FDE25610E0"
      unitRef="usd">3750000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2019Q3QTD_dei_LegalEntityAxis_nktr_OtherPartnerMember"
      decimals="-3"
      id="d103457909e892-wk-Fact-EF260FD26FD650798060F9DB8C17204F"
      unitRef="usd">371000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2018Q3QTD_dei_LegalEntityAxis_nktr_OtherPartnerMember"
      decimals="-3"
      id="d103457909e911-wk-Fact-12F1BA5AAAE4590C88EA3E792D458AFA"
      unitRef="usd">404000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2019Q3YTD_dei_LegalEntityAxis_nktr_OtherPartnerMember"
      decimals="-3"
      id="d103457909e931-wk-Fact-38CEDA60E0AB5409A0337607328B64B0"
      unitRef="usd">910000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2018Q3YTD_dei_LegalEntityAxis_nktr_OtherPartnerMember"
      decimals="-3"
      id="d103457909e950-wk-Fact-F2AF06ACDC63572CA026FEAC56350732"
      unitRef="usd">10703000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103457909e990-wk-Fact-14FFA03AF63B58FAB142EA88BF292AD2"
      unitRef="usd">3121000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103457909e1009-wk-Fact-EEB5B84A8627546985E87D07ECC8932C"
      unitRef="usd">4875000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103457909e1024-wk-Fact-EB306C31C12452CBB920A1A11D90DC96"
      unitRef="usd">9860000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103457909e1048-wk-Fact-DBA0B93BD9FA57C3B30358F85ECD2D87"
      unitRef="usd">1082848000</nktr:LicenseCollaborationOtherRevenue>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d103457909e1068-wk-Fact-4D2E5DF486685CA7BD8F34AFF53556E7"
      unitRef="usd">20500000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d103457909e1072-wk-Fact-437C416A0B9A588FAA0295356DB384C8"
      unitRef="usd">56600000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d103457909e1079-wk-Fact-F4AD62256B36537B9F2999AB600AD89E"
      unitRef="usd">18600000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d103457909e1083-wk-Fact-C01489E1188C571380B984056410073B"
      unitRef="usd">64200000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements
      contextRef="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BaxaltaIncorporatedOrTakedaPLCMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_TypeOfArrangementAxis_nktr_HemophiliaMember"
      decimals="-5"
      id="d103457909e1087-wk-Fact-EE334EE2C39D58639D715F02FC935E0A"
      unitRef="usd">10000000.0</nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-66C4EBF39B9F58809DA9460193489262-0-wk-Fact-A43FBEF4CAC352439265361B3940CD5B">&lt;div style="line-height:120%;padding-top:13px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the changes in our deferred revenue balance from our collaboration agreements during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine months ended &lt;br/&gt;September 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&#x2014;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Recognition of previously unearned revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9,465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&#x2014;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,171&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2018Q4"
      decimals="-3"
      id="d103457909e1158-wk-Fact-349EF174C7E453418A83DBCF61CFB34A"
      unitRef="usd">24636000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103457909e1173-wk-Fact-2A538D8B8D755B18A19AD734319AC813"
      unitRef="usd">9465000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q3"
      decimals="-3"
      id="d103457909e1199-wk-Fact-DFAA08BB19FE5363A6DB28C2F18F304E"
      unitRef="usd">15171000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d103457909e1211-wk-Fact-BEBE47B0FF415EC093A9E6F4A8003B75"
      unitRef="usd">8400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d103457909e1215-wk-Fact-317A3EC837A256F08310CABC2DE0CCF1"
      unitRef="usd">6800000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <nktr:PotentialDevelopmentAndRegulatoryMilestones
      contextRef="FI2019Q3"
      decimals="-8"
      id="d103457909e1226-wk-Fact-5FF6F313B8125AE0A6132FA3A68A2BD5"
      unitRef="usd">1700000000</nktr:PotentialDevelopmentAndRegulatoryMilestones>
    <nktr:ProfitsAndLossesSharingPercentage
      contextRef="D2018Q1Feb13-Feb13_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="INF"
      id="d103457909e1265-wk-Fact-EABD52E452405249BB69C78CB4204974"
      unitRef="number">0.65</nktr:ProfitsAndLossesSharingPercentage>
    <nktr:ProfitsAndLossesSharingPercentage
      contextRef="D2018Q1Feb13-Feb13_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="INF"
      id="d103457909e1269-wk-Fact-B038D58B0DCA579D80F86028E557FDAE"
      unitRef="number">0.35</nktr:ProfitsAndLossesSharingPercentage>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="D2018Q1Feb13-Feb13_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nktr_OpdivoMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="INF"
      id="d103457909e1278-wk-Fact-65AF7E5CA0DE5CEA95BC663D7C36004B"
      unitRef="number">0.675</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="D2018Q1Feb13-Feb13_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nktr_OpdivoMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="INF"
      id="d103457909e1282-wk-Fact-5603B85F9CF554D88769A15E2E954FC7"
      unitRef="number">0.325</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="D2018Q1Feb13-Feb13_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nktr_OpdivoAndYervoyMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="INF"
      id="d103457909e1294-wk-Fact-66B61D88013D5B038D967A08D198B6E6"
      unitRef="number">0.78</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="D2018Q1Feb13-Feb13_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_nktr_OpdivoAndYervoyMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="INF"
      id="d103457909e1299-wk-Fact-158AE323BB1A5C74A121BCAC4073AB7D"
      unitRef="number">0.22</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="D2018Q1Feb13-Feb13_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="INF"
      id="d103457909e1303-wk-Fact-324B90B4AC2E55D9932843AD0AA1FD8D"
      unitRef="number">0.35</nktr:PercentageOfSharingInProductionCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="D2018Q1Feb13-Feb13_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="INF"
      id="d103457909e1307-wk-Fact-AF86936142C05DE79AF4E2FAC38769C3"
      unitRef="number">0.65</nktr:PercentageOfSharingInProductionCosts>
    <nktr:PercentageOfOutOfPocketCostsToBeReimbursedByPartner
      contextRef="D2016Q3Sep1-Sep30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_ClinicalTrialAgreementMember"
      decimals="INF"
      id="d103457909e1318-wk-Fact-0D5BACCA7AC1545281A6046CD8BBC6FD"
      unitRef="number">0.50</nktr:PercentageOfOutOfPocketCostsToBeReimbursedByPartner>
    <nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements
      contextRef="D2018Q2Apr1-Apr30_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="-8"
      id="d103457909e1325-wk-Fact-9788EB79B6ED52BAA2FE4ABC085F296C"
      unitRef="usd">1000000000.0</nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements>
    <nktr:CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones
      contextRef="D2018Q2Apr1-Apr30_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="-8"
      id="d103457909e1329-wk-Fact-E5D3CBF836FE576DAB8D6AF6A5F4F296"
      unitRef="usd">1400000000</nktr:CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones>
    <nktr:EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones
      contextRef="D2018Q2Apr1-Apr30_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="INF"
      id="d103457909e1333-wk-Fact-718E5ED9A4D656F2AD7EB1E3067C3EBA"
      unitRef="usd">350000000.0</nktr:EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones>
    <us-gaap:SharesIssued
      contextRef="I2018Q2Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember"
      decimals="INF"
      id="d103457909e1337-wk-Fact-856A33E90A2B569A9DAA327943C183C5"
      unitRef="shares">8284600</us-gaap:SharesIssued>
    <nktr:SaleOfStockConsiderationReceived
      contextRef="D2018Q2Apr1-Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember"
      decimals="-5"
      id="d103457909e1341-wk-Fact-45298F108256595285DE7BD50ED78D67"
      unitRef="usd">850000000.0</nktr:SaleOfStockConsiderationReceived>
    <nktr:ReimbursementOfExpenses
      contextRef="FD2019Q3QTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d103457909e1356-wk-Fact-8E14A56549395958BD85D7377579F7FA"
      unitRef="usd">28300000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="FD2019Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d103457909e1360-wk-Fact-AFF5BA6DE63B5E53A89EC704AC81ED96"
      unitRef="usd">81400000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="FD2018Q3QTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d103457909e1373-wk-Fact-BC10003EC53050DEAA040573C3DB3324"
      unitRef="usd">18900000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="d103457909e1377-wk-Fact-E4C6440853FE547B819108D068BC612D"
      unitRef="usd">42800000</nktr:ReimbursementOfExpenses>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q3_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="-5"
      id="d103457909e1385-wk-Fact-D4693778639D589892D30FB2BA6CCDC6"
      unitRef="usd">27700000</us-gaap:AccountsReceivableNetCurrent>
    <nktr:AggregateConsiderationReceivedFromAgreements
      contextRef="D2018Q2Apr1-Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="-7"
      id="d103457909e1395-wk-Fact-E860D909A57057E0B0AA1ACE82C811A9"
      unitRef="usd">1850000000</nktr:AggregateConsiderationReceivedFromAgreements>
    <nktr:EstimatedFairValueOfShares
      contextRef="I2018Q2Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="-5"
      id="d103457909e1399-wk-Fact-41337E5107E35F4FA4D15EEBE3124C13"
      unitRef="usd">790200000</nktr:EstimatedFairValueOfShares>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="I2018Q2Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="2"
      id="d103457909e1403-wk-Fact-F586BFD3C87A511CB926EFB78F92EF7C"
      unitRef="usdPerShare">99.36</us-gaap:SaleOfStockPricePerShare>
    <nktr:RemainingAmountAllocatedToTransactionPrice
      contextRef="D2018Q2Apr1-Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="-5"
      id="d103457909e1407-wk-Fact-692C8C3945D155F5AB298CD373E56702"
      unitRef="usd">1059800000</nktr:RemainingAmountAllocatedToTransactionPrice>
    <nktr:PotentialDevelopmentRegulatoryAndSalesMilestones
      contextRef="I2018Q2Apr30_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_us-gaap_SubsidiarySaleOfStockAxis_nktr_SharePurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="-8"
      id="d103457909e1411-wk-Fact-F6CF1EC712045267941693293EA12620"
      unitRef="usd">1800000000</nktr:PotentialDevelopmentRegulatoryAndSalesMilestones>
    <nktr:AmountRecognizedForGrantingLicenses
      contextRef="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="-5"
      id="d103457909e1423-wk-Fact-0117A02329525157ABD19B56744C1B82"
      unitRef="usd">1059800000</nktr:AmountRecognizedForGrantingLicenses>
    <nktr:AmountRecognizedForGrantingLicenses
      contextRef="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BristolMyersSquibbCompanyMember_srt_ProductOrServiceAxis_nktr_NektarTwoOneFourMember_us-gaap_TypeOfArrangementAxis_nktr_BMSCollaborationAgreementMember"
      decimals="-5"
      id="d103457909e1427-wk-Fact-0117A02329525157ABD19B56744C1B82"
      unitRef="usd">1059800000</nktr:AmountRecognizedForGrantingLicenses>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="D2017Q3Sep1-Sep30_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember"
      decimals="-5"
      id="d103457909e1443-wk-Fact-F0E2BB8C119B5DD8AFC69410D9AF6C57"
      unitRef="usd">150000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:PotentialDevelopmentAndRegulatoryMilestones
      contextRef="I2017Q3Aug23_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember"
      decimals="INF"
      id="d103457909e1447-wk-Fact-0A336A4AC66156BCA5DB3FA68EDDB2F4"
      unitRef="usd">250000000.0</nktr:PotentialDevelopmentAndRegulatoryMilestones>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="D2017Q3Aug22-Aug23_dei_LegalEntityAxis_nktr_EliLillyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember"
      decimals="INF"
      id="d103457909e1455-wk-Fact-895356AD72DE56D681A05337639EF88B"
      unitRef="number">0.75</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="D2017Q3Aug22-Aug23_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember"
      decimals="INF"
      id="d103457909e1459-wk-Fact-D798E6A88E22578AB9A2A772FA520674"
      unitRef="number">0.25</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
      contextRef="D2017Q3Aug22-Aug23_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember"
      decimals="INF"
      id="d103457909e1463-wk-Fact-507E4E894AD15608B674C93B25895048"
      unitRef="number">0</nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne>
    <nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
      contextRef="D2017Q3Aug22-Aug23_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember"
      decimals="INF"
      id="d103457909e1467-wk-Fact-AF1D2001000556BBAEE2346706454EF2"
      unitRef="number">0.25</nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne>
    <nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions
      contextRef="D2017Q3Aug22-Aug23_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember"
      decimals="INF"
      id="d103457909e1471-wk-Fact-1D38E4A1399D55CF8A39C3A6D9576EBE"
      unitRef="number">0.50</nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions>
    <nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur
      contextRef="D2017Q3Aug22-Aug23_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember"
      decimals="INF"
      id="d103457909e1476-wk-Fact-FE204216587958B7AF427072326CC4B9"
      unitRef="number">0.75</nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="D2017Q3Sep1-Sep30_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember"
      decimals="-5"
      id="d103457909e1493-wk-Fact-F0E2BB8C119B5DD8AFC69410D9AF6C57"
      unitRef="usd">150000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="D2017Q3Sep1-Sep30_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_us-gaap_TypeOfArrangementAxis_nktr_NektarThreeFiveEightMember"
      decimals="-5"
      id="d103457909e1497-wk-Fact-F0E2BB8C119B5DD8AFC69410D9AF6C57"
      unitRef="usd">150000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation
      contextRef="D2017Q3Sep1-Sep30_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightLicenseMember"
      decimals="-5"
      id="d103457909e1501-wk-Fact-9776C0033BF55D82AFED661711FA9528"
      unitRef="usd">125900000</nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation>
    <nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation
      contextRef="D2017Q3Sep1-Sep30_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightLicenseMember_us-gaap_TypeOfArrangementAxis_nktr_PhaseOneClinicalDevelopmentMember"
      decimals="-5"
      id="d103457909e1505-wk-Fact-547A929E351C5EF38CC2315676A816E8"
      unitRef="usd">17600000</nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation>
    <nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation
      contextRef="D2017Q3Sep1-Sep30_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightLicenseMember_us-gaap_TypeOfArrangementAxis_nktr_DrugProductDevelopmentMember"
      decimals="-5"
      id="d103457909e1510-wk-Fact-BD3A872ADC33598EADE83F80FBA54DFB"
      unitRef="usd">6500000</nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2017Q3Aug01-Aug31_dei_LegalEntityAxis_nktr_EliLillyAndCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member"
      decimals="-5"
      id="d103457909e1517-wk-Fact-35D6949C54BB5F519E27275EE5B855DE"
      unitRef="usd">125900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q3_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_srt_ProductOrServiceAxis_nktr_NektarThreeFiveEightMember"
      decimals="-5"
      id="d103457909e1525-wk-Fact-9FF580609A9855F994713896BDF5A948"
      unitRef="usd">3100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q1Jan1-Jan31_dei_LegalEntityAxis_nktr_BaxaltaIncorporatedOrTakedaPLCMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_TypeOfArrangementAxis_nktr_HemophiliaMember"
      decimals="-5"
      id="d103457909e1544-wk-Fact-EB019ACFFC3556429F3C64A943334C6A"
      unitRef="usd">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q3YTD_dei_LegalEntityAxis_nktr_BaxaltaIncorporatedOrTakedaPLCMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_TypeOfArrangementAxis_nktr_HemophiliaMember"
      decimals="-5"
      id="d103457909e1548-wk-Fact-DCD019827B9B5494AC0BCBA7CFE0DB7B"
      unitRef="usd">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q4Dec1-Dec31_dei_LegalEntityAxis_nktr_BaxaltaIncorporatedOrTakedaPLCMember_us-gaap_ContractWithCustomerSalesChannelAxis_nktr_AnnualSalesLevelMilestoneMember_us-gaap_TypeOfArrangementAxis_nktr_HemophiliaMember"
      decimals="-5"
      id="d103457909e1565-wk-Fact-D04E3C7211C659FDBC55DB7A90AA28FF"
      unitRef="usd">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nktr:PaymentsReceivedUnderRightsToSublicenseAgreement
      contextRef="D2017Q4Nov1-Nov30_dei_LegalEntityAxis_nktr_BaxaltaIncorporatedOrTakedaPLCMember_us-gaap_TypeOfArrangementAxis_nktr_HemophiliaMember"
      decimals="-5"
      id="d103457909e1583-wk-Fact-0BF076993ECA58FE8B403D2E73492B76"
      unitRef="usd">12000000.0</nktr:PaymentsReceivedUnderRightsToSublicenseAgreement>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="D2010Q4Oct1-Dec31_dei_LegalEntityAxis_nktr_AmgenIncMember"
      decimals="-5"
      id="d103457909e1605-wk-Fact-45F63DF7CA6654CB8AFACDF88372B601"
      unitRef="usd">50000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q3_dei_LegalEntityAxis_nktr_AmgenIncMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member"
      decimals="-5"
      id="d103457909e1616-wk-Fact-967FB54A1116503EA38AA16E466D97E6"
      unitRef="usd">5400000</us-gaap:ContractWithCustomerLiability>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="D2015Q4Sep01-Dec31_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_MOVANTIKAndMOVENTIGMember"
      decimals="-5"
      id="d103457909e1655-wk-Fact-97C9791A40FB55F2881EAFCD04A9FAF5"
      unitRef="usd">385000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner
      contextRef="D2016Q1Mar1-Mar31_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_AstraZenecaAgreementWithKirinMember"
      decimals="INF"
      id="d103457909e1670-wk-Fact-83A9C0ED59D8577E927417F65D8D13D2"
      unitRef="number">0.60</nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner>
    <nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments
      contextRef="D2016Q1Mar1-Mar31_us-gaap_TypeOfArrangementAxis_nktr_NektarMember"
      decimals="INF"
      id="d103457909e1674-wk-Fact-B46008E439C0595A800BE244674517B8"
      unitRef="number">0.40</nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments>
    <nktr:CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement
      contextRef="FD2019Q3YTD_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_MOVANTIKAndMOVENTIGMember"
      decimals="INF"
      id="d103457909e1700-wk-Fact-3A10AC0208252A074C9E23BE86282CBF"
      unitRef="number">0.33</nktr:CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursement>
    <nktr:CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum
      contextRef="FD2019Q3YTD_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_MOVANTIKAndMOVENTIGMember"
      decimals="INF"
      id="d103457909e1704-wk-Fact-CAE9F1F4957C7B8D283F23BF8BBA5DC4"
      unitRef="usd">35000000.0</nktr:CostsIncurredAmountOfPostApprovalStudyExpensesEligibleForReimbursementMaximum>
    <nktr:CostsIncurredShareOfExpenses
      contextRef="FD2019Q3YTD_dei_LegalEntityAxis_nktr_AstraZenecaAbMember_us-gaap_TypeOfArrangementAxis_nktr_MOVANTIKAndMOVENTIGMember"
      decimals="-5"
      id="d103457909e1713-wk-Fact-25D35499B69FDA4CE04423CF6EF7DF22"
      unitRef="usd">1700000</nktr:CostsIncurredShareOfExpenses>
    <nktr:PotentialDevelopmentMilestones
      contextRef="FI2019Q3_dei_LegalEntityAxis_nktr_OtherPartnerMember"
      decimals="-5"
      id="d103457909e1727-wk-Fact-EDD5D3A5B67C528B9BA1E8AB33E0049D"
      unitRef="usd">45500000</nktr:PotentialDevelopmentMilestones>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q3_dei_LegalEntityAxis_nktr_OtherPartnerMember"
      decimals="-5"
      id="d103457909e1738-wk-Fact-037FF69C902E5AD4BF15D29DBFA91CE6"
      unitRef="usd">6000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-7E0BB8FC5C785883BB8653FA1A510087-0-wk-Fact-804C185B5D8150B4A7E3B12D3455D368">Stock-Based Compensation&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80842911877394%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,470&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,680&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,549&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,081&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,746&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,030&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,976&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,880&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,287&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;74,787&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;246&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average grant-date fair value of options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;39.28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;712&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average grant-date fair value of RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;57.27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31.80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;54.49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares issued under equity compensation plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;820&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;642&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,248&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-72AD93B849295A4D826DF2693D4422FA-0-wk-Fact-461F104C6E265519B3BC08B4137D07F8">&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80842911877394%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,470&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,680&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,549&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;40,449&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;8,081&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,746&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,030&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;19,976&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;24,880&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,287&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;74,787&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="d103442105e564-wk-Fact-E62084A31D40584B8DB62D9670EABD65"
      unitRef="usd">1119000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="d103442105e583-wk-Fact-63A2D38AD9B45EADA5CD9705BA39C6D2"
      unitRef="usd">1176000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="d103442105e602-wk-Fact-B78865A3BFD051FF856699AE0DDAAEA8"
      unitRef="usd">3208000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="d103442105e622-wk-Fact-A110D595BE865E47BEC44C34F030B080"
      unitRef="usd">3470000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d103442105e637-wk-Fact-966F5422ED2C5D51B560D44C057B87C7"
      unitRef="usd">15680000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d103442105e656-wk-Fact-6DBAC5483C4A5587BB392992F0320393"
      unitRef="usd">15365000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d103442105e675-wk-Fact-8ED4DBB15D9157AA8C7EF578A8D5C601"
      unitRef="usd">47549000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d103442105e695-wk-Fact-A912775E52865E4CAA08A23C03521D66"
      unitRef="usd">40449000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d103442105e715-wk-Fact-7966DDB757065392B675DBDC8BFF1962"
      unitRef="usd">8081000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d103442105e734-wk-Fact-76FD1E1C7F375FD78EE67F7DC8EE5E35"
      unitRef="usd">6746000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d103442105e753-wk-Fact-07A2C1BB53DB5184978259A459900345"
      unitRef="usd">24030000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="d103442105e773-wk-Fact-D73C151CA3325861AF58533A9EE22BEC"
      unitRef="usd">19976000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d103442105e798-wk-Fact-85E41C500D845BBF9F5D0C5FC655F460"
      unitRef="usd">24880000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3QTD"
      decimals="-3"
      id="d103442105e817-wk-Fact-08EC09F54E0C58FDA0B9CE1C01A691A5"
      unitRef="usd">23287000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d103442105e836-wk-Fact-B1BCA189DB1959319F6A8B4FBCF38A2E"
      unitRef="usd">74787000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q3YTD"
      decimals="-3"
      id="d103442105e856-wk-Fact-3BC234129E875B5891EA667CAB9217B1"
      unitRef="usd">63895000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-48470127683A2E4BD54423D7F22B7E96-0-wk-Fact-28CC4B059694E2A11A7523D824BBDD87">&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.61685823754789%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three months ended September&#160;30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;246&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average grant-date fair value of options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13.43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;30.52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;39.28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;712&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted-average grant-date fair value of RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;57.27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31.80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;54.49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares issued under equity compensation plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;820&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;642&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,248&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d103442105e1064-wk-Fact-9398F82F56C4541FBAAAD5BDBA3D0A7C"
      unitRef="shares">131000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d103442105e1083-wk-Fact-1C9A302C27B25A0DAE17F66E714465B7"
      unitRef="shares">190000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d103442105e1102-wk-Fact-C38BD20089735AE5A16C77E51BC014DC"
      unitRef="shares">246000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="d103442105e1122-wk-Fact-9E85B6AAB5455CD5A946F3BB8A872B75"
      unitRef="shares">929000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d103442105e1147-wk-Fact-4CF89C287D1957059C53099B0F4D6240"
      unitRef="usdPerShare">13.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d103442105e1166-wk-Fact-292A4DBA09E6578B8C263919703A45DF"
      unitRef="usdPerShare">30.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d103442105e1185-wk-Fact-12DA8440C322517AA70B1CEE125B14B7"
      unitRef="usdPerShare">15.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d103442105e1205-wk-Fact-26CA33E46226558C8B0821AAED832330"
      unitRef="usdPerShare">39.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d103442105e1220-wk-Fact-24F973298C465AAB9D46E844F0755461"
      unitRef="shares">316000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d103442105e1239-wk-Fact-E4CB38EDDEE054B68FA7739F05E25763"
      unitRef="shares">152000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d103442105e1258-wk-Fact-3F12EC5B15CC549D9C5F5467E893B61D"
      unitRef="shares">712000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d103442105e1278-wk-Fact-6B6DBB0E019A543794289B5525F4071C"
      unitRef="shares">558000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d103442105e1303-wk-Fact-F50D16668A8013CF281E198A57106E59"
      unitRef="usdPerShare">28.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d103442105e1322-wk-Fact-72BE3552DB7CB7E2B691198A58EAAC2A"
      unitRef="usdPerShare">57.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d103442105e1341-wk-Fact-CA34F71A23145A63A4B62330692E18BB"
      unitRef="usdPerShare">31.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d103442105e1361-wk-Fact-69650CD8511B0CEB2FEF1989F388524F"
      unitRef="usdPerShare">54.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q3QTD"
      decimals="INF"
      id="d103442105e1376-wk-Fact-0D6D128183115981A26D8211E23FFC99"
      unitRef="shares">820000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2018Q3QTD"
      decimals="INF"
      id="d103442105e1395-wk-Fact-071CD2B8744058AFA988EE9F64C71AE8"
      unitRef="shares">642000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d103442105e1414-wk-Fact-292F0256C56356D2B2E4C7F04A9E74BC"
      unitRef="shares">2256000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2018Q3YTD"
      decimals="INF"
      id="d103442105e1434-wk-Fact-5230F5A4D3915D97B830F8427FBAB1DF"
      unitRef="shares">5248000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-7DD3D0403DA75014BD5862285AE59026-0-wk-Fact-E851136122F85D98A8C89A7BA3459E8A">Net Income (Loss) Per Share&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;We calculate basic net income (loss) per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net income (loss) per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, our net income (loss) available to common stockholders equals the reported net income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and the three months ended September 30, 2018, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. During the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and the three months ended September 30, 2018, potentially dilutive securities consisted of the weighted-average common shares underlying outstanding stock options and RSUs, which totaled &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;17.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares, respectively.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the computation of diluted earnings per share for nine months ended September 30, 2018, we included approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; weighted-average common shares underlying stock options and RSUs under the treasury stock method and excluded approximately &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3.2 million&lt;/span&gt;&lt;/span&gt; of shares of common stock underlying stock options because their effect was antidilutive.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_nktr_StockOptionsAndRestrictedStockUnitsMember"
      decimals="-5"
      id="d103442218e380-wk-Fact-C2BDDFA6C08E5566BB0760145B5740DD"
      unitRef="shares">17200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_nktr_StockOptionsAndRestrictedStockUnitsMember"
      decimals="-5"
      id="d103442218e385-wk-Fact-F287B2D5916852169F7D7AF0B9F4CD9F"
      unitRef="shares">18000000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q3QTD"
      decimals="-5"
      id="d103442218e389-wk-Fact-735C079881674B10D689197FCA39CABA"
      unitRef="shares">17600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d103442218e396-wk-Fact-72D9A5D15BE42CEB3CEF19812EC4A19A"
      unitRef="shares">11300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q3YTD"
      decimals="-5"
      id="d103442218e400-wk-Fact-09D9B58E7D54EA0296C41980D5D652DE"
      unitRef="shares">3200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6840655456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Inventory (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,586<span></span>
</td>
<td class="nump">$ 1,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">7,961<span></span>
</td>
<td class="nump">6,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">4,173<span></span>
</td>
<td class="nump">3,132<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 13,720<span></span>
</td>
<td class="nump">$ 11,381<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
